symptoms,diseases,diagnosis
"['Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence', 'Death in early adulthood', 'Pustule']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Branched-chain amino acid accumulation**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate a defect in the metabolism of valine, leucine, and isoleucine—the branched-chain amino acids (BCAAs). This triad is pathognomonic for MSUD, caused by a deficiency in the branched-chain α-keto acid dehydrogenase (BCKDH) complex.  
2. **Early mortality**: Death in infancy, childhood, adolescence, or early adulthood aligns with severe MSUD phenotypes (e.g., classic or intermediate forms). Untreated, toxic BCAA accumulation leads to metabolic decompensation, cerebral edema, and multisystem failure.  
3. **Gastrointestinal inflammation**: Metabolic crises in MSUD cause vomiting, feeding difficulties, and mucosal injury, explaining gastrointestinal symptoms.  
4. **Recurrent infections and pustules**: Chronic metabolic stress and ketoacidosis impair immune function, increasing susceptibility to infections. Skin pustules may arise from secondary bacterial infections or inflammatory responses to metabolic byproducts.  
5. **Neonatal death**: Severe MSUD manifests within days of birth if undiagnosed, as BCAA levels rise rapidly post-feeding, causing acute neurological decline.  

This constellation of symptoms and biochemical findings is specific to MSUD, with no other disorder combining these features."
"['Lethargy', 'Generalized hypotonia', 'Hepatic steatosis', 'Death in infancy', 'Cardiomegaly', 'Pericardial effusion', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Tachypnea', 'Paroxysmal tachycardia', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Increased circulating lactate dehydrogenase concentration']",['Very long chain acyl-CoA dehydrogenasedeficiency; VLCADD/Very long chain acyl-CoA dehydrogenase deficiency/Very long-chain acyl-CoA dehydrogenase deficiency'],"Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Metabolic derangements**: Hypoglycemia, hyperammonemia, and metabolic acidosis align with impaired fatty acid β-oxidation, a hallmark of VLCADD. Fatty acids are critical for energy during fasting; their defective metabolism leads to hypoglycemia and compensatory protein catabolism (causing hyperammonemia).  
2. **Hepatic involvement**: Hepatic steatosis, hepatomegaly, and abnormal liver enzymes (elevated lactate dehydrogenase) reflect liver dysfunction due to toxic accumulation of unmetabolized long-chain fatty acids.  
3. **Cardiac manifestations**: Cardiomegaly, pericardial effusion, and paroxysmal tachycardia correlate with long-chain fatty acid deposition in cardiac tissue, leading to cardiomyopathy and arrhythmias.  
4. **Muscular symptoms**: Generalized hypotonia and lethargy result from energy deficiency in muscles, as long-chain fatty acids cannot fuel muscle metabolism.  
5. **Lab abnormalities**: Decreased plasma free carnitine (due to secondary carnitine deficiency from acyl-CoA trapping) and abnormal aspartate/alanine concentrations (indicative of mitochondrial dysfunction) strongly support a fatty acid oxidation disorder.  
6. **Respiratory and systemic signs**: Tachypnea and dyspnea may stem from metabolic acidosis, while vomiting/diarrhea reflect multisystem metabolic stress.  
7. **Severe prognosis**: Death in infancy is consistent with acute metabolic crises in untreated VLCADD, triggered by catabolic states (e.g., fasting, infection).  

VLCADD is distinguished from other fatty acid oxidation defects by its predilection for cardiac/hepatic involvement and characteristic laboratory markers (e.g., elevated C14:1 acylcarnitine). Early-onset symptoms with multisystemic dysfunction confirm this diagnosis."
"['Intellectual disability', 'Severe short stature', 'Death in childhood', 'Abnormality of galactoside metabolism']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient presents with intellectual disability and severe short stature, which are consistent with the neurological and growth impairments seen in untreated classic galactosemia. Death in childhood aligns with the severe complications of the disease (e.g., liver failure, sepsis) if galactose is not excluded from the diet. The abnormality of galactoside metabolism directly points to the enzymatic defect in galactose-1-phosphate uridylyltransferase (GALT), characteristic of classic galactosemia. Early dietary management is critical to mitigate symptoms, but residual issues may persist despite treatment.  

Disease: Galactosemia; GAL/Galactosemia  
Reasoning: This diagnosis is synonymous with classic galactosemia. The symptoms listed—intellectual disability, severe short stature, childhood mortality, and metabolic abnormalities—are hallmarks of galactosemia caused by GALT deficiency. Accumulation of toxic metabolites (e.g., galactitol) disrupts cellular function, leading to organ damage (liver, brain) and growth failure. The term ""abnormality of galactoside metabolism"" explicitly references the underlying biochemical defect in galactose processing pathways."
"['Difficulty walking', 'Myalgia', 'Difficulty climbing stairs', 'Episodic flaccid weakness', 'Death in childhood', 'Difficulty running', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating carnitine concentration', 'Abnormal circulating creatine kinase concentration', 'Episodic quadriplegia']","['Carnitine palmitoyl transferase II deficiency, myopathic form/Carnitine palmitoyltransferase II deficiency, myopathic, stress-induced']","Disease: Carnitine palmitoyl transferase II deficiency, myopathic form/Carnitine palmitoyltransferase II deficiency, myopathic, stress-induced  
Reasoning:  
1. **Episodic Muscle Weakness**: The patient’s episodic flaccid weakness and quadriplegia align with stress-induced attacks characteristic of CPT II deficiency, triggered by prolonged exercise, fasting, or infection.  
2. **Exercise Intolerance**: Difficulty walking, climbing stairs, and running reflect impaired fatty acid oxidation, leading to energy deficits in muscles during sustained activity.  
3. **Laboratory Abnormalities**:  
   - **Elevated Creatine Kinase (CK)**: Indicates recurrent muscle breakdown (rhabdomyolysis) during episodes.  
   - **Abnormal Carnitine Levels**: CPT II deficiency disrupts carnitine-dependent fatty acid transport, altering circulating carnitine.  
   - **Abnormal Aspartate Family Amino Acids**: Secondary metabolic derangements (e.g., hyperammonemia) during crises may perturb amino acid metabolism.  
4. **Death in Childhood**: Severe metabolic crises (e.g., renal failure from rhabdomyolysis) can lead to early mortality, though the myopathic form is typically less severe than infantile CPT II deficiency.  
5. **Exclusion of Alternatives**: Symptoms and labs rule out glycogenoses (e.g., McArdle disease) by the absence of ""second wind"" phenomenon and presence of lipid metabolism-specific abnormalities.  
6. **Genetic Confirmation**: While not stated, autosomal recessive mutations in *CPT2* would confirm the diagnosis."
"['Macrocephaly', 'Strabismus', 'Delayed speech and language development', 'Seizure', 'Ataxia', 'Lethargy', 'Death in infancy', 'Abnormal cerebral morphology', 'Increased serum lactate', 'Drowsiness', 'Progressive neurologic deterioration', 'Sleep disturbance', 'Death in childhood', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Macrocephaly**: A hallmark of Canavan disease due to spongiform degeneration of white matter and brain swelling.  
2. **Neurological Symptoms (Ataxia, Seizures, Progressive Deterioration)**: Caused by leukodystrophy disrupting myelination and neuronal function.  
3. **Abnormal Cerebral Morphology**: MRI typically shows diffuse white matter abnormalities and cyst-like changes.  
4. **Delayed Speech/Language Development**: Reflects global developmental delay from neurodegeneration.  
5. **Increased Serum Lactate & Abnormal Aspartate Metabolism**: Linked to ASPA gene mutations impairing N-acetylaspartate (NAA) breakdown, causing toxic accumulation and secondary mitochondrial dysfunction.  
6. **Lethargy/Drowsiness/Sleep Disturbance**: Result from cerebral energy deficits and neurochemical imbalances.  
7. **Fatal Early Course (Infancy/Childhood)**: Severe infantile-onset Canavan disease leads to rapid neurodegeneration and early mortality.  
8. **Strabismus**: Occurs due to optic nerve atrophy or impaired brainstem coordination.  

The combination of macrocephaly, leukodystrophy features, aspartate metabolism abnormalities, and early fatality strongly supports Canavan disease, confirmed by genetic testing for ASPA mutations or elevated NAA in urine/CSF."
"['Recurrent urinary tract infections', 'Death in infancy', 'Cystinuria', 'Argininuria', 'Hyperlysinuria', 'Ornithinuria']",['Cystinuria/Cystinuria'],"Disease: Cystinuria  
**Reasoning**:  
1. **Cystinuria** is characterized by impaired renal reabsorption of **cystine** and the dibasic amino acids **ornithine, arginine, and lysine** (COAL), leading to their excessive urinary excretion. The symptoms **cystinuria, argininuria, hyperlysinuria, and ornithinuria** directly align with this defect.  
2. **Recurrent urinary tract infections (UTIs)** are common in cystinuria due to cystine stone formation in the urinary tract, which predisposes to obstruction and infection.  
3. **Death in infancy** is atypical for classic cystinuria but may occur in severe cases with early-onset nephrolithiasis, obstructive uropathy, or sepsis secondary to recurrent UTIs, compounded by metabolic instability in infants.  
4. Other disorders (e.g., lysinuric protein intolerance) were excluded due to the absence of hallmark features (e.g., hyperammonemia, failure to thrive) and the presence of **cystinuria**, which is pathognomonic for this diagnosis.  
5. Genetic mutations in **SLC3A1** or **SLC7A9** disrupt the renal transporter responsible for COAL reabsorption, confirming cystinuria as the unifying diagnosis."
"['Death in infancy', 'Fever', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur transiently due to metabolic stress, secondary liver dysfunction, or overlapping tyrosinemia-like features in severe cases.  
3. **Severe short stature** aligns with untreated PKU, where chronic metabolic disruption impairs growth and development.  
4. **Neonatal death/Death in infancy/childhood** reflects untreated PKU complications (e.g., neurological collapse, seizures, or infections) in severe variants or delayed diagnosis.  
5. **Fever** may result from secondary infections exacerbated by metabolic instability or immunocompromise.  
6. While hypertyrosinemia suggests alternative diagnoses (e.g., tyrosinemia), PKU is prioritized here due to the explicit diagnostic label provided and the dominance of hyperphenylalaninemia.  

Note: Hypertyrosinemia warrants further investigation for coexisting conditions (e.g., tyrosinemia or BH4 deficiency), but PKU remains the primary diagnosis based on symptom prioritization."
"['Microcephaly', 'Diabetes mellitus', 'Intellectual disability', 'Seizure', 'Death in infancy', 'Abnormal cerebral white matter morphology', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood', 'Body odor']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity.  
2. **Intellectual disability & microcephaly**: Untreated PKU leads to neurotoxicity from phenylalanine accumulation, impairing brain development.  
3. **Seizures & abnormal cerebral white matter**: Chronic phenylalanine toxicity disrupts myelination and neuronal function, consistent with MRI findings.  
4. **Body odor**: Phenylacetate, a metabolite of phenylalanine, excreted in sweat, produces a musty odor.  
5. **Hypertyrosinemia**: Atypical in classic PKU but may occur in rare variants (e.g., BH4 cofactor deficiency) or secondary metabolic disturbances.  
6. **Early mortality**: Severe untreated PKU can lead to fatal neurological complications; survival into early adulthood suggests partial management.  
7. **Diabetes mellitus**: Unrelated to PKU but possibly a comorbid condition, as PKU does not directly affect glucose metabolism.  

Note: Hypertyrosinemia warrants investigation for BH4 deficiency (e.g., genetic testing) to exclude atypical PKU forms."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to elevated phenylalanine levels in the blood.  
2. **Abnormality of prenatal development or birth** may occur if maternal PKU is untreated during pregnancy, resulting in fetal exposure to high phenylalanine levels, causing microcephaly, congenital heart defects, or developmental delays.  
3. **Death in infancy/Neonatal death** is rare in classic PKU due to newborn screening and dietary management. However, untreated severe cases can lead to irreversible neurological damage, seizures, and failure to thrive, potentially progressing to fatal outcomes in early life.  
4. The combination of hyperphenylalaninemia with severe early-life complications aligns with PKU when undiagnosed/unmanaged, particularly in regions lacking newborn screening programs."
"['Hematuria', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Diarrhea', 'Increased serum lactate', 'Increased CSF lactate', 'Feeding difficulties', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The presence of **methylmalonic aciduria** directly indicates a defect in methylmalonyl-CoA metabolism. Combined with **metabolic acidosis**, **increased serum/CSF lactate**, and **feeding difficulties**, this aligns with MMA's hallmark metabolic decompensation. **Generalized hypotonia** and **death in infancy** reflect severe neurological and systemic involvement, while **diarrhea** and **hematuria** may stem from renal tubular dysfunction and metabolic stress.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The lack of vitamin B12 responsiveness points to a **mutase deficiency** (mut⁰ or mut⁻ subtypes). Elevated lactate in serum and CSF suggests impaired mitochondrial energy production due to dysfunctional methylmalonyl-CoA mutase. **Death in infancy** and severe acidosis are typical in B12-unresponsive forms, as residual enzyme activity is minimal. Genetic confirmation would identify mutations in the *MUT* gene, solidifying this subtype diagnosis."
"['Abnormality of prenatal development or birth', 'Intellectual disability', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylketones (e.g., phenylpyruvate, phenyllactate), which are excreted in urine as carboxylic acids.  
3. **Intellectual disability**: Untreated PKU leads to neurotoxic phenylalanine accumulation, disrupting brain development.  
4. **Neonatal/childhood death**: Severe metabolic derangements (e.g., seizures, failure to thrive) in untreated cases may result in early mortality.  
5. **Hypertyrosinemia (atypical for PKU)**: While classic PKU reduces tyrosine levels, secondary factors (e.g., transient liver dysfunction, dietary intake, or metabolic stress) may explain elevated tyrosine.  
6. **Prenatal abnormalities**: Maternal PKU during pregnancy can cause congenital anomalies, though postnatal PKU diagnosis aligns with neonatal symptoms.  

Note: Hypertyrosinemia warrants further investigation for coexisting disorders (e.g., tyrosinemia), but PKU remains the primary diagnosis based on hyperphenylalaninemia and phenylketonuria."
"['Apathy', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Splenomegaly', 'Hyperammonemia', 'Vomiting', 'Hyperlysinemia', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Elevated circulating glutaric acid concentration', 'Low plasma citrulline', 'Prolonged partial thromboplastin time', 'Recurrent viral infections', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Abnormal circulating ornithine concentration', 'Uraciluria', 'Abnormal circulating creatine kinase concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** + **vomiting** + **hepatomegaly**: Core features of urea cycle disorders (UCDs), indicating impaired ammonia detoxification.  
2. **Oroticaciduria** + **uraciluria**: Pathognomonic for OTCD. OTC deficiency causes carbamoyl phosphate accumulation, which enters pyrimidine synthesis, producing excess orotic acid/uracil.  
3. **Low citrulline**: OTC catalyzes ornithine + carbamoyl phosphate → citrulline; deficiency blocks this step, reducing citrulline synthesis.  
4. **Abnormal ornithine/arginine**: Secondary disruption of urea cycle intermediates.  
5. **Elevated glutamine/alanine/lysine**: Amino acid imbalances from alternative ammonia scavenging pathways (e.g., glutamine synthesis) and metabolic stress.  
6. **Hepatosplenomegaly** + **elevated liver enzymes**: Hepatic dysfunction due to toxic metabolite accumulation.  
7. **Prolonged PTT** + **recurrent infections**: Possible secondary coagulopathy/immune dysfunction from liver involvement.  
8. **Neurodevelopmental features** (apathy, intellectual disability) + **early mortality**: Reflects severe hyperammonemic crises causing irreversible neurological damage.  
OTCD aligns with the biochemical profile (orotic aciduria, citrulline depletion) and clinical progression of neonatal/infantile-onset UCD."
"['Delayed speech and language development', 'Pallor', 'Intellectual disability', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Leukopenia', 'Anemia', 'Hyperammonemia', 'Hyperglycinemia', 'Drowsiness', 'Sleep disturbance', 'Hyperalaninemia', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Atransferrinemia', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic Findings**: Hyperammonemia, hyperglycinemia, hyperalaninemia, and elevated urinary carboxylic acids align with PA's hallmark organic acidemia due to propionyl-CoA carboxylase deficiency, causing toxic metabolite accumulation.  
2. **Hematologic Abnormalities**: Leukopenia and anemia reflect bone marrow suppression from metabolic toxicity, common in PA crises.  
3. **Neurological Symptoms**: Intellectual disability, lethargy, generalized hypotonia, and delayed speech result from neurotoxic effects of ammonia/glycine and energy deficiency.  
4. **Early Mortality**: Death in infancy/childhood is typical in severe, untreated PA due to metabolic decompensation.  
5. **Carnitine Abnormalities**: Abnormal carnitine levels occur as carnitine is depleted to conjugate propionyl-CoA for excretion.  
6. **Atypical Features**: Atransferrinemia and hearing impairment are less common but may arise from chronic metabolic stress or secondary complications.  
7. **Sleep/Drowsiness**: Hyperammonemia disrupts CNS function, explaining drowsiness and sleep disturbances.  
8. **Porphyrin Anomalies**: Likely secondary to mitochondrial dysfunction affecting heme synthesis pathways.  

PA integrates metabolic, hematologic, and neurologic symptoms, with key biochemical markers (hyperammonemia, hyperglycinemia, elevated carboxylic acids) confirming the diagnosis."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death** or **death in infancy** in untreated cases aligns with severe PKU variants or lack of newborn screening/dietary intervention, resulting in metabolic crises, neurological damage, or organ failure.  
3. Classic PKU typically manifests with intellectual disability and seizures, but untreated cases in resource-limited settings may progress rapidly to fatal outcomes due to acute complications (e.g., cerebral edema, infections).  
4. Differential diagnoses (e.g., BH4 deficiency) were excluded as the provided diagnosis specifically lists PKU, and hyperphenylalaninemia alone suffices for PKU classification, even if BH4 defects are clinically distinct."
"['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Obesity', 'Death in infancy', 'Thromboembolism', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, leading to **ataxia** and **motor delay** due to impaired cerebellar function.  
2. **Intellectual disability**: Common in PMM2-CDG due to global neurodevelopmental deficits from abnormal glycosylation.  
3. **Strabismus**: Caused by cranial nerve dysfunction or cerebellar-related oculomotor coordination issues.  
4. **Thromboembolism**: Linked to hypoglycosylation of coagulation factors (e.g., antithrombin III deficiency), increasing clotting risk.  
5. **Early mortality (infancy/childhood)**: Severe PMM2-CDG cases involve multi-organ failure, infections, or thromboembolic events.  
6. **Obesity**: Less typical but possible due to endocrine dysregulation or hypothyroidism, which may occur in CDG.  
7. **Supporting evidence**: PMM2-CDG is the most prevalent CDG subtype, characterized by cerebellar abnormalities, neurodevelopmental deficits, and systemic complications. Isoelectric focusing of serum transferrin (abnormal glycosylation pattern) confirms diagnosis."
"['Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Facial palsy', 'Dark urine']",['Alkaptonuria/Alkaptonuria'],"Alkaptonuria:  
1. **Dark urine** is the hallmark symptom of alkaptonuria, caused by the accumulation and oxidation of homogentisic acid in urine. This is often the first sign noticed in infancy.  
2. **Generalized hypotonia** and **growth delay** may occur secondary to metabolic stress or systemic effects of chronic homogentisic acid accumulation, though these are not classic features of alkaptonuria and could indicate comorbid conditions.  
3. **Facial palsy** and **death in infancy** are atypical for alkaptonuria, which usually has a later-onset presentation (e.g., ochronosis, arthritis). These symptoms likely point to additional complications or misdiagnosis, but the presence of dark urine strongly prioritizes alkaptonuria as the primary diagnosis.  

*Note: While alkaptonuria explains the dark urine, the combination with severe infantile symptoms (e.g., death in infancy) suggests either an unusual presentation, coexisting disorders, or potential misalignment in the case details. Further testing for homogentisic acid in urine and genetic analysis for* HGD *gene mutations would confirm alkaptonuria.*"
"['Apathy', 'Cyanosis', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Opisthotonus', 'Cerebral edema', 'Oroticaciduria', 'Neonatal death', 'Feeding difficulties']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia (Citrullinemia type I/Classic Citrullinemia)  
Reasoning:  
1. **Hyperammonemia and Oroticaciduria**: Core features of urea cycle disorders (UCDs). Elevated ammonia results from impaired urea synthesis, while oroticaciduria arises due to mitochondrial carbamoyl phosphate ""shunting"" into cytoplasmic pyrimidine synthesis.  
2. **Neonatal/Infantile Presentation**: Death in infancy/neonatal death, feeding difficulties, and apathy align with severe UCDs presenting shortly after birth.  
3. **Neurological Symptoms**: Seizures, cerebral edema, and opisthotonus reflect acute hyperammonemic crises causing neurotoxicity and intracranial hypertension.  
4. **Citrullinemia Type I vs. Type II**:  
   - Type I (ASS1 deficiency) is neonatal-onset with marked citrulline elevation in plasma and urine.  
   - Type II (SLC25A13 mutation) typically presents later (adult-onset) and lacks oroticaciduria.  
   - The presence of **oroticaciduria** and **neonatal lethality** specifically points to Type I.  
5. **Cyanosis**: Likely secondary to metabolic acidosis or respiratory compromise during crisis.  

Conclusion: Classic citrullinemia (Type I) is confirmed by hyperammonemia, oroticaciduria, neonatal severity, and citrulline accumulation due to argininosuccinate synthetase (ASS1) deficiency."
"['Apathy', 'Delayed speech and language development', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Hepatic failure', 'Growth delay', 'Death in infancy', 'Congestive heart failure', 'Pancreatitis', 'Exocrine pancreatic insufficiency', 'Thrombocytopenia', 'Leukopenia', 'Anemia', 'Acute kidney injury', 'Dehydration', 'Hyperammonemia', 'Pneumonia', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Cerebral edema', 'Sparse scalp hair', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Hyperglycinuria', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating glutamine concentration', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating valine concentration', 'Abnormal circulating cysteine concentration', 'Abnormal circulating carnitine concentration', 'Abnormal circulating monocarboxylic acid concentration', 'Chronic kidney disease', 'Increased circulating lactate dehydrogenase concentration', 'Elevated urinary carboxylic acid']",['Propionic acidemia; PA/Propionic acidemia/Propionic acidemia'],"Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic Crisis Indicators**: Symptoms like hyperammonemia, increased serum lactate, and acute kidney injury suggest a metabolic disorder disrupting amino acid catabolism.  
2. **Amino Acid Abnormalities**: Elevated isoleucine, valine, and abnormal aspartate/glutamine align with PA’s defect in propionyl-CoA carboxylase, impairing breakdown of these amino acids.  
3. **Secondary Glycine Dysregulation**: Hyperglycinemia/hyperglycinuria occur due to propionate inhibition of glycine cleavage enzyme.  
4. **Hematologic Involvement**: Thrombocytopenia, leukopenia, and anemia stem from bone marrow suppression by toxic metabolites (e.g., propionyl-CoA).  
5. **Pancreatic/Kidney Dysfunction**: Exocrine pancreatic insufficiency and chronic kidney disease result from chronic acidosis and metabolic stress.  
6. **Neurological Features**: Seizures, cerebral edema, and developmental delays reflect neurotoxicity from hyperammonemia and organic acid accumulation.  
7. **Hepatic/Cardiac Manifestations**: Hepatomegaly, hepatic failure, and congestive heart failure arise from mitochondrial energy deficiency and toxic metabolite deposition.  
8. **Urinary Biomarkers**: Hyperglycinuria and elevated urinary carboxylic acids (e.g., methylcitrate, 3-hydroxypropionate) are pathognomonic for PA.  
9. **Early Mortality**: Death in infancy/childhood is consistent with severe PA phenotypes, often triggered by infections or metabolic decompensation.  
10. **Carnitine Dysregulation**: Abnormal carnitine levels occur due to sequestration by propionyl-CoA, exacerbating metabolic dysfunction.  

The constellation of metabolic derangements, multi-organ involvement, and characteristic biochemical markers confirm propionic acidemia."
"['Seizure', 'Lethargy', 'Hyperreflexia', 'Fever', 'Hyperammonemia', 'Vomiting', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Death in childhood', 'Abnormal circulating ornithine concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **vomiting** are hallmark features of urea cycle disorders (UCDs), including OTCD, due to impaired ammonia detoxification.  
2. **Oroticaciduria** is a critical clue: OTCD disrupts the urea cycle, causing carbamoyl phosphate accumulation, which shunts into pyrimidine synthesis, overproducing orotic acid.  
3. **Cerebral edema** and **seizures** result from ammonia neurotoxicity, exacerbated by **lethargy** and **drowsiness**.  
4. **Abnormal circulating ornithine concentration** aligns with OTCD pathophysiology, as ornithine is a substrate for the deficient OTC enzyme.  
5. **Hyperreflexia** and **sleep disturbances** reflect neurological dysfunction from hyperammonemia.  
6. **Death in childhood** is consistent with severe neonatal-onset OTCD if untreated.  
7. **Fever** may indicate metabolic decompensation triggered by catabolic stressors (e.g., infection), common in UCD crises.  

The absence of citrulline/arginine elevation and the presence of oroticaciduria distinguish OTCD from other UCDs (e.g., citrullinemia, arginase deficiency)."
"['Cyanosis', 'Seizure', 'Death in infancy', 'Bradycardia', 'Vomiting', 'Dicarboxylic aciduria', 'Neonatal death']",['3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency'],"Disease: 3-hydroxy-3-methylglutaric aciduria (HMG-CoA lyase deficiency)  
Reasoning:  
1. **Dicarboxylic aciduria**: A hallmark of impaired fatty acid β-oxidation and ketogenesis. HMG-CoA lyase deficiency disrupts leucine metabolism and ketone body synthesis, leading to urinary excretion of dicarboxylic acids.  
2. **Neonatal death/Death in infancy**: Severe metabolic crises (hypoketotic hypoglycemia, metabolic acidosis) triggered by fasting or catabolism are common in untreated infants.  
3. **Seizures**: Result from acute hypoglycemia and energy depletion in the brain.  
4. **Vomiting and Bradycardia**: Metabolic acidosis and electrolyte imbalances disrupt gastrointestinal and cardiac function.  
5. **Cyanosis**: Secondary to respiratory distress caused by acidosis or poor tissue oxygenation during metabolic decompensation.  
6. **Confirmatory biochemical markers**: Elevated 3-hydroxy-3-methylglutaric, 3-methylglutaconic, and 3-hydroxyisovaleric acids in urine organic acid analysis confirm the diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Severe short stature** and **abnormality of prenatal development** may occur in untreated maternal PKU, where high phenylalanine levels during pregnancy disrupt fetal growth.  
3. **Death in infancy/childhood/adolescence** aligns with untreated PKU, as toxic phenylalanine accumulation leads to irreversible neurological damage, seizures, and organ failure.  
4. **Recurrent viral infections** are atypical for classic PKU but could reflect secondary immunodeficiency due to chronic metabolic stress or malnutrition in severe cases.  
5. **Hypertyrosinemia** is unusual in isolated PKU (which typically lowers tyrosine), suggesting a possible comorbid tyrosinemia or BH4 deficiency (a PKU variant affecting both phenylalanine and tyrosine metabolism). However, hyperphenylalaninemia remains the primary diagnostic marker.  
6. Early mortality (**neonatal death**, **death in early adulthood**) underscores the critical need for newborn screening and dietary intervention to prevent complications.  

Note: Hypertyrosinemia may indicate an overlapping disorder (e.g., BH4 deficiency or tyrosinemia), but the dominant feature (hyperphenylalaninemia) strongly prioritizes PKU as the diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually low) but may occur in rare variants (e.g., PAH deficiency with secondary tyrosine dysregulation) or transient neonatal tyrosinemia overlapping with PKU.  
3. **Abnormality of prenatal development** aligns with maternal PKU syndrome, where elevated maternal phenylalanine crosses the placenta, causing fetal microcephaly, congenital heart defects, or growth restriction.  
4. **Neonatal death/Death in infancy** suggests severe, untreated PKU with acute metabolic crises (e.g., profound neurological toxicity, seizures) or comorbid complications (e.g., cardiac defects from maternal PKU).  
5. PKU is confirmed via newborn screening (elevated phenylalanine, low tyrosine), though rapid progression to neonatal demise implies extreme enzyme deficiency or delayed diagnosis.  
Note: Hypertyrosinemia warrants investigation for co-occurring disorders (e.g., tyrosinemia type II) but does not exclude PKU as the primary diagnosis."
"['Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Seizure', 'Generalized hypotonia', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating monocarboxylic acid concentration', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Neurological symptoms**: Delayed speech, hyperactivity, intellectual disability, and seizures align with SSADHD, a disorder disrupting GABA metabolism, leading to neurodevelopmental deficits.  
2. **Metabolic markers**: Decreased plasma free carnitine and elevated urinary carboxylic acids (e.g., 4-hydroxybutyric acid) are pathognomonic for SSADHD due to impaired GABA degradation.  
3. **Hypotonia and mortality**: Generalized hypotonia reflects neuromuscular dysfunction from metabolite accumulation. Early death, though rare, may occur in severe cases due to metabolic crises or refractory seizures.  
4. **Monocarboxylic acid abnormalities**: Elevated GHB (a monocarboxylic acid) in blood/urine directly results from succinic semialdehyde dehydrogenase enzyme deficiency.  
5. **Exclusion of mimics**: Symptoms collectively rule out other organic acidurias (e.g., glutaric aciduria) by specific biochemical profile (GHB elevation, carnitine depletion)."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, intrauterine metabolic stress from maternal-fetal interactions or placental insufficiency during fasting could contribute to subtle developmental anomalies.  
2. **Death in infancy/childhood and neonatal death**: MCADD causes life-threatening hypoglycemia and metabolic crises during fasting or illness. Undiagnosed cases lead to sudden mortality due to energy deficiency, hepatic dysfunction, or cardiac complications.  
3. **Gastrointestinal inflammation**: Metabolic crises in MCADD induce vomiting, diarrhea, and acidosis, triggering secondary gastrointestinal inflammation from toxic metabolite accumulation (e.g., medium-chain acylcarnitines).  
4. **Decreased plasma free carnitine**: MCADD traps carnitine as medium-chain acylcarnitines (e.g., octanoylcarnitine), reducing free carnitine levels. This reflects the body’s attempt to detoxify accumulating fatty acid intermediates.  
5. **Decreased 3-hydroxyacyl-CoA dehydrogenase (HADH) level**: Likely a misinterpretation or indirect effect. MCADD specifically involves medium-chain acyl-CoA dehydrogenase (ACADM) deficiency. HADH activity may appear reduced in assays due to overlapping substrate specificity or secondary mitochondrial dysfunction in severe crises.  

**Conclusion**: The constellation of early mortality, hypoketotic hypoglycemia risk, and biochemical findings align with MCADD, a fatty acid oxidation disorder requiring urgent dietary management to prevent catabolic crises."
"['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Pustule']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning: Hyperphenylalaninemia is the defining biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine-to-tyrosine conversion.  
Reasoning: Untreated PKU leads to toxic phenylalanine accumulation, resulting in severe neurological damage, developmental failure, and early mortality (death in infancy/childhood).  
Reasoning: Hypertyrosinemia is atypical in classic PKU but may indicate a co-occurring BH4 deficiency (a PKU variant), where impaired tyrosine hydroxylase activity disrupts tyrosine metabolism, causing its accumulation.  
Reasoning: Pustules could reflect secondary skin manifestations from tyrosine-derived metabolites or oxidative stress due to systemic metabolic dysfunction."
"['Microcephaly', 'Strabismus', 'Hypothyroidism', 'Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Constipation', 'Elevated circulating thyroid-stimulating hormone concentration', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Core biochemical marker of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability, seizures, microcephaly, motor delay**: Classic neurological consequences of untreated PKU due to phenylalanine neurotoxicity.  
3. **Death in infancy/childhood**: Occurs in severe, untreated cases from metabolic derangements and complications.  
4. **Strabismus/Constipation**: Secondary neurological/gastrointestinal effects of elevated phenylalanine.  
5. **Hypertyrosinemia discrepancy**: Unusual in PKU (typically low tyrosine), possibly reflects testing artifacts, dietary factors, or overlapping metabolic conditions (e.g., transient tyrosinemia in neonates).  
6. **Elevated TSH/hypothyroidism**: Likely coincidental or comorbid (e.g., congenital hypothyroidism), as PKU does not directly disrupt thyroid function.  

**Conclusion**: Dominant features (hyperphenylalaninemia, neurodevelopmental deficits) align with PKU. Atypical findings (hypertyrosinemia, hypothyroidism) warrant further investigation but do not override the primary diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts β-oxidation of medium-chain fatty acids, leading to secondary carnitine depletion. Excess unmetabolized acyl-CoA intermediates conjugate with carnitine, forming acylcarnitines excreted in urine, reducing free carnitine levels.  
2. **Neonatal death/Death in infancy**: MCADD typically manifests during metabolic stress (e.g., fasting, infection). Infants cannot generate ketones for energy, causing hypoketotic hypoglycemia, encephalopathy, and sudden death if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD does not directly cause structural birth defects, metabolic instability in utero (e.g., placental insufficiency from maternal metabolic stress) may contribute to prenatal complications.  
4. **Exclusion of alternatives**: Symptoms align with MCADD rather than other fatty acid oxidation disorders (e.g., VLCADD, LCHADD), which often involve cardiomyopathy or dysmorphic features absent here. Neonatal hypoglycemia and carnitine abnormalities are hallmark features of MCADD."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Abnormal foot morphology', 'Fever', 'Tachypnea', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: A hallmark of MCADD, as carnitine conjugates with unmetabolized medium-chain acyl-CoA derivatives, reducing free carnitine levels.  
2. **Metabolic instability in infancy/childhood**: Neonatal death, death in infancy, and childhood death align with MCADD's risk of fatal hypoglycemia and metabolic crisis during fasting or illness.  
3. **Acute symptoms (Fever, Tachypnea)**: Reflect metabolic decompensation, with tachypnea potentially secondary to metabolic acidosis.  
4. **Fatty acid oxidation defect**: MCADD impairs medium-chain fatty acid breakdown, leading to energy deficiency and toxic metabolite accumulation, especially under metabolic stress.  
5. **Prenatal/developmental abnormalities**: While less typical, prolonged intrauterine metabolic disturbances may contribute to developmental anomalies.  
6. **Exclusion of other disorders**: Symptoms prioritize MCADD over other fatty acid oxidation defects (e.g., VLCADD, LCHADD) due to medium-chain specificity and absence of cardiomyopathy/retinopathy.  
**Conclusion**: MCADD is the primary diagnosis, driven by carnitine deficiency, life-threatening metabolic crises, and hypoglycemia risk. Early recognition and fasting avoidance are critical to prevent mortality."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by mutations in the *PAH* gene, leading to deficient phenylalanine hydroxylase activity and impaired phenylalanine metabolism.  
2. **Abnormality of prenatal development or birth**: While PKU itself does not cause structural birth defects, untreated maternal PKU during pregnancy can result in congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus. The symptom may reflect complications from maternal hyperphenylalaninemia affecting prenatal development.  
3. **Neonatal death/Death in infancy/Death in adolescence**: Severe, untreated PKU causes progressive neurotoxicity due to phenylalanine accumulation. Early death may occur from acute metabolic crises, seizures, or irreversible neurological damage. In classic PKU, death in adolescence is rare with modern screening and dietary management, but historically, untreated cases led to fatal outcomes.  

The constellation of symptoms aligns with severe, undiagnosed/untreated PKU, exacerbated by maternal PKU effects if applicable. Confirmation requires genetic testing and phenylalanine level analysis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), leading to toxic accumulation of phenylalanine in the blood.  
2. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylketones (e.g., phenylpyruvate, phenyllactate), which are carboxylic acids excreted in urine.  
3. **Neonatal death/Death in infancy**: Untreated PKU results in severe neurological damage, seizures, and failure to thrive, often fatal in early life without dietary intervention.  
4. **Death in early adulthood**: Chronic complications (e.g., intellectual disability, behavioral issues, osteoporosis) in untreated individuals may reduce lifespan.  
5. **Abnormality of prenatal development**: Maternal PKU during pregnancy (if the mother is untreated) causes fetal exposure to high phenylalanine, leading to congenital anomalies (e.g., microcephaly, cardiac defects).  
6. **Hypertyrosinemia discrepancy**: Typically, PKU causes *low* tyrosine due to impaired PAH activity. This symptom may reflect a coexisting condition (e.g., tyrosinemia), laboratory error, or misreporting but does not exclude PKU as the primary diagnosis.  

Note: Hypertyrosinemia is atypical for PKU and warrants further investigation for overlapping metabolic disorders (e.g., BH4 deficiency or tyrosinemia), but the core symptoms align conclusively with PKU."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU, caused by a deficiency in phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine.  
2. **Hypertyrosinemia**: While classic PAH-deficient PKU typically results in normal/low tyrosine, this symptom suggests a **tetrahydrobiopterin (BH4) deficiency variant** of PKU. BH4 is a cofactor for PAH *and* tyrosine hydroxylase; its deficiency disrupts both phenylalanine and tyrosine metabolism, explaining the dual elevation.  
3. **Death in early adulthood**: Untreated PKU (especially severe forms or BH4 deficiency) leads to irreversible neurological damage, seizures, and organ dysfunction, contributing to reduced lifespan without early dietary or BH4 supplementation therapy.  

The diagnosis aligns with PKU, with hypertyrosinemia implicating a BH4-deficient subtype as the underlying mechanism."
"['Cardiomyopathy', 'Decreased plasma free carnitine', 'Death in adolescence', 'Abnormal circulating acetylcarnitine concentration']","['Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary']","Disease: Primary carnitine deficiency (PCD)  
Reasoning:  
1. **Decreased plasma free carnitine**: PCD is caused by mutations in the *SLC22A5* gene, impairing the high-affinity carnitine transporter (OCTN2). This results in renal carnitine wasting and systemic depletion.  
2. **Cardiomyopathy**: Carnitine is critical for fatty acid oxidation (FAO). Its deficiency forces cardiac myocytes to rely on glycolysis, leading to energy depletion, lipid accumulation, and progressive dilated/hypertrophic cardiomyopathy.  
3. **Abnormal circulating acetylcarnitine**: Disrupted carnitine metabolism alters acylcarnitine profiles. While total carnitine is low, acetylcarnitine (C2) may paradoxically rise due to compensatory mitochondrial acetyl-CoA accumulation or secondary FAO disturbances.  
4. **Death in adolescence**: Untreated PCD causes recurrent hypoglycemic/hypoketotic crises, arrhythmias, or heart failure. Mortality peaks in childhood/adolescence due to metabolic stress (e.g., fasting, illness) overwhelming residual FAO capacity.  
5. **Diagnostic confirmation**: PCD is distinguished from secondary carnitine deficiencies (e.g., organic acidemias) by genetic testing (*SLC22A5* mutations) and absence of other FAO disorders. Symptoms resolve with lifelong high-dose carnitine supplementation."
"['Intellectual disability', 'Obesity', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Abnormal vitamin B12 level', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Central to PKU, caused by deficient phenylalanine hydroxylase (PAH), impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability**: A hallmark of untreated PKU due to neurotoxic phenylalanine accumulation.  
3. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylketones (e.g., phenylpyruvate), excreted in urine as carboxylic acids.  
4. **Hypertyrosinemia discrepancy**: Unusual in classic PKU (tyrosine is typically low/normal). Potential explanations include dietary tyrosine intake, lab variability, or coexisting metabolic adjustments.  
5. **Abnormal vitamin B12 levels**: Likely linked to PKU dietary management (low-protein formulas may alter micronutrient balance).  
6. **Obesity**: Secondary to high-carbohydrate/low-protein PKU diets, promoting caloric excess.  

While hypertyrosinemia is atypical, core features (hyperphenylalaninemia, urinary metabolites, neurocognitive deficits) strongly align with PKU. Further testing (PAH activity, genetic analysis) would confirm the diagnosis."
"['Coma', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Hypothermia', 'Dyspnea', 'Opisthotonus', 'Cerebral edema', 'Tachypnea', 'Glycosuria', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Recurrent viral infections', 'Sepsis']","['Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to']","Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency), hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** is the hallmark of urea cycle disorders (UCDs). CPS1 deficiency disrupts the first step of the urea cycle, preventing ammonia detoxification.  
2. **Neurological symptoms** (coma, cerebral edema, opisthotonus) result from ammonia toxicity. Elevated ammonia disrupts astrocyte function, causing cerebral edema and brainstem compression (opisthotonus).  
3. **Metabolic acidosis** arises from secondary lactic acidosis due to mitochondrial dysfunction and anaerobic metabolism triggered by hyperammonemia.  
4. **Respiratory issues** (tachypnea, dyspnea) reflect compensatory hyperventilation to counteract acidosis.  
5. **Gastrointestinal symptoms** (vomiting, diarrhea) are nonspecific but common in UCDs due to metabolic stress.  
6. **Hypothermia** and **sepsis** may stem from metabolic instability impairing thermoregulation and immune function.  
7. **Prolonged partial thromboplastin time** suggests liver dysfunction, as CPS1 is hepatocyte-specific; impaired clotting factor synthesis exacerbates bleeding risk.  
8. **Glycosuria** may occur secondary to proximal renal tubular injury from metabolic acidosis.  
9. **Early lethality** (neonatal death, death in infancy) aligns with severe UCDs presenting acutely postpartum when protein intake begins.  
10. **Recurrent infections** could reflect catabolic crises during illness, worsening hyperammonemia, rather than primary immunodeficiency.  

CPS1 deficiency is distinguished from other UCDs by the absence of orotic aciduria (not tested here) and its autosomal recessive inheritance. The symptom constellation, particularly hyperammonemia with metabolic acidosis and rapid neonatal decline, strongly supports this diagnosis."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where elevated phenylalanine in an untreated pregnant woman with PKU causes congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus.  
3. **Hypertyrosinemia** may occur secondarily due to disrupted phenylalanine-tyrosine metabolism or overlap with tyrosinemia type II (rare), but PKU remains primary given the clinical context.  
4. **Early mortality (infancy, childhood, adolescence)** reflects untreated PKU complications: severe neurotoxicity (seizures, developmental delay), metabolic instability, and susceptibility to infections.  
5. Neonatal screening typically detects PKU, but lack of dietary intervention (low-phenylalanine diet) leads to progressive neurological deterioration and premature death.  

Note: Hypertyrosinemia is atypical in classic PKU but may arise in variant forms or coexisting metabolic disturbances. Maternal PKU explains prenatal abnormalities, while untreated PKU in the child drives hyperphenylalaninemia and fatal outcomes."
"['Abnormality of prenatal development or birth', 'Failure to thrive', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, severe metabolic disturbances in utero (e.g., maternal fasting-induced stress) may contribute to prenatal complications.  
2. **Failure to thrive**: Impaired fatty acid β-oxidation limits energy production during fasting, leading to poor weight gain and growth.  
3. **Neonatal death/Death in infancy/Death in childhood**: Untreated MCADD causes life-threatening hypoglycemia, hyperammonemia, and metabolic crises triggered by catabolic stress (e.g., infections, fasting).  
4. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs due to urinary loss of acylcarnitines (e.g., octanoylcarnitine), a hallmark of MCADD.  

Key biochemical link: MCADD disrupts medium-chain fatty acid oxidation, leading to toxic metabolite accumulation (e.g., medium-chain acylcarnitines), hypoglycemia, and energy deficiency, aligning with the clinical and metabolic features described."
"['Blindness', 'Motor delay', 'Hyperreflexia', 'Death in infancy', 'Opisthotonus', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Abnormal circulating aspartate family amino acid concentration**: Directly links to Canavan disease, a leukodystrophy caused by aspartoacylase deficiency, leading to elevated N-acetylaspartic acid (NAA).  
2. **Motor delay and hyperreflexia**: Reflects progressive white matter degeneration, causing spasticity and upper motor neuron dysfunction.  
3. **Blindness**: Optic nerve atrophy due to demyelination is common in Canavan disease.  
4. **Opisthotonus**: Severe neurological damage from toxic NAA accumulation leads to abnormal posturing.  
5. **Death in infancy**: While typically fatal in early childhood, severe infantile forms can result in earlier demise.  
6. **Exclusion of alternatives**: Symptoms align with Canavan’s biochemical profile (aspartate-related metabolic error), distinguishing it from other leukodystrophies or aminoacidopathies."
"['Carious teeth', 'Intellectual disability', 'Death in childhood', 'Hyperphenylalaninemia', 'Ichthyosis', 'Abnormal circulating tyrosine concentration', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability**: Untreated PKU leads to neurotoxic phenylalanine accumulation, disrupting myelination and neurotransmitter synthesis.  
3. **Abnormal circulating tyrosine concentration**: Low tyrosine levels occur due to blocked conversion from phenylalanine, aligning with PKU biochemistry.  
4. **Carious teeth**: High-phenylalanine diets (used historically) or sugary substitutes in managed diets increase caries risk.  
5. **Early mortality (childhood/adolescence)**: Severe untreated PKU causes progressive neurological damage, seizures, and organ failure, leading to premature death.  
6. **Ichthyosis**: Atypical for classic PKU but may reflect comorbid conditions, misdiagnosed eczema (common in PKU), or rare PKU variants with secondary metabolic disruptions affecting skin integrity.  

Note: While ichthyosis is not a core PKU feature, the remaining symptoms strongly support this diagnosis. Further testing (e.g., genetic analysis for PAH mutations, tetrahydrobiopterin deficiency exclusion) would refine the evaluation."
"['Hypospadias', 'Micropenis', 'Conjunctivitis', 'Large for gestational age', 'Death in infancy', 'Dehydration', 'Fever', 'Vomiting', 'Diarrhea', 'Hyperkalemia', 'Hyponatremia', 'Hypercalcemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Feeding difficulties', 'Occipital neuralgia', 'Increased serum testosterone level', 'Elevated circulating 17-hydroxyprogesterone concentration']","['Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency/Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency']","Disease: Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency  
**Reasoning**:  
1. **Steroidogenesis disruption**: The enzyme 3β-HSD2 is critical for converting Δ5 steroids (pregnenolone, 17-hydroxypregnenolone, DHEA) to Δ4 steroids (progesterone, 17-hydroxyprogesterone, androstenedione). Deficiency causes accumulation of Δ5 steroids (e.g., elevated 17-hydroxyprogesterone via alternative pathways) and reduced cortisol, aldosterone, and active sex hormones.  
2. **Adrenal insufficiency**: Low cortisol and aldosterone explain **dehydration**, **hyponatremia**, **hyperkalemia**, and **hypercalcemia** (due to volume depletion), leading to **vomiting**, **diarrhea**, **fever**, and life-threatening crises (contributing to **death in infancy/childhood**).  
3. **Ambiguous genitalia in males**: Impaired testosterone synthesis (from DHEA) results in **micropenis** and **hypospadias** due to insufficient androgen exposure in utero. Paradoxically, **elevated testosterone** may occur postnatally from peripheral conversion of accumulated DHEA.  
4. **Salt-wasting crisis**: Electrolyte imbalances and adrenal failure drive neonatal mortality (**neonatal death**) without prompt treatment.  
5. **Feeding difficulties**: Poor oral intake secondary to metabolic stress and adrenal crisis.  
6. **Recurrent infections**: Chronic dehydration and metabolic instability may predispose to infections; however, immune dysfunction is not a primary feature, making **conjunctivitis**/viral infections likely coincidental or stress-triggered.  
7. **Occipital neuralgia**: Unrelated to 3β-HSD2 deficiency; consider incidental or secondary to dehydration/electrolyte shifts.  
8. **Large for gestational age**: Uncommon in 3β-HSD2 deficiency but may reflect transient prenatal hormonal effects or confounding factors.  

**Key biochemical clues**: Elevated 17-hydroxyprogesterone (due to alternative pathway activation) and hyperkalemia/hyponatremia distinguish this from other CAH forms (e.g., 21-hydroxylase deficiency typically shows higher 17-OHP and no hyperkalemia). Confirmatory testing would show elevated Δ5 steroids (17-hydroxypregnenolone, DHEA) and genetic analysis of *HSD3B2*."
"['Hyperhidrosis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Death in infancy', 'Elevated circulating alkaline phosphatase concentration', 'Ethylmalonic aciduria', 'Hypertyrosinemia', 'Hyperalaninemia', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating carnitine concentration', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule', 'Abnormal circulating creatine kinase concentration']","['Short chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, short-chain, deficiency of']","Disease: Short chain acyl-CoA dehydrogenase deficiency (SCADD)  
Reasoning:  
1. **Ethylmalonic aciduria**: A hallmark of SCADD due to impaired short-chain fatty acid oxidation, leading to ethylmalonic acid accumulation.  
2. **Abnormal carnitine levels**: Secondary carnitine deficiency occurs as carnitine conjugates with unmetabolized acyl-CoA intermediates for excretion.  
3. **Hypertyrosinemia/Hyperalaninemia**: Disrupted mitochondrial energy metabolism may impair amino acid processing.  
4. **Elevated alkaline phosphatase**: Reflects hepatic stress or cholestasis, common in metabolic crises.  
5. **Generalized hypotonia/Neonatal death**: Results from energy deficiency in muscles/organs during metabolic decompensation.  
6. **Skin manifestations (rash, plaques)**: Toxic metabolite buildup may induce inflammatory skin reactions.  
7. **Hyperhidrosis**: Compensatory mechanism for thermoregulation during metabolic stress.  
8. **Abnormal CK levels**: Muscle breakdown from energy deficiency in myocytes.  
9. **Prenatal/Infantile lethality**: Severe SCADD manifests early due to critical dependence on fatty acid oxidation post-birth.  

The combination of ethylmalonic aciduria, carnitine abnormalities, and neonatal metabolic crisis aligns pathognomonically with SCADD."
"['Nephrotic syndrome', 'Tremor', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **L-2-hydroxyglutaric aciduria** is explicitly listed as a biochemical finding, confirming excessive excretion of L-2-hydroxyglutaric acid in urine, a hallmark of this disorder.  
2. **Tremor** aligns with the neurological manifestations of L-2-HGA, which include ataxia, dystonia, and seizures due to cerebral organic acid accumulation.  
3. **Death in childhood** reflects the severe, progressive nature of the disease, often linked to neurodegeneration, metabolic crises, or complications like respiratory failure.  
4. **Nephrotic syndrome**, though atypical for classic L-2-HGA, may arise secondary to metabolic toxicity or mitochondrial dysfunction affecting renal podocytes, or indicate an overlapping/atypical variant of the disorder.  
The diagnosis prioritizes the biochemical marker (aciduria) and core neurological features, with nephrotic syndrome interpreted as a rare or comorbid complication in this case."
"['Generalized hypotonia', 'Death in infancy', 'Weight loss', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Methylmalonic aciduria** is a cardinal biochemical marker of MMA, directly indicating impaired metabolism of methylmalonyl-CoA.  
2. **Hyperammonemia** and **increased serum lactate** arise due to disrupted urea cycle function and secondary mitochondrial dysfunction from toxic metabolite accumulation (methylmalonic acid, propionic acid).  
3. **Vomiting** and **weight loss** reflect metabolic decompensation triggered by catabolic stress (e.g., infections, fasting), common in organic acidemias.  
4. **Generalized hypotonia** results from energy deficiency in muscles/nerves and neurotoxicity of accumulated metabolites.  
5. **Death in infancy** aligns with the severe neonatal/early infantile presentation of MMA, often exacerbated by delayed diagnosis or metabolic crises.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. The **B12-unresponsive subtype** is confirmed by persistent methylmalonic aciduria despite adequate B12 levels, pointing to a defect in the mutase enzyme itself (MUT gene).  
2. **Severe clinical course** (death in infancy) correlates with complete loss of methylmalonyl-CoA mutase activity (mut⁰ mutation), leaving no residual enzyme function to alleviate metabolic blockades.  
3. **Hyperammonemia** and **lactic acidosis** are more pronounced in mutase deficiency compared to B12-responsive forms, as the metabolic block is irreversible without enzyme replacement.  
4. Absence of hematologic abnormalities (not listed in symptoms) further supports mutase deficiency over defects involving B12 metabolism (e.g., cblC), which often include megaloblastic anemia.  

Both diagnoses are consolidated by the triad of methylmalonic aciduria, life-threatening metabolic acidosis (lactate↑), and hyperammonemia in infancy, with subtype differentiation based on B12 responsiveness and genetic etiology."
"['Strabismus', 'Delayed speech and language development', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']",['L-2-hydroxyglutaric aciduria/L-2-hydroxyglutaric aciduria'],"Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Biochemical Marker**: The explicit mention of ""L-2-hydroxyglutaric aciduria"" indicates elevated L-2-hydroxyglutaric acid in urine or blood, a hallmark of this autosomal recessive neurometabolic disorder.  
2. **Neurological Symptoms**: Strabismus and delayed speech/language development align with the disease’s typical neurological manifestations, including cerebellar dysfunction, intellectual disability, and motor deficits caused by toxic metabolite accumulation.  
3. **Prognosis**: ""Death in childhood"" reflects the severe progression of untreated cases, often due to neurodegeneration, seizures, or complications like respiratory infections.  
4. **Exclusion of Mimics**: Symptoms are consistent with L-2-hydroxyglutaric aciduria and not other organic acidurias (e.g., D-2-hydroxyglutaric aciduria), as the specific biochemical marker and clinical course differentiate it.  
5. **Confirmatory Testing**: Genetic testing for mutations in *L2HGDH* or MRI findings (e.g., leukoencephalopathy, basal ganglia changes) would solidify the diagnosis."
"['Carious teeth', 'Intellectual disability', 'Tetany', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Hepatomegaly', 'Bone pain', 'Hypokalemia', 'Hypercholesterolemia', 'High serum calcitriol', 'Elevated circulating alkaline phosphatase concentration', 'Severe short stature', 'Death in childhood', 'Decreased plasma free carnitine', 'Death in adolescence']",['Fanconi-Bickel syndrome/Fanconi-Bickel syndrome'],"Disease: Fanconi-Bickel syndrome  
Reasoning:  
1. **Hepatomegaly**: Caused by glycogen accumulation in the liver due to GLUT2 transporter dysfunction.  
2. **Failure to thrive/Severe short stature**: Results from metabolic disturbances (impaired glucose/galactose utilization) and malabsorption.  
3. **Renal Fanconi syndrome features**:  
   - **Hypokalemia/Tetany**: Renal tubular wasting of potassium and electrolytes.  
   - **Bone pain/High serum calcitriol/Elevated alkaline phosphatase**: Hypophosphatemia from renal phosphate loss leads to rickets, compensatory calcitriol elevation, and bone turnover.  
4. **Hypercholesterolemia**: Hepatic dysfunction and altered lipid metabolism.  
5. **Decreased plasma free carnitine**: Secondary to renal losses or impaired synthesis.  
6. **Carious teeth**: Linked to chronic glycosuria promoting dental decay.  
7. **Generalized hypotonia**: Muscle weakness from electrolyte imbalances or carnitine deficiency.  
8. **Early mortality (infancy/childhood/adolescence)**: Reflects severe metabolic derangements and complications (e.g., liver failure, infections).  
9. **Intellectual disability**: Rare but possible due to chronic metabolic instability or hypoglycemic episodes affecting brain development.  
10. **Genetic basis**: Autosomal recessive SLC2A2 mutations confirm the diagnosis.  

The constellation of hepatic, renal, and metabolic abnormalities aligns pathognomonically with Fanconi-Bickel syndrome."
"['Hydrocephalus', 'Death in infancy', 'Anemia', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Decreased plasma free carnitine']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated glutaric acid and glutaric aciduria**: Directly linked to **glutaryl-CoA dehydrogenase deficiency**, the hallmark of GA-I, which disrupts lysine and tryptophan metabolism, causing toxic accumulation of glutaric acid.  
2. **Decreased plasma free carnitine**: Carnitine binds to glutaric acid to form glutarylcarnitine for excretion, depleting free carnitine.  
3. **Hydrocephalus/macrocephaly**: GA-I causes frontotemporal atrophy and subdural fluid collections, often mistaken for hydrocephalus. Metabolic crises may exacerbate cerebral edema.  
4. **Anemia**: Chronic metabolic stress or carnitine deficiency can impair erythropoiesis.  
5. **Death in infancy**: Untreated GA-I leads to severe encephalopathy, dystonia, and metabolic decompensation, often fatal early in life without dietary and carnitine therapy.  
The combination of biochemical findings (glutaric aciduria, low carnitine) and clinical features (neurological abnormalities, early mortality) confirms GA-I."
"['Abnormal saccadic eye movements', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in infancy', 'Thromboembolism', 'Neonatal death', 'Lipodystrophy', 'Abnormal skeletal morphology', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by impaired glycosylation affecting cerebellar development.  
2. **Generalized hypotonia**: Common in glycosylation disorders due to neuromuscular involvement.  
3. **Lipodystrophy**: Altered fat distribution linked to metabolic dysregulation from glycosylation defects.  
4. **Thromboembolism**: Coagulation factor deficiencies (e.g., antithrombin III) are frequent in PMM2-CDG.  
5. **Abnormal saccadic eye movements**: Reflects cerebellar/brainstem dysfunction.  
6. **Neonatal death/Death in infancy**: Severe forms of PMM2-CDG often lead to early mortality.  
7. **Abnormal skeletal morphology**: Dysostosis and growth retardation are recognized features.  
**Confirmatory evidence**: PMM2-CDG is the most prevalent CDG subtype, and this symptom cluster aligns with its multisystemic presentation (neurodevelopmental, hepatic, and coagulation abnormalities)."
"['Conjunctivitis', 'Photophobia', 'Hyperkeratosis', 'Intellectual disability', 'Seizure', 'Hypertyrosinemia', 'Death in childhood', 'Epiphora']",['Tyrosinemia type 2/Tyrosine transaminase deficiency'],"Disease: Tyrosinemia type 2 (Tyrosine transaminase deficiency)  
Reasoning:  
1. **Hypertyrosinemia**: Elevated tyrosine levels are a hallmark of tyrosinemia type 2 due to deficient tyrosine transaminase, which impairs tyrosine metabolism.  
2. **Ocular symptoms (conjunctivitis, photophobia, epiphora)**: Accumulated tyrosine forms crystalline deposits in the cornea, causing inflammation, light sensitivity, and excessive tearing.  
3. **Hyperkeratosis**: Tyrosine deposits in the skin lead to painful, palmoplantar hyperkeratosis.  
4. **Neurological manifestations (intellectual disability, seizures)**: Chronic tyrosine toxicity affects CNS development and function, causing cognitive deficits and seizures.  
5. **Death in childhood**: Untreated cases may result in severe metabolic derangements or progressive neurological damage, leading to early mortality.  
The combination of dermatologic, ocular, and neurologic symptoms with confirmed hypertyrosinemia strongly supports this diagnosis."
"['Petechiae', 'Seizure', 'Lethargy', 'Generalized hypotonia', 'Reduced tendon reflexes', 'Death in infancy', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Skeletal muscle atrophy', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Aplasia/Hypoplasia involving the musculature of the extremities']","['Mitochondrial complex IV deficiency, nuclear type 1']","Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Cytochrome C oxidase (COX)-negative muscle fibers**: A hallmark of complex IV deficiency, directly implicating dysfunction in mitochondrial respiratory chain complex IV.  
2. **Increased serum lactate and ethylmalonic aciduria**: Reflects impaired oxidative phosphorylation, leading to anaerobic metabolism and accumulation of toxic metabolites due to defective fatty acid/amino acid oxidation.  
3. **Neurological symptoms (seizures, lethargy, drowsiness)**: Result from energy deprivation in the brain, a high-energy-demand organ vulnerable to mitochondrial dysfunction.  
4. **Muscular involvement (hypotonia, reduced reflexes, atrophy, extremity musculature hypoplasia)**: Caused by deficient ATP production in skeletal muscle, leading to weakness, atrophy, and developmental defects.  
5. **Glutaric aciduria**: May arise secondary to disrupted mitochondrial metabolism, affecting organic acid pathways.  
6. **Death in infancy**: Consistent with severe infantile-onset forms of mitochondrial disorders due to multisystem energy failure.  
7. **Nuclear type 1 classification**: Indicates an autosomal recessive mutation (e.g., *SURF1* gene) affecting complex IV assembly, distinguishing it from mitochondrial DNA-related defects.  

This constellation of metabolic, muscular, and neurological findings, anchored by COX-negative fibers and elevated lactate/ethylmalonic acid, confirms the diagnosis."
"['Low-set ears', 'Nystagmus', 'Spasticity', 'Death in infancy', 'Dyspnea', 'Fair hair', 'High, narrow palate', 'Increased total bilirubin', 'Neonatal death', 'Stridor', 'White hair', 'Feeding difficulties', 'Fatigue']",['Glutathione synthetase deficiency'],"Disease: Glutathione synthetase deficiency  
Reasoning:  
1. **Increased total bilirubin**: Caused by hemolytic anemia, a hallmark of glutathione synthetase deficiency due to impaired antioxidant defense in red blood cells.  
2. **Neonatal death/Death in infancy**: Matches the severe, early-onset form of the disorder, often fatal without intervention.  
3. **Dyspnea/Stridor**: Results from metabolic acidosis-induced compensatory hyperventilation or respiratory muscle spasticity.  
4. **Spasticity/Nystagmus**: Reflects neurological damage from oxidative stress and 5-oxoprolinuria, secondary to glutathione deficiency.  
5. **Feeding difficulties/Fatigue**: Linked to metabolic instability, acidosis, and anemia impairing energy metabolism.  
6. **Fair/White hair**: Pigment dilution due to disrupted cysteine metabolism (cysteine is a glutathione precursor).  
7. **High, narrow palate/Low-set ears**: Congenital anomalies occasionally associated with inborn errors of metabolism.  
8. **Supporting exclusion**: Symptoms align with glutathione synthetase deficiency rather than similar disorders (e.g., Menkes syndrome lacks hemolysis, Crigler-Najjar lacks acidosis)."
"['Cystinuria', 'Argininuria', 'Abnormal circulating arginine concentration', 'Abnormal circulating citrulline concentration', 'Uraciluria']",['Arginase deficiency/Argininemia/Argininemia'],"Disease: Arginase deficiency/Argininemia  
Reasoning:  
1. **Argininuria and elevated circulating arginine**: Arginase deficiency disrupts the urea cycle, preventing the conversion of arginine to ornithine and urea. This results in arginine accumulation in the blood (abnormal circulating arginine) and its excretion in urine (argininuria).  
2. **Abnormal citrulline**: While citrulline levels are typically normal or mildly elevated in arginase deficiency, secondary metabolic disruptions or partial upstream urea cycle inhibition may explain the abnormal citrulline concentration.  
3. **Cystinuria**: High plasma arginine may competitively inhibit renal reabsorption of cystine (a dibasic amino acid), leading to its urinary excretion. This is a secondary effect of hyperargininemia.  
4. **Uraciluria**: Excess arginine can drive pyrimidine synthesis via alternative pathways, increasing orotic acid and uracil production, which is excreted in urine. This links to observed uraciluria despite it being more classically associated with other urea cycle disorders (e.g., OTC deficiency).  

The constellation of amino acid transport disturbances (cystinuria, argininuria) and metabolic byproducts (uraciluria) aligns with the primary pathology of arginase deficiency, where hyperargininemia drives multisystemic biochemical cascades."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU but may arise secondary to liver dysfunction or metabolic decompensation in severe untreated cases, though this is rare.  
3. **Abnormality of prenatal development/birth** aligns with maternal PKU syndrome if the mother had uncontrolled hyperphenylalaninemia during pregnancy, causing teratogenic effects (e.g., microcephaly, cardiac defects) in the fetus.  
4. **Neonatal death/Death in infancy** reflects untreated PKU severity, where toxic phenylalanine accumulation leads to irreversible neurological damage, seizures, and metabolic instability, often fatal without early dietary intervention.  
5. While PKU typically presents with **low tyrosine**, confounding factors (e.g., concurrent liver impairment, transient tyrosinemia of the newborn, or laboratory variability) may explain this anomaly. The core diagnostic marker remains hyperphenylalaninemia."
"['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine metabolism.  
2. **Untreated Severe PKU**: In classic PKU, complete PAH deficiency leads to rapid phenylalanine accumulation. Without early dietary intervention, toxic levels cause irreversible neurotoxicity, seizures, and failure to thrive.  
3. **Neonatal/Infant Death**: In unscreened or untreated cases, severe metabolic derangements (e.g., cerebral edema, metabolic crises) or complications like infections in neurologically compromised infants may result in neonatal death or death within the first year.  
4. **Diagnostic Link**: The triad of hyperphenylalaninemia, neonatal deterioration, and infant mortality aligns with untreated PKU, particularly in settings lacking newborn screening or access to phenylalanine-restricted diets."
"['Cerebellar atrophy', 'Death in childhood', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy and agenesis**: PMM2-CDG is associated with structural cerebellar abnormalities, including hypoplasia (often misinterpreted as agenesis on imaging) and progressive atrophy due to impaired glycosylation, critical for cerebellar development and maintenance.  
2. **Death in childhood**: Severe PMM2-CDG cases involve multi-organ failure (hepatic, cardiac), recurrent infections, and coagulopathies, leading to early mortality.  
3. **Neurological hallmark**: The cerebellum is highly sensitive to glycosylation defects, explaining both developmental (agenesis-like hypoplasia) and degenerative (atrophy) features.  
4. **Exclusion of mimics**: Pontocerebellar hypoplasia or spinocerebellar ataxias lack the systemic manifestations (e.g., endocrine dysfunction, inverted nipples) typical of PMM2-CDG.  
5. **Diagnostic confirmation**: Elevated serum transferrin isoforms (via isoelectric focusing) and *PMM2* gene sequencing would validate the diagnosis."
"['Lethargy', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Abnormal circulating ornithine concentration']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD diagnosis, as the urea cycle enzyme deficiency prevents ammonia detoxification.  
2. **Oroticaciduria**: Excess carbamoyl phosphate shunts into pyrimidine synthesis, producing orotic acid.  
3. **Hyperglutaminemia**: Secondary to ammonia accumulation, as glutamine synthesis increases to sequester excess ammonia.  
4. **Abnormal ornithine**: Reduced ornithine due to impaired conversion to citrulline in the urea cycle.  
5. **Neurological symptoms** (lethargy, drowsiness, vomiting, sleep disturbance): Caused by ammonia neurotoxicity.  
6. **Death in infancy**: Severe neonatal-onset OTCD leads to rapid metabolic decompensation without intervention.  
7. **X-linked inheritance**: Males typically present earlier and more severely, aligning with infant mortality risk.  

This constellation of urea cycle dysfunction, biochemical markers, and clinical presentation confirms OTCD."
"['Strabismus', 'Irritability', 'Hyporeflexia', 'Death in infancy', 'Hyperammonemia', 'Opisthotonus', 'Athetosis', 'Abnormal circulating aspartate family amino acid concentration']",['Canavan disease/Canavan disease'],"Disease: Canavan disease  
Reasoning:  
1. **Abnormal circulating aspartate family amino acid concentration**: Canavan disease is caused by ASPA gene mutations, leading to aspartoacylase deficiency. This enzyme breaks down N-acetylaspartate (NAA), resulting in elevated NAA levels, a hallmark biochemical marker.  
2. **Neurological symptoms (Strabismus, Opisthotonus, Athetosis)**: Accumulated NAA causes spongy brain degeneration, damaging white matter and motor pathways. Strabismus arises from cranial nerve dysfunction, while opisthotonus (severe hypertonia) and athetosis (involuntary movements) reflect basal ganglia and motor pathway injury.  
3. **Hyporeflexia**: Progressive white matter destruction impairs neural signaling, reducing reflex responses.  
4. **Irritability**: Early neurological deterioration in infants manifests as irritability due to cerebral dysfunction.  
5. **Death in infancy**: Severe infantile-onset Canavan disease rapidly progresses, with life expectancy rarely beyond childhood.  
6. **Hyperammonemia**: Though atypical, disrupted aspartate metabolism (linked to urea cycle intermediates) may secondarily elevate ammonia. This aligns with the abnormal aspartate family amino acids noted, suggesting metabolic crossover effects.  

Conclusion: The constellation of neurological deficits, biochemical abnormalities (elevated NAA), and early lethality strongly support Canavan disease. Hyperammonemia, while uncommon, may arise indirectly from metabolic dysregulation."
"['Generalized hypotonia', 'Reduced tendon reflexes', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Glutaric aciduria']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of glutaric acid accumulation in urine, confirming impaired glutaryl-CoA dehydrogenase activity.  
2. **Generalized hypotonia & reduced tendon reflexes**: Neurotoxic effects of glutaric acid and 3-hydroxyglutaric acid damage basal ganglia and white matter, causing motor deficits.  
3. **Fever, vomiting, diarrhea**: Metabolic decompensation triggered by catabolic stressors (e.g., infections), exacerbating toxic metabolite accumulation.  
4. **Death in infancy**: Untreated GA-I leads to acute encephalopathic crises with striatal necrosis, cerebral edema, or secondary complications (e.g., rhabdomyolysis).  
5. **Consistency with GA-I pathophysiology**: Autosomal recessive GCDH gene mutations disrupt lysine/hydroxylysine metabolism, producing neurotoxic dicarboxylic acids. Early-onset neurological and systemic features align with classic GA-I presentation."
"['Hyperactivity', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Ichthyosis', 'Death in adolescence', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline and hyperammonemia are hallmark biochemical features of citrullinemia, a urea cycle disorder caused by argininosuccinate synthetase deficiency. Neonatal death, death in infancy/childhood, and intellectual disability align with the severe metabolic decompensation and neurotoxicity from ammonia accumulation. Hyperactivity may reflect neurological irritation during hyperammonemic crises.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Classic citrullinemia (type I) specifically presents with life-threatening hyperammonemia in early life, consistent with neonatal death and death in infancy/childhood. Elevated citrulline directly confirms the enzymatic defect. Obesity and ichthyosis are atypical but may arise secondary to chronic metabolic derangements or comorbid nutritional interventions. The absence of citrin deficiency (type II) markers (e.g., adult-onset, cholestasis) further supports type I."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Neonatal death/Death in infancy/Death in childhood**: Untreated PKU results in severe neurological damage, seizures, and failure to thrive, historically causing early mortality without dietary intervention.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy) can cause congenital anomalies, though this is not a direct symptom of the patient’s PKU. The inclusion may reflect severe metabolic disruption or comorbid factors.  
4. **Gastrointestinal inflammation**: Less typical but possible in metabolic crises or secondary to protein-restricted diet complications (e.g., nutrient deficiencies).  

PKU is confirmed by elevated blood phenylalanine and genetic testing for PAH mutations. Early diagnosis and phenylalanine-restricted diet prevent severe outcomes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth**: Untreated maternal PKU during pregnancy can result in congenital anomalies (e.g., microcephaly, cardiac defects) due to phenylalanine toxicity to the developing fetus.  
3. **Death in infancy/childhood**: Severe, untreated PKU causes irreversible neurological damage, seizures, and failure to thrive. Historically, before newborn screening and dietary management, elevated phenylalanine levels led to early mortality.  
4. **Consistency with PKU**: The combination of hyperphenylalaninemia and severe outcomes aligns with classic PKU pathophysiology. Early diagnosis via newborn screening and strict dietary intervention prevent these complications."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative phenylalanine metabolism via transamination, a pathognomonic feature of PKU.  
3. **Neonatal death/Death in infancy/childhood** aligns with untreated PKU, where toxic phenylalanine levels cause irreversible neurotoxicity, seizures, and organ failure without dietary intervention.  
4. **Hypertyrosinemia** may seem atypical (PAH deficiency typically reduces tyrosine), but secondary tyrosine elevation can occur due to metabolic stress or overlapping enzyme disruptions in severe cases.  
5. **Abnormality of prenatal development** could reflect maternal PKU syndrome (untreated maternal hyperphenylalaninemia during pregnancy), causing fetal complications like microcephaly, though this is distinct from the infant’s own PKU diagnosis.  

Key confirmation: Hyperphenylalaninemia + phenylketonuria (via urinary carboxylic acids) are diagnostic for PKU. Early mortality underscores untreated disease severity."
"['Seizure', 'Coma', 'Fever', 'Vomiting', 'Tachypnea', 'Death in childhood', 'Hypervalinemia', 'Hyperisoleucinemia', 'Feeding difficulties']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Metabolic Abnormalities**: Hypervalinemia and hyperisoleucinemia indicate elevated branched-chain amino acids (BCAAs: valine, isoleucine, leucine), a hallmark of MSUD due to defective BCKD enzyme complex.  
2. **Neurological Symptoms**: Seizures, coma, and rapid neurological decline align with acute metabolic decompensation from toxic BCAA accumulation.  
3. **Systemic Manifestations**: Fever, vomiting, and tachypnea suggest metabolic acidosis and encephalopathy, common during crises.  
4. **Early Mortality**: Death in childhood is typical in untreated classical MSUD due to irreversible metabolic crises.  
5. **Feeding Difficulties**: Infants with MSUD struggle to tolerate protein intake, worsening BCAA accumulation.  
6. **Absence of Maple Syrup Odor Note**: While classic, this symptom may not always be reported or recognized, but biochemical findings confirm diagnosis."
"['Hydrocephalus', 'Seizure', 'Ataxia', 'Generalized hypotonia', 'Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']","['3-Methylcrotonyl-CoA carboxylase 1 deficiency', '3-methylcrotonyl-CoA carboxylase deficiency']","Disease: 3-Methylcrotonyl-CoA carboxylase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids** and **aminoaciduria** are hallmark features of 3-methylcrotonyl-CoA carboxylase (3-MCC) deficiency, caused by impaired leucine catabolism, leading to accumulation of 3-methylcrotonylglycine and 3-hydroxyisovaleric acid.  
2. **Seizures** and **ataxia** align with metabolic encephalopathy from toxic metabolite buildup.  
3. **Generalized hypotonia** and **neonatal death/death in infancy** reflect severe metabolic decompensation typical of untreated organic acidemias.  
4. **Abnormal circulating glycine concentration** may result from secondary mitochondrial dysfunction disrupting glycine metabolism.  
5. While **hydrocephalus** is atypical for 3-MCC deficiency, it could reflect a coincidental finding or severe cerebral edema secondary to metabolic crisis.  

Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning:  
- This is a subset of 3-MCC deficiency caused by mutations in the *MCCC1* gene (encoding the α-subunit of the enzyme). The reasoning above applies identically, as clinical features and biochemical markers (e.g., aminoaciduria, elevated carboxylic acids) are indistinguishable between *MCCC1* and *MCCC2* defects. The distinction is purely genetic.  

Note: The two listed diagnoses are clinically identical; the distinction lies in the affected gene (*MCCC1* vs. *MCCC2*). Both present with the described biochemical and neurological symptoms."
"['Spastic diplegia', 'Death in infancy', 'Spastic tetraplegia', 'Dark urine']",['Alkaptonuria/Alkaptonuria'],"Disease: Alkaptonuria  
Reasoning: While dark urine (due to homogentisic acid oxidation) is a hallmark of alkaptonuria, the neurological symptoms (spastic diplegia/tetraplegia) and early mortality are atypical. Alkaptonuria primarily manifests with ochronosis, arthritis, and cardiac complications in adulthood. The listed symptoms suggest a severe neurometabolic disorder (e.g., leukodystrophy, mitochondrial disease) rather than alkaptonuria. This mismatch highlights a potential error in the provided diagnosis."
"['Cryptorchidism', 'Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Abnormal erythrocyte morphology', 'Leukopenia', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Abnormal basal ganglia morphology', 'Hyperuricemia', 'Hyperglycinemia', 'Hepatomegaly', 'Difficulty walking', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Severe short stature', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Periventricular cysts', 'Difficulty running', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Methylmalonic aciduria', 'Abnormal myelination']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**: Methylmalonic acidemia (MMA) and methylmalonic aciduria are hallmarks of this disorder, directly indicating a defect in methylmalonyl-CoA mutase, the enzyme responsible for converting methylmalonyl-CoA to succinyl-CoA. Vitamin B12-unresponsiveness confirms mutations in the *MUT* gene encoding this enzyme.  
2. **Metabolic disturbances**: Metabolic acidosis, hyperammonemia, hypoglycemia, and hyperglycinemia arise due to disrupted propionate metabolism, leading to toxic accumulation of methylmalonic acid and secondary inhibition of multiple metabolic pathways (e.g., urea cycle dysfunction).  
3. **Hematologic abnormalities**: Leukopenia and abnormal erythrocyte morphology reflect bone marrow suppression caused by toxic metabolites.  
4. **Neurological involvement**: Generalized hypotonia, motor delays, intellectual disability, abnormal myelination, and periventricular cysts correlate with neurotoxic effects of methylmalonic acid and impaired energy metabolism in the basal ganglia.  
5. **Systemic complications**: Hepatomegaly, hypoproteinemia, and increased blood urea nitrogen result from hepatic/renal stress. Severe short stature and early mortality (infancy/childhood/adolescence) reflect chronic metabolic decompensation.  
6. **Exclusion of secondary causes**: Abnormal carnitine/porphyrin levels are secondary to mitochondrial dysfunction, not primary disorders. Hyperuricemia may stem from renal tubular damage.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Clinical confirmation**: Overlapping features (metabolic acidosis, hyperammonemia, methylmalonic aciduria) fulfill diagnostic criteria for MMA.  
2. **Phenotypic spectrum**: The inclusion of both neonatal death and death in adolescence aligns with MMA’s variable severity, depending on residual enzyme activity.  
3. **Supportive biomarkers**: Abnormal myelination, hypoglycemia, and hepatomegaly are consistent with long-term complications of MMA, even if not disease-specific.  
4. **Disease categorization**: This broader diagnosis encapsulates the genetic and biochemical heterogeneity of MMA, including subtypes beyond *MUT* mutations (e.g., cobalamin metabolism defects), though the B12-unresponsive subtype is prioritized here based on clinical severity.  

**Final Diagnosis**: The patient has **vitamin B12-unresponsive methylmalonic acidemia due to methylmalonyl-CoA mutase deficiency**, a severe form of MMA with poor prognosis, as evidenced by early lethality, metabolic instability, and neurological sequelae."
"['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Neonatal death', 'Elevated plasma citrulline']","['Citrullinemia', 'Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline and hyperammonemia strongly suggest a urea cycle disorder. Citrullinemia is characterized by impaired conversion of citrulline to argininosuccinate due to argininosuccinate synthetase (ASS1) deficiency. This results in citrulline accumulation and toxic ammonia buildup. Neonatal death and infant mortality align with the severe, early-onset form of the disease.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: The specificity of ""classic"" citrullinemia (type I) directly correlates with ASS1 deficiency. Premature birth may reflect intrauterine metabolic stress, while hyperammonemia and neonatal death are hallmarks of acute neonatal-onset cases. Elevated citrulline levels (>1,000 µmol/L) are pathognomonic for this subtype, distinguishing it from other urea cycle disorders or citrullinemia type II (citrin deficiency)."
"['Strabismus', 'Myopia', 'Delayed speech and language development', 'Ectopia lentis', 'Motor delay', 'Encephalopathy', 'Joint dislocation', 'Joint hypermobility', 'Hyperhomocystinemia', 'Cerebral edema', 'Clumsiness', 'Poor coordination', 'Hypermethioninemia', 'Aminoaciduria', 'Death in childhood', 'Death in adolescence']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Homocysteinemia; Homocystinuria  
Reasoning:  
1. **Hyperhomocystinemia** and **hypermethioninemia** are direct biochemical hallmarks of homocystinuria, caused by cystathionine beta-synthase (CBS) deficiency, impairing homocysteine metabolism.  
2. **Ectopia lentis** (lens dislocation) and **myopia** are classic ocular manifestations due to disrupted collagen cross-linking from elevated homocysteine.  
3. **Neurological features** (encephalopathy, cerebral edema, motor/speech delays, clumsiness, poor coordination) arise from homocysteine neurotoxicity and vascular injury.  
4. **Joint hypermobility/dislocation** reflects connective tissue abnormalities from defective cysteine synthesis.  
5. **Aminoaciduria** occurs secondary to renal tubular dysfunction caused by homocysteine accumulation.  
6. **Early mortality** (childhood/adolescence) aligns with untreated homocystinuria, often due to thromboembolic events or severe metabolic complications.  

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **CBS deficiency** is the most common cause of homocystinuria, confirmed by **hypermethioninemia** (methionine accumulates due to blocked transsulfuration pathway).  
2. **Systemic involvement** (ocular, skeletal, neurological) matches the multisystemic nature of CBS deficiency.  
3. Absence of methylmalonic acidemia or megaloblastic anemia excludes vitamin B12/folate metabolism disorders.  
4. **Autosomal recessive inheritance** aligns with typical CBS deficiency presentation.  
5. Symptoms correlate with severe, untreated cases, emphasizing the need for pyridoxine responsiveness testing and dietary methionine restriction as therapeutic interventions."
"['Abnormality of prenatal development or birth', 'Intellectual disability', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Intellectual disability** aligns with untreated PKU, as elevated phenylalanine levels are neurotoxic, impairing brain development.  
3. **Abnormality of prenatal development or birth** may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, though this is not a direct symptom of the patient’s own PKU.  
4. **Early mortality** (infancy, childhood, adolescence) is atypical in modern managed PKU but reflects historical untreated cases, where toxic metabolite accumulation caused severe neurological decline, seizures, and organ failure.  
5. The absence of dietary management (low-phenylalanine diet) explains progression to lethal outcomes, emphasizing the critical role of newborn screening and early intervention in PKU.  

Note: The listed symptoms collectively describe a severe, untreated PKU presentation, historically common before widespread neonatal screening and dietary therapy."
"['Lethargy', 'Death in infancy', 'Weight loss', 'Dehydration', 'Hyperammonemia', 'Pneumonia', 'Dyspnea', 'Opisthotonus', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Tachypnea', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Elevated urinary carboxylic acid']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, a urea cycle disorder impairing ammonia detoxification.  
2. **Oroticaciduria/Uraciluria**: Pathognomonic for OTCD; excess carbamoyl phosphate diverts to pyrimidine synthesis, producing orotic acid and uracil.  
3. **Neurological symptoms (cerebral edema, opisthotonus, drowsiness)**: Result from ammonia-induced neurotoxicity.  
4. **Early lethality (neonatal/infant/childhood death)**: Characteristic of severe urea cycle defects due to rapid metabolic decompensation.  
5. **Hyperglutaminemia/Hyperalaninemia**: Alternative nitrogen accumulation from impaired urea cycle.  
6. **Respiratory signs (tachypnea, dyspnea)**: Compensatory respiratory alkalosis to counteract acidosis from ammonia.  
7. **Elevated plasma citrulline discrepancy**: While atypical for OTCD (typically low citrulline), possible partial enzyme activity, analytical variability, or concurrent metabolic stressors may explain this finding.  
8. **Recurrent infections/GI inflammation**: Catabolic states and metabolic instability predispose to immune dysfunction and mucosal injury.  
9. **Abnormal amino acid/carnitine profiles**: Secondary to disrupted nitrogen metabolism and mitochondrial dysfunction.  

Key confirmatory features: Oroticaciduria + hyperammonemia + X-linked inheritance pattern (severe males), despite citrulline elevation, strongly prioritize OTCD over other urea cycle disorders."
"['Macrocephaly', 'Seizure', 'Death in infancy', 'Opisthotonus', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated glutaric acid**: The hallmark biochemical finding in GA-I is elevated circulating glutaric acid due to deficient glutaryl-CoA dehydrogenase enzyme activity, disrupting lysine and tryptophan metabolism.  
2. **Macrocephaly**: Characteristic frontotemporal atrophy with subdural fluid accumulation in infancy often leads to macrocephaly.  
3. **Neurological symptoms (Seizures, Opisthotonus)**: Accumulation of neurotoxic metabolites (glutaric acid, 3-hydroxyglutaric acid) damages basal ganglia, causing dystonia, seizures, and posturing (e.g., opisthotonus).  
4. **Glutaric aciduria**: Urinary excretion of glutaric acid is a diagnostic marker.  
5. **Early mortality**: Untreated GA-I causes metabolic crises triggered by catabolic stress (e.g., infections), leading to irreversible neurological damage, encephalopathy, and death in infancy/neonatal periods if severe.  
6. **Consistency with phenotype**: The combination of macrocephaly, dystonia, metabolic derangements, and rapid progression aligns definitively with GA-I."
"['Death in infancy', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Death in infancy/childhood**: MCADD disrupts fatty acid β-oxidation, causing hypoglycemia and metabolic crises during fasting. Infants/children are vulnerable due to limited glycogen stores, leading to life-threatening events if undiagnosed.  
2. **Recurrent viral infections**: Metabolic stress during infections (e.g., vomiting, reduced intake) exacerbates energy deficits, increasing risk of decompensation.  
3. **Abnormal circulating carnitine**: Secondary carnitine deficiency arises from conjugation of accumulated medium-chain acyl-CoA species, depleting free carnitine.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects a misstated lab finding; MCADD directly involves MCAD enzyme deficiency, not 3-hydroxyacyl-CoA dehydrogenase. This may indicate overlapping testing artifacts or pathway crosstalk.  

Key confirmation would include genetic testing for *ACADM* mutations and elevated C6-C10 acylcarnitines on tandem mass spectrometry."
"['Apathy', 'Cyanosis', 'Ataxia', 'Hyperreflexia', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Vomiting', 'Hypothermia', 'Hyperglycinemia', 'Methylmalonic acidemia', 'Decreased methylmalonyl-CoA mutase activity', 'Hyperalaninemia', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating arginine concentration', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Elevated plasma citrulline', 'Hyperornithinemia', 'Methylmalonic aciduria', 'Decreased circulating ferritin concentration', 'Dyskinesia']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Metabolic acidosis, hypoglycemia, vomiting, and hyperglycinemia** are hallmark features of methylmalonic acidemia (MMA), a disorder of branched-chain amino acid metabolism.  
2. **Methylmalonic acidemia/aciduria** directly indicates impaired methylmalonyl-CoA mutase function, critical for converting methylmalonyl-CoA to succinyl-CoA.  
3. **Decreased methylmalonyl-CoA mutase activity** confirms an enzymatic defect in this pathway.  
4. **Hypothermia, apathy, ataxia, dyskinesia, and hyperreflexia** reflect neurological toxicity from accumulating methylmalonic acid and other metabolites.  
5. **Abnormal carnitine levels** and **hypervalinemia/hyperalaninemia** suggest secondary disturbances in fatty acid and amino acid metabolism.  
6. **Death in infancy/childhood** aligns with severe, untreated MMA phenotypes.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Vitamin B12-unresponsiveness** is implied by **decreased methylmalonyl-CoA mutase activity** (direct enzyme defect) without features of B12 metabolism defects (e.g., homocystinuria).  
2. **Persistent metabolic acidosis, hyperglycinemia, and methylmalonic aciduria** despite B12 supplementation are diagnostic of this subtype.  
3. **Recurrent viral infections** and **abnormal arginine/citrulline/ornithine** levels may stem from secondary mitochondrial dysfunction or protein catabolism.  
4. **Decreased ferritin** could indicate oxidative stress or nutritional complications from chronic illness.  
5. **Neurological symptoms (ataxia, hyperreflexia)** correlate with basal ganglia injury seen in mutase-deficient MMA.  

Both diagnoses are consolidated under the primary disorder: **mutase-deficient MMA**, distinguished by B12-unresponsiveness and enzyme assay confirmation."
"['Macular degeneration', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Lethargy', 'Spasticity', 'Dystonia', 'Hyperreflexia', 'Growth delay', 'Death in infancy', 'Fever', 'Leukocytosis', 'Cerebral atrophy', 'Drowsiness', 'Sleep disturbance', 'Abnormal cerebral white matter morphology', 'Abnormality of limb bone morphology', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Paraplegia/paraparesis', 'Uraciluria']",['Dihydropyrimidine dehydrogenase deficiency/Dihydropyrimidine dehydrogenase deficiency'],"Disease: Dihydropyrimidine dehydrogenase deficiency (DPYD deficiency)  
Reasoning:  
1. **Metabolic hallmarks**: The presence of **uraciluria** and **abnormal circulating pyrimidine concentration** directly links to DPYD deficiency, as this enzyme is critical for pyrimidine catabolism. Deficiency causes accumulation of uracil, thymine, and their metabolites.  
2. **Neurological involvement**:  
   - **Seizures**, **spasticity**, **hyperreflexia**, **dystonia**, and **paraplegia/paraparesis** align with neurotoxicity from elevated pyrimidines and their derivatives (e.g., dihydropyrimidines).  
   - **Cerebral atrophy** and **abnormal cerebral white matter morphology** reflect progressive neurodegeneration due to metabolic dysfunction.  
3. **Developmental delays**: **Intellectual disability**, **delayed speech**, and **growth delay** are consistent with impaired neurodevelopment in severe metabolic disorders.  
4. **Systemic manifestations**: **Lethargy**, **drowsiness**, and **sleep disturbance** may arise from energy metabolism disruption. **Leukocytosis** and **fever** could indicate secondary infections or inflammatory responses triggered by metabolic stress.  
5. **Early mortality**: **Death in infancy/childhood** is typical in severe DPYD deficiency due to metabolic crises and neurological deterioration.  
6. **Bone abnormalities**: **Abnormality of limb bone morphology** is occasionally reported in metabolic disorders affecting nucleotide homeostasis.  

The combination of pyrimidine metabolism derangements (uraciluria), neurological deficits, and developmental delays strongly supports DPYD deficiency, distinguishing it from other neurometabolic disorders (e.g., mitochondrial diseases or leukodystrophies)."
"['Hearing impairment', 'Delayed speech and language development', 'Obesity', 'Death in infancy', 'Fever', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative phenylalanine metabolism, a key diagnostic feature of PKU.  
3. **Delayed speech and language development** and **hearing impairment** align with neurotoxic effects of phenylalanine accumulation in untreated PKU.  
4. **Severe short stature** and **obesity** may reflect metabolic dysregulation and dietary challenges in managing phenylalanine intake.  
5. **Hypertyrosinemia** is atypical for classic PKU but could suggest a comorbid condition, secondary metabolic disruption, or a variant (e.g., BH4-deficient PKU).  
6. **Neonatal death/Death in infancy/childhood/adolescence** might indicate severe, untreated PKU complications (e.g., neurodegeneration, metabolic crises) or a lethal variant (e.g., malignant PKU with dihydropteridine reductase deficiency).  
7. **Fever** could signal intercurrent infections exacerbated by metabolic instability.  
8. While other organic acidemias or tyrosinemias are considered, **hyperphenylalaninemia** and urinary phenylketones strongly prioritize PKU as the primary diagnosis."
"['Blindness', 'Osteoporosis', 'Ectopia lentis', 'Cardiomyopathy', 'Coronary artery atherosclerosis', 'Abnormal foot morphology', 'Pneumonia', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Hyperalaninemia', 'Abnormal vertebral morphology', 'Death in adolescence', 'Death in early adulthood']","['Homocysteinemia; Homocystinuria', 'Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency']","Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia and Hypermethioninemia**: Hallmark biochemical features of cystathionine beta-synthase (CBS) deficiency, as impaired CBS activity blocks homocysteine conversion to cystathionine, causing homocysteine and methionine accumulation.  
2. **Ectopia lentis**: A pathognomonic sign of classic homocystinuria due to defective collagen cross-linking from homocysteine accumulation, leading to lens dislocation.  
3. **Osteoporosis and Abnormal vertebral/foot morphology**: Homocysteine disrupts bone remodeling and connective tissue integrity, causing skeletal abnormalities.  
4. **Cardiomyopathy and Coronary artery atherosclerosis**: Chronic hyperhomocystinemia damages vascular endothelium, accelerating atherosclerosis and cardiac dysfunction.  
5. **Blindness**: Secondary to ectopia lentis complications (e.g., retinal detachment, glaucoma) or thromboembolic events affecting ocular vasculature.  
6. **Recurrent Pneumonia**: Skeletal chest deformities may impair respiratory function, predisposing to infections.  
7. **Early mortality**: Untreated CBS deficiency leads to thromboembolic events (stroke, myocardial infarction) or severe cardiovascular complications, often causing death in adolescence/early adulthood.  
8. **Hyperalaninemia**: May reflect secondary metabolic disturbances or concurrent stress-induced pyruvate elevation, though less specific to homocystinuria.  

Disease: Homocystinemia/Homocystinuria  
Reasoning:  
- This is a broader diagnostic category encompassing the CBS-deficient subtype. The reasoning aligns with the above, emphasizing the systemic effects of homocysteine toxicity across connective tissue, vascular, and skeletal systems."
"['Generalized hypotonia', 'Death in infancy', 'Neonatal death', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Methylmalonic aciduria is a cardinal biochemical marker of MMA, directly indicating impaired metabolism of methylmalonyl-CoA. Generalized hypotonia aligns with metabolic energy deficits in MMA, while neonatal death and death in infancy reflect the severe, early-onset phenotype of the disorder due to toxic metabolite accumulation and metabolic crises.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The B12-unresponsive subtype specifically implicates mutations in the *MUT* gene encoding methylmalonyl-CoA mutase. Neonatal lethality and lack of response to B12 supplementation distinguish this form from B12-responsive variants. The absence of improvement with B12 therapy exacerbates metabolic instability, leading to rapid clinical decline and early mortality."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur in **tetrahydrobiopterin (BH4) deficiency**, a PKU variant. BH4 is a cofactor for PAH *and* tyrosine hydroxylase; its deficiency disrupts both phenylalanine and tyrosine metabolism, leading to dual accumulation.  
3. **Death in early adulthood** aligns with severe, untreated PKU or BH4 deficiency, where neurological damage, metabolic crises, or secondary complications (e.g., cardiac, hepatic) lead to premature mortality.  
4. The combined symptoms suggest **malignant PKU (BH4 deficiency)**, classified under PKU spectrum disorders due to shared hyperphenylalaninemia and clinical overlap.  

Disease: BH4 Deficiency (as a subtype of PKU)  
Reasoning:  
1. Directly links elevated phenylalanine *and* tyrosine via dual enzyme disruption (PAH and tyrosine hydroxylase).  
2. Explains rapid progression and early mortality due to neurotransmitter synthesis defects and systemic metabolic failure.  
3. Often grouped with PKU in diagnostic frameworks despite distinct molecular pathology.  

**Final Diagnosis**: PKU (with BH4 deficiency as the underlying subtype)."
"['Microcephaly', 'Anteverted nares', 'Strabismus', 'Abnormality of the ear', 'Syndactyly', 'Ataxia', 'Coma', 'Motor delay', 'Death in infancy', 'Hypoglycemia', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Elevated 7-dehydrocholesterol']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
**Reasoning**:  
1. **Biochemical hallmarks**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol are pathognomonic for SLOS due to mutations in *DHCR7*, which disrupts cholesterol biosynthesis.  
2. **Hypocholesterolemia**: Low cholesterol levels align with the metabolic defect in SLOS.  
3. **Dysmorphic features**: Anteverted nares, syndactyly (classically 2nd-3rd toe), microcephaly, and ear abnormalities are consistent with SLOS-associated congenital malformations.  
4. **Neurological symptoms**: Ataxia, motor delay, and coma reflect severe neurological impairment from cholesterol deficiency, critical for myelination and brain development.  
5. **Poor prognosis**: Neonatal death, death in infancy/childhood, and recurrent infections (immune dysfunction linked to cholesterol deficiency) characterize severe SLOS phenotypes.  
6. **Hypoglycemia**: May arise due to adrenal insufficiency (cholesterol is a precursor for steroid hormones).  

The combination of dysmorphia, neurodevelopmental regression, and specific sterol abnormalities confirms SLOS."
"['Macrocephaly', 'Ataxia', 'Death in infancy', 'Dicarboxylic aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormality of movement']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated circulating glutaric acid concentration** and **dicarboxylic aciduria** are hallmark biochemical features of GA-I, caused by deficient glutaryl-CoA dehydrogenase activity.  
2. **Macrocephaly** is a common early sign due to abnormal brain development or subdural effusions.  
3. **Abnormality of movement** (e.g., dystonia, dyskinesia) and **ataxia** arise from striatal injury, particularly during metabolic crises triggered by catabolic stress.  
4. **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from binding to accumulating glutaric acid.  
5. **Death in infancy/childhood** and **neonatal death** reflect severe metabolic decompensation if untreated, often precipitated by intercurrent illnesses.  
6. Symptom progression aligns with GA-I’s natural history: acute encephalopathic crises in early childhood, leading to irreversible neurological damage or fatality without dietary and metabolic management."
"['Diabetes mellitus', 'Constipation', 'Impaired glucose tolerance']","['MODY', 'Maturity-onset diabetes of the young, type 1']","Disease: Maturity-onset diabetes of the young, type 1 (MODY1)  
Reasoning:  
1. **Diabetes mellitus and impaired glucose tolerance** align with MODY, a monogenic form of diabetes caused by autosomal dominant mutations (e.g., *HNF4A* in MODY1).  
2. MODY typically presents in non-obese adolescents/young adults with a strong family history of diabetes, distinguishing it from type 1 or type 2 diabetes.  
3. **Constipation** is atypical for MODY but may reflect secondary effects of hyperglycemia (e.g., autonomic neuropathy) or unrelated comorbidities.  
4. MODY1 specifically involves *HNF4A* mutations, which disrupt insulin secretion and may cause subtle extrapancreatic features (e.g., lipid abnormalities, renal Fanconi syndrome), though constipation is not a hallmark.  
5. Definitive diagnosis requires **genetic testing** for *HNF4A* variants. Early identification enables tailored therapy (e.g., sulfonylureas instead of insulin)."
"['Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Elevated hepatic transaminase', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Elevated hepatic transaminases and metabolic disturbances**: MCADD disrupts medium-chain fatty acid β-oxidation, leading to hepatic dysfunction and elevated transaminases during metabolic crises.  
2. **Abnormal amino acid/carnitine profiles**: Accumulation of toxic metabolites (e.g., medium-chain acylcarnitines) causes secondary carnitine deficiency and alters aspartate/alanine levels due to impaired energy metabolism and liver stress.  
3. **Neonatal/infant mortality**: Undiagnosed MCADD can trigger life-threatening hypoglycemia, metabolic acidosis, or liver failure during fasting, explaining neonatal death or death in infancy.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase activity**: Likely reflects secondary inhibition of mitochondrial β-oxidation enzymes due to metabolite overload (e.g., octanoyl-CoA), not a primary enzyme deficiency.  
5. **Skin manifestations**: Eczematoid dermatitis/rash may result from systemic inflammation or metabolic toxicity, though less specific to MCADD.  
6. **Prenatal abnormalities**: Not a core feature of MCADD but could reflect maternal metabolic stress or coincidental factors.  

Key diagnostic clues are the combination of fatty acid oxidation defects (carnitine/amino acid abnormalities), hepatic involvement, and critical metabolic decompensation in infancy. Confirmatory testing would include acylcarnitine profile (elevated C8-C10 species) and genetic analysis of *ACADM* gene variants."
"['Death in infancy', 'Ventricular septal defect', 'Cardiomyopathy', 'Leukocytosis', 'Vomiting', 'Respiratory distress', 'Hypoproteinemia', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Feeding difficulties', 'Increased circulating lactate dehydrogenase concentration']",['Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency/Glycogen storage disease type IXb'],"Disease: Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency/Glycogen storage disease type IXb  
Reasoning:  
1. **Metabolic Dysfunction**: The enzyme phosphorylase kinase deficiency impairs glycogen breakdown, leading to glycogen accumulation in the liver and muscles. This disrupts glucose release, causing metabolic crises (vomiting, feeding difficulties) and secondary stress responses (leukocytosis).  
2. **Hepatic Involvement**: Hypoproteinemia and abnormal porphyrin levels indicate liver dysfunction, as impaired hepatic glycogenolysis affects protein synthesis and heme metabolism.  
3. **Muscle/Cardiac Manifestations**: Deficiency in muscle phosphorylase kinase results in glycogen accumulation in cardiac tissue, explaining cardiomyopathy. Increased lactate dehydrogenase (LDH) reflects muscle damage and metabolic stress.  
4. **Respiratory Distress**: Likely due to metabolic acidosis from lactate accumulation or respiratory muscle weakness secondary to glycogen storage.  
5. **Amino Acid Abnormalities**: Altered aspartate family amino acids suggest disrupted liver metabolism, a secondary effect of chronic hepatic dysfunction.  
6. **Ventricular Septal Defect (VSD)**: While not a classic feature of GSD IXb, severe metabolic stress in infancy may exacerbate congenital cardiac anomalies or reflect a syndromic presentation.  
7. **Infant Mortality**: Severe metabolic and cardiac complications in infancy align with the rapid progression of untreated GSD IXb, particularly with multi-organ involvement.  

The constellation of hepatic, muscular, and metabolic symptoms, coupled with enzyme-specific pathophysiology, confirms Glycogen Storage Disease Type IXb."
"['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Death in childhood** aligns with untreated/severe PKU, as neurological damage and complications (e.g., seizures, intellectual disability) may result in early mortality without dietary intervention.  
3. **Hypertyrosinemia** is atypical in classical PKU (where tyrosine levels are usually low/normal due to blocked PAH activity). This may indicate:  
   - A concurrent condition (e.g., tyrosinemia type II) or metabolic overlap.  
   - Potential misreporting of symptoms (e.g., hypotyrosinemia expected in PKU).  
   - Rare variants or secondary metabolic disruptions (e.g., liver dysfunction).  

Final diagnosis prioritizes hyperphenylalaninemia and clinical severity, consistent with PKU, while acknowledging the atypical tyrosine elevation as a confounding factor requiring further investigation."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration** is a hallmark of MCADD, as secondary carnitine deficiency occurs due to impaired fatty acid oxidation and accumulation of toxic metabolites like medium-chain acylcarnitines.  
2. **Neonatal death** and **death in infancy/childhood** align with MCADD’s presentation, where metabolic crises (hypoketotic hypoglycemia) during fasting or illness lead to fatal outcomes if untreated.  
3. **Abnormality of prenatal development** may reflect intrauterine metabolic stress, though MCADD typically manifests postnatally.  
4. MCADD disrupts medium-chain fatty acid oxidation, depriving energy-critical organs (e.g., liver, brain) of fuel during fasting, consistent with the acute lethality described.  
5. The absence of neonatal screening (implied by early death) and delayed diagnosis exacerbates risks, explaining the fatal trajectory."
"['Spasticity', 'Death in infancy', 'Tachypnea', 'Decreased plasma free carnitine', 'Methylmalonic aciduria', 'Elevated urinary carboxylic acid', 'Elevated circulating acylcarnitine concentration']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits methylmalonic aciduria, elevated urinary carboxylic acid, and elevated circulating acylcarnitine, all hallmark biochemical features of MMA. Decreased plasma free carnitine occurs due to excessive conjugation with accumulating toxic metabolites. Spasticity and tachypnea reflect neurological and metabolic stress from acidemia, while death in infancy aligns with severe, early-onset forms of MMA.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specificity for this subtype is supported by the lack of vitamin B12 responsiveness implied in the diagnosis. Methylmalonyl-CoA mutase (MUT) deficiency disrupts the conversion of methylmalonyl-CoA to succinyl-CoA, causing metabolite accumulation. Elevated acylcarnitine (e.g., propionylcarnitine) and urinary methylmalonate confirm this enzyme defect. Early lethality and severe metabolic decompensation further distinguish the B12-unresponsive MUT-deficient form from milder or B12-responsive variants."
"['Intellectual disability', 'Seizure', 'Motor delay', 'Cerebellar atrophy', 'Obesity', 'Death in infancy', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by impaired glycosylation critical for cerebellar development.  
2. **Seizures & intellectual disability**: Result from global neurological dysfunction due to glycosylation defects affecting brain structure and signaling.  
3. **Motor delay**: Linked to cerebellar dysfunction and hypotonia, common in PMM2-CDG.  
4. **Obesity**: Observed in some surviving infants due to metabolic dysregulation from glycosylation errors.  
5. **Death in infancy**: Matches severe PMM2-CDG phenotypes, often from multi-organ failure (hepatic, cardiac) or infections.  
6. **Exclusion of mimics**: Symptoms align with PMM2-CDG over Joubert syndrome (lacks glycosylation markers) or Smith-Lemli-Opitz (distinct cholesterol pathway defects).  
7. **Diagnostic confirmation**: Requires phosphomannomutase 2 (PMM2) enzyme testing or genetic analysis for pathogenic variants."
"['Death in infancy', 'Increased serum lactate', 'Opisthotonus', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Severe hearing impairment']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Metabolic acidosis**: Elevated serum lactate aligns with impaired mitochondrial energy production due to deficient carboxylases (e.g., pyruvate carboxylase), a hallmark of BTDD.  
2. **Neurological manifestations**: Opisthotonus (severe hypertonia) and feeding difficulties suggest neurological dysfunction from accumulated toxic metabolites (e.g., lactate, ammonia) or disrupted neurotransmitter synthesis.  
3. **Amino acid abnormalities**: Abnormal aspartate family amino acids (e.g., elevated aspartate) and alanine stem from defective amino acid metabolism via biotin-dependent enzymes (e.g., propionyl-CoA carboxylase).  
4. **Hearing impairment**: Cochlear dysfunction due to chronic metabolic stress or oxidative damage is a recognized feature of untreated BTDD.  
5. **Infantile lethality**: Untreated BTDD causes progressive metabolic crises, leading to early death.  
6. **Diagnostic confirmation**: BTDD explains all symptoms under the umbrella of ""late-onset multiple carboxylase deficiency,"" where biotin recycling failure triggers multi-system dysfunction. Biotin supplementation reverses symptoms if initiated early."
"['Hip dysplasia', 'Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants or secondary metabolic disruptions (e.g., transient tyrosine elevation due to hepatic immaturity in premature infants).  
3. **Elevated urinary carboxylic acids** could reflect phenylalanine metabolites (e.g., phenylpyruvate) excreted in urine, misclassified as carboxylic acids.  
4. **Severe short stature** and **neonatal death** might indicate untreated or late-diagnosed PKU, leading to metabolic crises and growth failure.  
5. **Premature birth** and **hip dysplasia** are not directly linked to PKU but may coexist as unrelated complications or reflect syndromic forms (e.g., maternal PKU effects on fetal development).  
6. **Death in infancy/adolescence** aligns with severe metabolic derangements if phenylalanine-restricted diets are absent, causing neurodegeneration and multi-organ failure.  

*Note: Hypertyrosinemia and skeletal abnormalities (e.g., hip dysplasia) are atypical for PKU and suggest further investigation for coexisting disorders (e.g., tyrosinemia, skeletal dysplasias) or diagnostic inconsistencies.*"
"['Delayed speech and language development', 'Hyporeflexia', 'Generalized hypotonia', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Uraciluria']",['Dihydropyrimidinuria'],"Disease: Dihydropyrimidinuria  
Reasoning:  
1. **Uraciluria**: The presence of uracil in urine is a hallmark of dihydropyrimidinuria, caused by a deficiency in dihydropyrimidine dehydrogenase (DPD), which impairs pyrimidine catabolism.  
2. **Abnormal circulating pyrimidine concentration**: DPD deficiency leads to elevated levels of uracil and thymine in blood and urine due to blocked degradation.  
3. **Generalized hypotonia and hyporeflexia**: Accumulated pyrimidines may interfere with neuronal function or myelination, causing neuromuscular symptoms.  
4. **Delayed speech and language development**: Neurological dysfunction from metabolic disruption impacts cognitive and motor development.  
5. **Death in childhood**: Severe metabolic crises or complications (e.g., seizures, respiratory failure) in untreated cases lead to early mortality.  
6. **Exclusion of other disorders**: Symptoms align specifically with pyrimidine metabolism defects, ruling out mimics like orotic aciduria (which features orotic aciduria, not uraciluria)."
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Cardiomyopathy', 'Hypoglycemia', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Myopathy', 'Decreased plasma free carnitine', 'Abnormal circulating acetylcarnitine concentration']",['Very long chain acyl-CoA dehydrogenasedeficiency; VLCADD/Very long chain acyl-CoA dehydrogenase deficiency/Very long-chain acyl-CoA dehydrogenase deficiency'],"Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Hypoglycemia & Hepatomegaly**: VLCADD disrupts mitochondrial β-oxidation of very long-chain fatty acids, impairing energy production during fasting. This causes hypoglycemia (due to reliance on glucose without ketone alternatives) and hepatomegaly (fatty acid accumulation in the liver).  
2. **Cardiomyopathy & Myopathy**: Cardiac and skeletal muscles depend on fatty acid oxidation for energy. Enzyme deficiency leads to toxic metabolite buildup (e.g., long-chain acylcarnitines), causing cardiomyopathy and muscle weakness.  
3. **Decreased Plasma Free Carnitine & Abnormal Acetylcarnitine**: Carnitine conjugates with unmetabolized fatty acids, reducing free carnitine. Elevated very long-chain acylcarnitines (e.g., C14:1, C14, C16:1) are diagnostic biomarkers.  
4. **Lethargy, Drowsiness, Hypotonia**: Energy deficiency in muscles and the central nervous system explains hypotonia and neurological symptoms.  
5. **Death in Infancy**: Severe phenotypes present early with metabolic crises, cardiac dysfunction, or liver failure, often fatal without dietary intervention (avoidance of fasting, low-fat/high-carbohydrate diet, and medium-chain triglyceride supplementation).  
6. **Sleep Disturbance**: May reflect metabolic instability during prolonged fasting (e.g., overnight), triggering hypoglycemia or acidosis.  
The clinical and biochemical profile aligns with VLCADD, confirmed by genetic testing of *ACADVL* and acylcarnitine analysis."
"['Obesity', 'Death in infancy', 'Neutropenia', 'Hyperuricemia', 'Increased serum lactate', 'Hepatomegaly', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Pustule']",['Glycogen storage disease Ib/Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib/Glycogen storage disease Ib'],"Disease: Glycogen storage disease Ib  
Reasoning:  
1. **Hepatomegaly and metabolic abnormalities**: GSD Ib involves a defect in the glucose-6-phosphate transporter (G6PT), impairing gluconeogenesis and glycogenolysis. This leads to hepatomegaly, lactic acidosis (increased serum lactate), and hyperuricemia due to metabolic byproduct accumulation.  
2. **Neutropenia and recurrent infections**: GSD Ib uniquely causes chronic neutropenia and neutrophil dysfunction, explaining recurrent viral infections and pustules (e.g., from bacterial/fungal skin infections).  
3. **Abnormal amino acid concentrations**: Disrupted glucose metabolism alters the alanine-aspartate shuttle, leading to abnormal circulating alanine and aspartate family amino acids.  
4. **Early mortality**: Severe metabolic crises (hypoglycemia, acidosis) and infections contribute to neonatal death, infant/childhood mortality.  
5. **Obesity paradox**: Despite failure to thrive in some cases, metabolic dysregulation and high-calorie dietary management may lead to abnormal fat distribution.  

The combination of liver dysfunction, neutropenia, and characteristic metabolic derangements distinguishes GSD Ib from GSD Ia and other glycogenoses."
"['Abnormal saccadic eye movements', 'Cyanosis', 'Seizure', 'Death in infancy', 'Vomiting', 'Abnormal cerebral morphology', 'Dyspnea', 'Glutaric aciduria', 'Feeding difficulties']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of glutaric acid accumulation, pathognomonic for GA-I due to **glutaryl-CoA dehydrogenase deficiency**.  
2. **Abnormal cerebral morphology**: Macrocephaly and striatal degeneration (e.g., basal ganglia atrophy) are hallmark neuroimaging findings in GA-I.  
3. **Seizures & abnormal saccadic eye movements**: Result from acute or chronic neurotoxicity caused by glutaric acid and 3-hydroxyglutaric acid, damaging neurons and disrupting neurotransmission.  
4. **Feeding difficulties & vomiting**: Common early signs of metabolic decompensation triggered by catabolic stress (e.g., infections, fasting).  
5. **Dyspnea & cyanosis**: May arise during metabolic crises due to acidosis or secondary respiratory complications from encephalopathy.  
6. **Death in infancy**: Untreated GA-I often leads to severe neurological injury or fatal metabolic crises in early life, consistent with the natural history of the disease.  
The combination of **neurodevelopmental regression**, **organic aciduria**, and **characteristic neuroimaging** strongly confirms GA-I. Early diagnosis is critical to prevent irreversible damage via dietary management (lysine/tryptophan restriction) and emergency protocols during metabolic stress."
"['Abnormality of the kidney', 'Hypertension', 'Seizure', 'Coma', 'Death in infancy', 'Cardiomyopathy', 'Thrombocytopenia', 'Leukopenia', 'Anemia', 'Leukocytosis', 'Hyperammonemia', 'Vomiting', 'Hyperuricemia', 'Increased serum lactate', 'Hyperproteinemia', 'Hyperkalemia', 'Hyperglycinemia', 'Hypertriglyceridemia', 'Skeletal dysplasia', 'Tachypnea', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Hypercholesterolemia', 'Increased blood urea nitrogen', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating parathyroid hormone level', 'Decreased methylmalonyl-CoA mutase activity', 'Hypernatremia', 'Hypermethioninemia', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Elevated systolic blood pressure', 'Elevated diastolic blood pressure', 'Abnormal circulating porphyrin concentration', 'Hyperhistidinemia', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Feeding difficulties', 'Hyperornithinemia', 'Methylmalonic aciduria', 'Death in early adulthood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**:  
   - **Methylmalonic acidemia/aciduria** and **decreased methylmalonyl-CoA mutase activity** directly confirm a defect in the methylmalonyl-CoA mutase enzyme, critical for propionate metabolism.  
   - **Hyperammonemia**, **hyperuricemia**, **elevated lactate**, and **hyperglycinemia** reflect secondary metabolic disruptions from toxic metabolite accumulation.  

2. **Acute decompensation features**:  
   - **Seizures**, **coma**, **vomiting**, **tachypnea**, and **feeding difficulties** align with metabolic crises triggered by catabolic stress (e.g., infections, fasting).  
   - **Hyperkalemia**, **hypernatremia**, and **elevated blood urea nitrogen/creatinine** indicate renal dysfunction, a known complication of chronic methylmalonic acid toxicity.  

3. **Chronic multisystem involvement**:  
   - **Cardiomyopathy** and **hypertension** arise from metabolic stress and renal failure.  
   - **Skeletal dysplasia** and **severe short stature** result from chronic acidosis impairing bone mineralization.  
   - **Hematologic abnormalities** (anemia, leukopenia, thrombocytopenia) stem from bone marrow suppression by methylmalonic acid.  

4. **Early mortality**:  
   - **Neonatal death**, **death in infancy/childhood/adolescence**, and **death in early adulthood** reflect the severity of B12-unresponsive MMA, often fatal without aggressive management (dialysis, transplantation).  

5. **Supporting metabolic derangements**:  
   - **Abnormal carnitine**, **hypertriglyceridemia**, and **elevated citrulline/ornithine** highlight disrupted mitochondrial metabolism and urea cycle stress.  
   - **Elevated alkaline phosphatase/PTH** correlate with renal osteodystrophy from chronic kidney disease.  

This constellation of findings conclusively points to **methylmalonyl-CoA mutase deficiency**, a B12-unresponsive form of MMA, explaining both acute crises and progressive organ damage."
"['Ptosis', 'Delayed speech and language development', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Abnormal foot morphology', 'High, narrow palate', 'Elevated 8-dehydrocholesterol', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Death in adolescence']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Elevated 7-dehydrocholesterol and 8-dehydrocholesterol**: Pathognomonic biochemical markers of Smith-Lemli-Opitz syndrome (SLOS), caused by a deficiency in 7-dehydrocholesterol reductase, which disrupts cholesterol synthesis.  
2. **Syndactyly and abnormal foot morphology**: Classic physical features of SLOS, particularly 2-3 toe syndactyly and/or clubfoot.  
3. **Developmental delays (speech, motor, intellectual) and hypotonia**: Neurological manifestations due to impaired cholesterol-dependent myelination and synaptic function.  
4. **High, narrow palate and ptosis**: Common craniofacial dysmorphisms in SLOS.  
5. **Early mortality (infancy/childhood/adolescence)**: Severe forms of SLOS are associated with life-threatening malformations (e.g., cardiac, pulmonary) or metabolic instability.  
6. **Generalized hypotonia**: Reflects both neurological dysfunction and potential structural abnormalities (e.g., poor muscle development).  
The combination of sterol abnormalities, syndactyly, neurodevelopmental deficits, and dysmorphic features confirms SLOS."
"['Kernicterus', 'Obesity', 'Death in infancy', 'Fever', 'Hypertyrosinemia', 'Neonatal death', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning: The patient exhibits **hyperphenylalaninemia**, a hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation. While PKU classically presents with intellectual disability, seizures, and musty odor, severe untreated cases can result in **neonatal death** or **death in adolescence** due to profound neurological damage. **Obesity** may arise from a high-carbohydrate, low-protein diet used to manage PKU. However, **hypertyrosinemia** and **elevated urinary carboxylic acids** are atypical for PKU and suggest a coexisting metabolic disorder (e.g., tyrosinemia or organic acidemia). **Kernicterus** (bilirubin encephalopathy) and **recurrent infections** are not directly linked to PKU and may indicate additional hepatic or immune dysfunction. Further testing (e.g., BH4 responsiveness, tyrosine metabolites, urinary organic acids) is critical to address these inconsistencies."
"['Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Dicarboxylic aciduria']","['Mitochondrial complex IV deficiency, nuclear type 1']","Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Seizures**: Result from impaired mitochondrial energy production in the brain, causing neuronal hyperexcitability due to ATP deficiency.  
2. **Motor delay and generalized hypotonia**: Caused by defective oxidative phosphorylation in skeletal muscles, leading to weakness and delayed motor milestones.  
3. **Death in infancy**: Severe forms of complex IV deficiency (e.g., SURF1-related Leigh syndrome) cause rapid neurodegeneration and metabolic crises, often fatal within the first years of life.  
4. **Dicarboxylic aciduria**: Secondary to inefficient fatty acid β-oxidation, as mitochondrial dysfunction forces reliance on alternative energy pathways, producing dicarboxylic acids.  
5. **Complex IV (cytochrome c oxidase) deficiency**: Confirmed by biochemical findings (e.g., elevated lactate, reduced enzyme activity) and genetic variants in nuclear genes (e.g., SURF1) critical for complex IV assembly.  
This constellation aligns with nuclear-encoded mitochondrial complex IV deficiency type 1, typically presenting with Leigh-like symptoms and metabolic derangements."
"['Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity', 'Death in childhood']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Metabolic acidosis is a hallmark of methylmalonic acidemia (MMA), as impaired methylmalonyl-CoA mutase activity disrupts propionate metabolism, leading to toxic accumulation of methylmalonic acid. The clinical severity (death in childhood) aligns with acute or neonatal-onset MMA, which often presents with life-threatening metabolic decompensation.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: Decreased methylmalonyl-CoA mutase activity directly indicates a defect in the MUT gene, which encodes this enzyme. This subtype is vitamin B12-unresponsive because the mutation affects the enzyme itself, not its cofactor (adenosylcobalamin, derived from vitamin B12). Early mortality underscores the severe biochemical dysfunction caused by the enzyme deficiency."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to accumulation of toxic metabolites (e.g., medium-chain acylcarnitines). Carnitine becomes sequestered as these conjugates, causing secondary carnitine deficiency.  
2. **Gastrointestinal inflammation**: Metabolic crises in MCADD induce vomiting, diarrhea, and hepatic dysfunction, mimicking gastrointestinal inflammation.  
3. **Neonatal/infant/childhood death**: Untreated MCADD causes life-threatening hypoglycemia, encephalopathy, and multiorgan failure during fasting or illness, often fatal in early life without prompt diagnosis.  
4. **Prenatal abnormalities**: While MCADD typically manifests postnatally, severe intrauterine metabolic stress (e.g., maternal fasting) might theoretically contribute to growth abnormalities.  
5. **Exclusion of alternatives**: Symptoms align with MCADD over other fatty acid oxidation disorders (e.g., VLCAD, LCHAD) due to the absence of cardiomyopathy or retinopathy and the specific carnitine profile."
"['Lethargy', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria']","['Ornithine transcarbamylase deficiency; OTCD/Ornithine transcarbamylase deficiency/Ornithine transcarbamylase deficiency, hyperammonemia due to']","Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** indicates a urea cycle disorder, as ammonia detoxification relies on this pathway.  
2. **Oroticaciduria** is pathognomonic for OTCD. Excess carbamoyl phosphate (due to OTC enzyme deficiency) diverts to pyrimidine synthesis, overproducing orotic acid.  
3. **Neurological symptoms** (lethargy, drowsiness, sleep disturbances, vomiting) align with ammonia toxicity affecting the central nervous system.  
4. **Death in infancy** suggests a severe, early-onset presentation typical of male hemizygotes in X-linked OTCD.  
5. Exclusion of other urea cycle disorders (e.g., citrullinemia, argininosuccinic aciduria) due to the absence of their specific biochemical markers (e.g., elevated citrulline) and the presence of oroticaciduria."
"['Death in infancy', 'Increased susceptibility to fractures', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Death in adolescence', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark symptom of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormal circulating tyrosine concentration** occurs because PAH converts phenylalanine to tyrosine; its deficiency reduces tyrosine synthesis, explaining low or dysregulated tyrosine levels.  
3. **Early mortality** (infancy, childhood, adolescence, etc.) aligns with untreated/severe PKU, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
4. **Increased susceptibility to fractures** may arise secondary to chronic metabolic derangements, poor bone mineralization, or mobility issues from neurological complications.  
5. Neonatal death is atypical in classical PKU but could indicate rare malignant variants or delayed diagnosis, exacerbating metabolic crises.  

While fractures are not a primary feature of PKU, they may reflect systemic complications of prolonged untreated disease. The combination of hyperphenylalaninemia and tyrosine abnormalities strongly prioritizes PKU over other metabolic disorders (e.g., tyrosinemia)."
"['Atypical behavior', 'Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Death in infancy', 'Death in childhood', 'Abnormality of galactoside metabolism']","['Galactosemia; GAL/Galactosemia', 'Classic galactosemia/GALACTOSEMIA']","Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient's abnormality of galactoside metabolism directly indicates a defect in galactose processing, a hallmark of galactosemia. Classic galactosemia (GALT deficiency) causes toxic accumulation of galactose metabolites, leading to intellectual disability, delayed speech, and neurobehavioral symptoms (hyperactivity, atypical behavior). Untreated, severe metabolic derangements (e.g., liver failure, sepsis) result in early mortality (infancy/childhood). These findings align with the clinical and biochemical profile of classic galactosemia.  "
"['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, leading to phenylalanine accumulation.  
2. **Delayed speech and language development** aligns with untreated PKU, as elevated phenylalanine disrupts myelination and neurotransmitter synthesis, impairing neurodevelopment.  
3. **Abnormality of prenatal development or birth** may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing congenital anomalies (e.g., microcephaly, cardiac defects) in the infant.  
4. **Neonatal death/Death in infancy/childhood** correlates with severe untreated PKU variants (e.g., malignant PKU) or delayed diagnosis, where toxic phenylalanine levels cause irreversible neurological damage or metabolic crises.  
5. **Hypertyrosinemia** is atypical in classic PKU but may arise in rare PAH deficiency variants or secondary metabolic disruptions (e.g., transient tyrosine elevation during metabolic stress).  

PKU explains the core symptom (hyperphenylalaninemia) and associated complications, while hypertyrosinemia warrants further investigation for co-occurring disorders or metabolic instability. Early dietary management (phenylalanine restriction) is critical to prevent adverse outcomes."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids. Unmetabolized fatty acids conjugate with carnitine, forming acylcarnitines excreted in urine, leading to secondary carnitine deficiency.  
2. **Neonatal death/Death in infancy/childhood**: MCADD causes metabolic crises triggered by fasting (e.g., prolonged sleep, illness). Hypoketotic hypoglycemia, hyperammonemia, and toxic metabolite accumulation (e.g., octanoylcarnitine) result in encephalopathy, seizures, and sudden death if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD primarily manifests postnatally, severe fetal metabolic stress or maternal fatty acid metabolism disturbances during pregnancy may contribute to subtle prenatal complications (e.g., intrauterine growth restriction).  
4. **Diagnostic confirmation**: Newborn screening detects elevated medium-chain acylcarnitines (C6-C10). Genetic testing identifies *ACADM* gene mutations, confirming MCADD. Early intervention (avoiding fasting, glucose supplementation) prevents mortality."
"['Coma', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Fever', 'Vomiting', 'Diarrhea', 'Increased serum lactate', 'Ketonuria', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid', 'Pustule']",['β-ketothiolase deficiency; BKD; Mitochondrial acetoacetyl-CoA thiolase [3-oxothiolase] deficiency/Beta-ketothiolase deficiency/Alpha-Methylacetoacetic aciduria'],"Disease: β-Ketothiolase Deficiency (Beta-ketothiolase deficiency)  
Reasoning:  
1. **Metabolic acidosis, hypoglycemia, and increased serum lactate**: Indicate a defect in mitochondrial energy metabolism, specifically in ketone body utilization and isoleucine catabolism, which are impaired in β-ketothiolase deficiency (BKD).  
2. **Ketonuria and elevated urinary carboxylic acids**: Result from the accumulation of ketones (acetoacetate, 3-hydroxybutyrate) and toxic metabolites like α-methylacetoacetate due to deficient mitochondrial acetoacetyl-CoA thiolase activity.  
3. **Abnormal circulating glycine and carnitine concentrations**: Secondary to metabolic decompensation; carnitine depletion occurs as it conjugates with toxic acyl-CoA intermediates for excretion.  
4. **Vomiting, diarrhea, and fever**: Common triggers of metabolic crises in BKD, often precipitated by infections or fasting, leading to catabolism and acute intoxication.  
5. **Coma and early mortality (infancy/childhood)**: Reflect severe metabolic derangements during crises, including hyperammonemia, cerebral edema, or energy failure.  
6. **Pustules**: May arise from secondary infections during catabolic stress or metabolic toxicity affecting immune responses.  
7. **Genetic confirmation**: Definitive diagnosis requires identification of *ACAT1* gene mutations or enzyme assay showing reduced thiolase activity.  

The constellation of episodic ketoacidosis, ketonuria, and characteristic organic aciduria aligns pathognomonically with BKD."
"['Seborrheic dermatitis', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Increased serum lactate', 'Elevated urinary carboxylic acid']","['Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiencymultiple carboxylase deficiency, late-onset']","Disease: Biotinidase deficiency  
Reasoning:  
1. **Seborrheic dermatitis**: A hallmark of biotinidase deficiency due to biotin's role in keratinocyte function and skin health.  
2. **Metabolic acidosis & elevated lactate**: Caused by impaired activity of biotin-dependent carboxylases (e.g., pyruvate carboxylase), disrupting gluconeogenesis and mitochondrial energy metabolism.  
3. **Elevated urinary carboxylic acids**: Accumulation of 3-hydroxyisovaleric acid, 3-methylcrotonylglycine, and propionylglycine due to dysfunctional 3-methylcrotonyl-CoA carboxylase and propionyl-CoA carboxylase.  
4. **Neurological symptoms (seizures, hypotonia)**: Result from lactic acidosis, energy deficiency, and neurotoxic metabolite accumulation.  
5. **Death in infancy**: Untreated biotinidase deficiency leads to progressive metabolic decompensation, respiratory failure, and fatal outcomes.  
6. **Diagnostic confirmation**: Aligns with biochemical findings (low serum biotinidase activity) and rapid clinical improvement with biotin supplementation."
"['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, which impairs the conversion of phenylalanine to tyrosine. Elevated phenylalanine levels are diagnostic.  
2. **Hypertyrosinemia**: While atypical in classic PKU (where tyrosine is typically low/normal), this could result from **dietary management**. PKU treatment includes tyrosine supplementation to compensate for reduced endogenous synthesis. Excess supplementation or impaired tyrosine metabolism (e.g., secondary liver dysfunction from untreated PKU) might explain elevated tyrosine.  
3. **Death in early adulthood**: Untreated PKU leads to severe neurological damage, seizures, and organ failure. Early death aligns with historical cases before newborn screening and dietary interventions.  

Note: The coexistence of hyperphenylalaninemia and hypertyrosinemia is unusual in PKU. Consider ruling out **BH4 deficiency** (a PKU mimic) or **tyrosinemia type I/II** (primary tyrosine disorders) if confirmatory testing (e.g., enzyme assays, genetic analysis) is available. However, the provided diagnosis prioritizes PKU as the primary condition."
"['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Feeding difficulties', 'Body odor']",['Maple syrup urine disease; MSUD/Maple syrup urine disease/Maple syrup urine disease'],"Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Key Symptom - Body Odor**: The presence of a distinctive sweet, maple syrup-like odor (often noted in urine, sweat, or cerumen) is pathognomonic for MSUD, caused by accumulation of branched-chain keto acids.  
2. **Neonatal Onset & Severe Outcomes**: Symptoms like feeding difficulties, lethargy, and generalized hypotonia appearing in infancy, alongside neonatal death or death in infancy, align with the classic severe form of MSUD, which manifests within days of birth if untreated.  
3. **Neurological Involvement**: Drowsiness, sleep disturbances, and hypotonia result from neurotoxicity due to elevated branched-chain amino acids (leucine, isoleucine, valine) and their keto-acid derivatives, which disrupt cerebral function.  
4. **Hyperammonemia**: Though not a primary feature of MSUD, secondary hyperammonemia can occur during metabolic crises due to liver dysfunction or catabolic stress overwhelming urea cycle capacity.  
5. **Metabolic Crisis**: The combination of lethargy, feeding difficulties, and rapid deterioration reflects acute metabolic decompensation, a hallmark of untreated MSUD.  

This pattern of symptoms, especially the characteristic odor and neonatal presentation, strongly supports MSUD as the diagnosis."
"['Ptosis', 'Progressive visual loss', 'Ophthalmoplegia', 'Reduced tendon reflexes', 'Ragged-red muscle fibers', 'Generalized muscle weakness', 'Generalized amyotrophy', 'Acute hepatitis', 'Chronic hepatitis']",['Mitochondrial DNA depletion syndrome 3 (hepatocerebral type)'],"Disease: Mitochondrial DNA depletion syndrome 3 (hepatocerebral type)  
Reasoning:  
1. **Hepatocerebral involvement**: The coexistence of *acute hepatitis* and *chronic hepatitis* (liver dysfunction) with neurological symptoms (*ptosis*, *ophthalmoplegia*, *progressive visual loss*) aligns with the hepatocerebral phenotype of mitochondrial disorders.  
2. **Neuromuscular features**: *Generalized muscle weakness*, *generalized amyotrophy*, and *ragged-red muscle fibers* (observed on biopsy) are hallmark signs of mitochondrial myopathies caused by impaired oxidative phosphorylation due to mtDNA depletion.  
3. **Ocular manifestations**: *Ptosis* and *ophthalmoplegia* are classic findings in mitochondrial disorders like chronic progressive external ophthalmoplegia (CPEO), often linked to mtDNA defects.  
4. **Reduced tendon reflexes**: Suggests peripheral nerve or motor neuron involvement, consistent with multisystemic mitochondrial dysfunction.  
5. **Ragged-red fibers**: Pathognomonic for mitochondrial myopathy, caused by abnormal mitochondrial proliferation in muscle fibers.  
6. **Genetic confirmation**: Mitochondrial DNA depletion syndrome 3 is caused by *DGUOK* mutations, disrupting mitochondrial DNA maintenance and leading to combined hepatic, neurological, and muscular degeneration.  
This constellation of liver disease, progressive neuromuscular deterioration, and biopsy findings strongly supports the diagnosis of MDDS3."
"['Metabolic acidosis', 'Vomiting', 'Death in childhood', 'Methylmalonic aciduria']","['Methylmalonic acidemia; MMA; Methylmalonic aciduria', 'Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-coa mutase deficiency']","Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with metabolic acidosis, vomiting, and methylmalonic aciduria—hallmark features of methylmalonic acidemia (MMA). MMA is an autosomal recessive disorder caused by defects in methylmalonyl-CoA metabolism, leading to toxic accumulation of methylmalonic acid. The symptom ""death in childhood"" aligns with severe forms of MMA, which can result in early mortality due to metabolic crises or organ failure if untreated.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specificity of ""vitamin B12-unresponsive"" points to mutations in the *MUT* gene, which encodes methylmalonyl-CoA mutase. This enzyme deficiency prevents the conversion of methylmalonyl-CoA to succinyl-CoA, independent of vitamin B12 (cobalamin) metabolism. The lack of response to B12 supplementation distinguishes this subtype from other MMA forms (e.g., cblA/cblB types). Early lethality underscores the severe biochemical disruption caused by complete mutase deficiency."
"['Alopecia', 'Vomiting', 'Diarrhea', 'Hyperphenylalaninemia', 'Death in early adulthood']",['Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria'],"Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Vomiting and diarrhea** may occur in untreated PKU due to metabolic instability or secondary effects of phenylalanine toxicity on gastrointestinal function.  
3. **Alopecia** is atypical in classic PKU but could arise from severe malnutrition, micronutrient deficiencies (e.g., biotin), or comorbid autoimmune conditions exacerbated by chronic metabolic stress.  
4. **Death in early adulthood** aligns with untreated/severe PKU, where long-term complications (neurodegeneration, organ damage) or acute metabolic crises reduce life expectancy.  
5. Classic PKU symptoms (e.g., intellectual disability, seizures) may be absent if partially treated, but hyperphenylalaninemia remains critical for diagnosis. Early dietary management failure could explain the atypical progression."
"['Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Pneumonia', 'Hepatomegaly', 'Decreased plasma free carnitine', 'Elevated urinary carboxylic acid']",['Succinic semialdehyde dehydrogenase deficiency/Succinic semialdehyde dehydrogenase deficiency'],"Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Neurological Symptoms**: Seizures, motor delay, and generalized hypotonia align with SSADHD, a disorder disrupting GABA metabolism. Accumulation of γ-aminobutyric acid (GABA) and γ-hydroxybutyrate (GHB) causes neurotoxicity.  
2. **Elevated Urinary Carboxylic Acid**: SSADHD is characterized by elevated urinary GHB, often reported as a carboxylic acid in screening tests.  
3. **Decreased Plasma Free Carnitine**: Secondary carnitine deficiency may occur due to conjugation of carnitine with accumulating metabolites (e.g., GHB derivatives), reducing free carnitine levels.  
4. **Hepatomegaly**: Could stem from metabolic stress or carnitine deficiency impairing fatty acid oxidation, leading to hepatic lipid accumulation.  
5. **Pneumonia/Death in Infancy**: Severe hypotonia and seizures increase aspiration risk, predisposing to pneumonia. Early mortality reflects complications like refractory seizures or respiratory infections.  
6. **Exclusion of Other Disorders**: While hepatomegaly and carnitine deficiency suggest fatty acid oxidation disorders, the combination with elevated GHB (via urinary carboxylic acids) and neurological symptoms specifically points to SSADHD."
"['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine']","['Medium chain acyl-CoA dehydrogenase deficiency; MCADD/Medium chain acyl-CoA dehydrogenase deficiency/Acyl-Coa dehydrogenase, medium-chain, deficiency of']","Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Fatty acid oxidation disorder**: MCADD impairs breakdown of medium-chain fatty acids into acetyl-CoA, causing energy deficiency during fasting.  
2. **Neonatal/infant/childhood mortality**: Unrecognized MCADD leads to hypoketotic hypoglycemia, metabolic acidosis, and encephalopathy during metabolic stress (e.g., infections or fasting), explaining death in early life stages.  
3. **Gastrointestinal inflammation**: Acute crises trigger vomiting/diarrhea due to metabolic decompensation. Chronic carnitine deficiency may exacerbate mucosal damage.  
4. **Decreased plasma free carnitine**: Secondary carnitine depletion occurs as carnitine conjugates with accumulating toxic metabolites (e.g., octanoylcarnitine) for urinary excretion.  
5. **Prenatal abnormalities**: While less common, intrauterine metabolic stress from placental insufficiency or maternal fasting could theoretically contribute to developmental perturbations in severe cases.  

Key biochemical clues: Hypoketotic hypoglycemia + elevated C6-C10 acylcarnitines (especially C8) on tandem mass spectrometry would confirm MCADD. Early diagnosis via newborn screening prevents mortality."
"['Strabismus', 'Nystagmus', 'Intellectual disability', 'Ataxia', 'Hyporeflexia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Encephalopathy', 'Growth delay', 'Death in infancy', 'Cerebellar agenesis']","['PMM2-CDG/Congenital disorder of glycosylation, type Ia']","Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: Core feature of PMM2-CDG, caused by impaired glycosylation critical for cerebellar development.  
2. **Ataxia, motor delay, hypotonia, hyporeflexia**: Directly linked to cerebellar dysfunction and neuromuscular involvement.  
3. **Strabismus/nystagmus**: Ocular motor abnormalities due to cerebellar/brainstem malformations.  
4. **Encephalopathy**: Metabolic instability from glycosylation defects affecting multiple organ systems.  
5. **Intellectual disability/growth delay**: Result from systemic glycosylation failure impacting neurodevelopment and metabolism.  
6. **Death in infancy**: Severe PMM2-CDG phenotypes often lead to early mortality due to multiorgan failure.  
7. **Consistency with PMM2-CDG**: The triad of cerebellar anomalies, neurodevelopmental deficits, and multisystem involvement aligns with type Ia CDG pathophysiology."
"['Malar flattening', 'Micrognathia', 'Preauricular skin tag', 'Conductive hearing impairment', 'Atresia of the external auditory canal', 'Choanal atresia', 'Myopia', 'Microtia', 'Aplasia/Hypoplasia of the middle ear', 'Proximal placement of thumb', 'Increased nuchal translucency', 'Mild global developmental delay', 'Primary microcephaly', 'Gastrostomy tube feeding in infancy']","['Mandibulofacial dysostosis-microcephaly syndrome/Mandibulofacial dysostosis, Guion-Almeida type']","Disease: Mandibulofacial dysostosis-microcephaly syndrome (Guion-Almeida type)  
Reasoning:  
1. **Craniofacial features**: Malar flattening (underdeveloped cheekbones) and micrognathia (small jaw) are hallmark signs of mandibulofacial dysostosis.  
2. **Ear anomalies**: Preauricular skin tag, microtia (small ears), atresia of the external auditory canal, and middle ear aplasia/hypoplasia explain the conductive hearing impairment, consistent with this syndrome.  
3. **Airway/feeding issues**: Choanal atresia (nasal passage obstruction) and gastrostomy tube feeding in infancy reflect structural anomalies causing respiratory and feeding difficulties.  
4. **Neurological involvement**: Primary microcephaly and mild global developmental delay align with the syndrome’s association with neurodevelopmental deficits.  
5. **Associated findings**: Increased nuchal translucency (prenatal marker for structural anomalies), proximal thumb placement (skeletal anomaly), and myopia (eye involvement) further support the diagnosis.  
6. **Exclusion of mimics**: The absence of coloboma/heart defects (seen in CHARGE) and presence of microcephaly distinguish it from Treacher Collins syndrome.  
This constellation of craniofacial, auditory, skeletal, and neurodevelopmental features is pathognomonic for Guion-Almeida type mandibulofacial dysostosis-microcephaly syndrome."
"['Progressive microcephaly', 'Optic atrophy', 'Global developmental delay', 'Spastic tetraparesis', 'Myoclonus', 'Small for gestational age', 'Short distal phalanx of toe', 'Birth length less than 3rd percentile', 'Simplified gyral pattern', 'Short distal phalanx of finger', 'Primary microcephaly', 'Infantile spasms', 'Arteriovenous malformation']",['Microcephaly-Capillary malformation syndrome'],"Disease: Microcephaly-Capillary Malformation Syndrome (MIC-CAP)  
Reasoning:  
1. **Progressive microcephaly/Primary microcephaly**: Core feature of MIC-CAP, caused by STAMBP mutations leading to defective neurodevelopment.  
2. **Simplified gyral pattern**: Reflects cortical malformations, consistent with MIC-CAP’s brain abnormalities (e.g., polymicrogyria or reduced cortical folding).  
3. **Global developmental delay/Spastic tetraparesis/Infantile spasms/Myoclonus**: Aligns with severe neurological involvement, including epilepsy and motor deficits, typical of MIC-CAP.  
4. **Growth restriction (SGA, birth length <3rd percentile)**: Prenatal-onset growth retardation is a hallmark of MIC-CAP.  
5. **Short distal phalanges (fingers/toes)**: Suggests distal limb hypoplasia, a recognized skeletal anomaly in MIC-CAP.  
6. **Optic atrophy**: May result from progressive neurodegeneration or axonal damage secondary to metabolic dysfunction in MIC-CAP.  
7. **Arteriovenous malformation (AVM)**: Less common but plausible in MIC-CAP, as vascular dysregulation (beyond capillary malformations) can occur.  
**Exclusion of mimics**: Features distinguish MIC-CAP from other microcephaly syndromes (e.g., Seckel syndrome lacks vascular anomalies; Galloway-Mowat syndrome includes nephrosis).  
**Conclusion**: Symptom constellation strongly supports MIC-CAP, driven by genetic testing for STAMBP variants to confirm."
"['Sensorineural hearing impairment', 'Rod-cone dystrophy', 'Cerebellar atrophy', 'Areflexia', 'Pes cavus', 'Hammertoe', 'Expressive language delay', 'Axonal loss', 'Somatic sensory dysfunction', 'Sensorimotor neuropathy', 'Progressive gait ataxia', 'Speech articulation difficulties', 'Peripheral demyelination', 'Peripheral retinal atrophy']",['Perrault syndrome 1'],"Disease: Perrault syndrome 1  
Reasoning:  
1. **Sensorineural hearing impairment** and **rod-cone dystrophy** are hallmark features of Perrault syndrome, particularly in subtypes with neurological involvement.  
2. **Cerebellar atrophy** explains **progressive gait ataxia** and **speech articulation difficulties**, aligning with neurological manifestations in Perrault syndrome type 1.  
3. **Areflexia**, **sensorimotor neuropathy**, **axonal loss**, and **peripheral demyelination** indicate peripheral neuropathy, consistent with the axonal and demyelinating neuropathies reported in HSD17B4-related Perrault syndrome.  
4. **Pes cavus** and **hammertoe** are secondary to chronic neuropathy, commonly seen in neurogenetic disorders affecting peripheral nerves.  
5. **Expressive language delay** and **somatic sensory dysfunction** correlate with cerebellar and sensory nerve dysfunction.  
6. **Peripheral retinal atrophy** complements **rod-cone dystrophy**, reinforcing the multisystem retinal involvement in this syndrome.  
7. While ovarian dysgenesis (typical in Perrault syndrome) is not explicitly listed, the combination of hearing loss, vision loss, cerebellar atrophy, and neuropathy strongly supports Perrault syndrome type 1 (HSD17B4 mutations), which can present with variable expressivity, including isolated neurological phenotypes."
"['Delayed gross motor development', 'Gray matter heterotopia', 'Cerebellar dysplasia', 'Aplasia/Hypoplasia of the optic nerve']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Delayed gross motor development**: Common in Poretti-Boltshauser syndrome due to cerebellar dysfunction, which disrupts coordination and motor skill acquisition.  
2. **Gray matter heterotopia**: Reflects neuronal migration defects, a hallmark of neurodevelopmental disorders; while not pathognomonic, it aligns with the spectrum of brain malformations in this syndrome.  
3. **Cerebellar dysplasia**: A core feature of Poretti-Boltshauser syndrome, characterized by structural cerebellar abnormalities (e.g., cysts, dysplasia) contributing to ataxia and motor delays.  
4. **Aplasia/Hypoplasia of the optic nerve**: Observed in this syndrome due to congenital optic nerve defects, differentiating it from other cerebellar ataxias (e.g., Joubert syndrome, which typically involves retinal dystrophy instead).  
The combination of cerebellar dysplasia, optic nerve hypoplasia, and neurodevelopmental delays strongly supports this diagnosis, especially when genetic testing confirms pathogenic variants in *LAMA1* or *COL4A1*, genes implicated in the syndrome."
"['Narrow mouth', 'Cataract', 'Thick eyebrow', 'Decreased response to growth hormone stimulation test', 'Delayed gross motor development', 'Genu valgum', 'Thoracic scoliosis', 'Severe short stature', 'Multiple skeletal anomalies', 'Distal peripheral sensory neuropathy', 'Bilateral sensorineural hearing impairment', 'Prominent forehead']","['Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome/Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia']","Disease: Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia (CGHS syndrome)  
Reasoning:  
1. **Cataract**: Present in the patient’s symptoms, aligning with the ocular manifestation of the syndrome.  
2. **Growth hormone deficiency**: Supported by the ""decreased response to growth hormone stimulation test"" and ""severe short stature,"" a hallmark of GH deficiency.  
3. **Sensory neuropathy**: Matches ""distal peripheral sensory neuropathy,"" indicating peripheral nerve involvement.  
4. **Sensorineural hearing loss**: Corresponds to ""bilateral sensorineural hearing impairment,"" a key auditory feature of the syndrome.  
5. **Skeletal dysplasia**: Explains ""multiple skeletal anomalies,"" including thoracic scoliosis, genu valgum, and severe short stature. Additional dysmorphic features (narrow mouth, thick eyebrows, prominent forehead) and delayed gross motor development further support skeletal and systemic involvement.  

This constellation of symptoms is pathognomonic for the rare autosomal recessive disorder caused by *PRDM5* gene mutations, which disrupt extracellular matrix integrity, leading to multi-systemic manifestations."
"['Strabismus', 'Nystagmus', 'Delayed speech and language development', 'Abnormally large globe', 'Motor delay', 'Agenesis of corpus callosum', 'Cerebellar vermis hypoplasia', 'Dilated fourth ventricle', 'Cerebellar cyst', 'Abnormal midbrain morphology', 'Cerebellar dysplasia', 'High myopia', 'Abnormal superior cerebellar peduncle morphology', 'Partial absence of the septum pellucidum']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar and Brain Abnormalities**: Cerebellar cysts, cerebellar vermis hypoplasia, cerebellar dysplasia, dilated fourth ventricle, and abnormal superior cerebellar peduncle morphology align with the hallmark cerebellar malformations of Poretti-Boltshauser syndrome.  
2. **Midbrain and Corpus Callosum Involvement**: Abnormal midbrain morphology and agenesis of the corpus callosum are supportive findings, as structural midbrain defects and variable corpus callosum anomalies are reported in this syndrome.  
3. **Ocular Features**: Strabismus, nystagmus, high myopia, and abnormally large globes correlate with the syndrome’s characteristic oculomotor apraxia and severe refractive errors.  
4. **Developmental Delays**: Motor delay and delayed speech/language development reflect the intellectual disability and ataxia components of the disorder.  
5. **Exclusion of Mimics**: The absence of ""molar tooth sign"" (ruling out Joubert syndrome) and the presence of cerebellar cysts (uncommon in other cerebellar hypoplasia disorders) further solidify this diagnosis."
"['Strabismus', 'Myopia', 'Nystagmus', 'Abnormally large globe', 'Motor delay', 'Cerebellar vermis hypoplasia', 'Dilated fourth ventricle', 'Cerebellar cyst', 'Cerebellar dysplasia', 'Absent retinal pigment epithelium']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar anomalies**: Cerebellar vermis hypoplasia, dysplasia, cysts, and dilated fourth ventricle align with the hallmark cerebellar structural defects in Poretti-Boltshauser syndrome.  
2. **Ocular manifestations**: Strabismus, myopia, nystagmus, and absent retinal pigment epithelium reflect the syndrome’s retinal dystrophy and high myopia phenotype. The abnormally large globe (megalophthalmos) further supports congenital ocular abnormalities.  
3. **Neurological deficits**: Motor delay correlates with cerebellar dysfunction and ataxia, a core feature of the syndrome.  
4. **Exclusion of mimics**: The absence of ""molar tooth sign"" (Joubert syndrome), liver involvement (COACH syndrome), or severe muscular/lissencephaly findings (Walker-Warburg syndrome) strengthens the diagnosis.  
5. **Genetic confirmation**: While not explicitly stated, Poretti-Boltshauser syndrome is linked to LAMA1 mutations, which underlie the observed neuro-ocular developmental defects."
"['Strabismus', 'Cataract', 'Amblyopia', 'Autistic behavior', 'Delayed speech and language development', 'Abnormally large globe', 'Retinal atrophy', 'Motor delay', 'Cerebellar vermis hypoplasia', 'Dilated fourth ventricle', 'Cerebellar cyst', 'Abnormal midbrain morphology', '2-3 toe syndactyly', 'Cerebellar dysplasia', 'Absent retinal pigment epithelium', 'High myopia', 'Splayed superior cerebellar peduncle']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar anomalies**: Cerebellar vermis hypoplasia, cerebellar cysts, dilated fourth ventricle, and cerebellar dysplasia are hallmark features of Poretti-Boltshauser syndrome (PTBHS).  
2. **Ocular abnormalities**: High myopia, retinal atrophy, absent retinal pigment epithelium, strabismus, and cataracts align with PTBHS-associated retinal dystrophy and structural eye defects.  
3. **Neurodevelopmental delays**: Motor delay, delayed speech, and autistic behavior correlate with intellectual disability and cerebellar dysfunction in PTBHS.  
4. **Midbrain/cerebellar peduncle anomalies**: Splayed superior cerebellar peduncles and abnormal midbrain morphology are consistent with PTBHS neuroimaging findings.  
5. **Syndactyly**: 2-3 toe syndactyly is a rare but reported skeletal feature in PTBHS, supporting the diagnosis.  
6. **Exclusion of mimics**: The absence of nephronophthisis (Joubert syndrome) or liver fibrosis (COACH syndrome), combined with cerebellar cysts and retinal changes, distinguishes PTBHS."
"['Abnormal retinal morphology', 'Myopia', 'Oculomotor apraxia', 'Delayed speech and language development', 'Motor delay', 'Generalized hypotonia', 'Dilated fourth ventricle', 'Cerebellar dysplasia', 'Inferior cerebellar vermis hypoplasia']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar Abnormalities**: The presence of *dilated fourth ventricle*, *cerebellar dysplasia*, and *inferior cerebellar vermis hypoplasia* aligns with the hallmark cerebellar structural defects in Poretti-Boltshauser syndrome, often including cerebellar cysts or dysplasia.  
2. **Oculomotor Apraxia**: Directly matches the defining feature of the syndrome, explaining difficulties in initiating voluntary eye movements.  
3. **Neurodevelopmental Delays**: *Motor delay*, *delayed speech and language development*, and *generalized hypotonia* correlate with the intellectual disability and ataxia characteristic of the disorder.  
4. **Ocular Findings**: *Abnormal retinal morphology* and *myopia* are consistent with reported ocular anomalies linked to LAMA1 mutations, the genetic cause of the syndrome.  
5. **Exclusion of Alternatives**: The combination of cerebellar vermis hypoplasia, oculomotor apraxia, and retinal changes distinguishes it from similar disorders (e.g., Joubert syndrome, which typically shows a ""molar tooth sign"" absent here)."
"['Strabismus', 'Chorioretinal atrophy', 'Nystagmus', 'Oculomotor apraxia', 'Delayed speech and language development', 'Abnormally large globe', 'Motor delay', 'Generalized hypotonia', 'Cerebellar dysplasia', 'Inferior cerebellar vermis hypoplasia', 'High myopia']",['Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome'],"Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar Abnormalities**: The patient exhibits *cerebellar dysplasia* and *inferior cerebellar vermis hypoplasia*, key neuroimaging features of Poretti-Boltshauser syndrome (PBS). These structural defects disrupt cerebellar function, contributing to *motor delay*, *generalized hypotonia*, and ataxia (implied by cerebellar signs).  
2. **Oculomotor Deficits**: *Oculomotor apraxia* and *nystagmus* are hallmark ocular motor impairments in PBS, linked to cerebellar malformations. *Strabismus* and *abnormally large globe* may arise from disrupted coordination of eye movements and structural ocular abnormalities.  
3. **Retinal Involvement**: *Chorioretinal atrophy* and *high myopia* align with PBS-associated retinal dystrophy caused by pathogenic variants in *LAMA1*, a gene critical for retinal and cerebellar basement membrane integrity.  
4. **Developmental Delays**: *Delayed speech and language development* and *motor delay* reflect global developmental delays secondary to cerebellar dysfunction and potential intellectual disability (a core feature of PBS).  
5. **Exclusion of Mimics**: The constellation of cerebellar cysts/hypoplasia, retinal changes, and oculomotor apraxia distinguishes PBS from similar disorders (e.g., Joubert syndrome, which typically presents with a ""molar tooth sign"" on imaging and lacks chorioretinal atrophy).  

This pattern strongly supports a diagnosis of Poretti-Boltshauser syndrome, confirmed genetically via *LAMA1* testing."
"['Cleft palate', 'Pierre-Robin sequence', 'Specific learning disability', 'Feeding difficulties', 'Hypoxemia', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular Syndrome:  
1. **Cleft palate & Pierre-Robin sequence**: Cerebrocostomandibular syndrome (CCMS) is characterized by micrognathia (small jaw), glossoptosis, and cleft palate, which collectively define Pierre-Robin sequence. These structural anomalies explain airway obstruction and feeding difficulties.  
2. **Posterior rib gaps**: A hallmark feature of CCMS is rib dysplasia, including posterior rib gaps or ""missing"" rib segments. This disrupts thoracic cage integrity, contributing to respiratory insufficiency (hypoxemia).  
3. **Feeding difficulties & hypoxemia**: Micrognathia and cleft palate impair sucking/swallowing, while rib defects reduce lung capacity, exacerbating hypoxemia.  
4. **Specific learning disability**: Chronic hypoxia from respiratory compromise or potential central nervous system involvement (rarely reported in CCMS) may underlie neurodevelopmental delays.  
5. **Exclusion of mimics**: The combination of rib gaps, Pierre-Robin sequence, and neurodevelopmental issues distinguishes CCMS from isolated Pierre-Robin or syndromes like Stickler or Treacher Collins."
"['Pierre-Robin sequence', 'High palate', 'Downslanted palpebral fissures', 'Carious teeth', '11 pairs of ribs', 'Specific learning disability', 'Feeding difficulties', 'Hypoplastic L5 vertebral pedicle', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular syndrome: The patient exhibits Pierre-Robin sequence (micrognathia, glossoptosis, and cleft palate/high palate), a hallmark of CCMS. The skeletal anomalies—11 pairs of ribs (rib hypoplasia), posterior rib gaps, and hypoplastic L5 vertebral pedicle—align with costovertebral defects central to this syndrome. Feeding difficulties are secondary to craniofacial and airway challenges from PRS. Downslanted palpebral fissures and specific learning disability suggest broader craniofacial and neurodevelopmental involvement. Carious teeth may reflect oral anatomical challenges or enamel defects. The combined craniofacial, vertebral, and rib anomalies strongly support CCMS, excluding isolated PRS or other rib malformation syndromes."
"['Cleft palate', 'Pierre-Robin sequence', 'Hypertelorism', 'Downslanted palpebral fissures', 'Spasticity', 'Morphological central nervous system abnormality', 'Chorea', 'Restrictive ventilatory defect', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular Syndrome: The patient presents with cleft palate and Pierre-Robin sequence (micrognathia, glossoptosis, airway obstruction), which are hallmark craniofacial features of CCMS. Posterior rib gaps and restrictive ventilatory defect correlate with the syndrome’s characteristic costovertebral anomalies (missing or malformed posterior rib segments), leading to thoracic insufficiency. Spasticity, chorea, and morphological CNS abnormalities align with neurological involvement seen in severe CCMS cases. Hypertelorism and downslanted palpebral fissures further support the syndromic craniofacial dysmorphism. The combination of these structural and neurological findings strongly points to CCMS."
"['Cleft palate', 'Pierre-Robin sequence', 'Choanal atresia', 'Webbed neck', 'Cystic hygroma', 'Multiple pterygia', 'Atrial septal defect', 'Scoliosis', 'Abnormal rib ossification']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Disease: Cerebrocostomandibular syndrome  
Reasoning:  
1. **Cleft palate & Pierre-Robin sequence**: Core features of CCMS, involving micrognathia (small jaw), glossoptosis, and airway obstruction, often accompanied by cleft palate.  
2. **Abnormal rib ossification & scoliosis**: Hallmark skeletal defects in CCMS, including rib gaps, malformation, and scoliosis secondary to thoracic abnormalities.  
3. **Choanal atresia**: Observed in some CCMS cases due to craniofacial maldevelopment.  
4. **Atrial septal defect**: Congenital heart defects, though less common, are reported in CCMS.  
5. **Webbed neck, cystic hygroma, multiple pterygia**: These may overlap with lymphatic or connective tissue anomalies, potentially linked to broader developmental disruptions in CCMS. While not classic features, they could reflect phenotypic variability or secondary effects of skeletal and craniofacial defects.  

The diagnosis prioritizes the triad of micrognathia (Pierre-Robin), cleft palate, and rib malformations, with other symptoms contextualized within the syndrome’s spectrum."
"['Pierre-Robin sequence', 'High palate', 'Abnormal thorax morphology']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Disease: Cerebrocostomandibular syndrome (CCMS)  
Reasoning:  
1. **Pierre-Robin sequence (PRS)** is a hallmark of CCMS, presenting with micrognathia (small jaw), glossoptosis (tongue displacement), and airway obstruction.  
2. **High palate** is a secondary feature of PRS due to restricted oral cavity space during fetal development.  
3. **Abnormal thorax morphology** (e.g., rib gaps, hypoplastic ribs, or ""coat-hanger"" rib defects) is a critical diagnostic criterion for CCMS, distinguishing it from isolated PRS.  
4. CCMS is a rare autosomal recessive disorder caused by variants in the *SNRPB* gene, linking craniofacial and thoracic anomalies.  
5. The triad of PRS, high palate, and thoracic defects aligns with CCMS, excluding other syndromes (e.g., Stickler or Treacher Collins syndromes) that lack rib abnormalities."
"['Cleft palate', 'Pierre-Robin sequence', 'Conductive hearing impairment', 'Decreased response to growth hormone stimulation test', 'Scoliosis', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Disease: Cerebrocostomandibular syndrome (CCMS)  
Reasoning:  
1. **Cleft palate and Pierre-Robin sequence**: CCMS is characterized by mandibular hypoplasia (micrognathia), glossoptosis, and cleft palate, consistent with Pierre-Robin sequence.  
2. **Posterior rib gaps**: A hallmark of CCMS, involving abnormal rib development with gaps or defects in the posterior ribs.  
3. **Scoliosis**: Likely secondary to thoracic rib abnormalities, which destabilize spinal alignment.  
4. **Conductive hearing impairment**: Associated with craniofacial malformations affecting middle ear structures.  
5. **Decreased growth hormone response**: While not a primary feature, growth issues may arise from systemic developmental anomalies or indirect endocrine disruptions in severe syndromic cases.  
The combination of craniofacial, rib, spinal, and endocrine abnormalities strongly supports a diagnosis of CCMS."
"['Cleft palate', 'Pierre-Robin sequence', 'Thin ribs', 'Anal stenosis', 'Scoliosis', 'Cognitive impairment']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular syndrome: The patient exhibits Pierre-Robin sequence (micrognathia, glossoptosis, airway obstruction) and cleft palate, core craniofacial features of CCMS. Thin ribs align with characteristic costovertebral anomalies (hypoplastic ribs, rib gaps). Scoliosis reflects vertebral involvement, while anal stenosis (a rare gastrointestinal anomaly) and cognitive impairment further support this multisystem syndrome. No dominant features of overlapping disorders (e.g., Stickler syndrome, VACTERL) are present, solidifying CCMS as the diagnosis."
"['Cleft palate', 'Pierre-Robin sequence', 'Atrial septal defect', 'Respiratory insufficiency', 'Hyperechogenic kidneys', 'Feeding difficulties', 'Posterior rib gap', '10 pairs of ribs']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular syndrome (CCMS):  
1. **Rib anomalies**: The patient exhibits **posterior rib gaps** and **10 pairs of ribs** (vs. the normal 12 pairs). These defects are pathognomonic for CCMS, characterized by ""missing"" or maldeveloped ribs with costovertebral discontinuities.  
2. **Pierre-Robin sequence (PRS)**: The **cleft palate** and associated PRS (micrognathia, glossoptosis) align with CCMS, as mandibular hypoplasia and airway/respiratory challenges are common.  
3. **Respiratory insufficiency**: Likely secondary to rib defects (restrictive lung disease) and PRS-related airway obstruction.  
4. **Additional features**: **Atrial septal defect** and **hyperechogenic kidneys** are occasionally reported in CCMS, supporting multisystem involvement. **Feeding difficulties** correlate with PRS and orofacial structural abnormalities.  
5. **Exclusion**: Other rib-gap syndromes (e.g., cerebro-costo-mandibular-like syndrome) lack full phenotypic overlap, making CCMS the definitive diagnosis."
"['Cleft palate', 'Pierre-Robin sequence', 'Cleft upper lip', 'Respiratory distress', 'Scoliosis', 'Posterior rib gap', '10 pairs of ribs']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Disease: Cerebrocostomandibular syndrome  
Reasoning:  
1. **Cleft palate, Pierre-Robin sequence, and cleft upper lip**: These craniofacial anomalies align with CCMS, which is characterized by mandibular hypoplasia (micrognathia, a key feature of Pierre-Robin sequence) and oral clefts.  
2. **Respiratory distress**: Likely secondary to micrognathia (obstructing the airway) and rib abnormalities impairing lung development/function.  
3. **Scoliosis and posterior rib gaps**: CCMS involves severe rib malformations, including posterior ""rib gaps"" (missing rib segments) and abnormal rib count.  
4. **10 pairs of ribs**: A hallmark of CCMS, as affected individuals often have fewer than the typical 12 pairs, with severe costal defects contributing to thoracic insufficiency.  
5. **Exclusion of alternatives**: While Pierre-Robin sequence and clefts occur in other syndromes (e.g., Stickler or Treacher Collins), the combination with rib gaps and rib count reduction is pathognomonic for CCMS."
"['Pierre-Robin sequence', 'Conductive hearing impairment', 'Strabismus', 'Hypermetropia', 'Atrial septal defect', 'Respiratory distress', 'Scoliosis', 'Feeding difficulties', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Disease: Cerebrocostomandibular syndrome  
Reasoning:  
1. **Pierre-Robin sequence**: A hallmark of CCMS, caused by micrognathia and glossoptosis, leading to airway obstruction and feeding difficulties.  
2. **Posterior rib gaps**: Pathognomonic feature of CCMS, involving costovertebral abnormalities with missing or malformed posterior rib segments.  
3. **Scoliosis**: Associated with vertebral anomalies and rib defects in CCMS.  
4. **Respiratory distress**: Secondary to rib gaps (impaired chest wall mechanics) and micrognathia-related airway obstruction.  
5. **Atrial septal defect**: Reported in some CCMS cases, reflecting broader developmental anomalies.  
6. **Conductive hearing impairment**: Likely due to craniofacial malformations affecting Eustachian tube function.  
7. **Strabismus/Hypermetropia**: May arise from craniofacial dysmorphism or connective tissue involvement, though less specific to CCMS.  
8. **Feeding difficulties**: Direct consequence of micrognathia and glossoptosis in PRS.  
The combination of rib gaps, PRS, and multisystem involvement strongly supports CCMS over other syndromes (e.g., Stickler or Treacher Collins)."
"['Cleft palate', 'Pierre-Robin sequence', 'Conductive hearing impairment', '11 pairs of ribs', 'Thin ribs', 'Scoliosis', 'Posterior rib gap']",['Cerebrocostomandibular syndrome/Cerebrocostomandibular syndrome'],"Cerebrocostomandibular syndrome:  
1. **Pierre-Robin sequence and cleft palate**: Core features of CCMS, involving micrognathia (small jaw), glossoptosis (tongue displacement), and cleft palate.  
2. **Rib anomalies**: Pathognomonic findings include reduced rib count (11 pairs), thin ribs, posterior rib gaps, and scoliosis secondary to thoracic skeletal defects.  
3. **Conductive hearing impairment**: Linked to recurrent middle ear dysfunction, often associated with craniofacial malformations.  
4. **Exclusion of mimics**: Rib gaps and specific rib count abnormalities distinguish CCMS from other syndromes (e.g., Stickler or Treacher Collins).  
The constellation of craniofacial, auditory, and severe rib defects confirms the diagnosis."
"['Narrow mouth', 'Malar flattening', 'Epicanthus', 'Broad forehead', 'Nystagmus', 'Seizure', 'Short nose', 'Low hanging columella', 'Severe global developmental delay', 'Abnormality of ocular abduction']","['Epilepsy, focal, with speech disorder and with or without mental retardation']","Disease: Epilepsy, focal, with speech disorder and with or without mental retardation  
Reasoning:  
1. **Seizure** is a core feature of epilepsy, specifically focal seizures in this diagnosis.  
2. **Severe global developmental delay** aligns with the potential inclusion of intellectual disability or mental retardation in the disease description.  
3. **Speech disorder** is explicitly noted in the diagnosis, often linked to developmental delays or neurological dysfunction caused by epilepsy.  
4. While **nystagmus** and **abnormality of ocular abduction** suggest neurological involvement, they may reflect broader central nervous system disturbances secondary to epileptic activity.  
5. Dysmorphic features (**narrow mouth, malar flattening, epicanthus, broad forehead, short nose, low hanging columella**) are not directly explained by the diagnosis but could indicate an underlying genetic or syndromic cause contributing to both the epilepsy and structural anomalies. These findings warrant further genetic testing to identify a potential unifying etiology.  

*Note: The listed diagnosis captures the neurological phenotype, but the dysmorphology suggests a broader syndromic condition that may require additional evaluation.*"
"['Platyspondyly', 'Broad metacarpals', 'Abnormal facial shape', 'Apnea', 'Hypoplastic iliac wing', 'Metaphyseal irregularity', 'Flat acetabular roof', 'Thoracic hypoplasia', 'Broad phalanx', 'Six lumbar vertebrae', 'Rhizomelia', 'Short metacarpal', 'Arrhythmia', '11 thoracic vertebrae']","['Spondylometaphyseal dysplasia, Sedaghatian type/Spondylometaphyseal dysplasia, Sedaghatian type']","Disease: Spondylometaphyseal dysplasia, Sedaghatian type  
Reasoning:  
1. **Platyspondyly** and **six lumbar vertebrae/11 thoracic vertebrae** indicate vertebral abnormalities, consistent with ""spondylo"" (spinal) involvement in SMD.  
2. **Metaphyseal irregularity**, **broad/short metacarpals**, **broad phalanx**, and **rhizomelia** reflect metaphyseal and skeletal dysplasia, core features of SMD.  
3. **Hypoplastic iliac wing** and **flat acetabular roof** align with pelvic dysplasia seen in skeletal dysplasias.  
4. **Thoracic hypoplasia** and **apnea** suggest respiratory compromise, typical in severe neonatal forms like Sedaghatian type.  
5. **Arrhythmia** correlates with reported cardiac anomalies in Sedaghatian type.  
6. **Abnormal facial shape** supports craniofacial dysmorphism associated with skeletal dysplasias.  
7. The combination of lethal skeletal dysplasia, metaphyseal/spinal defects, and cardiac involvement distinguishes this subtype from other SMDs."
"['Platyspondyly', 'Hypoplastic ilia', 'Short tubular bones of the hand', 'Generalized hypotonia', 'Cerebellar hypoplasia', 'Atrioventricular block', 'Hypoplasia of the corpus callosum', 'Respiratory distress', 'Generalized myoclonic seizure', 'Flat acetabular roof', 'Narrow greater sciatic notch', 'Cupped metaphyses of hand bones', 'Abnormal intervertebral disk morphology', 'Simplified gyral pattern', 'Metaphyseal dysplasia']","['Spondylometaphyseal dysplasia, Sedaghatian type/Spondylometaphyseal dysplasia, Sedaghatian type']","Disease: Spondylometaphyseal dysplasia, Sedaghatian type  
Reasoning:  
1. **Skeletal Features**: Platyspondyly, hypoplastic ilia, flat acetabular roof, narrow greater sciatic notch, and cupped metaphyses of hand bones align with the ""spondylometaphyseal"" component, characteristic of skeletal dysplasia in this disorder.  
2. **Metaphyseal Dysplasia**: Short tubular bones of the hands and metaphyseal cupping confirm metaphyseal irregularities, a hallmark of the disease.  
3. **Neurological Involvement**: Cerebellar hypoplasia, simplified gyral pattern, and corpus callosum hypoplasia indicate severe central nervous system malformations, consistent with Sedaghatian type’s association with brain abnormalities.  
4. **Systemic Manifestations**: Generalized hypotonia, respiratory distress, and myoclonic seizures reflect neuromuscular and respiratory compromise, common in this lethal infantile form.  
5. **Cardiac Anomaly**: Atrioventricular block supports the diagnosis, as cardiac conduction defects are reported in Sedaghatian type.  
6. **Exclusion of Mimics**: The combination of severe skeletal, neurological, and cardiac features differentiates it from other spondylometaphyseal dysplasias lacking multisystem involvement."
"['Recurrent corneal erosions', 'Alacrima', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Hepatic fibrosis', 'Short foot', 'Constipation', 'Gliosis', 'EEG abnormality', 'Elevated hepatic transaminase', 'Elevated circulating alpha-fetoprotein concentration', 'Prolonged neonatal jaundice', 'Peripheral neuropathy', 'Chalazion', 'Dilation of Virchow-Robin spaces', 'Small hand']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1  
Reasoning:  
1. **Alacrima** (absent tear production) is a cardinal feature of this disorder and directly reflects the ""alacrimia"" in the syndrome's name.  
2. **Hepatic fibrosis**, **elevated hepatic transaminases**, and **prolonged neonatal jaundice** align with the liver dysfunction component, a hallmark of the disease.  
3. **Seizures**, **hypotonia**, **global developmental delay**, **EEG abnormality**, and **gliosis** indicate severe neurological involvement, consistent with the ""choreoathetosis"" and neurodegenerative features of the disorder.  
4. **Peripheral neuropathy** and **reduced tendon reflexes** reflect peripheral nervous system pathology, a known manifestation of congenital disorders of deglycosylation.  
5. **Elevated alpha-fetoprotein** is a biomarker frequently associated with glycosylation defects, supporting the molecular diagnosis.  
6. **Recurrent corneal erosions** and **chalazion** correlate with ocular surface abnormalities secondary to alacrima and systemic inflammation.  
7. **Dilation of Virchow-Robin spaces** and **small hand/short foot** suggest congenital structural anomalies linked to abnormal glycosylation during development.  
8. **Constipation** may stem from autonomic neuropathy or gastrointestinal dysmotility, common in systemic metabolic disorders.  
This constellation of ocular, hepatic, neurological, and developmental abnormalities, combined with biomarker findings, strongly implicates a congenital disorder of deglycosylation (NGLY1 deficiency or related subtype)."
"['Microcephaly', 'Recurrent corneal erosions', 'Alacrima', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Intrauterine growth retardation', 'Constipation', 'Increased serum lactate', 'EEG abnormality', 'Scoliosis', 'Elevated hepatic transaminase', 'Peripheral neuropathy']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (CDDG1)  
Reasoning:  
1. **Alacrima**: A core diagnostic feature of CDDG1, explaining the absence of tears.  
2. **Recurrent corneal erosions**: Secondary to alacrima due to lack of tear lubrication and corneal protection.  
3. **Elevated hepatic transaminase**: Reflects liver dysfunction, a key component of the syndrome.  
4. **Global developmental delay & Hypotonia**: Consistent with neurological involvement in CDDG1, linked to defective deglycosylation affecting brain development.  
5. **Microcephaly & Intrauterine growth retardation (IUGR)**: Aligns with congenital growth and neurodevelopmental deficits in CDDG1.  
6. **Increased serum lactate**: Suggests mitochondrial dysfunction, common in metabolic disorders like CDDG1.  
7. **EEG abnormality & Peripheral neuropathy**: Indicates central and peripheral nervous system abnormalities, typical of deglycosylation defects.  
8. **Reduced tendon reflexes**: Likely due to peripheral neuropathy or hypotonia.  
9. **Scoliosis**: May arise from neuromuscular hypotonia or connective tissue involvement.  
10. **Constipation**: Gastrointestinal dysmotility, often seen in CDGs due to autonomic or muscular dysfunction.  

The triad of **alacrima, liver dysfunction, and neurological deficits** (developmental delay, hypotonia, neuropathy), alongside supportive features (IUGR, metabolic derangements), confirms CDDG1, typically caused by *NGLY1* mutations impairing deglycosylation pathways."
"['Strabismus', 'Recurrent corneal erosions', 'Alacrima', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Hepatic fibrosis', 'Intrauterine growth retardation', 'Short foot', 'Constipation', 'Increased serum lactate', 'Gliosis', 'EEG abnormality', 'Scoliosis', 'Elevated hepatic transaminase', 'Elevated circulating alpha-fetoprotein concentration', 'Prolonged neonatal jaundice', 'Abnormal auditory evoked potentials', 'Chalazion', 'Delayed myelination', 'Dilation of Virchow-Robin spaces', 'Small hand']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (NGLY1 deficiency)  
Reasoning:  
1. **Alacrima**: A defining feature of the syndrome, directly linked to impaired glycosylation affecting lacrimal gland function.  
2. **Hepatic fibrosis/elevated transaminases/prolonged jaundice**: Reflects liver dysfunction, a core component of the disorder due to defective protein deglycosylation in hepatocytes.  
3. **Seizures/EEG abnormality/hypotonia/global developmental delay/delayed myelination/gliosis**: Indicates severe neurological involvement, consistent with NGLY1 deficiency disrupting neuronal glycoprotein homeostasis.  
4. **Elevated alpha-fetoprotein**: Associated with hepatic injury and impaired glycosylation, common in congenital disorders of deglycosylation.  
5. **Intrauterine growth retardation/short foot/small hand**: Suggests congenital growth restriction, often seen in systemic metabolic disorders.  
6. **Recurrent corneal erosions/chalazion**: Secondary to alacrima-induced dry eye and ocular surface damage.  
7. **Increased serum lactate**: May indicate mitochondrial dysfunction, a known overlap in glycosylation disorders.  
8. **Abnormal auditory evoked potentials/dilation of Virchow-Robin spaces**: Reflects central nervous system abnormalities, including white matter changes.  
9. **Reduced tendon reflexes/constipation**: Autonomic or peripheral nerve involvement due to glycosylation defects.  
10. **Scoliosis**: Often secondary to neuromuscular hypotonia.  
The constellation of alacrima, liver disease, neurodevelopmental deficits, and multi-system involvement aligns pathognomonically with NGLY1-related congenital disorder of deglycosylation."
"['High palate', 'Microcephaly', 'Epicanthus', 'Micrognathia', 'Ptosis', 'Alacrima', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Intrauterine growth retardation', 'Short foot', 'Constipation', 'Ventriculomegaly', 'Increased serum lactate', 'EEG abnormality', 'Abnormal midbrain morphology', 'Scoliosis', 'Short nose', 'Elevated circulating alpha-fetoprotein concentration', 'Prolonged neonatal jaundice', 'Alveolar ridge overgrowth', 'Peripheral neuropathy', 'Underdeveloped supraorbital ridges', 'Small hand']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (CDDG1)  
Reasoning:  
1. **Alacrima**: A hallmark feature of CDDG1, directly listed in the patient’s symptoms.  
2. **Liver dysfunction**: Suggested by elevated alpha-fetoprotein (marker for hepatic issues) and prolonged neonatal jaundice.  
3. **Neurological involvement**: Global developmental delay, seizures, hypotonia, EEG abnormalities, and ventriculomegaly align with CDDG1’s neurodevelopmental deficits.  
4. **Craniofacial/skeletal anomalies**: Microcephaly, micrognathia, epicanthus, short nose, underdeveloped supraorbital ridges, small hands, short feet, and scoliosis reflect multisystem dysmorphism typical of glycosylation disorders.  
5. **Peripheral neuropathy**: Reduced tendon reflexes and peripheral neuropathy suggest nerve involvement, consistent with deglycosylation defects.  
6. **Metabolic markers**: Elevated serum lactate and abnormal midbrain morphology support mitochondrial or metabolic dysfunction seen in CDG disorders.  
7. **Supportive features**: Intrauterine growth retardation, constipation, and alveolar ridge overgrowth further correlate with systemic manifestations of CDDG1.  
8. **Exclusion of mimics**: While other CDG types (e.g., PMM2-CDG) share overlapping symptoms, the presence of alacrima and elevated AFP specifically points to CDDG1/NGLY1 deficiency."
"['Microcephaly', 'Epicanthus', 'Hypotonia', 'Global developmental delay', 'Hepatic fibrosis', 'Intrauterine growth retardation', 'EEG abnormality', 'Short nose', 'Prolonged neonatal jaundice', 'Lateral ventricle dilatation', 'Abnormality of movement']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (CDDG1)  
Reasoning:  
1. **Hepatic fibrosis** and **prolonged neonatal jaundice** align with the liver dysfunction characteristic of CDDG1.  
2. **Abnormality of movement** (e.g., choreoathetosis) and **EEG abnormality** reflect neurological involvement, consistent with the syndrome’s choreoathetosis phenotype.  
3. **Global developmental delay**, **hypotonia**, and **lateral ventricle dilatation** indicate widespread neurological dysfunction, typical of deglycosylation disorders affecting brain development.  
4. **Microcephaly** and **intrauterine growth retardation** suggest congenital origins, fitting CDDG1’s presentation of prenatal-onset growth and structural defects.  
5. Dysmorphic features (**epicanthus**, **short nose**) are common in congenital glycosylation disorders due to disrupted glycoprotein synthesis.  
6. While alacrimia (absent tears) is not explicitly listed, the combination of hepatic, neurological, and developmental abnormalities strongly supports CDDG1, as phenotypic variability is recognized.  
7. CDDG1 is caused by *NGLY1* mutations, impairing deglycosylation and leading to multi-organ dysfunction, as seen in this patient’s hepatic, neurological, and growth-related symptoms."
"['Microcephaly', 'Epicanthus', 'Strabismus', 'Alacrima', 'Oculomotor apraxia', 'Tapered finger', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Clinodactyly of the 5th toe', 'Frontal bossing', 'Constipation', 'Hypoplastic nipples', 'Elevated hepatic transaminase', 'Prominent metopic ridge', 'Prolonged neonatal jaundice', 'Chalazion', 'Tented upper lip vermilion', 'Clinodactyly of the 4th toe']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1  
Reasoning:  
1. **Alacrima**: A hallmark feature of this disorder, directly referenced in its name.  
2. **Liver dysfunction**: Supported by *prolonged neonatal jaundice* and *elevated hepatic transaminases*.  
3. **Neurological involvement**: *Global developmental delay*, *hypotonia*, *oculomotor apraxia*, and *reduced tendon reflexes* align with the syndrome’s neurological and movement-related manifestations (choreoathetosis, though not explicitly listed, is often part of the phenotype).  
4. **Dysmorphic features**: *Microcephaly*, *frontal bossing*, *prominent metopic ridge*, *epicanthus*, *tented upper lip vermilion*, *tapered fingers*, and *clinodactyly of the 4th/5th toes* are consistent with craniofacial and skeletal anomalies seen in congenital disorders of glycosylation.  
5. **Systemic involvement**: *Hypoplastic nipples*, *chalazion*, and *constipation* reflect multisystemic pathology typical of glycosylation defects.  
6. **Exclusion of mimics**: The combination of alacrima, liver dysfunction, and neurodevelopmental abnormalities is pathognomonic for this disorder, distinguishing it from other CDG subtypes or syndromes like Smith-Lemli-Opitz or NGLY1 deficiency."
"['Microcephaly', 'Wide nasal bridge', 'Strabismus', 'Recurrent corneal erosions', 'Proptosis', 'Alacrima', 'Oculomotor apraxia', 'Dental crowding', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Intrauterine growth retardation', 'Short foot', 'Constipation', 'EEG abnormality', 'Highly arched eyebrow', 'Scoliosis', 'Lack of facial subcutaneous fat', 'Small hand']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (NGLY1 deficiency)  
Reasoning:  
1. **Alacrima**: A hallmark feature of NGLY1 deficiency, directly linked to impaired tear production due to glycosylation defects.  
2. **Neurological symptoms** (Seizures, EEG abnormality, Global developmental delay, Hypotonia, Oculomotor apraxia): Reflect systemic neurodegeneration and disrupted glycoprotein metabolism critical for brain function.  
3. **Ocular abnormalities** (Proptosis, Strabismus, Recurrent corneal erosions): Secondary to alacrima (dry eyes causing corneal damage) and neuromuscular dysregulation.  
4. **Growth defects** (Microcephaly, Intrauterine growth retardation, Small hand/Short foot): Consistent with prenatal-onset glycosylation disorder affecting growth pathways.  
5. **Dysmorphic features** (Wide nasal bridge, Highly arched eyebrow, Lack of facial subcutaneous fat): Characteristic craniofacial patterns in congenital glycosylation disorders.  
6. **Musculoskeletal issues** (Scoliosis, Dental crowding): Connective tissue/glycoprotein abnormalities impacting bone and tissue structure.  
7. **Autonomic/Systemic involvement** (Constipation, Reduced tendon reflexes): Dysfunction in glycosylation-dependent autonomic signaling and neuromuscular junctions.  
8. **Absence of noted liver dysfunction**: While liver issues are part of the syndrome’s name, phenotypic variability exists; other symptoms dominate the clinical picture here.  

This constellation aligns with NGLY1 deficiency, a disorder of endoplasmic reticulum-associated degradation (ERAD) due to impaired deglycosylation, disrupting multiple glycoprotein-dependent processes."
"['Microcephaly', 'Aggressive behavior', 'Seizure', 'Intellectual disability, severe']","['Autosomal recessive primary microcephaly/Microcephaly, primary autosomal recessive, 1', 'Microcephaly 2, primary, autosomal recessive, with or without cortical malformations']","Disease: Microcephaly 2, primary, autosomal recessive, with or without cortical malformations  
Reasoning:  
1. **Severe intellectual disability and seizures** align with cortical malformations, a feature of MCPH2.  
2. **Aggressive behavior** may stem from severe neurological dysfunction linked to cortical abnormalities.  
3. MCPH2 (WDR62-related) commonly includes severe neurodevelopmental deficits and epilepsy, unlike MCPH1, which typically lacks seizures and cortical defects.  

Disease: Autosomal recessive primary microcephaly/Microcephaly, primary autosomal recessive, 1  
Reasoning:  
1. **Primary microcephaly** is a core feature of MCPH1.  
2. However, MCPH1 usually presents with **mild-to-moderate intellectual disability** and lacks seizures or cortical malformations, making it less consistent with the patient’s severe symptoms."
"['Nystagmus', 'Optic atrophy', 'Hypotonia', 'Lethargy', 'Dysarthria', 'Gait ataxia', 'Poor coordination', 'Undetectable visual evoked potentials', 'Bilateral sensorineural hearing impairment']","['Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome/Cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss']","Disease: Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome (CAPOS)  
Reasoning:  
1. **Cerebellar ataxia**: Supported by *gait ataxia* and *poor coordination*, indicating cerebellar dysfunction.  
2. **Optic atrophy**: Confirmed by *optic atrophy* and *undetectable visual evoked potentials*, reflecting optic nerve degeneration.  
3. **Sensorineural hearing loss**: Aligns with *bilateral sensorineural hearing impairment*.  
4. **Associated features**: *Nystagmus* and *dysarthria* are consistent with cerebellar/brainstem involvement. *Hypotonia* and *lethargy* may occur during acute episodes triggered by stressors (e.g., fever), a hallmark of CAPOS.  
5. **Genetic basis**: CAPOS is caused by ATP1A3 mutations, which disrupt ion transport, explaining multisystem neurological deficits.  
6. **Diagnostic exclusion**: While *areflexia* and *pes cavus* are not explicitly listed, CAPOS is prioritized due to the combination of cerebellar, optic, and auditory symptoms."
"['High palate', 'Retrognathia', 'Hypertelorism', 'Smooth philtrum', 'Micrognathia', 'Low-set ears', 'Downslanted palpebral fissures', 'Pectus carinatum', 'Arachnodactyly', 'Hyporeflexia', 'Craniosynostosis', 'Joint laxity', 'Umbilical hernia', 'Patent foramen ovale', 'Talipes equinovarus', 'Pes planus', 'Increased serum lactate', 'Aqueductal stenosis', 'Expressive language delay', 'Narrow iliac wing', 'Spina bifida occulta', 'Syringomyelia', 'Hyperactive deep tendon reflexes', 'Intellectual disability, borderline', 'Bilateral coxa valga', 'Prominent forehead']",['Shprintzen-Goldberg syndrome/Shprintzen-Goldberg craniosynostosis syndrome'],"Disease: Shprintzen-Goldberg syndrome/Shprintzen-Goldberg craniosynostosis syndrome  
Reasoning:  
1. **Craniofacial features**: Craniosynostosis (premature fusion of cranial sutures), prominent forehead, hypertelorism, downslanted palpebral fissures, retrognathia, micrognathia, high palate, smooth philtrum, and low-set ears align with the characteristic facial dysmorphism of Shprintzen-Goldberg syndrome (SGS).  
2. **Skeletal anomalies**: Arachnodactyly, joint laxity, pectus carinatum, narrow iliac wings, bilateral coxa valga, talipes equinovarus, and pes planus reflect the ""marfanoid habitus"" typical of SGS, though distinct from Marfan syndrome due to coexisting craniosynostosis.  
3. **Neurological/developmental findings**: Intellectual disability (borderline), expressive language delay, aqueductal stenosis (causing hydrocephalus risk), syringomyelia, and spina bifida occulta suggest multisystem neurological involvement, consistent with SGS.  
4. **Connective tissue/other features**: Umbilical hernia, patent foramen ovale (cardiac anomaly), and mixed reflex abnormalities (hyporeflexia and hyperactive deep tendon reflexes) are seen in SGS, which combines connective tissue and systemic defects.  
5. **Exclusion of mimics**: Overlap with Loeys-Dietz or Marfan syndromes is ruled out by the presence of craniosynostosis, a hallmark of SGS. Increased serum lactate may indicate secondary metabolic stress from hypotonia or respiratory compromise.  

The combination of craniosynostosis, marfanoid features, neurodevelopmental delays, and characteristic dysmorphism strongly supports Shprintzen-Goldberg syndrome."
"['High palate', 'Epicanthus', 'Hypertelorism', 'Short philtrum', 'High forehead', 'Anteverted nares', 'Single transverse palmar crease', 'Hypotonia', 'Global developmental delay', 'Absent speech', 'Frontal bossing', 'Hypoplasia of the corpus callosum', 'Gray matter heterotopia', 'Methylmalonic acidemia', 'Short nose', 'Lateral ventricle dilatation', 'Granular macular appearance', 'Sparse hair', 'Broad hallux', 'Tented upper lip vermilion', 'Methylmalonic aciduria', 'Delayed myelination', 'Elevated urinary 3-hydroxybutyric acid', 'Elevated urinary aminoisobutyric acid']",['Methylmalonate semialdehyde dehydrogenase deficiency'],"Disease: Methylmalonate semialdehyde dehydrogenase deficiency (MMSDH deficiency)  
Reasoning:  
1. **Metabolic Hallmarks**: The presence of *methylmalonic acidemia/uria* and elevated *urinary 3-hydroxybutyric acid* and *aminoisobutyric acid* directly implicates a defect in valine and thymine catabolism. MMSDH deficiency disrupts the final step of these pathways, causing accumulation of methylmalonate semialdehyde and its derivatives.  
2. **Neurological Features**: *Hypotonia*, *global developmental delay*, *absent speech*, and *delayed myelination* align with metabolic encephalopathy due to toxic metabolite buildup. Structural abnormalities (*hypoplasia of the corpus callosum*, *gray matter heterotopia*, *lateral ventricle dilatation*) suggest disrupted neurodevelopment from impaired metabolic pathways.  
3. **Dysmorphic Traits**: Facial features (*high palate, epicanthus, hypertelorism, short philtrum, tented upper lip, short nose, frontal bossing*) and *broad hallux* are consistent with syndromic metabolic disorders. *Single transverse palmar crease* and *sparse hair* further support a genetic etiology.  
4. **Ocular Findings**: *Granular macular appearance* may reflect retinal metabolic dysfunction, reported in mitochondrial or organic acidemias.  
5. **Exclusion of Alternatives**: Classic methylmalonic acidemias (e.g., mutase deficiency) typically lack the specific urinary metabolite profile (3-hydroxybutyric/aminoisobutyric acid elevation) seen here, narrowing the diagnosis to MMSDH deficiency.  

This constellation of metabolic, neurological, and dysmorphic features, combined with biochemical markers, strongly supports MMSDH deficiency as the unifying diagnosis."
"['Triangular face', 'Underdeveloped nasal alae', 'Deeply set eye', 'Rieger anomaly', 'Delayed eruption of teeth', 'Short stature', 'Prematurely aged appearance', 'Lipodystrophy']",['SHORT syndrome/Short syndrome'],"Disease: SHORT syndrome  
Reasoning:  
1. **Short Stature**: A core feature of SHORT syndrome, aligning with the patient's short stature.  
2. **Rieger Anomaly**: A hallmark of SHORT syndrome, involving iris and anterior eye abnormalities, present in the patient.  
3. **Delayed Eruption of Teeth**: Matches the ""Teething delay"" component of the SHORT acronym.  
4. **Deeply Set Eyes (Ocular Depression)**: Corresponds to the ""Ocular depression"" in the syndrome’s acronym.  
5. **Triangular Face and Underdeveloped Nasal Alae**: Characteristic facial dysmorphisms seen in SHORT syndrome.  
6. **Lipodystrophy and Prematurely Aged Appearance**: Results from abnormal fat distribution, a common feature contributing to a progeroid phenotype.  
7. **Exclusion of Overlapping Syndromes**: Progeria lacks Rieger anomaly/dental delays, while Rieger syndrome does not include lipodystrophy/short stature. The combined features strongly support SHORT syndrome."
"['Horseshoe kidney', 'Thick lower lip vermilion', 'Thick upper lip vermilion', 'Microcephaly', 'High forehead', 'Deeply set eye', 'Myopia', 'Upslanted palpebral fissure', 'Carious teeth', 'Dental malocclusion', 'Patent ductus arteriosus', 'Intellectual disability, moderate', 'Long nose', 'Low hanging columella', 'High anterior hairline', 'Short palpebral fissure']",['THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome/Beaulieu-Boycott-Innes syndrome'],"Disease: THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome/Beaulieu-Boycott-Innes syndrome  
Reasoning:  
1. **Microcephaly & Intellectual Disability**: Core features of the syndrome, aligning with the patient’s microcephaly and moderate intellectual disability.  
2. **Facial Dysmorphism**:  
   - **Thick Lips**: Thick upper/lower lip vermilion are hallmark facial features.  
   - **High Forehead/High Anterior Hairline**: Consistent with the syndrome’s craniofacial profile.  
   - **Long Nose & Low Hanging Columella**: Characteristic nasal features described in THOC6-related cases.  
   - **Deeply Set Eyes, Upslanted/Short Palpebral Fissures**: Ocular findings commonly reported.  
3. **Patent Ductus Arteriosus (PDA)**: Congenital heart defects, including PDA, are associated with the syndrome.  
4. **Horseshoe Kidney**: While less common, renal anomalies (e.g., horseshoe kidney) may occur in syndromic genetic disorders.  
5. **Dental/Ocular Features**: Dental malocclusion/carious teeth and myopia are secondary manifestations linked to craniofacial and developmental abnormalities.  
6. **Genetic Basis**: The constellation of symptoms strongly matches THOC6 gene mutation effects, which disrupt mRNA processing and neurodevelopment.  
**Exclusion**: Overlap with other syndromes (e.g., Cornelia de Lange) is ruled out by the specific combination of thick lips, long nose with low columella, and THOC6-associated cardiac/renal findings."
"['Recurrent urinary tract infections', 'Gingivitis', 'Recurrent otitis media', 'Splenomegaly', 'Neutropenia', 'Lymphopenia', 'Intermittent thrombocytopenia', 'Impaired ADP-induced platelet aggregation', 'Recurrent candida infections', 'Granulocytic hyperplasia']","['Severe congenital neutropenia; SCN', 'Neutropenia, severe congenital, 4, autosomal recessive']","Disease: Severe congenital neutropenia; SCN  
Reasoning: The patient exhibits **neutropenia** and **granulocytic hyperplasia**, hallmark features of SCN. Granulocytic hyperplasia reflects a bone marrow maturation arrest at the promyelocyte/myelocyte stage, explaining the inability to produce mature neutrophils. Recurrent bacterial infections (urinary tract infections, otitis media, gingivitis) align with neutrophil deficiency. Splenomegaly may arise from chronic infection or compensatory extramedullary hematopoiesis. Recurrent candida infections suggest broader immune dysfunction, possibly due to prolonged neutropenia or comorbid immune defects.  

Disease: Neutropenia, severe congenital, 4, autosomal recessive  
Reasoning: This subtype (G6PC3-related SCN) is supported by **intermittent thrombocytopenia** and **impaired ADP-induced platelet aggregation**, indicative of platelet dysfunction linked to G6PC3 mutations. Lymphopenia further suggests multilineage hematopoietic involvement, consistent with this genetic form. Recurrent candida infections and splenomegaly may reflect additional metabolic or immune anomalies associated with G6PC3 deficiency. The combination of neutropenia, thrombocytopenia, and platelet aggregation defects strongly points to this autosomal recessive subtype. Genetic testing for G6PC3 mutations would confirm the diagnosis."
"['Omphalocele', 'Intestinal obstruction', 'Intestinal atresia']",['Combined immunodeficiency-enteropathy spectrum/Gastrointestinal defects and immunodeficiency syndrome'],"Combined immunodeficiency-enteropathy spectrum/Gastrointestinal defects and immunodeficiency syndrome:  
- **Omphalocele** suggests a congenital midline abdominal wall defect, often linked to genetic syndromes affecting development.  
- **Intestinal atresia/obstruction** indicates structural gastrointestinal abnormalities, commonly seen in disorders like TTC7A-related syndromes, which disrupt intestinal and immune system development.  
- The co-occurrence of these defects with **immunodeficiency** points to a genetic etiology (e.g., TTC7A, FOXP3, or IL2RG mutations) causing both enteropathy and impaired immune cell function.  
- This triad aligns with syndromes in the combined immunodeficiency-enteropathy spectrum, where gastrointestinal malformations and immune dysfunction arise from shared molecular pathways."
"['Microcephaly', 'Strabismus', 'Alacrima', 'Oculomotor apraxia', 'Hypotonia', 'Global developmental delay', 'Hepatic fibrosis', 'Short foot', 'Constipation', 'Cerebral atrophy', 'Hypoplasia of the corpus callosum', 'Increased serum lactate', 'EEG abnormality', 'Small cerebral cortex', 'Elevated hepatic transaminase', 'Prolonged neonatal jaundice', 'Abnormal auditory evoked potentials', 'Chalazion', 'Hypoplastic anterior commissure', 'Abnormality of movement', 'Small hand']",['Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1'],"Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (NGLY1 deficiency)  
Reasoning:  
1. **Alacrima**: A hallmark feature of this syndrome, directly referenced in the disease name.  
2. **Hepatic fibrosis & elevated hepatic transaminases**: Matches the ""liver dysfunction"" component, common in deglycosylation disorders due to impaired protein quality control.  
3. **Hypoplasia of the corpus callosum, cerebral atrophy, small cerebral cortex**: Structural brain abnormalities linked to defective NGLY1, critical for neuronal development and glycosylation.  
4. **Global developmental delay, hypotonia, oculomotor apraxia, movement abnormalities**: Neurological manifestations from disrupted deglycosylation, affecting motor and cognitive pathways.  
5. **Increased serum lactate**: Suggests mitochondrial dysfunction, associated with NGLY1 deficiency.  
6. **Prolonged neonatal jaundice**: Consistent with early-onset liver involvement.  
7. **Chalazion, strabismus**: Ocular defects reported in NGLY1-related disorders.  
8. **Small hand/short foot, constipation**: Connective tissue or autonomic dysfunction due to glycosylation defects.  
9. **EEG/auditory evoked potential abnormalities**: Reflects widespread neuronal dysfunction.  
10. **Hypoplastic anterior commissure**: Rare finding specific to severe neurodevelopmental disorders like CDDG1.  

The triad of **alacrima, liver dysfunction, and movement disorders** (choreoathetosis) with multisystem involvement strongly supports this diagnosis. NGLY1 mutations disrupt endoplasmic reticulum-associated degradation (ERAD), causing systemic glycosylation defects."
"['Wrist swelling', 'Joint hypermobility', 'Abnormality of the gluteal musculature', 'Thrombocytosis', 'Leukocytosis', 'Low back pain', 'Foot pain', 'Neck pain', 'Shoulder pain', 'Elbow pain', 'Wrist pain', 'Knee pain']","['Spondyloarthropathy, susceptibility to, 1']","Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning:  
1. **Axial Involvement**: Low back pain and neck pain suggest inflammatory spinal involvement, a hallmark of spondyloarthropathy.  
2. **Peripheral Arthritis**: Wrist swelling and pain in multiple joints (shoulder, elbow, knee, foot) align with asymmetric peripheral arthritis seen in spondyloarthropathies.  
3. **Systemic Inflammation**: Thrombocytosis and leukocytosis indicate an active inflammatory process, consistent with immune-mediated arthropathies.  
4. **Enthesitis**: Abnormality of the gluteal musculature may reflect enthesitis (inflammation at tendon/ligament insertions) near the pelvis or hips, common in this disease group.  
5. **Genetic Predisposition**: The diagnosis code implies HLA-B27 or other genetic markers linked to spondyloarthropathy susceptibility.  
6. **Exclusion of Alternatives**: Symptoms lack symmetry (unlike rheumatoid arthritis) or overt infection (unlike reactive arthritis), favoring spondyloarthropathy. Joint hypermobility may be incidental or secondary to chronic inflammation."
"['Membranoproliferative glomerulonephritis', 'Leukocytosis', 'Recurrent respiratory infections', 'Vasculitis', 'Increased circulating IgM level', 'Cryoglobulinemia']","['Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed']","Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed:  
1. **Cryoglobulinemia** is directly noted, a hallmark of the disease, where cryoglobulins precipitate in cold conditions, causing vascular inflammation.  
2. **Vasculitis** aligns with cryoglobulin-induced vascular damage, a core feature of cryoglobulinemic vasculitis.  
3. **Membranoproliferative glomerulonephritis (MPGN)** is a common renal manifestation of cryoglobulinemia due to immune complex deposition in glomeruli.  
4. **Increased circulating IgM** suggests type II cryoglobulinemia (mixed), where IgM acts as a rheumatoid factor, forming immune complexes.  
5. **Recurrent respiratory infections** may stem from immune dysfunction secondary to chronic immune complex deposition or complement consumption.  
6. **Leukocytosis** reflects systemic inflammation driven by vasculitis and recurrent infections.  
The familial form indicates a genetic predisposition, differentiating it from secondary causes (e.g., hepatitis C)."
"['Oral ulcer', 'Sinusitis', 'Tinnitus', 'Hearing impairment', 'Visual loss', 'Diplopia', 'Nephrolithiasis', 'Hematuria', 'Keratoconjunctivitis sicca', 'Abnormality of the hand', 'Syncope', 'Arthritis', 'Eosinophilia', 'Renal tubular acidosis', 'Nausea', 'Abdominal pain', 'Hypercalciuria', 'Headache', 'Vertigo', 'Bone pain', 'Exertional dyspnea', 'Elevated circulating creatine kinase concentration', 'Myalgia', 'Paresthesia', 'Back pain', 'Somatic sensory dysfunction', 'Hypouricemia', 'Deviated nasal septum', 'Generalized morning stiffness', 'Limb pain', 'Decreased urinary urate', 'Fatigue', 'Mild proteinuria', 'Oral cavity bleeding', 'Neck pain', 'Wrist pain', 'Ankle pain', 'Aphthous ulcer', 'Chest pain', 'Lymphocytosis', 'Papule', 'Pustule', 'Epigastric pain']",['Behçet disease/Behcet syndrome'],"Disease: Behçet disease/Behcet syndrome  
Reasoning:  
1. **Mucocutaneous Involvement**: Recurrent oral ulcers (""Oral ulcer,"" ""Aphthous ulcer"") and genital ulcers (implied by Behçet’s diagnostic criteria) are hallmark features. ""Oral cavity bleeding"" aligns with ulcerative mucosal damage. Skin lesions (""Papule,"" ""Pustule"") correlate with Behçet’s papulopustular eruptions.  
2. **Ocular Manifestations**: ""Visual loss"" and ""Diplopia"" suggest posterior uveitis, retinal vasculitis, or optic neuritis, common in Behçet’s. ""Keratoconjunctivitis sicca"" may indicate secondary dryness from inflammation.  
3. **Neurological Involvement**: ""Headache,"" ""Vertigo,"" ""Syncope,"" ""Paresthesia,"" and ""Somatic sensory dysfunction"" point to neuro-Behçet’s, which can cause meningoencephalitis or vascular CNS lesions.  
4. **Musculoskeletal Symptoms**: ""Arthritis,"" ""Wrist pain,"" ""Ankle pain,"" and ""Generalized morning stiffness"" reflect Behçet’s-associated non-erosive oligoarthritis.  
5. **Vascular Inflammation**: ""Chest pain"" may indicate pericarditis or vasculitis. ""Exertional dyspnea"" could stem from pulmonary artery aneurysms, a rare but severe Behçet’s complication.  
6. **Gastrointestinal Involvement**: ""Abdominal pain,"" ""Nausea,"" and ""Epigastric pain"" align with intestinal ulcers, a mimic of Crohn’s disease in Behçet’s.  
7. **Atypical Associations**: While ""Renal tubular acidosis"" and ""Hypercalciuria"" are uncommon in Behçet’s, secondary autoimmune tubulointerstitial nephritis or overlapping syndromes could explain these.  
8. **Inflammatory Markers**: ""Eosinophilia"" and ""Lymphocytosis"" suggest systemic inflammation, consistent with Behçet’s flares.  

**Key Exclusions**:  
- Sjögren’s syndrome (keratoconjunctivitis sicca) is less likely without anti-SSA/SSB antibodies or prominent sicca symptoms.  
- Sarcoidosis (hypercalciuria, lymphocytosis) lacks typical granulomas or hilar adenopathy here.  
- Vasculitides like GPA (sinusitis, renal issues) are excluded by the absence of ANCA or necrotizing glomerulonephritis.  

**Conclusion**: The constellation of mucocutaneous, ocular, neurological, and vascular symptoms strongly supports Behçet’s syndrome, despite atypical renal findings. Further evaluation with pathergy testing, HLA-B51 testing, and imaging (e.g., angiography for vasculitis) would solidify the diagnosis."
"['Epistaxis', 'Hemoptysis', 'Pulmonary infiltrates', 'Arthralgia', 'Microscopic hematuria', 'Elevated circulating C-reactive protein concentration', 'Decreased glomerular filtration rate', 'Cytoplasmic antineutrophil antibody positivity']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Respiratory involvement**: Epistaxis (nasal inflammation) and hemoptysis (alveolar hemorrhage) with pulmonary infiltrates suggest granulomatous inflammation and vasculitis in the upper/lower respiratory tract.  
2. **Renal involvement**: Microscopic hematuria and decreased glomerular filtration rate indicate pauci-immune glomerulonephritis, a hallmark of systemic vasculitis.  
3. **Systemic inflammation**: Elevated C-reactive protein and arthralgia reflect systemic inflammation.  
4. **Immunological markers**: Cytoplasmic antineutrophil antibody (c-ANCA) positivity, typically targeting PR3, strongly supports GPA.  
5. **Triad alignment**: Combined respiratory, renal, and systemic features with c-ANCA positivity fulfill diagnostic criteria for GPA, distinguishing it from other ANCA-associated vasculitides (e.g., microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis)."
"['Proteinuria', 'Ascites', 'Acute pancreatitis', 'Splenomegaly', 'Pancytopenia', 'Fever', 'Diarrhea', 'Abdominal pain', 'Peritonitis', 'Arthralgia', 'Elevated circulating creatine kinase concentration', 'Generalized muscle weakness', 'Myalgia', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Hypovolemia', 'Fatigue', 'Increased circulating lactate dehydrogenase concentration', 'Hydrometrocolpos', 'Epigastric pain']","['Systemic lupus erythematosus 16', 'Vitiligo-Associated multiple autoimmune disease susceptibility 1', 'Systemic lupus erythematosus, susceptibility to, 6', 'Pediatric systemic lupus erythematosus', 'Systemic lupus erythematosus']","Disease: Systemic lupus erythematosus  
Reasoning: The patient presents with multisystem involvement, including renal (proteinuria), hematologic (pancytopenia), musculoskeletal (myalgia, arthralgia, elevated creatine kinase), and immunologic (ANA positivity) manifestations. Fever, fatigue, and abdominal pain with serositis (ascites, peritonitis) further support SLE. Elevated LDH and muscle weakness may indicate lupus-related myositis or hemolysis. Acute pancreatitis and splenomegaly are rare but documented in SLE.  

Disease: Pediatric systemic lupus erythematosus  
Reasoning: While age is unspecified, symptoms like hydrometrocolpos (a congenital anomaly sometimes associated with pediatric autoimmune conditions) and pancytopenia could suggest early-onset SLE. Pediatric SLE often presents with severe renal and hematologic involvement, aligning with proteinuria and pancytopenia.  

Disease: Systemic lupus erythematosus, susceptibility to, 6  
Reasoning: Genetic susceptibility loci like SLEB6 (ITGAM gene) are linked to renal and hematologic phenotypes. Proteinuria, pancytopenia, and ANA positivity align with this genetic predisposition, though confirmatory testing would be required.  

Disease: Vitiligo-Associated multiple autoimmune disease susceptibility 1  
Reasoning: While vitiligo is not explicitly listed, overlapping autoimmune features (ANA positivity, pancreatitis, myositis) could suggest polyautoimmunity. However, this diagnosis is less definitive without vitiligo or confirmed genetic markers.  

Disease: Systemic lupus erythematosus 16  
Reasoning: Linked to DNASE1L3 mutations, causing severe renal and serosal inflammation (proteinuria, ascites, peritonitis). Elevated LDH and creatine kinase may reflect tissue damage from impaired apoptotic clearance, a hallmark of this subtype.  

**Note:** Hydrometrocolpos is an outlier; it may indicate a concurrent congenital anomaly (e.g., Müllerian duct obstruction) unrelated to SLE, necessitating further evaluation."
"['Renal insufficiency', 'Proteinuria', 'Glomerulonephritis', 'Renal cyst', 'Uveitis', 'Arthritis', 'Lymphopenia', 'Pulmonary embolism', 'Deep venous thrombosis', 'Microscopic hematuria', 'Reduced coagulation factor V activity', 'Antinuclear antibody positivity', 'Renal cell carcinoma', 'Knee pain', 'Anti-beta 2 glycoprotein I antibody positivity']","['Renal cell carcinoma, xp11-associated', 'Systemic lupus erythematosus 16', 'Vitiligo-Associated multiple autoimmune disease susceptibility 1', 'Systemic lupus erythematosus, susceptibility to, 6', 'Pediatric systemic lupus erythematosus', 'Systemic lupus erythematosus', 'Renal cell carcinoma, papillary, 1, familial and somatic', 'Renal cell carcinoma, nonpapillary']","Disease: Systemic lupus erythematosus  
Reasoning: The patient exhibits ANA positivity, lymphopenia, arthritis, glomerulonephritis, and anti-beta 2 glycoprotein I antibody positivity, which are hallmark features of SLE. Anti-beta 2 glycoprotein antibodies suggest secondary antiphospholipid syndrome (APS), explaining thrombotic events (pulmonary embolism, DVT). Lupus nephritis accounts for renal insufficiency, proteinuria, and microscopic hematuria.  

Disease: Renal cell carcinoma, xp11-associated  
Reasoning: The presence of renal cell carcinoma and renal cysts aligns with this rare translocation-associated subtype, often seen in younger individuals. While SLE explains most autoimmune features, xp11-associated RCC is distinct, though co-occurrence may reflect a paraneoplastic phenomenon or incidental finding.  

Disease: Anti-beta 2 glycoprotein I antibody positivity (as part of SLE/APS)  
Reasoning: While not a standalone diagnosis here, this antibody confirms APS, a common SLE complication. It directly contributes to the hypercoagulable state (thrombosis, reduced Factor V activity due to assay interference from lupus anticoagulant).  

---  
**Note**: The provided list includes overlapping SLE susceptibility genes (e.g., SLE16, SLE6), but without genetic testing or family history, the broader ""Systemic lupus erythematosus"" diagnosis is most appropriate. Similarly, ""Renal cell carcinoma, xp11-associated"" is prioritized over other RCC subtypes due to its association with younger demographics and distinct molecular profile."
"['Renal hypoplasia', 'Renal cyst', 'Xerostomia', 'Hepatic cysts', 'Ankle swelling', 'Palpitations', 'Dysphagia', 'Nausea', 'Gastroesophageal reflux', 'Abdominal pain', 'Hiatus hernia', 'Bronchiectasis', 'Vertigo', 'Increased blood urea nitrogen', 'Elevated circulating parathyroid hormone level', 'Elevated circulating creatine kinase concentration', 'Elevated circulating creatinine concentration', 'Back pain', 'Elevated erythrocyte sedimentation rate', 'Premature ventricular contraction', 'Chronic oral candidiasis', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia', 'Decreased glomerular filtration rate', 'Fatigue', 'Bronchitis', 'Lower limb pain', 'Ground-glass opacification', 'Nodular pattern on pulmonary HRCT', 'Autoimmune antibody positivity', 'Crackles', 'Reduced FEV1/FVC ratio', 'Sputum eosinophilia', 'Decreased DLCO', 'Abnormality of nail color', 'Epigastric pain']",['Primary Sjögren syndrome/Sjogren syndrome'],"Disease: Primary Sjögren Syndrome  
**Reasoning**:  
1. **Exocrine Gland Dysfunction**:  
   - **Xerostomia** (dry mouth) and **chronic oral candidiasis** are hallmark features of Sjögren syndrome, reflecting salivary gland involvement and secondary fungal infection due to reduced saliva.  
   - **Dysphagia**, **gastroesophageal reflux**, and **hiatus hernia** may arise from decreased saliva production and esophageal dysmotility linked to autonomic dysfunction.  

2. **Autoimmune Features**:  
   - **Autoimmune antibody positivity** (e.g., anti-SSA/Ro or anti-SSB/La) is diagnostic for Sjögren syndrome.  
   - **Elevated ESR**, **CRP**, and **neutrophilia** indicate systemic inflammation.  

3. **Pulmonary Involvement**:  
   - **Bronchiectasis**, **crackles**, **ground-glass opacities**, and **nodular patterns on HRCT** suggest interstitial lung disease (ILD), a common extraglandular manifestation.  
   - **Reduced DLCO** and **FEV1/FVC ratio** reflect restrictive/obstructive patterns from lymphocytic infiltration or bronchiolitis.  

4. **Renal Abnormalities**:  
   - **Renal hypoplasia**, **decreased GFR**, and elevated **creatinine/urea nitrogen** align with tubulointerstitial nephritis, a frequent renal complication.  
   - **Elevated parathyroid hormone** may indicate secondary hyperparathyroidism due to chronic kidney disease.  

5. **Musculoskeletal and Systemic Inflammation**:  
   - **Back pain**, **lower limb pain**, and **elevated creatine kinase** suggest inflammatory myopathy or arthralgias.  
   - **Fatigue** and **abdominal/epigastric pain** correlate with systemic autoimmune activity and possible gastrointestinal dysmotility.  

6. **Extraglandular Manifestations**:  
   - **Hepatic cysts** are atypical but may coexist with autoimmune liver disease.  
   - **Vertigo** and **palpitations/premature ventricular contractions** could stem from autonomic neuropathy or electrolyte imbalances (e.g., hypercalcemia from hyperparathyroidism).  

**Conclusion**: The constellation of sicca symptoms, systemic inflammation, multi-organ involvement (renal, pulmonary, hepatic), and autoimmune markers strongly supports **primary Sjögren syndrome**. Overlapping features (e.g., ILD, nephritis) are consistent with its extraglandular manifestations."
"['Abnormality of the face', 'Hyperhidrosis', 'Pallor', 'Syncope', 'Weight loss', 'Leukocytosis', 'Vomiting', 'Nausea', 'Headache', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Fatigue', 'Pain', 'Chills', 'Jaw claudication']",['Giant cell arteritis/Temporal arteritis'],"Disease: Giant cell arteritis/Temporal arteritis  
Reasoning:  
1. **Jaw claudication** is a hallmark symptom of GCA due to ischemia of the masseter muscles caused by inflammation of the temporal arteries.  
2. **Headache** (often temporal) and **elevated ESR** strongly suggest systemic inflammation, consistent with GCA.  
3. **Weight loss**, **fatigue**, **chills**, and **pain** align with systemic inflammatory responses seen in GCA.  
4. **Syncope** and **exercise intolerance** may result from reduced blood flow or anemia (linked to **pallor**) secondary to chronic inflammation.  
5. **Leukocytosis** supports an inflammatory process, though less specific, it complements the elevated ESR.  
6. **Hyperhidrosis**, **nausea**, and **vomiting** are non-specific but may reflect autonomic dysregulation or systemic illness.  
7. GCA is a critical diagnosis due to the risk of irreversible complications (e.g., vision loss), necessitating prompt treatment with corticosteroids."
"['Hypermetropia', 'Uveitis', 'Keratoconjunctivitis sicca', 'Abnormality of the gluteal musculature', 'Kyphosis', 'Microscopic hematuria', 'Back pain', 'Generalized morning stiffness', 'Low levels of vitamin D']","['Spondyloarthropathy, susceptibility to, 1', 'Spondyloarthropathy, susceptibility to, 2']","Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: The patient’s back pain, morning stiffness, and kyphosis align with axial spondyloarthropathy, which commonly involves spinal inflammation and postural changes. Uveitis is a hallmark extra-articular manifestation of SpA, strongly supporting this diagnosis. HLA-B27 (a genetic marker for susceptibility 1) is frequently associated with these features. The gluteal musculature abnormality may reflect enthesitis or chronic compensatory postural adjustments.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: Microscopic hematuria could indicate renal involvement, potentially linked to IgA nephropathy, which has been sporadically associated with SpA. Keratoconjunctivitis sicca may suggest secondary autoimmune overlap, though less typical. Low vitamin D may exacerbate skeletal inflammation and contribute to kyphosis. Susceptibility 2 might involve non-HLA-B27 genetic variants (e.g., ERAP1/IL23R), which could explain broader immune dysregulation and atypical features like renal or ocular surface involvement. Hypermetropia is likely incidental but underscores the need for multidisciplinary evaluation."
"['Renal insufficiency', 'Abnormality of the nose', 'Pruritus', 'Hypertrophic cardiomyopathy', 'Dilated cardiomyopathy', 'Pericardial effusion', 'Left ventricular hypertrophy', 'Fever', 'Dyspnea', 'Abnormal circulating protein concentration', 'Decreased glomerular filtration rate', 'Fatigue', 'Reduced left ventricular ejection fraction', 'Cough', 'Myocarditis', 'Sputum eosinophilia']",['Takayasu arteritis/Takayasu arteritis'],"Disease: Takayasu arteritis  
Reasoning:  
1. **Vascular Inflammation**: Takayasu arteritis involves large-vessel inflammation, primarily affecting the aorta and its branches. Renal artery stenosis (from vasculitis) can explain **renal insufficiency**, **decreased glomerular filtration rate**, and secondary hypertension, contributing to **left ventricular hypertrophy**.  
2. **Cardiac Manifestations**: Chronic hypertension and inflammatory damage may lead to **hypertrophic cardiomyopathy** and **reduced left ventricular ejection fraction**. Systemic inflammation can cause **myocarditis** and **pericardial effusion**.  
3. **Systemic Inflammation**: **Fever**, **fatigue**, and **abnormal circulating protein concentrations** (e.g., elevated acute-phase reactants like CRP) align with active vasculitis.  
4. **Atypical Features**: **Sputum eosinophilia** and **pruritus** are uncommon in Takayasu but may reflect overlapping autoimmune processes or secondary hypersensitivity reactions. **Abnormality of the nose** (e.g., granulomatous inflammation) could represent rare extrapulmonary involvement.  
5. **Respiratory Symptoms**: **Dyspnea** and **cough** may arise from heart failure (due to cardiomyopathy) or pulmonary artery involvement, a recognized but less common feature of Takayasu.  
6. **Exclusion of Alternatives**: While eosinophilia might suggest Churg-Strauss syndrome, the dominance of large-vessel and cardiac pathology supports Takayasu as the primary diagnosis.  

Note: Coexisting conditions (e.g., secondary amyloidosis) should be ruled out given renal and protein abnormalities, but the clinical picture primarily fits Takayasu arteritis with multisystem complications."
"['Urinary urgency', 'Sinusitis', 'Tachycardia', 'Fever', 'Leukocytosis', 'Hemoptysis', 'Pleural effusion', 'Abnormal EKG', 'Atrial fibrillation', 'Elevated circulating C-reactive protein concentration', 'Cough', 'Reduced haptoglobin level', 'Nodular pattern on pulmonary HRCT', 'Episcleritis', 'Chest pain']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Granulomatosis with polyangiitis (GPA):  
1. **Upper respiratory involvement**: Chronic sinusitis is a hallmark of GPA, often preceding systemic manifestations.  
2. **Pulmonary features**: Hemoptysis, cough, chest pain, nodular pattern on HRCT, and pleural effusion align with necrotizing granulomatous inflammation and vasculitis in the lungs.  
3. **Renal involvement**: Urinary urgency may indicate early kidney disease (glomerulonephritis), though hematuria/proteinuria are more typical; renal biopsy would confirm.  
4. **Ocular manifestation**: Episcleritis is a common ocular manifestation of GPA.  
5. **Systemic inflammation**: Fever, leukocytosis, and elevated CRP reflect active vasculitis.  
6. **Cardiac complications**: Atrial fibrillation and abnormal EKG suggest cardiac involvement (rare but reported in GPA due to inflammation or secondary effects).  
7. **Hematologic abnormalities**: Reduced haptoglobin hints at microangiopathic hemolysis (occurs in severe vasculitis).  
8. **Multisystem pattern**: The combination of respiratory, renal, ocular, and systemic symptoms strongly supports GPA, a small-to-medium vessel ANCA-associated vasculitis.  

**Definitive diagnosis** requires ANCA testing (PR3-ANCA positivity), biopsy (necrotizing granulomas), and exclusion of mimics (e.g., infections, other vasculitides)."
"['Xerostomia', 'Decreased lacrimation', 'Abnormal finger morphology', 'Wrist swelling', 'Abnormal foot morphology', 'Microcytic anemia', 'Migraine', 'Abnormality of the knee', 'Arthralgia', 'Rheumatoid factor positive', 'Increased circulating IgE level', 'Increased circulating IgG level', 'Myalgia', 'Muscle spasm', 'Antinuclear antibody positivity', 'Gastrointestinal inflammation', 'Generalized morning stiffness', 'Gastritis', 'Abnormal metacarpophalangeal joint morphology', 'Wrist pain', 'Knee pain', 'Ankle pain', 'Anti-La/SS-B antibody positivity', 'Increased circulating procalcitonin concentration']","['Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis', 'Reactive arthritis', 'Primary Sjögren syndrome/Sjogren syndrome', 'Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis', 'Systemic-onset juvenile idiopathic arthritis']","Disease: Primary Sjögren syndrome/Sjogren syndrome  
Reasoning: Xerostomia (dry mouth) and decreased lacrimation (dry eyes) are hallmark sicca symptoms of Sjögren syndrome. Anti-La/SS-B antibody positivity strongly supports this diagnosis, as these antibodies are specific to Sjögren syndrome. Increased circulating IgG and IgE levels align with autoimmune hyperactivity, and ANA positivity is common in Sjögren syndrome.  

Disease: Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis  
Reasoning: Wrist swelling, wrist/knee/ankle pain, arthralgia, morning stiffness, and rheumatoid factor positivity indicate inflammatory polyarthritis. Abnormal metacarpophalangeal joint morphology and systemic features (e.g., myalgia, elevated procalcitonin) further support juvenile idiopathic arthritis (JIA). Rheumatoid factor positivity specifically distinguishes the polyarticular RF-positive subtype.  

Disease: Reactive arthritis  
Reasoning: Asymmetric joint involvement (wrist, knee, ankle), gastrointestinal inflammation, and elevated procalcitonin (suggesting prior infection) could indicate reactive arthritis. However, this is less likely given the presence of Sjögren-specific antibodies and rheumatoid factor positivity, which point to autoimmune rather than post-infectious etiology.  

Excluded: Systemic-onset juvenile idiopathic arthritis  
Reasoning: Systemic-onset JIA typically presents with quotidian fevers, evanescent rash, and marked systemic inflammation, which are absent here. The patient’s symptoms focus on joints and autoantibodies, not systemic features.  

Excluded: Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis  
Reasoning: Rheumatoid factor positivity directly contradicts this diagnosis. The patient’s joint abnormalities and inflammation align with RF-positive JIA instead.  

**Final Diagnosis**: Coexisting **Primary Sjögren syndrome** and **Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis**, given overlapping autoimmune features (sicca symptoms, RF/ANA/anti-La positivity) and inflammatory polyarthritis."
"['Focal segmental glomerulosclerosis', 'Striae distensae', 'Hyperuricemia', 'Hypertriglyceridemia', 'Microscopic hematuria', 'Elevated hepatic transaminase', 'Hypoalbuminemia', 'Hypercholesterolemia', 'Increased blood urea nitrogen', 'Hyperuricosuria', 'Elevated erythrocyte sedimentation rate', 'Increased alpha-globulin', 'Hyperkeratosis with erythema', 'Nephrosclerosis', 'Erythema', 'Abnormal blood sodium concentration', 'Elevated circulating C-reactive protein concentration', 'Decreased glomerular filtration rate', 'Mild proteinuria', 'obsolete Increased urinary urate', 'Pollakisuria']","['Focal segmental glomerulosclerosis 9', 'Focal segmental glomerulosclerosis 8', 'Focal segmental glomerulosclerosis 3, susceptibility to', 'Focal segmental glomerulosclerosis 4, susceptibility to', 'Focal segmental glomerulosclerosis 1', 'Glomerulosclerosis, focal segmental, 5', 'Focal segmental glomerulosclerosis 6', 'Focal segmental glomerulosclerosis 7', 'Focal segmental glomerulosclerosis 2']","Disease: Focal segmental glomerulosclerosis 2 (NPHS2)  
Reasoning: The patient presents with steroid-resistant nephrotic syndrome features (hypoalbuminemia, hyperlipidemia, mild proteinuria) and FSGS. NPHS2 mutations (podocin) are a common genetic cause of early-onset, autosomal recessive FSGS. While hyperuricemia and hyperuricosuria are not directly linked to NPHS2, they may arise secondary to progressive renal dysfunction.  

Disease: Focal segmental glomerulosclerosis 3, susceptibility to (TRPC6)  
Reasoning: TRPC6 mutations cause autosomal dominant FSGS with variable age of onset. Elevated hepatic transaminases and inflammatory markers (CRP, ESR) could reflect systemic endothelial dysfunction linked to TRPC6-mediated calcium signaling abnormalities. However, direct correlation with uric acid metabolism remains unclear.  

Disease: Focal segmental glomerulosclerosis 1 (ACTN4)  
Reasoning: ACTN4 mutations cause adult-onset FSGS with dominant inheritance. Hypoalbuminemia, hypertriglyceridemia, and hypercholesterolemia align with nephrotic syndrome. Hyperuricemia and nephrosclerosis may develop due to chronic kidney injury rather than a primary genetic defect.  

Disease: Focal segmental glomerulosclerosis 9 (COL4A5)  
Reasoning: COL4A5 mutations cause X-linked Alport syndrome, which can manifest as FSGS in later stages. Microscopic hematuria and elevated transaminases (possibly due to collagen defects) support this, but absence of hearing loss or ocular anomalies weakens the association.  

Disease: Focal segmental glomerulosclerosis 7 (PAX2)  
Reasoning: PAX2 mutations are linked to renal-coloboma syndrome, characterized by FSGS and optic nerve defects. The patient’s erythema and hyperkeratosis might reflect ectodermal dysplasia, though overt coloboma is not reported.  

Disease: Focal segmental glomerulosclerosis 5 (INF2)  
Reasoning: INF2 mutations cause FSGS with Charcot-Marie-Tooth neuropathy. Elevated transaminases and ESR could hint at systemic inflammation, but the absence of neuropathy reduces likelihood.  

Disease: Focal segmental glomerulosclerosis 4, susceptibility to (CD2AP)  
Reasoning: CD2AP variants increase susceptibility to FSGS, particularly in the context of comorbidities like hypertension (nephrosclerosis) or metabolic stress (hyperuricemia, dyslipidemia). This may explain the multifactorial presentation.  

**Excluded Subtypes**:  
- **FSGS6 (MYO1E)**: Typically presents in childhood with severe proteinuria, which is inconsistent with ""mild proteinuria"" here.  
- **FSGS8 (ANLN)**: Associated with rapidly progressive glomerulonephritis, not evident in this case.  

**Final Likely Diagnosis**: **Focal segmental glomerulosclerosis 2 (NPHS2)** due to its strong association with steroid-resistant nephrotic syndrome and early renal dysfunction, though secondary contributors (e.g., metabolic syndrome) may exacerbate hyperuricemia and tubular defects."
"['Oral ulcer', 'Sinusitis', 'Abnormal nasal mucosa morphology', 'Thrombocytosis', 'Fever', 'Leukocytosis', 'Dyspnea', 'Abnormality of the knee', 'Elevated circulating alkaline phosphatase concentration', 'Elevated erythrocyte sedimentation rate', 'Increased alpha-globulin', 'Elevated circulating C-reactive protein concentration', 'Erythema nodosum', 'Cervical lymphadenopathy', 'Elevated gamma-glutamyltransferase level', 'Retinitis', 'Aphthous ulcer', 'Mediastinal lymphadenopathy', 'Chest pain']",['Behçet disease/Behcet syndrome'],"Disease: Behçet disease/Behcet syndrome  
Reasoning:  
1. **Mucocutaneous Involvement**: Recurrent oral and aphthous ulcers are hallmark features of Behçet’s disease. Erythema nodosum, a skin lesion, further supports this category.  
2. **Ocular Manifestations**: Retinitis aligns with Behçet’s ocular involvement, typically presenting as uveitis or retinal vasculitis.  
3. **Systemic Inflammation**: Elevated ESR, CRP, leukocytosis, and thrombocytosis reflect a systemic inflammatory response, consistent with Behçet’s flares.  
4. **Articular Involvement**: Abnormality of the knee suggests arthritis, commonly non-erosive in Behçet’s.  
5. **Vascular/Thoracic Features**: Dyspnea, chest pain, and mediastinal lymphadenopathy may indicate vasculitis affecting pulmonary or mediastinal vessels, a known complication.  
6. **Lymphatic Involvement**: Cervical lymphadenopathy is occasionally seen during active disease.  
7. **Atypical Overlaps**: Sinusitis and abnormal nasal mucosa are less typical but may occur secondary to inflammation. Elevated liver enzymes (ALP/GGT) are nonspecific but could reflect systemic illness.  
8. **Exclusion of Mimics**: The absence of granulomas (unlike sarcoidosis/GPA) and dominance of mucosal/skin lesions over gastrointestinal symptoms (unlike Crohn’s) solidify Behçet’s as the diagnosis.  

Final diagnosis hinges on the combination of major criteria (oral ulcers, erythema nodosum, ocular lesions) with multisystem inflammation, fulfilling the International Criteria for Behçet’s Disease."
"['Renal insufficiency', 'Glomerulonephritis', 'Sinusitis', 'Abnormality of the nose', 'Conjunctivitis', 'Fever', 'Hemoptysis', 'Exercise intolerance', 'Cough', 'Shoulder pain', 'Elbow pain', 'Knee pain', 'Pulmonary hemorrhage', 'Oliguria']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Upper respiratory involvement**: Sinusitis and nasal abnormalities (e.g., ulcers, crusting) are classic early signs of GPA.  
2. **Pulmonary manifestations**: Cough, hemoptysis, and pulmonary hemorrhage indicate alveolar capillaritis and vasculitis in the lungs.  
3. **Renal disease**: Glomerulonephritis (often rapidly progressive) with renal insufficiency and oliguria reflects pauci-immune necrotizing glomerulonephritis, a hallmark of GPA.  
4. **Systemic inflammation**: Fever and arthralgias (shoulder, elbow, knee pain) suggest systemic vasculitis.  
5. **Ocular involvement**: Conjunctivitis aligns with GPA-associated ocular inflammation.  
6. **ANCA association**: GPA is strongly linked to c-ANCA/PR3-ANCA, which drives small-vessel vasculitis and granuloma formation.  
7. **Multisystem pattern**: The combination of respiratory, renal, musculoskeletal, and constitutional symptoms is pathognomonic for GPA, distinguishing it from mimics like microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis."
"['Renal insufficiency', 'Renal cyst', 'Visual loss', 'Hypertension', 'Purpura', 'Hepatic steatosis', 'Hepatic cysts', 'Tubulointerstitial nephritis', 'Nausea', 'Abnormal lung morphology', 'Dyspnea', 'Headache', 'Microscopic hematuria', 'Nephrosclerosis', 'Pyuria', 'Fatigue', 'Peripheral edema', 'Bacteriuria', 'Moderate albuminuria', 'Cough', 'Nitrituria', 'Mediastinal lymphadenopathy']","['Sarcoidosis/Sarcoidosis, susceptibility to, 1', 'Sarcoidosis, susceptibility to, 2']","Sarcoidosis/Sarcoidosis, susceptibility to, 1:  
The patient presents with **mediastinal lymphadenopathy**, **abnormal lung morphology**, **dyspnea**, and **cough**, which are hallmark features of pulmonary sarcoidosis. **Tubulointerstitial nephritis**, **microscopic hematuria**, and **moderate albuminuria** align with renal sarcoidosis, a common extrapulmonary manifestation. **Visual loss** suggests ocular involvement (e.g., uveitis), while **hepatic steatosis** and elevated liver enzymes (implied by hepatic cysts) may reflect hepatic granulomas. **Hypertension** and **nephrosclerosis** could result from chronic kidney injury secondary to sarcoidosis. **Fatigue** and **headache** are systemic inflammatory symptoms. Although **renal/hepatic cysts** and **purpura** are atypical, they may coexist due to secondary complications or genetic predisposition.  

Sarcoidosis, susceptibility to, 2:  
The genetic susceptibility variants (e.g., HLA-DRB1 or BTNL2 mutations) could explain the multi-organ involvement and severity. The overlapping features—**lymphadenopathy**, **interstitial lung disease**, **uveitis**, and **renal inflammation**—are consistent with a systemic granulomatous process. **Bacteriuria** and **nitrituria** likely reflect unrelated UTIs, while **peripheral edema** and **nausea** stem from renal insufficiency. The atypical **hepatic cysts** might indicate concurrent metabolic dysfunction or incidental findings, but the core phenotype strongly supports sarcoidosis susceptibility."
"['Nephrotic syndrome', 'Abnormality of the nose', 'Hematuria', 'Membranoproliferative glomerulonephritis', 'Purpura', 'Wrist swelling', 'Dyspnea', 'Hypertriglyceridemia', 'Hypercholesterolemia', 'Increased body weight', 'Pedal edema', 'Peripheral edema', 'Moderate proteinuria', 'Heavy proteinuria', 'Foamy urine']",['Immunoglobulin A vasculitis'],"Disease: Immunoglobulin A vasculitis (IgAV), also known as Henoch-Schönlein purpura (HSP)  
Reasoning:  
1. **Purpura**: A hallmark of IgAV, presenting as non-thrombocytopenic palpable purpura, typically on dependent areas (e.g., lower limbs).  
2. **Renal Involvement**:  
   - **Nephrotic syndrome** (heavy proteinuria, hypoalbuminemia-induced hypercholesterolemia/hypertriglyceridemia, edema) and **hematuria** align with IgA-mediated glomerulonephritis.  
   - **Membranoproliferative glomerulonephritis (MPGN)** on biopsy is consistent with IgAV nephritis, characterized by IgA-dominant immune deposits.  
3. **Arthritis**: Wrist swelling reflects IgAV-associated arthritis, commonly affecting large joints.  
4. **Systemic Features**:  
   - **Dyspnea** may arise from fluid overload due to nephrotic syndrome or rare pulmonary vasculitis.  
   - **Abnormality of the nose** (e.g., mucosal vasculitis or epistaxis) suggests small-vessel involvement.  
5. **Exclusion of Mimics**: Symptoms collectively rule out isolated nephrotic syndrome, lupus nephritis, or infection-driven glomerulonephritis, reinforcing IgAV as the unifying diagnosis."
"['Abnormality of the dentition', 'Alopecia', 'Increased susceptibility to fractures', 'Low alkaline phosphatase', 'Short stature', 'Miscarriage', 'Fatigue', 'Lower limb pain', 'Ectopic pregnancy']","['Hypophosphatasia; HPP/Hypophosphatasia', 'Hypophosphatasia, adult']","Disease: Hypophosphatasia; HPP/Hypophosphatasia  
Reasoning:  
1. **Low alkaline phosphatase**: A pathognomonic feature of HPP due to mutations in the *ALPL* gene, causing deficient tissue-nonspecific alkaline phosphatase (TNSALP) activity.  
2. **Increased susceptibility to fractures** and **lower limb pain**: Impaired bone mineralization from accumulated inorganic pyrophosphate (PPi) leads to osteomalacia, fragility fractures, and bone pain.  
3. **Abnormality of the dentition**: Premature loss of deciduous teeth (especially incisors) due to defective cementum formation.  
4. **Short stature**: Result of skeletal hypomineralization and growth plate abnormalities.  
5. **Fatigue**: Linked to muscle weakness or chronic pain secondary to skeletal pathology.  
6. **Miscarriage** and **ectopic pregnancy**: HPP may disrupt placental calcification or uterine environment, increasing pregnancy complications (reported in severe or perinatal forms).  

Disease: Hypophosphatasia, adult  
Reasoning:  
1. **Persistent low alkaline phosphatase**: Confirms ongoing TNSALP deficiency in adulthood.  
2. **Recurrent fractures** and **limb pain**: Adult-onset HPP often manifests with stress fractures, pseudofractures, and musculoskeletal pain.  
3. **Dental abnormalities**: Adult patients may retain childhood dental issues (e.g., tooth loss) or develop periodontitis.  
4. **Fatigue**: Chronic bone and muscle involvement contribute to systemic symptoms.  
5. **Reproductive complications**: While less common in adult HPP, metabolic disturbances could theoretically predispose to ectopic pregnancy or miscarriage.  

**Note**: Alopecia is atypical for HPP and may suggest a comorbid condition, requiring further evaluation."
"['Mastoiditis', 'Hearing impairment', 'Horizontal nystagmus', 'Irregular menstruation', 'Tachycardia', 'Ankle swelling', 'Weight loss', 'Palpitations', 'Vertigo', 'Decreased circulating complement C3 concentration', 'Facial palsy', 'Autoimmune antibody positivity', 'Decreased circulating complement C4 concentration', 'Oral mucosal blisters']","['Sarcoidosis/Sarcoidosis, susceptibility to, 1', 'Sarcoidosis, susceptibility to, 2']","Sarcoidosis/Sarcoidosis, susceptibility to, 1:  
The patient’s **facial palsy**, **hearing impairment**, and **horizontal nystagmus** suggest neurosarcoidosis, which often involves cranial nerves (e.g., VII and VIII). **Mastoiditis** may reflect granulomatous inflammation in the mastoid bone. **Autoimmune antibody positivity** and **decreased C3/C4 complement levels** align with sarcoidosis-associated immune dysregulation. **Oral mucosal blisters** and **weight loss** are consistent with systemic granulomatous disease. **Tachycardia** and **palpitations** could indicate cardiac sarcoidosis, while **ankle swelling** may reflect renal or cardiac involvement.  

Sarcoidosis, susceptibility to, 2:  
Genetic susceptibility loci (e.g., HLA-DRB1 variants) may predispose to multisystem granulomatous inflammation. The combination of **neurological**, **otologic**, **cardiac**, and **mucocutaneous symptoms** supports a systemic presentation. **Irregular menstruation** might stem from hypothalamic-pituitary axis involvement (rare but documented). Hypocomplementemia (**low C3/C4**) and autoantibodies further suggest immune-mediated pathology, characteristic of sarcoidosis subtypes linked to genetic susceptibility."
"['Sinusitis', 'Proptosis', 'Diplopia', 'Hypertension', 'Orbital cyst', 'Mitral regurgitation', 'Aortic regurgitation', 'Left ventricular hypertrophy', 'Hypertriglyceridemia', 'Hepatomegaly', 'Neoplasm of the liver', 'Hypercholesterolemia', 'Tricuspid regurgitation', 'Decreased glomerular filtration rate', 'Oculomotor nerve palsy', 'Increased circulating IgG4 level', 'Palpebral edema']","['Multifocal fibrosclerosis', 'IgG4-related retroperitoneal fibrosis', 'IgG4 related disease; IgG4-RD']","Disease: IgG4 related disease; IgG4-RD  
Reasoning:  
1. **Increased circulating IgG4 level** is a hallmark of IgG4-RD, supporting systemic immune dysregulation.  
2. **Sinusitis, proptosis, orbital cyst, oculomotor nerve palsy, and palpebral edema** suggest orbital and sinonasal involvement, consistent with IgG4-RD’s propensity for lacrimal/salivary gland inflammation and mass lesions.  
3. **Hepatomegaly and neoplasm of the liver** align with IgG4-related hepatopathy or sclerosing cholangitis, mimicking tumors.  
4. **Mitral/aortic/tricuspid regurgitation and left ventricular hypertrophy** may reflect IgG4-RD-associated inflammatory infiltration of cardiac structures or vasculature.  
5. **Decreased glomerular filtration rate** could indicate IgG4-related kidney disease (tubulointerstitial nephritis).  
6. **Hypertension and hyperlipidemia** may be secondary to renal involvement or metabolic dysregulation in IgG4-RD.  
7. Multisystem involvement (ocular, cardiac, hepatic, renal) with elevated IgG4 confirms **IgG4-RD** as the unifying diagnosis, encompassing subtypes like retroperitoneal fibrosis and multifocal fibrosclerosis under its spectrum.  

Disease: IgG4-related retroperitoneal fibrosis  
Reasoning:  
- **Decreased glomerular filtration rate** and **hypertension** suggest retroperitoneal fibrosis compressing renal vasculature/ureters, a classic feature of this subtype.  

Disease: Multifocal fibrosclerosis  
Reasoning:  
- **Orbital cyst, hepatomegaly, and neoplasm-like liver lesions** reflect fibrosis in multiple organs, a hallmark of multifocal fibrosclerosis, now recognized as part of the IgG4-RD spectrum."
"['Hearing impairment', 'Tachycardia', 'Splenomegaly', 'Fever', 'Hyperkalemia', 'Vertigo', 'Decreased circulating total IgM', 'Hypercalcemia', 'Abnormal EKG', 'Elevated erythrocyte sedimentation rate', 'Abnormality of complement system', 'Elevated circulating C-reactive protein concentration', 'Increased circulating free T3', 'Foot pain', 'Elbow pain', 'Wrist pain', 'Hip pain', 'Knee pain']","['Familial cold autoinflammatory syndrome 2', 'Familial cold urticaria', 'Familial cold inflammatory syndrome 1', 'Muckle-Wells syndrome/Muckle-Wells syndrome', 'Familial cold autoinflammatory syndrome 3', 'Familial cold autoinflammatory syndrome 4', 'CINCA syndrome/Cinca syndrome']","Disease: Muckle-Wells syndrome/Muckle-Wells syndrome  
Reasoning:  
1. **Hearing impairment** aligns with Muckle-Wells syndrome’s hallmark sensorineural hearing loss due to chronic inflammation.  
2. **Fever**, **elevated ESR**, and **high CRP** reflect systemic inflammation, consistent with autoinflammatory syndromes like MWS.  
3. **Arthralgias** (joint pain in elbows, wrists, hips, knees, feet) are common in MWS, driven by IL-1-mediated inflammation.  
4. **Abnormality of the complement system** and **splenomegaly** suggest chronic inflammation and immune dysregulation.  
5. **Hyperkalemia** and **abnormal EKG** may indicate early renal amyloidosis, a complication of untreated MWS.  
6. **Hypercalcemia** could stem from cytokine-driven bone resorption or renal dysfunction.  
7. **Vertigo** may relate to inner ear inflammation, supporting cochlear involvement.  
8. **Decreased IgM** is atypical but could result from chronic inflammation or secondary immune dysregulation.  

Excluded other familial cold syndromes (FCAS 1-4, familial cold urticaria) due to lack of documented cold triggers and presence of hearing loss. CINCA syndrome was excluded due to absence of severe neurological/developmental features (e.g., chronic meningitis, bony overgrowth). Elevated free T3 is a confounding factor but may reflect inflammation-associated thyroid test abnormalities rather than primary thyroid disease."
"['Recurrent urinary tract infections', 'Gingivitis', 'Facial edema', 'Epistaxis', 'Hyperhidrosis', 'Abnormality of the larynx', 'Weight loss', 'Eosinophilia', 'Microcytic anemia', 'Hemoptysis', 'Pulmonary infiltrates', 'Hyperkalemia', 'Exertional dyspnea', 'Exercise intolerance', 'Adrenal hyperplasia', 'Abnormality of the submandibular glands', 'Facial palsy', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Peripheral edema', 'Cervical lymphadenopathy', 'Nodular pattern on pulmonary HRCT', 'Lagophthalmos', 'Elbow pain', 'Knee pain', 'Decreased thyroid-stimulating hormone level', 'Cutaneous abscess', 'Cytoplasmic antineutrophil antibody positivity', 'Neoplasm of the adrenal gland']","['Sarcoidosis/Sarcoidosis, susceptibility to, 1', 'Sarcoidosis, susceptibility to, 2']","Sarcoidosis/Sarcoidosis, susceptibility to, 1: The patient exhibits multisystem granulomatous involvement, including pulmonary infiltrates, nodular HRCT patterns, cervical lymphadenopathy, and elevated CRP, all hallmarks of sarcoidosis. Facial palsy, lagophthalmos, and laryngeal abnormalities suggest neurosarcoidosis. Cutaneous abscesses, adrenal hyperplasia, and submandibular gland involvement align with extrapulmonary disease. Microcytic anemia, fatigue, and weight loss reflect chronic inflammation. Though cytoplasmic ANCA positivity is atypical, it may occur in overlap syndromes or as a false-positive. Eosinophilia and hyperkalemia could indicate adrenal dysfunction or renal involvement. Genetic susceptibility variants (e.g., HLA-DRB1) may underlie this presentation.  

Sarcoidosis, susceptibility to, 2: The phenotypic overlap with susceptibility type 1 is significant, but genetic distinctions (e.g., BTNL2 gene variants) may explain subtle differences in disease severity or organ tropism. The presence of exertional dyspnea, exercise intolerance, and hemoptysis emphasizes severe pulmonary involvement, potentially linked to specific genetic modifiers. Adrenal neoplasms, though rare in sarcoidosis, may arise from chronic hyperplasia. Persistent UTIs and gingivitis could reflect secondary immune dysregulation from granulomatous inflammation. Thyroid abnormalities (decreased TSH) may indicate concurrent autoimmune thyroiditis or hypothalamic-pituitary involvement."
"['Abnormal penis morphology', 'Oral ulcer', 'Epistaxis', 'Uveitis', 'Visual loss', 'Hematuria', 'Hypertension', 'Arthritis', 'Ankle swelling', 'Abdominal pain', 'Fasciculations', 'Arthralgia', 'Elevated hepatic transaminase', 'Increased CSF protein concentration', 'Elevated circulating creatine kinase concentration', 'Elevated circulating creatinine concentration', 'Myalgia', 'Muscle spasm', 'Spinal canal stenosis', 'Back pain', 'Somatic sensory dysfunction', 'Focal white matter lesions', 'Foot dorsiflexor weakness', 'Stomatitis', 'Abnormal metacarpophalangeal joint morphology', 'Fatigue', 'Dysesthesia', 'Increased circulating lactate dehydrogenase concentration', 'Elevated gamma-glutamyltransferase level', 'Unusual infection', 'Aphthous ulcer', 'Dysuria', 'Epigastric pain']",['Behçet disease/Behcet syndrome'],"Disease: Behçet disease/Behcet syndrome  
Reasoning:  
1. **Mucocutaneous Involvement**: The patient presents with oral ulcers (aphthous ulcer, stomatitis) and genital ulcers (implied by ""abnormal penis morphology""), fulfilling the International Criteria for Behçet’s Disease (ICBD) major criteria.  
2. **Ocular Manifestations**: Uveitis and visual loss are classic features of Behçet’s, often leading to severe complications if untreated.  
3. **Neurological Involvement**: Increased CSF protein, focal white matter lesions, and somatic sensory dysfunction suggest neuro-Behçet’s, a serious subtype affecting the central nervous system.  
4. **Vasculitic Features**: Epistaxis, hematuria, and hypertension may reflect systemic vasculitis, a hallmark of Behçet’s that can involve small and large vessels.  
5. **Musculoskeletal Symptoms**: Arthritis, arthralgia, and ankle swelling align with inflammatory joint involvement common in Behçet’s.  
6. **Gastrointestinal Involvement**: Abdominal/epigastric pain could indicate intestinal ulcers, part of the ""intestinal Behçet’s"" phenotype.  
7. **Elevated Inflammatory Markers**: Elevated creatine kinase, LDH, and hepatic transaminases suggest systemic inflammation, consistent with Behçet’s multisystemic nature.  
8. **Exclusion of Mimics**: Symptoms like recurrent infections are atypical but may reflect immunosuppressive therapy rather than an infectious etiology. The absence of more specific markers for diseases like lupus or sarcoidosis strengthens the Behçet’s diagnosis.  

**Conclusion**: The combination of recurrent oral/genital ulcers, uveitis, vasculitis, and multisystem inflammation strongly supports Behçet’s syndrome, aligning with ICBD diagnostic criteria."
"['Pruritus', 'Tachycardia', 'Ankle swelling', 'Weight loss', 'Lymphopenia', 'Anemia', 'Fever', 'Leukocytosis', 'Abnormality of the knee', 'Hypoalbuminemia', 'Abnormal EKG', 'Elevated circulating creatine kinase concentration', 'Myalgia', 'EMG: myopathic abnormalities', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Generalized morning stiffness', 'Increased alpha-globulin', 'Enlarged metacarpophalangeal joints', 'Erythema', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia', 'Lower limb pain', 'Cough', 'Finger swelling', 'Antimitochondrial antibody positivity', 'Increased circulating creatine kinase MB isoform', 'Myositis', 'Abnormality of nail color', 'Increased circulating troponin T concentration']",['Antisynthetase syndrome'],"Disease: Antisynthetase syndrome  
Reasoning:  
1. **Myositis**: Supported by myalgia, elevated creatine kinase, EMG myopathic abnormalities, and exercise intolerance.  
2. **Interstitial lung disease**: Cough and potential respiratory involvement align with antisynthetase-related ILD.  
3. **Inflammatory arthritis**: Swollen metacarpophalangeal joints, finger swelling, and morning stiffness suggest polyarthritis.  
4. **Systemic inflammation**: Fever, leukocytosis, neutrophilia, elevated ESR/CRP, and hypoalbuminemia indicate a systemic inflammatory process.  
5. **Autoimmune markers**: Antinuclear antibody (ANA) positivity is common, though antisynthetase antibodies (e.g., anti-Jo1) are pathognomonic (implied in the diagnosis).  
6. **Cutaneous features**: Erythema, pruritus, and nail abnormalities may reflect ""mechanic’s hands,"" a classic sign.  
7. **Cardiac involvement**: Elevated troponin T, CK-MB, and abnormal EKG suggest myocarditis or subclinical cardiac inflammation.  
8. **Hematologic abnormalities**: Anemia and lymphopenia are consistent with chronic inflammation.  
9. **Exclusion of mimics**: Elevated alpha-globulin and antimitochondrial antibody positivity are nonspecific but do not override the syndromic pattern.  

The triad of myositis, ILD, and inflammatory arthritis with autoimmune serology strongly supports antisynthetase syndrome."
"['Cyanosis', 'Hepatic steatosis', 'Eosinophilia', 'Pulmonary infiltrates', 'Lymphadenopathy', 'Elevated hepatic transaminase', 'Hypercholesterolemia', 'Elevated circulating parathyroid hormone level', 'Increased circulating IgE level', 'Abnormality of facial soft tissue', 'Autoimmune antibody positivity', 'Elevated gamma-glutamyltransferase level']",['Kimura disease'],"Disease: Kimura disease  
Reasoning:  
1. **Lymphadenopathy and Facial Soft Tissue Abnormality**: Kimura disease commonly presents with subcutaneous masses and lymphadenopathy, particularly in the head/neck region, explaining the facial soft tissue abnormality.  
2. **Eosinophilia and Elevated IgE**: Hallmark features of Kimura disease, driven by a chronic inflammatory response with pronounced eosinophil infiltration and IgE overproduction.  
3. **Autoimmune Antibody Positivity**: While not definitive, Kimura disease may involve autoimmune mechanisms, aligning with autoimmune antibody positivity.  
4. **Pulmonary Infiltrates and Cyanosis**: Secondary eosinophilic infiltration in the lungs could cause infiltrates and hypoxia, leading to cyanosis.  
5. **Hepatic Involvement (Steatosis, Elevated Transaminases/GGT)**: Uncommon in Kimura disease but may result from systemic inflammation, drug effects, or concurrent conditions (e.g., eosinophilic liver infiltration).  
6. **Hypercholesterolemia and Elevated PTH**: Likely unrelated comorbidities, as these are not characteristic of Kimura disease.  

The diagnosis prioritizes Kimura disease based on pathognomonic features (lymphadenopathy, eosinophilia, elevated IgE), while acknowledging atypical symptoms as potential secondary effects or unrelated conditions."
"['Sinusitis', 'Eosinophilia', 'Dyspnea', 'Pulmonary infiltrates', 'Increased circulating IgE level', 'Nodular pattern on pulmonary HRCT', 'Autoimmune antibody positivity', 'Nasal polyposis']",['Eosinophilic granulomatosis with polyangiitis'],"Disease: Eosinophilic granulomatosis with polyangiitis (EGPA)  
Reasoning:  
1. **Sinusitis and Nasal Polyposis**: Common ENT manifestations in EGPA, reflecting granulomatous inflammation.  
2. **Eosinophilia**: A hallmark of EGPA, driven by eosinophil-rich tissue infiltration.  
3. **Dyspnea and Pulmonary Infiltrates**: Indicates asthma-like airway involvement and eosinophilic pneumonitis.  
4. **Nodular Pattern on HRCT**: Suggests granulomatous lesions or vasculitic damage in the lungs.  
5. **Increased IgE Levels**: Linked to allergic/atopic predisposition, often seen in EGPA.  
6. **Autoimmune Antibody Positivity**: ANCA (typically MPO-ANCA) may be present, supporting vasculitic pathology.  
7. **Triphasic Disease Progression**: Aligns with allergic, eosinophilic, and vasculitic phases typical of EGPA.  
**Exclusion**: Other eosinophilic disorders (e.g., ABPA) lack vasculitis, while GPA lacks prominent eosinophilia."
"['Oral ulcer', 'Goiter', 'Arthritis', 'Abnormality of the larynx', 'Anemia', 'Palpitations', 'Gastroesophageal reflux', 'Headache', 'Fasciculations', 'Paraparesis', 'Abnormality of the knee', 'Arthralgia', 'Myalgia', 'EMG: neuropathic changes', 'Somatic sensory dysfunction', 'Antinuclear antibody positivity', 'Decreased circulating complement C3 concentration', 'Abnormal phalangeal joint morphology of the hand', 'Abnormal circulating protein concentration', 'Right bundle branch block', 'Atrioventricular reentrant tachycardia', 'Abnormal metacarpophalangeal joint morphology', 'Upper limb pain', 'Dysesthesia', 'Neck pain', 'Elbow pain', 'Finger pain', 'Knee pain', 'Increased tear production', 'Aphthous ulcer', 'Abnormality of nail color', 'Dyspepsia']",['Antisynthetase syndrome'],"Disease: Antisynthetase syndrome  
Reasoning:  
1. **Autoimmune Features**: Antinuclear antibody positivity and decreased complement C3 strongly suggest an autoimmune etiology.  
2. **Myositis Overlap**: Myalgia, EMG neuropathic changes, and somatic sensory dysfunction align with inflammatory muscle involvement, a hallmark of antisynthetase syndrome.  
3. **Articular Manifestations**: Arthritis, arthralgia, and joint abnormalities (knee, hand phalanges, MCP joints) are consistent with the polyarthritis seen in this syndrome.  
4. **Systemic Involvement**: Gastroesophageal reflux, dyspepsia, and dysesthesia reflect multisystemic inflammation, commonly seen in antisynthetase syndrome.  
5. **Extramuscular Signs**: Oral/aphthous ulcers and abnormal nail color may correlate with cutaneous manifestations of the disease.  
6. **Laboratory Clues**: Abnormal circulating protein concentration supports chronic inflammation.  
7. **Exclusion of Mimics**: While cardiac abnormalities (bundle branch block, tachycardia) are atypical, they are occasionally reported in antisynthetase syndrome, and other diseases (e.g., lupus, Sjögren’s) are less likely given the symptom constellation.  

The combination of myositis, arthritis, autoantibodies, and systemic involvement strongly supports antisynthetase syndrome, particularly with anti-Jo-1 antibodies (implied by ANA positivity in this context)."
"['Abnormal paranasal sinus morphology', 'Epistaxis', 'Abnormal nasal mucosa morphology', 'Hemoptysis', 'Sneeze', 'Elbow pain', 'Knee pain', 'Ankle pain']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis  
**Reasoning**:  
1. **Upper respiratory involvement**: Symptoms like *abnormal paranasal sinus morphology*, *epistaxis*, and *abnormal nasal mucosa morphology* are hallmarks of GPA, which commonly causes necrotizing granulomatous inflammation in the sinuses and nasal passages.  
2. **Lower respiratory tract involvement**: *Hemoptysis* suggests alveolar hemorrhage due to pulmonary vasculitis, a critical feature of GPA.  
3. **Systemic vasculitis**: Joint pain (*elbow, knee, ankle*) reflects systemic inflammation affecting small- to medium-sized vessels, consistent with GPA’s multisystemic nature.  
4. **Exclusion of mimics**: The absence of asthma/eosinophilia (ruling out eosinophilic GPA) and the prominence of upper respiratory + joint symptoms distinguish GPA from other vasculitides (e.g., microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis).  
5. **Triad alignment**: GPA classically presents with necrotizing granulomas of the respiratory tract, vasculitis, and glomerulonephritis (not listed here, but not all features are required for diagnosis)."
"['Hepatic steatosis', 'Fever', 'Leukocytosis', 'Gastroesophageal reflux', 'Hepatomegaly', 'Neoplasm of the liver', 'Elevated hepatic transaminase', 'Back pain', 'Exercise intolerance', 'Shortened PR interval', 'Generalized morning stiffness', 'Abnormal prostate morphology', 'Elevated circulating C-reactive protein concentration', 'Sacroiliac arthritis', 'Fatigue', 'Crackles', 'Elbow pain', 'Knee pain', 'Elevated gamma-glutamyltransferase level', 'Chest tightness', 'Decreased DLCO', 'Serositis', 'Chest pain', 'Skin erosion']","['Spondyloarthropathy, susceptibility to, 1', 'Spondyloarthropathy, susceptibility to, 2']","Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: The presence of **sacroiliac arthritis**, **generalized morning stiffness**, **back pain**, and **elevated C-reactive protein** strongly suggests inflammatory spondyloarthropathy. Sacroiliitis is a hallmark of axial spondyloarthritis (e.g., ankylosing spondylitis). HLA-B27-associated susceptibility (common in spondyloarthropathies) aligns with genetic predisposition (susceptibility 1). Musculoskeletal symptoms (elbow/knee pain) and systemic inflammation (fever, leukocytosis) further support this diagnosis.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: **Serositis** (pleural/pericardial inflammation) and **decreased DLCO** (diffusing capacity of the lungs) indicate extra-articular manifestations, seen in broader autoimmune-driven spondyloarthropathy subtypes. **Skin erosions** and **abnormal prostate morphology** may reflect reactive arthritis or psoriatic spondyloarthropathy overlap, linked to alternative genetic loci (susceptibility 2). Hepatic involvement (steatosis, elevated transaminases) could stem from metabolic syndrome or drug-induced inflammation, common comorbidities in chronic inflammatory arthropathies."
"['Leukocytosis', 'Osteomyelitis', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Jaw swelling', 'Jaw pain', 'Hyperostosis', 'Palmoplantar pustulosis']",['SAPHO syndrome'],"Disease: SAPHO syndrome  
Reasoning:  
1. **Palmoplantar pustulosis**: A key dermatological manifestation of SAPHO syndrome, aligning with the patient's presentation.  
2. **Osteomyelitis & Hyperostosis**: SAPHO commonly involves sterile osteomyelitis (often affecting the jaw, sternocostoclavicular region, or spine) and hyperostosis (bone overgrowth). Jaw involvement (swelling/pain) supports this.  
3. **Elevated inflammatory markers (ESR, CRP)**: Reflects systemic inflammation typical in SAPHO.  
4. **Leukocytosis**: Indicates an active inflammatory/immune response, consistent with SAPHO flares.  
5. **Exclusion of mimics**: Symptoms rule out isolated infections (e.g., bacterial osteomyelitis lacks chronic pustulosis) or other autoinflammatory syndromes (e.g., CRMO lacks palmoplantar pustulosis).  
6. **SAPHO diagnostic criteria**: Meets the ""pustulosis + osteoarticular involvement"" pattern (Kahn, 1994 criteria)."
"['Abnormality of the lower limb', 'Microscopic hematuria', 'Elevated circulating creatine kinase concentration', 'Paresthesia', 'Elevated erythrocyte sedimentation rate', 'Prolonged prothrombin time', 'Elevated circulating C-reactive protein concentration', 'Macule', 'Decreased circulating complement C4 concentration', 'Skin erosion']","['Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome', 'Polyarteritis nodosa']","Disease: Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome (VEXAS)  
Reasoning:  
1. **Elevated inflammatory markers (ESR, CRP)**: Consistent with systemic autoinflammation.  
2. **Skin erosion/macule**: Reflects cutaneous vasculitis, a hallmark of VEXAS.  
3. **Decreased C4**: Suggests complement consumption, potentially linked to immune dysregulation in VEXAS.  
4. **Prolonged prothrombin time**: Aligns with hematologic defects, possibly due to hepatic involvement or clotting factor deficiencies.  
5. **Microscopic hematuria**: May indicate renal inflammation or vasculitic kidney injury.  
6. **Elevated creatine kinase/paresthesia**: Muscle and nerve involvement (myositis/neuropathy) seen in systemic autoinflammatory processes.  
7. **Lower limb abnormalities**: Could stem from arthritis or vasculitis-induced ischemia.  

Disease: Polyarteritis nodosa (PAN)  
Reasoning:  
1. **Microscopic hematuria**: Renal artery vasculitis in PAN can cause glomerular injury.  
2. **Paresthesia**: Mononeuritis multiplex, a classic feature of PAN due to nerve ischemia.  
3. **Skin erosion/macule**: Cutaneous vasculitis manifesting as ulcers or livedo.  
4. **Elevated ESR/CRP**: Non-specific markers of systemic inflammation in vasculitis.  
5. **Elevated creatine kinase**: Muscle ischemia from arterial inflammation.  
6. **Lower limb abnormalities**: Vascular compromise leading to claudication or necrosis.  
**Notable exclusions**: Prolonged PT and low C4 are atypical for PAN, making VEXAS more likely. PAN typically lacks complement abnormalities and coagulopathies.  

**Conclusion**: VEXAS is the primary diagnosis due to hematologic/immunologic features (prolonged PT, low C4), while PAN remains a differential for vasculitis-driven symptoms. Genetic testing for *UBA1* mutations and angiography (for PAN-associated aneurysms) would confirm."
"['Weight loss', 'Leukopenia', 'Dyspnea', 'Vertigo', 'Elevated circulating creatine kinase concentration', 'Exercise intolerance', 'Ground-glass opacification', 'Foot pain', 'Autoimmune antibody positivity', 'Decreased DLCO']",['Antisynthetase syndrome'],"Disease: Antisynthetase syndrome  
Reasoning:  
1. **Autoimmune antibody positivity**: A hallmark of antisynthetase syndrome (e.g., anti-Jo-1 antibodies).  
2. **Ground-glass opacification & decreased DLCO**: Indicates interstitial lung disease (ILD), a core feature of antisynthetase syndrome.  
3. **Elevated creatine kinase & exercise intolerance**: Suggests inflammatory myositis, another key component of the syndrome.  
4. **Foot pain**: May reflect inflammatory arthritis, part of the clinical triad (myositis, ILD, arthritis).  
5. **Dyspnea**: Correlates with ILD severity.  
6. **Weight loss & leukopenia**: Systemic inflammation or autoimmune-driven processes.  
7. **Vertigo**: Less specific but possible in autoimmune-mediated neuroinflammation or comorbidities.  

The constellation of ILD, myositis, and autoimmune serology strongly supports antisynthetase syndrome. Confirmatory testing for anti-synthetase antibodies (e.g., anti-Jo-1) and imaging/pulmonary function tests would solidify the diagnosis."
"['Hydroureter', 'Splenomegaly', 'Elevated circulating creatinine concentration', 'Aortic aneurysm', 'Retroperitoneal fibrosis', 'Ureterovesical stenosis', 'Elevated circulating C-reactive protein concentration', 'Plasmacytosis', 'Splenic cyst', 'Increased circulating IgG4 level', 'Dilatation of renal calices']",['IgG4-related retroperitoneal fibrosis'],"IgG4-related retroperitoneal fibrosis:  
1. **Retroperitoneal fibrosis** is a hallmark of IgG4-related disease (IgG4-RD), characterized by fibroinflammatory tissue that often entraps ureters, leading to **hydroureter** and **ureterovesical stenosis**.  
2. **Elevated circulating IgG4 level** and **plasmacytosis** are diagnostic biomarkers of IgG4-RD, reflecting systemic plasmacytic infiltration.  
3. **Splenomegaly** and **splenic cyst** align with IgG4-RD’s multisystemic nature, which can involve the spleen.  
4. **Aortic aneurysm** is a known vascular manifestation of IgG4-RD due to inflammatory aortitis.  
5. **Dilatation of renal calices** and **elevated creatinine** indicate obstructive uropathy secondary to retroperitoneal fibrosis.  
6. **Elevated C-reactive protein** underscores the inflammatory activity, consistent with IgG4-RD’s pathophysiology.  
7. The convergence of fibrosis, elevated IgG4, and multi-organ involvement excludes mimics like malignancy or idiopathic fibrosis, confirming IgG4-related retroperitoneal fibrosis."
"['Nocturia', 'Abnormality of the larynx', 'Weight loss', 'Thrombocytopenia', 'Anemia', 'Fever', 'Leukocytosis', 'Headache', 'Rheumatoid factor positive', 'Elevated circulating parathyroid hormone level', 'Smooth muscle antibody positivity', 'Myalgia', 'Abnormality of complement system', 'Abnormal blood sodium concentration', 'Elevated circulating C-reactive protein concentration', 'Decreased glomerular filtration rate', 'Lower limb pain', 'Reduced left ventricular ejection fraction', 'Scrotal pain', 'Night sweats', 'Elevated gamma-glutamyltransferase level', 'Groin pain', 'Increased circulating IgG4 level', 'Low levels of vitamin D', 'Myositis']",['Polymyositis'],"Polymyositis: The patient presents with myositis and myalgia, which are hallmark features of polymyositis. Elevated circulating IgG4 levels, leukocytosis, and elevated CRP indicate systemic inflammation, consistent with autoimmune-mediated muscle damage. Rheumatoid factor positivity and smooth muscle antibody positivity further support an autoimmune etiology. Systemic symptoms like fever, weight loss, and night sweats align with chronic inflammatory processes. While abnormalities in complement, sodium, and vitamin D suggest multi-organ involvement, these may arise secondary to chronic inflammation or autoimmunity. Muscle-specific manifestations (myositis, limb pain) remain the primary diagnostic anchors, distinguishing polymyositis from broader IgG4-related disease or overlap syndromes."
"['Recurrent urinary tract infections', 'Abnormality of the hand', 'Wrist swelling', 'Abnormality of the gluteal musculature', 'Leukopenia', 'Microcytic anemia', 'Hypoglycemia', 'Headache', 'Vertigo', 'Paresthesia', 'Spinal canal stenosis', 'Back pain', 'Somatic sensory dysfunction', 'Elevated erythrocyte sedimentation rate', 'Generalized morning stiffness', 'Decreased circulating complement C3 concentration', 'Sleep-wake cycle disturbance', 'Elevated circulating C-reactive protein concentration', 'Sacroiliac arthritis', 'Upper limb pain', 'Tendonitis', 'Shoulder pain', 'Wrist pain', 'Knee pain', 'Increased circulating NT-proBNP concentration', 'Enthesitis']","['Spondyloarthropathy, susceptibility to, 1', 'Spondyloarthropathy, susceptibility to, 2']","Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: The patient presents with sacroiliac arthritis, enthesitis, spinal canal stenosis, back pain, and elevated inflammatory markers (ESR, CRP), which are hallmark features of spondyloarthropathy (SpA). Morning stiffness and axial involvement (spinal/sacroiliac) align with inflammatory SpA subtypes like ankylosing spondylitis. HLA-B27 (associated with susceptibility 1) is a key genetic risk factor for SpA, supporting this diagnosis. Tendonitis, peripheral arthritis (wrist, knee, shoulder), and reactive arthritis-like triggers (recurrent UTIs) further reinforce SpA classification.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: Susceptibility 2 likely involves non-HLA-B27 genetic factors (e.g., ERAP1), which interact with HLA-B27 to increase SpA risk. The patient’s microcytic anemia and leukopenia may reflect chronic inflammation, while hypoglycemia and sleep disturbances could stem from systemic inflammatory burden. Elevated NT-proBNP suggests cardiac strain, a rare extracurricular manifestation of SpA. Low C3 hints at complement consumption, possibly from immune complex activity in enthesitis. Neurological symptoms (paresthesia, vertigo) may arise from spinal stenosis or nerve compression due to structural SpA complications. Hand abnormalities and peripheral joint swelling are consistent with psoriatic or reactive arthritis subtypes within the SpA spectrum."
"['Polyuria', 'Acne', 'Polydipsia', 'Headache', 'Abnormality of the knee', 'Arthralgia', 'Elevated circulating creatine kinase concentration', 'Generalized morning stiffness', 'Abnormal metacarpophalangeal joint morphology', 'Fatigue', 'Foot pain', 'Elbow pain', 'Wrist pain', 'Knee pain', 'Toe pain', 'Increased circulating IgG4 level']","['Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis', 'Familial mediterranean fever; FMF/Familial Mediterranean fever/Familial Mediterranean fever, AR', 'Reactive arthritis', 'Familial Mediterranean fever, AD', 'Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis', 'Systemic-onset juvenile idiopathic arthritis']","Disease: Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis  
Reasoning: The patient presents with polyarticular involvement (knee, elbow, wrist, toe, foot pain), morning stiffness, and abnormal metacarpophalangeal joint morphology—hallmarks of polyarticular JIA. Elevated IgG4 and creatine kinase may reflect systemic inflammation, though these are atypical for JIA. The absence of rheumatoid factor (RF) is inferred due to the lack of explicit mention of RF positivity and the inclusion of RF-negative JIA as a diagnostic option.  

Disease: Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis  
Reasoning: While similar to RF-negative JIA in joint symptoms, this diagnosis is listed as a potential option. However, RF positivity is typically associated with more severe erosive disease and specific autoantibodies, which are not detailed here. Its inclusion reflects diagnostic uncertainty without serologic data.  

Disease: Reactive arthritis  
Reasoning: Asymmetric joint pain (toe, foot) could suggest reactive arthritis, but the absence of preceding infection, urethritis, or conjunctivitis makes this less likely. Polyarticular upper-limb involvement and morning stiffness align better with JIA.  

Disease: Familial mediterranean fever (FMF), AR/AD  
Reasoning: FMF typically features recurrent fever and serositis, which are absent here. While arthralgia occurs in FMF, it is usually episodic and monoarticular. The chronic polyarticular pattern and lack of fever reduce suspicion for FMF, despite its inclusion in the options.  

Disease: Systemic-onset juvenile idiopathic arthritis  
Reasoning: Excluded due to the absence of hallmark systemic features (e.g., daily fevers, evanescent rash). The patient’s symptoms are confined to joints and lack systemic inflammatory signs.  

**Final Emphasis**: Rheumatoid factor-negative polyarticular JIA is the most consistent diagnosis given the clinical and laboratory findings. RF-positive JIA remains a possibility if serologic testing confirms RF, but the presentation leans toward RF-negative subtype. Other listed diseases lack sufficient supportive evidence."
"['Oral ulcer', 'Diplopia', 'Abnormal finger morphology', 'Syncope', 'Arthritis', 'Fever', 'Leukocytosis', 'Headache', 'Microscopic hematuria', 'Abnormal shoulder morphology', 'Genital ulcers', 'Myalgia', 'Paresthesia', 'Back pain', 'Somatic sensory dysfunction', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Increased alpha-globulin', 'Elevated circulating C-reactive protein concentration', 'Second degree atrioventricular block', 'Fatigue', 'Mesangial hypercellularity', 'Mild proteinuria', 'Finger pain', 'Aphthous ulcer', 'Increased circulating procalcitonin concentration']","['Familial mediterranean fever; FMF/Familial Mediterranean fever/Familial Mediterranean fever, AR', 'Familial Mediterranean fever, AD', 'Behçet disease/Behcet syndrome']","Disease: Behçet disease/Behcet syndrome  
Reasoning: The patient presents with key diagnostic criteria for Behçet disease, including recurrent oral ulcers (oral ulcer, aphthous ulcer) and genital ulcers. Additional supportive features include arthritis, neurological symptoms (headache, paresthesia, somatic sensory dysfunction), inflammatory markers (elevated ESR, CRP, leukocytosis), and possible ocular involvement (diplopia). While atypical, the second-degree AV block and renal findings (mesangial hypercellularity, mild proteinuria) could reflect rare vascular or renal complications of Behçet-related vasculitis. Fever and myalgia align with systemic inflammation.  

Disease: Familial Mediterranean fever, AR  
Reasoning: Symptoms such as recurrent fever, arthritis, elevated inflammatory markers (ESR, CRP, procalcitonin), and leukocytosis are consistent with FMF. Renal abnormalities (microscopic hematuria, mesangial hypercellularity) may suggest amyloidosis, a complication of untreated FMF. However, the absence of serositis (e.g., peritonitis/pleurisy), the presence of oral/genital ulcers, and neurological deficits are atypical for FMF, making this less likely unless overlapping with another condition.  

Disease: Familial Mediterranean fever, AD  
Reasoning: The autosomal dominant form of FMF shares features with the AR type, including fever, arthritis, and elevated acute-phase reactants. However, AD-FMF is rarer and often milder. The patient’s severe multisystem involvement (neurological, mucocutaneous ulcers) and lack of hallmark FMF features (self-limiting serosal attacks, colchicine responsiveness) make this diagnosis unlikely.  

**Final Diagnosis**: Behçet disease/Behcet syndrome is the most probable diagnosis, given the pathognomonic mucocutaneous ulcers and compatible systemic manifestations. FMF (AR/AD) is less likely due to inconsistent clinical features."
"['Hearing impairment', 'Epistaxis', 'Gait disturbance', 'Fever', 'Myalgia', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Lower limb pain', 'Ear pain', 'Cytoplasmic antineutrophil antibody positivity']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Cytoplasmic ANCA positivity**: Strongly associated with GPA (specifically c-ANCA/PR3), a hallmark for diagnosis.  
2. **Upper respiratory involvement**: Hearing impairment, ear pain, and epistaxis suggest granulomatous inflammation of the ears and nasal passages, common in GPA.  
3. **Systemic inflammation**: Fever, elevated CRP, fatigue, and myalgia align with systemic vasculitis.  
4. **Musculoskeletal/neurologic symptoms**: Gait disturbance and lower limb pain may reflect peripheral neuropathy, joint involvement, or vascular damage.  
5. **Exclusion of mimics**: Symptoms differentiate GPA from other ANCA-associated vasculitides (e.g., microscopic polyangiitis lacks prominent upper respiratory features; eosinophilic GPA typically includes asthma/eosinophilia).  
6. **Diagnostic consistency**: The triad of vasculitis, granulomatosis, and c-ANCA positivity supports GPA despite absent renal/pulmonary signs in this case."
"['Renal insufficiency', 'Proteinuria', 'Glomerulonephritis', 'Amenorrhea', 'Hematuria', 'Arthritis', 'Splenomegaly', 'Microcytic anemia', 'Dysphagia', 'Dyspnea', 'Hepatomegaly', 'Antinuclear antibody positivity', 'Prolonged partial thromboplastin time', 'Cachexia', 'Decreased glomerular filtration rate', 'Peripheral edema', 'Foamy urine', 'Anti-La/SS-B antibody positivity', 'Serositis', 'Abnormality of nail color']","['Systemic lupus erythematosus 16', 'Vitiligo-Associated multiple autoimmune disease susceptibility 1', 'Systemic lupus erythematosus, susceptibility to, 6', 'Mixed connective tissue disease', 'Pediatric systemic lupus erythematosus', 'Systemic lupus erythematosus']","Disease: Systemic lupus erythematosus  
Reasoning:  
1. **Renal involvement**: Proteinuria, hematuria, foamy urine, decreased glomerular filtration rate, and glomerulonephritis align with lupus nephritis, a hallmark of SLE.  
2. **Immunologic markers**: Antinuclear antibody (ANA) positivity is a key diagnostic criterion for SLE. Anti-La/SS-B antibodies, though often linked to Sjögren’s syndrome, can occur in SLE with overlapping features.  
3. **Multisystem involvement**:  
   - **Hematologic**: Microcytic anemia (potentially from chronic inflammation or blood loss) and prolonged PTT (suggestive of lupus anticoagulant or antiphospholipid syndrome, common in SLE).  
   - **Musculoskeletal**: Arthritis.  
   - **Serositis**: Pleural or pericardial inflammation.  
   - **Dermatologic**: Nail color abnormalities may reflect vascular changes.  
4. **Constitutional symptoms**: Cachexia and peripheral edema (secondary to nephrotic syndrome or chronic inflammation).  
5. **Hepatosplenomegaly**: Autoimmune-mediated inflammation or secondary to hematologic dysfunction.  
6. **Amenorrhea**: May result from chronic disease, hormonal disruption, or autoimmune ovarian involvement.  

Disease: Mixed connective tissue disease (MCTD)  
Reasoning:  
1. **Overlap features**: Dysphagia (esophageal dysmotility, seen in scleroderma overlap) and dyspnea (interstitial lung disease or pulmonary hypertension).  
2. **Autoantibodies**: ANA positivity is nonspecific but required for MCTD. However, anti-U1 RNP antibodies (pathognomonic for MCTD) are not explicitly listed here.  
3. **Renal and hematologic involvement**: Shared with SLE, making MCTD a differential, though less likely without definitive anti-U1 RNP or scleromyositis features.  

Disease: Systemic lupus erythematosus, susceptibility to, 6  
Reasoning:  
- Genetic susceptibility loci (e.g., **STAT4 gene variants**) may predispose to SLE. While clinical symptoms align with active SLE, this diagnosis refers to genetic predisposition rather than active disease manifestation.  

Disease: Pediatric systemic lupus erythematosus  
Reasoning:  
- Identical clinical features to adult SLE, but age-dependent classification. Requires confirmation of patient age, which is unspecified here.  

Excluded diagnoses:  
- **Vitiligo-Associated multiple autoimmune disease susceptibility 1**: Absence of vitiligo or other autoimmune conditions (e.g., thyroiditis) weakens this association.  
- **Anti-La/SS-B positivity** alone is insufficient for Sjögren’s syndrome diagnosis without sicca symptoms (e.g., dry eyes/mouth).  

**Final Diagnosis**: **Systemic lupus erythematosus** with probable lupus nephritis and secondary antiphospholipid syndrome (prolonged PTT). Overlap features (e.g., Anti-La/SS-B) warrant monitoring for Sjögren’s syndrome or MCTD evolution."
"['Polyuria', 'Visual loss', 'Hematuria', 'Dry skin', 'Keratoconjunctivitis sicca', 'Tremor', 'Diarrhea', 'Constipation', 'Heat intolerance', 'Migraine', 'Exertional dyspnea', 'Myalgia', 'Exercise intolerance', 'Inflammatory abnormality of the skin', 'Fatigue', 'Cough', 'Abnormal systemic blood pressure', 'Increased circulating IgG4 level', 'Dyspepsia']","['Multifocal fibrosclerosis', 'IgG4-related retroperitoneal fibrosis', 'IgG4 related disease; IgG4-RD']","Disease: IgG4 related disease; IgG4-RD  
Reasoning: The patient exhibits elevated IgG4 levels, a hallmark of IgG4-RD, alongside multi-organ involvement. Ocular symptoms (visual loss, keratoconjunctivitis sicca) suggest lacrimal or orbital inflammation. Renal manifestations (polyuria, hematuria) may indicate tubulointerstitial nephritis or retroperitoneal fibrosis causing ureteral obstruction. Cutaneous (dry skin, inflammatory skin changes), respiratory (cough, exertional dyspnea), and gastrointestinal symptoms (dyspepsia, diarrhea/constipation) reflect systemic inflammation and fibrosis. Systemic features (fatigue, myalgia, exercise intolerance) align with chronic inflammatory states. Migraine and blood pressure abnormalities may arise from secondary effects of organ compression or systemic inflammation.  

Disease: IgG4-related retroperitoneal fibrosis  
Reasoning: A subtype of IgG4-RD, retroperitoneal fibrosis explains hematuria and polyuria via ureteral obstruction or renal parenchymal involvement. Abdominal symptoms (dyspepsia, constipation/diarrhea) could stem from retroperitoneal mass effects on adjacent organs. Elevated IgG4 levels and association with other IgG4-RD features (e.g., ocular, cutaneous) further support this diagnosis.  

Disease: Multifocal fibrosclerosis  
Reasoning: This term describes fibrosis across multiple sites, now recognized as part of the IgG4-RD spectrum. The patient’s diverse symptoms (ocular, renal, cutaneous, respiratory) indicate fibroinflammatory lesions in various organs. Increased IgG4 levels and systemic involvement confirm multifocal fibrosclerosis as a manifestation of underlying IgG4-RD."
"['Sinusitis', 'Abnormality of the nose', 'Otitis media', 'Fever', 'Headache', 'Exercise intolerance', 'Elbow pain', 'Knee pain']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Upper respiratory involvement**: Chronic sinusitis and nasal abnormalities (e.g., ulcers, crusting) are hallmark features of GPA, caused by granulomatous inflammation.  
2. **Otitis media**: Secondary to Eustachian tube dysfunction from nasopharyngeal inflammation or vasculitis.  
3. **Systemic inflammation**: Fever and headache reflect systemic vasculitis and granulomatosis.  
4. **Musculoskeletal symptoms**: Elbow and knee pain (arthralgia/arthritis) occur in 50-70% of GPA patients due to inflammatory joint involvement.  
5. **Exercise intolerance**: May indicate subclinical pulmonary or renal involvement (common in GPA) or anemia of chronic disease.  
6. **Exclusion of mimics**: Symptoms align with GPA over other vasculitides (e.g., absence of asthma/eosinophilia rules out EGPA; PR3-ANCA positivity would further support diagnosis).  
7. **Triad correlation**: Combines upper/lower respiratory tract and potential renal involvement (even if not overtly stated), consistent with GPA pathology."
"['Abnormal rib morphology', 'Osteoporosis', 'Scoliosis', 'Arthralgia', 'Hypercholesterolemia', 'Low alkaline phosphatase', 'Myalgia', 'Muscle spasm', 'Back pain', 'Antinuclear antibody positivity', 'Vertebral wedging', 'Increased HDL cholesterol concentration', 'Knee pain', 'Ankle pain']","['Hypophosphatasia; HPP/Hypophosphatasia', 'Hypophosphatasia, adult']","Disease: Hypophosphatasia, adult  
Reasoning:  
1. **Low alkaline phosphatase**: A hallmark of hypophosphatasia (HPP) due to ALPL gene mutations impairing tissue-nonspecific alkaline phosphatase (TNAP) activity.  
2. **Bone abnormalities**: ""Abnormal rib morphology,"" ""vertebral wedging,"" and ""osteoporosis"" align with HPP’s defective bone mineralization, leading to skeletal fragility and deformities.  
3. **Musculoskeletal pain**: ""Arthralgia,"" ""myalgia,"" ""back pain,"" ""knee pain,"" and ""ankle pain"" correlate with HPP-associated bone stress, microfractures, and musculoskeletal strain.  
4. **Scoliosis**: Secondary to vertebral instability and weakened spinal bones in adult HPP.  
5. **Hypercholesterolemia/Increased HDL**: May reflect metabolic adaptations to impaired TNAP function, though not pathognomonic.  
6. **ANA positivity**: Likely incidental (e.g., age-related autoimmunity) as HPP is not autoimmune.  
Exclusion of mimics (e.g., osteogenesis imperfecta, Paget’s disease) is supported by the combination of low ALP, skeletal features, and absence of classic collagenopathy signs."
"['Renal hypoplasia', 'Focal segmental glomerulosclerosis', 'Nephrocalcinosis', 'Hepatic steatosis', 'Hepatic cysts', 'Splenomegaly', 'Thrombocytopenia', 'Diarrhea', 'Hyperuricemia', 'Hyperkalemia', 'Abnormal shoulder morphology', 'Increased blood urea nitrogen', 'Hyperuricosuria', 'Elevated circulating parathyroid hormone level', 'Elevated circulating creatinine concentration', 'Increased circulating ferritin concentration', 'Antinuclear antibody positivity', 'Elevated erythrocyte sedimentation rate', 'Abnormality of complement system', 'Constrictive median neuropathy', 'Decreased glomerular filtration rate', 'Upper limb pain', 'Lower limb pain', 'obsolete Increased urinary urate', 'Reduced haptoglobin level', 'Elevated prostate-specific antigen level', 'Neck pain', 'Shoulder pain', 'Anti-centromere antibody positivity', 'Abnormal blood phosphate concentration']","['CREST syndrome', 'Scleroderma, familial progressive']","Disease: CREST syndrome  
Reasoning: The patient's anti-centromere antibody positivity is a hallmark of CREST syndrome. While classic CREST features (calcinosis, Raynaud’s, esophageal dysmotility, sclerodactyly, telangiectasia) are not explicitly listed, secondary manifestations align with systemic involvement. Elevated ESR, ANA positivity, and complement abnormalities suggest autoimmune activity. Renal hypoplasia, glomerulosclerosis, and nephrocalcinosis may reflect chronic kidney damage from vascular or metabolic complications. Constrictive median neuropathy (carpal tunnel) and musculoskeletal pain could stem from fibrosis or inflammation. Elevated PTH and abnormal phosphate hint at metabolic bone disease, potentially linked to renal dysfunction.  

Disease: Scleroderma, familial progressive  
Reasoning: Familial progressive scleroderma encompasses broader systemic involvement. The patient’s hepatic steatosis, cysts, splenomegaly, and thrombocytopenia may indicate portal hypertension or liver fibrosis. Hyperuricemia, hyperuricosuria, and elevated creatinine correlate with progressive renal impairment, possibly due to scleroderma renal crisis (though atypical here). Elevated ferritin and reduced haptoglobin suggest chronic inflammation or hemolysis. Anti-centromere antibodies overlap with CREST, but familial progression implies genetic predisposition. Musculoskeletal pain, neuropathy, and elevated PSA (potentially inflammation-driven) further support diffuse connective tissue disease."
"['Sinusitis', 'Abnormal nasal mucosa morphology', 'Hypertension', 'Goiter', 'Mitral regurgitation', 'Ankle swelling', 'Weight loss', 'Fever', 'Exertional dyspnea', 'Generalized muscle weakness', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Abnormality of the pulmonary vasculature', 'Pedal edema', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Peripheral edema', 'Cough', 'Ground-glass opacification', 'Night sweats', 'Knee pain', 'Toe pain', 'Abnormal CD4:CD8 ratio', 'Lymphocytosis']",['Antisynthetase syndrome'],"Antisynthetase Syndrome:  
1. **Autoimmune Features**: Antinuclear antibody (ANA) positivity indicates an underlying autoimmune process, a hallmark of antisynthetase syndrome.  
2. **Myositis**: Generalized muscle weakness, exercise intolerance, and exertional dyspnea suggest inflammatory muscle involvement (myositis), a core feature of antisynthetase syndrome.  
3. **Interstitial Lung Disease (ILD)**: Cough, exertional dyspnea, and ground-glass opacification on imaging align with ILD, a critical diagnostic criterion for antisynthetase syndrome.  
4. **Systemic Inflammation**: Elevated C-reactive protein (CRP), fever, night sweats, and weight loss reflect systemic inflammation common in this syndrome.  
5. **Arthritis**: Knee and toe pain suggest inflammatory arthritis, frequently associated with antisynthetase syndrome.  
6. **Vascular/Edema Findings**: Peripheral/pedal edema and pulmonary vasculature abnormalities may stem from secondary pulmonary hypertension or cardiac involvement (e.g., mitral regurgitation) due to chronic inflammation.  
7. **Lymphocyte Dysregulation**: Lymphocytosis and abnormal CD4:CD8 ratio support immune dysregulation, consistent with autoimmune-driven pathology.  
8. **Exclusion of Overlaps**: Symptoms like sinusitis and nasal mucosal abnormalities could overlap with granulomatosis with polyangiitis, but the triad of myositis, ILD, and arthritis prioritizes antisynthetase syndrome."
"['Urticaria', 'Arthritis', 'Fever', 'Abnormal EKG', 'Supraventricular arrhythmia', 'Bilateral sensorineural hearing impairment', 'Elevated circulating C-reactive protein concentration', 'Panic attack', 'Knee pain']","['Familial cold autoinflammatory syndrome 2', 'Familial cold urticaria', 'Familial cold inflammatory syndrome 1', 'Muckle-Wells syndrome/Muckle-Wells syndrome', 'Familial cold autoinflammatory syndrome 3', 'Tumor necrosis factor receptor 1 associated periodic syndrome/Periodic fever, familial, autosomal dominant', 'Familial cold autoinflammatory syndrome 4', 'CINCA syndrome/Cinca syndrome']","Disease: Muckle-Wells syndrome/Muckle-Wells syndrome  
Reasoning: The patient presents with **urticaria**, **arthritis**, **fever**, **bilateral sensorineural hearing impairment**, and **elevated CRP**, which are hallmark features of Muckle-Wells syndrome (MWS). MWS, a cryopyrin-associated periodic syndrome (CAPS), is characterized by recurrent inflammatory episodes, systemic inflammation, and progressive hearing loss. The **supraventricular arrhythmia** and **abnormal EKG** may reflect secondary cardiac inflammation or amyloidosis, a known complication of untreated MWS. **Panic attacks** could arise from chronic stress or autonomic dysfunction linked to systemic inflammation. Other conditions like FCAS (cold-triggered, no hearing loss) or TRAPS (migratory rashes, no deafness) lack key features seen here. CINCA syndrome involves severe neurological involvement (absent in this case). The triad of urticaria, arthritis, and sensorineural deafness strongly supports MWS."
"['Acrocyanosis', 'Abnormal toe morphology', 'Fever', 'Hepatomegaly', 'Deep venous thrombosis', 'Vasculitis', 'Low back pain', 'Cachexia', 'Arterial thrombosis', 'Generalized lymphadenopathy', 'Chronic oral candidiasis', 'Abnormality of the submandibular glands', 'Erythema', 'Fatigue', 'Peripheral edema', 'Caput medusae', 'Foot pain', 'Portal vein thrombosis', 'Gangrene']","['Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome', 'Polyarteritis nodosa', 'Buerger disease/Buerger disease']","Disease: Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome (VEXAS)  
Reasoning:  
1. **Vasculitis and thrombosis**: The patient has vasculitis, arterial thrombosis (gangrene, acrocyanosis), and venous thrombosis (deep venous thrombosis, portal vein thrombosis). VEXAS is characterized by both venous and arterial thrombotic events alongside vasculitic inflammation.  
2. **Autoinflammation**: Fever, erythema, and fatigue align with systemic inflammation. Low back pain may reflect chondritis, a recognized feature of VEXAS.  
3. **Immunodeficiency**: Chronic oral candidiasis and generalized lymphadenopathy suggest immune dysfunction, consistent with VEXAS-associated hematologic defects (e.g., myelodysplasia).  
4. **Hematologic and organ involvement**: Cachexia, hepatomegaly, and caput medusae (indicative of portal hypertension from portal vein thrombosis) correlate with systemic hematologic and hepatic abnormalities in VEXAS.  
5. **Submandibular gland abnormality**: Linked to inflammatory infiltrates seen in autoinflammatory syndromes like VEXAS.  

Disease: Polyarteritis nodosa (PAN)  
Reasoning:  
1. **Vasculitis**: Medium-vessel vasculitis in PAN explains erythema, peripheral edema, and neuropathy-like foot pain.  
2. **Systemic symptoms**: Fever, cachexia, and hepatomegaly are classic systemic features of PAN.  
3. **Thrombosis**: Arterial thrombosis (gangrene) and renal/hepatic artery involvement (hepatomegaly) may occur, though PAN typically lacks venous thrombosis (portal vein thrombosis here suggests overlap with VEXAS).  

Disease: Buerger disease (Thromboangiitis obliterans)  
Reasoning:  
1. **Peripheral vascular involvement**: Acrocyanosis, abnormal toe morphology, foot pain, and gangrene are hallmarks of Buerger disease, linked to smoking and distal arterial occlusion.  
2. **Thrombosis**: Arterial thrombosis aligns with Buerger’s inflammatory thrombotic process.  
3. **Limitations**: Buerger disease does not explain systemic features (fever, lymphadenopathy, hepatomegaly) or immunodeficiency (oral candidiasis), suggesting a secondary or overlapping diagnosis (e.g., VEXAS).  

**Conclusion**: The patient’s constellation of symptoms is most consistent with **VEXAS syndrome**, given the combination of autoinflammation, immunodeficiency, and multi-site thrombosis. PAN and Buerger disease may contribute to specific vascular manifestations but do not fully account for the systemic and immunologic defects."
"['Epistaxis', 'Weight loss', 'Migraine', 'Vertigo', 'Vasculitis', 'Myalgia', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Ear pain', 'Neck pain', 'Carotid artery stenosis']",['Takayasu arteritis/Takayasu arteritis'],"Disease: Takayasu arteritis  
Reasoning:  
1. **Vasculitis**: Takayasu arteritis is a large-vessel vasculitis, directly aligning with the patient's vasculitis diagnosis.  
2. **Carotid artery stenosis**: Inflammation in large arteries (e.g., carotids) leads to stenosis, a hallmark of Takayasu.  
3. **Elevated ESR**: Indicates systemic inflammation, consistent with active arteritis.  
4. **Weight loss, Exercise intolerance**: Systemic inflammatory responses and reduced blood flow to muscles.  
5. **Migraine, Vertigo, Neck pain**: Caused by compromised cerebral blood flow due to carotid/vertebral artery involvement.  
6. **Myalgia**: Muscle pain from ischemia or systemic inflammation.  
7. **Epistaxis, Ear pain**: Rare but possible with vascular compromise in nasal or auricular arteries.  
8. **Demographic context**: While age is unspecified, symptom clusters (vascular stenosis + systemic inflammation) are classic for Takayasu.  

Exclusion of mimics (e.g., Giant Cell Arteritis) hinges on carotid involvement and lack of temporal artery symptoms."
"['Renal insufficiency', 'Oral ulcer', 'Abnormality of the nose', 'Abnormal pinna morphology', 'Abnormal sternum morphology', 'Facial erythema', 'Congestive heart failure', 'Tachycardia', 'Aortic regurgitation', 'Palpitations', 'Hyperuricemia', 'Pleural effusion', 'Lymphadenopathy', 'Microscopic hematuria', 'Hyperuricosuria', 'Myalgia', 'Back pain', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Left bundle branch block', 'Abnormal metacarpophalangeal joint morphology', 'Sacroiliac arthritis', 'Fatigue', 'obsolete Increased urinary urate', 'Foot pain', 'Elbow pain', 'Ankle pain', 'Aphthous ulcer', 'Enthesitis']",['Relapsing polychondritis'],"Disease: Relapsing polychondritis  
Reasoning:  
1. **Cartilage involvement**: Key features include ""oral ulcer"" (mucosal inflammation), ""abnormality of the nose"" (saddle nose deformity from nasal chondritis), and ""abnormal pinna morphology"" (auricular chondritis).  
2. **Cardiovascular manifestations**: ""Aortic regurgitation"" and ""left bundle branch block"" align with RP’s propensity to damage cartilaginous structures in the heart valves and conduction system. ""Congestive heart failure"" may result from chronic valvular dysfunction.  
3. **Musculoskeletal inflammation**: ""Enthesitis,"" ""sacroiliac arthritis,"" and joint pain (elbow, ankle, foot) reflect systemic inflammation, though atypical for RP, suggesting overlap or secondary autoimmune processes.  
4. **Systemic inflammation**: Elevated ESR and CRP support an autoimmune etiology.  
5. **Respiratory/renal involvement**: ""Pleural effusion"" and ""renal insufficiency"" may stem from diffuse inflammation or secondary amyloidosis in advanced RP.  
6. **Exclusion of mimics**: Absence of granulomas (unlike GPA) or genital ulcers/uveitis (unlike Behçet’s) strengthens RP’s likelihood.  
7. **Hyperuricemia/hyperuricosuria**: Likely incidental or secondary to renal dysfunction rather than RP itself.  

Distinctive RP markers (cartilage destruction, aortic valve disease) outweigh atypical features (lymphadenopathy, sacroiliitis), warranting this diagnosis."
"['Optic neuropathy', 'Elevated hepatic transaminase', 'Hypercholesterolemia', 'Increased LDL cholesterol concentration', 'Focal white matter lesions', 'Reduced visual acuity', 'CSF polymorphonuclear pleocytosis', 'Lupus anticoagulant', 'Neck pain', 'Elevated gamma-glutamyltransferase level', 'CSF lymphocytic pleiocytosis']","['Antiphospholipid syndrome, familial']","Disease: Antiphospholipid syndrome, familial  
Reasoning:  
1. **Lupus anticoagulant** is a key laboratory marker for antiphospholipid syndrome (APS), indicating the presence of antiphospholipid antibodies.  
2. **Optic neuropathy** and **reduced visual acuity** suggest thrombosis in the retinal or optic nerve vasculature, a common neurological manifestation of APS.  
3. **Focal white matter lesions** likely represent cerebral microthromboses or ischemic infarcts due to hypercoagulability.  
4. **Elevated hepatic transaminases** and **gamma-glutamyltransferase (GGT)** may indicate hepatic vein thrombosis (Budd-Chiari syndrome), a thrombotic complication of APS.  
5. **CSF pleocytosis** (both polymorphonuclear and lymphocytic) could reflect inflammatory responses secondary to ischemic brain injury or cerebral venous thrombosis.  
6. **Neck pain** may arise from cervical artery or venous thrombosis, a thrombotic event consistent with APS.  
7. **Hypercholesterolemia** and **elevated LDL** may exacerbate thrombotic risk, aligning with the familial presentation of APS where comorbid metabolic disorders could coexist.  
8. The **familial** designation implies a genetic predisposition, supported by recurrent thrombosis and laboratory criteria (persistent lupus anticoagulant) in family members.  

This constellation of multi-organ thrombotic events, serological evidence, and familial pattern confirms the diagnosis."
"['Weight loss', 'Arthralgia', 'Elevated circulating creatinine concentration', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Fatigue', 'Restless legs', 'Abnormality of nail color']","['Scleroderma, familial progressive', 'Systemic sclerosi; SSc/Systemic sclerosis', 'Diffuse cutaneous systemic sclerosis', 'Limited cutaneous systemic sclerosis', 'CREST syndrome']","Systemic sclerosis/Systemic scleroderma; SSc/Systemic sclerosis: The patient exhibits hallmark features of systemic sclerosis (SSc), including antinuclear antibody positivity (present in >95% of cases), arthralgia, and elevated creatinine (suggesting possible renal involvement). Weight loss and fatigue may reflect gastrointestinal or multisystem disease. Abnormal nail color could indicate nailfold capillary changes, a key microvascular feature of SSc.  

Diffuse cutaneous systemic sclerosis: Elevated creatinine raises concern for scleroderma renal crisis (SRC), a life-threatening complication strongly associated with diffuse cutaneous SSc. Rapid progression of skin thickening (not explicitly listed but inferred from systemic symptoms) and early internal organ involvement (renal, musculoskeletal) align with this subtype.  

Limited cutaneous systemic sclerosis: Arthralgia, fatigue, and ANA positivity are consistent, but the absence of explicit CREST features (e.g., calcinosis, telangiectasia) or isolated distal skin thickening makes this less definitive. However, subtle nailfold abnormalities and restless legs (linked to vascular dysfunction) may suggest early limited disease.  

CREST syndrome: Requires at least two of Calcinosis, Raynaud’s, Esophageal dysmotility, Sclerodactyly, or Telangiectasia. While restless legs and nail changes might hint at vascular dysfunction (Raynaud’s-like), insufficient specific CREST features are documented to prioritize this diagnosis.  

Scleroderma, familial progressive: This rare inherited form presents similarly to SSc but typically manifests in childhood with progressive skin hardening. The absence of family history or pediatric-onset clues makes this less likely compared to acquired systemic sclerosis.  

**Final Emphasis:** The combination of renal involvement (elevated creatinine), autoimmune markers (ANA+), and systemic symptoms strongly favors **diffuse cutaneous systemic sclerosis** with incipient scleroderma renal crisis. Urgent evaluation for hypertension, proteinuria, and renal imaging is critical."
"['Renal insufficiency', 'Proteinuria', 'Nephrotic syndrome', 'Hematuria', 'Membranoproliferative glomerulonephritis', 'Hypertension', 'Purpura', 'Splenomegaly', 'Ankle swelling', 'Metabolic acidosis', 'Nausea', 'Abdominal pain', 'Dyspnea', 'Abnormal lung lobation', 'Pulmonary infiltrates', 'Pleural effusion', 'Headache', 'Hypoalbuminemia', 'Elevated circulating creatinine concentration', 'Exercise intolerance', 'Decreased circulating IgG level', 'Abnormality of the pulmonary vasculature', 'Decreased circulating complement C3 concentration', 'Generalized lymphadenopathy', 'Elevated circulating C-reactive protein concentration', 'Increased circulating beta-2-microglobulin level', 'Ankle pain', 'Increased circulating NT-proBNP concentration', 'Parenchymal consolidation', 'Decreased circulating complement C4 concentration', 'Cryoglobulinemia']","['Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed']","Disease: Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed  
Reasoning:  
1. **Renal Involvement**: Membranoproliferative glomerulonephritis (MPGN) is a hallmark of cryoglobulinemic vasculitis. Proteinuria, hematuria, nephrotic syndrome, hypoalbuminemia, and elevated creatinine align with renal damage from cryoglobulin deposition and immune complex-mediated injury.  
2. **Cutaneous Manifestations**: Purpura is characteristic of small-vessel vasculitis driven by cryoglobulinemia.  
3. **Hypocomplementemia**: Decreased C3 and C4 levels indicate complement consumption due to immune complex formation, a key feature of cryoglobulinemia.  
4. **Systemic Inflammation**: Elevated C-reactive protein and generalized lymphadenopathy reflect chronic inflammatory activity.  
5. **Pulmonary Involvement**: Dyspnea, pulmonary infiltrates, pleural effusion, and abnormal vasculature suggest cryoglobulin-mediated vascular injury and inflammation in the lungs.  
6. **Cryoglobulinemia Confirmation**: Direct presence of cryoglobulins in the patient’s symptoms confirms the diagnosis.  
7. **Familial Component**: The ""familial mixed"" subtype implies genetic predisposition, though specific genetic markers (e.g., *CFHR5* mutations) may require further testing.  
8. **Secondary Features**: Hypertension, metabolic acidosis, and edema (ankle swelling) are consequences of renal dysfunction, while nausea and abdominal pain may arise from systemic vasculitis.  
9. **Immunologic Dysregulation**: Decreased IgG and elevated beta-2-microglobulin suggest chronic immune activation and possible underlying lymphoproliferative disorder, often associated with cryoglobulinemia.  
10. **Cardiac Stress**: Elevated NT-proBNP may indicate volume overload from nephrotic syndrome or cardiac strain secondary to hypertension.  

This pattern of multi-organ involvement (renal, cutaneous, pulmonary), hypocomplementemia, and cryoglobulin presence strongly supports familial mixed cryoglobulinemic vasculitis."
"['Otitis media', 'Cyanosis', 'Pericardial effusion', 'Abnormal toe morphology', 'Pleural effusion', 'Arthralgia', 'Peripheral neuropathy', 'Abnormal cardiovascular system physiology', 'Gangrene']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Granulomatosis with polyangiitis (GPA):  
1. **Otitis media**: GPA frequently involves upper respiratory tract inflammation, leading to chronic otitis media or sinusitis.  
2. **Cyanosis & Pleural/Pericardial effusions**: Systemic vasculitis in GPA can cause lung parenchymal disease (nodules, hemorrhage) and serositis, reducing oxygenation (cyanosis) and triggering fluid accumulation in pleural/pericardial spaces.  
3. **Arthralgia & Peripheral neuropathy**: Immune-mediated vascular inflammation damages joints and vasa nervorum, causing joint pain and neuropathic symptoms.  
4. **Abnormal cardiovascular physiology**: Vasculitis-induced endothelial injury disrupts blood flow dynamics, while pericardial effusion exacerbates cardiac dysfunction.  
5. **Gangrene & Abnormal toe morphology**: Necrotizing vasculitis compromises distal blood supply, leading to ischemic tissue damage (gangrene) and structural toe changes (e.g., digital clubbing or necrosis).  
6. **Multi-organ involvement**: The combination of ENT, pulmonary, cardiovascular, musculoskeletal, and peripheral vascular symptoms aligns with GPA’s systemic nature. ANCA-associated pathology (e.g., PR3-ANCA) further supports this diagnosis."
"['Hypothyroidism', 'Pruritus', 'Cholelithiasis', 'obsolete Mood changes', 'Dilated cardiomyopathy', 'Bradycardia', 'Acute pancreatitis', 'Weight loss', 'Macrocytic anemia', 'Leukocytosis', 'Nausea', 'Loss of speech', 'Incomprehensible speech', 'Vasculitis', 'Obstructive sleep apnea', 'Elevated circulating thyroid-stimulating hormone concentration', 'Abnormal EKG', 'Elevated circulating parathyroid hormone level', 'Antinuclear antibody positivity', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Atrioventricular dissociation', 'Elevated gamma-glutamyltransferase level', 'Unhappy demeanor', 'Decreased circulating free T3', 'Perinuclear antineutrophil antibody positivity', 'Increased circulating IgG4 level', 'Carotid artery stenosis', 'Thyroiditis']","['Multifocal fibrosclerosis', 'IgG4-related retroperitoneal fibrosis', 'IgG4 related disease; IgG4-RD']","Disease: IgG4 related disease; IgG4-RD  
**Reasoning**:  
1. **Elevated IgG4 level** (Increased circulating IgG4 level) is a hallmark diagnostic criterion for IgG4-RD.  
2. **Multi-organ involvement**:  
   - **Thyroid**: Hypothyroidism, thyroiditis, elevated TSH, and low free T3 align with IgG4-related thyroid disease (e.g., Riedel’s thyroiditis).  
   - **Pancreas/biliary**: Acute pancreatitis, cholelithiasis, and elevated gamma-glutamyltransferase suggest IgG4-related autoimmune pancreatitis/sclerosing cholangitis.  
   - **Vascular**: Vasculitis, carotid stenosis, and antinuclear/ANCA positivity reflect systemic fibroinflammatory vasculopathy.  
3. **Inflammatory markers**: Elevated ESR, CRP, leukocytosis, and antinuclear antibody positivity support systemic inflammation.  
4. **Fibrosis**: Dilated cardiomyopathy (cardiac fibrosis), obstructive sleep apnea (airway fibrosis), and retroperitoneal fibrosis (linked to IgG4-RD spectrum).  
5. **Exclusion of mimics**: Macrocytic anemia and mood changes may arise from chronic inflammation, while antineutrophil antibodies and parathyroid hormone elevation are atypical but not contradictory in systemic autoimmune disorders.  

Disease: IgG4-related retroperitoneal fibrosis  
**Reasoning**:  
- A subset of IgG4-RD, retroperitoneal fibrosis explains **weight loss**, **nausea**, and potential ureteral obstruction (not explicitly listed but commonly associated).  
- Linked to elevated IgG4 levels and perivascular fibrosis (carotid stenosis, vasculitis).  

Disease: Multifocal fibrosclerosis  
**Reasoning**:  
- Historical term for IgG4-RD manifestations, encompassing fibrosis in **thyroid**, **pancreas**, **retroperitoneum**, and **vascular system** (carotid stenosis, AV dissociation from cardiac fibrosis).  
- Explains **dilated cardiomyopathy** (myocardial fibrosis) and **pruritus** (bile duct fibrosis/cholestasis).  

**Conclusion**: The patient’s multi-organ fibrosis, autoimmune features, and elevated IgG4 confirm **IgG4-RD** with retroperitoneal fibrosis and multifocal fibrosclerosis as overlapping phenotypes."
"['Abnormality of the hand', 'Weight loss', 'Elevated hepatic transaminase', 'Rheumatoid factor positive', 'Increased circulating ferritin concentration', 'Elevated erythrocyte sedimentation rate', 'Abnormality of complement system', 'Increased alpha-globulin', 'Limited wrist movement', 'Elevated circulating C-reactive protein concentration', 'Upper limb pain', 'Dysesthesia', 'Neck pain', 'Arterial stenosis', 'Cryoglobulinemia', 'Skin erosion']","['Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed']","Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed:  
The patient presents with cryoglobulinemia, a hallmark of this disease, alongside systemic inflammation (elevated CRP, ESR, ferritin). Rheumatoid factor positivity and complement system abnormalities suggest immune complex deposition, driving vasculitis. Skin erosions, dysesthesia, and arterial stenosis align with small-to-medium vessel inflammation. Elevated hepatic transaminases and alpha-globulins indicate liver involvement, common in cryoglobulinemia. Upper limb/neck pain, limited wrist movement, and hand abnormalities reflect joint and soft tissue damage from vasculitis or cryoglobulin precipitation. Familial mixed type implies a genetic predisposition to mixed cryoglobulin production (IgM-IgG complexes), corroborated by multisystemic features."
"['Petechiae', 'Thrombocytopenia', 'Leukocytosis', 'Headache', 'Vasculitis', 'Elevated hepatic transaminase', 'Smooth muscle antibody positivity', 'Antinuclear antibody positivity', 'Elevated erythrocyte sedimentation rate', 'Decreased circulating complement C3 concentration', 'Viral hepatitis', 'Peripheral neuropathy', 'Pedal edema', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Lower limb pain', 'Foot pain', 'Antimitochondrial antibody positivity', 'Decreased circulating complement C4 concentration', 'Abnormality of nail color', 'Cryoglobulinemia']","['Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed']","Disease: Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed  
Reasoning:  
1. **Cryoglobulinemia**: Directly listed as a symptom, indicating abnormal immunoglobulin complexes precipitating in cold temperatures.  
2. **Vasculitis**: Present and central to the diagnosis; explains petechiae, peripheral neuropathy, and organ involvement (e.g., liver via elevated transaminases).  
3. **Complement consumption**: Decreased C3/C4 levels suggest immune complex deposition, a hallmark of cryoglobulinemic vasculitis.  
4. **Autoimmune markers**: Smooth muscle antibody (SMA), antinuclear antibody (ANA), and antimitochondrial antibody (AMA) positivity indicate autoimmune dysregulation, though AMA may overlap with viral hepatitis.  
5. **Viral hepatitis**: A common trigger for mixed cryoglobulinemia (often hepatitis C), linking liver injury and cryoglobulin production.  
6. **Inflammation**: Elevated ESR, CRP, leukocytosis, and fatigue align with systemic inflammation from vasculitis.  
7. **Cutaneous/neurologic involvement**: Petechiae, nail discoloration, peripheral neuropathy, and limb pain reflect small-vessel damage.  
8. **Familial component**: ""Familial mixed"" suggests genetic predisposition, though viral cofactors (hepatitis) may drive disease expression.  
9. **Renal/edema**: Pedal edema hints at possible renal involvement (glomerulonephritis) secondary to cryoglobulin deposition.  

The constellation of immune complexes, vasculitis, hepatitis, and complement abnormalities confirms **cryoglobulinemic vasculitis**, with familial mixed type indicating hereditary susceptibility."
"['Epididymitis', 'Conjunctivitis', 'Pericarditis', 'Splenomegaly', 'Weight loss', 'Fever', 'Leukocytosis', 'Diarrhea', 'Abdominal pain', 'Abnormality of the knee', 'Hypoalbuminemia', 'Generalized amyloid deposition', 'Elevated circulating creatinine concentration', 'Elevated erythrocyte sedimentation rate', 'Erythema', 'Elevated circulating C-reactive protein concentration', 'Intestinal lymphoid nodular hyperplasia', 'Fatigue', 'Moderate proteinuria', 'Heavy proteinuria', 'Night sweats', 'Hip pain', 'Abnormality of mesentery morphology', 'Periorbital edema']","['Tumor necrosis factor receptor 1 associated periodic syndrome/Periodic fever, familial, autosomal dominant']","Disease: Tumor necrosis factor receptor 1 associated periodic syndrome/Periodic fever, familial, autosomal dominant (TRAPS)  
Reasoning:  
1. **Systemic inflammation**: Fever, leukocytosis, elevated ESR, and CRP align with TRAPS’ hallmark of prolonged inflammatory episodes.  
2. **Mucocutaneous features**: Conjunctivitis and erythema reflect characteristic ocular/periocular inflammation and migratory rash in TRAPS.  
3. **Serositis**: Pericarditis matches recurrent serosal inflammation seen in TRAPS.  
4. **Amyloidosis**: Hypoalbuminemia, proteinuria, and generalized amyloid deposition indicate AA amyloidosis, a severe TRAPS complication from chronic inflammation.  
5. **Gastrointestinal involvement**: Abdominal pain, diarrhea, and mesenteric lymphoid hyperplasia suggest gut inflammation, consistent with TRAPS’ systemic effects.  
6. **Musculoskeletal symptoms**: Hip/knee pain and mesenteric morphology abnormalities (e.g., fat wrapping) correlate with TRAPS-associated arthralgia and tissue inflammation.  
7. **Periorbital edema**: A pathognomonic feature of TRAPS during flares.  
8. **Autosomal dominant pattern**: Familial periodic fever history (implied by diagnosis) supports genetic etiology of TNFRSF1A mutations.  
9. **Exclusion of mimics**: Symptoms overlap with other periodic fever syndromes (e.g., FMF, HIDS), but amyloidosis, prolonged attacks (>7 days), and periorbital edema favor TRAPS."
"['Ovarian cyst', 'Hepatic steatosis', 'Splenomegaly', 'Fever', 'Arthralgia', 'Exertional dyspnea', 'Myalgia', 'Exercise intolerance', 'Elevated circulating C-reactive protein concentration', 'Night sweats']","['Familial mediterranean fever; FMF/Familial Mediterranean fever/Familial Mediterranean fever, AR', 'Familial Mediterranean fever, AD']","Disease: Familial mediterranean fever; FMF (AR)  
Reasoning:  
1. **Fever and elevated CRP**: Hallmark of FMF, reflecting systemic inflammation during attacks.  
2. **Arthralgia/Myalgia**: Common musculoskeletal manifestations in FMF due to serosal inflammation.  
3. **Splenomegaly**: Occurs in severe or chronic FMF due to recurrent inflammatory insults.  
4. **Night sweats**: Associated with febrile episodes.  
5. **Exertional dyspnea/Exercise intolerance**: May stem from subclinical pleuritis (a classic FMF feature) limiting respiratory capacity.  
6. **Hepatic steatosis/Ovarian cyst**: Indirectly linked; chronic inflammation or secondary amyloidosis (a complication of untreated FMF) could contribute to hepatic involvement. Ovarian cysts are not specific but may coexist.  

Disease: Familial Mediterranean fever, AD  
Reasoning:  
1. Overlapping features (fever, arthralgia, elevated CRP) align with AD-FMF, a rare variant with similar but often milder symptoms.  
2. AD inheritance may present with atypical organ involvement (e.g., hepatic steatosis) due to differing genetic modifiers.  
3. Splenomegaly and exercise intolerance are less typical but plausible in prolonged undiagnosed cases.  
4. Requires genetic confirmation (e.g., *MEFV* heterozygous pathogenic variants with AD penetrance).  

**Conclusion**: Both AR and AD forms are plausible. AR-FMF is more likely given the classic triad (fever, serositis, elevated CRP), but AD-FMF should be considered if family history suggests dominant inheritance or genetic testing is inconclusive for biallelic mutations."
"['Nocturia', 'Renal cyst', 'Ovarian cyst', 'Hyperhidrosis', 'Facial erythema', 'Joint swelling', 'Hepatic steatosis', 'Ascites', 'Tachycardia', 'Acute pancreatitis', 'Abnormal toe morphology', 'Vomiting', 'Diarrhea', 'Nausea', 'Cerebral atrophy', 'Dyspnea', 'Pleuritis', 'Hyperuricemia', 'Hypertriglyceridemia', 'Pleural effusion', 'Hepatomegaly', 'Arthralgia', 'Neoplasm of the liver', 'Rheumatoid factor positive', 'Hypercholesterolemia', 'Hyperuricosuria', 'Increased circulating ferritin concentration', 'Myalgia', 'Back pain', 'Increased circulating IgM level', 'Exercise intolerance', 'Increased total bilirubin', 'Generalized morning stiffness', 'Abnormality of complement system', 'Enlarged metacarpophalangeal joints', 'Renal neoplasm', 'Peripheral neuropathy', 'Elevated circulating C-reactive protein concentration', 'obsolete Increased urinary urate', 'Increased circulating beta-2-microglobulin level', 'Neck pain', 'Shoulder pain', 'Finger pain', 'Elevated gamma-glutamyltransferase level', 'Perinephric fluid collection', 'Groin pain', 'Increased circulating IgG4 level', 'Low levels of vitamin D', 'Abnormality of nail color', 'Insomnia', 'Increased hepatitis A virus antibody level']",['Antisynthetase syndrome'],"Disease: Antisynthetase syndrome  
Reasoning:  
1. **Key Triad Features**:  
   - **Myositis**: Suggested by *myalgia* and *exercise intolerance* (common in muscle inflammation).  
   - **Interstitial Lung Disease (ILD)**: Supported by *dyspnea*, *pleural effusion*, and *pleuritis*.  
   - **Inflammatory Arthritis**: Evidenced by *joint swelling*, *arthralgia*, *enlarged metacarpophalangeal joints*, and *morning stiffness*.  

2. **Autoimmune Markers**:  
   - *Rheumatoid factor positive* and *elevated CRP* align with systemic inflammation.  
   - *Abnormality of complement system* and *increased IgG4/IgM* suggest immune dysregulation, though anti-synthetase antibodies (e.g., anti-Jo-1) are pathognomonic (not explicitly listed but inferred).  

3. **Overlapping Systemic Involvement**:  
   - *Hepatomegaly* and *hepatic steatosis* may reflect secondary metabolic dysfunction or inflammation.  
   - *Hyperuricemia* and *hypertriglyceridemia* could arise from systemic inflammation or comorbid metabolic syndrome.  

4. **Exclusions/Comorbidities**:  
   - *Renal cysts*, *neoplasms*, and *cerebral atrophy* are atypical for antisynthetase syndrome, suggesting comorbidities or alternative diagnoses (e.g., genetic disorders like HNF1B or VHL).  
   - *Acute pancreatitis* and *vitamin D deficiency* likely stem from metabolic disturbances rather than primary autoimmune pathology.  

5. **Supportive Findings**:  
   - *Facial erythema* and *abnormal nail color* may reflect vasculopathy or Raynaud’s phenomenon (common in overlap syndromes).  
   - *Peripheral neuropathy* and *fatigue* are nonspecific but compatible with chronic inflammatory states.  

Conclusion: The constellation of myositis, ILD, and inflammatory arthritis, alongside autoimmune markers, strongly supports antisynthetase syndrome. Further confirmation requires anti-synthetase antibody testing (e.g., anti-Jo-1) and imaging (e.g., HRCT for ILD)."
"['Proteinuria', 'Abnormal paranasal sinus morphology', 'Abnormal pinna morphology', 'Abnormal nasal mucosa morphology', 'Hematuria', 'Acrocyanosis', 'Ankle swelling', 'Anemia', 'Elevated hepatic transaminase', 'Elevated circulating creatinine concentration', 'Elevated circulating C-reactive protein concentration', 'Decreased glomerular filtration rate', 'Cytoplasmic antineutrophil antibody positivity']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with Polyangiitis  
Reasoning:  
1. **c-ANCA Positivity**: Cytoplasmic antineutrophil antibody (c-ANCA) targeting PR3 is strongly associated with GPA, supporting an autoimmune vasculitis diagnosis.  
2. **Upper Respiratory Involvement**: Abnormal paranasal sinus, nasal mucosa, and pinna morphology align with GPA’s granulomatous inflammation in the respiratory tract, often causing sinusitis, nasal ulcers, or otitis.  
3. **Renal Manifestations**: Proteinuria, hematuria, elevated creatinine, and decreased GFR indicate pauci-immune glomerulonephritis, a hallmark of severe GPA.  
4. **Systemic Inflammation**: Elevated CRP and anemia reflect chronic inflammation, typical of active vasculitis.  
5. **Multisystem Features**: Acrocyanosis and ankle swelling suggest small-vessel vasculitis affecting peripheral circulation and fluid retention from renal dysfunction. Elevated hepatic transaminases may indicate secondary inflammation or drug-induced liver injury (e.g., from immunosuppressants).  
6. **Exclusion of Mimics**: The absence of anti-GBM antibodies (Goodpasture’s), eosinophilia (Churg-Strauss), or ANA/dsDNA (SLE) further narrows the diagnosis to GPA.  

This constellation of c-ANCA positivity, granulomatous upper respiratory lesions, and necrotizing glomerulonephritis is pathognomonic for Granulomatosis with Polyangiitis."
"['Oral ulcer', 'Xerostomia', 'Tinnitus', 'Hearing impairment', 'Proptosis', 'Visual loss', 'Decreased lacrimation', 'Diplopia', 'Nephrolithiasis', 'Abnormal finger morphology', 'Hemiparesis', 'Gait disturbance', 'Arthritis', 'Mitral regurgitation', 'Renal tubular acidosis', 'Leukocytosis', 'Migraine', 'Vertigo', 'Arthralgia', 'Exertional dyspnea', 'Elevated circulating thyroid-stimulating hormone concentration', 'Somatic sensory dysfunction', 'Hypouricemia', 'Exercise intolerance', 'Decreased urinary urate', 'Neck pain', 'Aphthous ulcer', 'Low levels of vitamin D', 'Skin vesicle', 'Pustule']","['Behçet disease/Behcet syndrome', 'Spondyloarthropathy, susceptibility to, 1', 'Spondyloarthropathy, susceptibility to, 2']","Disease: Behçet disease/Behcet syndrome  
Reasoning: The patient presents with recurrent oral/aphthous ulcers, a hallmark of Behçet disease. Ocular involvement (proptosis, visual loss, diplopia) aligns with uveitis or retinal vasculitis. Skin vesicles/pustules suggest pathergy or cutaneous manifestations. Neurological symptoms (hemiparesis, gait disturbance, somatic sensory dysfunction) indicate possible neuro-Behçet. Arthritis and arthralgia are common systemic features. While atypical symptoms like xerostomia, renal tubular acidosis, and hypouricemia are not classic for Behçet, the core criteria (oral ulcers + multisystem inflammation) strongly support this diagnosis.  

Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: Arthritis, neck pain, and uveitis (implied by visual loss) are consistent with spondyloarthropathy (SpA). Elevated leukocytosis and HLA-B27 susceptibility (inferred from ""susceptibility to, 1"") may predispose to axial involvement. However, oral ulcers, neurological deficits, and cutaneous symptoms are less typical, suggesting incomplete alignment with SpA.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: Similar to SpA-1, arthritic and axial symptoms (neck pain) are present. However, the absence of hallmark SpA features (e.g., enthesitis, sacroiliitis) and prominence of non-SpA symptoms (oral ulcers, renal/metabolic abnormalities) reduce confidence. Genetic susceptibility (e.g., ERAP1 variants in SpA-2) may contribute but does not override the stronger evidence for Behçet syndrome."
"['Sinusitis', 'Hypertension', 'Dry skin', 'Pallor', 'Thrombocytosis', 'Anemia', 'Renal artery stenosis', 'Fever', 'Leukocytosis', 'Vomiting', 'Abdominal pain', 'Dyspnea', 'Osteomyelitis', 'Elevated hepatic transaminase', 'Increased blood urea nitrogen', 'Increased circulating IgG level', 'Elevated circulating creatinine concentration', 'Back pain', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Poor appetite', 'Epileptic spasm', 'Elevated circulating C-reactive protein concentration', 'Flank pain', 'Elevated gamma-glutamyltransferase level', 'Elevated carcinoma antigen 125 level', 'obsolete Abnormal fecal test result', 'Abnormality of mesentery morphology', 'Papule', 'Epigastric pain']",['Takayasu arteritis/Takayasu arteritis'],"Disease: Takayasu arteritis  
Reasoning:  
1. **Vascular involvement**: Renal artery stenosis (a hallmark of Takayasu arteritis) explains hypertension, elevated blood urea nitrogen, and creatinine. Flank/back pain may reflect ischemic kidney injury.  
2. **Systemic inflammation**: Fever, leukocytosis, elevated ESR, CRP, and IgG levels align with chronic inflammatory vasculitis.  
3. **Mesenteric ischemia**: Abdominal/epigastric pain, mesentery abnormality, and vomiting suggest compromised mesenteric artery blood flow.  
4. **Anemia/Thrombocytosis**: Common in chronic inflammatory states.  
5. **Autoimmune features**: Antinuclear antibody positivity (non-specific but supportive of autoimmune etiology).  
6. **Exclusion of mimics**: Elevated CA-125 and hepatic enzymes may reflect secondary inflammation; sinusitis and papules are atypical but do not rule out Takayasu.  
**Key omissions**: Angiographic evidence (e.g., aortic/pulmonary artery stenosis) is required for definitive diagnosis, but clinical and lab findings strongly suggest Takayasu arteritis."
"['Hepatic steatosis', 'Paraparesis', 'Abnormality of the upper limb', 'Elevated hepatic transaminase', 'Abnormal EKG', 'Elevated circulating creatine kinase concentration', 'Elevated circulating creatinine concentration', 'Myalgia', 'Antinuclear antibody positivity', 'Atrial fibrillation', 'Coronary artery stenosis', 'Necrotizing myopathy', 'Left bundle branch block', 'Decreased glomerular filtration rate', 'Moderate proteinuria', 'Heavy proteinuria', 'Antimitochondrial antibody positivity', 'Elevated gamma-glutamyltransferase level', 'Increased circulating NT-proBNP concentration', 'Arterial stenosis']","['Polymyositis', 'Primary sclerosing cholangitis']","Disease: Polymyositis  
Reasoning: The patient presents with myalgia, elevated creatine kinase, and necrotizing myopathy, all indicative of muscle inflammation and damage. Antinuclear antibody (ANA) positivity supports an autoimmune etiology. Paraparesis and upper limb abnormalities align with proximal muscle weakness typical of polymyositis. Elevated creatinine, decreased glomerular filtration rate (GFR), and proteinuria may result from myoglobinuria secondary to muscle breakdown, linking renal dysfunction to rhabdomyolysis.  

Disease: Primary sclerosing cholangitis  
Reasoning: Hepatic involvement (hepatic steatosis, elevated transaminases, and gamma-glutamyltransferase) suggests cholestatic liver disease. While antimitochondrial antibody (AMA) positivity is classically associated with primary biliary cholangitis (PBC), the diagnosis of primary sclerosing cholangitis (PSC) may rely on imaging evidence of bile duct strictures. Elevated gamma-glutamyltransferase (GGT) and cholestatic enzyme patterns further support PSC. The coexistence of ANA and AMA could indicate overlap syndromes or atypical serology, but clinical and imaging findings take precedence in diagnosing PSC."
"['Hearing abnormality', 'Visual loss', 'Hypertension', 'Hyperhidrosis', 'Gait disturbance', 'Hepatic steatosis', 'obsolete Mood changes', 'Aortic regurgitation', 'Splenomegaly', 'Diarrhea', 'Nausea', 'Constipation', 'Heat intolerance', 'Abnormal intestine morphology', 'Headache', 'Vertigo', 'Abnormality of the lower limb', 'Arthralgia', 'Exertional dyspnea', 'Elevated hepatic transaminase', 'Abnormal EKG', 'Increased LDL cholesterol concentration', 'Elevated circulating creatine kinase concentration', 'Abdominal distention', 'Increased circulating ferritin concentration', 'Back pain', 'Somatic sensory dysfunction', 'Exercise intolerance', 'Gastrointestinal inflammation', 'Ventricular tachycardia', 'Gastritis', 'Premature ventricular contraction', 'Elevated circulating C-reactive protein concentration', 'Right bundle branch block', 'Abnormal metacarpophalangeal joint morphology', 'Constrictive median neuropathy', 'Sacroiliac arthritis', 'Upper limb pain', 'Lower limb pain', 'Dysesthesia', 'Panic attack', 'Neck pain', 'Hip pain', 'Groin pain', 'Unhappy demeanor', 'Low levels of vitamin D', 'Chest pain', 'Insomnia']","['Spondyloarthropathy, susceptibility to, 1', 'Spondyloarthropathy, susceptibility to, 2']","Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning:  
1. **Axial skeletal involvement**: Sacroiliac arthritis, back pain, neck pain, hip/groin pain, and abnormal lower limb morphology align with axial spondyloarthritis (e.g., ankylosing spondylitis), a hallmark of spondyloarthropathy.  
2. **Peripheral joint manifestations**: Arthralgia, abnormal metacarpophalangeal joint morphology, and limb pain suggest peripheral arthritis, common in spondyloarthropathies.  
3. **Extra-articular features**:  
   - **Gastrointestinal inflammation**: Diarrhea, constipation, gastritis, and abnormal intestine morphology may indicate inflammatory bowel disease (IBD), frequently comorbid with spondyloarthropathy.  
   - **Cardiac abnormalities**: Aortic regurgitation and conduction defects (right bundle branch block, ventricular tachycardia) are recognized complications of chronic inflammation in HLA-B27-associated diseases.  
   - **Elevated inflammatory markers**: Elevated CRP and ferritin reflect systemic inflammation.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning:  
1. **Genetic predisposition**: Susceptibility loci (e.g., HLA-B27) are strongly linked to spondyloarthropathies, explaining familial clustering and disease severity.  
2. **Neurological and sensory symptoms**: Constrictive median neuropathy, dysesthesia, and somatic sensory dysfunction may stem from enthesitis or nerve compression due to chronic inflammation.  
3. **Dermatological/autonomic features**: Hyperhidrosis and heat intolerance could reflect autonomic dysregulation, occasionally observed in systemic autoimmune disorders.  
4. **Vitamin D deficiency**: Common in chronic inflammatory diseases due to reduced sunlight exposure or malabsorption, exacerbating musculoskeletal pain.  
5. **Psychosocial components**: Unhappy demeanor, panic attacks, and insomnia are consistent with chronic pain syndromes and inflammation-driven neuropsychiatric effects.  

**Key Overlap**: Both diagnoses share core features (axial/peripheral arthritis, IBD association, cardiac involvement) but highlight genetic heterogeneity (e.g., non-HLA genes in susceptibility 2). The breadth of symptoms (musculoskeletal, gastrointestinal, cardiac, neurological) underscores the multisystem nature of spondyloarthropathies, necessitating a holistic diagnostic approach."
"['Goiter', 'Cholelithiasis', 'Arthritis', 'Abnormality of the larynx', 'Abnormal aortic morphology', 'Thrombocytosis', 'Anemia', 'Fever', 'Leukocytosis', 'Hepatomegaly', 'Abnormal intestine morphology', 'Arthralgia', 'Elevated hepatic transaminase', 'Hypercalcemia', 'Elevated circulating alkaline phosphatase concentration', 'Myalgia', 'Exercise intolerance', 'Increased alpha-globulin', 'Elevated circulating C-reactive protein concentration', 'Decreased erythrocyte sedimentation rate', 'Cervical lymphadenopathy', 'Night sweats', 'Knee pain', 'Elevated gamma-glutamyltransferase level']","['Familial cold autoinflammatory syndrome 2', 'Familial cold urticaria', 'Familial cold inflammatory syndrome 1', 'Muckle-Wells syndrome/Muckle-Wells syndrome', 'Familial cold autoinflammatory syndrome 3', 'Familial cold autoinflammatory syndrome 4', 'CINCA syndrome/Cinca syndrome']","Disease: Muckle-Wells syndrome/Muckle-Wells syndrome  
Reasoning:  
1. **Systemic Inflammation**: Elevated CRP, leukocytosis, thrombocytosis, and fever align with chronic inflammation seen in Muckle-Wells syndrome (MWS).  
2. **Musculoskeletal Involvement**: Arthritis, arthralgia, myalgia, and knee pain are consistent with recurrent inflammatory episodes characteristic of MWS.  
3. **Hepatic Abnormalities**: Hepatomegaly, elevated transaminases, and GGT suggest systemic inflammation affecting the liver, common in MWS.  
4. **ENT Manifestations**: Laryngeal abnormalities and cervical lymphadenopathy may reflect chronic mucosal inflammation.  
5. **Laboratory Findings**: Increased alpha-globulin and hypercalcemia (though atypical) could stem from chronic inflammation or secondary dysregulation. Decreased ESR paradoxically occurs due to hypergammaglobulinemia inhibiting rouleaux formation.  
6. **Absence of Cold Triggers**: Symptoms lack cold-induced triggers, making FCAS less likely.  
7. **Organ Damage**: Abnormal aortic/intestine morphology may reflect long-term inflammatory damage or amyloidosis, a known complication of MWS.  
8. **Exclusion of CINCA**: No neonatal onset, neurological deficits, or bony overgrowth, ruling out CINCA.  

Disease: Familial cold autoinflammatory syndrome 2  
Reasoning:  
1. **Overlapping Inflammation**: Fever, leukocytosis, and elevated CRP match FCAS2’s inflammatory profile.  
2. **Lymphatic Involvement**: Cervical lymphadenopathy and night sweats align with FCAS2’s systemic presentation.  
3. **Gastrointestinal Features**: Abnormal intestine morphology and hepatomegaly may reflect abdominal inflammation reported in FCAS2.  
4. **Musculoskeletal Symptoms**: Arthralgia and myalgia are consistent but less specific.  
5. **Cold Trigger Ambiguity**: Lack of explicit cold triggers in the history reduces likelihood but does not exclude FCAS2.  

Disease: CINCA syndrome/Cinca syndrome  
Reasoning:  
1. **Severe Inflammation**: Marked leukocytosis, thrombocytosis, and hepatomegaly suggest systemic involvement.  
2. **Growth Abnormalities**: Abnormal aortic/intestine morphology could reflect chronic tissue inflammation.  
3. **Exclusion Factors**: Absence of neonatal onset, rash, or neurological deficits makes CINCA unlikely but not impossible in atypical cases.  

**Final Diagnosis**: **Muckle-Wells syndrome** is the most likely, given the chronic systemic inflammation, multi-organ involvement, and absence of neonatal or cold-triggered features. FCAS2 and CINCA are less probable but remain differentials."
"['Renal insufficiency', 'Renal hypoplasia', 'Focal segmental glomerulosclerosis', 'Hypothyroidism', 'Anemia', 'Diarrhea', 'Hyperkalemia', 'Hypoalbuminemia', 'Increased blood urea nitrogen', 'Elevated circulating parathyroid hormone level', 'Elevated circulating creatinine concentration', 'Decreased glomerular filtration rate', 'Mild proteinuria', 'Low levels of vitamin D', 'Papule']",['Fabry disease/Fabry disease/Fabry disease'],"Disease: Fabry disease  
Reasoning:  
1. **Renal Involvement**: Renal insufficiency, hypoplasia, focal segmental glomerulosclerosis (FSGS), elevated creatinine, and reduced GFR are hallmark renal manifestations of Fabry disease. FSGS and tubular dysfunction are common in advanced stages due to glycolipid accumulation.  
2. **Multisystem Symptoms**:  
   - **Hypothyroidism**: Fabry disease can cause endocrine dysfunction via cellular glycosphingolipid deposition.  
   - **Anemia/Hyperkalemia/Hypoalbuminemia**: Secondary to chronic kidney disease (CKD) from Fabry-related nephropathy.  
   - **Diarrhea**: Gastrointestinal involvement (e.g., autonomic neuropathy or vascular ischemia) is frequent.  
3. **Metabolic Abnormalities**: Elevated PTH and low vitamin D indicate CKD-mineral bone disorder, consistent with Fabry-induced renal failure.  
4. **Dermatologic Feature**: Papules (likely angiokeratomas), a pathognomonic sign of Fabry disease, caused by glycolipid deposits in skin vasculature.  
5. **Exclusion of Alternatives**: Combined renal, endocrine, and cutaneous symptoms rule out isolated CKD or thyroid disorders, aligning with Fabry’s lysosomal storage pathology (α-galactosidase A deficiency)."
"['Short attention span', 'Thrombocytopenia', 'Schistocytosis', 'Postural instability', 'Vertigo', 'Elevated hepatic transaminase', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Exercise intolerance', 'Loss of consciousness', 'Reduced von Willebrand factor activity', 'Decreased glomerular filtration rate', 'Reduced haptoglobin level', 'Increased circulating lactate dehydrogenase concentration', 'Increased circulating procalcitonin concentration', 'Trigeminal neuralgia']","['Thrombotic thrombocytopenic purpura, hereditary', 'Thrombotic thrombocytopenic purpura']","Disease: Thrombotic thrombocytopenic purpura, hereditary  
Reasoning:  
1. **Thrombocytopenia** and **schistocytosis** are hallmark features of TTP, caused by microvascular thrombosis and mechanical red blood cell destruction.  
2. **Reduced haptoglobin** and **elevated LDH** confirm hemolysis, consistent with TTP.  
3. **Neurological symptoms** (postural instability, vertigo, loss of consciousness, trigeminal neuralgia) align with microthrombi-induced ischemia in the CNS.  
4. **Renal dysfunction** (elevated urea, creatinine, reduced GFR) reflects kidney microvascular injury.  
5. Hereditary TTP (Upshaw-Schulman syndrome) is suggested by **reduced von Willebrand factor (vWF) activity**, as congenital ADAMTS13 deficiency prevents cleavage of ultra-large vWF multimers, leading to platelet aggregation. However, this finding requires confirmation via ADAMTS13 activity testing (<10% without inhibitors).  

Disease: Thrombotic thrombocytopenic purpura  
Reasoning:  
1. The classic pentad of TTP (thrombocytopenia, hemolytic anemia, neurological symptoms, renal dysfunction, fever) is partially fulfilled, with fever implied by **elevated procalcitonin** (a nonspecific marker of inflammation/infection).  
2. **Schistocytosis**, **thrombocytopenia**, and hemolysis (LDH↑, haptoglobin↓) are diagnostic cornerstones.  
3. **Neurological and renal involvement** strongly support TTP over other thrombotic microangiopathies.  
4. Acquired TTP is more likely in adults, often triggered by autoantibodies against ADAMTS13. Elevated hepatic transaminases and procalcitonin may indicate an underlying infection or inflammatory trigger.  
5. Definitive diagnosis requires demonstrating severe ADAMTS13 deficiency (<10%) with detectable inhibitors.  

**Note**: Differentiation between hereditary and acquired TTP hinges on ADAMTS13 testing and inhibitor assays, which are not provided in the symptom list. Clinical context (age, recurrence, family history) would further refine the diagnosis."
"['Secondary amenorrhea', 'Ventricular septal defect', 'Aortic regurgitation', 'Splenomegaly', 'Weight loss', 'Thrombocytosis', 'Microcytic anemia', 'Fever', 'Tubulointerstitial nephritis', 'Dyspnea', 'Arthralgia', 'Increased blood urea nitrogen', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Abnormal facility in opposing the shoulders', 'Right bundle branch block', 'Anterior uveitis', 'Decreased glomerular filtration rate', 'Upper limb pain', 'Mild proteinuria', 'Cough', 'Flank pain', 'Neck pain', 'Systolic heart murmur', 'Pollakisuria', 'Endocarditis']",['Tubulointerstitial nephritis and uveitis'],"Disease: Tubulointerstitial nephritis and uveitis (TINU syndrome)  
Reasoning:  
1. **Tubulointerstitial nephritis** and **anterior uveitis** are hallmark features of TINU syndrome, a rare autoimmune disorder.  
2. **Elevated ESR**, **fever**, **weight loss**, **arthralgia**, and **microcytic anemia** align with systemic inflammation, common in TINU.  
3. **Decreased GFR**, **increased blood urea nitrogen**, **mild proteinuria**, and **pollakisuria** reflect kidney dysfunction from tubulointerstitial injury.  
4. **Anterior uveitis** directly supports the ocular component of TINU.  
5. Secondary symptoms like **dyspnea**, **exercise intolerance**, and **splenomegaly** may stem from chronic inflammation or anemia.  
6. Cardiac findings (e.g., **ventricular septal defect**, **aortic regurgitation**, **endocarditis**) are likely unrelated congenital or acquired complications, as TINU primarily targets renal and ocular systems.  
7. **Thrombocytosis** and **flank/neck pain** could result from inflammatory or autoimmune processes.  

Disease: Infective endocarditis (complicating congenital heart defects)  
Reasoning:  
1. **Ventricular septal defect** (VSD) predisposes to **endocarditis**, explaining **systolic heart murmur**, **fever**, **weight loss**, and **splenomegaly**.  
2. **Aortic regurgitation** may arise from valve damage due to endocarditis or congenital anomalies.  
3. **Right bundle branch block** and **cough** could reflect cardiac strain or embolic events.  

*Note:* TINU syndrome is the primary diagnosis based on nephritis and uveitis. Cardiac abnormalities and endocarditis are likely separate, though VSD increases endocarditis risk."
"['Myopia', 'Diplopia', 'Dry skin', 'Abnormality of the hand', 'Hyporeflexia', 'Abnormal foot morphology', 'Neutropenia', 'Steatorrhea', 'Upper airway obstruction', 'Arthralgia', 'Hyperventilation', 'Elevated circulating creatine kinase concentration', 'Airway obstruction', 'Lower limb amyotrophy', 'Upper limb pain', 'Dysesthesia', 'Foot pain', 'Abnormal vitamin B12 level', 'Lymphocytosis', 'Dyspepsia']","['Primary erythromelalgia/Erythermalgia, primary']","Disease: Primary erythromelalgia/Erythermalgia, primary  
Reasoning:  
1. **Foot pain** and **upper limb pain** align with the hallmark of erythromelalgia: episodic burning pain in extremities.  
2. **Dysesthesia** (abnormal burning/pricking sensations) supports neuropathic pain, a key feature of the disease.  
3. **Abnormal foot morphology** may reflect chronic vascular or tissue changes from recurrent inflammation.  
4. **Elevated creatine kinase (CK)** could indicate secondary muscle stress due to prolonged pain episodes.  
5. **Hyporeflexia** and **lower limb amyotrophy** suggest peripheral neuropathy, which may coexist with erythromelalgia.  

**Exclusions/Considerations:**  
- Symptoms like **neutropenia**, **lymphocytosis**, **steatorrhea**, and **abnormal B12** suggest unrelated systemic or metabolic conditions (e.g., autoimmune disorders, malabsorption).  
- **Airway obstruction**, **arthralgia**, and **myopia/diplopia** lack direct mechanistic links to erythromelalgia and may indicate comorbidities.  
- The absence of explicit ""erythema"" or ""warmth"" in symptoms could reflect documentation gaps or atypical presentation, but pain and dysesthesia remain diagnostically critical.  

**Conclusion:** Core features (extremity pain, dysesthesia) dominate, supporting primary erythromelalgia, while additional symptoms warrant investigation for overlapping or secondary conditions."
"['Proteinuria', 'Abnormal vagina morphology', 'Abnormality of the dentition', 'Sinusitis', 'Abnormal nasal mucosa morphology', 'Agitation', 'Hypertension', 'Facial erythema', 'Gait disturbance', 'Abnormal hip joint morphology', 'Alopecia', 'Abnormality of the larynx', 'Ankle swelling', 'Fever', 'Polydipsia', 'Palpitations', 'Constipation', 'Gastroesophageal reflux', 'Abdominal pain', 'Headache', 'Vertigo', 'Arthralgia', 'Exertional dyspnea', 'Rheumatoid factor positive', 'Low back pain', 'Somatic sensory dysfunction', 'Antinuclear antibody positivity', 'Generalized morning stiffness', 'Swelling of proximal interphalangeal joints', 'Abnormality of hand joint mobility', 'Focal white matter lesions', 'Pedal edema', 'Abnormal metacarpophalangeal joint morphology', 'Pyuria', 'Decreased glomerular filtration rate', 'Erythema nodosum', 'Fatigue', 'Temporomandibular joint crepitus', 'Lower limb pain', 'Dysesthesia', 'Flank pain', 'Night sweats', 'Increased circulating insulin-like growth factor 1 concentration', 'Finger pain', 'Hip pain', 'Pruritis on hand', 'Flushing', 'Chest tightness', 'Groin pain', 'Jaw pain', 'Pollakisuria', 'Palpebral edema', 'Chest pain', 'Epigastric pain']","['Polymyositis', 'Localized scleroderma', 'Scleroderma, familial progressive', 'Scleroderma', 'Systemic sclerosi; SSc/Systemic sclerosis', 'Diffuse cutaneous systemic sclerosis', 'Limited cutaneous systemic sclerosis', 'CREST syndrome']","Disease: Systemic sclerosis (SSc)  
Reasoning: The patient presents with key features of systemic sclerosis including Raynaud's-like symptoms (flushing, finger pain), gastrointestinal involvement (GERD, constipation, abdominal pain), renal abnormalities (proteinuria, decreased GFR, hypertension suggestive of scleroderma renal crisis), and musculoskeletal issues (arthralgia, joint swelling, morning stiffness). Antinuclear antibody positivity and rheumatoid factor support autoimmune etiology. Skin and mucosal changes (facial erythema, pruritus, abnormal nasal/vaginal mucosa) align with sclerotic processes. Pulmonary symptoms (exertional dyspnea) may indicate interstitial lung disease or pulmonary hypertension.  

Disease: Diffuse cutaneous systemic sclerosis  
Reasoning: Renal crisis (hypertension, proteinuria, flank pain) and widespread organ involvement (GI, musculoskeletal, pulmonary) are hallmarks of diffuse cutaneous SSc. Skin abnormalities (hand pruritus, facial erythema) and somatic sensory dysfunction suggest extensive fibrosis.  

Disease: CREST syndrome (Limited cutaneous systemic sclerosis subset)  
Reasoning: GERD (esophageal dysmotility), telangiectasia (flushing, facial erythema), and potential sclerodactyly (abnormal hand joints) fit CREST criteria. Calcinosis is not explicitly listed but may correlate with joint pain. Antinuclear antibodies (often anticentromere in CREST) further support this subtype.  

Disease: Scleroderma (general)  
Reasoning: Broad scleroderma features include skin/mucosal abnormalities, fibrosis-related organ damage (renal, pulmonary), and autoimmune markers (ANA positivity). The absence of polymyositis-specific muscle weakness argues against overlap syndromes.  

Excluded: Polymyositis  
Reasoning: Lack of predominant proximal muscle weakness, elevated creatine kinase, or myositis-specific antibodies makes polymyositis less likely despite fatigue and exertional dyspnea. Symptoms align more with systemic sclerosis complications (e.g., ILD).  

Excluded: Localized scleroderma  
Reasoning: Localized forms (e.g., morphea) lack systemic involvement (renal, pulmonary, GI), which is prominent here.  

Key Clues: Multi-organ fibrosis (renal, GI, skin), autoantibodies, and CREST-like features differentiate systemic sclerosis subtypes. Renal crisis and diffuse symptoms prioritize diffuse cutaneous SSc, while esophageal and vascular symptoms support CREST."
"['Xerostomia', 'Visual impairment', 'Weight loss', 'Fever', 'Microscopic hematuria', 'Elevated hepatic transaminase', 'Back pain', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Poor appetite', 'Erythema', 'Elevated circulating C-reactive protein concentration', 'Enlargement of parotid gland', 'Anterior uveitis', 'Thin glomerular basement membrane', 'Mild proteinuria', 'Cervical lymphadenopathy', 'Night sweats', 'Ocular pain']","['Sarcoidosis/Sarcoidosis, susceptibility to, 1', 'Sarcoidosis, susceptibility to, 2']","Sarcoidosis/Sarcoidosis, susceptibility to, 1:  
The patient presents with multisystem involvement characteristic of sarcoidosis. Anterior uveitis and visual impairment align with ocular sarcoidosis, while parotid gland enlargement and xerostomia suggest salivary gland infiltration. Systemic inflammation (fever, night sweats, elevated ESR/CRP) and lymphadenopathy reflect active granulomatous disease. Elevated hepatic transaminases indicate liver involvement, and renal findings (microscopic hematuria, mild proteinuria) may correlate with interstitial nephritis or hypercalcemia-induced nephropathy. Back pain could stem from musculoskeletal or granulomatous spinal lesions. Erythema may represent cutaneous sarcoidosis or erythema nodosum, a marker of acute disease. Exercise intolerance may arise from pulmonary or cardiac involvement (e.g., restrictive lung disease, arrhythmias). Genetic susceptibility (e.g., HLA-DRB1 variants in susceptibility type 1) could predispose to this dysregulated immune response.  

Sarcoidosis, susceptibility to, 2:  
The phenotypic overlap with susceptibility type 1 is significant, but susceptibility type 2 is linked to distinct genetic loci (e.g., ANXA11 mutations). The combination of anterior uveitis, parotid enlargement, and lymphadenopathy meets criteria for Heerfordt syndrome, a sarcoidosis subtype. Thin glomerular basement membrane and proteinuria may indicate concurrent IgA nephropathy or direct granulomatous renal injury, both reported in sarcoidosis. Persistent weight loss and poor appetite suggest chronic inflammatory burden. Ocular pain reinforces uveitis severity, while cervical lymphadenopathy and hepatic transaminase elevation underscore systemic granuloma formation. This presentation aligns with polygenic susceptibility (type 2), where environmental triggers exacerbate genetic risk."
"['Oral ulcer', 'Headache', 'Memory impairment', 'Osteomyelitis', 'Osteoarthritis', 'Kyphosis', 'Obstructive sleep apnea', 'Abnormality of the ankle', 'Back pain', 'Intervertebral disc degeneration', 'Ankle pain', 'Aphthous ulcer', 'Pustule']",['SAPHO syndrome'],"Disease: SAPHO syndrome  
Reasoning:  
1. **Osteomyelitis and Osteoarthritis**: Core features of SAPHO syndrome, which involves osteitis and hyperostosis, explaining bone inflammation and joint degeneration.  
2. **Pustule and Aphthous/Oral Ulcers**: Align with cutaneous manifestations (pustulosis) and occasional mucosal involvement seen in SAPHO.  
3. **Spinal Abnormalities (Kyphosis, Back Pain, Disc Degeneration)**: Reflects axial skeleton hyperostosis, a hallmark of SAPHO, leading to structural changes and pain.  
4. **Ankle Pain/Abnormality**: Synovitis and joint inflammation in SAPHO can target peripheral joints like the ankle.  
5. **Obstructive Sleep Apnea**: Potential secondary effect from spinal kyphosis altering airway mechanics.  
6. **Headache/Memory Impairment**: Likely indirect (e.g., chronic pain, sleep disruption) rather than direct neurological involvement.  
7. **Exclusion of Alternatives**: Behçet’s disease lacks bone involvement; CRMO lacks pustular lesions. The triad of bone, joint, and skin symptoms strongly supports SAPHO."
"['Tall stature', 'Renal cyst', 'Ovarian cyst', 'Glaucoma', 'Myopia', 'Abnormal finger morphology', 'Pes cavus', 'Weight loss', 'Hypotension', 'Varicose veins', 'Abnormal cartilage morphology', 'Arthralgia', 'Genu valgum', 'Exertional dyspnea', 'Microscopic hematuria', 'Gastrointestinal inflammation', 'Knee osteoarthritis', 'Abnormal intervertebral disk morphology', 'Gastritis', 'Reduced visual acuity', 'Pedal edema', 'Elbow pain', 'Hip pain', 'Knee pain', 'Groin pain', 'Torn meniscus']","['Stickler syndrome, type V', 'Stickler syndrome type 2/Stickler syndrome, type II', 'Stickler syndrome, type IV', 'Autosomal dominant otospondylomegaepiphyseal dysplasia/Stickler syndrome, type III', 'Autosomal recessive Stickler syndrome', 'Stickler syndrome type 1/Stickler syndrome, type I', 'Stickler syndrome']","Disease: Stickler syndrome type 1/Stickler syndrome, type I  
Reasoning: The patient exhibits hallmark features of Stickler syndrome, including ocular manifestations (myopia, glaucoma, reduced visual acuity), skeletal/joint abnormalities (arthralgia, osteoarthritis, genu valgum, pes cavus, torn meniscus), and connective tissue involvement (abnormal cartilage morphology, abnormal intervertebral disk morphology). Tall stature and abnormal finger morphology align with skeletal dysplasia. While renal/ovarian cysts and gastrointestinal symptoms are atypical for Stickler syndrome, they may represent comorbid conditions or variable expressivity. Type I (COL2A1) is prioritized due to its strong association with vitreoretinal abnormalities and early-onset arthropathy, despite the absence of explicitly noted hearing loss or craniofacial anomalies.  

Disease: Stickler syndrome, type IV  
Reasoning: Autosomal recessive Stickler syndrome (type IV, COL9A1) is considered due to the patient’s severe joint involvement (arthralgia, hip/knee pain, osteoarthritis) and ocular features (myopia, glaucoma). COL9A1 mutations can present with systemic connective tissue defects, potentially explaining renal cysts (rarely reported in recessive forms). However, gastrointestinal inflammation and hypotension remain poorly explained, making this a less likely but plausible secondary consideration.  

Disease: Autosomal dominant otospondylomegaepiphyseal dysplasia/Stickler syndrome, type III  
Reasoning: Type III (COL11A2) is noted for spondyloepiphyseal dysplasia, arthralgia, and hearing loss, but typically lacks ocular involvement. The patient’s glaucoma and myopia argue against this subtype, though skeletal features (tall stature, genu valgum) and joint pain may overlap. Absence of reported hearing loss further reduces likelihood.  

Disease: Stickler syndrome, type II  
Reasoning: Type II (COL11A1) shares ocular and joint features with type I, but often includes distinct vitreous abnormalities and craniofacial dysmorphism (e.g., cleft palate). The absence of reported craniofacial anomalies or hearing loss makes this less likely, though not excluded.  

Disease: Autosomal recessive Stickler syndrome  
Reasoning: Broadly, recessive forms (e.g., types IV/V) may present with severe phenotypes. Microscopic hematuria and renal cysts could hint at collagen-related renal defects, but these are not well-documented in Stickler syndromes. This category remains a tentative option if genetic testing excludes dominant types.  

Disease: Stickler syndrome, type V  
Reasoning: Type V (COL9A2) overlaps with type IV but is exceedingly rare. Similar reasoning applies, with renal cysts and gastrointestinal inflammation remaining unexplained. Limited evidence for COL9A2 in Stickler phenotypes reduces confidence.  

**Final Diagnosis**: **Stickler syndrome type 1/Stickler syndrome, type I** is the most likely, given the concordance of ocular, joint, and skeletal features. Uncommon symptoms (e.g., cysts) may require additional evaluation for comorbidities or atypical presentations."
"['Renal insufficiency', 'Nephrotic syndrome', 'Pericardial effusion', 'Pericarditis', 'Anemia', 'Elevated circulating creatinine concentration', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Complement deficiency', 'Fatigue', 'Moderate proteinuria', 'Heavy proteinuria']","['Systemic lupus erythematosus 16', 'Vitiligo-Associated multiple autoimmune disease susceptibility 1', 'Systemic lupus erythematosus, susceptibility to, 6', 'Pediatric systemic lupus erythematosus', 'Systemic lupus erythematosus']","Disease: Systemic lupus erythematosus  
Reasoning: The patient presents with multi-system involvement, including renal insufficiency, nephrotic syndrome, pericarditis/pericardial effusion, and hematologic abnormalities (anemia). Antinuclear antibody (ANA) positivity and complement deficiency are hallmark immunologic features of SLE. Proteinuria (moderate to heavy) and elevated creatinine indicate lupus nephritis, a common complication. Fatigue and exercise intolerance align with systemic inflammation.  

Disease: Systemic lupus erythematosus, susceptibility to, 6  
Reasoning: Genetic susceptibility loci, such as those near *TNFSF4* or *STAT4*, may contribute to the patient’s presentation. While clinical symptoms define SLE, this subtype reflects a specific genetic predisposition linked to dysregulated immune pathways.  

Disease: Pediatric systemic lupus erythematosus  
Reasoning: If the patient is under 18, pediatric SLE is applicable. Children often present with severe renal involvement (nephrotic syndrome, heavy proteinuria) and constitutional symptoms like fatigue, consistent with this case.  

Disease: Systemic lupus erythematosus 16  
Reasoning: This subtype references a specific genetic association (e.g., *IRF5* or *HLA* polymorphisms). The clinical phenotype matches SLE criteria, and genetic markers may explain disease severity or organ tropism (e.g., renal/pericardial manifestations).  

Disease: Vitiligo-Associated multiple autoimmune disease susceptibility 1  
Reasoning: Less likely, as vitiligo or other autoimmune disorders (e.g., thyroid disease) are not reported. However, *NALP1* gene variants linked to this subtype could theoretically predispose to SLE-like autoimmunity, though primary evidence points to SLE itself."
"['Abnormal vagina morphology', 'Oral ulcer', 'Xerostomia', 'Keratoconjunctivitis sicca', 'Abnormal finger morphology', 'Diarrhea', 'Abdominal pain', 'Hepatomegaly', 'Headache', 'Abnormality of the lower limb', 'Arthralgia', 'Neoplasm of the liver', 'Hypercholesterolemia', 'Low alkaline phosphatase', 'Somatic sensory dysfunction', 'Exercise intolerance', 'Cachexia', 'Gastritis', 'Focal white matter lesions', 'Uterine neoplasm', 'Abnormal circulating protein concentration', 'Lower limb pain', 'Dysesthesia', 'Autoimmune antibody positivity', 'Oral cavity bleeding', 'Night sweats', 'obsolete Abnormal fecal test result', 'Esophagitis', 'Abnormality of nail color']",['Primary Sjögren syndrome/Sjogren syndrome'],"Disease: Primary Sjögren syndrome/Sjogren syndrome  
Reasoning:  
1. **Key diagnostic criteria**: Keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth) are hallmark features of Sjögren syndrome, reflecting exocrine gland dysfunction.  
2. **Autoimmune evidence**: Autoimmune antibody positivity (e.g., anti-SSA/Ro or anti-SSB/La) supports an autoimmune etiology, a core component of Sjögren syndrome.  
3. **Systemic involvement**:  
   - **Mucocutaneous**: Oral ulcers and oral cavity bleeding may arise from mucosal dryness and inflammation.  
   - **Gastrointestinal**: Gastritis, esophagitis, and abdominal pain align with dysmotility or autoimmune-mediated mucosal injury.  
   - **Neurological**: Somatic sensory dysfunction, dysesthesia, and focal white matter lesions suggest peripheral/CNS involvement, recognized in Sjögren-related neuropathy or vasculitis.  
   - **Musculoskeletal**: Arthralgia and lower limb pain reflect common inflammatory joint manifestations.  
4. **Lymphoproliferative risk**: Neoplasm of the liver (possibly lymphoma) and uterine neoplasm, alongside night sweats and cachexia, raise suspicion for Sjögren-associated B-cell lymphoma, a known severe complication.  
5. **Laboratory anomalies**: Abnormal circulating protein concentration (e.g., hypergammaglobulinemia) and low alkaline phosphatase (potential cholestatic liver involvement) fit with chronic autoimmune activity.  
6. **Exclusion of overlap syndromes**: While symptoms like abnormal nail color or hepatomegaly could suggest other conditions (e.g., scleroderma or autoimmune hepatitis), the constellation of sicca symptoms, autoantibodies, and systemic features prioritizes Primary Sjögren syndrome as the unifying diagnosis.  

Note: Further evaluation (e.g., salivary gland biopsy, lymphoma workup) is critical to confirm and assess disease severity."
"['Hypothyroidism', 'Splenomegaly', 'Lymphopenia', 'Microcytic anemia', 'Fever', 'Nausea', 'Dyspnea', 'Pleuritis', 'Pleural effusion', 'Hypocalcemia', 'Poor appetite', 'Abnormal blood sodium concentration', 'Elevated circulating C-reactive protein concentration', 'Sinus tachycardia', 'Fatigue', 'Chills', 'Increased circulating lactate dehydrogenase concentration', 'Cervicitis', 'Chest pain']","['Familial mediterranean fever; FMF/Familial Mediterranean fever/Familial Mediterranean fever, AR', 'Familial Mediterranean fever, AD']","Disease: Familial Mediterranean fever, AR  
Reasoning:  
1. **Recurrent fever, chills, and systemic inflammation**: Elevated CRP and lactate dehydrogenase (LDH) align with FMF’s hallmark episodic inflammatory attacks.  
2. **Serositis manifestations**: Pleuritis, pleural effusion, and chest pain reflect pleural inflammation, a classic FMF feature. Dyspnea may arise from pleural effusion.  
3. **Splenomegaly and lymphopenia**: Common during acute FMF flares due to immune activation and cytokine release.  
4. **Microcytic anemia**: Likely secondary to chronic inflammation (anemia of chronic disease) rather than iron deficiency.  
5. **Hypocalcemia and abnormal sodium**: Electrolyte imbalances may occur due to transient renal dysfunction or inflammatory stress.  
6. **Absence of infectious etiology**: Fever, nausea, and fatigue are nonspecific but recurrent without clear infection (e.g., cervicitis could be coincidental).  
7. **Autosomal recessive (AR) inheritance**: FMF is predominantly AR (MEFV gene mutations); the AD form is exceedingly rare and less consistent with this presentation.  

Disease: Familial Mediterranean fever, AD  
Reasoning:  
1. **Overlap in inflammatory symptoms**: Fever, CRP elevation, and pleuritis are shared with AR-FMF.  
2. **Atypical features**: Cervicitis and hypothyroidism are not typical for FMF but might suggest comorbid autoimmune processes, which are less commonly associated with AD-FMF.  
3. **Limited evidence**: AD-FMF is poorly characterized compared to AR-FMF; this diagnosis is less likely unless family history strongly supports autosomal dominant transmission.  

**Final Diagnosis**: Familial Mediterranean fever, AR is the most probable diagnosis given the recurrent serositis, inflammatory markers, and population prevalence of AR inheritance. AD-FMF remains a differential but requires genetic confirmation."
"['Hearing impairment', 'Gait disturbance', 'Hepatic steatosis', 'Hepatic cysts', 'Pericardial effusion', 'Splenomegaly', 'Abnormal lung morphology', 'Hepatomegaly', 'Paraparesis', 'Somatic sensory dysfunction', 'Rhinitis', 'Lower limb pain', 'Splenic cyst', 'Cytoplasmic antineutrophil antibody positivity', 'Insomnia']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Cytoplasmic antineutrophil antibody (c-ANCA) positivity**: Highly specific for GPA, supporting an autoimmune vasculitis diagnosis.  
2. **Rhinitis and hearing impairment**: Reflect upper respiratory tract involvement, common in early GPA due to granulomatous inflammation.  
3. **Abnormal lung morphology**: GPA often causes pulmonary nodules, cavities, or infiltrates.  
4. **Paraparesis and somatic sensory dysfunction**: Indicates neurologic involvement, possibly from vasculitic neuropathy or CNS inflammation.  
5. **Pericardial effusion**: Suggests systemic vasculitis affecting serous membranes.  
6. **Hepatomegaly, hepatic steatosis, and splenomegaly**: Less common but documented in systemic GPA due to granulomatous infiltration or secondary inflammation.  
7. **Splenic/hepatic cysts**: Rare manifestations, potentially linked to chronic inflammation or ischemic injury.  
8. **Lower limb pain and gait disturbance**: May result from neuropathy, myositis, or joint involvement.  
9. **Insomnia**: Likely secondary to chronic pain or systemic illness.  

While hepatic/splenic cysts are atypical, the combination of c-ANCA positivity, multi-organ involvement (respiratory, renal, neurologic), and classic vasculitic features strongly aligns with GPA. Differential diagnoses (e.g., eosinophilic granulomatosis with polyangiitis) are less likely given the absence of eosinophilia or asthma."
"['Renal cyst', 'Nephrocalcinosis', 'Gait disturbance', 'Arthritis', 'Splenomegaly', 'Neutropenia', 'Leukopenia', 'Granulocytopenia', 'Microcytic anemia', 'Hypophosphatemia', 'Hepatomegaly', 'Headache', 'Vertigo', 'Lymphadenopathy', 'Abnormality of the lower limb', 'Exertional dyspnea', 'Back pain', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Thrombophlebitis', 'Abnormal intervertebral disk morphology', 'Miscarriage', 'Abnormality of hand joint mobility', 'Abnormal phalangeal joint morphology of the hand', 'Lower limb amyotrophy', 'Abnormality of the submandibular glands', 'Upper limb pain', 'Lower limb pain', 'Dysesthesia', 'Foot pain', 'Neck pain', 'Wrist pain', 'Finger pain', 'Hip pain', 'Knee pain', 'Ankle pain']",['Felty syndrome/Felty syndrome'],"Disease: Felty syndrome  
Reasoning: Felty syndrome is classically defined by the triad of **rheumatoid arthritis (RA)**, **splenomegaly**, and **neutropenia**.  
1. **Arthritis** and joint abnormalities (hand/wrist pain, reduced mobility, abnormal morphology) align with RA.  
2. **Splenomegaly** and **hepatomegaly** suggest systemic involvement, common in Felty syndrome.  
3. **Neutropenia**, **leukopenia**, and **granulocytopenia** explain recurrent infections and are hallmarks of Felty-related immune dysregulation.  
4. **Microcytic anemia** and **elevated ESR** reflect chronic inflammation from RA.  
5. **Exercise intolerance**, **gait disturbance**, and musculoskeletal pain likely stem from chronic joint damage and systemic inflammation.  
**Exclusions/Considerations**: Renal cysts, nephrocalcinosis, and hypophosphatemia are atypical for Felty syndrome and may suggest a coexisting metabolic or renal disorder (e.g., hyperparathyroidism or tubular defects). However, the core triad strongly supports Felty syndrome as the primary diagnosis."
"['Hearing impairment', 'Hypertension', 'Hemoptysis', 'Headache', 'Arthralgia', 'Rhinitis', 'Wrist pain', 'Knee pain', 'Ankle pain']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Hemoptysis and Rhinitis**: GPA classically involves upper and lower respiratory tracts. Hemoptysis suggests pulmonary capillaritis or alveolar hemorrhage, while rhinitis indicates granulomatous inflammation in the nasal mucosa.  
2. **Hearing Impairment**: Secondary to Eustachian tube dysfunction, middle ear involvement, or sensorineural hearing loss from vasculitic damage to cranial nerves or cochlear blood supply.  
3. **Hypertension**: May reflect renal involvement (e.g., glomerulonephritis), a critical feature of GPA that can lead to secondary hypertension.  
4. **Arthralgia (Wrist/Knee/Ankle Pain)**: Non-erosive inflammatory arthritis is common in systemic vasculitis, driven by immune complex deposition.  
5. **Headache**: Could arise from sinusitis (due to nasal granulomas), hypertension, or rare central nervous system vasculitis.  
6. **Multi-Organ Pattern**: GPA’s triad of respiratory tract, kidney, and musculoskeletal involvement aligns with the patient’s symptoms. Biopsy (e.g., nasal/pulmonary lesions) and positive ANCA (PR3-ANCA) would confirm diagnosis."
"['Renal insufficiency', 'Abnormality of the nose', 'Abnormal pinna morphology', 'Visual loss', 'Osteopenia', 'Facial erythema', 'Abnormal finger morphology', 'Wrist swelling', 'Abnormal toe morphology', 'Eosinophilia', 'Microcytic anemia', 'Exercise intolerance', 'Upper limb amyotrophy', 'Pedal edema', 'Abnormal metacarpophalangeal joint morphology', 'Foot pain', 'Shoulder pain', 'Episcleritis', 'Gangrene']",['Relapsing polychondritis'],"Disease: Relapsing polychondritis  
Reasoning:  
1. **Cartilage involvement**:  
   - **Abnormality of the nose** (saddle nose deformity from nasal cartilage collapse) and **abnormal pinna morphology** (ear cartilage inflammation) are hallmark features of relapsing polychondritis (RP).  
   - **Wrist swelling**, **abnormal metacarpophalangeal joint morphology**, and **abnormal finger/toe morphology** suggest inflammatory arthritis secondary to cartilage damage.  

2. **Ocular manifestations**:  
   - **Episcleritis** and **visual loss** align with RP-associated ocular inflammation.  

3. **Systemic inflammation**:  
   - **Facial erythema** and **eosinophilia** reflect systemic autoimmune activity.  
   - **Renal insufficiency** may stem from vasculitis or secondary amyloidosis, both linked to advanced RP.  

4. **Musculoskeletal complications**:  
   - **Osteopenia** and **upper limb amyotrophy** correlate with chronic inflammation and immobility due to joint pain (**shoulder pain**, **foot pain**).  

5. **Vascular involvement**:  
   - **Gangrene** and **pedal edema** suggest vasculitis-induced ischemia, a rare but severe RP complication.  

6. **Hematologic abnormalities**:  
   - **Microcytic anemia** and **exercise intolerance** are consistent with chronic disease and renal dysfunction.  

The constellation of cartilage destruction, multisystem inflammation, and vasculitic features strongly supports RP."
"['Abnormal sternum morphology', 'Leukocytosis', 'Dyspnea', 'Osteomyelitis', 'Osteoarthritis', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Chest pain', 'Hyperostosis']",['SAPHO syndrome'],"Disease: SAPHO syndrome  
Reasoning: The patient presents with a combination of osteoarticular and inflammatory symptoms.  
1. **Hyperostosis** and **abnormal sternum morphology** are hallmark features of SAPHO, often involving the anterior chest wall.  
2. **Osteomyelitis** (non-infectious osteitis) and **osteoarthritis** align with the synovitis-hyperostosis-osteitis triad in SAPHO.  
3. **Elevated ESR/CRP** and **leukocytosis** reflect systemic inflammation, consistent with SAPHO’s inflammatory pathophysiology.  
4. **Chest pain** and **dyspnea** correlate with sternocostoclavicular joint involvement, a common site in SAPHO.  
5. Exclusion of infectious osteomyelitis is supported by the lack of cited fever or microbiological evidence, favoring sterile inflammation.  
6. The constellation of musculoskeletal and inflammatory markers, without dermatologic symptoms (e.g., palmoplantar pustulosis), still fits SAPHO’s variable presentation."
"['Abnormality of taste sensation', 'Membranoproliferative glomerulonephritis', 'Petechiae', 'Headache', 'Fatigue']",['Immunoglobulin A vasculitis'],"Disease: Immunoglobulin A vasculitis  
Reasoning:  
1. **Petechiae**: A hallmark of IgA vasculitis (Henoch-Schönlein purpura), caused by small-vessel inflammation and IgA-mediated immune complex deposition in the skin.  
2. **Membranoproliferative glomerulonephritis (MPGN)**: While IgA nephropathy is more typical, MPGN can occur in severe IgA vasculitis due to chronic immune complex deposition in renal glomeruli, leading to histopathological overlap.  
3. **Fatigue and Headache**: Non-specific systemic symptoms linked to inflammation, cytokine release, and potential renal dysfunction.  
4. **Abnormality of taste sensation**: Likely secondary to uremia from renal impairment (due to glomerulonephritis), causing dysgeusia (metallic taste), rather than a direct feature of vasculitis.  
5. **Consistent diagnostic framework**: The triad of cutaneous vasculitis (petechiae), renal involvement, and systemic symptoms aligns with IgA vasculitis, despite atypical MPGN histology. Differential diagnoses (e.g., cryoglobulinemia, lupus nephritis) were excluded based on IgA dominance and clinical context."
"['Xerostomia', 'Irregular menstruation', 'Keratoconjunctivitis sicca', 'Leukopenia', 'Diarrhea', 'Reduced haptoglobin level', 'Autoimmune antibody positivity']","['Systemic lupus erythematosus 16', 'Vitiligo-Associated multiple autoimmune disease susceptibility 1', 'Systemic lupus erythematosus, susceptibility to, 6', 'Pediatric systemic lupus erythematosus', 'Systemic lupus erythematosus', 'Primary Sjögren syndrome/Sjogren syndrome']","Disease: Primary Sjögren syndrome/Sjogren syndrome  
Reasoning: Xerostomia and keratoconjunctivitis sicca are hallmark symptoms of Sjögren syndrome, directly reflecting exocrine gland dysfunction. Autoimmune antibody positivity (e.g., anti-SSA/Ro or anti-SSB/La) supports this diagnosis. While leukopenia and reduced haptoglobin suggest systemic involvement, these can occur in Sjögren syndrome due to secondary autoimmune processes or overlap with other conditions.  

Disease: Systemic lupus erythematosus  
Reasoning: Leukopenia, autoimmune antibody positivity (e.g., ANA, anti-dsDNA), and reduced haptoglobin (indicating potential hemolytic anemia) align with SLE diagnostic criteria (SLICC or ACR). Irregular menstruation may reflect SLE-related hormonal or inflammatory effects. Diarrhea could stem from autoimmune enteritis or vasculitis, though further evaluation is needed. While sicca symptoms suggest Sjögren overlap, SLE is prioritized due to broader systemic features.  

Disease: Systemic lupus erythematosus, susceptibility to, 6  
Reasoning: If genetic testing reveals variants in *ITGAM* or other loci linked to SLE susceptibility 6, this could explain predisposition. However, clinical diagnosis of SLE is already supported by symptoms, making this a secondary genetic risk annotation rather than a primary diagnosis.  

Disease: Vitiligo-Associated multiple autoimmune disease susceptibility 1  
Reasoning: This applies if vitiligo is present (unstated here) and polyautoimmunity is confirmed. Current symptoms lack vitiligo-specific features, making this less likely unless additional findings are reported.  

Disease: Pediatric systemic lupus erythematosus  
Reasoning: Pediatric SLE is considered if the patient is under 18, but age is unspecified. Symptoms overlap with adult SLE, so this diagnosis is conditional on demographic context.  

Disease: Systemic lupus erythematosus 16  
Reasoning: This refers to a specific genetic susceptibility locus (e.g., *TNFAIP3*). Like susceptibility 6, it requires genetic confirmation and does not replace the clinical diagnosis of SLE.  

**Final Prioritization**: Primary Sjögren syndrome and Systemic lupus erythematosus are the most clinically relevant diagnoses based on symptoms and criteria. Overlap syndrome (SLE-Sjögren) should be considered if both sets of criteria are fully met. Genetic susceptibilities (e.g., SLE 6/16) are secondary findings."
"['Sinusitis', 'Eosinophilia', 'Dyspnea', 'Pulmonary infiltrates', 'Colitis', 'Elevated hepatic transaminase', 'Increased circulating IgE level', 'Elevated circulating creatine kinase concentration', 'Chronic oral candidiasis', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia', 'Decreased glomerular filtration rate', 'Bronchitis', 'Decreased mean corpuscular volume', 'Nodular pattern on pulmonary HRCT', 'Autoimmune antibody positivity', 'Reduced FEV1/FVC ratio', 'Increased circulating IgG4 level', 'Low levels of vitamin D', 'Nasal polyposis']",['Eosinophilic granulomatosis with polyangiitis'],"Disease: Eosinophilic granulomatosis with polyangiitis (EGPA)  
Reasoning:  
1. **Eosinophilia and Sinusitis/Nasal Polyposis**: EGPA is characterized by eosinophilic inflammation and upper respiratory involvement, explaining chronic sinusitis and nasal polyps.  
2. **Asthma Spectrum (Dyspnea, Bronchitis, Reduced FEV1/FVC)**: The reduced FEV1/FVC ratio and recurrent bronchitis align with the asthma-like airway obstruction typical in early EGPA.  
3. **Pulmonary Infiltrates and Nodular HRCT Pattern**: Pulmonary infiltrates and nodular lesions on imaging reflect eosinophilic lung involvement and vasculitic granulomas.  
4. **Multisystem Involvement**:  
   - **Colitis**: Gastrointestinal tract inflammation due to eosinophilic infiltration.  
   - **Elevated Hepatic Transaminases**: Liver involvement from vasculitis or eosinophilic tissue damage.  
   - **Decreased GFR**: Renal impairment secondary to glomerulonephritis or vasculitis.  
5. **Autoimmune Antibody Positivity**: ANCA (commonly MPO-ANCA) is positive in ~40% of EGPA cases, supporting vasculitic pathology.  
6. **Inflammatory Markers (Elevated CRP, Neutrophilia)**: Systemic inflammation correlates with active vasculitis.  
7. **Elevated IgE/IgG4**: IgE elevation reflects allergic predisposition, while IgG4 may indicate a Th2-driven immunologic overlap.  
8. **Elevated Creatine Kinase**: Suggests muscle inflammation (myositis), a rare but documented feature of EGPA.  
9. **Chronic Oral Candidiasis/Low Vitamin D**: Potential sequelae of prolonged corticosteroid use (implied but not explicitly stated in history).  
10. **Exclusion of Mimics**: Elevated IgG4 and nodular lung lesions could suggest IgG4-related disease, but eosinophilia, asthma, and ANCA positivity favor EGPA.  

EGPA integrates asthma, eosinophilia, and vasculitis across multiple organs, satisfying the 2022 ACR/EULAR diagnostic criteria."
"['Vasculitis', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Increased carotid artery intimal medial thickness', 'Fatigue', 'Cervical lymphadenopathy', 'Neck pain']",['Takayasu arteritis/Takayasu arteritis'],"Disease: Takayasu arteritis  
Reasoning:  
1. **Vasculitis**: Takayasu arteritis is a large-vessel vasculitis primarily affecting the aorta and its branches. The presence of vasculitis aligns with this diagnosis.  
2. **Elevated ESR/CRP**: These markers indicate systemic inflammation, consistent with active arteritis.  
3. **Increased carotid intimal thickness**: Characteristic of arterial wall inflammation and remodeling in Takayasu arteritis, often visualized via ultrasound or angiography.  
4. **Cervical lymphadenopathy/neck pain**: Inflammation of adjacent lymph nodes and arterial involvement (e.g., carotidynia) may explain these symptoms.  
5. **Fatigue**: A nonspecific but common systemic symptom of chronic inflammatory diseases.  
6. **Exclusion of mimics**: Symptoms differentiate it from other vasculitides (e.g., giant cell arteritis, which typically involves temporal arteries) or infections.  
Diagnosis is supported by the combination of vascular, inflammatory, and structural findings, meeting criteria for Takayasu arteritis (e.g., ACR classification)."
"['Hyperpigmentation of the skin', 'Thrombocytosis', 'Normocytic anemia', 'Fever', 'Increased susceptibility to fractures', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Increased circulating IgA level', 'Myalgia', 'Elevated erythrocyte sedimentation rate', 'Tricuspid regurgitation', 'Concave nasal ridge', 'Elevated circulating C-reactive protein concentration', 'Cough', 'Nodular pattern on pulmonary HRCT', 'Decreased mean corpuscular hemoglobin concentration', 'Abnormal periosteum morphology', 'Ankle pain', 'Elevated gamma-glutamyltransferase level', 'Cytoplasmic antineutrophil antibody positivity', 'Lymphocytosis']",['Granulomatosis with polyangiitis/Granulomatosis with polyangiitis'],"Disease: Granulomatosis with polyangiitis (GPA)  
**Reasoning**:  
1. **C-ANCA positivity**: Cytoplasmic antineutrophil antibody (c-ANCA), typically targeting PR3, is highly specific for GPa.  
2. **Upper respiratory involvement**: Concave nasal ridge suggests chronic nasal inflammation or cartilage damage, common in GPA due to granulomatous lesions.  
3. **Pulmonary manifestations**: Nodular pattern on HRCT and cough align with necrotizing granulomas in the lungs.  
4. **Systemic inflammation**: Fever, elevated ESR, CRP, and lymphocytosis reflect a systemic inflammatory process.  
5. **Musculoskeletal symptoms**: Myalgia and ankle pain correlate with vasculitis-induced inflammation.  
6. **Hematologic abnormalities**: Thrombocytosis and normocytic anemia are reactive findings in chronic inflammation.  
7. **Additional markers**: Elevated hepatic transaminases and alkaline phosphatase may indicate secondary liver involvement or drug toxicity (e.g., from immunosuppressants).  
8. **Renal implication**: While not explicitly listed, elevated IgA (common in autoimmune dysregulation) and cytoplasmic ANCA often precede glomerulonephritis in GPA.  
9. **Radiologic and pathologic features**: Abnormal periosteum morphology and fractures could stem from chronic inflammation or steroid therapy complications.  

**Conclusion**: The constellation of c-ANCA positivity, sinonasal/pulmonary lesions, systemic inflammation, and multi-organ involvement strongly supports GPA."
"['Acne', 'Tachycardia', 'Left ventricular hypertrophy', 'Palpitations', 'Arthralgia', 'Abnormal EKG', 'Abnormality of galactoside metabolism', 'Edema of the dorsum of hands', 'Upper limb pain', 'Finger swelling', 'Finger pain', 'Knee pain', 'Ankle pain', 'Papule']",['Fabry disease/Fabry disease/Fabry disease'],"Disease: Fabry disease  
Reasoning:  
1. **Cardiac Manifestations**: Tachycardia, palpitations, left ventricular hypertrophy (LVH), and abnormal EKG align with Fabry disease's progressive cardiac involvement due to globotriaosylceramide (Gb3) accumulation in myocardial tissue, leading to arrhythmias and structural changes.  
2. **Neuropathic Pain**: Arthralgia, upper limb pain, finger/knee/ankle pain correlate with Fabry-associated acroparesthesias, characterized by episodic burning or tingling in extremities.  
3. **Metabolic Abnormality**: The explicit mention of ""abnormality of galactoside metabolism"" directly implicates alpha-galactosidase A deficiency, the enzymatic defect in Fabry disease.  
4. **Dermatologic Features**: Papules may represent angiokeratomas, a pathognomonic skin lesion of Fabry disease.  
5. **Edema and Swelling**: Edema of the hands and finger swelling may reflect vascular dysfunction or secondary renal impairment, though less typical, they reinforce multisystem involvement.  
6. **Exclusion of Alternatives**: Symptoms collectively point to a lysosomal storage disorder, with the metabolic clue excluding rheumatologic or isolated cardiac conditions."
"['Abnormal finger morphology', 'Wrist swelling', 'Arthritis', 'Joint swelling', 'Hepatic steatosis', 'Abnormality of the larynx', 'Abnormal right ventricle morphology', 'Abnormal toe morphology', 'Ankle swelling', 'Weight loss', 'Fever', 'Abdominal pain', 'Pulmonary arterial hypertension', 'Hyperuricemia', 'Gastric ulcer', 'Abnormality of the knee', 'Arthralgia', 'Hyperuricosuria', 'Myalgia', 'Paresthesia', 'Back pain', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Poor appetite', 'Generalized morning stiffness', 'Helicobacter pylori infection', 'Pedal edema', 'Elevated circulating C-reactive protein concentration', 'Intestinal lymphoid nodular hyperplasia', 'Constrictive median neuropathy', 'Peripheral edema', 'obsolete Increased urinary urate', 'Tendonitis', 'Flank pain', 'Night sweats', 'Wrist pain', 'Hip pain', 'Knee pain', 'Ankle pain', 'Toe pain', 'Elevated gamma-glutamyltransferase level', 'Abnormality of mesentery morphology', 'Epigastric pain']",['Whipple disease'],"Disease: Whipple disease  
Reasoning:  
1. **Systemic Symptoms**: Fever, weight loss, night sweats, and poor appetite suggest a chronic infectious or inflammatory process, aligning with Whipple disease's systemic nature caused by *Tropheryma whipplei*.  
2. **Musculoskeletal Involvement**: Arthritis, joint swelling (wrist, ankle, knee, hip), arthralgia, tendonitis, and generalized morning stiffness reflect the migratory polyarthropathy commonly seen in early Whipple disease.  
3. **Gastrointestinal Manifestations**: Abdominal pain, epigastric pain, hepatic steatosis, and intestinal lymphoid nodular hyperplasia indicate intestinal involvement, consistent with Whipple-associated malabsorption and mucosal infiltration.  
4. **Cardiopulmonary Features**: Pulmonary arterial hypertension and abnormal right ventricle morphology may result from chronic inflammation or direct bacterial infiltration of cardiac tissue, a rare but documented complication.  
5. **Neurological Signs**: Paresthesia and constrictive median neuropathy suggest peripheral nerve involvement, which can occur in advanced Whipple disease with neurological dissemination.  
6. **Inflammatory Markers**: Elevated ESR, CRP, and ANA positivity (though atypical for pure Whipple disease) may reflect secondary autoimmune activation or coexisting conditions, but the overall pattern prioritizes infection.  
7. **Metabolic Abnormalities**: Hyperuricemia and hyperuricosuria could stem from renal tubular dysfunction due to chronic inflammation or malabsorption.  
8. **Hepatic and Mesenteric Involvement**: Elevated GGT, hepatic steatosis, and mesentery abnormalities correlate with Whipple-related infiltration of abdominal organs and lymphatic tissues.  
9. **Chronicity and Multi-Organ Spread**: The combination of prolonged symptoms (arthritis, weight loss) with cardiac, neurological, and gastrointestinal pathology strongly supports Whipple disease over isolated autoimmune disorders.  
**Exclusion Notes**: While H. pylori infection and gastric ulcer are present, they likely represent a comorbidity rather than the primary diagnosis. The systemic, multi-organ nature of symptoms points to Whipple disease as the unifying etiology."
"['Recurrent urinary tract infections', 'Purpura', 'Fever', 'Leukocytosis', 'Vasculitis', 'Pedal edema', 'Lower limb pain', 'Groin pain']",['Immunoglobulin A vasculitis'],"Disease: Immunoglobulin A vasculitis  
Reasoning:  
1. **Purpura**: A hallmark of IgA vasculitis, typically presenting as palpable purpura on the lower limbs and buttocks, aligning with the patient's symptom.  
2. **Vasculitis**: IgA vasculitis is a small-vessel vasculitis mediated by IgA immune deposits, directly confirmed in the patient's diagnosis.  
3. **Lower limb pain & Groin pain**: Consistent with arthralgia or inflammatory joint involvement, common in IgA vasculitis.  
4. **Pedal edema**: Suggests possible renal involvement (e.g., glomerulonephritis), a frequent complication of IgA vasculitis, which may also predispose to secondary infections.  
5. **Fever & Leukocytosis**: Reflect systemic inflammation, characteristic of active vasculitis.  
6. **Recurrent urinary tract infections**: May indicate renal compromise (e.g., proteinuria or hematuria) secondary to IgA vasculitis, creating a susceptibility to UTIs, or could represent overlapping inflammatory renal injury.  

The combination of purpura, vasculitis, systemic inflammation, and renal/articular manifestations strongly supports IgA vasculitis, despite atypical features like recurrent UTIs, which may require further nephrological evaluation."
"['Conjunctivitis', 'Urticaria', 'Papilledema', 'Headache', 'Increased intracranial pressure', 'Vasculitis', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia']",['Muckle-Wells syndrome/Muckle-Wells syndrome'],"Disease: Muckle-Wells syndrome  
Reasoning:  
1. **Urticaria & Conjunctivitis**: Hallmark features of cryopyrin-associated periodic syndromes (CAPS), including Muckle-Wells syndrome (MWS), caused by NLRP3 gene mutations.  
2. **Systemic Inflammation**: Elevated ESR, CRP, and neutrophilia align with chronic autoinflammatory dysregulation in MWS.  
3. **Neurological Involvement**: Headache, papilledema, and increased intracranial pressure suggest meningeal inflammation, a rare but documented CNS manifestation of CAPS.  
4. **Vasculitis**: Likely secondary to systemic inflammation from IL-1β overproduction, a key cytokine driver in MWS.  
5. **Exclusion of Alternatives**: Symptoms lack specificity for other autoinflammatory diseases (e.g., FMF, TRAPS) due to the absence of serositis or prolonged fever, while urticaria and neurological signs favor MWS. Early-stage MWS may not yet exhibit amyloidosis or deafness.  

This constellation of mucocutaneous, inflammatory, and neurological symptoms strongly supports Muckle-Wells syndrome."
"['Macrocephaly', 'Dystonia', 'Cerebral atrophy', 'Glutaric aciduria', 'Subdural hemorrhage']",['Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I'],"Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of GA-I, caused by deficient glutaryl-CoA dehydrogenase activity, leading to accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly**: Often presents in infancy due to frontotemporal atrophy or benign external hydrocephalus, a common early sign of GA-I.  
3. **Dystonia**: Results from striatal neurodegeneration (especially caudate/putamen damage), triggered by metabolic crises during catabolic states (e.g., infections), a hallmark of GA-I.  
4. **Cerebral atrophy**: Progressive neurodegeneration in basal ganglia and white matter, exacerbated by untreated metabolic decompensation.  
5. **Subdural hemorrhage**: Secondary to cerebral atrophy and vascular fragility, sometimes mimicking non-accidental trauma in infants.  

The combination of neurodevelopmental regression, characteristic biochemical markers, and neuroimaging findings aligns definitively with GA-I."
"['Coarse facial features', 'Eczematoid dermatitis', 'Eosinophilia', 'Recurrent Staphylococcus aureus infections', 'Impaired oxidative burst', 'Increased circulating IgE level', 'Recurrent pneumonia', 'Prominent forehead', 'Pulmonary pneumatocele', 'Cutaneous abscess', 'Abnormal proportion of CD4-positive T cells', 'Abnormal proportion of CD8-positive T cells']",['Autosomal dominant hyper-IgE syndrome/Hyper-IgE recurrent infection syndrome'],"Disease: Autosomal dominant hyper-IgE syndrome/Hyper-IgE recurrent infection syndrome  
Reasoning:  
1. **Elevated IgE and eosinophilia**: The increased circulating IgE level and eosinophilia are hallmark features of hyper-IgE syndromes (HIES), particularly AD-HIES.  
2. **Recurrent infections**: Recurrent *Staphylococcus aureus* infections (cutaneous abscesses, pneumonia) align with impaired immune responses to pyogenic bacteria, a key characteristic of AD-HIES.  
3. **Pulmonary complications**: Recurrent pneumonia and pulmonary pneumatoceles suggest chronic lung damage due to unresolved infections, commonly seen in AD-HIES.  
4. **Facial and skeletal features**: Coarse facial features and a prominent forehead are dysmorphic traits associated with STAT3 mutations, the genetic cause of AD-HIES.  
5. **Immune dysregulation**: Abnormal CD4/CD8 T-cell proportions and eczematoid dermatitis reflect T-cell dysfunction, consistent with STAT3 deficiency.  
6. **Oxidative burst impairment**: While not a primary feature of STAT3 deficiency, chronic inflammation or secondary neutrophil dysfunction may explain this finding.  

The constellation of symptoms, genetic traits, and immune abnormalities strongly supports a diagnosis of autosomal dominant hyper-IgE syndrome."
"['Malar flattening', 'Conductive hearing impairment', 'Short neck', 'Angiokeratoma', 'Ataxia', 'Intellectual disability, mild', 'Hepatosplenomegaly', 'Aortic valve stenosis', 'Abnormality of extrapyramidal motor function', 'Tracheomalacia', 'Aminoaciduria', 'Short stature', 'Cherry red spot of the macula']",['Galactosialidosis/Galactosialidosis'],"Disease: Galactosialidosis  
Reasoning:  
1. **Cherry red spot of the macula**: A hallmark of lysosomal storage disorders, particularly sialidosis and galactosialidosis, caused by abnormal glycosphingolipid accumulation.  
2. **Angiokeratoma**: Common in lysosomal disorders like Fabry disease but also seen in galactosialidosis due to glycosphingolipid deposition in skin vasculature.  
3. **Hepatosplenomegaly**: Reflects systemic lysosomal storage, typical of galactosialidosis.  
4. **Aortic valve stenosis**: Associated with glycosaminoglycan deposition in cardiac tissue, a feature of late-onset galactosialidosis.  
5. **Ataxia & extrapyramidal motor dysfunction**: Indicates progressive neurodegeneration, consistent with the neurologic decline in galactosialidosis.  
6. **Conductive hearing impairment**: Linked to skeletal abnormalities (e.g., ossicle defects) and recurrent infections from immune dysfunction in lysosomal disorders.  
7. **Short stature, short neck, malar flattening**: Suggests skeletal dysplasia, common in lysosomal storage diseases due to impaired bone remodeling.  
8. **Mild intellectual disability**: Aligns with the slower progression of neurologic involvement in juvenile/adult-onset galactosialidosis.  
9. **Tracheomalacia**: Caused by connective tissue weakness from lysosomal accumulation, seen in systemic forms.  
10. **Aminoaciduria**: Renal tubular dysfunction due to lysosomal storage in kidney cells.  
Galactosialidosis is confirmed by combined β-galactosidase and neuraminidase deficiency, with protective protein/cathepsin A mutations, explaining the multisystemic presentation."
"['Microcephaly', 'Prominent occiput', 'Long face', 'Smooth philtrum', 'Narrow forehead', 'Bulbous nose', 'Prominent nasal bridge', 'Deeply set eye', 'Widely spaced teeth', 'Delayed speech and language development', 'Pectus excavatum', 'Tapered finger', 'Ataxia', 'Bilateral tonic-clonic seizure', 'Febrile seizure (within the age range of 3 months to 6 years)', 'Asymmetry of the ears', 'Feeding difficulties', 'Stereotypical hand wringing', 'Tongue thrusting']","['DYRK1A-related intellectual disability syndrome/Mental retardation, autosomal dominant 7']","Disease: DYRK1A-related intellectual disability syndrome/Mental retardation, autosomal dominant 7  
Reasoning:  
1. **Core Features**: Microcephaly, intellectual disability (delayed speech), and characteristic facial features (long face, smooth philtrum, narrow forehead, bulbous nose, prominent nasal bridge, deeply set eyes) align with DYRK1A syndrome.  
2. **Supporting Craniofacial Signs**: Widely spaced teeth, prominent occiput, and ear asymmetry further match reported dysmorphisms in DYRK1A.  
3. **Neurological/Developmental**: Ataxia, seizures (tonic-clonic and febrile within the typical age range), and stereotypies (hand wringing, tongue thrusting) correlate with the syndrome’s neurological profile.  
4. **Musculoskeletal/Somatic**: Pectus excavatum, tapered fingers, and feeding difficulties are consistent with systemic involvement.  
5. **Exclusion of Mimics**: Overlap with Rett or Angelman syndromes is ruled out by the absence of regression (Rett) and distinct facial/genetic markers (Angelman).  
6. **Genetic Confirmation**: While clinical features are diagnostic, molecular testing for DYRK1A mutations would confirm."
"['Vesicoureteral reflux', 'Microretrognathia', 'Abnormal repetitive mannerisms', 'Hypotonia', 'Global developmental delay', 'Choreoathetosis', 'Broad-based gait', 'Clinodactyly of the 5th finger', '2-3 toe cutaneous syndactyly', 'Feeding difficulties']","['Mental retardation, autosomal dominant 42']","Disease: Mental retardation, autosomal dominant 42 (MRD42)  
Reasoning:  
1. **Global developmental delay** and **autosomal dominant mental retardation** are hallmark features of MRD42, directly aligning with its core diagnostic criteria.  
2. **Microretrognathia** and **clinodactyly of the 5th finger** are dysmorphic features commonly associated with genetic neurodevelopmental disorders like MRD42.  
3. **Hypotonia** and **feeding difficulties** in infancy are frequently observed in MRD42 due to neuromuscular involvement.  
4. **Choreoathetosis** and **abnormal repetitive mannerisms** suggest neurological dysfunction, consistent with MRD42’s link to movement disorders and behavioral abnormalities.  
5. **Broad-based gait** may result from hypotonia and delayed motor development, both characteristic of MRD42.  
6. **2-3 toe cutaneous syndactyly** is a congenital anomaly that fits within the spectrum of limb malformations reported in some MRD42 cases.  
7. **Vesicoureteral reflux**, while not a primary feature, could represent variable expressivity of associated connective tissue or structural anomalies in rare presentations.  
8. The absence of pathognomonic findings for other syndromes (e.g., Angelman, Rett) and the convergence of neurodevelopmental, dysmorphic, and neurological symptoms strongly support MRD42, often caused by pathogenic variants in *SYNGAP1*."
"['Micrognathia', 'Hearing impairment', 'Macrotia', 'Thick eyebrow', 'Osteoporosis', 'Memory impairment', 'Vertebral compression fracture', 'Short stature', 'Reduced bone mineral density', 'Osteolytic defects of the phalanges of the hand', 'Short digit', 'Flat face']",['Hajdu-Cheney syndrome/Hajdu-Cheney syndrome'],"Disease: Hajdu-Cheney syndrome  
Reasoning:  
1. **Osteolytic defects of the phalanges of the hand** and **short digits** are pathognomonic for Hajdu-Cheney syndrome, reflecting acro-osteolysis (progressive bone resorption).  
2. **Reduced bone mineral density**, **osteoporosis**, and **vertebral compression fractures** align with the syndrome’s severe skeletal fragility and abnormal bone remodeling.  
3. **Micrognathia**, **flat face**, and **thick eyebrows** match characteristic craniofacial dysmorphisms.  
4. **Hearing impairment** and **macrotia** correlate with otological abnormalities seen in this disorder.  
5. **Short stature** and **memory impairment** (potentially linked to cranial base anomalies or neurovascular complications) further support the diagnosis.  
The constellation of skeletal, craniofacial, and auditory findings strongly points to Hajdu-Cheney syndrome."
"['Long eyelashes', 'Chorioretinal atrophy', 'Nystagmus', 'Hypothyroidism', 'Decreased response to growth hormone stimulation test', 'Dysarthria', 'Hyporeflexia', 'Patent ductus arteriosus', 'Pes cavus', 'Gait ataxia', 'Intention tremor', 'Unsteady gait', 'Peripheral axonal neuropathy', 'Short stature', 'Cerebellar vermis atrophy', 'Sparse hair', 'High myopia']","['Oliver-Mcfarlane syndrome', 'Trichomegaly-retina pigmentary degeneration-dwarfism syndrome']","Disease: Oliver-Mcfarlane syndrome  
Reasoning: The patient presents with **long eyelashes (trichomegaly)**, **chorioretinal atrophy**, and **short stature**, which are hallmark features of Oliver-McFarlane syndrome. The **decreased response to growth hormone stimulation test** and **hypothyroidism** indicate pituitary dysfunction, a key component of the syndrome. Neurological symptoms (**dysarthria**, **hyporeflexia**, **gait ataxia**, **intention tremor**, **peripheral axonal neuropathy**, **cerebellar vermis atrophy**) align with its progressive neurodegenerative phenotype. **High myopia** and **nystagmus** are consistent with severe retinal involvement, while **sparse hair** and **pes cavus** further support the diagnosis.  

Disease: Trichomegaly-retina pigmentary degeneration-dwarfism syndrome  
Reasoning: This syndrome overlaps significantly with Oliver-McFarlane syndrome, sharing core features such as **trichomegaly**, **retinal degeneration (chorioretinal atrophy)**, and **dwarfism (short stature)**. The patient’s **high myopia** and **nystagmus** correlate with retinal dysfunction, while **sparse hair** and **hypothyroidism** may reflect broader endocrine disruption. However, this diagnosis primarily emphasizes the triad of trichomegaly, retinal pathology, and growth failure, without explicitly requiring the cerebellar or neurodegenerative findings seen here. The inclusion of both diagnoses reflects historical nomenclature variations, but Oliver-McFarlane syndrome better accounts for the full clinical spectrum."
"['Short chin', 'Abnormal pinna morphology', 'Blepharitis', 'Exotropia', 'Upslanted palpebral fissure', 'Pectus excavatum', 'Global developmental delay', 'Craniosynostosis', 'Hip dysplasia', 'Failure to thrive', 'Eosinophilia', 'Hypertriglyceridemia', 'Skeletal dysplasia', 'Coxa vara', 'Lumbar hyperlordosis', 'Thoracic scoliosis', 'Spinal canal stenosis', 'Severe combined immunodeficiency', 'Severe platyspondyly', 'Pear-shaped vertebrae', 'Severe T-cell immunodeficiency', 'Wide intermamillary distance', 'Cervical spinal canal stenosis', 'Infantile muscular hypotonia', 'Limb undergrowth', 'Chalazion', 'Hip subluxation', 'Increased intervertebral space']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Immunodeficiency**: Severe combined immunodeficiency (SCID) and severe T-cell immunodeficiency are hallmark features of ISDNA, linked to defects in EXTL3, which disrupts glycosaminoglycan synthesis critical for immune cell function.  
2. **Skeletal Abnormalities**: Severe platyspondyly, pear-shaped vertebrae, coxa vara, pectus excavatum, and spinal canal stenosis align with ISDNA’s characteristic skeletal dysplasia due to aberrant bone development.  
3. **Neurodevelopmental Delays**: Global developmental delay and infantile hypotonia reflect the neurodevelopmental component of ISDNA, caused by EXTL3’s role in neural development.  
4. **Supportive Features**: Limb undergrowth, failure to thrive, and facial dysmorphisms (short chin, wide intermamillary distance) further support a multisystem disorder. Eosinophilia and hypertriglyceridemia may stem from metabolic dysregulation secondary to immunodeficiency.  
5. **Exclusion of Alternatives**: Absence of nephropathy (unlike Schimke immuno-osseous dysplasia) or retinal defects (unlike Roifman syndrome) strengthens ISDNA as the diagnosis.  

This triad of skeletal, immune, and neurodevelopmental abnormalities, alongside genetic and biochemical mechanisms, confirms ISDNA."
"['Hepatic steatosis', 'Reduced antithrombin III activity', 'Hypercholesterolemia', 'Increased LDL cholesterol concentration', 'Elevated circulating alkaline phosphatase concentration', 'Abnormal circulating copper concentration', 'Decreased circulating ceruloplasmin concentration', 'Abnormal protein N-linked glycosylation', 'Abnormal protein O-linked glycosylation', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Glycosylation Defects**: Abnormal N-linked and O-linked glycosylation are hallmark features of congenital disorders of glycosylation (CDGs). TMEM199-CDG specifically disrupts both pathways, distinguishing it from CDGs affecting only one type.  
2. **Hepatic Involvement**: Hepatic steatosis, elevated AST/ALT, and alkaline phosphatase indicate liver dysfunction, common in TMEM199-CDG due to impaired glycosylation-dependent hepatic protein trafficking.  
3. **Coagulation Abnormalities**: Reduced antithrombin III activity arises from defective glycosylation of this glycoprotein, critical for its function.  
4. **Cholesterol Dysregulation**: Hypercholesterolemia and elevated LDL stem from disrupted lipid metabolism, linked to hepatic glycosylation defects affecting lipoprotein processing.  
5. **Copper/Ceruloplasmin Abnormalities**: Decreased ceruloplasmin (a glycosylated copper transporter) and abnormal copper levels result from failed glycosylation, mimicking Wilson’s disease but distinct in mechanism.  
6. **Consistent Phenotype**: TMEM199-CDG is specifically associated with combined hepatic, coagulation, lipid, and copper abnormalities, aligning with the patient’s profile.  

(The two diagnoses provided are synonymous: TMEM199-CDG is the molecular designation for CDG type IIP.)"
"['High palate', 'Muscle weakness', 'Flexion contracture', 'Hip dysplasia', 'Hypernasal speech', 'Broad-based gait', 'Scoliosis', 'Sensory axonal neuropathy', 'Increased variability in muscle fiber diameter', 'Type 1 muscle fiber predominance', 'Impaired proprioception', 'Feeding difficulties']","['Arthrogryposis, distal, with impaired proprioception and touch']","Disease: Arthrogryposis, distal, with impaired proprioception and touch  
Reasoning:  
1. **Distal joint contractures**: Flexion contracture aligns with ""distal arthrogryposis,"" which primarily affects extremities.  
2. **Sensory neuropathy**: Sensory axonal neuropathy and impaired proprioception directly correlate with the disease’s hallmark neurological involvement.  
3. **Musculoskeletal anomalies**: Hip dysplasia and scoliosis suggest congenital connective tissue/structural defects, common in syndromic arthrogryposis.  
4. **Neuromuscular features**: Muscle weakness, type 1 fiber predominance, and fiber size variability indicate mixed neuropathic/myopathic changes, consistent with the disease’s neuromuscular pathology.  
5. **Craniofacial involvement**: High palate and hypernasal speech point to velopharyngeal dysfunction, often seen in congenital syndromes.  
6. **Functional impairments**: Broad-based gait (due to proprioceptive loss) and feeding difficulties (linked to oropharyngeal weakness) further support systemic involvement.  
This constellation of distal contractures, sensory neuropathy, and multi-system features distinctively matches the rare diagnosis."
"['Hyperextensible skin', 'Soft skin', 'Generalized hypotonia', 'Muscle weakness', 'Joint hypermobility', 'Delayed gross motor development', 'Kyphoscoliosis', 'Widened atrophic scar']","['Ehlers-Danlos syndrome, classic type, 2']","Disease: Ehlers-Danlos syndrome, classic type, 2  
Reasoning:  
1. **Hyperextensible and soft skin**: Core features of classic EDS due to collagen defects (COL5A1/COL5A2 mutations).  
2. **Widened atrophic scars**: Pathognomonic for classic EDS, reflecting impaired tissue repair.  
3. **Joint hypermobility**: Consistent with generalized connective tissue fragility in EDS.  
4. **Muscle weakness & generalized hypotonia**: Secondary to joint instability and collagen dysfunction affecting muscle support.  
5. **Delayed gross motor development**: Linked to hypotonia and joint laxity delaying motor milestones.  
6. **Kyphoscoliosis**: Seen in severe classic EDS cases due to poor connective tissue support of the spine.  
7. **Exclusion of other subtypes**: Absence of vascular fragility (rules out vascular EDS) or severe kyphoscoliosis at birth (rules out kyphoscoliotic EDS).  
8. **Type 2 distinction**: Milder skin/joint involvement compared to type 1, aligning with the patient’s presentation."
"['Cleft palate', 'Micrognathia', 'Proptosis', 'Blue sclerae', 'Platyspondyly', 'Cutis laxa', 'Soft, doughy skin', 'Wrist flexion contracture', 'Hypotonia', 'Joint hypermobility', 'Joint laxity', 'Talipes', 'Epiphyseal dysplasia', 'Hyperplasia of the femoral trochanters', 'Hip dislocation', 'Limited elbow movement', 'Flared metaphysis', 'Advanced ossification of carpal bones', 'Beaking of vertebral bodies', 'Increased laxity of fingers', 'obsolete Fusion of midphalangeal joints', 'Overtubulated long bones', 'Sparse hair', 'Abnormality of the elbow', 'Prominent forehead', 'Broad fingertip', 'Long upper lip', 'Flat face', 'Short iliac bones']","['Spondyloepimetaphyseal dysplasia with joint laxity/Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures']","Disease: Spondyloepimetaphyseal dysplasia with joint laxity, type 1 (SEMDJL1)  
Reasoning:  
1. **Skeletal dysplasia**: Platyspondyly, epiphyseal dysplasia, flared metaphysis, beaking of vertebral bodies, hyperplasia of femoral trochanters, and advanced ossification of carpal bones are hallmark features of spondyloepimetaphyseal dysplasia.  
2. **Joint abnormalities**: Wrist flexion contracture, hip dislocation, limited elbow movement, and overtubulated long bones align with skeletal dysplasias, while joint hypermobility/laxity and increased finger laxity specifically match SEMDJL1’s paradoxical combination of laxity and contractures.  
3. **Craniofacial features**: Cleft palate, micrognathia, proptosis, blue sclerae, prominent forehead, flat face, and long upper lip are consistent with SEMDJL1’s connective tissue and craniofacial manifestations.  
4. **Connective tissue/cutaneous signs**: Cutis laxa, soft doughy skin, and sparse hair reflect underlying extracellular matrix defects, a key component of SEMDJL1 (linked to *KIF22* mutations).  
5. **Extremity anomalies**: Talipes, hypoplastic iliac bones, and broad fingertips further support a systemic skeletal dysplasia.  
6. **Exclusion of mimics**: Features like platyspondyly and joint laxity distinguish SEMDJL1 from other dysplasias (e.g., Larsen syndrome lacks metaphyseal changes), while blue sclerae and fractures (if present) help differentiate it from osteogenesis imperfecta."
"['Hypoplastic labia majora', 'Brachycephaly', 'Microcephaly', 'Short philtrum', 'Narrow forehead', 'Cupped ear', 'Broad nasal tip', 'Anteverted nares', 'Microcornea', 'Deeply set eye', 'Long eyelashes', 'Esotropia', 'Thick eyebrow', 'Synophrys', '11 pairs of ribs', 'Osteopenia', 'Global developmental delay', 'Intrauterine growth retardation', 'Patent ductus arteriosus', 'Short columella', 'Gastroesophageal reflux', 'Recurrent respiratory infections', 'Highly arched eyebrow', 'Short nose', 'Clinodactyly of the 5th finger', '2-3 toe cutaneous syndactyly', 'Attached earlobe', 'Midface retrusion']","['CTCF-related neurodevelopmental disorder/Intellectual developmental disorder, autosomal dominant 21']","Disease: CTCF-related neurodevelopmental disorder/Intellectual developmental disorder, autosomal dominant 21 (MRD21)  
Reasoning:  
1. **Craniofacial features**: Microcephaly, brachycephaly, narrow forehead, midface retrusion, short nose, broad nasal tip, anteverted nares, short philtrum, deeply set eyes, synophrys, thick eyebrows, long eyelashes, and cupped ears align with the characteristic facial dysmorphism of MRD21.  
2. **Ocular findings**: Microcornea and esotropia are consistent with ocular anomalies reported in CTCF-related disorders.  
3. **Skeletal anomalies**: 11 pairs of ribs (hypoplastic ribs), clinodactyly of the 5th finger, 2-3 toe syndactyly, and osteopenia correlate with skeletal manifestations of MRD21.  
4. **Neurodevelopmental/Growth issues**: Global developmental delay, intrauterine growth retardation (IUGR), and gastroesophageal reflux reflect the neurodevelopmental and systemic growth deficits central to this disorder.  
5. **Cardiac and systemic involvement**: Patent ductus arteriosus (PDA) and recurrent respiratory infections are common in MRD21 due to connective tissue and immune dysregulation.  
6. **Genetic consistency**: CTCF haploinsufficiency disrupts chromatin organization, explaining multisystem involvement (craniofacial, skeletal, neurological) observed here. Overlapping features with reported MRD21 cases confirm the diagnosis."
"['Coarse facial features', 'Epicanthus', 'Hypertelorism', 'Nystagmus', 'Intellectual disability', 'Seizure', 'Global developmental delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Secundum atrial septal defect', 'Inability to walk', 'Bronchomalacia', 'Recurrent lower respiratory tract infections', 'Aminoaciduria', 'Depressed nasal bridge', 'Mucopolysacchariduria', 'Oligosacchariduria', 'Abnormal nerve conduction velocity']","['Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome/Spinocerebellar ataxia, autosomal recessive 20']","Disease: Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome/Spinocerebellar ataxia, autosomal recessive 20 (SNX14-related disorder)  
Reasoning:  
1. **Core Features**:  
   - **Intellectual disability** and **global developmental delay** are hallmark features of SNX14-related disorders.  
   - **Coarse facial features** (epicanthus, hypertelorism, depressed nasal bridge) align with the syndrome’s characteristic facial dysmorphism.  
   - **Cerebellar atrophy** corresponds to ""cerebellar hypotrophy"" in the diagnosis, explaining **nystagmus**, **inability to walk** (ataxia), and **hypotonia**.  

2. **Neurological Manifestations**:  
   - **Seizures** and **abnormal nerve conduction velocity** are consistent with neuronal dysfunction caused by SNX14 mutations, which disrupt autophagy and lysosomal function.  

3. **Metabolic Abnormalities**:  
   - **Mucopolysacchariduria** and **oligosacchariduria** suggest lysosomal storage defects, likely secondary to SNX14’s role in lipid metabolism and lysosomal homeostasis.  
   - **Aminoaciduria** may reflect broader metabolic dysregulation.  

4. **Systemic Involvement**:  
   - **Secundum atrial septal defect** and **bronchomalacia** are atypical but reported in rare cases, possibly due to connective tissue or developmental impacts of SNX14 dysfunction.  
   - **Recurrent respiratory infections** are linked to hypotonia and bronchomalacia.  

5. **Exclusion of Alternatives**:  
   - While mucopolysacchariduria might suggest a lysosomal storage disease (e.g., Hurler syndrome), the combination of cerebellar atrophy, coarse facies, and autosomal recessive inheritance pattern matches SNX14-related disorder.  

**Conclusion**: The constellation of neurological, metabolic, and structural anomalies aligns with SNX14 mutations, confirming the diagnosis."
"['Renal insufficiency', 'Trigonocephaly', 'Low-set ears', 'Microphthalmia', 'Hypotelorism', 'Ectropion', 'Natal tooth', 'Hepatosplenomegaly', 'Failure to thrive', 'Intrauterine growth retardation', 'Pes planus', 'Premature rupture of membranes', 'Thrombocytopenia', 'Neutropenia', 'Lymphopenia', 'Vomiting', 'Pyloric stenosis', 'Pneumonia', 'Hypophosphatemia', 'Hypocalcemia', 'Hypoalbuminemia', 'Hypoproteinemia', 'Congenital ichthyosiform erythroderma', 'Congenital nonbullous ichthyosiform erythroderma', 'Ichthyosis', 'Bilateral cryptorchidism', 'Eclabion']","['Trichothiodystrophy 3, photosensitive']","Disease: Trichothiodystrophy 3, photosensitive  
Reasoning:  
1. **Cutaneous Features**: The presence of congenital ichthyosiform erythroderma, ichthyosis, and eclabion aligns with the hallmark skin manifestations of trichothiodystrophy (TTD), a disorder characterized by sulfur-deficient brittle hair and photosensitivity. While hair abnormalities are not explicitly listed, the ichthyosiform erythroderma strongly suggests TTD.  
2. **Craniofacial Abnormalities**: Trigonocephaly, microphthalmia, hypotelorism, ectropion, and low-set ears reflect neuroectodermal dysplasia, consistent with TTD’s association with developmental defects. Natal teeth may indicate ectodermal involvement.  
3. **Growth and Metabolic Issues**: Intrauterine growth retardation, failure to thrive, hypoalbuminemia, and hypoproteinemia correlate with TTD’s systemic impact on nutrient absorption and metabolic dysfunction, often linked to DNA repair deficits.  
4. **Hematologic Dysfunction**: Neutropenia, lymphopenia, and thrombocytopenia suggest bone marrow involvement, plausible in TTD due to impaired DNA repair affecting rapidly dividing cells.  
5. **Hepatosplenomegaly and Renal Insufficiency**: May stem from metabolic derangements or progressive organ dysfunction in severe TTD phenotypes.  
6. **Photosensitivity**: Implicit in the diagnosis (subtype “photosensitive”), though not explicitly listed, is a key feature of TTD caused by mutations in DNA repair genes (e.g., ERCC2/XPD).  
7. **Miscellaneous Features**: Cryptorchidism and pyloric stenosis, while less typical, may occur in multisystem genetic syndromes. Pneumonia likely results from immunodeficiency secondary to neutropenia.  

The constellation of ectodermal, craniofacial, hematologic, and growth abnormalities, anchored by ichthyosiform erythroderma and implied photosensitivity, confirms the diagnosis of photosensitive TTD."
"['Hypothyroidism', 'Intellectual disability', 'Seizure', 'Dysarthria', 'Confusion', 'Hyperammonemia', 'Myopathic facies', 'Gait ataxia', 'Clonus', 'Elevated circulating thyroid-stimulating hormone concentration', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Prolonged QTc interval', 'Hyperactive deep tendon reflexes', 'Lower limb muscle weakness', 'Distal lower limb muscle weakness']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Hyperammonemia, Confusion, Seizures**: Indicate recurrent metabolic encephalopathy, a hallmark of the syndrome, likely due to defects in energy metabolism or ammonia detoxification.  
2. **Rhabdomyolysis, Elevated CK**: Suggest recurrent muscle breakdown (rhabdomyolysis), consistent with metabolic crises triggered by stress, infection, or fasting.  
3. **Prolonged QTc Interval, Cardiac Arrhythmia Risk**: Aligns with cardiac involvement, a critical feature of the syndrome, potentially linked to electrolyte imbalances or mitochondrial dysfunction.  
4. **Intellectual Disability, Dysarthria, Gait Ataxia**: Reflect progressive neurodegeneration and CNS impairment, typical in chronic phases of the disorder.  
5. **Hypothyroidism with Elevated TSH**: May arise secondary to metabolic dysfunction or coexist as part of a multisystem mitochondrial disorder.  
6. **Myopathic Facies, Lower Limb Weakness, Hyperactive Reflexes**: Suggest mixed neuromuscular pathology, combining myopathy (weakness) and upper motor neuron involvement (hyperreflexia/clonus), atypical for isolated hypothyroidism.  
7. **Clonus and Ataxia**: Point to cerebellar/brainstem dysfunction, reinforcing the encephalomyopathic nature.  
The constellation of metabolic crises, rhabdomyolysis, cardiac arrhythmias, and neurodegeneration distinguishes this syndrome from isolated endocrine or neuromuscular disorders."
"['Lens subluxation', 'Disproportionate tall stature', 'Aortic dissection', 'High myopia']","['Marfan syndrome', 'Marfan syndrome type 1']","Disease: Marfan syndrome  
Reasoning:  
1. **Lens subluxation**: A hallmark of Marfan syndrome due to defective fibrillin-1 (FBN1 gene), weakening zonular fibers that hold the lens.  
2. **Disproportionate tall stature**: Characterized by long limbs (arm span > height) and arachnodactyly, consistent with skeletal manifestations of Marfan.  
3. **Aortic dissection**: Caused by progressive aortic root dilation and connective tissue fragility, a life-threatening feature of Marfan syndrome.  
4. **High myopia**: Associated with elongation of the globe and structural weakness in the eye, common in Marfan-related ocular abnormalities.  

Disease: Marfan syndrome type 1  
Reasoning:  
1. **Genetic confirmation**: Type 1 specifically refers to classic Marfan syndrome caused by pathogenic FBN1 mutations, which explain all listed symptoms.  
2. **Systemic involvement**: The combination of ocular (lens subluxation, myopia), skeletal (tall stature), and cardiovascular (aortic dissection) features aligns with the multisystemic criteria for Marfan syndrome type 1.  
3. **Exclusion of overlap syndromes**: No features of Loeys-Dietz syndrome (e.g., hypertelorism, bifid uvula) or other fibrillinopathies, reinforcing the diagnosis of type 1."
"['Ptosis', 'Proptosis', 'Waddling gait', 'Bone pain', 'Arthralgia', 'Abnormal EKG', 'Elevated circulating alkaline phosphatase concentration', 'Skeletal muscle atrophy', 'Humeral cortical thickening', 'Prominent forehead', 'Abnormal circulating creatinine concentration', 'Cognitive impairment', 'Hyperostosis']",['Camurati-Engelmann disease/Camurati-Engelmann disease'],"Disease: Camurati-Engelmann disease  
Reasoning:  
1. **Hyperostosis**: A hallmark feature, evident in the humeral cortical thickening and skull involvement (proptosis, ptosis, prominent forehead).  
2. **Bone pain/Arthralgia**: Caused by progressive cortical bone thickening and medullary cavity narrowing.  
3. **Elevated alkaline phosphatase**: Reflects increased bone remodeling.  
4. **Waddling gait/Skeletal muscle atrophy**: Secondary to bone deformities and muscle weakness from nerve compression or reduced mobility.  
5. **Cranial manifestations**: Skull hyperostosis leads to proptosis (bulging eyes), ptosis (eyelid droop), and prominent forehead.  
6. **Abnormal EKG/Cognitive impairment**: Rare complications due to cranial hyperostosis compressing vasculature or neural structures.  
7. **Abnormal creatinine**: May arise from reduced muscle mass (atrophy) or secondary renal effects of chronic disease.  

The combination of skeletal hyperostosis, cranial abnormalities, and systemic markers aligns definitively with Camurati-Engelmann disease."
"['Sloping forehead', 'Bulbous nose', 'Abnormality of eye movement', 'Upslanted palpebral fissure', 'Delayed speech and language development', 'Eczema', 'Intellectual disability', 'Seizure', 'Generalized hypotonia', 'Absent speech', 'Decreased fetal movement', 'Oligohydramnios', 'Asthma', 'Global brain atrophy', 'Developmental regression', 'Ventilator dependence with inability to wean', 'Severe muscular hypotonia', 'Tented upper lip vermilion', 'Severe global developmental delay', 'Brain atrophy']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial dysmorphism**: ""Sloping forehead,"" ""bulbous nose,"" ""upslanted palpebral fissure,"" and ""tented upper lip vermilion"" align with the characteristic facies of TBCK syndrome, which often includes coarse facial features and distinct lip morphology.  
2. **Neurological/developmental features**: ""Severe global developmental delay,"" ""intellectual disability,"" ""absent speech,"" and ""developmental regression"" correlate with the syndrome’s hallmark psychomotor retardation. ""Seizure"" and ""global brain atrophy"" are consistent with progressive neurological involvement.  
3. **Hypotonia**: ""Severe muscular hypotonia"" and ""generalized hypotonia"" are cardinal features of TBCK-related disorders, often leading to respiratory complications like ""ventilator dependence with inability to wean.""  
4. **Prenatal/neonatal history**: ""Decreased fetal movement"" and ""oligohydramnios"" suggest congenital onset, reported in severe TBCK cases.  
5. **Comorbidities**: ""Eczema"" and ""asthma"" are common immune-related associations in TBCK syndrome.  
6. **Exclusion of mimics**: The combination of hypotonia, distinct facies, brain atrophy, and developmental regression differentiates TBCK from other neurogenetic disorders (e.g., Rett syndrome or mitochondrial disorders). Genetic testing for TBC1-domain-containing kinase (TBCK) mutations would confirm the diagnosis."
"['Open mouth', 'Brachycephaly', 'Sloping forehead', 'Long philtrum', 'Deeply set eye', 'Esotropia', 'Shallow orbits', 'Reduced eye contact', 'Motor delay', 'Absent speech', 'Hyperreflexia', 'Poor head control', 'Respiratory failure', 'Severe muscular hypotonia', 'Tented upper lip vermilion', 'Self-injurious behavior']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Brachycephaly, sloping forehead, long philtrum, deeply set eyes, shallow orbits, tented upper lip vermilion, and open mouth align with the craniofacial dysmorphisms reported in TBCK syndrome.  
2. **Neuromuscular deficits**: Severe muscular hypotonia (a hallmark of TBCK) explains poor head control, respiratory failure (due to weakness), and motor delay. Hyperreflexia may reflect mixed upper/lower motor neuron dysfunction.  
3. **Developmental delays**: Absent speech and reduced eye contact correlate with profound intellectual disability and psychomotor retardation.  
4. **Neurobehavioral features**: Self-injurious behavior is consistent with behavioral phenotypes observed in genetic neurodevelopmental disorders like TBCK.  
5. **Ocular findings**: Esotropia and shallow orbits are recurrently associated with TBCK-related syndromes.  
6. **Systemic involvement**: Respiratory failure secondary to hypotonia further supports the diagnosis, as respiratory complications are common in severe infantile-onset TBCK cases."
"['Gingival overgrowth', 'Irritability', 'Flexion contracture', 'Weight loss', 'Acidosis', 'Hyperkalemia', 'Protein-losing enteropathy', 'Hyponatremia', 'Hypoalbuminemia', 'Malnutrition', 'Pain', 'Erythematous papule', 'Cutaneous sclerotic plaque']",['Hyaline fibromatosis syndrome'],"Disease: Hyaline fibromatosis syndrome  
Reasoning:  
1. **Gingival overgrowth** and **cutaneous lesions** (erythematous papules, sclerotic plaques) are hallmark features of HFS due to abnormal hyaline deposits in connective tissues.  
2. **Flexion contractures** result from progressive joint stiffness caused by hyaline infiltration in periarticular tissues.  
3. **Protein-losing enteropathy** leads to **hypoalbuminemia**, contributing to **malnutrition**, **weight loss**, and **edema** (not listed but often associated).  
4. Electrolyte imbalances (**hyperkalemia**, **hyponatremia**, **acidosis**) may stem from renal tubular dysfunction secondary to systemic hyaline deposition.  
5. **Irritability** and **pain** correlate with chronic discomfort from skin/joint involvement and malnutrition.  
6. **HFS diagnosis** is confirmed genetically (ANTXR2 mutations) but symptomatically aligns with this rare autosomal recessive disorder."
"['High palate', 'Periodontitis', 'Hyperextensible skin', 'Bruising susceptibility', 'Molluscoid pseudotumors', 'Soft, doughy skin', 'Fragile skin', 'Poor wound healing', 'Intellectual disability', 'Motor delay', 'Neonatal hypotonia', 'Umbilical hernia', 'Redundant skin', 'Pes planus', 'Varicose veins', 'Neonatal respiratory distress', 'Scoliosis', 'Low back pain', 'Intermittent claudication', 'Recurrent thrombophlebitis', 'Knee dislocation', 'Chronic fatigue', 'Widened atrophic scar']","['Classical-like Ehlers-Danlos syndrome type 2/Ehlers-Danlos syndrome, classic-like, 2']","Disease: Classical-like Ehlers-Danlos syndrome type 2  
Reasoning:  
1. **Connective Tissue Manifestations**: Symptoms like *hyperextensible skin*, *fragile skin*, *soft doughy skin*, and *widened atrophic scars* align with collagen defects typical of Ehlers-Danlos syndromes (EDS).  
2. **Classic EDS Overlap**: *Molluscoid pseudotumors* (pressure-point lesions) and *poor wound healing* are hallmarks of classical EDS, but their presence in classical-like EDS type 2 (clEDS-2) suggests a related but distinct subtype.  
3. **Oral/Craniofacial Features**: *High palate* and *periodontitis* correlate with TNXB-related clEDS-2, where connective tissue fragility affects oral structures.  
4. **Musculoskeletal Involvement**: *Neonatal hypotonia*, *motor delay*, *pes planus*, *scoliosis*, *knee dislocation*, and *umbilical hernia* reflect systemic joint hypermobility and connective tissue weakness.  
5. **Vascular/Soft Tissue Signs**: *Bruising susceptibility*, *varicose veins*, and *recurrent thrombophlebitis* indicate vascular fragility, while *redundant skin* and *chronic fatigue* further support connective tissue dysfunction.  
6. **Developmental Considerations**: *Intellectual disability* and *neonatal respiratory distress*, though atypical in most EDS subtypes, are reported in clEDS-2 due to TNXB mutations affecting tenascin-X, which influences neural and tissue development.  
7. **Exclusion of Other Subtypes**: Absence of severe arterial rupture (ruling out vascular EDS) and presence of atrophic scars (less severe than classical EDS scarring) refine the diagnosis to clEDS-2.  

This constellation of symptoms, particularly the overlap of classic EDS features with unique neuromuscular and developmental elements, strongly supports **Classical-like EDS type 2**. Genetic testing for TNXB mutations would confirm the diagnosis."
"['Intellectual disability', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Intellectual disability**: A hallmark of TBCK syndrome, linked to biallelic loss-of-function mutations in the *TBCK* gene, which disrupt neuronal development and synaptic function.  
2. **Hypotonia**: Consistently observed in TBCK patients due to combined central (brain-related) and peripheral (motor neuron/neuropathy) mechanisms.  
3. **Global developmental delay**: Matches the syndrome’s profile of impaired motor, speech, and cognitive milestones, often with regression or plateauing.  
4. **Reduced tendon reflexes**: Reflects peripheral nervous system involvement, such as axonal neuropathy or lower motor neuron dysfunction, reported in TBCK cases.  
5. **Absence of progressive neurodegeneration**: Distinguishes it from disorders like SMA or lysosomal storage diseases, aligning with TBCK’s stable/non-degenerative course.  
6. **Genetic confirmation**: Definitive diagnosis requires identifying pathogenic *TBCK* variants, but clinical features strongly prioritize this evaluation."
"['Blepharitis', 'Photophobia', 'Sparse eyelashes', 'Sparse body hair', 'Congenital ichthyosiform erythroderma', 'Sparse hair', 'Sparse eyebrow']","['Ichthyosis-hypotrichosis syndrome/Ichthyosis, congenital, autosomal recessive 11']","Disease: Ichthyosis-hypotrichosis syndrome/Ichthyosis, congenital, autosomal recessive 11  
Reasoning:  
1. **Congenital ichthyosiform erythroderma** is a hallmark of autosomal recessive congenital ichthyosis (ARCI), specifically linked to mutations in *ST14* (matriptase) in ARCI11.  
2. **Sparse hair, eyebrows, eyelashes, and body hair** align with the ""hypotrichosis"" component, indicating a systemic defect in hair follicle development/maintenance.  
3. **Blepharitis and photophobia** are secondary to eyelid margin inflammation (from scaling skin) and reduced ocular protection due to sparse lashes.  
4. The triad of **ichthyosis, hypotrichosis, and ocular involvement** is pathognomonic for ichthyosis-hypotrichosis syndrome.  
5. Exclusion of mimics (e.g., Netherton/KID syndromes) is supported by the absence of specific features like bamboo hair or keratitis."
"['Hypogonadotropic hypogonadism', 'Hyporeflexia', 'Cerebellar atrophy', 'Dysdiadochokinesis', 'Retinal pigment epithelial atrophy', 'Decreased circulating follicle stimulating hormone concentration', 'Decreased circulating luteinizing hormone level', 'Decreased serum testosterone concentration']",['Ataxia-hypogonadism-choroidal dystrophy syndrome/Boucher-Neuhauser syndrome'],"Disease: Ataxia-hypogonadism-choroidal dystrophy syndrome/Boucher-Neuhauser syndrome  
Reasoning:  
1. **Hypogonadotropic hypogonadism** (evidenced by low FSH, LH, and testosterone) aligns with the syndrome’s hallmark endocrine dysfunction due to impaired hypothalamic-pituitary-gonadal axis signaling.  
2. **Cerebellar atrophy** and **dysdiadochokinesis** indicate progressive cerebellar degeneration, a core neurological feature of the syndrome.  
3. **Retinal pigment epithelial atrophy** corresponds to choroidal dystrophy, a defining ocular manifestation.  
4. **Hyporeflexia** further supports cerebellar or spinocerebellar pathway involvement.  
5. The triad of **ataxia** (from cerebellar atrophy), **hypogonadotropic hypogonadism**, and **retinal/choroidal degeneration** is pathognomonic for Boucher-Neuhauser syndrome, distinguishing it from mimics like Gordon Holmes syndrome (which lacks retinal involvement)."
"['Hypertonia', 'Morphological central nervous system abnormality', 'Pneumothorax', 'Dilatation of the renal pelvis', 'Dyskinesia']",['Hereditary hyperekplexia/Hyperekplexia 1'],"Disease: Hereditary hyperekplexia/Hyperekplexia 1  
Reasoning:  
1. **Hypertonia**: A hallmark symptom of hereditary hyperekplexia, caused by mutations in the *GLRA1* gene, leading to glycine receptor dysfunction in the spinal cord and brainstem, resulting in sustained muscle stiffness.  
2. **Morphological central nervous system abnormality**: While hyperekplexia is primarily a functional disorder, rare cases may exhibit structural CNS anomalies (e.g., brainstem hypoplasia) due to disrupted glycine-mediated neurodevelopment.  
3. **Dyskinesia**: May arise from chronic hypertonia or compensatory mechanisms in motor pathways, though atypical for classic hyperekplexia. This could suggest a complex phenotype or overlapping movement disorder.  
4. **Pneumothorax and renal pelvis dilatation**: Not directly linked to hyperekplexia. These may represent unrelated comorbidities, secondary complications (e.g., trauma from severe spasms), or a syndromic form with multi-organ involvement (not well-documented in literature).  

Final diagnosis prioritizes the pathognomonic triad of hypertonia, exaggerated startle, and stiffness, while acknowledging atypical features that warrant further investigation for coexisting conditions."
"['Long face', 'Recurrent otitis media', 'Prominent nasal bridge', 'Posterior embryotoxon', 'Polyhydramnios', 'Ventricular septal defect', 'Esophageal atresia', 'Tracheoesophageal fistula', 'Bronchomalacia', 'Spina bifida occulta', 'Hypoplasia of the semicircular canal', 'Delayed ability to walk', 'Bilateral cleft lip', 'Bilateral cleft palate']",['CHARGE syndrome/Charge syndrome'],"Disease: CHARGE syndrome  
Reasoning:  
1. **Major Criteria**:  
   - **Hypoplasia of the semicircular canals**: A hallmark feature of CHARGE syndrome, contributing to balance issues and **delayed ability to walk**.  
   - **Bilateral cleft lip/palate**: While cleft palate is a minor criterion, bilateral cleft lip/palate aligns with craniofacial anomalies seen in CHARGE.  
   - **Ventricular septal defect (VSD)**: Congenital heart defects (e.g., VSD) are a core feature (the ""H"" in CHARGE).  

2. **Supportive Features**:  
   - **Esophageal atresia and tracheoesophageal fistula**: Represent the ""A"" (atresia) in CHARGE, typically choanal atresia, but esophageal atresia is occasionally included.  
   - **Recurrent otitis media**: Linked to CHARGE-associated ear anomalies (e.g., hypoplastic cochlea, ""cup-shaped"" ears).  
   - **Posterior embryotoxon**: Though not a classic coloboma (the ""C"" in CHARGE), anterior segment eye anomalies like this are reported.  
   - **Bronchomalacia and polyhydramnios**: Polyhydramnios may reflect fetal swallowing difficulties (esophageal atresia), while bronchomalacia correlates with tracheal anomalies.  

3. **Additional Clues**:  
   - **Spina bifida occulta**: Rarely reported in CHARGE but fits the spectrum of skeletal anomalies.  
   - **Prominent nasal bridge and long face**: Part of the characteristic facial dysmorphism.  

Conclusion: The combination of major criteria (semicircular canal hypoplasia, VSD, craniofacial clefts) and supportive features (atresias, ear/eye anomalies) strongly supports CHARGE syndrome."
"['Abnormal repetitive mannerisms', 'Seizure', 'Hypotonia', 'Hypoplasia of the corpus callosum', 'Sleep disturbance', 'Bruxism', 'Secondary microcephaly', 'Hypoplasia of the frontal lobes', 'Feeding difficulties in infancy']","['Rett syndrome, congenital variant']","Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Secondary microcephaly** and **hypoplasia of the corpus callosum/frontal lobes** are hallmark neuroanatomical features of Rett syndrome (RTT), particularly in congenital variants where brain development anomalies are evident early.  
2. **Hypotonia** and **feeding difficulties in infancy** align with the congenital variant’s neonatal-onset hypotonia and failure to thrive.  
3. **Seizures** are common in RTT due to cortical hyperexcitability from MECP2 mutations or related genetic defects.  
4. **Abnormal repetitive mannerisms** (e.g., hand stereotypies) and **bruxism** are classic motor manifestations of RTT.  
5. **Sleep disturbances** correlate with autonomic dysfunction seen in RTT.  
6. The absence of a distinct regression phase (implied by congenital presentation) distinguishes this from typical RTT, fitting the *congenital variant* subtype (e.g., FOXG1-related or early-truncating MECP2 mutations).  
7. Structural brain abnormalities (corpus callosum/frontal hypoplasia) and early developmental stagnation further support this diagnosis over mimics like Angelman syndrome or CDKL5 deficiency disorder."
"['Cataract', 'Parkinsonism', 'Pes cavus', 'Hammertoe', 'Postural tremor', 'Difficulty walking', 'Distal muscle weakness', 'Ragged-red muscle fibers', 'Cytochrome C oxidase-negative muscle fibers', 'Distal amyotrophy', 'Bilateral sensorineural hearing impairment', 'Laryngeal dystonia', 'Dyskinesia']","['Parkinson disease 7, autosomal recessive early-onset']","Disease: Parkinson disease 7, autosomal recessive early-onset (PARK7)  
Reasoning:  
1. **Parkinsonism and Dyskinesia**: Core features of PARK7 include early-onset parkinsonism (often before age 40) and movement abnormalities like dyskinesia.  
2. **Postural Tremor and Laryngeal Dystonia**: Tremor and dystonia (including laryngeal involvement) are recognized in PARK7 due to DJ-1 gene dysfunction affecting basal ganglia pathways.  
3. **Distal Muscle Weakness/Amyotrophy and Pes Cavus/Hammertoe**: DJ-1 mutations may cause mitochondrial instability, leading to neurogenic atrophy and peripheral neuropathy, manifesting as distal weakness, foot deformities, and amyotrophy.  
4. **Ragged-Red Fibers and COX-Negative Fibers**: While classically mitochondrial, PARK7-associated oxidative stress and mitochondrial dysfunction can secondarily induce these muscle abnormalities.  
5. **Bilateral Sensorineural Hearing Loss and Cataracts**: Systemic oxidative damage in PARK7 may explain early-onset cataracts and cochlear degeneration.  
6. **Autosomal Recessive Inheritance**: Matches PARK7’s genetic pattern, distinguishing it from mitochondrial disorders (often maternally inherited) or other Parkinsonian syndromes (e.g., PARK2, PARK6).  

This constellation of neurological, neuromuscular, and systemic symptoms aligns with PARK7’s multifactorial pathology, driven by DJ-1’s role in oxidative stress response and mitochondrial regulation."
"['Cryptorchidism', 'Abnormality of male external genitalia', 'Shawl scrotum', 'Micropenis', 'Abnormality of the face', 'Hypertelorism', 'Facial asymmetry', 'Abnormality of the outer ear', 'Posteriorly rotated ears', 'Low-set ears', 'Prominent nose', 'Abnormality of the eye', 'Atypical behavior', 'Autistic behavior', 'Cutis marmorata', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Impaired smooth pursuit', 'Pineal cyst', 'Lymphangioma']",['Stankiewicz-Isidor syndrome'],"Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Genetic Basis**: Caused by heterozygous pathogenic variants in *PHIP*, aligning with multi-system congenital anomalies.  
2. **Facial Dysmorphism**: Hypertelorism, facial asymmetry, prominent nose, and ear anomalies (posteriorly rotated, low-set) match reported craniofacial features.  
3. **Genital Abnormalities**: Cryptorchidism, micropenis, and shawl scrotum correlate with urogenital malformations documented in the syndrome.  
4. **Neurological Features**: Intellectual disability, seizures, hypotonia, and impaired smooth pursuit are hallmark neurodevelopmental traits.  
5. **Behavioral Phenotype**: Autistic behavior aligns with developmental delay and social communication deficits.  
6. **Cutaneous Findings**: Cutis marmorata may reflect vascular dysregulation, occasionally observed in genetic syndromes.  
7. **Ancillary Features**: Pineal cyst and lymphangioma, while less specific, fit within the spectrum of variable congenital anomalies.  
8. **Exclusion**: Overlap with Noonan or Smith-Lemli-Opitz syndromes is unlikely due to absence of key features (e.g., cardiac defects, cholesterol deficiency signs).  

Conclusion: The constellation of symptoms strongly supports Stankiewicz-Isidor syndrome, driven by *PHIP* dysfunction."
"['Severe periodontitis', 'Palmoplantar hyperkeratosis', 'Premature loss of primary teeth', 'Chronic furunculosis', 'Folliculitis', 'Alveolar bone loss around teeth']",['Papillon-Lefèvre syndrome/Papillon-Lefevre syndrome'],"Disease: Papillon-Lefèvre syndrome  
Reasoning:  
1. **Palmoplantar hyperkeratosis**: Thickened skin on palms and soles is a hallmark feature of Papillon-Lefèvre syndrome (PLS), caused by mutations in the *CTSC* gene encoding cathepsin C.  
2. **Severe periodontitis and alveolar bone loss**: PLS leads to aggressive destruction of periodontal tissues due to dysregulated immune response and bacterial susceptibility, resulting in premature loss of **both primary and permanent teeth** (here, primary teeth loss is noted).  
3. **Chronic furunculosis and folliculitis**: Recurrent skin infections arise from impaired neutrophil function secondary to *CTSC* mutations, reducing protease activity critical for combating pathogens like *Staphylococcus aureus*.  
4. **Exclusion of alternatives**: Conditions like Haim-Munk syndrome (similar but with additional features) or isolated periodontitis lack the combined dermatological and immunological findings seen here.  
The triad of palmoplantar hyperkeratosis, early-onset periodontitis, and susceptibility to infections confirms PLS."
"['Keratoconus', 'Dysarthria', 'Dysmetria', 'Lower limb spasticity', 'Gait ataxia', 'Limb ataxia', 'Upper limb spasticity']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Autosomal recessive spastic paraplegia type 76 (SPG76): The patient exhibits lower and upper limb spasticity, consistent with hereditary spastic paraplegia (HSP). The additional cerebellar features (gait ataxia, limb ataxia, dysmetria, dysarthria) indicate a complex HSP subtype. SPG76, caused by CAPN1 mutations, is characterized by progressive spastic paraplegia, cerebellar ataxia, dysarthria, and dysphagia. While keratoconus is not a classic feature of SPG76, the combination of spasticity, cerebellar dysfunction, and autosomal recessive inheritance strongly supports this diagnosis. Keratoconus may represent an atypical or coincidental manifestation in this case."
"['Urinary incontinence', 'Depression', 'Hallucinations', 'Apathy', 'Mental deterioration', 'Confusion', 'Dystonia', 'Slurred speech', 'Dysphagia', 'Cerebral atrophy', 'Abnormality of speech or vocalization', 'Postural instability', 'Falls', 'Cachexia', 'Hyperactive deep tendon reflexes', 'Abnormal pyramidal sign', 'Freezing of gait', 'Dyskinesia']","['Parkinson disease 23, autosomal recessive early-onset']","Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Early-onset parkinsonism**: Symptoms like dystonia, dyskinesia, freezing of gait, and postural instability align with early-onset Parkinsonian features.  
2. **Neuropsychiatric and cognitive decline**: Depression, apathy, hallucinations, mental deterioration, and confusion suggest rapid neurodegeneration beyond typical Parkinson’s disease, consistent with severe genetic forms.  
3. **Pyramidal involvement**: Hyperactive deep tendon reflexes and abnormal pyramidal signs (e.g., Babinski) indicate upper motor neuron dysfunction, atypical in idiopathic Parkinson’s but reported in PARK23 (VPS13C-related).  
4. **Bulbar and autonomic dysfunction**: Dysphagia, slurred speech, and urinary incontinence point to widespread neurodegeneration, including brainstem and autonomic systems.  
5. **Structural CNS changes**: Cerebral atrophy on imaging supports progressive neurodegenerative pathology.  
6. **Systemic progression**: Cachexia and frequent falls reflect advanced disease severity, typical of rapidly progressive autosomal recessive forms like PARK23.  
7. **Genetic consistency**: Autosomal recessive inheritance (implied by diagnosis) matches VPS13C mutations, which cause early-onset, aggressive parkinsonism with pyramidal and cognitive features."
"['Ectopia lentis', 'Arachnodactyly', 'Global developmental delay', 'Disproportionate tall stature']",['Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency'],"Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Ectopia lentis**: A hallmark feature of homocystinuria, caused by defective cysteine metabolism weakening zonular fibers that secure the lens.  
2. **Arachnodactyly and disproportionate tall stature**: Marfanoid habitus (long limbs, slender fingers) arises from disrupted collagen cross-linking due to homocysteine accumulation.  
3. **Global developmental delay**: Elevated homocysteine levels are neurotoxic, impairing myelination and neuronal function, leading to intellectual/developmental deficits.  
4. **Exclusion of Marfan syndrome**: While Marfan shares arachnodactyly and ectopia lentis, it lacks metabolic abnormalities or developmental delay, directing suspicion toward homocystinuria.  
5. **Biochemical confirmation**: Suspected diagnosis aligns with cystathionine beta-synthase deficiency, confirmed via elevated plasma homocysteine, low methionine, and genetic testing."
"['Bifid uvula', 'Low anterior hairline', 'Epistaxis', 'Prominent nose', 'Strabismus', 'Deeply set eye', 'Long eyelashes', 'Thick eyebrow', 'Synophrys', 'Dry skin', 'Palmoplantar keratoderma', 'Hirsutism', 'Spasticity', 'Global developmental delay', 'Absent speech', 'Dysphagia', 'Kyphoscoliosis', 'Recurrent pneumonia', 'Dysplastic corpus callosum']","['CEDNIK syndrome/Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome']","Disease: CEDNIK syndrome (Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome)  
Reasoning:  
1. **Cerebral dysgenesis**: Supported by *global developmental delay*, *absent speech*, and *dysplastic corpus callosum*, indicating structural brain abnormalities.  
2. **Neuropathy**: Evidenced by *spasticity* and *dysphagia*, reflecting neurological dysfunction.  
3. **Ichthyosis**: Suggested by *dry skin* and *palmoplantar keratoderma* (thickened palms/soles), hallmark features of CEDNIK.  
4. **Systemic involvement**: *Recurrent pneumonia* likely secondary to aspiration from dysphagia; *kyphoscoliosis* may arise from neuromuscular compromise.  
5. **Dysmorphic features**: *Prominent nose*, *deeply set eyes*, *synophrys*, *long eyelashes*, *thick eyebrows*, *bifid uvula*, and *low anterior hairline* align with syndromic genetic etiology.  
6. **Exclusion**: Overlap with other neuro-ichthyosis disorders (e.g., Sjögren-Larsson syndrome) is ruled out by the unique combination of cerebral dysgenesis and palmoplantar keratoderma."
"['Spasticity', 'Morphological central nervous system abnormality', 'Frequent falls', 'Osteomyelitis', 'Babinski sign', 'Hyperactive deep tendon reflexes', 'Pain insensitivity', 'Skin ulcer']","['Neuropathy, hereditary sensory and autonomic, type IIB']","Disease: Neuropathy, hereditary sensory and autonomic, type IIB  
Reasoning:  
1. **Pain insensitivity** and **skin ulcers** indicate a severe sensory neuropathy, specifically affecting nociceptive fibers, leading to unrecognized injuries and chronic wounds.  
2. **Osteomyelitis** is a common complication of untreated infections due to pain insensitivity.  
3. **Hyperactive deep tendon reflexes** and **Babinski sign** suggest upper motor neuron involvement, which may coexist with the peripheral neuropathy in rare HSAN subtypes or reflect secondary spinal cord changes from chronic inflammation/infection.  
4. **Spasticity** and **morphological CNS abnormality** could indicate structural central nervous system defects, possibly linked to genetic mutations (e.g., *FAM134B*) affecting both peripheral and central pathways.  
5. **Frequent falls** result from combined sensory deficits (poor proprioception) and spasticity impairing motor coordination.  
6. While HSANs are primarily peripheral neuropathies, type IIB may involve atypical CNS features or overlapping syndromes, aligning with the clinical profile."
"['Ventricular septal defect', 'Patent ductus arteriosus', 'Transposition of the great arteries', 'Complete atrioventricular canal defect', 'Asplenia', 'Single ventricle', 'Arrhinencephaly', 'Abdominal situs inversus', 'Pulmonary artery atresia', 'Pulmonary artery hypoplasia', 'Abnormal ciliary motility', 'Posteriorly placed anus']","['Heterotaxy, visceral, 1, X-linked']","Disease: Heterotaxy, visceral, 1, X-linked  
Reasoning:  
1. **Abdominal situs inversus**: Indicates abnormal visceral arrangement, a hallmark of heterotaxy syndromes.  
2. **Asplenia**: Common in heterotaxy (particularly right isomerism), associated with immune dysfunction and abnormal organ symmetry.  
3. **Complex congenital heart defects**:  
   - *Ventricular septal defect (VSD)*, *Patent ductus arteriosus (PDA)*, *Transposition of the great arteries (TGA)*, *Complete atrioventricular canal defect*, *Single ventricle*, *Pulmonary artery atresia/hypoplasia*: These defects reflect severe laterality disturbances during cardiac development, typical of heterotaxy.  
4. **Abnormal ciliary motility**: Implicates ciliary dysfunction, which disrupts left-right patterning in early embryogenesis (linked to ZIC3 mutations in X-linked heterotaxy).  
5. **Posteriorly placed anus**: Suggests midline developmental anomalies, consistent with heterotaxy-associated gastrointestinal malformations.  
6. **Arrhinencephaly**: Rarely reported in heterotaxy but may reflect broader dysregulation of embryonic midline signaling pathways.  

The combination of situs anomalies, complex cardiac defects, asplenia, and ciliary dysfunction aligns with *Heterotaxy, visceral, 1, X-linked* (OMIM #306955), caused by pathogenic variants in the ZIC3 gene critical for left-right axis determination."
"['Dry skin', 'Pallor', 'Abnormality of the hand', 'Abnormal foot morphology', 'Sparse scalp hair', 'Pili torti', 'Abnormality of dental morphology', 'Macular atrophy', 'Follicular hyperkeratosis', 'Reduced visual acuity', 'Macular hyperpigmentation', 'Sparse eyebrow', 'Epidermoid cyst', 'Absent sebaceous glands']","['Hypotrichosis with juvenile macular degeneration/Hypotrichosis, congenital, with juvenile macular dystrophy']","Disease: Hypotrichosis with juvenile macular degeneration (HJMD)  
Reasoning:  
1. **Hair Abnormalities**: Symptoms like sparse scalp hair, sparse eyebrows, and pili torti (twisted hair shafts) directly align with **hypotrichosis**, a hallmark of HJMD.  
2. **Ocular Features**: Reduced visual acuity, macular atrophy, and macular hyperpigmentation indicate **juvenile macular dystrophy**, the second defining feature of HJMD.  
3. **Cutaneous Manifestations**: Dry skin, follicular hyperkeratosis, and absent sebaceous glands suggest a congenital ectodermal defect, consistent with HJMD’s pathogenesis.  
4. **Supporting Signs**: Epidermoid cysts, abnormal dental morphology, and hand/foot abnormalities further support a systemic ectodermal dysplasia, a common underlying mechanism in HJMD.  
5. **Exclusion of Overlap Syndromes**: The combination of hair, skin, and macular pathology without neurological or skeletal dominance distinguishes HJMD from similar disorders (e.g., Sjögren-Larsson syndrome).  

This constellation of ectodermal defects and early-onset macular degeneration confirms the diagnosis."
"['High palate', 'Microcephaly', 'Epicanthus', 'Micrognathia', 'Intellectual disability', 'Motor delay', 'Hypertonia', 'Sleep disturbance', 'Lateral ventricle dilatation', 'Simplified gyral pattern']","['Microcephaly 5, primary, autosomal recessive']","Disease: Microcephaly 5, primary, autosomal recessive  
Reasoning:  
1. **Core Symptom Alignment**: The patient exhibits **primary microcephaly** (congenital small head size), a hallmark of MCPH5 caused by biallelic *ASPM* mutations.  
2. **Neurological Features**: **Simplified gyral pattern** and **lateral ventricle dilatation** reflect reduced cerebral cortex volume and impaired neuronal migration, consistent with ASPM-related brain malformations.  
3. **Developmental Delays**: **Intellectual disability** and **motor delay** correlate with cortical underdevelopment and disrupted neural connectivity.  
4. **Hypertonia**: Likely stems from corticospinal tract dysfunction due to abnormal cortical organization.  
5. **Craniofacial Findings**: **High palate**, **micrognathia**, and **epicanthus** are nonspecific but recurrently observed in syndromic microcephaly disorders, including MCPH5.  
6. **Sleep Disturbance**: May arise from dysregulation of sleep-wake cycles secondary to central nervous system abnormalities.  
7. **Exclusion of Alternatives**: Features align with MCPH5 rather than other microcephaly subtypes (e.g., no severe seizures or limb anomalies seen in MCPH2 or MCPH4). Autosomal recessive inheritance matches the genetic profile."
"['Hyperextensible skin', 'Bruising susceptibility', 'Striae distensae', 'Atrophic scars', 'Joint dislocation', 'Joint hypermobility', 'Pes planus', 'Arthralgia', 'Piezogenic pedal papules']","['Classical Ehlers-Danlos syndrome/Ehlers-danlos syndrome, type I']","Disease: Classical Ehlers-Danlos syndrome/Ehlers-Danlos syndrome, type I  
Reasoning:  
1. **Hyperextensible skin** and **joint hypermobility** are hallmark features of Ehlers-Danlos syndromes (EDS), particularly Classical EDS (cEDS).  
2. **Atrophic scars** (thin, ""cigarette-paper"" scars) and **striae distensae** (stretch marks) are specific to cEDS due to abnormal collagen structure impacting skin integrity.  
3. **Bruising susceptibility** aligns with fragile skin and blood vessel walls caused by collagen defects in cEDS.  
4. **Joint dislocation** and **arthralgia** correlate with connective tissue laxity and chronic joint instability in cEDS.  
5. **Pes planus** (flat feet) and **piezogenic pedal papules** (heel papules under pressure) reflect connective tissue weakness in weight-bearing areas, common in cEDS.  
6. The absence of severe vascular or organ complications rules out other EDS subtypes (e.g., Vascular EDS), while the combination of skin and joint symptoms strongly supports Classical EDS type I."
"['Abnormality of visual evoked potentials', 'Decreased nerve conduction velocity', 'Pes cavus', 'Gait ataxia', 'Limb ataxia', 'Progressive cerebellar ataxia', 'Positive Romberg sign', 'Paresthesia', 'Somatic sensory dysfunction', 'Decreased amplitude of sensory action potentials', 'Sensorimotor neuropathy', 'Distal lower limb muscle weakness', 'Abnormal cranial nerve physiology', 'Cognitive impairment']","['Charcot-Marie-Tooth disease type 1C', 'Charcot-Marie-Tooth disease, demyelinating, type 1C']","Charcot-Marie-Tooth disease type 1C:  
The patient exhibits classic features of a demyelinating hereditary neuropathy, including **decreased nerve conduction velocity** (a hallmark of CMT1 subtypes) and **sensorimotor neuropathy**. **Pes cavus**, **distal lower limb muscle weakness**, and **somatic sensory dysfunction** align with progressive peripheral nerve damage. **Decreased amplitude of sensory action potentials** suggests secondary axonal degeneration, common in advanced demyelinating neuropathies. **Gait ataxia**, **limb ataxia**, and **positive Romberg sign** are likely due to severe proprioceptive loss (sensory ataxia) from sensory neuropathy rather than cerebellar dysfunction. While **cognitive impairment** and **abnormal cranial nerve physiology** are atypical for CMT, they may represent comorbidities or phenotypic variability. **Progressive cerebellar ataxia** could be misattributed to profound sensory deficits. The diagnosis is strongly supported by demyelinating electrophysiology (slow conduction velocities) and structural abnormalities (pes cavus), consistent with CMT1C linked to *LITAF* mutations."
"['Cryptorchidism', 'Chordee', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Low-set ears', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic nerve hypoplasia', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Dysarthria', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Hip dysplasia', 'Intrauterine growth retardation', 'Small for gestational age', 'Premature birth', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Dysphagia', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Duodenal atresia', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Mild neurosensory hearing impairment', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Placental infarction', 'Unilateral microphthalmos', 'Hypoplasia of the pons', 'Delayed myelination', 'Thick vermilion border', 'Anisometropia', 'Abnormal hippocampus morphology', 'Clinodactyly', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
**Reasoning**:  
1. **Neurodevelopmental and CNS anomalies**: Global developmental delay, seizures, hypotonia, dysarthria, spastic tetraparesis, ADHD, and abnormal hippocampus morphology align with core neurodevelopmental dysfunction. Structural brain abnormalities (hypoplasia of the corpus callosum, ventriculomegaly, pontine hypoplasia, cerebral hypomyelination) are hallmark features of NEDBEH.  
2. **Ocular anomalies**: Coloboma, Peters anomaly, optic nerve hypoplasia, and unilateral microphthalmos directly correlate with the ""eye"" component of NEDBEH, particularly given the specificity of Peters anomaly (a rare anterior segment defect).  
3. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return fulfill the ""heart"" criterion, common in NEDBEH.  
4. **Craniofacial dysmorphism**: Microcephaly/macrocephaly (variable expressivity), triangular face, epicanthus, hypertelorism, smooth philtrum, and cleft lip reflect the syndromic facial gestalt seen in neurodevelopmental genetic disorders.  
5. **Multi-system involvement**: Choanal atresia, duodenal atresia, renal cysts, and genitourinary anomalies (cryptorchidism, hypospadias) support a systemic genetic disorder, consistent with NEDBEH’s broad phenotypic spectrum.  
6. **Growth anomalies**: Intrauterine growth restriction (IUGR), small for gestational age, and short stature (contradicts ""tall stature,"" possibly an error) align with prenatal-onset growth issues seen in NEDBEH.  
7. **Supportive features**: Hypotonia, hypertrichosis, and café-au-lait spots, while non-specific, are reported in NEDBEH cases. Delayed myelination and hypoplastic corpus callosum further strengthen the diagnosis.  

**Exclusion Notes**: Overlap with CHARGE syndrome is considered (coloboma, choanal atresia), but the absence of arhinia, semicircular canal defects, and the prominence of brain malformations favor NEDBEH. Peters anomaly and hypomyelination are more characteristic of NEDBEH."
"['Increased circulating ferritin concentration', 'Abnormal circulating copper concentration', 'Increased circulating lactate dehydrogenase concentration', 'Hyperintensity of cerebral white matter on MRI', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration']","['Hemophagocytic lymphohistiocytosis, familial, 2']","Disease: Hemophagocytic lymphohistiocytosis, familial, 2 (FHL2)  
Reasoning:  
1. **Increased ferritin**: A hallmark of HLH due to cytokine storm and macrophage activation.  
2. **Abnormal copper**: Secondary to liver dysfunction (common in HLH) or altered ceruloplasmin synthesis during inflammation.  
3. **Elevated LDH**: Reflects widespread tissue damage and cytolysis, typical in HLH.  
4. **Cerebral white matter hyperintensity**: Indicates CNS involvement, a known feature of advanced HLH.  
5. **Elevated AST/ALT**: Hepatic injury from immune-mediated inflammation or hemophagocytosis in the liver.  
6. **FHL2 specificity**: PRF1 mutations impair perforin function, leading to defective cytotoxic cell activity, triggering uncontrolled immune activation. The triad of cytopenia, fever, and organomegaly (implied by liver/CNS involvement) further supports HLH. Genetic testing for PRF1 would confirm FHL2."
"['Hydrocele testis', 'Narrow mouth', 'Narrow palate', 'Microcephaly', 'Posteriorly rotated ears', 'Low-set ears', 'Prominent nose', 'Strabismus', 'Downslanted palpebral fissures', 'Long eyelashes', 'Thick eyebrow', 'Coloboma', 'Dental crowding', 'Dental malocclusion', 'Abnormal repetitive mannerisms', 'Anxiety', 'Delayed speech and language development', 'Hirsutism', 'Global developmental delay', 'Intellectual disability, moderate', 'Highly arched eyebrow', 'Scoliosis', 'Low hanging columella', 'Broad hallux', 'Talon cusp', 'Broad thumb']",['Rubinstein-Taybi syndrome due to EP300 haploinsufficiency/Rubinstein-Taybi syndrome 2'],"Disease: Rubinstein-Taybi syndrome due to EP300 haploinsufficiency/Rubinstein-Taybi syndrome 2  
Reasoning:  
1. **Broad thumbs/hallux and skeletal anomalies**: The patient exhibits ""Broad hallux"" and ""Broad thumb,"" hallmark features of Rubinstein-Taybi syndrome (RSTS). ""Talon cusp"" and ""Scoliosis"" further support skeletal involvement.  
2. **Craniofacial dysmorphism**: Features like ""Narrow mouth,"" ""Narrow palate,"" ""Prominent nose,"" ""Low hanging columella,"" ""Posteriorly rotated ears,"" ""Low-set ears,"" ""Downslanted palpebral fissures,"" ""Long eyelashes,"" ""Thick eyebrow,"" and ""Highly arched eyebrow"" align with the characteristic facial gestalt of RSTS.  
3. **Ocular abnormalities**: ""Coloboma"" and ""Strabismus"" are recurrent in RSTS, linked to EP300 or CREBBP mutations.  
4. **Dental anomalies**: ""Dental crowding"" and ""Dental malocclusion"" correlate with maxillary hypoplasia and palate abnormalities in RSTS.  
5. **Neurodevelopmental delays**: ""Global developmental delay,"" ""Moderate intellectual disability,"" ""Delayed speech,"" and ""Abnormal repetitive mannerisms"" reflect the syndrome’s cognitive and behavioral profile.  
6. **Ancillary features**: ""Hirsutism"" and ""Hydrocele testis"" are less specific but reported in RSTS. ""Microcephaly"" and ""Anxiety"" further consolidate the clinical overlap.  
7. **EP300-specific subtype**: While CREBBP (RSTS1) and EP300 (RSTS2) mutations cause overlapping phenotypes, EP300-related cases may show milder physical features but similar neurodevelopmental profiles. The combination of typical RSTS traits with the listed symptoms strongly supports this molecular subtype."
"['Mental deterioration', 'Slurred speech', 'Spastic tetraplegia', 'Dyskinesia']","['Parkinson disease 23, autosomal recessive early-onset']","Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Mental deterioration**: Observed in DNAJC6-related PARK23 due to rapid neurodegeneration and early cognitive decline.  
2. **Slurred speech**: Linked to dysarthria from basal ganglia dysfunction and possible pyramidal tract involvement.  
3. **Spastic tetraplegia**: Reflects pyramidal tract damage (spasticity), atypical in classic Parkinson’s but characteristic of PARK23’s broader neurological pathology.  
4. **Dyskinesia**: Arises from basal ganglia dysfunction and may occur earlier in genetic forms, independent of levodopa therapy.  
The combination of parkinsonism, pyramidal signs, cognitive decline, and dyskinesia aligns with PARK23’s phenotype caused by biallelic DNAJC6 mutations."
"['Syncope', 'Prolonged QT interval', 'Ventricular fibrillation', 'Atrial arrhythmia', 'Cardiac arrest', 'Ventricular arrhythmia', 'Arrhythmia', 'Abnormal QT interval']","['Ventricular tachycardia, catecholaminergic polymorphic, 3']","Disease: Ventricular tachycardia, catecholaminergic polymorphic, 3 (CPVT3)  
Reasoning:  
1. **Ventricular arrhythmia/fibrillation and cardiac arrest**: Core features of CPVT3, caused by adrenergically triggered calcium dysregulation (CALM1 mutation), leading to polymorphic/bidirectional ventricular tachycardia.  
2. **Syncope**: Typically occurs during physical/emotional stress due to arrhythmia-induced cerebral hypoperfusion.  
3. **Atrial arrhythmia**: CALM1 mutations may disrupt atrial calcium handling, explaining atrial involvement.  
4. **Abnormal/prolonged QT interval**: Unlike classic CPVT (normal QT), CPVT3 linked to CALM1 can concurrently impair potassium channels (e.g., delayed rectifiers), causing QT prolongation as a secondary phenomenon.  
5. **Exclusion of pure Long QT syndrome**: Adrenergic triggers and ventricular arrhythmia morphology align more with CPVT3 than isolated LQTS, despite QT abnormalities.  

Genetic testing for CALM1 mutations would confirm CPVT3, distinguishing it from other CPVT subtypes or overlapping channelopathies."
"['Delayed speech and language development', 'Intellectual disability, mild', 'Global developmental delay', 'Brisk reflexes', 'Talipes equinovarus', 'Hypoplasia of the corpus callosum', 'Progressive spasticity', 'Unsteady gait', 'Frontal cortical atrophy', 'Axial hypotonia', 'Ankle clonus', 'Abnormal optic disc morphology', 'Hyperintensity of cerebral white matter on MRI']","['Autosomal recessive spastic paraplegia type 45/Spastic paraplegia 45, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 45 (SPG45)  
Reasoning:  
1. **Neurodevelopmental and cognitive features**: Delayed speech, mild intellectual disability, and global developmental delay align with early-onset genetic neurological disorders, consistent with complicated hereditary spastic paraplegia (HSP).  
2. **Upper motor neuron signs**: Brisk reflexes, progressive spasticity, ankle clonus, and unsteady gait indicate corticospinal tract dysfunction, hallmark features of HSP.  
3. **Structural brain abnormalities**: Hypoplasia of the corpus callosum, frontal cortical atrophy, and cerebral white matter hyperintensity on MRI are characteristic of SPG45, which often involves brain malformations and leukoencephalopathy.  
4. **Axial hypotonia with peripheral spasticity**: A paradoxical combination seen in HSPs, where truncal weakness coexists with limb spasticity.  
5. **Talipes equinovarus**: Congenital foot deformity occasionally associated with neurogenetic disorders like SPG45 due to prenatal neuromuscular dysfunction.  
6. **Progression**: Progressive spasticity and gait deterioration match the natural history of SPG45, which involves neurodegeneration.  
7. **Optic disc abnormality**: May reflect subtle optic nerve involvement, reported in some HSP subtypes.  
8. **Exclusion of mimics**: Features distinguish SPG45 from leukodystrophies (no metabolic crises) or mitochondrial disorders (lack of multisystemic involvement). Genetic confirmation of *NT5C2* mutations would confirm SPG45."
"['Recurrent urinary tract infections', 'Neck muscle weakness', 'Edema', 'Skin rash', 'Global developmental delay', 'Motor delay', 'Areflexia', 'Muscle weakness', 'Decreased fetal movement', 'Arthralgia', 'Microscopic hematuria', 'Abnormal EKG', 'EMG: myopathic abnormalities', 'Centrally nucleated skeletal muscle fibers', 'Shoulder girdle muscle atrophy', 'Distal lower limb amyotrophy', 'Macroscopic hematuria', 'Abnormal cranial nerve physiology', 'obsolete Toe walking', 'Abnormal nerve conduction velocity', 'obsolete Hyperkeratosis pilaris']",['Bethlem myopathy/Bethlem myopathy 1'],"Disease: Bethlem myopathy/Bethlem myopathy 1  
Reasoning:  
1. **Muscle Weakness and Atrophy**: Neck muscle weakness, shoulder girdle atrophy, and distal lower limb amyotrophy align with Bethlem myopathy’s progressive proximal-to-distal muscle involvement.  
2. **Congenital Onset**: Decreased fetal movement and global/motor delays suggest early-onset muscle hypotonia, consistent with congenital myopathies like Bethlem.  
3. **Myopathic EMG and Muscle Biopsy**: EMG showing myopathic abnormalities and centrally nucleated skeletal muscle fibers indicate a congenital myopathy with regenerative changes, characteristic of collagen VI disorders.  
4. **Skin Involvement**: Skin rash (historically linked to hyperkeratosis pilaris) correlates with collagen VI defects affecting skin integrity.  
5. **Joint and Tendon Features**: Arthralgia and toe walking (Achilles contractures) reflect collagen VI’s role in connective tissue, leading to contractures.  
6. **Collagen VI Pathology**: Abnormal cranial nerve physiology and possible cardiac involvement (abnormal EKG) may stem from collagen VI’s extracellular matrix role, though typically less severe in Bethlem vs. Ullrich CMD.  
7. **Exclusion of Neuropathy**: Areflexia and abnormal nerve conduction velocity are atypical but may coexist due to secondary effects; primary myopathic features dominate.  
8. **Hematuria**: Unrelated to Bethlem but may indicate a separate renal issue, requiring further evaluation.  

The constellation of muscle, skin, and joint findings strongly supports a collagen VI-related disorder, specifically Bethlem myopathy 1 (COL6A1/A2/A3 mutations)."
"['Brachycephaly', 'Strabismus', 'Proptosis', 'Shallow orbits', 'Precocious puberty', 'Single transverse palmar crease', 'Seizure', 'Global developmental delay', 'Overlapping toe', 'Bilateral tonic-clonic seizure', 'EEG abnormality', 'Inverted nipples', 'Deep palmar crease', 'Cardiorespiratory arrest', 'Severe muscular hypotonia', 'Infantile muscular hypotonia']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Severe Muscular Hypotonia (Infantile)**: A hallmark of TBCK syndrome, present from birth, aligning with the patient's severe and infantile hypotonia.  
2. **Global Developmental Delay**: Consistent with TBCK’s core phenotype of intellectual disability and psychomotor retardation.  
3. **Seizures/EEG Abnormalities**: Recurrent seizures (tonic-clonic) and abnormal EEG patterns are common due to neuronal dysfunction in TBCK-related disorders.  
4. **Characteristic Facies**:  
   - **Brachycephaly/Shallow Orbits**: Broad, short skull and structural orbital anomalies are typical dysmorphic features.  
   - **Proptosis/Strabismus**: Eye abnormalities linked to shallow orbits and craniofacial dysmorphism.  
5. **Limb Anomalies**:  
   - **Single Transverse Palmar Crease/Deep Palmar Crease**: Frequent in TBCK syndrome as part of connective tissue or developmental hand findings.  
   - **Overlapping Toe**: Minor skeletal anomalies are reported in this syndrome.  
6. **Inverted Nipples**: A noted dysmorphic feature in TBCK cases, supporting the diagnosis.  
7. **Cardiorespiratory Arrest**: Severe hypotonia and neurological instability in TBCK can lead to life-threatening events, especially during infancy.  
8. **Precocious Puberty**: While less common, endocrine dysregulation has been observed in some TBCK patients, potentially explaining this feature.  

The constellation of severe hypotonia, developmental delay, seizures, craniofacial/limb dysmorphism, and supporting features strongly aligns with TBCK syndrome, a disorder caused by biallelic TBCK mutations affecting mTOR signaling and neuronal survival."
"['Hyperreflexia', 'Babinski sign', 'Lower limb hypertonia', 'obsolete Toe walking']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Upper Motor Neuron Dysfunction**: Symptoms like hyperreflexia, Babinski sign, and lower limb hypertonia indicate upper motor neuron involvement, consistent with hereditary spastic paraplegias (HSPs).  
2. **Spastic Paraplegia Hallmarks**: Lower limb hypertonia and toe walking align with progressive spasticity and gait abnormalities characteristic of HSPs.  
3. **Genetic Inheritance**: Autosomal recessive SPG76 is linked to biallelic *CAPN1* mutations, which disrupt axonal integrity, explaining the pyramidal tract signs (e.g., Babinski reflex).  
4. **Exclusion of Mimics**: The absence of sensory deficits, cognitive decline, or cerebellar signs supports a ""pure"" HSP diagnosis, narrowing it to SPG76 over complex HSP subtypes or acquired causes (e.g., spinal cord injury).  
5. **Toe Walking Context**: Persistent toe walking in older children/adults, combined with spasticity, is a compensatory adaptation to calf muscle stiffness, reinforcing HSP as the etiology."
"['Femoral bowing', 'Hypoplasia of the radius', 'Short tibia', 'Short humerus']","['Osteogenesis imperfecta, type VIII']","Disease: Osteogenesis imperfecta, type VIII  
Reasoning:  
1. **Femoral bowing**: A hallmark of severe osteogenesis imperfecta (OI) due to defective collagen leading to bone fragility and deformities. Type VIII OI is characterized by severe skeletal underdevelopment.  
2. **Hypoplasia of the radius**: Seen in recessive OI types (including type VIII) due to impaired bone growth and mineralization, resulting in underdeveloped or absent bones.  
3. **Short tibia and humerus**: Reflects rhizomelic (proximal) and mesomelic (middle-limb) shortening, consistent with type VIII OI’s severe growth deficiency and skeletal dysplasia.  
4. **Genetic correlation**: OI type VIII is linked to mutations in *P3H1* (LEPRE1), disrupting collagen prolyl hydroxylation, leading to extreme bone fragility and growth retardation. This matches the patient’s constellation of skeletal anomalies.  
5. **Exclusion of other OI types**: Type II/III OI typically involves fractures and blue sclera (not mentioned here), while type VIII presents with profound skeletal hypoplasia without these features."
"['Microcephaly', 'Exotropia', 'Intellectual disability', 'Seizure', 'Dysarthria', 'Hypoglycemia', 'Hyperammonemia', 'Myopathic facies', 'Apnea', 'Febrile seizure (within the age range of 3 months to 6 years)', 'Developmental regression', 'Myoglobinuria', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Babinski sign', 'Hyperactive deep tendon reflexes', 'obsolete Loss of ability to walk', 'Focal-onset seizure', 'Arrhythmia', 'Arrhythmia']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
- **Metabolic disturbances**: Hypoglycemia and hyperammonemia indicate systemic metabolic dysfunction, consistent with recurrent crises.  
- **Neuromuscular involvement**: Myopathic facies, dysarthria, elevated creatine kinase, myoglobinuria, and rhabdomyolysis suggest severe muscle pathology.  
- **Cardiac arrhythmias**: Repeated mention of arrhythmias highlights cardiac involvement, a hallmark of this syndrome.  
- **Neurological regression**: Developmental regression, seizures (focal-onset, febrile), intellectual disability, Babinski sign, hyperactive reflexes, and loss of ambitation point to progressive neurodegeneration.  
- **Encephalopathic features**: Apnea, microcephaly, and exotropia align with central nervous system deterioration.  
- **Recurrent crises**: The cyclical nature of rhabdomyolysis, metabolic derangements, and neurological decline matches the syndrome’s phenotype of episodic metabolic encephalomyopathy.  
- **Exclusion of mimics**: The combination of hyperammonemia, hypoglycemia, arrhythmias, and rhabdomyolysis distinguishes this from isolated mitochondrial disorders or fatty acid oxidation defects."
"['Progressive microcephaly', 'Pectus carinatum', 'Hypertrichosis', 'Seizure', 'Flexion contracture', 'Failure to thrive', 'Rocker bottom foot', 'Kyphosis', 'Babinski sign', 'Joint hyperflexibility', 'Abnormality of somatosensory evoked potentials', 'Palmoplantar hyperhidrosis', 'Increased muscle glycogen content', 'Abnormal activity of mitochondrial respiratory chain', 'Brain atrophy', 'Delayed myelination', 'Moderate hearing impairment']","['PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies']","Disease: PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies  
Reasoning:  
1. **Progressive microcephaly**: A hallmark of PLAA-associated disorder, aligning with the disease’s defining feature of progressive reduction in head circumference due to impaired brain growth.  
2. **Brain atrophy/Delayed myelination**: Consistent with brain anomalies described in the disorder, reflecting neurodegeneration and disrupted white matter development.  
3. **Seizures**: Commonly reported in PLAA-related neurodevelopmental dysfunction due to cortical hyperexcitability.  
4. **Babinski sign/Flexion contractures**: Indicate upper motor neuron involvement and spasticity, core features of the disorder.  
5. **Failure to thrive**: Linked to global developmental delay and metabolic dysregulation seen in PLAA mutations.  
6. **Rocker bottom foot/Kyphosis/Pectus carinatum**: Suggest skeletal involvement, which may arise from connective tissue or neuromuscular abnormalities secondary to PLAA dysfunction.  
7. **Abnormality of somatosensory evoked potentials**: Correlates with delayed myelination and disrupted sensory pathways.  
8. **Increased muscle glycogen content/Abnormal mitochondrial activity**: PLAA’s role in protein homeostasis may indirectly impair glycogen metabolism and mitochondrial function.  
9. **Hypertrichosis/Palmoplantar hyperhidrosis**: Rare but reported ectodermal features in neurogenetic disorders, possibly due to autonomic dysregulation.  
10. **Joint hyperflexibility**: Contrasts with spasticity but may reflect heterogeneous connective tissue effects.  
11. **Moderate hearing impairment**: Could stem from central auditory pathway deficits or neurodegeneration.  

The constellation of progressive microcephaly, spasticity, brain anomalies, and metabolic disturbances strongly supports PLAA-associated disorder, with other symptoms representing secondary multisystemic involvement."
"['Hearing impairment', 'Intellectual disability', 'Seizure', 'Global developmental delay', 'Bicoronal synostosis']",['Muenke syndrome/Muenke syndrome'],"Disease: Muenke syndrome  
Reasoning:  
1. **Bicoronal synostosis**: A hallmark feature of Muenke syndrome, caused by the FGFR3 p.Pro250Arg mutation, which leads to premature fusion of both coronal sutures.  
2. **Hearing impairment**: Common in Muenke syndrome, often conductive or sensorineural hearing loss.  
3. **Intellectual disability/Global developmental delay**: Present in a subset of patients, though severity varies.  
4. **Seizure**: Rare but reported in some cases, possibly due to structural brain anomalies or secondary complications.  
5. **Exclusion of other craniosynostosis syndromes**: Features like severe midface hypoplasia (Pfeiffer/Crouzon) or limb anomalies (Apert) are absent, supporting Muenke syndrome. Genetic testing for FGFR3 mutation would confirm the diagnosis."
"['Tall stature', 'Entropion', 'Cutis laxa', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Abnormal heart morphology', 'Hypertrophic cardiomyopathy', 'Abnormal facial shape', 'Bilateral tonic-clonic seizure', 'Ventriculomegaly', 'Kyphoscoliosis', 'Aortic aneurysm']","['Cutis laxa, autosomal recessive, type IID']","Disease: Cutis laxa, autosomal recessive, type IID  
Reasoning: The patient's symptoms align with ARCL2D caused by PYCR1 mutations. Key indicators include cutis laxa (characteristic loose skin), generalized hypotonia, flexion contractures, hip dysplasia, and kyphoscoliosis (musculoskeletal involvement). Neurological features (bilateral tonic-clonic seizures, ventriculomegaly) and cardiovascular abnormalities (hypertrophic cardiomyopathy, aortic aneurysm) support systemic connective tissue dysfunction. Entropion and abnormal facial shape correlate with craniofacial manifestations of PYCR1 deficiency. Disproportionate tall stature, though atypical in some cutis laxa subtypes, is compatible with ARCL2D's variable phenotypic spectrum. The combination of skin, skeletal, neurological, and cardiac findings distinguishes this from other ARCL subtypes or Marfan-like syndromes."
"['Ventricular fibrillation', 'Prolonged QTc interval', 'Myocarditis', 'Polymorphic ventricular tachycardia']",['Long QT syndrome 14'],"Disease: Long QT syndrome 14  
Reasoning:  
1. **Prolonged QTc interval**: A hallmark of Long QT syndrome (LQTS), indicating delayed ventricular repolarization.  
2. **Polymorphic ventricular tachycardia (e.g., torsades de pointes)**: Characteristic of LQTS, particularly in calmodulin-related subtypes like LQT14 due to severe electrical instability.  
3. **Ventricular fibrillation**: A life-threatening arrhythmia often triggered by untreated polymorphic VT, consistent with high-risk LQTS subtypes.  
4. **Myocarditis**: Overlaps with CALM1/2/3-associated LQTS (types 14-16), as calmodulin mutations may predispose to inflammation or mimic myocarditis via calcium signaling dysregulation.  
5. **Genetic basis**: LQT14 is linked to CALM1 mutations, disrupting calmodulin function critical for cardiac ion channels (e.g., L-type calcium channels), aligning with the arrhythmic and inflammatory phenotypes observed."
"['Seizure', 'Flexion contracture', 'Fasciculations', 'Waddling gait', 'Scoliosis', 'Exertional dyspnea', 'Skeletal muscle atrophy', 'Progressive muscle weakness', 'Axial muscle weakness', 'Gowers sign', 'Fatigable weakness', 'Congenital bilateral ptosis', 'Distal lower limb amyotrophy', 'Sleep apnea', 'Tongue atrophy', 'Upgaze palsy', 'Anti-acetylcholine receptor antibody positivity']","['Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency']","Disease: Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency  
Reasoning:  
1. **Fatigable weakness** and **anti-acetylcholine receptor (AChR) antibody positivity**: Core features of neuromuscular junction dysfunction. While congenital myasthenic syndromes (CMS) are typically genetic (e.g., CHRNE mutations causing AChR deficiency), the presence of anti-AChR antibodies here may indicate a rare overlap or secondary autoimmunity, though CMS itself is not autoimmune.  
2. **Congenital bilateral ptosis** and **upgaze palsy**: Indicate lifelong ocular muscle weakness, aligning with CMS’s early-onset neuromuscular transmission defects.  
3. **Gowers sign**, **waddling gait**, and **axial/progressive muscle weakness**: Reflect proximal and truncal muscle involvement, consistent with AChR deficiency impairing synaptic transmission in skeletal muscles.  
4. **Scoliosis** and **flexion contractures**: Secondary to chronic axial and limb muscle weakness, leading to postural deformities.  
5. **Exertional dyspnea** and **sleep apnea**: Result from respiratory muscle fatigue and bulbar weakness (evidenced by **tongue atrophy**), common in severe CMS.  
6. **Distal amyotrophy** and **skeletal muscle atrophy**: Chronic denervation and disuse due to persistent neuromuscular signaling failure.  
7. **Fasciculations**: May arise from compensatory neuronal hyperexcitability or secondary neuropathy.  
8. **Seizures**: Atypical for CMS but could occur due to hypoxia from respiratory insufficiency or comorbid conditions.  

Though anti-AChR antibodies are classically linked to autoimmune myasthenia gravis, this diagnosis prioritizes the genetic AChR deficiency (CMS type 9) given congenital onset, structural myopathy signs, and systemic progression. Antibody positivity may reflect an atypical immune response to reduced receptor availability."
"['Wide mouth', 'Hypertelorism', 'Low-set ears', 'Cutis marmorata', 'Aplasia cutis congenita', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Decreased fetal movement', 'Frontal bossing', 'Hip dislocation', 'Tricuspid regurgitation', 'Depressed nasal bridge', 'Wide intermamillary distance', 'Broad thumb', 'Epileptic encephalopathy']","['ALG9-CDG/Congenital disorder of glycosylation, type Il']","Disease: ALG9-CDG/Congenital disorder of glycosylation, type Il  
Reasoning:  
1. **Neurological involvement**: Symptoms like *seizures*, *hypotonia*, *global developmental delay*, and *epileptic encephalopathy* align with the severe neurological deficits typical of ALG9-CDG, a disorder disrupting glycosylation critical for brain function.  
2. **Dysmorphic features**: *Hypertelorism*, *low-set ears*, *frontal bossing*, *depressed nasal bridge*, *wide mouth*, and *wide intermamillary distance* are consistent with the craniofacial abnormalities reported in ALG9-CDG.  
3. **Cutaneous manifestations**: *Cutis marmorata* (vascular patterning) and *aplasia cutis congenita* (congenital absence of skin) are hallmark signs strongly associated with ALG9-CDG, distinguishing it from other CDG subtypes.  
4. **Musculoskeletal and cardiac anomalies**: *Hip dislocation* reflects connective tissue/ligamentous laxity, while *tricuspid regurgitation* suggests structural cardiac involvement, both reported in ALG9-CDG due to impaired glycoprotein synthesis.  
5. **Prenatal history**: *Decreased fetal movement* correlates with congenital hypotonia, a common prenatal feature of glycosylation disorders.  
6. **Specificity of findings**: The combination of *aplasia cutis congenita* with neurodevelopmental and multisystemic involvement is pathognomonic for ALG9-CDG, as this feature is rare in other CDG types (e.g., PMM2-CDG lacks skin aplasia)."
"['Hydrocephalus', 'Ventriculomegaly', 'Semilobar holoprosencephaly']",['Holoprosencephaly 5'],"Disease: Holoprosencephaly 5 (HPE5, OMIM 609637)  
Reasoning:  
1. **Semilobar holoprosencephaly** is a key diagnostic feature of holoprosencephaly (HPE), a spectrum disorder caused by failed forebrain division.  
2. **Hydrocephalus** and **ventriculomegaly** are common secondary findings in HPE due to impaired cerebrospinal fluid dynamics.  
3. HPE5 is specifically linked to **heterozygous pathogenic variants in the ZIC2 gene**, which regulates early forebrain patterning.  
4. ZIC2-associated HPE often presents with semilobar HPE and characteristic facial features (e.g., hypotelorism, midline defects), though facial dysmorphism may not always be severe.  
5. The triad of symptoms aligns with ZIC2 dysfunction, distinguishing HPE5 from other HPE subtypes (e.g., SHH, SIX3, or TGIF1-related HPE)."
"['Strabismus', 'Intellectual disability', 'Encephalopathy', 'Scoliosis', 'CNS hypomyelination']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **CNS hypomyelination**: A hallmark feature of hypomyelinating leukodystrophies, directly linked to NKX6-2 mutations, which disrupt oligodendrocyte function and myelination.  
2. **Encephalopathy**: Common in leukodystrophies due to widespread white matter dysfunction and neuroinflammation.  
3. **Intellectual disability**: Reflects progressive neurological deterioration from impaired myelination and synaptic connectivity.  
4. **Strabismus**: Associated with brainstem/cranial nerve involvement, often seen in leukodystrophies affecting motor coordination pathways.  
5. **Scoliosis**: Secondary to spasticity and axial hypotonia from corticospinal tract degeneration, a feature of spastic ataxia in this disorder.  
6. **Autosomal recessive inheritance**: Matches NKX6-2-related disease etiology, requiring biallelic pathogenic variants.  

The combination of hypomyelination, neurodevelopmental regression, and motor deficits aligns precisely with NKX6-2 dysfunction, distinguishing it from other leukodystrophies (e.g., Pelizaeus-Merzbacher disease) by genetic and phenotypic specificity."
"['Platyspondyly', 'Waddling gait', 'Flared metaphysis', 'Wide pubic symphysis', 'Beaking of vertebral bodies', 'Hypoplasia of the femoral head', 'Short finger', 'Limb undergrowth', 'Small hand']",['Pseudoachondroplasia/Pseudoachondroplasia'],"Disease: Pseudoachondroplasia  
Reasoning:  
1. **Platyspondyly and Beaking of Vertebral Bodies**: Hallmark features of pseudoachondroplasia, caused by defective growth plate cartilage leading to flattened vertebrae with anterior tonguing (""beaking"").  
2. **Waddling Gait**: Results from hip dysplasia (e.g., hypoplastic femoral heads) and joint instability, common in pseudoachondroplasia.  
3. **Flared Metaphysis**: Characteristic metaphyseal widening due to disorganized endochondral ossification.  
4. **Wide Pubic Symphysis**: Reflects pelvic dysplasia, a frequent radiographic finding in skeletal dysplasias like pseudoachondroplasia.  
5. **Hypoplasia of the Femoral Head**: Directly linked to epiphyseal involvement in pseudoachondroplasia, contributing to hip deformity and gait abnormalities.  
6. **Short Fingers, Small Hands, and Limb Undergrowth**: Consistent with disproportionate short stature and brachydactyly caused by defective COMP protein, which disrupts cartilage matrix organization.  
7. **Exclusion of Alternatives**: Features overlap with achondroplasia but lack craniofacial involvement, and Morquio syndrome is excluded by absence of metabolic/lysosomal storage signs. Genetic testing for **COMP mutations** would confirm the diagnosis."
"['Mental deterioration', 'Pes cavus', 'Lactic acidosis', 'Elevated circulating creatinine concentration', 'Myalgia', 'Thenar muscle atrophy', 'Muscle spasm', 'Exercise intolerance', 'Percussion-induced rapid rolling muscle contractions', 'Involuntary movements', 'Intrinsic hand muscle atrophy', 'Distal upper limb muscle weakness', 'Calf muscle hypertrophy', 'Hand muscle atrophy', 'Fatigue', 'Finger flexor weakness']","['Distal myopathy, Tateyama type/Myopathy, distal, Tateyama type']","Disease: Distal myopathy, Tateyama type  
Reasoning:  
1. **Distal muscle weakness and atrophy**: Symptoms like intrinsic hand muscle atrophy, thenar atrophy, hand muscle atrophy, and finger flexor weakness align with distal myopathies, which primarily affect distal muscles. Tateyama type specifically targets distal upper limbs.  
2. **Calf muscle hypertrophy**: A recognized feature in some distal myopathies, including Tateyama type, often compensating for proximal weakness or reflecting fibrofatty replacement.  
3. **Percussion-induced rapid rolling contractions**: Suggests hyperirritable muscle membranes, a rare but reported finding in hereditary myopathies, including certain distal subtypes.  
4. **Exercise intolerance and lactic acidosis**: Indicates impaired mitochondrial energy production or glycolytic pathway dysfunction, common in metabolic myopathies. Tateyama type may involve secondary metabolic disturbances.  
5. **Mental deterioration**: Uncommon in classic distal myopathies, but chronic metabolic stress (e.g., persistent lactic acidosis) or rare CNS involvement in genetic variants could explain this.  
6. **Pes cavus**: Likely secondary to long-standing muscle imbalance and atrophy in distal limbs.  
7. **Elevated creatinine**: Reflects muscle breakdown (myopathy-related rhabdomyolysis) rather than primary renal dysfunction.  
8. **Involuntary movements and myalgia**: May arise from neuromuscular irritability or compensatory mechanisms in degenerating muscles.  

The combination of distal-predominant weakness, metabolic derangements, and unique features (e.g., calf hypertrophy, percussion-induced contractions) strongly supports Tateyama type, a rare hereditary distal myopathy linked to specific genetic or metabolic dysfunction."
"['Retrognathia', 'Hypomimic face', 'Low-set ears', 'Dysarthria', 'Gait disturbance', 'Hyperreflexia', 'Rigidity', 'Spastic gait', 'Bradykinesia', 'Short stature', 'Upgaze palsy', 'Dyskinesia']",['Kufor-Rakeb syndrome/Kufor-Rakeb syndrome'],"Disease: Kufor-Rakeb syndrome  
Reasoning:  
1. **Parkinsonian features** (rigidity, bradykinesia, hypomimic face, dyskinesia): Aligns with juvenile-onset Parkinsonism characteristic of Kufor-Rakeb syndrome, caused by ATP13A2 mutations.  
2. **Pyramidal signs** (hyperreflexia, spastic gait, gait disturbance): Reflects upper motor neuron involvement, consistent with spasticity seen in this syndrome.  
3. **Upgaze palsy**: A hallmark of supranuclear gaze abnormalities, a key diagnostic feature of Kufor-Rakeb syndrome.  
4. **Dysmorphic features** (retrognathia, low-set ears, short stature): May indicate a systemic genetic disorder; while not exclusive to Kufor-Rakeb, they support a syndromic diagnosis.  
5. **Dysarthria**: Common in neurodegenerative disorders with both pyramidal and extrapyramidal involvement.  
6. **Exclusion of mimics**: The combination of Parkinsonism, spasticity, and supranuclear gaze palsy distinguishes it from isolated juvenile Parkinson’s disease or other lysosomal storage disorders (e.g., Niemann-Pick type C lacks pyramidal signs here).  

Final diagnosis is strongly supported by the triad of early-onset Parkinsonism, spasticity, and vertical gaze palsy."
"['Broad metacarpals', 'Intellectual disability', 'Short toe', 'Fibular hypoplasia', 'Short stature', 'Short tibia', 'Broad phalanx', 'Short finger', 'Short metacarpal', 'Broad hallux']","['Acromesomelic dysplasia, Maroteaux type/Acromesomelic dysplasia, Maroteaux type']","Disease: Acromesomelic dysplasia, Maroteaux type  
Reasoning:  
1. **Skeletal Abnormalities**: The patient exhibits hallmark features of acromesomelic dysplasia, including **broad metacarpals**, **broad phalanx**, **short metacarpals**, and **short fingers/toes**, which reflect disproportionate shortening and broadening of the distal and middle limb segments (acromesomelia).  
2. **Lower Limb Involvement**: **Fibular hypoplasia**, **short tibia**, and **short stature** align with the characteristic limb underdevelopment and rhizomelic (proximal) or mesomelic (middle) shortening seen in this disorder.  
3. **Broad Hallux and Short Toe**: These are typical of abnormal growth in the hands/feet, consistent with NPR2 gene mutations affecting bone morphogenesis.  
4. **Intellectual Disability**: While uncommon in Maroteaux type, mild cognitive delays may rarely co-occur, though this symptom warrants further evaluation to exclude comorbidities.  
5. **Exclusion of Alternatives**: The specific pattern of skeletal defects (absence of severe spinal/rib involvement) differentiates it from other skeletal dysplasias (e.g., achondroplasia).  
The combination of acromesomelic limb shortening, broad bones, and autosomal recessive inheritance pattern strongly supports the diagnosis."
"['Cataract', 'Ataxia', 'Global developmental delay', 'Cerebellar atrophy', 'Coronal cleft vertebrae', 'Absent ossification of capital femoral epiphysis', 'Crumpled ear', 'Flat face']",['CODAS syndrome/CODAS syndrome'],"Disease: CODAS syndrome  
Reasoning:  
1. **Cataract**: A common ocular manifestation in CODAS syndrome.  
2. **Ataxia**: Linked to cerebellar atrophy, a neurological feature of the syndrome.  
3. **Global developmental delay**: Reflects central nervous system involvement.  
4. **Cerebellar atrophy**: Directly correlates with neurological symptoms like ataxia.  
5. **Coronal cleft vertebrae**: A skeletal anomaly characteristic of CODAS.  
6. **Absent ossification of capital femoral epiphysis**: Indicates hip dysplasia, part of the skeletal spectrum.  
7. **Crumpled ear** and **flat face**: Distinctive craniofacial/dysmorphic features (auricular and facial abnormalities).  
The combination of cerebro-ocular, dental, auricular, and skeletal anomalies aligns definitively with CODAS syndrome, a rare autosomal recessive disorder caused by *LONP1* mutations."
"['Proteinuria', 'Anemia', 'Vitamin B12 deficiency']",['Imerslund-Gräsbeck syndrome/Megaloblastic anemia 1'],"Disease: Imerslund-Gräsbeck syndrome/Megaloblastic anemia 1  
Reasoning:  
1. **Vitamin B12 deficiency**: Imerslund-Gräsbeck syndrome (IGS) is an autosomal recessive disorder caused by mutations in *CUBN* or *AMN* genes, impairing intestinal absorption of vitamin B12 via defective cubilin-amnionless receptors in the ileum. This explains the deficiency despite normal dietary intake.  
2. **Megaloblastic anemia**: B12 deficiency disrupts DNA synthesis in erythroblasts, leading to megaloblastic anemia (large, immature red blood cells), consistent with the patient's anemia.  
3. **Proteinuria**: The cubilin receptor is also critical for protein reabsorption in the renal proximal tubules. Mutations in *CUBN/AMN* cause selective proteinuria (typically low-molecular-weight proteins like albumin), distinguishing IGS from other causes of B12 deficiency.  
4. **Exclusion of alternatives**: Pernicious anemia (autoimmune) lacks proteinuria, and dietary B12 deficiency is unlikely without risk factors. The triad of B12 deficiency, anemia, and proteinuria strongly supports IGS."
"['Hepatosplenomegaly', 'Lymphadenopathy', 'Abnormal immunoglobulin level', 'Reduced granulocyte CD18 level']","['Leukocyte adhesion deficiency, type III', 'Leukocyte adhesion deficiency type III']","Disease: Leukocyte adhesion deficiency type III  
Reasoning:  
1. **Hepatosplenomegaly and Lymphadenopathy**: These suggest systemic immune dysregulation or chronic infections, which align with LAD III's broader integrin dysfunction affecting leukocyte migration and lymphoid organ involvement.  
2. **Abnormal Immunoglobulin Levels**: Indicates B-cell dysfunction or dysregulated antibody production, consistent with LAD III's impact on integrin-mediated immune cell interactions beyond neutrophils (e.g., T/B-cell defects).  
3. **Reduced Granulocyte CD18**: While classically linked to LAD I, LAD III involves defective integrin *activation* (via FERMT3 mutations) rather than absent CD18. Reduced surface CD18 here may reflect impaired integrin stabilization or secondary downregulation due to chronic inflammation.  
4. **Differentiation from LAD I**: LAD I typically presents with severe bacterial infections and leukocytosis without prominent lymphoid enlargement. LAD III’s platelet dysfunction (not explicitly listed) and immune dysregulation better explain hepatosplenomegaly/lymphadenopathy in this context.  

Disease: Leukocyte adhesion deficiency, type III  
Reasoning:  
- Reiterates the above, emphasizing the genetic basis (FERMT3 mutation) and multifactorial integrin activation defects affecting granulocytes, lymphocytes, and platelets, leading to the observed clinical and laboratory phenotype."
"['Glaucoma', 'Myopia', 'Hypotonia', 'Joint hypermobility', 'Recurrent fractures', 'Proportionate short stature', 'Retinal dysplasia', 'Knee pain', 'Ankle pain']","['Stickler syndrome type 2/Stickler syndrome, type II']","Disease: Stickler syndrome type 2  
Reasoning:  
1. **Ocular features**: Glaucoma, high myopia, and retinal dysplasia are hallmark signs of Stickler syndrome, particularly type 2, which is linked to mutations in the *COL11A1* gene affecting collagen XI. Retinal dysplasia is a key distinguishing feature of type 2.  
2. **Musculoskeletal involvement**: Joint hypermobility, hypotonia, and chronic joint pain (knee/ankle) align with connective tissue abnormalities caused by collagen defects.  
3. **Skeletal anomalies**: Recurrent fractures and proportionate short stature suggest underlying bone fragility, which, while less common in Stickler syndrome, can occur due to collagen-related structural weaknesses.  
4. **Exclusion of other disorders**: The absence of cleft palate (common in type 1 Stickler) and the presence of retinal dysplasia favor type 2. Ehlers-Danlos or osteogenesis imperfecta are less likely due to the prominent ocular findings.  
5. **Collagen pathway correlation**: Type 2 Stickler’s association with *COL11A1* explains the combination of ocular, auditory (if present), and joint abnormalities, though hearing loss may not always be reported initially."
"['Nephrolithiasis', 'Secondary amenorrhea', 'Headache', 'Duodenal ulcer', 'Pituitary adenoma', 'Elevated circulating parathyroid hormone level', 'Back pain', 'Primary hyperparathyroidism', 'Adrenocorticotropic hormone deficiency', 'Macroscopic hematuria', 'Thymoma', 'Carcinoid tumor', 'Neuroendocrine neoplasm', 'Galactorrhea', 'Hypergastrinemia']",['Multiple endocrine neoplasia type 1/Multiple endocrine neoplasia 1'],"Multiple endocrine neoplasia type 1 (MEN1):  
1. **Primary hyperparathyroidism and elevated parathyroid hormone**: MEN1 classically presents with parathyroid hyperplasia/adenomas, leading to hypercalcemia and complications like nephrolithiasis (kidney stones) and back pain.  
2. **Pituitary adenoma**: MEN1-associated pituitary tumors (e.g., prolactinoma) explain galactorrhea (excess prolactin) and secondary amenorrhea (disrupted menstrual cycle). ACTH deficiency suggests partial pituitary dysfunction.  
3. **Neuroendocrine neoplasms**: Duodenal ulcer with hypergastrinemia indicates a gastrinoma (pancreatic/duodenal neuroendocrine tumor), a hallmark of MEN1. Thymoma and carcinoid tumor are additional neuroendocrine tumors linked to MEN1.  
4. **Multi-gland involvement**: The coexistence of parathyroid, pituitary, and gastroenteropancreatic neuroendocrine tumors fulfills the diagnostic criteria for MEN1. Genetic testing for *MEN1* gene mutations would confirm the diagnosis."
"['Renal insufficiency', 'Renal cyst', 'Microcephaly', 'Cyanosis', 'Partial agenesis of the corpus callosum', 'Death in infancy', 'Ventricular septal defect', 'Truncus arteriosus', 'Abnormal cardiac septum morphology', 'Overlapping toe', 'Pulmonary artery atresia', 'Persistent left superior vena cava', 'Generalized edema', 'Polydactyly', 'Partial anomalous pulmonary venous return', 'Interrupted aortic arch', 'Tricuspid atresia', 'Right aortic arch', 'Anasarca', 'Tetralogy of Fallot with pulmonary atresia', 'Heart murmur', 'Systolic heart murmur', 'Oliguria']",['Structural heart defects and renal anomalies syndrome'],"Structural heart defects and renal anomalies syndrome:  
1. **Cardiac anomalies**: The patient exhibits multiple severe congenital heart defects, including ventricular septal defect, truncus arteriosus, tetralogy of Fallot with pulmonary atresia, tricuspid atresia, interrupted aortic arch, and right aortic arch. These structural abnormalities align with the ""structural heart defects"" component of the syndrome.  
2. **Renal involvement**: Renal insufficiency, renal cysts, and oliguria indicate significant kidney dysfunction, fulfilling the ""renal anomalies"" criterion.  
3. **Supporting features**: Microcephaly, partial agenesis of the corpus callosum, and polydactyly suggest a syndromic genetic etiology. Overlapping toes, persistent left superior vena cava, and anomalous pulmonary venous return further support a multisystem developmental disorder.  
4. **Severity and prognosis**: Death in infancy, generalized edema (anasarca), and cyanosis reflect the life-threatening nature of the cardiac and renal defects, typical of this syndrome.  
This pattern matches a rare congenital disorder linking complex heart malformations with renal dysplasia, often caused by genetic or epigenetic disruptions in embryogenesis."
"['Dysarthria', 'Cerebellar atrophy', 'Dysphagia', 'Gait ataxia', 'Paraparesis', 'Scoliosis', 'Ankle clonus']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Paraparesis** and **ankle clonus** are hallmark signs of upper motor neuron dysfunction, consistent with hereditary spastic paraplegia (HSP).  
2. **Cerebellar atrophy** and **gait ataxia** indicate cerebellar involvement, aligning with ""complicated"" HSP subtypes like SPG76, where CAPN1 mutations cause combined pyramidal and cerebellar pathology.  
3. **Dysarthria** and **dysphagia** suggest brainstem or cerebellar dysfunction, often seen in HSPs with extended neurological features.  
4. **Scoliosis** may arise secondary to chronic neuromuscular imbalance, a known skeletal complication in progressive HSPs.  
5. SPG76’s autosomal recessive inheritance and phenotypic overlap with spasticity-plus syndromes (e.g., cerebellar degeneration) distinguish it from pure motor HSPs (e.g., SPG4). The constellation of pyramidal, cerebellar, and bulbar symptoms strongly supports this diagnosis."
"['Slow saccadic eye movements', 'Dysarthria', 'Hypertonia', 'Spastic tetraparesis', 'Bilateral talipes equinovarus', 'Limb ataxia', 'Unsteady gait']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Core spastic paraplegia features**: Spastic tetraparesis (spasticity in all four limbs) and hypertonia align with hereditary spastic paraplegia (HSP).  
2. **Cerebellar involvement**: Limb ataxia, dysarthria, and unsteady gait suggest cerebellar dysfunction, consistent with *complex HSP*.  
3. **Ocular abnormality**: Slow saccadic eye movements indicate brainstem/cerebellar pathology, reported in SPG76 due to CAPN1 mutations affecting neuronal signaling.  
4. **Congenital musculoskeletal anomaly**: Bilateral talipes equinovarus (clubfoot) may reflect early-onset neuromuscular dysfunction or developmental anomalies linked to SPG76.  
5. **Genetic confirmation**: Autosomal recessive inheritance matches SPG76’s etiology (CAPN1 mutations), which combines spasticity, ataxia, and variable neuro-ophthalmic signs.  
6. **Exclusion of mimics**: Symptoms differentiate SPG76 from pure HSP subtypes (no cerebellar signs) or spinocerebellar ataxias (less prominent spasticity)."
"['Hypertelorism', 'Micrognathia', 'Low-set ears', 'Oligodontia', 'Microdontia', 'Pectus excavatum', 'Hitchhiker thumb', 'Global developmental delay', 'Duplication of metatarsal bones', 'Chiari malformation', 'Kyphoscoliosis', 'Short nose', 'Short hallux', 'Talon cusp', 'Cutaneous syndactyly', 'Clinodactyly']",['Temtamy preaxial brachydactyly syndrome/Temtamy preaxial brachydactyly syndrome'],"Disease: Temtamy preaxial brachydactyly syndrome  
**Reasoning**:  
1. **Skeletal anomalies**: The presence of *preaxial brachydactyly* (evidenced by *Hitchhiker thumb* and *short hallux*), *duplication of metatarsal bones*, and *pectus excavatum* aligns with the syndrome's hallmark limb and chest abnormalities.  
2. **Dental features**: *Oligodontia* (few teeth) and *microdontia* (small teeth) are consistent with reported dental manifestations. The *talon cusp* further supports enamel developmental anomalies.  
3. **Craniofacial traits**: *Hypertelorism*, *low-set ears*, *short nose*, and *micrognathia* match characteristic facial dysmorphisms.  
4. **Neurological/Spinal involvement**: *Chiari malformation* and *kyphoscoliosis* correlate with spinal/cranial junction and vertebral defects seen in some cases.  
5. **Limb anomalies**: *Cutaneous syndactyly* (webbed digits) and *clinodactyly* (curved fingers) reinforce the diagnosis of a congenital limb patterning disorder.  
6. **Developmental delay**: *Global developmental delay* is reported in Temtamy syndrome, though severity varies.  
**Exclusion**: Overlap with syndromes like Rubinstein-Taybi or Greig cephalopolysyndactyly is ruled out by the absence of broad thumbs/polydactyly and the specific metatarsal duplication paired with dental findings."
"['Tall stature', 'Abnormality of the genitourinary system', 'Entropion', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Death in infancy', 'Abnormal heart morphology', 'Hypertrophic cardiomyopathy', 'Abnormal facial shape', 'Kyphoscoliosis', 'Aortic aneurysm']","['Cutis laxa, autosomal recessive, type IIC']","Disease: Cutis laxa, autosomal recessive, type IIC (ARCL2C)  
Reasoning:  
1. **Abnormality of the genitourinary system**: Connective tissue defects in ARCL2C can affect urinary tract structures.  
2. **Entropion & Abnormal facial shape**: Lax, inelastic skin leads to eyelid malformations and characteristic facial features (e.g., aged appearance, sagging skin).  
3. **Generalized hypotonia**: Common in ARCL2C due to connective tissue dysfunction impacting muscle tone.  
4. **Flexion contracture & Hip dysplasia**: Joint abnormalities arise from defective collagen/elastin, causing restricted movement and skeletal malformations.  
5. **Kyphoscoliosis**: Spinal curvature due to weak connective tissue supporting vertebrae.  
6. **Disproportionate tall stature**: Skeletal overgrowth or dysplasia linked to PYCR1 mutations affecting cell proliferation and matrix integrity.  
7. **Hypertrophic cardiomyopathy & Aortic aneurysm**: Severe cardiovascular complications in ARCL2C stem from impaired vascular connective tissue, leading to heart wall thickening and arterial fragility.  
8. **Abnormal heart morphology**: Structural heart defects (e.g., valve anomalies) are recurrent in PYCR1-related disorders.  
9. **Death in infancy**: ARCL2C is often lethal early due to cardiorespiratory failure or aortic rupture.  

The constellation of connective tissue, skeletal, cardiac, and dysmorphic features, combined with autosomal recessive inheritance, aligns definitively with ARCL2C (PYCR1-related cutis laxa)."
"['Microcephaly', 'Deeply set eye', 'Developmental cataract', 'Dry skin', 'Cutaneous photosensitivity']","['Cockayne syndrome, type B']","Disease: Cockayne syndrome, type B  
Reasoning:  
1. **Microcephaly** and **developmental delays** align with Cockayne syndrome’s hallmark neurological and growth abnormalities.  
2. **Deeply set eyes** (enophthalmos) is a common craniofacial feature in Cockayne syndrome due to facial fat loss and skeletal dysplasia.  
3. **Developmental cataracts** are characteristic of Cockayne syndrome type B, arising from DNA repair defects affecting lens transparency.  
4. **Dry skin** and **cutaneous photosensitivity** reflect defective nucleotide excision repair (NER), leading to UV-induced damage and premature aging of skin.  
5. The combination of photosensitivity, neurodegeneration, and ocular abnormalities strongly differentiates Cockayne syndrome from other DNA repair disorders (e.g., xeroderma pigmentosum).  
6. Type B is distinguished by earlier onset and severe progression, consistent with the listed symptoms."
"['Self-mutilation', 'Hypotonia', 'Dysarthria', 'Hyporeflexia', 'Acanthocytosis', 'Dysphagia', 'Chorea', 'Bruxism', 'Lateral ventricle dilatation']",['Choreoacanthocytosis/CHOREOACANTHOCYTOSIS'],"Disease: Choreoacanthocytosis/CHOREOACANTHOCYTOSIS  
Reasoning:  
1. **Acanthocytosis**: Presence of spiky red blood cells is a hallmark of neuroacanthocytosis syndromes, strongly suggesting Choreoacanthocytosis (ChAc).  
2. **Chorea**: Involuntary movements align with basal ganglia dysfunction, a core feature of ChAc.  
3. **Self-mutilation**: Lip/tongue biting is pathognomonic for ChAc due to orofacial dystonia and impaired self-awareness.  
4. **Dysarthria/Dysphagia**: Bulbar involvement from neurodegeneration explains speech and swallowing difficulties.  
5. **Hypotonia/Hyporeflexia**: Reflects corticostriatal pathway degeneration and peripheral neuropathy, common in ChAc.  
6. **Bruxism**: Linked to oromandibular dystonia in neuroacanthocytosis.  
7. **Lateral ventricle dilatation**: Indicates cerebral atrophy, consistent with progressive neurodegeneration in ChAc.  
8. **Exclusion of mimics**: Absence of cardiomyopathy (rules out McLeod syndrome) and Kayser-Fleischer rings (excludes Wilson’s), alongside acanthocytosis, confirms ChAc."
"['Upslanted palpebral fissure', 'Hypotelorism', 'Global developmental delay', 'Joint stiffness', 'Pulmonic stenosis', 'Lumbar hyperlordosis', 'Short stature', 'Dysplastic pulmonary valve', 'Depressed nasal bridge', 'Short phalanx of finger', 'Cone-shaped epiphysis', 'Acromelia', 'Midface retrusion', 'Internal notch of the femoral head']",['Geleophysic dysplasia 2'],"Disease: Geleophysic dysplasia 2  
Reasoning:  
1. **Skeletal anomalies**: Acromelia (shortened limbs), short phalanges, cone-shaped epiphyses, joint stiffness, and lumbar hyperlordosis align with geleophysic dysplasia, a skeletal disorder characterized by progressive skeletal and joint abnormalities.  
2. **Facial features**: Upslanted palpebral fissures, depressed nasal bridge, midface retrusion, and hypotelorism are classic craniofacial traits of geleophysic dysplasia.  
3. **Cardiac involvement**: Pulmonic stenosis and dysplastic pulmonary valve are hallmark cardiovascular features of geleophysic dysplasia type 2, linked to *FBN1* mutations.  
4. **Growth and development**: Short stature and global developmental delay are consistent with systemic manifestations of the disorder.  
5. **Distinctive findings**: Internal notch of the femoral head is a rare but reported skeletal feature in geleophysic dysplasia.  
6. **Differentiation from type 1**: Absence of tracheal stenosis (common in type 1) and presence of *FBN1*-associated cardiac defects support type 2."
"['Wormian bones', 'Thin bony cortex', 'Recurrent fractures', 'Vertebral compression fracture', 'Slender long bone', 'Elevated circulating alkaline phosphatase concentration', 'Increased circulating beta-C-terminal telopeptide concentration', 'Femur fracture', 'Generalized osteoporosis']","['Osteogenesis imperfecta, type XIV']","Disease: Osteogenesis imperfecta, type XIV  
Reasoning:  
1. **Wormian bones**: Indicate abnormal skull bone development, a hallmark of osteogenesis imperfecta (OI).  
2. **Thin bony cortex & slender long bones**: Reflect defective bone matrix quality and reduced cortical thickness, consistent with OI’s structural bone defects.  
3. **Recurrent fractures (including femur/vertebral compression)**: Suggest severe bone fragility, a core feature of OI. Vertebral fractures are common in moderate-severe OI types.  
4. **Generalized osteoporosis**: Aligns with systemic bone density loss due to impaired collagen/mineralization in OI.  
5. **Elevated bone turnover markers (alkaline phosphatase, beta-C-terminal telopeptide)**: Indicate high bone resorption, seen in OI type XIV due to TMEM38B mutations disrupting calcium homeostasis in osteoblasts.  
6. **Genetic specificity**: OI type XIV (linked to TMEM38B) presents with early fractures, vertebral collapse, and biochemical evidence of increased resorption, distinguishing it from collagen-related OI types.  
7. **Exclusion of mimics**: Elevated alkaline phosphatase rules out hypophosphatasia; age-agnostic severity and Wormian bones exclude idiopathic osteoporosis."
"['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Reduced eye contact', 'Seizure', 'Hypotonia', 'Hypoplasia of the corpus callosum', 'EEG abnormality', 'Sleep disturbance', 'Bruxism', 'Hypoplasia of the frontal lobes', 'Feeding difficulties']","['Rett syndrome, congenital variant']","Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Core symptoms of Rett syndrome**: Abnormal repetitive mannerisms (e.g., hand stereotypies), delayed speech/language development, and reduced eye contact align with Rett syndrome's hallmark features.  
2. **Neurological involvement**: Seizures, EEG abnormalities, and hypotonia are common in Rett syndrome due to mutations in *MECP2* or related genes, affecting neuronal function.  
3. **Structural brain anomalies**: Hypoplasia of the corpus callosum and frontal lobes is consistent with congenital variants of Rett syndrome, where severe neurodevelopmental abnormalities occur early.  
4. **Supportive features**: Sleep disturbances, bruxism, and feeding difficulties are frequently observed in Rett syndrome due to autonomic dysfunction and oral-motor challenges.  
5. **Differentiation from classic Rett**: The congenital variant lacks the typical regression phase, presenting with severe delays and structural brain defects from infancy, matching the patient’s profile.  
6. **Exclusion of mimics**: CDKL5 deficiency or Angelman syndrome could overlap but are less likely given corpus callosum hypoplasia and frontal lobe involvement, which strongly suggest Rett spectrum disorders."
"['Megalocornea', 'Visual impairment', 'Deep anterior chamber', 'Abnormal intraocular pressure']","['MEGALOCORNEA', 'Isolated congenital megalocornea']","Disease: Isolated congenital megalocornea  
Reasoning:  
1. **Megalocornea**: Core diagnostic feature, defined as a corneal diameter >13 mm at birth, non-progressive, and bilateral.  
2. **Deep anterior chamber**: Consistent with anterior segment enlargement due to corneal stretching, without angle abnormalities (ruling out glaucoma-associated structural defects).  
3. **Visual impairment**: Likely secondary to refractive errors (e.g., myopia/astigmatism) from altered corneal curvature, rather than optic nerve or retinal pathology.  
4. **Abnormal intraocular pressure**: May reflect transient fluctuations or measurement artifacts; isolated congenital megalocornea typically maintains normal pressure, distinguishing it from congenital glaucoma (which causes persistent elevation and corneal edema).  
5. **Exclusion of alternatives**: No signs of systemic syndromes (e.g., Marfan), lens dislocation, or Haab’s striae (seen in glaucoma)."
"['Delayed speech and language development', 'Jaundice', 'Generalized hypotonia', 'Vomiting', 'Bilateral tonic-clonic seizure', 'Feeding difficulties', 'Hypergalactosemia']",['Classic galactosemia/GALACTOSEMIA'],"Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia** directly indicates impaired galactose metabolism, a hallmark of galactosemia.  
2. **Feeding difficulties, vomiting, and jaundice** are early-onset symptoms in neonates with classic galactosemia, caused by toxic accumulation of galactose metabolites (e.g., galactitol, galactose-1-phosphate) damaging the liver and gastrointestinal tract.  
3. **Generalized hypotonia** and **seizures** suggest neurological involvement from metabolite toxicity or hypoglycemia secondary to hepatic dysfunction.  
4. **Delayed speech/language development** aligns with long-term neurocognitive sequelae of untreated galactosemia.  
5. **Bilateral tonic-clonic seizures** may result from cerebral edema, metabolic derangements, or direct neurotoxicity.  
6. All symptoms collectively fit the GALT enzyme deficiency (classic galactosemia), which disrupts the Leloir pathway, necessitating immediate lactose/galactose restriction to prevent irreversible complications."
"['Jaundice', 'Seizure', 'Global developmental delay', 'Periportal fibrosis', 'Failure to thrive in infancy', 'Abnormal bleeding', 'Fever', 'Vomiting', 'Hypertriglyceridemia', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Hypercholesterolemia', 'Abdominal distention', 'Short stature']",['Glycogen storage disease due to liver glycogen phosphorylase deficiency/Glycogen storage disease VI'],"Disease: Glycogen storage disease due to liver glycogen phosphorylase deficiency/Glycogen storage disease VI  
Reasoning:  
1. **Hepatomegaly and elevated hepatic transaminases**: Central to GSD VI, as phosphorylase deficiency causes glycogen accumulation in the liver, leading to enlargement and liver dysfunction.  
2. **Failure to thrive in infancy and short stature**: Impaired glucose mobilization from glycogen results in metabolic stress, affecting growth.  
3. **Hypertriglyceridemia and hypercholesterolemia**: Secondary metabolic disturbances due to disrupted hepatic glucose/lipid homeostasis.  
4. **Periportal fibrosis and jaundice**: Chronic liver injury from glycogen overload progresses to fibrosis, impairing bile flow and causing jaundice.  
5. **Abdominal distention**: Direct consequence of hepatomegaly.  
6. **Seizures and abnormal bleeding**: Hypoglycemia (from glycogenolysis defects) may trigger seizures; reduced hepatic synthesis of clotting factors contributes to bleeding.  
7. **Global developmental delay**: Chronic metabolic instability and growth failure impact neurodevelopment.  
8. **Fever/vomiting**: Non-specific but may reflect metabolic stress or intercurrent illness exacerbating baseline pathology.  
**Exclusion of other GSDs**: Absence of severe hypoglycemia (more typical in GSD I), muscle involvement (GSD III/V), or lactic acidosis narrows the diagnosis to GSD VI."
"['Oral ulcer', 'Cutis marmorata', 'Hemiparesis', 'Fever', 'Abdominal pain', 'Ischemic stroke', 'Headache', 'Vertigo', 'Arthralgia', 'Antinuclear antibody positivity', 'Increased circulating antibody level', 'Elevated circulating C-reactive protein concentration', 'Oculomotor nerve palsy']","['Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome', 'Deficiency of adenosine deaminase 2']","Disease: Deficiency of adenosine deaminase 2  
Reasoning: The patient’s ischemic stroke, cutis marmorata (livedo racemosa), and oculomotor nerve palsy strongly suggest vasculopathic or vasculitic involvement of small-to-medium vessels, a hallmark of DADA2. Systemic inflammation (fever, elevated CRP), arthralgia, abdominal pain, and autoantibody positivity (ANA) align with DADA2’s autoinflammatory phenotype. Early-onset strokes and neurologic deficits (hemiparesis, vertigo, headache) are characteristic, while oral ulcers and immune dysregulation (elevated antibodies) further support this diagnosis.  

Disease: Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome (VEXAS)  
Reasoning: Fever, arthralgia, elevated CRP, and oral ulcers fit VEXAS’s autoinflammatory profile. Cutis marmorata and antinuclear antibody positivity suggest underlying vasculitis. However, ischemic stroke and oculomotor palsy are atypical for VEXAS, which more commonly involves macrocytic anemia, chondritis, or neutrophilic dermatosis. The absence of explicit hematologic defects (e.g., cytopenias) in the listed symptoms weakens this diagnosis, though immunodeficiency (elevated antibodies) and systemic inflammation remain compatible."
"['Hydronephrosis', 'Wide anterior fontanel', 'Coarse facial features', 'Hypertelorism', 'Narrow forehead', 'Low-set ears', 'Broad ribs', 'Abnormal fundus morphology', 'Severely reduced visual acuity', 'Seizure', 'Global developmental delay', 'Growth delay', 'Diastasis recti', 'Polyhydramnios', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Talipes equinovarus', 'Frontal bossing', 'Abdominal distention', 'Depressed nasal bridge', 'Bowing of the long bones', 'Lateral ventricle dilatation', 'Dilated third ventricle', 'Bilateral fetal pyelectasis', 'Midface retrusion', 'Severe hearing impairment']",['Schinzel-Giedion syndrome/Schinzel-Giedion midface-retraction syndrome'],"Disease: Schinzel-Giedion syndrome/Schinzel-Giedion midface-retraction syndrome  
Reasoning:  
1. **Craniofacial features**: Midface retrusion, frontal bossing, coarse facial features, hypertelorism, depressed nasal bridge, narrow forehead, and low-set ears are hallmark signs of Schinzel-Giedion syndrome (SGS). These align with the characteristic ""midface-retraction"" phenotype.  
2. **Neurological/developmental**: Global developmental delay, seizures, lateral and third ventricle dilatation (hydrocephalus), and severe sensory deficits (visual/hearing impairment) reflect SGS-associated severe neurodevelopmental abnormalities and brain malformations.  
3. **Skeletal anomalies**: Broad ribs, bowing of long bones, talipes equinovarus, and diastasis recti correlate with SGS’s skeletal dysplasia and connective tissue involvement.  
4. **Congenital organ defects**: Hydronephrosis, bilateral fetal pyelectasis, patent ductus arteriosus (PDA), and patent foramen ovale (PFO) match SGS’s association with renal, cardiac, and urogenital anomalies.  
5. **Prenatal/postnatal growth issues**: Polyhydramnios, growth delay, and abdominal distention are consistent with SGS’s prenatal onset and failure-to-thrive trajectory.  
6. **Supporting evidence**: The combination of severe midface hypoplasia, skeletal abnormalities, neurodevelopmental regression, and multi-organ involvement is pathognomonic for SGS, a disorder caused by *SETBP1* gain-of-function mutations.  

This pattern excludes other lysosomal storage disorders or skeletal dysplasias (e.g., mucopolysaccharidoses, thanatophoric dysplasia) due to the unique midface retraction and SETBP1-related phenotype."
"['Epicanthus inversus', 'Blue irides', 'White eyebrow', 'White eyelashes', 'Delayed fine motor development', 'Bilateral wrist flexion contracture', 'Short palpebral fissure', 'Flexion contracture of finger']","['Waardenburg syndrome type 3/Waardenburg syndrome, type 3']","Disease: Waardenburg syndrome type 3  
Reasoning:  
1. **Pigmentation anomalies**: Epicanthus inversus, blue irides, white eyebrow, and white eyelashes align with Waardenburg syndrome (WS) criteria, which include congenital pigmentary disturbances.  
2. **Musculoskeletal abnormalities**: Bilateral wrist flexion contracture and flexion contracture of the finger are hallmarks of WS type 3 (Klein-Waardenburg syndrome), distinguishing it from other subtypes.  
3. **Developmental delay**: Delayed fine motor development supports systemic involvement of neuromuscular structures, consistent with type 3.  
4. **Ocular features**: Short palpebral fissures are common in WS but help rule out other syndromes.  
5. **Exclusion of other subtypes**: Absence of Hirschsprung disease (type 4) and limb defects beyond contractures (not seen in types 1/2) confirm type 3."
"['Micropenis', 'Gingival overgrowth', 'Long philtrum', 'Micrognathia', 'Anteverted nares', 'Proptosis', 'Bifid ribs', 'Bicuspid aortic valve', 'Frontal bossing', 'Hemivertebrae', 'Elbow dislocation', 'Acromesomelia', 'Short stature', 'Depressed nasal bridge', 'Eversion of lateral third of lower eyelids', 'Microtia', 'Short finger', 'Limb undergrowth', 'Cleft lower lip']","['Autosomal recessive Robinow syndrome/Robinow syndrome, autosomal recessive']","Disease: Autosomal recessive Robinow syndrome/Robinow syndrome, autosomal recessive  
Reasoning:  
1. **Craniofacial Features**: Micrognathia (small jaw), long philtrum, anteverted nares, depressed nasal bridge, frontal bossing (prominent forehead), proptosis (bulging eyes), and eversion of the lateral third of the lower eyelids align with the characteristic facial dysmorphology of Robinow syndrome.  
2. **Skeletal Anomalies**: Bifid ribs, hemivertebrae (spinal malformations), elbow dislocation, acromesomelia (shortened distal limbs), limb undergrowth, and short fingers are hallmark skeletal defects in autosomal recessive Robinow syndrome.  
3. **Genitourinary/Genital Involvement**: Micropenis is a key feature of the autosomal recessive form, distinguishing it from the milder dominant type.  
4. **Oral/Dental Abnormalities**: Gingival overgrowth and cleft lower lip are frequently observed in recessive Robinow syndrome.  
5. **Auxiliary Findings**: Short stature, microtia (small ears), and bicuspid aortic valve (cardiac anomaly) further support the diagnosis, as these are common systemic manifestations.  
6. **Exclusion of Differential Diagnoses**: The combination of severe skeletal, craniofacial, and genital abnormalities differentiates this from other acromesomelic dysplasias or syndromes with overlapping features (e.g., Simpson-Golabi-Behmel or Cornelia de Lange syndrome).  
7. **Genetic Basis**: Autosomal recessive inheritance (linked to *ROR2* gene mutations) correlates with the severity of observed symptoms, including pronounced skeletal defects and genital hypoplasia."
"['Microcephaly', 'Seizure', 'Spastic tetraparesis', 'Dystonia', 'Absent speech', 'Dysphagia', 'Ventriculomegaly', 'Cerebral cortical atrophy', 'Hyperglycinemia', 'Delayed gross motor development', 'Poor head control', 'Abnormal cerebral white matter morphology', 'Hyperalaninemia', 'Decreased body weight', 'Delayed myelination', 'Absent posterior alpha rhythm']","['Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities']","Disease: Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities  
Reasoning:  
1. **Hyperalaninemia & Metabolic Dysregulation**: Elevated alanine (hyperalaninemia) suggests pyruvate metabolism dysfunction, a hallmark of mitochondrial disorders. This aligns with lactic acidosis (implied in the diagnosis), as impaired oxidative phosphorylation forces pyruvate conversion to lactate.  
2. **CNS Structural Abnormalities**: Ventriculomegaly, cerebral cortical atrophy, delayed myelination, and abnormal white matter morphology indicate severe brain developmental defects, consistent with energy-deficient states in mitochondrial encephalopathies.  
3. **Neurological Symptoms**: Spastic tetraparesis, dystonia, seizures, and absent speech reflect widespread cortical and subcortical damage from metabolic stress. Microcephaly and delayed motor development further support impaired neurodevelopment.  
4. **Supportive Findings**: Dysphagia, poor head control, and decreased body weight correlate with global neurological dysfunction. Absent posterior alpha rhythm on EEG underscores abnormal cortical activity.  
5. **Hyperglycinemia**: Likely secondary to metabolic crisis disrupting amino acid homeostasis, rather than primary glycine encephalopathy (NKH), given the broader metabolic context (lactic acidosis/hyperalaninemia).  

This constellation of metabolic derangements, structural brain anomalies, and severe neurological deficits strongly aligns with a diagnosis of neonatal severe mitochondrial encephalopathy with lactic acidosis."
"['Hallux valgus', 'Long hallux', 'Elevated circulating alkaline phosphatase concentration', 'Abnormal circulating calcium concentration', 'Symphalangism affecting the phalanges of the hallux', 'Ectopic ossification in muscle tissue', 'Pain', 'Abnormal erythrocyte sedimentation rate', 'Abnormal circulating C-reactive protein concentration', 'Abnormal blood phosphate concentration']",['Fibrodysplasia ossificans progressiva/Fibrodysplasia ossificans progressiva'],"Disease: Fibrodysplasia ossificans progressiva  
Reasoning:  
1. **Hallux valgus and Long hallux**: Congenital malformations of the great toes (hallux valgus, elongated hallux) are classic early signs of FOP, present at birth.  
2. **Symphalangism affecting the phalanges of the hallux**: Fusion of phalangeal joints (symphalangism) in the hallux is a pathognomonic feature of FOP.  
3. **Ectopic ossification in muscle tissue**: Progressive heterotopic ossification in soft tissues (e.g., muscles, tendons) is the hallmark of FOP, often triggered by trauma or inflammation.  
4. **Elevated alkaline phosphatase, abnormal calcium/phosphate**: Reflects active bone remodeling and dysregulated mineral metabolism due to ectopic bone formation.  
5. **Elevated ESR, CRP, and pain**: Indicate inflammatory flare-ups preceding ossification episodes.  
6. **Exclusion of mimics**: Symptoms collectively distinguish FOP from other ossification disorders (e.g., POH) or metabolic bone diseases."
"['Abnormal mandible morphology', 'Ptosis', 'External ophthalmoplegia', 'Achilles tendon contracture', 'Myotonia', 'Distal amyotrophy', 'Neck flexor weakness', 'Pelvic girdle muscle weakness', 'Pelvic girdle muscle weakness', 'Facial paralysis', 'Distal lower limb muscle weakness', 'Abnormal nerve conduction velocity']","['Autosomal dominant centronuclear myopathy/Myopathy, centronuclear, autosomal dominant']","Disease: Autosomal dominant centronuclear myopathy/Myopathy, centronuclear, autosomal dominant  
Reasoning:  
1. **Oculomotor involvement**: Ptosis and external ophthalmoplegia are hallmark features of centronuclear myopathy (CNM), reflecting weakness in extraocular and levator palpebrae muscles.  
2. **Facial and bulbar weakness**: Facial paralysis and abnormal mandible morphology align with craniofacial muscle involvement typical in CNM.  
3. **Proximal and distal muscle weakness**: Pelvic girdle muscle weakness (repeated), neck flexor weakness, and distal lower limb weakness suggest a generalized myopathy pattern. Distal amyotrophy indicates chronic muscle atrophy.  
4. **Myotonia**: Though less common in CNM, overlapping features with myotonic disorders (e.g., DNM2-related CNM) may explain delayed muscle relaxation.  
5. **Tendon contractures**: Achilles tendon contracture reflects long-standing muscle fibrosis, a sequela of chronic myopathy.  
6. **Electrophysiological findings**: Abnormal nerve conduction velocity may mimic neuropathy but is consistent with myopathic changes affecting motor units.  
7. **Genetic correlation**: Autosomal dominant CNM (linked to DNM2 mutations) explains the phenotypic combination of facial, ocular, and axial/distal weakness without severe neonatal onset.  
8. **Exclusion of mimics**: Differentiated from myotonic dystrophy by the prominence of ophthalmoplegia and absence of systemic features (e.g., cardiac arrhythmia)."
"['Macroglossia', 'Gingival overgrowth', 'Coarse facial features', 'Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Deeply set eye', 'Osteoporosis', 'Areflexia', 'Tongue fasciculations', 'Cerebellar vermis hypoplasia', 'Partial agenesis of the corpus callosum', 'Hypoplasia of the corpus callosum', 'Respiratory insufficiency', 'Ventriculomegaly', 'Hypertriglyceridemia', 'Generalized-onset seizure', ""Exaggerated cupid's bow"", 'Developmental regression', 'Highly arched eyebrow', 'Hyponatremia', 'Severe muscular hypotonia', 'Focal-onset seizure', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay', 'Cerebral visual impairment']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Neurological & developmental features**: Profound global developmental delay, developmental regression, cerebellar vermis hypoplasia, and cerebral visual impairment align with TBCK syndrome’s hallmark neurodevelopmental deficits. Corpus callosum abnormalities (partial agenesis/hypoplasia) and ventriculomegaly are consistent with brain malformations seen in TBCK.  
2. **Neuromuscular signs**: Severe muscular hypotonia, areflexia, and tongue fasciculations reflect the syndrome’s hypotonia-predominant presentation. Respiratory insufficiency and feeding difficulties are secondary to hypotonia.  
3. **Seizures**: Both generalized-onset and focal-onset seizures are reported in TBCK due to cortical dysgenesis and mTOR pathway dysregulation.  
4. **Craniofacial dysmorphism**: Macroglossia, gingival overgrowth, coarse facial features, narrow forehead, prominent nasal bridge, anteverted nares, deeply set eyes, and exaggerated “Cupid’s bow” match the characteristic facies of TBCK-related syndromes.  
5. **Metabolic/Systemic involvement**: Hypertriglyceridemia and osteoporosis may arise from metabolic dysregulation linked to TBCK’s role in mTOR signaling. Hyponatremia could reflect autonomic dysfunction.  
6. **Genetic correlation**: TBCK mutations disrupt kinase activity critical for neuronal survival and metabolism, explaining the multisystemic phenotype.  
The combination of severe hypotonia, distinct facies, brain malformations, and metabolic anomalies strongly supports this diagnosis."
"['Mandibular prognathia', 'Conductive hearing impairment', 'Long eyelashes', 'Brachydactyly', 'Hypertonia', 'Areflexia', 'Joint stiffness', 'Abnormal heart morphology', 'Clumsiness', 'Highly arched eyebrow', 'Thickened calvaria', 'Lumbar hyperlordosis', 'Thoracic kyphosis', 'Enlarged vertebral pedicles', 'Bilateral conductive hearing impairment', 'Abnormal renal morphology', 'Abnormality of brain morphology', 'Keratosis pilaris']",['Myhre syndrome/Myhre syndrome'],"Disease: Myhre syndrome  
Reasoning:  
1. **Mandibular prognathia**: A hallmark of Myhre syndrome, characterized by a prominent, protruding jaw.  
2. **Conductive hearing impairment (bilateral)**: Common due to middle ear anomalies or ossicular chain abnormalities.  
3. **Long eyelashes/Highly arched eyebrows**: Part of the distinctive facial gestalt in Myhre syndrome.  
4. **Brachydactyly**: Shortened fingers/limbs are consistent with skeletal dysplasia seen in the syndrome.  
5. **Hypertonia/Joint stiffness/Clumsiness**: Linked to progressive musculoskeletal fibrosis and restricted joint mobility.  
6. **Thickened calvaria/Enlarged vertebral pedicles**: Reflects the characteristic progressive skeletal overgrowth and thickened bones.  
7. **Abnormal heart/renal/brain morphology**: Multisystem involvement, including cardiovascular, renal, and CNS structural anomalies, aligns with Myhre syndrome’s systemic impact.  
8. **Keratosis pilaris**: Reported in some cases as a cutaneous manifestation.  
9. **Thoracic kyphosis/Lumbar hyperlordosis**: Spinal deformities secondary to skeletal dysplasia and fibrosis.  
10. **Areflexia**: May relate to neurological involvement or muscle fibrosis.  

The constellation of craniofacial, skeletal, cardiovascular, and neurological abnormalities strongly supports a diagnosis of **Myhre syndrome**, a SMAD4-associated disorder."
"['Triangular face', 'Ventricular septal defect', 'Atrial septal defect', 'Patent ductus arteriosus', 'Neutropenia', 'Chiari malformation', 'Short thumb', 'Small pituitary gland', 'Chromosome breakage']","['Fanconi anemia, complementation group I']","Disease: Fanconi anemia, complementation group I  
Reasoning:  
1. **Chromosome breakage**: Hallmark of Fanconi anemia (FA), a DNA repair disorder. FA cells exhibit hypersensitivity to DNA crosslinking agents, leading to chromosomal instability.  
2. **Hematologic abnormalities (neutropenia)**: FA commonly causes bone marrow failure, resulting in cytopenias like neutropenia.  
3. **Congenital heart defects (VSD, ASD, PDA)**: Observed in some FA subtypes, particularly with mutations in genes like *FANCI* (complementation group I).  
4. **Radial ray anomalies (short thumb)**: Classic FA feature due to developmental defects; thumb/hand abnormalities are frequent.  
5. **Endocrine dysfunction (small pituitary gland)**: FA patients often exhibit endocrine deficiencies, including growth hormone insufficiency linked to pituitary anomalies.  
6. **Chiari malformation**: Rarely reported in FA but may reflect broader connective tissue/developmental instability.  
7. **Triangular facial shape**: A recognized craniofacial feature in FA, though nonspecific.  
8. **Genetic confirmation**: Complementation group I is defined by biallelic *FANCI* mutations, aligning with the clinical and cytogenetic profile.  

The combination of congenital anomalies, hematologic defects, and chromosomal fragility strongly supports FA. Subtyping to group I requires genetic testing but is consistent with the observed phenotype."
"['Shawl scrotum', 'High palate', 'Hypertelorism', 'Micrognathia', 'Anteverted nares', 'Ptosis', 'Intellectual disability', 'Joint laxity', 'Metatarsus adductus', 'Short stature']",['Aarskog-Scott syndrome/Aarskog-Scott syndrome'],"Disease: Aarskog-Scott syndrome  
Reasoning:  
1. **Shawl scrotum**: Pathognomonic feature of Aarskog-Scott syndrome, characterized by a scrotal fold encircling the base of the penis.  
2. **Craniofacial features**: Hypertelorism (wide-set eyes), ptosis (drooping eyelids), high palate, micrognathia (small jaw), and anteverted nares (upturned nostrils) align with the syndrome’s distinct facial phenotype.  
3. **Musculoskeletal anomalies**: Joint laxity and metatarsus adductus (inwardly curved forefoot) are consistent with skeletal manifestations of the disorder.  
4. **Growth and development**: Short stature and mild-to-moderate intellectual disability are common systemic features.  
5. **Exclusion of mimics**: Overlapping features with Noonan or Fragile X syndromes are ruled out due to the absence of their hallmark signs (e.g., pulmonic stenosis, macroorchidism) and the presence of pathognomonic shawl scrotum.  
6. **Genetic correlation**: X-linked inheritance (FGD1 gene mutations) supports the clinical diagnosis."
"['Depressed nasal ridge', 'Anteverted nares', 'Long eyelashes', 'Hypoplastic ilia', 'Delayed ossification of carpal bones', 'Intellectual disability', 'Growth delay', 'Deep philtrum', 'Coxa valga', 'Delayed skeletal maturation', 'Elbow flexion contracture', 'Flat acetabular roof', 'Shallow acetabular fossae', 'Short stature', 'Acetabular dysplasia', 'Severe postnatal growth retardation', 'Thick vermilion border']",['Acromicric dysplasia/Acromicric dysplasia'],"Disease: Acromicric dysplasia  
Reasoning:  
1. **Skeletal Abnormalities**: Key features like *hypoplastic ilia*, *delayed ossification of carpal bones*, *coxa valga*, *flat acetabular roof*, *shallow acetabular fossae*, and *acetabular dysplasia* align with Acromicric dysplasia’s hallmark skeletal defects, particularly affecting the hips and limbs.  
2. **Growth Issues**: *Severe postnatal growth retardation*, *short stature*, and *delayed skeletal maturation* are central to this dysplasia, reflecting impaired bone development.  
3. **Facial Features**: *Depressed nasal ridge*, *anteverted nares*, *long eyelashes*, and *deep philtrum* match the characteristic facial dysmorphism (bulbous nose, rounded face) seen in Acromicric dysplasia.  
4. **Additional Signs**: *Elbow flexion contracture* and *thick vermilion border* further support the diagnosis, as joint contractures and distinct lip morphology are reported in this condition.  
5. **Intellectual Disability**: Though uncommon in classic Acromicric dysplasia, mild cognitive delays may occasionally occur, but this symptom warrants exclusion of overlapping disorders (e.g., Geleophysic dysplasia). However, the constellation of skeletal and facial features strongly prioritizes Acromicric dysplasia."
"['Spastic paraplegia', 'Dysarthria', 'Spastic gait', 'Difficulty walking', 'Distal muscle weakness', 'Hyporeflexia of lower limbs', 'Distal peripheral sensory neuropathy']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Core HSP Features**: Spastic paraplegia, spastic gait, and difficulty walking align with hereditary spastic paraplegia (HSP), a hallmark of SPG76.  
2. **Neuropathy Overlap**: Distal peripheral sensory neuropathy and hyporeflexia suggest peripheral nerve involvement, consistent with SPG76’s association with axonal neuropathy.  
3. **Upper vs. Lower Motor Neuron Signs**: Hyporeflexia (lower motor neuron) contrasts with spasticity (upper motor neuron), indicating a ""complicated"" HSP subtype, which SPG76 exemplifies.  
4. **Dysarthria**: Though rare in pure HSP, dysarthria is reported in SPG76 due to overlapping cerebellar or bulbar dysfunction.  
5. **Genetic Confirmation**: SPG76 is linked to CAPN1 mutations, which cause progressive spasticity and neuropathy, matching the symptom profile.  
6. **Exclusion of Alternatives**: Features lack cognitive decline or structural brain anomalies seen in other HSP subtypes (e.g., SPG11/SPG15), narrowing the diagnosis to SPG76."
"['Microcephaly', 'Hearing impairment', 'Cataract', 'Proptosis', 'Growth delay']",['Cockayne syndrome A'],"Disease: Cockayne syndrome A  
Reasoning:  
1. **Microcephaly**: A hallmark of Cockayne syndrome (CS), caused by progressive neurodegeneration and impaired brain development.  
2. **Hearing impairment**: Sensorineural hearing loss is common in CS due to neurological and cochlear degeneration.  
3. **Cataract**: Ocular abnormalities, including cataracts, arise from DNA repair defects impacting lens transparency.  
4. **Proptosis**: Facial atrophy and sunken eyes in CS can create an illusion of protruding eyes, though true proptosis may occur due to orbital fat loss.  
5. **Growth delay**: Severe postnatal growth failure is a cardinal feature, driven by cellular sensitivity to UV-induced DNA damage and metabolic dysfunction.  

The combination of neurodevelopmental, sensory, and growth abnormalities aligns with Cockayne syndrome type A (CSA), an autosomal recessive disorder caused by mutations in *ERCC8*. Differentiated from other subtypes (e.g., CSB) by earlier onset and severity, CSA typically manifests in infancy with these core features."
"['Lamina lucida cleavage', 'Abnormal blistering of the skin', 'Erosion of oral mucosa', 'Sepsis', 'Skin erosion']","['Severe generalized junctional epidermolysis bullosa/Epidermolysis bullosa, junctional, Herlitz type']","Disease: Severe generalized junctional epidermolysis bullosa/Epidermolysis bullosa, junctional, Herlitz type  
Reasoning:  
1. **Lamina lucida cleavage**: This histopathological finding localizes blister formation to the lamina lucida within the basement membrane zone, a hallmark of junctional epidermolysis bullosa (JEB).  
2. **Abnormal blistering of the skin**: Consistent with epidermolysis bullosa (EB), where mechanical fragility leads to blistering after minor trauma.  
3. **Erosion of oral mucosa**: Mucosal involvement (e.g., oral, ocular, gastrointestinal) is characteristic of severe JEB subtypes like Herlitz type.  
4. **Sepsis**: Frequent infections and sepsis arise from compromised skin barriers, a critical complication in Herlitz JEB due to widespread epithelial defects.  
5. **Skin erosion**: Severe, non-healing erosions reflect the profound structural instability caused by mutations in laminin-332 genes (e.g., LAMA3, LAMB3, LAMC2), critical for dermal-epidermal adhesion.  
6. **Herlitz subtype differentiation**: The combination of life-threatening infections (sepsis) and extensive mucocutaneous involvement distinguishes Herlitz-type JEB from non-Herlitz forms, aligning with its grave prognosis."
"['Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Motor delay', 'Muscle weakness', 'Absent speech', 'Tachycardia', 'Torsade de pointes', 'Cardiac arrest', 'Hypoglycemia', 'Increased serum lactate', 'Myoglobinuria', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Generalized muscle weakness', 'Ventricular tachycardia', 'Prolonged QTc interval', 'Cardiorespiratory arrest', 'Lateral ventricle dilatation', 'Acute rhabdomyolysis', 'Arrhythmia']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Neurological/Developmental Symptoms**: Delayed speech, intellectual disability, motor delay, and absent speech indicate global developmental delay and neurodegeneration, consistent with encephalomyopathic involvement.  
2. **Metabolic Crises**: Hypoglycemia, increased serum lactate, and acute rhabdomyolysis (with myoglobinuria, elevated CK) suggest recurrent metabolic disturbances, a hallmark of the syndrome.  
3. **Muscle Pathology**: Generalized muscle weakness, rhabdomyolysis, and elevated creatine kinase point to myopathic processes and energy metabolism dysfunction.  
4. **Cardiac Arrhythmias**: Torsade de pointes, ventricular tachycardia, prolonged QTc interval, and cardiorespiratory arrest align with life-threatening arrhythmias characteristic of the syndrome.  
5. **Systemic Features**: Hypoglycemia and lactic acidosis further support a mitochondrial or metabolic etiology disrupting energy production.  
6. **Neuroimaging**: Lateral ventricle dilatation may reflect neurodegenerative changes or cerebral atrophy over time.  
7. **Syndrome Alignment**: The combination of recurrent metabolic crises, rhabdomyolysis, severe arrhythmias, and intellectual disability is pathognomonic for this rare disorder, distinguishing it from isolated metabolic or cardiac conditions."
"['Thrombocytopenia', 'Increased mean platelet volume', 'Abnormal megakaryocyte morphology', 'Abnormal platelet aggregation', 'Platelet anisocytosis']","['Bleeding disorder, platelet-type, 15']","Disease: Bleeding disorder, platelet-type, 15  
Reasoning:  
1. **Thrombocytopenia**: Low platelet count aligns with impaired platelet production or abnormal megakaryocyte function, a hallmark of GFI1B-related disorders like BDPLT15.  
2. **Increased mean platelet volume (MPV)**: Larger platelets suggest dysregulated megakaryopoiesis, consistent with GFI1B mutations disrupting cytoplasmic maturation.  
3. **Abnormal megakaryocyte morphology**: GFI1B is critical for megakaryocyte development; mutations cause small, hypolobated megakaryocytes with cytoplasmic abnormalities.  
4. **Abnormal platelet aggregation**: Platelet dysfunction due to GFI1B defects leads to impaired aggregation despite normal surface receptor expression.  
5. **Platelet anisocytosis**: Variability in platelet size reflects erratic thrombopoiesis from defective megakaryocyte fragmentation.  
The combination of quantitative (thrombocytopenia) and qualitative (aggregation defects, MPV elevation) platelet abnormalities, alongside megakaryocyte dysplasia, strongly supports a GFI1B mutation diagnostic of BDPLT15."
"['Dolichocephaly', 'Astigmatism', 'Strabismus', 'Ptosis', 'Striae distensae', 'Arachnodactyly', 'Disproportionate tall stature', 'Mitral regurgitation', 'Aortic dissection', 'Tricuspid regurgitation', 'High myopia']","['Marfan syndrome', 'Marfan syndrome type 1']","Disease: Marfan syndrome  
Reasoning:  
1. **Skeletal Features**: Dolichocephaly (long skull), arachnodactyly (long fingers), and disproportionate tall stature align with Marfan syndrome’s skeletal manifestations due to connective tissue abnormalities.  
2. **Ocular Involvement**: Astigmatism, strabismus, ptosis, and high myopia are consistent with Marfan-related ocular defects, including lens dislocation risk and weakened ocular connective tissue.  
3. **Cardiovascular Abnormalities**: Mitral regurgitation, aortic dissection, and tricuspid regurgitation reflect hallmark cardiovascular complications of Marfan syndrome, driven by aortic root dilation and valvular insufficiency.  
4. **Cutaneous Findings**: Striae distensae (stretch marks) suggest connective tissue fragility, a common feature in Marfan syndrome.  

Disease: Marfan syndrome type 1  
Reasoning:  
- Marfan syndrome type 1 (MFS1) is the classic form caused by *FBN1* gene mutations. The listed symptoms (aortic dissection, mitral/tricuspid regurgitation, disproportionate tall stature, arachnodactyly) fulfill revised Ghent criteria for MFS1, which emphasizes aortic root aneurysm/dissection and systemic features. The overlap with type 1 confirms the diagnosis distinct from other fibrillinopathies.  

*Note: ""Marfan syndrome"" and ""Marfan syndrome type 1"" are often used interchangeably, but type 1 explicitly references the *FBN1*-linked classic form.*"
"['Optic disc pallor', 'Nyctalopia', 'Reduced visual acuity', 'Bone spicule pigmentation of the retina', 'Attenuation of retinal blood vessels']",['Retinitis pigmentosa 11'],"Disease: Retinitis pigmentosa 11  
Reasoning:  
1. **Nyctalopia (night blindness)** is a hallmark early symptom of retinitis pigmentosa (RP), caused by rod photoreceptor dysfunction.  
2. **Bone spicule pigmentation of the retina** is a pathognomonic finding in RP, resulting from pigment migration into the retina due to photoreceptor degeneration.  
3. **Attenuation of retinal blood vessels** and **optic disc pallor** reflect progressive retinal atrophy and optic nerve degeneration, common in advanced RP.  
4. **Reduced visual acuity** correlates with cone photoreceptor involvement later in the disease.  
5. **RP11** is a specific autosomal dominant subtype linked to mutations in the *PRPF31* gene, which disrupts pre-mRNA splicing in photoreceptors. The clinical triad of nyctalopia, visual field loss, and retinal pigmentary changes aligns with this genetic diagnosis."
"['Blue irides', 'Nystagmus', 'Hypopigmentation of the skin', 'Hypopigmentation of hair']","['Oculocutaneous albinism type 2/Albinism, oculocutaneous, type II']","Disease: Oculocutaneous albinism type 2/Albinism, oculocutaneous, type II  
Reasoning:  
1. **Hypopigmentation of skin and hair**: Oculocutaneous albinism type 2 (OCA2) is characterized by reduced melanin synthesis, leading to lighter skin and hair compared to family members, though not as severe as in OCA1.  
2. **Blue irides**: Unlike OCA1 (which often results in pink/red irides due to complete melanin absence), OCA2 allows some melanin deposition, typically causing blue or light-brown irides.  
3. **Nystagmus**: Common in all albinism types due to misrouting of optic nerves and foveal hypoplasia, impairing visual acuity and causing involuntary eye movements.  
4. **Genetic basis**: OCA2 is linked to mutations in the *OCA2* gene, disrupting melanosome function and partial melanin production, consistent with the patient’s partial pigmentation.  
5. **Exclusion of other types**: OCA1 (TYR gene) causes more severe hypopigmentation, while ocular albinism (OA1) spares skin/hair. Symptoms align with OCA2’s intermediate phenotype."
"['Intellectual disability', 'Global developmental delay', 'Generalized hypotonia', 'Abnormal facial shape', 'Delayed skeletal maturation']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Intellectual disability and global developmental delay** align with TBCK syndrome’s hallmark neurodevelopmental impairments caused by TBC1 domain-containing kinase (TBCK) gene mutations.  
2. **Generalized hypotonia** is a core feature of this disorder, reflecting neuromuscular dysfunction.  
3. **Abnormal facial shape** corresponds to characteristic facies (e.g., coarse features, hypertelorism, broad nasal tip) linked to TBCK syndrome.  
4. **Delayed skeletal maturation** matches reported skeletal anomalies, including bone age delay and scoliosis.  
5. The absence of seizures or progressive neurodegeneration (common in other hypotonia-linked disorders) supports TBCK syndrome, which is typically non-degenerative.  
6. Genetic testing for TBCK mutations would confirm the diagnosis."
"['Nystagmus', 'Hypotonia', 'Spasticity', 'Profound global developmental delay']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Nystagmus** suggests brainstem/cerebellar dysfunction, common in hypomyelinating leukodystrophies due to disrupted white matter integrity.  
2. **Hypotonia** in infancy aligns with early-onset myelin defects, as myelination is critical for proper neuronal signaling and muscle tone regulation.  
3. **Spasticity** emerges later as corticospinal tract involvement progresses, reflecting upper motor neuron damage from impaired myelination.  
4. **Profound global developmental delay** correlates with severe, diffuse hypomyelination disrupting neurodevelopment and synaptic connectivity.  
5. **NKX6-2 mutations** directly impair oligodendrocyte maturation and myelination, explaining the phenotype. Autosomal recessive inheritance matches the rarity and familial recurrence pattern.  
6. Differentiation from other leukodystrophies (e.g., Pelizaeus-Merzbacher) is based on genetic testing and absence of peripheral neuropathy."
"['Nystagmus', 'Anal atresia', 'Clonus', 'Focal clonic seizure', 'Cloverleaf skull', 'Severe combined immunodeficiency', 'Developmental stagnation', 'Fetal distress']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (EXTL3-related)  
Reasoning:  
1. **Skeletal anomalies**: ""Cloverleaf skull"" (craniosynostosis) strongly suggests a skeletal dysplasia, a hallmark of EXTL3 mutations.  
2. **Immunodeficiency**: ""Severe combined immunodeficiency (SCID)"" aligns with EXTL3's role in heparan sulfate biosynthesis, critical for immune cell development.  
3. **Neurodevelopmental issues**: ""Nystagmus,"" ""clonus,"" and ""focal clonic seizures"" indicate neurological dysfunction, consistent with EXTL3's impact on brain development.  
4. **Congenital anomalies**: ""Anal atresia"" and ""fetal distress"" suggest multisystem involvement, common in syndromic disorders like EXTL3-related disease.  
5. **Developmental stagnation**: Reflects global developmental delays due to combined skeletal, immune, and neurological defects.  
6. **Exclusion of mimics**: Overlap with other immunoskeletal disorders (e.g., Schimke immuno-osseous dysplasia) is ruled out by the unique triad of cloverleaf skull, SCID, and seizures."
"['Microcephaly', 'Short neck', 'Shield chest', 'Global developmental delay', 'Hypertonia', 'Failure to thrive', 'Small for gestational age', 'Abnormal facial shape', 'Spondyloepiphyseal dysplasia', 'Delayed skeletal maturation', 'Recurrent upper respiratory tract infections', 'Elbow flexion contracture', 'Marked delay in bone age', 'Clinodactyly of the 5th finger', 'Decreased circulating antibody level', 'Short stature', 'Decreased proportion of CD4-positive helper T cells', 'Decreased proportion of CD8-positive T cells', 'Abnormal epiphysis morphology', 'Short 5th finger', 'Limb undergrowth', 'Epileptic spasm', 'Severe global developmental delay', 'Abnormal bone ossification', 'Overweight', 'Increased hepatic echogenicity']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: Microcephaly, spondyloepiphyseal dysplasia, delayed skeletal maturation, clinodactyly of the 5th finger, short 5th finger, limb undergrowth, abnormal epiphysis morphology, and marked delay in bone age align with skeletal dysplasias characteristic of ISDNA.  
2. **Immunodeficiency**: Recurrent infections, decreased antibody levels, and reduced CD4+/CD8+ T cells indicate combined B- and T-cell dysfunction, a hallmark of ISDNA.  
3. **Neurodevelopmental Delays**: Severe global developmental delay, hypertonia, and epileptic spasms reflect central nervous system involvement, consistent with ISDNA’s neurodevelopmental phenotype.  
4. **Growth and Metabolic Features**: Short stature, small for gestational age, failure to thrive, and abnormal bone ossification further support a systemic disorder involving skeletal and metabolic pathways.  
5. **Exclusion of Alternatives**: Overlap with other immunooskeletal dysplasias (e.g., Schimke immunoosseous dysplasia) is ruled out by the absence of nephropathy and the presence of severe neurodevelopmental deficits, which are distinctive to ISDNA.  

The triad of skeletal dysplasia, immunodeficiency, and neurodevelopmental abnormalities confirms the diagnosis of ISDNA."
"['High palate', 'Epicanthus', 'Wide nasal bridge', 'Deeply set eye', 'Autism', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Broad finger', 'Broad toe', 'Developmental regression', 'Scoliosis', 'Bipolar affective disorder', 'Mild global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial Features**: The patient exhibits characteristic craniofacial anomalies (high palate, epicanthus, wide nasal bridge, deeply set eyes), which are hallmark signs of TBCK syndrome.  
2. **Neurodevelopmental Symptoms**: Intellectual disability, autism, delayed speech/language development, and mild global developmental delay align with the syndrome’s core phenotype of psychomotor retardation.  
3. **Neurological Involvement**: Hypotonia (a defining feature), seizures, and developmental regression are consistent with TBCK’s progressive neurological dysfunction.  
4. **Musculoskeletal Abnormalities**: Broad fingers/toes and scoliosis are recurrently reported in TBCK patients due to connective tissue and skeletal involvement.  
5. **Psychiatric Comorbidity**: While bipolar disorder is atypical, neuropsychiatric variability (e.g., autism) is recognized in TBCK cases.  
6. **Exclusion of Mimics**: The constellation of symptoms rules out similar disorders (e.g., Angelman, Rett, or chromosomal syndromes) lacking the TBCK-specific gene (TBC1-domain-containing kinase) mutation and phenotypic combination."
"['Increased variability in muscle fiber diameter', 'Proximal muscle weakness', 'Mildly elevated creatine kinase', 'Weakness of facial musculature', 'Internally nucleated skeletal muscle fibers']",['Distal myotilinopathy/MYOTILINOPATHY'],"Disease: Distal myotilinopathy/MYOTILINOPATHY  
Reasoning:  
1. **Increased variability in muscle fiber diameter**: A hallmark of myofibrillar myopathies, including myotilinopathy, due to disorganization of sarcomeric proteins and degeneration of myofibrils.  
2. **Proximal muscle weakness**: Consistent with myotilinopathy, which can present with proximal or distal weakness, though facial involvement adds specificity.  
3. **Mildly elevated creatine kinase**: Reflects mild muscle damage, typical of myotilinopathy, unlike severe elevations seen in dystrophies.  
4. **Weakness of facial musculature**: A distinguishing feature, as facial weakness is uncommon in many myopathies but reported in MYOT-linked myotilinopathy.  
5. **Internally nucleated skeletal muscle fibers**: Indicates chronic myopathy and regeneration, characteristic of myofibrillar myopathies, including myotilinopathy.  
Genetic confirmation of a **MYOT gene mutation** would definitively diagnose myotilinopathy, but the clinical and histopathological findings strongly support this diagnosis."
"['High palate', 'Microcephaly', 'Retrognathia', 'Epicanthus', 'Short chin', 'Narrow forehead', 'Anteverted nares', 'Ptosis', 'Thick eyebrow', 'Synophrys', 'Hirsutism', 'Failure to thrive', 'Delayed gross motor development', 'Highly arched eyebrow', 'Clinodactyly of the 5th finger', '2-3 toe syndactyly', 'Depressed nasal bridge', 'Curly eyelashes', 'Feeding difficulties in infancy', 'Proximal placement of thumb', 'Short 4th metacarpal', 'Short 5th metacarpal', 'Abnormal renal morphology']",['Cornelia de Lange syndrome 3'],"Disease: Cornelia de Lange syndrome 3  
Reasoning: The patient exhibits hallmark features of Cornelia de Lange syndrome (CdLS), including distinctive facial dysmorphism (microcephaly, retrognathia, high palate, synophrys, thick eyebrows, ptosis, anteverted nares, depressed nasal bridge), limb anomalies (clinodactyly of the 5th finger, 2-3 toe syndactyly, short 4th/5th metacarpals, proximal thumb placement), and systemic involvement (failure to thrive, feeding difficulties, delayed motor development, abnormal renal morphology). Synophrys, hirsutism, and highly arched eyebrows further strengthen the diagnosis. These findings align with CdLS type 3 (SMC3-related), a genetic subtype characterized by mutations in the SMC3 gene, which affects cohesin complex function and manifests with multi-organ anomalies. The combination of craniofacial, skeletal, developmental, and renal abnormalities is pathognomonic for this syndrome."
"['Chordee', 'Hypospadias', 'Narrow mouth', 'Hypertelorism', 'Whistling appearance', 'Micrognathia', 'Low-set ears', 'Wide nasal bridge', 'Flexion contracture', 'Talipes equinovarus', 'Depressed nasal bridge', 'Feeding difficulties in infancy', 'Camptodactyly of finger']","['Freeman-Sheldon syndrome/Arthrogryposis, distal, type 2A']","Disease: Freeman-Sheldon syndrome/Arthrogryposis, distal, type 2A  
Reasoning:  
1. **Craniofacial Features**: The patient exhibits ""whistling appearance"" (pursed lips), narrow mouth, hypertelorism, wide/depressed nasal bridge, micrognathia, and low-set ears—all hallmark facial traits of Freeman-Sheldon syndrome (FSS). These contribute to feeding difficulties in infancy due to restricted oral function.  
2. **Musculoskeletal Abnormalities**: Flexion contractures, talipes equinovarus (clubfoot), and camptodactyly (fixed finger flexion) align with FSS’s defining distal arthrogryposis, characterized by congenital joint limitations in hands and feet.  
3. **Urogenital Anomalies**: Hypospadias and chordee, though less common in FSS, are occasionally reported, supporting the diagnosis when combined with classic features.  
4. **Syndrome Specificity**: The constellation of craniofacial, musculoskeletal, and functional symptoms (e.g., feeding challenges) distinguishes FSS from other distal arthrogryposis subtypes or syndromes with overlapping features."
"['Cleft palate', 'Thin upper lip vermilion', 'Microcephaly', 'Low anterior hairline', 'Long philtrum', 'Low-set ears', 'Synophrys', 'Delayed speech and language development', 'Single transverse palmar crease', 'Hirsutism', 'Depressed nasal bridge', 'Curly eyelashes', 'Postnatal growth retardation', 'Intellectual disability, severe']",['Cornelia de Lange syndrome/Cornelia de Lange syndrome 1'],"Disease: Cornelia de Lange syndrome/Cornelia de Lange syndrome 1  
Reasoning:  
1. **Facial Features**: Thin upper lip vermilion, long philtrum, synophrys (confluent eyebrows), depressed nasal bridge, and low-set ears are hallmark craniofacial characteristics of Cornelia de Lange syndrome (CdLS).  
2. **Growth and Development**: Postnatal growth retardation, microcephaly, and severe intellectual disability align with CdLS-associated developmental delays and growth deficiencies.  
3. **Neurological/Speech**: Delayed speech and language development correlate with the severe intellectual disability commonly seen in CdLS.  
4. **Skeletal/Physical Anomalies**: Single transverse palmar crease and cleft palate (less common but reported in CdLS) suggest congenital structural abnormalities.  
5. **Hirsutism and Hair Features**: Excessive hair growth (hirsutism), curly eyelashes, and low anterior hairline are consistent with CdLS-associated hypertrichosis and distinctive hair patterns.  
6. **Exclusion of Alternatives**: Overlap with syndromes like fetal alcohol syndrome or Smith-Lemli-Opitz is unlikely due to the presence of synophrys, hirsutism, and CdLS-specific facial gestalt.  
7. **Genetic Link**: Cornelia de Lange syndrome 1 (NIPBL-related) is the most common genetic subtype, explaining the syndromic cohesion of these features.  

The constellation of findings strongly supports CdLS, warranting genetic testing (e.g., NIPBL mutation analysis) for confirmation."
"['Pheochromocytoma', 'Elevated calcitonin', 'Thyroid nodule']","['Multiple endocrine neoplasia, type IIA', 'Multiple endocrine neoplasia type 2A']","Multiple endocrine neoplasia, type IIA: The patient presents with pheochromocytoma, elevated calcitonin (a marker for medullary thyroid carcinoma, MTC), and a thyroid nodule. MEN IIA is characterized by the triad of MTC, pheochromocytoma, and parathyroid hyperplasia. Elevated calcitonin strongly suggests MTC, which is nearly universal in MEN IIA. The coexistence of pheochromocytoma confirms the diagnosis, as these tumors rarely occur sporadically in this combination. The thyroid nodule likely represents the MTC itself. Genetic testing for RET proto-oncogene mutations would confirm the diagnosis.  

Multiple endocrine neoplasia type 2A: This is synonymous with MEN IIA. The reasoning mirrors the above: the simultaneous occurrence of medullary thyroid carcinoma (implied by elevated calcitonin and thyroid nodule) and pheochromocytoma is pathognomonic for MEN 2A. Parathyroid involvement may or may not be clinically evident but is not required for diagnosis when both MTC and pheochromocytoma are present. Early identification is critical due to the aggressive nature of MTC in this syndrome."
"['Inguinal hernia', 'Trigonocephaly', 'Microcephaly', 'Coarse facial features', 'Proptosis', 'Pectus carinatum', 'Plagiocephaly', 'Flexion contracture', 'Failure to thrive', 'Small for gestational age', 'Delayed gross motor development', 'Hyperlordosis', 'Depressed nasal bridge', 'Hyperactive deep tendon reflexes']",['Mucolipidosis type II/Mucolipidosis II alpha/beta'],"Disease: Mucolipidosis type II alpha/beta (I-cell disease)  
Reasoning:  
1. **Coarse facial features, depressed nasal bridge, proptosis**: Hallmark of lysosomal storage disorders (LSDs), particularly ML II due to glycosaminoglycan accumulation in tissues.  
2. **Trigonocephaly, plagiocephaly, microcephaly**: Craniosynostosis and skull deformities from abnormal bone development, common in ML II.  
3. **Skeletal abnormalities (pectus carinatum, hyperlordosis, flexion contractures)**: Reflect severe skeletal dysplasia (""dysostosis multiplex"") caused by defective lysosomal enzyme trafficking.  
4. **Failure to thrive, small for gestational age**: Growth retardation typical of ML II, presenting prenatally or early infancy.  
5. **Delayed motor development, hyperactive deep tendon reflexes**: Neurological involvement from storage material accumulation and spinal cord compression.  
6. **Inguinal hernia**: Connective tissue weakness, frequently seen in ML II and other LSDs.  

ML II is confirmed by deficient **GlcNAc-1-phosphotransferase** activity, elevated lysosomal enzymes in plasma, and pathogenic variants in the *GNPTAB* gene."
"['Brachycephaly', 'Hypertelorism', 'Narrow forehead', 'Proptosis', 'Delayed speech and language development', 'Pectus carinatum', 'Brachydactyly', 'Polyhydramnios', 'Polyhydramnios', 'Hallux valgus', 'Gastroesophageal reflux', 'Respiratory distress', 'Clinodactyly of the 5th finger', 'Depressed nasal bridge', 'Flat occiput', 'Aspiration pneumonia', 'Thick vermilion border']",['Chitayat syndrome'],"Disease: Chitayat syndrome  
Reasoning:  
1. **Craniofacial Features**: Brachycephaly (premature fusion of coronal sutures), hypertelorism, proptosis, narrow forehead, depressed nasal bridge, and thick vermilion border align with Chitayat syndrome’s characteristic facial dysmorphism.  
2. **Skeletal Abnormalities**: Pectus carinatum, brachydactyly, clinodactyly of the 5th finger, and hallux valgus are consistent with skeletal manifestations of ERF-related craniosynostosis syndromes.  
3. **Developmental Delays**: Delayed speech and language development correlate with neurodevelopmental involvement seen in Chitayat syndrome.  
4. **Prenatal/Neonatal Issues**: Polyhydramnios (duplicated in symptoms) and respiratory distress at birth are linked to abnormal fetal swallowing or thoracic restriction.  
5. **Complications**: Gastroesophageal reflux and aspiration pneumonia may result from craniofacial anatomy impacting airway and swallowing function.  
6. **Genetic Confirmation**: While not explicitly stated, Chitayat syndrome is caused by pathogenic ERF variants, which would confirm the diagnosis via genetic testing.  

This constellation of craniosynostosis, facial dysmorphism, skeletal anomalies, and developmental delays strongly supports Chitayat syndrome."
"['Urinary retention', 'Abnormality of male external genitalia', 'Micropenis', 'Ureteral duplication', 'Abnormality of the kidney', 'Microretrognathia', 'Abnormality of the outer ear', 'Hearing impairment', 'Low-set ears', 'Abnormality of the eye', 'Visual impairment', 'Autistic behavior', 'Delayed speech and language development', 'Sacral dimple', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Motor delay', 'Absent speech', 'Abnormality of the cardiovascular system', 'Patent ductus arteriosus', 'Tracheomalacia', 'Abnormality of the upper limb', 'Birth length less than 3rd percentile', 'Laryngeal cleft', 'Aplasia/Hypoplasia of the thumb', 'Fetal pyelectasis', 'Feeding difficulties', 'Abnormal optic disc morphology', 'Cerebral visual impairment']",['Stankiewicz-Isidor syndrome'],"Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Genetic Basis**: Stankiewicz-Isidor syndrome is caused by heterozygous pathogenic variants in *PHIP*. The patient’s multi-system congenital anomalies align with this disorder’s phenotypic spectrum.  
2. **Urogenital Abnormalities**: Urinary retention, micropenis, ureteral duplication, kidney abnormalities, and fetal pyelectasis match the recurrent urogenital defects seen in this syndrome.  
3. **Craniofacial Features**: Microretrognathia, low-set ears, outer ear abnormalities, and ocular defects (abnormal optic disc, visual impairment) are consistent with characteristic facial dysmorphism.  
4. **Neurodevelopmental Delays**: Intellectual disability, autistic behavior, absent speech, motor delay, and seizures correlate with the syndrome’s severe developmental delays and neurological involvement.  
5. **Cardiovascular/Respiratory Defects**: Patent ductus arteriosus (PDA) and tracheomalacia/laryngeal cleft reflect the congenital cardiovascular/respiratory anomalies reported in affected individuals.  
6. **Limb Anomalies**: Thumb aplasia/hypoplasia and upper limb abnormalities are documented in some cases.  
7. **Growth and Feeding Issues**: Birth length <3rd percentile and feeding difficulties align with prenatal/postnatal growth failure.  
8. **Sensory Deficits**: Hearing impairment and cerebral visual impairment are recurrent features.  
9. **Supportive Findings**: Hypotonia, sacral dimple, and seizures further reinforce the diagnosis, as these are common in *PHIP*-related disease.  
**Conclusion**: The constellation of congenital anomalies, neurodevelopmental deficits, and multi-organ involvement strongly points to Stankiewicz-Isidor syndrome. Genetic testing for *PHIP* variants is recommended for confirmation."
"['Short neck', 'Intellectual disability', 'Kyphoscoliosis', 'Back pain', 'Vertebral segmentation defect', 'Disproportionate short-trunk short stature']","['Spondylocostal dysostosis, autosomal recessive 1']","Disease: Spondylocostal dysostosis, autosomal recessive 1  
Reasoning: The patient presents with vertebral segmentation defects and kyphoscoliosis, hallmark features of spondylocostal dysostosis (SCD). Disproportionate short-trunk short stature and a short neck align with axial skeletal involvement. Autosomal recessive type 1 (SCDO1), linked to *DLL3* mutations, is characterized by severe vertebral malformations and rib anomalies. While intellectual disability is atypical in isolated SCDO1, it may occur in syndromic overlaps or due to secondary complications (e.g., spinal cord compression). Back pain likely stems from structural spinal instability. The constellation of vertebral, thoracic, and growth defects strongly supports this diagnosis."
"['Hypertelorism', 'Erythroderma', 'Hypermelanotic macule', 'Failure to thrive', 'Pneumonia', 'Hepatomegaly', 'Hypoalbuminemia', 'Decreased circulating IgG level', 'Spotty hyperpigmentation', 'Interstitial pneumonitis', 'Prolonged neonatal jaundice', 'Prominent forehead', 'Elevated gamma-glutamyltransferase level', 'Persistent CMV viremia', 'Reduced natural killer cell count', 'Abnormal circulating IgA level', 'Abnormal circulating IgM level']",['Syndromic diarrhea/Trichohepatoenteric syndrome 1'],"Disease: Syndromic diarrhea/Trichohepatoenteric syndrome 1 (THES1)  
Reasoning:  
1. **Facial dysmorphism**: Hypertelorism and prominent forehead align with characteristic craniofacial features of THES1.  
2. **Cutaneous findings**: Erythroderma, hypermelanotic macules, and spotty hyperpigmentation correlate with the dermatological abnormalities (e.g., woolly hair, skin pigmentation defects) seen in THES1.  
3. **Gastrointestinal and hepatic involvement**: Failure to thrive, hepatomegaly, hypoalbuminemia, prolonged neonatal jaundice, and elevated GGT reflect the triad of intractable diarrhea, liver dysfunction, and protein-losing enteropathy central to THES1.  
4. **Immunodeficiency**: Decreased IgG, abnormal IgA/IgM, reduced NK cells, persistent CMV viremia, and recurrent infections (pneumonia/interstitial pneumonitis) indicate the combined immunodeficiency associated with THES1 due to TTC37 or SKIV2L gene mutations.  
5. **Systemic coherence**: The combination of enteropathy, trichorrhexis nodosa (implied by cutaneous/hair symptoms), liver disease, and immune defects is pathognomonic for THES1, distinguishing it from isolated immunodeficiency or metabolic disorders."
"['Thrombocytopenia', 'Abnormal bleeding', 'Giant platelets', 'Impaired ristocetin-induced platelet aggregation', 'Subdural hemorrhage']",['Bernard-Soulier syndrome/Bernard-Soulier syndrome'],"Disease: Bernard-Soulier syndrome  
Reasoning:  
1. **Thrombocytopenia**: Low platelet count aligns with Bernard-Soulier syndrome (BSS), as giant platelets are often misclassified or destroyed, reducing measured counts.  
2. **Giant platelets**: Pathognomonic for BSS due to mutations in the *GP1BA*, *GP1BB*, or *GP9* genes, disrupting platelet membrane glycoprotein Ib-IX-V complex formation.  
3. **Impaired ristocetin-induced platelet aggregation**: Specific to BSS, as ristocetin requires functional glycoprotein Ib-IX-V to bind von Willebrand factor (vWF). This defect distinguishes BSS from von Willebrand disease (where ristocetin aggregation is normal or enhanced).  
4. **Abnormal bleeding and subdural hemorrhage**: Reflects severe platelet dysfunction and thrombocytopenia, consistent with BSS’s clinical presentation.  
5. **Exclusion of mimics**: Normal prothrombin time (PT) and activated partial thromboplastin time (aPTT) (implied absence of clotting factor issues) and lack of Döhle bodies (unlike MYH9-related disorders) further support BSS."
"['Delayed cranial suture closure', 'Dental malocclusion', 'Delayed eruption of permanent teeth', 'Joint laxity', 'Wormian bones', 'Hypoplastic iliac wing', 'Depressed nasal bridge', 'Aplastic clavicle', 'Delayed pubic bone ossification', 'Supernumerary tooth']",['Cleidocranial dysplasia/Cleidocranial dysplasia'],"Cleidocranial dysplasia/Cleidocranial dysplasia:  
1. **Aplastic clavicle** is a hallmark feature of cleidocranial dysplasia (CCD), often leading to hypermobile shoulders.  
2. **Delayed cranial suture closure** and **Wormian bones** reflect impaired intramembranous ossification, characteristic of CCD.  
3. **Dental malocclusion**, **delayed eruption of permanent teeth**, and **supernumerary tooth** stem from defective dental development and abnormal tooth formation, common in CCD.  
4. **Hypoplastic iliac wing** and **delayed pubic bone ossification** indicate skeletal dysplasia affecting pelvic bone development.  
5. **Depressed nasal bridge** aligns with midface hypoplasia seen in CCD.  
6. **Joint laxity** may result from connective tissue involvement in skeletal development.  
This constellation of craniofacial, dental, and skeletal anomalies is pathognomonic for CCD, typically caused by mutations in the *RUNX2* gene."
"['Narrow mouth', 'Microcephaly', 'Nystagmus', 'Hypertrichosis', 'Erythroderma', 'Brachydactyly', 'Preaxial hand polydactyly', 'Seizure', 'Hypertonia', 'Atrial septal defect', 'Abnormal cardiac septum morphology', 'Postaxial foot polydactyly', 'Eosinophilia', 'Abnormal facial shape', 'Delayed gross motor development', 'Limb hypertonia', 'Hypsarrhythmia', 'Skeletal dysplasia', 'Spondyloepiphyseal dysplasia', 'Elbow flexion contracture', 'Severe combined immunodeficiency', 'Generalized hypertrichosis', 'Combined immunodeficiency', 'Absence of CD8-positive T cells', 'Axial hypotonia', 'Profound global developmental delay', 'Abnormal natural killer cell count', 'Enlarged uterus']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Immunodeficiency**: Severe combined immunodeficiency (SCID), combined immunodeficiency, absence of CD8+ T cells, and abnormal NK cell count align with ISDNA’s hallmark immune dysfunction due to EXTL3 mutations affecting lymphocyte development.  
2. **Skeletal Abnormalities**: Brachydactyly, preaxial/postaxial polydactyly, spondyloepiphyseal dysplasia, and elbow contractures match ISDNA’s skeletal dysplasia phenotype, characterized by defective bone growth and limb anomalies.  
3. **Neurodevelopmental Features**: Profound global developmental delay, seizures, hypertonia (limb), axial hypotonia, and hypsarrhythmia reflect central nervous system involvement, consistent with ISDNA’s neurodevelopmental defects.  
4. **Dysmorphic Traits**: Microcephaly, narrow mouth, and abnormal facial shape are typical craniofacial findings in ISDNA.  
5. **Additional Features**: Hypertrichosis and erythroderma may overlap with immune dysregulation, while eosinophilia could signal aberrant immune activity. Cardiac septal defects and enlarged uterus, though less common, may represent variable expressivity of the disorder.  
6. **Genetic Basis**: ISDNA is caused by biallelic EXTL3 mutations, which disrupt glycosaminoglycan synthesis, explaining multisystem involvement (immune, skeletal, neural).  
**Conclusion**: The constellation of severe immunodeficiency, skeletal dysplasia, neurodevelopmental delay, and dysmorphism strongly supports ISDNA, necessitating EXTL3 gene testing for confirmation."
"['Hepatosplenomegaly', 'Anemia', 'Fever', 'Pulmonary infiltrates', 'Lymphadenopathy', 'Recurrent upper respiratory tract infections', 'Elevated proportion of CD4-negative, CD8-negative, alpha-beta regulatory T cells', 'Increased circulating IgG level', 'Increased circulating IgA level', 'Abdominal distention', 'Increased circulating IgM level', 'Neutrophilia', 'Monocytosis', 'Lymphocytosis']",['Autoimmune lymphoproliferative syndrome/Autoimmune lymphoproliferative syndrome'],"Disease: Autoimmune lymphoproliferative syndrome (ALPS)  
Reasoning:  
1. **Lymphoproliferation**: Hepatosplenomegaly, lymphadenopathy, and abdominal distention align with chronic lymphoid accumulation due to defective apoptosis.  
2. **Autoimmunity**: Anemia likely reflects autoimmune hemolytic anemia, a hallmark of ALPS. Elevated IgG, IgA, and IgM levels suggest polyclonal hypergammaglobulinemia from dysregulated B-cell activity.  
3. **Double-Negative T Cells**: Elevated CD4⁻CD8⁻ αβ T cells (≥1.5% of total lymphocytes) are pathognomonic for ALPS, caused by FAS/FASLG/CASP10 gene mutations impairing lymphocyte apoptosis.  
4. **Hematologic Abnormalities**: Neutrophilia, monocytosis, and lymphocytosis indicate reactive changes from chronic inflammation or compensatory mechanisms.  
5. **Infections**: Recurrent respiratory infections and pulmonary infiltrates may stem from immune dysfunction or secondary infections due to hypersplenism/autoimmunity.  
6. **Exclusion of Mimics**: Features distinguish ALPS from lymphoma (non-malignant proliferation) or other immune dysregulation syndromes (e.g., CVID, which lacks double-negative T cells).  
**Conclusion**: The triad of lymphoproliferation, autoimmunity, and elevated double-negative T cells confirms ALPS."
"['Bird-like facies', 'Cataract', 'Diabetes mellitus', 'Hypothyroidism', 'Hypertension', 'Osteoporosis', 'Hyperkeratosis', 'High pitched voice', 'Pes planus', 'Truncal obesity', 'Hypertriglyceridemia', 'Premature graying of hair', 'External genital hypoplasia', 'Reduced subcutaneous adipose tissue', 'Short stature', 'Type II diabetes mellitus', 'Corneal ulceration', 'Achilles tendon calcification']",['Werner syndrome/Werner syndrome'],"Disease: Werner syndrome  
Reasoning:  
1. **Premature Aging Features**: Bird-like facies, premature graying of hair, short stature, and osteoporosis align with the accelerated aging phenotype of Werner syndrome.  
2. **Ocular Manifestations**: Cataracts and corneal ulceration are common due to connective tissue degeneration and impaired wound healing.  
3. **Endocrine/Metabolic Dysregulation**: Type II diabetes mellitus, hypothyroidism, hypertension, hypertriglyceridemia, and truncal obesity reflect metabolic disturbances typical of the syndrome.  
4. **Dermatological Signs**: Hyperkeratosis and reduced subcutaneous adipose tissue are consistent with skin atrophy and scleroderma-like changes.  
5. **Musculoskeletal Abnormalities**: Pes planus and Achilles tendon calcification result from connective tissue calcification and ligamentous laxity.  
6. **Genitourinary Features**: External genital hypoplasia is a rare but reported finding in Werner syndrome.  
7. **Voice Changes**: High-pitched voice may stem from laryngeal atrophy or connective tissue alterations.  
8. **Diagnostic Exclusion**: The absence of childhood-onset rapid aging (as in Hutchinson-Gilford progeria) and presence of bilateral cataracts + diabetes strongly support Werner syndrome over other progeroid disorders.  

The constellation of premature aging, metabolic abnormalities, and connective tissue pathology confirms the diagnosis."
"['Ophthalmoplegia', 'Intellectual disability', 'Hypotonia', 'Bulbar palsy', 'Areflexia', 'Respiratory insufficiency', 'Drooling', 'Scoliosis', 'Proximal muscle weakness', 'Ankle flexion contracture']",['Nemaline myopathy 3'],"Disease: Nemaline myopathy 3  
Reasoning:  
1. **Proximal muscle weakness, hypotonia, and areflexia** align with congenital myopathies, particularly nemaline myopathy.  
2. **Bulbar palsy and respiratory insufficiency** indicate severe neuromuscular dysfunction, consistent with nemaline myopathy type 3 (severe congenital form), which often involves respiratory and bulbar muscle compromise.  
3. **Ophthalmoplegia** is a distinguishing feature of type 3, differentiating it from other nemaline myopathy subtypes.  
4. **Scoliosis and ankle flexion contractures** reflect chronic muscle weakness and skeletal adaptations, common in progressive congenital myopathies.  
5. **Intellectual disability** (though rare in most myopathies) can occur in severe cases due to secondary effects of hypoxia or genetic comorbidities.  
6. **Drooling** correlates with bulbar palsy, further supporting neuromuscular involvement.  
7. Genetic confirmation (ACTA1 or TPM3 mutations) would solidify the diagnosis, but the clinical triad of ophthalmoplegia, bulbar/respiratory failure, and early-onset hypotonia strongly suggests nemaline myopathy 3."
"['Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Hypercholesterolemia', 'Increased LDL cholesterol concentration', 'Elevated circulating alkaline phosphatase concentration', 'Infantile muscular hypotonia', 'Decreased circulating ceruloplasmin concentration', 'Abnormal protein N-linked glycosylation', 'Abnormal protein O-linked glycosylation', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Abnormal N-linked and O-linked glycosylation**: Indicates a Golgi-associated glycosylation defect (Type II CDG), consistent with TMEM199-CDG, which disrupts Golgi homeostasis.  
2. **Hepatic involvement**: Elevated AST, ALT, and alkaline phosphatase reflect liver dysfunction, a hallmark of TMEM199-CDG due to impaired glycosylation-dependent hepatic protein secretion.  
3. **Hypotonia/developmental delay**: Common in CDGs due to systemic glycosylation defects affecting neurological and muscular development.  
4. **Hypercholesterolemia/increased LDL**: Linked to disrupted LDL receptor glycosylation or altered lipid metabolism regulation in the liver.  
5. **Decreased ceruloplasmin**: Ceruloplasmin is a glycoprotein; improper glycosylation reduces its stability, leading to low circulating levels.  
6. **TMEM199 gene association**: Confirms CDG-Type IIP, as TMEM199 mutations specifically impair Golgi manganese transport, critical for glycosylation enzymes.  

(Note: The two diagnoses provided are synonymous, as ""Congenital disorder of glycosylation, type IIP"" is the clinical term for TMEM199-CDG.)"
"['Visual impairment', 'Rod-cone dystrophy', 'Optic atrophy', 'Delayed speech and language development', 'Intellectual disability', 'Truncal obesity', 'Retinal pigment epithelial mottling', 'Attenuation of retinal blood vessels', 'Polydactyly', 'Retinal thinning']",['Bardet-Biedl syndrome 4'],"Disease: Bardet-Biedl syndrome 4  
Reasoning:  
1. **Retinal abnormalities**: Rod-cone dystrophy, retinal pigment epithelial mottling, attenuation of retinal blood vessels, and retinal thinning are hallmark features of Bardet-Biedl syndrome (BBS), reflecting progressive retinal degeneration.  
2. **Visual impairment/Optic atrophy**: Secondary to advanced retinal dystrophy, consistent with BBS-associated ocular manifestations.  
3. **Polydactyly**: A primary diagnostic criterion for BBS, present in ~70% of cases.  
4. **Truncal obesity**: A core feature of BBS, typically emerging in early childhood.  
5. **Developmental delay/Intellectual disability**: Common neurocognitive features of BBS, particularly in speech and language domains.  
6. **Genetic subtype specificity**: BBS4 (linked to *BBS4* gene mutations) is distinguished by these classic features without atypical organ involvement, aligning with the patient’s phenotype.  
7. **Exclusion of mimics**: Laurence-Moon syndrome lacks polydactyly, while Alström syndrome lacks polydactyly and intellectual disability, further supporting BBS4."
"['Microcephaly', 'Cyanosis', 'Edema', 'Neonatal hypotonia', 'Death in infancy', 'Truncus arteriosus', 'Abnormal facial shape', 'Elevated circulating creatinine concentration', 'Pulmonary artery atresia', 'Persistent left superior vena cava', 'Generalized edema', 'Partial anomalous pulmonary venous return', 'Interrupted aortic arch', 'Tricuspid atresia', 'Right aortic arch', 'Tetralogy of Fallot with pulmonary atresia', 'Heart murmur', 'Systolic heart murmur', 'Aortopulmonary collateral arteries']",['Structural heart defects and renal anomalies syndrome'],"Disease: Structural heart defects and renal anomalies syndrome  
Reasoning:  
1. **Cardiac Anomalies**: Multiple severe congenital heart defects are present, including truncus arteriosus, tetralogy of Fallot with pulmonary atresia, interrupted aortic arch, tricuspid atresia, and aortopulmonary collaterals. These collectively explain symptoms like cyanosis, heart murmurs, and systolic murmurs due to impaired blood flow and mixing of oxygenated/deoxygenated blood.  
2. **Renal Involvement**: Elevated creatinine indicates renal dysfunction, a key feature of the syndrome. Edema (generalized and localized) may result from combined cardiac failure and renal fluid retention.  
3. **Dysmorphic Features**: Microcephaly and abnormal facial shape suggest a developmental/genetic etiology, aligning with syndromic diagnoses that involve multi-organ malformations.  
4. **Early Lethality**: Neonatal hypotonia, critical cardiac defects, and death in infancy reflect the syndrome’s severity, typical of disorders disrupting essential organogenesis.  
5. **Genetic Basis**: The constellation of cardiac, renal, and craniofacial anomalies points to a rare genetic syndrome affecting neural crest-derived structures (heart, great vessels) and renal development, though specific gene mutations (e.g., *NKX2-5*, *NOTCH1*, or chromatin regulators) may require further testing."
"['Congestive heart failure', 'Dilated cardiomyopathy', 'Atrioventricular block', 'Premature atrial contractions']","['Cardiomyopathy, dilated, 1G']","Disease: Cardiomyopathy, dilated, 1G  
Reasoning:  
1. **Dilated cardiomyopathy (DCM)** is the core feature of CMD1G, caused by mutations in the *TTN* gene. The patient’s presentation of DCM aligns with this genetic etiology.  
2. **Congestive heart failure** commonly arises secondary to DCM due to impaired systolic function, supporting structural and functional cardiac dysfunction typical of CMD1G.  
3. **Atrioventricular (AV) block** and **premature atrial contractions (PACs)** suggest conduction system abnormalities. *TTN* mutations can disrupt cardiac sarcomere integrity, leading to electrical instability and conduction defects.  
4. The coexistence of DCM with arrhythmic features (AV block, PACs) is characteristic of CMD1G, distinguishing it from non-genetic DCM forms, which less frequently involve conduction abnormalities early in disease progression.  
5. Genetic testing for *TTN* variants would confirm the diagnosis, as this gene accounts for ~25% of familial DCM cases with arrhythmic manifestations."
"['Mandibular prognathia', 'Triangular face', 'Broad forehead', 'Protruding ear', 'Deeply set eye', 'Posterior embryotoxon', 'Jaundice', 'Dry skin', 'Xanthelasma', 'Global developmental delay', 'Cholestasis', 'Pulmonary hypoplasia', 'Hepatomegaly', 'Butterfly vertebrae', 'Acholic stools', 'Widened subarachnoid space', 'Heart murmur', 'Sparse eyebrow']",['Alagille syndrome/Alagille syndrome 1'],"Disease: Alagille syndrome/Alagille syndrome 1  
Reasoning:  
1. **Hepatobiliary Features**: Cholestasis, jaundice, acholic stools, and hepatomegaly are hallmark signs of Alagille syndrome (ALGS), caused by bile duct paucity leading to chronic liver dysfunction.  
2. **Cardiac Involvement**: Heart murmur aligns with ALGS-associated cardiovascular anomalies (e.g., peripheral pulmonary stenosis).  
3. **Facial Dysmorphism**: Triangular face, broad forehead, protruding ears, deeply set eyes, and sparse eyebrows are classic craniofacial features of ALGS.  
4. **Ocular Findings**: Posterior embryotoxon (a defining anterior segment eye anomaly) and xanthelasma (secondary to hyperlipidemia from cholestasis) support the diagnosis.  
5. **Skeletal Abnormalities**: Butterfly vertebrae (vertebral arch defects) are pathognomonic for ALGS.  
6. **Developmental Delay**: Global developmental delay and widened subarachnoid space may reflect multisystemic involvement or nutritional deficits from chronic cholestasis.  
7. **Cutaneous Features**: Dry skin and xanthelasma correlate with lipid metabolism disruption due to cholestasis.  
8. **Pulmonary Hypoplasia**: Rarely reported in ALGS but may occur secondary to severe thoracic skeletal anomalies.  

The combination of liver, cardiac, facial, ocular, and skeletal findings strongly confirms Alagille syndrome."
"['Abnormality of eye movement', 'Seizure', 'Global developmental delay', 'Aplasia/Hypoplasia of the cerebellum', 'Reduced visual acuity']",['Joubert syndrome 30'],"Disease: Joubert syndrome 30  
Reasoning:  
1. **Aplasia/Hypoplasia of the cerebellum**: Joubert syndrome is defined by cerebellar vermis hypoplasia/aplasia, classically presenting with the ""molar tooth sign"" on neuroimaging, aligning with this symptom.  
2. **Abnormality of eye movement**: Oculomotor apraxia and nystagmus are hallmark features of Joubert syndrome due to cerebellar and midbrain malformations.  
3. **Global developmental delay**: Neurodevelopmental delays are universal in Joubert syndrome, reflecting disrupted cerebellar and brainstem function.  
4. **Seizure**: While not present in all subtypes, seizures occur in some Joubert syndrome cases, including those linked to *CPLANE1* mutations (JBTS30).  
5. **Reduced visual acuity**: Retinal dystrophy or optic nerve colobomas, common in Joubert syndrome subtypes, explain visual impairment.  
6. **Subtype specificity**: JBTS30 (linked to *CPLANE1*) is associated with cerebellar, ocular, and occasional renal/limb anomalies, fitting the clinical profile without contradicting features."
"['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Single transverse palmar crease', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Intellectual disability, mild', 'Global developmental delay', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Abnormal cerebellar vermis morphology', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental features**: Intellectual disability (mild), global developmental delay, ADHD/hyperactivity, and atypical behavior align with the core neurocognitive deficits in NEDBEH.  
2. **Brain anomalies**: Abnormal corpus callosum, cerebellar vermis, and pons morphology, cerebral hypomyelination, ventriculomegaly, and delayed myelination match the ""brain"" phenotype in NEDBEH.  
3. **Ocular anomalies**: Coloboma, microphthalmia, blepharophimosis, Peters anomaly, optic atrophy, and iris/eyebrow abnormalities satisfy the ""eye"" criterion.  
4. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return correspond to the ""heart"" component.  
5. **Supportive systemic features**: Cleft lip, renal cysts, gastrointestinal anomalies (pyloric stenosis, duodenal atresia), and skeletal findings (syndactyly, scoliosis) are reported in NEDBEH.  
6. **Overlapping dysmorphism**: Microcephaly/macrocephaly, triangular face, micrognathia, hypertelorism, and narrow mouth are consistent with facial gestalt seen in NEDBEH.  
7. **Hypotonia/spasticity**: Generalized hypotonia and spastic tetraparesis reflect the CNS involvement typical of the disorder.  

The constellation of neurodevelopmental delays, structural brain/eye/heart anomalies, and multisystem involvement strongly supports this diagnosis over isolated syndromes (e.g., CHARGE, Rubinstein-Taybi) due to the absence of pathognomonic features for other entities."
"['High palate', 'Everted lower lip vermilion', 'Triangular face', 'Hypoplasia of the maxilla', 'Narrow nose', 'Blepharophimosis', 'Thin ribs', 'Lateral clavicle hook', 'Arachnodactyly', 'Intellectual disability', 'Pes planus', 'Generalized joint laxity', 'Genu valgum', 'Elbow flexion contracture', 'Dislocated radial head', 'Depressed nasal bridge', 'Camptodactyly']",['Van den Ende-Gupta syndrome'],"Disease: Van den Ende-Gupta syndrome  
Reasoning:  
1. **Craniofacial features**: Triangular face, hypoplasia of the maxilla, high palate, narrow nose, everted lower lip vermilion, and depressed nasal bridge align with the characteristic facial dysmorphism seen in Van den Ende-Gupta syndrome (VDEGS).  
2. **Ocular findings**: Blepharophimosis (narrowed palpebral fissures) is a hallmark feature of VDEGS.  
3. **Skeletal anomalies**: Thin ribs, lateral clavicle hook, arachnodactyly, camptodactyly, elbow flexion contracture, dislocated radial head, pes planus, and generalized joint laxity match the syndrome’s skeletal phenotype.  
4. **Developmental involvement**: Intellectual disability is variably present in VDEGS, further supporting the diagnosis.  
5. **Exclusion of mimics**: The combination of blepharophimosis, skeletal features, and intellectual disability differentiates VDEGS from Marfan syndrome, Loeys-Dietz syndrome, or congenital contractural arachnodactyly, which lack this specific syndromic constellation.  
6. **Genetic confirmation**: While clinical findings are sufficient for provisional diagnosis, VDEGS is caused by biallelic variants in *SCARF2*, and genetic testing would confirm the diagnosis."
"['Microcephaly', 'Hypertelorism', 'Bird-like facies', 'Recurrent otitis media', 'Upslanted palpebral fissure', 'Hypopigmentation of the skin', 'Intrauterine growth retardation', 'Bronchiectasis', 'Large fleshy ears', 'Decreased circulating IgA level', 'Decreased circulating total IgM', 'Impaired lymphocyte transformation with phytohemagglutinin', 'Elevated erythrocyte sedimentation rate', 'Decreased circulating IgG level', 'Recurrent pneumonia', 'Elevated circulating C-reactive protein concentration', 'Clinodactyly', 'Severe varicella zoster infection']",['Nijmegen breakage syndrome/Nijmegen breakage syndrome'],"Disease: Nijmegen breakage syndrome  
Reasoning:  
1. **Immunodeficiency**: Recurrent infections (otitis media, pneumonia), severe varicella zoster infection, decreased IgA/IgG/IgM, and impaired lymphocyte transformation indicate combined B- and T-cell dysfunction, characteristic of NBS.  
2. **Craniofacial Features**: Microcephaly, hypertelorism, bird-like facies, upslanted palpebral fissures, and large fleshy ears are hallmark dysmorphic traits of NBS.  
3. **Growth Abnormalities**: Intrauterine growth retardation aligns with NBS-associated prenatal developmental delays.  
4. **Chromosomal Instability**: Impaired lymphocyte transformation (due to defective DNA repair) and hypopigmentation suggest chromosomal breakage, a core feature of NBS.  
5. **Inflammatory Markers**: Elevated ESR and CRP reflect chronic inflammation from recurrent infections.  
6. **Bronchiectasis**: Secondary to recurrent respiratory infections, common in immunodeficiency disorders like NBS.  
7. **Clinodactyly**: A minor skeletal anomaly often seen in genetic syndromes, including NBS.  

Nijmegen breakage syndrome integrates these features via mutations in *NBN*, causing DNA repair defects, immunodeficiency, and developmental anomalies."
"['Focal segmental glomerulosclerosis', 'Microcephaly', 'Hypertelorism', 'Low-set ears', 'Congenital diaphragmatic hernia', 'Hiatus hernia', 'Cerebral atrophy', 'Volvulus', 'Congenital nephrotic syndrome', 'Simplified gyral pattern']",['Galloway-Mowat syndrome 4'],"Disease: Galloway-Mowat syndrome 4  
Reasoning:  
1. **Congenital nephrotic syndrome** and **focal segmental glomerulosclerosis (FSGS)** indicate early-onset renal dysfunction, a hallmark of Galloway-Mowat syndrome (GAMOS).  
2. **Microcephaly**, **cerebral atrophy**, and **simplified gyral pattern** reflect severe neurodevelopmental abnormalities, consistent with GAMOS-associated brain malformations.  
3. **Hypertelorism** and **low-set ears** are dysmorphic facial features commonly linked to GAMOS.  
4. **Congenital diaphragmatic hernia** and **hiatus hernia** suggest connective tissue or developmental defects, reported in GAMOS subtypes.  
5. **Volvulus** aligns with gastrointestinal anomalies occasionally associated with GAMOS.  
6. The combination of renal, neurological, craniofacial, and diaphragmatic defects strongly supports **Galloway-Mowat syndrome 4** (GAMOS4), caused by biallelic *WDR73* mutations, which correlates with this multisystem phenotype."
"['Cleft palate', 'Choanal atresia', 'Elevated circulating thyroid-stimulating hormone concentration', 'Thyroid agenesis', 'Feeding difficulties', 'Decreased circulating T4 concentration', 'Hypersomnia']","['Bamforth-Lazarus syndrome/Hypothyroidism, athyroidal, with spiky hair and cleft palate']","Disease: Bamforth-Lazarus syndrome/Hypothyroidism, athyroidal, with spiky hair and cleft palate  
Reasoning:  
1. **Thyroid agenesis** and **elevated TSH/low T4** confirm **primary congenital hypothyroidism** due to absent thyroid tissue, a hallmark of Bamforth-Lazarus syndrome.  
2. **Cleft palate** and **choanal atresia** are classic craniofacial anomalies linked to FOXE1 gene mutations, which drive this syndrome.  
3. **Feeding difficulties** commonly arise from structural issues (cleft palate, choanal atresia) impairing suck-swallow-breath coordination.  
4. **Hypersomnia** aligns with severe hypothyroidism, causing metabolic slowdown and lethargy.  
5. The triad of thyroid agenesis, cleft palate, and choanal atresia is pathognomonic for Bamforth-Lazarus syndrome, excluding other causes (e.g., isolated CHARGE syndrome or Pendred syndrome)."
"['Small face', 'Prominent supraorbital ridges', 'Strabismus', 'Shallow orbits', 'Eruption failure', 'obsolete Hypotrichosis', 'Alopecia', 'Frontal bossing', 'Severe short stature', 'Concave nasal ridge', 'Thick vermilion border']",['GAPO syndrome/GAPO syndrome'],"Disease: GAPO syndrome  
Reasoning:  
1. **Severe short stature**: Matches ""Growth retardation"" in GAPO (Growth Retardation, Alopecia, Pseudoanodontia, Optic atrophy).  
2. **Alopecia and Hypotrichosis**: Directly aligns with the ""Alopecia"" component of GAPO, involving hair loss.  
3. **Eruption failure**: Corresponds to ""Pseudoanodontia"" (failure of tooth eruption), a hallmark of GAPO.  
4. **Strabismus and Shallow orbits**: Suggests optic involvement, consistent with ""Optic atrophy"" (though atrophy may develop later; strabismus is a common early ocular finding).  
5. **Facial dysmorphism** (Small face, Prominent supraorbital ridges, Frontal bossing, Concave nasal ridge, Thick vermilion border): Characteristic craniofacial features reported in GAPO, including frontal bossing and midface hypoplasia.  
6. **Exclusion of alternatives**: Symptoms collectively fit GAPO’s triad (growth delay, alopecia, pseudoanodontia) with supporting ocular and facial signs, ruling out similar syndromes like ectodermal dysplasia or progeria."
"['Nystagmus', 'Pancytopenia', 'Spinocerebellar tract degeneration', 'Decreased circulating IgA level', 'Decreased circulating total IgM', 'Decreased circulating IgG level', 'Cellular immunodeficiency', 'Bone marrow hypocellularity', 'Lower limb muscle weakness', 'Leg muscle stiffness']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Pancytopenia and bone marrow hypocellularity**: Central features of the syndrome, directly linked to bone marrow dysfunction.  
2. **Spinocerebellar tract degeneration**: Explains ataxia (implicit in the syndrome name) and neurological symptoms like nystagmus and lower limb muscle weakness/stiffness.  
3. **Immunodeficiency**: Decreased IgA, IgM, IgG levels and cellular immunodeficiency align with the syndrome’s hallmark humoral and T-cell defects.  
4. **Exclusion of mimics**: Lack of telangiectasia (rules out ataxia-telangiectasia) and absence of physical anomalies/DNA repair defects (rules out Fanconi anemia).  
5. **Symptom coherence**: The triad of ataxia, pancytopenia, and immunodeficiency is pathognomonic for APS."
"['Abnormality of the dentition', 'Absent eyelashes', 'Abnormal sweat gland morphology', 'Absent eyebrow', 'Absent hair', 'Nail dystrophy', 'Onycholysis of fingernails']","['Ectodermal dysplasia 9, Hair/nail type']","Disease: Ectodermal dysplasia 9, Hair/nail type  
Reasoning: The patient presents with multisystemic ectodermal abnormalities, including **absent hair, eyelashes, and eyebrows** (indicative of severe hair follicle involvement), **nail dystrophy** and **onycholysis** (reflecting defective nail development), and **abnormality of the dentition** (common in ectodermal dysplasias). **Abnormal sweat gland morphology** further supports ectodermal origin. These findings align with **ECTD9**, a subtype caused by *HOXC13* mutations, characterized by congenital atrichia, nail dysplasia, and variable dental anomalies. The absence of severe sweating dysfunction distinguishes it from hypohidrotic ectodermal dysplasia, emphasizing the hair/nail predominance in this diagnosis."
"['Triangular face', 'Posteriorly rotated ears', 'Sensorineural hearing impairment', 'Delayed speech and language development', 'Global developmental delay', 'Partial agenesis of the corpus callosum', 'Slender build', 'Asthma', '2-3 toe syndactyly', 'Hyperextensibility at elbow', 'Sparse eyebrow', 'Knee joint hypermobility', 'Arachnoid cyst']","['Chudley-Mccullough syndrome', 'Chudley-McCullough syndrome']","Disease: Chudley-McCullough syndrome  
**Reasoning**:  
1. **Sensorineural hearing impairment** and **partial agenesis of the corpus callosum** are hallmark features of Chudley-McCullough syndrome, a rare autosomal recessive disorder linked to mutations in the *GPSM2* gene.  
2. **Arachnoid cyst** and **global developmental delay** align with the neuroimaging findings and neurological manifestations typical of the syndrome.  
3. **Delayed speech and language development** correlates with both hearing loss and structural brain abnormalities.  
4. While **triangular face**, **posteriorly rotated ears**, and **2-3 toe syndactyly** are less specific, they may represent variable dysmorphic features occasionally reported in genetic syndromes affecting neurodevelopment.  
5. **Slender build**, **hyperextensibility at joints**, and **sparse eyebrow** are nonspecific but do not exclude the diagnosis, as phenotypic variability exists.  
6. **Asthma** is likely unrelated to the syndrome but noted as a comorbid condition.  

The combination of severe sensorineural hearing loss, corpus callosum anomalies, arachnoid cysts, and developmental delays strongly supports Chudley-McCullough syndrome. Genetic testing for *GPSM2* mutations is recommended for confirmation."
"['Bifid uvula', 'Malar flattening', 'Micrognathia', 'Pectus carinatum', 'Arachnodactyly', 'Atrial septal defect', 'Patent foramen ovale', 'Aortic regurgitation', 'Tricuspid valve prolapse', 'Aortic root aneurysm', 'Scoliosis', 'Pulmonary artery dilatation', 'Tricuspid regurgitation', 'Dilatation of the sinus of Valsalva', 'Camptodactyly']",['Loeys-Dietz syndrome 2'],"Disease: Loeys-Dietz syndrome 2  
Reasoning:  
1. **Bifid uvula**: A hallmark feature of Loeys-Dietz syndrome (LDS), distinguishing it from Marfan syndrome. While more prominent in LDS type 1, its presence here supports LDS.  
2. **Craniofacial abnormalities (Malar flattening, Micrognathia)**: Indicate connective tissue involvement; LDS type 2 often presents with milder craniofacial features compared to type 1.  
3. **Skeletal manifestations (Pectus carinatum, Scoliosis, Camptodactyly, Arachnodactyly)**: Reflect systemic connective tissue dysfunction, common in LDS. Camptodactyly is atypical in Marfan, further supporting LDS.  
4. **Cardiovascular anomalies (Atrial septal defect, Patent foramen ovale, Aortic root aneurysm, Dilatation of the sinus of Valsalva, Pulmonary artery dilatation)**: LDS is characterized by aggressive vascular pathology, including aneurysms and arterial tortuosity. Aortic root aneurysm and sinus of Valsalva dilatation are critical markers.  
5. **Valvular defects (Aortic regurgitation, Tricuspid valve prolapse, Tricuspid regurgitation)**: Result from connective tissue weakness, aligning with LDS pathophysiology.  
6. **Differentiation from Marfan syndrome**: Absence of lens dislocation and presence of bifid uvula argue against Marfan. The combination of craniofacial, skeletal, and cardiovascular features with bifid uvula is pathognomonic for LDS.  
7. **LDS type 2 vs. type 1**: Type 2 typically lacks severe craniofacial defects (e.g., cleft palate, craniosynostosis) but retains systemic vascular and skeletal involvement, consistent with this presentation. Genetic testing for *TGFBR2* mutations would confirm LDS type 2."
"['Renal insufficiency', 'Renal cyst', 'Gout', 'Hyperuricemia', 'Elevated circulating creatinine concentration', 'Stage 5 chronic kidney disease']","['UMOD-related autosomal dominant tubulointerstitial kidney disease', 'Tubulointerstitial kidney disease, autosomal dominant, 1']","Disease: UMOD-related autosomal dominant tubulointerstitial kidney disease  
Reasoning: The patient exhibits hyperuricemia, gout, renal insufficiency, and Stage 5 CKD, which are hallmark features of UMOD-related disease. UMOD mutations impair urinary uric acid excretion, leading to hyperuricemia and early-onset gout. Progressive tubulointerstitial fibrosis causes renal cysts (often corticomedullary) and chronic kidney disease, typically advancing to end-stage renal disease (ESRD). Elevated creatinine reflects reduced glomerular filtration rate. Autosomal dominant inheritance aligns with family history (if present).  

Disease: Tubulointerstitial kidney disease, autosomal dominant, 1 (ADTKD1)  
Reasoning: ADTKD1 is a subtype of UMOD-related kidney disease. The diagnosis is confirmed by the triad of hyperuricemia/gout, progressive CKD without significant proteinuria, and renal cysts. Genetic testing for UMOD mutations would validate this. ADTKD1 manifests with slowly worsening tubulointerstitial damage, explaining the elevated creatinine and ESRD. Renal cysts in ADTKD1 are less prominent than in polycystic kidney diseases but are still a recognized feature."
"['Large fontanelles', 'Parietal bossing', 'Delayed eruption of primary teeth', 'Narrow chest', 'Short clavicles', 'Frontal bossing', 'Wormian bones', 'Scoliosis', 'Hypoplastic iliac wing', 'Syringomyelia', 'Short stature', 'Abnormal facility in opposing the shoulders', 'Depressed nasal bridge', 'Enamel hypoplasia', 'Delayed pubic bone ossification', 'Broad femoral head', 'Metopic depression', 'Midface retrusion', 'Short femoral neck']",['Cleidocranial dysplasia/Cleidocranial dysplasia'],"Disease: Cleidocranial dysplasia  
**Reasoning**:  
1. **Cranial/skull features**:  
   - **Large fontanelles**, **parietal bossing**, **frontal bossing**, **metopic depression**, and **Wormian bones** align with CCD’s hallmark skull defects, including delayed fontanelle closure and abnormal ossification.  
   - **Midface retrusion** and **depressed nasal bridge** reflect hypoplastic facial bones, common in CCD.  

2. **Dental abnormalities**:  
   - **Delayed eruption of primary teeth** and **enamel hypoplasia** are classic CCD features due to disrupted tooth development and eruption pathways.  

3. **Clavicular/thoracic defects**:  
   - **Short clavicles** (often hypoplastic or absent) explain **abnormal facility in opposing the shoulders**.  
   - **Narrow chest** may arise from clavicular and rib anomalies.  

4. **Pelvic and limb findings**:  
   - **Hypoplastic iliac wings**, **broad femoral heads**, and **short femoral necks** correlate with CCD’s pelvic dysplasia and abnormal long bone growth.  
   - **Short stature** results from skeletal underdevelopment.  

5. **Spinal/skeletal anomalies**:  
   - **Scoliosis** and **delayed pubic bone ossification** reflect generalized skeletal dysplasia.  
   - **Syringomyelia** is atypical but may occur secondary to spinal abnormalities.  

**Conclusion**: The constellation of craniofacial, dental, clavicular, pelvic, and skeletal features is pathognomonic for **cleidocranial dysplasia**, a *RUNX2*-related disorder. Syringomyelia warrants further evaluation but does not exclude CCD."
"['Triangular face', 'Cupped ear', 'Protruding ear', 'Myopia', 'Exotropia', 'Autistic behavior', 'Intellectual disability', 'Global developmental delay', 'Clinodactyly of the 5th finger', 'Clinodactyly of the 2nd toe', 'Bilateral sensorineural hearing impairment', 'Prominent ear helix', 'Cerebral palsy']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Craniofacial features**: Triangular face, cupped/protruding ears, and prominent ear helix are consistent with dysmorphic facial features observed in NEDBEH.  
2. **Neurodevelopmental symptoms**: Autistic behavior, intellectual disability, and global developmental delay align with the disorder’s core neurocognitive phenotype.  
3. **Ocular anomalies**: Myopia and exotropia (eye misalignment) correlate with the ""eye anomalies"" component of NEDBEH.  
4. **Skeletal findings**: Clinodactyly (5th finger and 2nd toe) supports subtle skeletal involvement, a recognized feature.  
5. **Neurological overlap**: Cerebral palsy-like motor dysfunction may reflect underlying brain anomalies (e.g., structural malformations or white matter changes).  
6. **Hearing impairment**: Bilateral sensorineural hearing loss, while not universally present in NEDBEH, can occur due to genetic or neurodevelopmental disruptions.  
7. **Exclusion of mimics**: The constellation rules out syndromes like Fragile X (no hyperextensible joints/macrocephaly) or chromosomal disorders (clinodactyly alone is nonspecific).  
8. **Genetic basis**: PHF21A variants are implicated in NEDBEH, which disrupt neurodevelopment and craniofacial patterning, explaining multisystem involvement."
"['Gait disturbance', 'Shoulder flexion contracture', 'Hip contracture', 'Nemaline bodies', 'Proximal muscle weakness in lower limbs']",['Nemaline myopathy 4'],"Disease: Nemaline Myopathy 4  
Reasoning:  
1. **Nemaline bodies** are a hallmark pathological feature of nemaline myopathies, directly implicating this disease group.  
2. **Proximal muscle weakness in lower limbs** aligns with muscle involvement typical of nemaline myopathies, particularly in lower extremities.  
3. **Shoulder flexion contracture** and **hip contracture** suggest a subtype associated with joint contractures, which is characteristic of Nemaline Myopathy 4 (NM4, autosomal dominant form linked to *TPM3* mutations).  
4. **Gait disturbance** is a secondary consequence of proximal muscle weakness and contractures, common in NM4 due to impaired ambulation.  
5. Exclusion of severe neonatal/respiratory involvement (not mentioned here) and presence of contractures further narrows the diagnosis to NM4 over other nemaline myopathy subtypes (e.g., NM1 or NM2)."
"['Supranuclear gaze palsy', 'Nystagmus', 'Ataxia', 'Dysarthria', 'Cerebellar atrophy', 'Lower limb spasticity', 'EEG abnormality', 'Difficulty walking', 'Lower limb hyperreflexia', 'Babinski sign', 'Abnormality of somatosensory evoked potentials', 'Abnormal motor evoked potentials', 'Cognitive impairment']","['Spastic paraplegia type 7/Spastic paraplegia 7, autosomal recessive']","Disease: Spastic paraplegia type 7/Spastic paraplegia 7, autosomal recessive  
Reasoning:  
1. **Core HSP features**: Lower limb spasticity, hyperreflexia, Babinski sign, and difficulty walking align with hereditary spastic paraplegia (HSP).  
2. **Cerebellar involvement**: Ataxia, dysarthria, and cerebellar atrophy suggest a ""complicated"" HSP subtype, which SPG7 is known to exhibit.  
3. **Ocular abnormalities**: Supranuclear gaze palsy and nystagmus are consistent with SPG7’s reported extrapyramidal and brainstem involvement.  
4. **Neurophysiological findings**: Abnormal motor/somatosensory evoked potentials reflect corticospinal tract and sensory pathway dysfunction, typical in SPG7. EEG abnormalities may indicate broader neuronal disruption.  
5. **Cognitive impairment**: Though less common in HSPs, cognitive decline has been documented in SPG7 due to progressive neurodegeneration.  
6. **Genetic correlation**: SPG7 is autosomal recessive and linked to *SPG7* gene mutations, which disrupt mitochondrial function, explaining multisystem neurological degeneration.  
7. **Differential exclusion**: The combination of cerebellar atrophy, spasticity, and gaze palsy distinguishes SPG7 from other HSPs (e.g., SPG4/SPAST lacks cerebellar signs) and mimics like spinocerebellar ataxia (SCA)."
"['Spasticity', 'Dysarthria', 'Cerebellar atrophy', 'Dysphagia', 'Gait ataxia']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Spasticity and gait ataxia**: Core features of hereditary spastic paraplegias (HSPs), indicating upper motor neuron dysfunction.  
2. **Cerebellar atrophy**: Suggests a ""complicated"" HSP subtype; SPG76 is associated with cerebellar degeneration.  
3. **Dysarthria and dysphagia**: Reflects brainstem/cerebellar involvement, aligning with SPG76's extrapyramidal and bulbar symptoms.  
4. **Autosomal recessive inheritance**: Matches SPG76's genetic pattern (CAPN1 mutations), distinguishing it from dominant HSPs (e.g., SPG4/SPAST) or mitochondrial disorders.  
5. **Exclusion of mimics**: Differentiated from spinocerebellar ataxias (SCAs) by predominant spasticity over cerebellar signs and from SPG7 (also cerebellar atrophy) by genetic testing for CAPN1."
"['Cryptorchidism', 'Micropenis', 'Microretrognathia', 'Incomplete partition of the cochlea type II', 'Retinal coloboma', 'Generalized hypotonia', 'Congestive heart failure', 'Dysphagia', 'Gastroesophageal reflux', 'Poor suck', 'Neonatal respiratory distress', 'Respiratory failure', 'Facial palsy', 'Aplasia of the semicircular canal']",['CHARGE syndrome/Charge syndrome'],"Disease: CHARGE syndrome/Charge syndrome  
Reasoning:  
1. **Coloboma**: Retinal coloboma is a hallmark feature of CHARGE syndrome, directly aligning with the ""C"" in the acronym.  
2. **Heart defects**: Congestive heart failure suggests congenital heart anomalies, corresponding to the ""H"" (Heart defects).  
3. **Genital hypoplasia**: Cryptorchidism and micropenis fulfill the ""G"" (Genital anomalies) criterion.  
4. **Ear abnormalities**: Incomplete partition of the cochlea type II and aplasia of the semicircular canal are characteristic inner ear malformations linked to the ""E"" (Ear anomalies).  
5. **Cranial nerve dysfunction**: Facial palsy and dysphagia/poor suck indicate cranial nerve involvement (CN VII, IX, X), common in CHARGE.  
6. **Multi-system involvement**: Neonatal respiratory distress, hypotonia, gastroesophageal reflux, and microretrognathia reflect the syndrome’s broad impact on respiratory, neuromuscular, and craniofacial systems.  
7. **Diagnostic criteria**: While choanal atresia (""A"") is not explicitly listed, the combination of major features (coloboma, semicircular canal hypoplasia) and minor features (heart defects, facial palsy) meets clinical diagnostic criteria for CHARGE syndrome."
"['Hyperreflexia', 'Lower limb spasticity', 'Spastic ataxia', 'Diffuse cerebral atrophy', 'Ankle clonus']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Hyperreflexia** and **ankle clonus** indicate upper motor neuron dysfunction, consistent with hereditary spastic paraplegias (HSPs).  
2. **Lower limb spasticity** is a hallmark of HSPs, reflecting corticospinal tract degeneration.  
3. **Spastic ataxia** suggests combined pyramidal (spasticity) and cerebellar (ataxia) involvement, aligning with SPG76’s phenotypic overlap between HSP and spinocerebellar ataxia.  
4. **Diffuse cerebral atrophy** supports a complex HSP subtype, as SPG76 (linked to *CAPN1* mutations) often involves cerebellar and cerebral degeneration.  
5. Autosomal recessive inheritance matches SPG76’s genetic pattern, distinguishing it from dominant HSPs or other ataxias with similar features (e.g., SPG11/SPG15 may also show atrophy but typically include additional manifestations like neuropathy or retinopathy).  
6. Symptom triad (spasticity, ataxia, cerebral atrophy) and exclusion of mimics confirm SPG76."
"['Seizure', 'Muscle weakness', 'Hepatosplenomegaly', 'Developmental regression', 'Elevated circulating creatine kinase concentration', 'Neurodevelopmental abnormality', 'Increased circulating lactate dehydrogenase concentration', 'Elevated circulating aspartate aminotransferase concentration']",['Neurodegeneration with brain iron accumulation 2B'],"Disease: Neurodegeneration with brain iron accumulation 2B (PLA2G6-associated neurodegeneration)  
Reasoning:  
1. **Neurodevelopmental/neurodegenerative features**: Developmental regression and neurodevelopmental abnormalities align with progressive neurodegeneration seen in PLA2G6-associated disorders.  
2. **Neuromuscular involvement**: Muscle weakness and elevated creatine kinase (CK) suggest myopathy or axonal degeneration, consistent with PLA2G6-related infantile neuroaxonal dystrophy (INAD).  
3. **Seizures**: Common in advanced stages of PLA2G6-associated neurodegeneration due to cortical and basal ganglia iron accumulation.  
4. **Hepatosplenomegaly**: While atypical for classic NBIA, PLA2G6 mutations can rarely cause liver iron overload or secondary lipid storage, contributing to organ enlargement.  
5. **Elevated LDH and AST**: Reflects muscle breakdown (LDH, AST) and possible subclinical hepatic involvement, though AST may also originate from muscle damage.  
6. **Exclusion of mimics**: Elevated CK and neurodegeneration distinguish this from lysosomal storage disorders (e.g., Niemann-Pick), while hepatosplenomegaly and brain iron accumulation differentiate it from mitochondrial diseases.  
7. **Genetic confirmation**: PLA2G6 mutations (autosomal recessive) confirm NBIA 2B, linking neurodegeneration, iron deposition on MRI, and biochemical abnormalities."
"['Platyspondyly', 'Intellectual disability, mild', 'Hepatosplenomegaly', 'Abnormality of extrapyramidal motor function', 'Decreased beta-galactosidase activity', 'Cherry red spot of the macula']","['GM1-gangliosidosis, type III', 'GM1 gangliosidosis type 3']","Disease: GM1-gangliosidosis, type III / GM1 gangliosidosis type 3  
Reasoning:  
1. **Decreased beta-galactosidase activity** is a hallmark of GM1-gangliosidosis, directly linking to the enzymatic defect in this lysosomal storage disorder.  
2. **Cherry red spot of the macula** is a classic ocular finding in GM1-gangliosidosis due to ganglioside accumulation in retinal neurons.  
3. **Hepatosplenomegaly** reflects visceral involvement from substrate storage (glycoproteins/oligosaccharides) in lysosomes.  
4. **Platyspondyly** (flattened vertebrae) indicates skeletal dysplasia, a feature of chronic/subacute forms (type II/III) of GM1-gangliosidosis.  
5. **Mild intellectual disability** and **extrapyramidal motor dysfunction** correlate with progressive, later-onset neurodegeneration in type III, sparing severe cognitive decline seen in infantile (type I) cases.  
6. Type III aligns with partial enzyme activity, explaining slower progression and milder symptoms compared to earlier-onset subtypes."
"['Abnormal hair morphology', 'Abnormality of the nail', 'Abnormality of dental morphology', 'Punctate palmoplantar hyperkeratosis']","['Palmoplantar keratoderma, punctate type IA']","Disease: Palmoplantar keratoderma, punctate type IA  
Reasoning:  
1. **Punctate palmoplantar hyperkeratosis** is the defining feature of this disease, characterized by discrete hyperkeratotic papules on pressure areas of the palms and soles.  
2. **Abnormality of the nail** (e.g., dystrophy, pitting) is commonly associated with this subtype of PPK due to shared ectodermal origin of skin and nails.  
3. **Abnormal hair morphology** (e.g., thinning, brittleness) and **dental abnormalities** (e.g., enamel defects, misalignment) suggest broader ectodermal involvement, which can occur in some genetic variants of punctate PPK type IA, linked to mutations in *AAGAB* or other genes affecting keratinocyte adhesion.  
4. The combination of these findings aligns with the phenotypic spectrum of punctate type IA PPK, where extracutaneous ectodermal features may manifest variably despite the primary diagnostic focus on palmoplantar lesions."
"['Pectus excavatum', 'Cafe-au-lait spot', 'Hypopigmentation of the skin', 'Neurofibroma', 'Freckling', 'Kyphoscoliosis', 'Multiple cafe-au-lait spots', 'Plexiform neurofibroma']","['Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion/Neurofibromatosis, type I']","Disease: Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion/Neurofibromatosis, type I  
Reasoning:  
1. **Multiple café-au-lait spots**: A hallmark of NF1, requiring ≥6 spots (>5 mm prepubertal, >15 mm postpubertal) for diagnostic criteria.  
2. **Freckling (axillary/inguinal)**: Known as Crowe's sign, pathognomonic for NF1.  
3. **Neurofibromas**: Benign nerve sheath tumors, with ≥2 required for diagnosis.  
4. **Plexiform neurofibroma**: A subtype involving multiple nerve bundles, specific to NF1 and a major diagnostic criterion.  
5. **Skeletal abnormalities (pectus excavatum, kyphoscoliosis)**: Common NF1-associated features due to connective tissue dysplasia.  
6. **Hypopigmentation of the skin**: May occur alongside café-au-lait spots due to melanocyte dysfunction linked to NF1 mutations.  
The combination fulfills NIH diagnostic criteria (≥2 clinical features), confirming NF1. Genetic testing for *NF1* variants or deletions is definitive."
"['Hepatic steatosis', 'Periportal fibrosis', 'Hypercholesterolemia', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating creatine kinase concentration', 'Decreased circulating ceruloplasmin concentration', 'Decreased circulating copper concentration']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Hepatic steatosis & periportal fibrosis**: TMEM199-CDG is associated with hepatic involvement, including fatty liver and fibrosis due to disrupted glycosylation-dependent hepatic function.  
2. **Hypercholesterolemia**: Impaired glycosylation of lipoproteins (e.g., LDL receptors) disrupts cholesterol metabolism, leading to elevated serum cholesterol.  
3. **Elevated alkaline phosphatase**: Reflects cholestatic liver injury, a common feature in TMEM199-CDG.  
4. **Elevated creatine kinase**: Suggests muscle involvement, occasionally seen in glycosylation disorders due to defective glycoprotein synthesis in muscle tissue.  
5. **Decreased ceruloplasmin & copper**: Ceruloplasmin, a copper-carrying glycoprotein, requires proper glycosylation for stability. Defective glycosylation reduces ceruloplasmin levels, leading to secondary hypocupremia (low serum copper) without copper overload.  
6. **Genetic basis**: TMEM199-CDG is caused by mutations in *TMEM199*, disrupting Golgi glycosylation processes, aligning with the multisystemic symptoms observed."
"['Rod-cone dystrophy', 'Pigmentary retinopathy', 'Nyctalopia', 'Visual field defect', 'Reduced visual acuity', 'Attenuation of retinal blood vessels', 'Diffuse optic disc pallor', 'Hypoautofluorescent retinal lesion']",['Retinitis pigmentosa 78'],"Disease: Retinitis pigmentosa 78  
Reasoning:  
1. **Rod-cone dystrophy**: A hallmark of retinitis pigmentosa (RP), where rod photoreceptor degeneration precedes cone loss, aligning with progressive nyctalopia and visual field constriction.  
2. **Pigmentary retinopathy**: Characteristic bone-spicule pigment deposits in RP, caused by retinal pigment epithelium migration into the retina.  
3. **Nyctalopia**: Early symptom due to rod dysfunction, typical in RP.  
4. **Visual field defect**: Progressive peripheral vision loss (""tunnel vision"") from peripheral retinal degeneration.  
5. **Reduced visual acuity**: Occurs later as cones become affected.  
6. **Attenuation of retinal blood vessels & diffuse optic disc pallor**: Reflects chronic retinal atrophy and optic nerve degeneration in advanced RP.  
7. **Hypoautofluorescent retinal lesions**: Indicates areas of photoreceptor/RPE atrophy, consistent with RP progression.  
**RP78** specifically involves mutations in the **RP1L1** gene, which disrupts photoreceptor structure. The clinical triad of nyctalopia, pigmentary retinopathy, and vascular attenuation strongly supports this diagnosis. Genetic testing for RP1L1 variants would confirm RP78."
"['Optic disc pallor', 'Spasticity', 'Dysphagia', 'Delayed gross motor development', 'Mutism', 'Poor head control', 'Reduced visual acuity', 'Infantile muscular hypotonia', 'Gastrostomy tube feeding in infancy', 'Pendular nystagmus']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Neurological and motor deficits**: Spasticity, delayed gross motor development, and poor head control align with hypomyelinating leukodystrophies, which disrupt white matter integrity, impairing motor neuron signaling.  
2. **Optic pathway involvement**: Optic disc pallor, reduced visual acuity, and pendular nystagmus suggest optic nerve hypomyelination, a hallmark of NKX6-2-related disorders due to oligodendrocyte dysfunction.  
3. **Developmental trajectory**: Infantile muscular hypotonia progressing to spasticity reflects the evolving nature of myelination defects, where initial low tone transitions to hypertonia as myelination fails.  
4. **Bulbar dysfunction**: Dysphagia and gastrostomy tube dependence indicate brainstem involvement, common in severe leukodystrophies affecting cranial nerve nuclei.  
5. **Mutism**: Likely secondary to severe motor dysfunction (anarthria) or corticobulbar tract damage, rather than cognitive impairment, typical in NKX6-2-related disease.  
6. **Genetic consistency**: Autosomal recessive NKX6-2 mutations disrupt transcriptional regulation of myelination, correlating with the observed hypomyelination phenotype.  
7. **Differential exclusion**: Overlap with Pelizaeus-Merzbacher disease is ruled out by the absence of PLP1 mutations and the presence of gastrostomy dependence/mutism, more specific to NKX6-2 pathology."
"['Abnormality of the genitourinary system', 'Hydrocephalus', 'Intellectual disability, mild', 'Cerebellar hypoplasia', 'Pancytopenia', 'Asthma', 'Unsteady gait', 'Abnormal cerebral white matter morphology', 'Coxa valga', 'Decreased circulating IgG level', 'Short telomere length', 'Arachnoid cyst']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Core diagnostic criteria**:  
   - **Pancytopenia** (key feature of ATXPC) and **unsteady gait** (ataxia) are hallmark symptoms.  
   - **Cerebellar hypoplasia** directly explains ataxia and is a defining neurological feature of the syndrome.  
   - **Short telomere length** aligns with bone marrow dysfunction, a recognized mechanism in ATXPC.  

2. **Supportive neurological findings**:  
   - **Abnormal cerebral white matter morphology** and **hydrocephalus** may reflect structural brain anomalies linked to SAMD9L mutations.  
   - **Arachnoid cyst** and **mild intellectual disability** could arise from disrupted neurodevelopment.  

3. **Systemic manifestations**:  
   - **Decreased circulating IgG level** suggests immune dysfunction secondary to bone marrow failure.  
   - **Coxa valga** and **genitourinary abnormalities** fit the multisystemic nature of SAMD9L-related disorders.  

4. **Exclusion of mimics**:  
   - Asthma is likely incidental or secondary to immune deficiency.  
   - Telomere shortening distinguishes ATXPC from isolated cerebellar hypoplasia or other bone marrow failure syndromes (e.g., Dyskeratosis congenita lacks cerebellar features).  

Conclusion: The constellation of neurological, hematological, and systemic features strongly supports ATXPC, driven by SAMD9L mutations."
"['Seizure', 'Tongue fasciculations', 'Myoclonus', 'Bilateral tonic-clonic seizure', 'Resting tremor', 'Waddling gait', 'Gowers sign', 'Limb muscle weakness', 'Proximal muscle weakness', 'Atonic seizure', 'Tongue atrophy', 'Abnormal circulating creatine kinase concentration', 'Abnormal lactate dehydrogenase level']",['Spinal muscular atrophy-progressive myoclonic epilepsy syndrome/Spinal muscular atrophy with progressive myoclonic epilepsy'],"Disease: Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME)  
Reasoning:  
1. **Proximal Muscle Weakness & Motor Neuron Signs**: Gowers sign, waddling gait, and proximal/limb muscle weakness indicate spinal muscular atrophy (SMA), reflecting lower motor neuron degeneration.  
2. **Seizures & Myoclonus**: Bilateral tonic-clonic, atonic seizures, and myoclonus align with progressive myoclonic epilepsy (PME), a hallmark of SMA-PME progression.  
3. **Neuromuscular Features**: Tongue fasciculations and atrophy suggest lower motor neuron involvement, consistent with SMA pathology.  
4. **Biomarkers**: Elevated creatine kinase (CK) and lactate dehydrogenase (LDH) indicate muscle damage, supporting SMA-related degeneration.  
5. **Exclusion of Mimics**: Symptoms lack features of mitochondrial disorders (e.g., multi-organ involvement) or Lafora disease (e.g., cognitive decline, Lafora bodies), narrowing the diagnosis to SMA-PME.  
6. **Genetic Correlation**: SMA-PME is linked to *ASAH1* mutations, which disrupt ceramide metabolism, explaining both neuromuscular and epileptic features."
"['Coarse facial features', 'Strabismus', 'Pectus excavatum', 'Deformed rib cage', 'Hypotonia', 'Motor delay', 'Hepatic cysts', 'Omphalocele', 'Redundant skin', 'Mitral regurgitation', 'Abnormal facial shape', 'Spinal cord compression', 'Spondyloepimetaphyseal dysplasia', 'Coxa valga', 'Kyphoscoliosis', 'Radial head subluxation', 'Hypoplasia of the capital femoral epiphysis', 'Neonatal hyperbilirubinemia', 'Abnormality of the cervical spine', 'Short stature', 'Severe platyspondyly', 'Cervical instability', 'Abnormal pelvis bone morphology']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: The patient exhibits *spondyloepimetaphyseal dysplasia*, *severe platyspondyly*, *coxa valga*, and *abnormal pelvis bone morphology*, which are hallmark features of ISDNA. These align with the ""immunoskeletal"" component of the disease, reflecting dysostosis multiplex-like skeletal dysplasia.  
2. **Neurodevelopmental Delays**: *Hypotonia* and *motor delay* correlate with ISDNA-associated neurodevelopmental impairments, often linked to cerebellar hypoplasia or white matter changes.  
3. **Cervical Instability/Spinal Involvement**: *Cervical instability*, *spinal cord compression*, and *abnormality of the cervical spine* are critical findings in ISDNA due to defective bone maturation and ligamentous laxity.  
4. **Hepatic and Neonatal Features**: *Hepatic cysts* and *neonatal hyperbilirubinemia* suggest systemic involvement, consistent with ISDNA’s multisystemic nature. *Omphalocele* may reflect connective tissue dysfunction.  
5. **Dysmorphic Features**: *Coarse facial features*, *abnormal facial shape*, and *redundant skin* are seen in ISDNA, likely due to glycosylation defects or extracellular matrix disruption.  
6. **Cardiac and Ocular Manifestations**: *Mitral regurgitation* and *strabismus* align with connective tissue/craniofacial anomalies reported in ISDNA.  
7. **Genetic Link**: While not explicitly stated, ISDNA is caused by biallelic *EXOC6B* mutations, which disrupt exocytosis and glycosylation, explaining the skeletal, hepatic, and neurodevelopmental phenotypes.  

The constellation of severe skeletal dysplasia, neurodevelopmental delays, systemic involvement (hepatic/cardiac), and dysmorphism strongly supports ISDNA over other skeletal dysplasias (e.g., Morquio syndrome lacks neurodevelopmental features; COMP-associated disorders lack hepatic cysts)."
"['Acute myeloid leukemia', 'Abnormal dense granules', 'Abnormal platelet aggregation']","['Platelet disorder, familial, with associated myeloid malignancy']","Disease: Platelet disorder, familial, with associated myeloid malignancy  
Reasoning:  
1. **Acute Myeloid Leukemia (AML)**: The presence of AML indicates a myeloid lineage malignancy, a hallmark of this disorder. Familial platelet disorders with associated myeloid malignancy often progress to AML due to genetic predisposition (e.g., RUNX1 mutations).  
2. **Abnormal Dense Granules**: Dense granule defects in platelets are characteristic of inherited platelet disorders, such as those caused by mutations in genes like RUNX1, which impair granule biogenesis or secretion.  
3. **Abnormal Platelet Aggregation**: Dysfunctional platelet aggregation aligns with impaired dense granule function, as these granules store critical agonists (e.g., ADP) necessary for aggregation. This defect is consistent with familial platelet disorders.  
4. **Genetic Link**: The co-occurrence of AML and platelet abnormalities strongly suggests a germline mutation (e.g., RUNX1, ANKRD26, or ETV6), which predisposes to both hematologic malignancy and platelet dysfunction.  
5. **Diagnostic Confirmation**: Genetic testing for RUNX1 or related mutations would confirm the familial nature and solidify the diagnosis."
"['Micrognathia', 'Ptosis', 'Hypertension', 'Areflexia', 'Lumbar hyperlordosis', 'Elbow flexion contracture', 'Hyperlipidemia', 'Absence of subcutaneous fat', 'Prematurely aged appearance', 'Plantar flexion contracture', 'Proximal muscle weakness in lower limbs', 'Difficulty running']","['Emery-Dreifuss muscular dystrophy 3, autosomal recessive']","Disease: Emery-Dreifuss muscular dystrophy 3, autosomal recessive  
Reasoning:  
1. **Elbow/plantar flexion contractures**: Hallmark features of EDMD, caused by progressive fibrosis and tendon shortening.  
2. **Proximal muscle weakness in lower limbs/difficulty running**: Consistent with muscular dystrophy-related myopathy.  
3. **Lumbar hyperlordosis**: Compensatory posture due to pelvic muscle weakness and contractures.  
4. **Hypertension**: Suggests cardiac involvement (e.g., cardiomyopathy or arrhythmias), common in EDMD.  
5. **Prematurely aged appearance/absence of subcutaneous fat**: Linked to *LMNA* gene mutations causing laminopathies, which include lipodystrophy and progeroid features in recessive EDMD3.  
6. **Areflexia**: Secondary to muscle degeneration rather than neuropathy.  
7. **Micrognathia/ptosis**: Rarely reported in laminopathies but may occur due to craniofacial muscle involvement.  
8. **Hyperlipidemia**: Associated with lipodystrophy in *LMNA*-related disorders.  
The triad of **contractures, progressive muscle weakness, and cardiac complications** with autosomal recessive inheritance and progeroid/lipodystrophy signs confirms EDMD3."
"['Autistic behavior', 'Delayed speech and language development', 'Intellectual disability', 'Absent speech', 'Sleep apnea', 'Enuresis nocturna']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Core neurodevelopmental symptoms**: Autistic behavior, delayed speech/absent speech, and intellectual disability are hallmark features of NEDBEH, a disorder linked to DIDO1 gene mutations. These align with its characteristic developmental delays.  
2. **Sleep apnea**: Could reflect brainstem dysfunction or structural airway anomalies, which fall under the ""brain anomalies"" spectrum of NEDBEH.  
3. **Enuresis nocturna**: Often secondary to neurodevelopmental delays in bladder control maturation, consistent with global intellectual disability.  
4. **Absence of specified eye/heart anomalies**: The diagnosis accommodates presentations without these features, focusing on the neurodevelopmental core.  
5. **Exclusion of mimics**: Symptoms collectively fit NEDBEH better than isolated autism spectrum disorder or other syndromic intellectual disabilities due to the combination with sleep-disordered breathing."
"['Intellectual disability', 'Seizure', 'Ataxia', 'Lethargy', 'Dysarthria', 'Gait disturbance', 'Muscle weakness', 'Tachycardia', 'Acidosis', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Myopathic facies', 'Dyspnea', 'Increased serum lactate', 'Drooling', 'Elevated hepatic transaminase', 'Myoglobinuria', 'Ketonuria', 'Lactic acidosis', 'Myopathy', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Limb muscle weakness', 'Ventricular tachycardia', 'Prolonged QTc interval', 'Premature ventricular contraction', 'Lateral ventricle dilatation', 'Lower limb muscle weakness', 'Elevated circulating aldolase concentration', 'Elevated circulating acylcarnitine concentration', 'Lateral ventricular asymmetry']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Metabolic Dysregulation**: Acidosis (metabolic/lactic), hypoglycemia, hyperammonemia, ketonuria, and elevated lactate/acylcarnitine suggest impaired mitochondrial energy metabolism and fatty acid oxidation.  
2. **Neuromuscular Involvement**: Myopathy, rhabdomyolysis, limb muscle weakness, elevated CK/aldolase, and myoglobinuria indicate recurrent muscle breakdown, consistent with metabolic crises.  
3. **Cardiac Arrhythmias**: Ventricular tachycardia, prolonged QTc, and premature contractions align with cardiac ion channel dysfunction or metabolic toxicity from rhabdomyolysis.  
4. **Neurodegeneration/Encephalopathy**: Intellectual disability, seizures, ataxia, lethargy, dysarthria, and ventricular dilatation/asymmetry point to chronic/progressive CNS injury from metabolic insults.  
5. **Systemic Features**: Elevated hepatic transaminases, dyspnea, and drooling reflect multi-organ dysfunction during crises.  
6. **Pattern Recognition**: The combination of recurrent metabolic decompensation, muscle breakdown, arrhythmias, and neurodegeneration matches this specific syndrome’s phenotype, distinct from isolated mitochondrial disorders or fatty acid oxidation defects."
"['Cryptorchidism', 'Hydronephrosis', 'High palate', 'Thin upper lip vermilion', 'Hypertelorism', 'Low-set ears', 'Downslanted palpebral fissures', 'Synophrys', 'Hyperextensible skin', 'Adducted thumb', 'Tapered finger', 'Generalized hypotonia', 'Talipes equinovarus', 'Arthrogryposis multiplex congenita', 'Finger joint hypermobility', 'Absent palmar crease']","['Musculocontractural Ehlers-Danlos syndrome/Ehlers-Danlos syndrome, musculocontractural type 1']","Disease: Musculocontractural Ehlers-Danlos syndrome, type 1 (mcEDS-1)  
Reasoning:  
1. **Major Diagnostic Criteria**:  
   - **Congenital Musculoskeletal Abnormalities**: Arthrogryposis multiplex congenita (multiple joint contractures), talipes equinovarus (clubfoot), and adducted thumbs align with hallmark contractures in mcEDS-1.  
   - **Characteristic Craniofacial Features**: Hypertelorism, low-set ears, downslanted palpebral fissures, synophrys (confluent eyebrows), high palate, and thin upper lip vermilion match the facial dysmorphism seen in mcEDS-1.  
   - **Cutaneous Features**: Hyperextensible skin and absent palmar crease reflect connective tissue fragility, a core feature of EDS subtypes.  

2. **Supportive Findings**:  
   - **Generalized Hypotonia**: Common in connective tissue disorders due to muscular and ligamentous laxity.  
   - **Tapered Fingers and Finger Joint Hypermobility**: Paradoxical hypermobility in some joints alongside contractures is typical in mcEDS-1.  
   - **Hydronephrosis**: May arise from connective tissue weakness in urinary tract structures.  
   - **Cryptorchidism**: Occasionally reported in mcEDS-1, possibly linked to developmental connective tissue defects.  

3. **Exclusion of Similar Disorders**:  
   - Overlap with other EDS subtypes (e.g., classical EDS) is ruled out by the presence of congenital contractures and distinct facial features.  
   - Differentiated from Loeys-Dietz syndrome or Marfan syndrome by the absence of aortic/arterial complications and specific gene associations (mcEDS-1 is linked to *CHST14* or *DSE* mutations).  

This constellation of congenital contractures, facial dysmorphism, cutaneous hyperextensibility, and systemic connective tissue involvement strongly supports mcEDS-1. Genetic testing for *CHST14* variants is recommended for confirmation."
"['Spastic paraplegia', 'Spastic gait', 'Difficulty walking']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Symptom alignment**: Spastic paraplegia, spastic gait, and difficulty walking are hallmark features of hereditary spastic paraplegias (HSPs), a group of disorders characterized by progressive lower limb spasticity and weakness.  
2. **Genetic inheritance**: SPG76 is autosomal recessive, requiring biallelic pathogenic variants in the *CAPN1* gene. The absence of dominant family history supports this mode of inheritance.  
3. **Clinical specificity**: SPG76 typically presents with early-onset (childhood to adulthood) progressive spastic paraplegia, consistent with the described symptoms. While classified as a ""pure"" HSP, subtle additional features (e.g., mild neuropathy) may occur but are not required for diagnosis.  
4. **Exclusion of mimics**: The lack of overt cerebellar ataxia, intellectual disability, or peripheral neuropathy in the symptom list helps differentiate SPG76 from other HSP subtypes (e.g., SPG7, SPG11) or complex forms.  
5. **Confirmation pathway**: Definitive diagnosis requires genetic testing for *CAPN1* mutations, alongside neuroimaging (e.g., spinal MRI to rule out structural causes) and exclusion of acquired causes (e.g., vitamin deficiencies, inflammatory myelopathy).  

**Note**: Family segregation analysis and genetic counseling are critical next steps due to the autosomal recessive inheritance pattern."
"['Ataxia', 'Spasticity', 'Spastic gait', 'Clonus', 'Clumsiness', 'Paresthesia', 'Babinski sign', 'Impaired distal vibration sensation', 'Peripheral neuropathy', 'Dysesthesia', 'Abnormal cranial nerve physiology', 'Cognitive impairment']","['Autosomal dominant spastic paraplegia type 10/Spastic paraplegia 10, autosomal dominant']","Disease: Autosomal dominant spastic paraplegia type 10/Spastic paraplegia 10, autosomal dominant  
Reasoning:  
1. **Upper Motor Neuron (UMN) Features**: Spasticity, spastic gait, clonus, and Babinski sign indicate corticospinal tract dysfunction, a hallmark of hereditary spastic paraplegias (HSPs).  
2. **Peripheral Nervous System Involvement**: Peripheral neuropathy, paresthesia, dysesthesia, and impaired distal vibration sensation suggest axonal neuropathy, which aligns with SPG10’s association with *KIF5A* mutations affecting neuronal transport.  
3. **Mixed Phenotype**: Co-occurrence of UMN signs (spasticity) and lower motor neuron/sensory symptoms (neuropathy) is characteristic of complex HSP subtypes like SPG10.  
4. **Cognitive Impairment & Cranial Nerve Abnormalities**: Mild cognitive deficits and cranial nerve dysfunction (e.g., optic neuropathy, hearing loss) are reported in SPG10 due to widespread neuronal degeneration.  
5. **Exclusion of Mimics**: The absence of prominent cerebellar atrophy (ataxia here may stem from spasticity or neuropathy) and systemic features rules out alternatives like spinocerebellar ataxias or ALS.  
6. **Genetic Consistency**: SPG10 is autosomal dominant, fitting a family history (if present), and *KIF5A* mutations disrupt axonal transport, explaining both central and peripheral nervous system involvement."
"['Proteinuria', 'Edema', 'Small for gestational age', 'Pneumonia', 'Pleural effusion', 'Hypoalbuminemia', 'Hypercholesterolemia', 'Neonatal hypoproteinemia', 'Congenital nephrotic syndrome']","['Congenital nephrotic syndrome, Finnish type/Nephrotic syndrome, type 1']","Disease: Congenital nephrotic syndrome, Finnish type/Nephrotic syndrome, type 1  
Reasoning:  
1. **Proteinuria** and **Hypoalbuminemia**: Hallmarks of nephrotic syndrome, caused by glomerular damage leading to excessive urinary protein loss and subsequent low serum albumin.  
2. **Edema** and **Pleural Effusion**: Result from hypoalbuminemia reducing oncotic pressure, causing fluid leakage into tissues and serous cavities.  
3. **Hypercholesterolemia**: Compensatory hepatic synthesis of lipoproteins due to protein loss.  
4. **Small for Gestational Age (SGA)**: Intrauterine proteinuria in congenital nephrotic syndrome impairs fetal nutrition and growth.  
5. **Neonatal Hypoproteinemia**: Severe albumin loss begins prenatally, leading to critically low protein levels at birth.  
6. **Congenital Nephrotic Syndrome**: Early-onset (birth/infancy) aligns with the Finnish type (NPHS1 mutation), characterized by NPHS1/NEPHRIN gene defects causing podocyte dysfunction.  
7. **Pneumonia**: Secondary to edema-related respiratory compromise and immunosuppression from urinary immunoglobulin loss.  

The constellation of severe proteinuria, hypoalbuminemia, and neonatal presentation confirms **Congenital Nephrotic Syndrome, Finnish Type** (NPHS1-related), distinguishing it from later-onset or secondary nephrotic syndromes."
"['Low-set ears', 'Rod-cone dystrophy', 'Sparse eyelashes', 'Delayed speech and language development', 'Cafe-au-lait spot', 'Brachydactyly', 'Short stature', 'Sparse hair', 'High anterior hairline', 'Thick vermilion border', 'Delayed ability to walk', 'Sparse eyebrow']",['Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies'],"Disease: Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies  
Reasoning:  
1. **Brachydactyly**: Explicitly listed as a symptom, directly aligning with the syndrome's name and diagnostic criteria.  
2. **Short stature**: A core feature of the syndrome, present in the patient.  
3. **Rod-cone dystrophy**: Matches retinitis pigmentosa (RP), a hallmark of the syndrome, characterized by progressive retinal degeneration.  
4. **Sparse hair/eyebrows/eyelashes and high anterior hairline**: Consistent with ectodermal dysplasia-like features reported in some cases of the syndrome.  
5. **Thick vermilion border**: A documented facial dysmorphism in skeletal-RP overlap syndromes.  
6. **Delayed speech/walking**: Developmental delays are part of the phenotypic spectrum, possibly secondary to systemic involvement.  
7. **Cafe-au-lait spot**: While atypical, it does not exclude the diagnosis given the strong alignment of other features; may reflect phenotypic variability.  
8. Exclusion of alternatives: Key symptoms (e.g., brachydactyly, RP) distinguish this from Cohen, Bardet-Biedl, or Alström syndromes.  

Final diagnosis is supported by the triad of brachydactyly, short stature, and RP, alongside supportive dysmorphic and developmental features."
"['Macroglossia', 'Turricephaly', 'Coarse facial features', 'Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Deeply set eye', 'Esotropia', 'Optic atrophy', '11 pairs of ribs', 'Hypertrichosis', 'Seizure', 'Areflexia', 'Cerebellar vermis hypoplasia', 'Partial agenesis of the corpus callosum', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', ""Exaggerated cupid's bow"", 'EEG abnormality', 'Developmental regression', 'Highly arched eyebrow', 'Severe muscular hypotonia', 'Feeding difficulties', 'Right aortic arch', 'Small basal ganglia', 'Profound global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Macroglossia, turricephaly, coarse facial features, narrow forehead, prominent nasal bridge, anteverted nares, deeply set eyes, highly arched eyebrows, and ""exaggerated cupid's bow"" align with the dysmorphic facial phenotype described in TBCK syndrome.  
2. **Neurological/developmental hallmarks**: Severe muscular hypotonia, profound global developmental delay, developmental regression, seizures, EEG abnormality, and areflexia match the core features of TBCK-related disorders, which involve progressive neurodegeneration and psychomotor impairment.  
3. **Brain malformations**: Cerebellar vermis hypoplasia, hypoplasia/agenesis of the corpus callosum, ventriculomegaly, and small basal ganglia are recurrent neuroimaging findings in TBCK syndrome, linked to disrupted neuronal development and maintenance.  
4. **Systemic features**: Feeding difficulties (due to hypotonia), hypertrichosis, and right aortic arch (vascular anomaly) are consistent with multisystem involvement reported in TBCK cases.  
5. **Genetic correlation**: The combination of hypotonia, intellectual disability, characteristic facies, and brain anomalies strongly suggests a monogenic disorder like TBCK syndrome, caused by biallelic pathogenic variants in the *TBCK* gene affecting mTOR signaling and autophagy.  
6. **Exclusion of mimics**: Features such as optic atrophy and 11 pairs of ribs (likely a typo for rib anomalies) do not contradict the diagnosis and may represent variable expressivity of TBCK-related disease."
"['Macrocephaly', 'Hypertelorism', 'Broad forehead', 'Low-set ears', 'Short neck', 'Broad neck', 'Downslanted palpebral fissures', 'Cafe-au-lait spot', 'Freckling', 'Bilateral ptosis', 'Growth delay', 'Cardiomyopathy', 'Low posterior hairline', 'Attention deficit hyperactivity disorder', 'Feeding difficulties']",['Noonan syndrome 6'],"Disease: Noonan syndrome 6  
Reasoning:  
1. **Facial features**: Hypertelorism, broad forehead, downslanted palpebral fissures, low-set ears, and bilateral ptosis align with classic Noonan syndrome craniofacial characteristics.  
2. **Neck anomalies**: Short/broad neck and low posterior hairline are consistent with Noonan-associated neck and lymphatic abnormalities.  
3. **Cardiac involvement**: Cardiomyopathy, though less common than pulmonary stenosis, is reported in Noonan syndrome, particularly linked to specific genetic subtypes like NS6 (LZTR1 mutations).  
4. **Growth/developmental delays**: Growth delay and feeding difficulties are hallmark features of Noonan syndrome. ADHD is a recognized neurodevelopmental component.  
5. **Cutaneous features**: Café-au-lait spots and freckling suggest overlap with RASopathy-associated skin manifestations. NS6 is tied to LZTR1 mutations, which may explain NF1-like pigmentation due to shared RAS/MAPK pathway dysregulation.  
6. **Genetic specificity**: NS6 (OMIM #613224) is distinguished by LZTR1 mutations, which can present with variable pigmentation anomalies alongside typical Noonan traits, ruling out other RASopathies like NF1 or LEOPARD syndrome."
"['Myopia', 'Exotropia', 'Ectopia lentis', 'Arachnodactyly', 'Intellectual disability', 'Ataxia', 'Dysarthria', 'Gait disturbance', 'Abnormal pyramidal sign', 'Brain atrophy', 'Scleral staphyloma', 'Flushing']",['Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency'],"Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Ectopia lentis**: A hallmark feature of homocystinuria, caused by defective collagen cross-linking due to cystathionine beta-synthase (CBS) deficiency.  
2. **Arachnodactyly and Myopia**: Connective tissue abnormalities from disrupted sulfur metabolism, mimicking Marfan-like features but with distinct metabolic etiology.  
3. **Intellectual disability, Ataxia, Dysarthria, Gait disturbance**: Reflect chronic CNS involvement due to homocysteine neurotoxicity, vascular insults, or secondary folate deficiency.  
4. **Brain atrophy and Abnormal pyramidal signs**: Long-standing metabolic derangement leads to neuronal loss and corticospinal tract damage.  
5. **Exotropia and Scleral staphyloma**: Ocular connective tissue weakness and lens displacement contribute to strabismus and scleral thinning.  
6. **Flushing**: Potentially linked to endothelial dysfunction from elevated homocysteine levels affecting vasoregulation.  
7. **Exclusion of mimics**: Differentiated from Marfan syndrome (no aortic root dilation) and other metabolic disorders (e.g., sulfite oxidase deficiency) by the combination of biochemical, ocular, and neuropsychiatric features.  
**Conclusion**: The constellation of connective, ocular, neurological, and vascular symptoms aligns with CBS-deficient homocystinuria, confirmed by elevated plasma homocysteine and low methionine levels."
"['Gingival overgrowth', 'Microcephaly', 'Progressive microcephaly', 'Micrognathia', 'Anteverted nares', 'Proptosis', 'Carious teeth', 'Abnormality of the skeletal system', 'Sacral dimple', 'Hemangioma', 'Brachydactyly', 'Hypotonia', 'Hyporeflexia', 'Motor delay', 'Generalized hypotonia', 'Muscle weakness', 'Hepatic cysts', 'Failure to thrive', 'Overgrowth', 'Polyhydramnios', 'Frontal bossing', 'Rigidity', 'Pneumonia', 'Spinal cord compression', 'Hepatomegaly', 'Kyphosis', 'Decreased circulating total IgM', 'Abnormal ilium morphology', 'Hyperbilirubinemia', 'Lumbar hyperlordosis', 'Metaphyseal widening', 'Short nose', 'Neonatal hyperbilirubinemia', 'Hyperlordosis', 'Spinal canal stenosis', 'Limb muscle weakness', 'Trident hand', 'Decreased circulating IgG level', 'Severe platyspondyly', 'Restricted large joint movement', 'Depressed nasal bridge', 'Capillary hemangioma', 'Thoracolumbar kyphosis', 'Recurrent pneumonia', 'Lower limb muscle weakness', 'Axial hypotonia', 'Limb undergrowth', 'Cognitive impairment', 'Enlarged thorax', 'Broad ischia']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: Microcephaly (progressive), brachydactyly, kyphosis, severe platyspondyly, metaphyseal widening, and spinal canal stenosis align with skeletal dysplasia, a hallmark of ISDNA.  
2. **Immunodeficiency**: Recurrent pneumonia, decreased IgG/IgM levels, and failure to thrive suggest humoral immune dysfunction, consistent with ISDNA’s B-cell defects.  
3. **Neurodevelopmental Delays**: Cognitive impairment, motor delay, axial/limb hypotonia, and muscle weakness reflect the neurodevelopmental axis of ISDNA, linked to EXTL3 mutations affecting heparan sulfate synthesis.  
4. **Hepatic Involvement**: Hepatic cysts and hepatomegaly are reported in ISDNA due to disrupted glycosaminoglycan metabolism.  
5. **Dysmorphic Features**: Anteverted nares, depressed nasal bridge, frontal bossing, and trident hand correlate with craniofacial and skeletal anomalies in ISDNA.  
6. **Overlap with Known Cases**: ISDNA’s triad of skeletal dysplasia, immune deficiency, and neurodevelopmental deficits matches the patient’s multisystem presentation, excluding mimics like mucopolysaccharidoses (no coarse features) or isolated skeletal dysplasias (no immune/neuro involvement)."
"['Pes cavus', 'Falls', 'Abnormal cerebrospinal fluid morphology', 'Decreased sensory nerve conduction velocity', 'Babinski sign', 'Periventricular leukomalacia', 'Lower limb muscle weakness', 'Decreased Achilles reflex', 'Decreased patellar reflex', 'Oppenheim reflex', 'Gordon reflex']","['Autosomal dominant Charcot-Marie-Tooth disease type 2A2/Charcot-marie-tooth disease, axonal, type 2A2A']","Disease: Autosomal dominant Charcot-Marie-Tooth disease type 2A2/Charcot-Marie-Tooth disease, axonal, type 2A2A  
Reasoning:  
1. **Pes cavus**: A hallmark of CMT, caused by chronic muscle weakness and imbalance in the feet.  
2. **Lower limb muscle weakness, falls**: Reflects distal axonal neuropathy, typical in CMT2A2A due to MFN2 mutations affecting motor neurons.  
3. **Decreased Achilles/patellar reflexes**: Indicates lower motor neuron involvement, consistent with axonal degeneration.  
4. **Decreased sensory nerve conduction velocity**: Suggests axonal (not demyelinating) pathology; CMT2A2A shows reduced amplitudes with mild conduction slowing.  
5. **Babinski, Oppenheim, and Gordon reflexes**: Atypical for CMT but may indicate rare phenotypic overlap or coexisting pyramidal tract involvement in some MFN2-related cases.  
6. **Abnormal CSF morphology/periventricular leukomalacia**: Likely incidental or unrelated to CMT2A2A, as CSF is typically normal in CMT, and leukomalacia suggests prior ischemic injury.  
7. **Genetic alignment**: CMT2A2A is autosomal dominant, aligning with hereditary patterns, and MFN2 mutations explain the axonal neuropathy.  

The diagnosis prioritizes characteristic CMT features (pes cavus, axonal neuropathy) while acknowledging atypical signs as potential phenotypic expansions or comorbidities."
"['Malar flattening', 'Microretrognathia', 'Hearing impairment', 'Downslanted palpebral fissures']",['Treacher collins syndrome 2'],"Disease: Treacher Collins syndrome 2  
Reasoning:  
1. **Malar flattening** (underdeveloped zygomatic bones) aligns with the hallmark craniofacial hypoplasia in Treacher Collins syndrome (TCS).  
2. **Microretrognathia** (small, recessed jaw) is a cardinal feature of TCS due to mandibular hypoplasia.  
3. **Hearing impairment** correlates with TCS-associated middle/inner ear malformations (e.g., ossicular defects, cochlear anomalies).  
4. **Downslanted palpebral fissures** are characteristic of TCS, often accompanied by colobomas of the lower eyelids.  
5. TCS2 (caused by *POLR1D* mutations) shares these features with classical TCS (*TCOF1*-related TCS1), confirming the diagnosis given the phenotypic match."
"['Median cleft lip', 'Microcephaly', 'Depressed nasal tip', 'Diabetes insipidus', 'Absent nasal septal cartilage', 'Lobar holoprosencephaly', 'Median cleft palate']",['Holoprosencephaly 4'],"Disease: Holoprosencephaly 4 (HPE4)  
Reasoning:  
1. **Lobar holoprosencephaly** is a defining feature of HPE4, representing incomplete separation of the cerebral hemispheres.  
2. **Median cleft lip/palate** and **absent nasal septal cartilage** are midline facial defects, characteristic of HPE due to disrupted Sonic Hedgehog (SHH) signaling, which governs midline craniofacial development.  
3. **Microcephaly** aligns with impaired forebrain growth in HPE.  
4. **Depressed nasal tip** further supports midline structural abnormalities.  
5. **Diabetes insipidus** suggests hypothalamic-pituitary dysfunction, a known but less common feature of HPE4 linked to SHH mutations affecting neuroendocrine development.  
6. Genetic etiology: HPE4 is caused by heterozygous mutations in *SHH* (18q11.2), critical for forebrain and facial midline patterning. This gene’s role explains the syndromic combination of brain, facial, and endocrine anomalies."
"['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Seizure', 'Hypotonia', 'Delayed CNS myelination', 'EEG abnormality', 'Sleep disturbance', 'Secondary microcephaly', 'Feeding difficulties in infancy']","['Rett syndrome, congenital variant']","Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Secondary microcephaly**: A hallmark of Rett syndrome, reflecting postnatal deceleration of head growth due to impaired brain development.  
2. **Delayed speech and language development**: Consistent with neurodevelopmental regression or stagnation, a core feature of Rett syndrome.  
3. **Abnormal repetitive mannerisms**: Stereotypic hand movements (e.g., wringing, tapping) are pathognomonic in Rett syndrome, though they may manifest atypically in the congenital variant.  
4. **Seizures and EEG abnormality**: Epileptic activity and abnormal EEG patterns (e.g., slow background, epileptiform discharges) are common in Rett syndrome due to cortical hyperexcitability.  
5. **Hypotonia and feeding difficulties in infancy**: Early-onset axial hypotonia and oral-motor dysfunction align with congenital variant presentations, distinguishing it from classic Rett syndrome.  
6. **Delayed CNS myelination**: Observed on neuroimaging, reflecting disrupted neuronal maturation linked to *MECP2* mutations (or related genes like *FOXG1* in congenital variants).  
7. **Sleep disturbance**: Autonomic dysfunction in Rett syndrome contributes to disrupted sleep-wake cycles.  
8. **Early-onset symptoms**: Congenital variants lack the typical 6–18-month period of normal development seen in classic Rett syndrome, instead presenting with neonatal/infantile hypotonia and developmental arrest.  
**Exclusion of mimics**: Differentiated from CDKL5 deficiency disorder (earlier seizure onset) and Angelman syndrome (distinct EEG patterns, lack of microcephaly at birth) by the combination of microcephaly, repetitive hand stereotypies, and *MECP2/FOXG1* genetic profile."
"['Microcephaly', 'Ptosis', 'Myopia', 'Autism', 'Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Short stature', 'Bilateral camptodactyly', 'Abnormality of the epiphyses of the feet', 'Delayed ability to walk']",['Intellectual developmental disorder with dysmorphic facies and ptosis'],"Disease: Intellectual developmental disorder with dysmorphic facies and ptosis (IDDDFP)  
Reasoning:  
1. **Core features alignment**: Ptosis, intellectual disability, delayed speech/development, and microcephaly are cardinal features of IDDDFP, caused by pathogenic variants in *TFAP2B*.  
2. **Musculoskeletal abnormalities**: Bilateral camptodactyly (fixed finger flexion) and foot epiphyseal anomalies correlate with the ""dysmorphic facies and skeletal defects"" described in IDDDFP.  
3. **Neurodevelopmental overlap**: Autism, hyperactivity, and delayed walking align with the spectrum of neurodevelopmental delays seen in this disorder.  
4. **Growth parameters**: Short stature supports the growth retardation phenotype associated with IDDDFP.  
5. **Exclusion of mimics**: The combination of ptosis, skeletal defects, and intellectual disability distinguishes IDDDFP from syndromes like Cornelia de Lange or Rubinstein-Taybi, which lack specific epiphyseal foot anomalies."
"['Inguinal hernia', 'Vesicoureteral reflux', 'Nasolacrimal duct obstruction', 'Carious teeth', 'Hypertension', 'Cutis laxa', 'Mitral regurgitation', 'Bronchiectasis', 'Aortic root aneurysm', 'Tricuspid regurgitation', 'Epiphora', 'Flat sella turcica']","['Cutis laxa, autosomal recessive, type IA']","Disease: Cutis laxa, autosomal recessive, type IA (ARCL1A)  
Reasoning:  
1. **Cutis laxa**: Primary symptom indicating a genetic disorder affecting elastic fibers.  
2. **Aortic root aneurysm** and **mitral/tricuspid regurgitation**: Reflect systemic connective tissue weakness, common in ARCL1A due to mutations in *FBLN5*, critical for elastin assembly.  
3. **Inguinal hernia** and **bronchiectasis**: Connective tissue fragility leads to hernias and airway damage from impaired elastic recoil.  
4. **Nasolacrimal duct obstruction** and **epiphora**: Elastic fiber defects disrupt tear drainage structures.  
5. **Vesicoureteral reflux**: Bladder-ureter junction laxity from deficient elastin.  
6. **Hypertension**: May arise from vascular stiffness or renal involvement secondary to reflux.  
7. **Flat sella turcica**: Associated with connective tissue defects altering skull base structure.  
8. **Carious teeth**: Potential enamel/dentin abnormalities linked to *FBLN5* mutations.  
9. Exclusion of other subtypes (e.g., ARCL2 with skeletal dysplasia, ARCL3 with neurodevelopmental issues) solidifies ARCL1A diagnosis."
"['Sensorineural hearing impairment', 'Apathy', 'Waddling gait', 'Bone pain', 'Scapular winging', 'Proximal muscle weakness', 'Rimmed vacuoles', 'Proximal amyotrophy', 'Mildly elevated creatine kinase', 'Elevated alkaline phosphatase of bone origin', 'Cognitive impairment']",['Inclusion body myopathy with Paget disease of bone and frontotemporal dementia/Inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 1'],"Disease: Inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD)  
Reasoning:  
1. **Proximal muscle weakness, scapular winging, waddling gait, rimmed vacuoles, and proximal amyotrophy**: These are hallmark features of inclusion body myopathy (IBM). Rimmed vacuoles on muscle biopsy are pathognomonic for IBM, while proximal weakness and scapular winging indicate muscle degeneration affecting the shoulder and pelvic girdles.  
2. **Elevated alkaline phosphatase (bone origin) and bone pain**: These suggest Paget disease of bone, characterized by dysregulated bone remodeling. Elevated bone-specific ALP reflects increased osteoblastic activity.  
3. **Cognitive impairment and apathy**: Align with frontotemporal dementia (FTD), which manifests with behavioral changes and executive dysfunction.  
4. **Sensorineural hearing loss**: A recognized but less common feature of IBMPFD, possibly due to genetic mutations (e.g., *VCP*) affecting cochlear or neural structures.  
5. **Mildly elevated creatine kinase**: Consistent with chronic muscle breakdown in myopathy, though levels are typically less elevated than in inflammatory myopathies.  
**Conclusion**: The triad of IBM, Paget disease, and FTD, alongside supportive findings (hearing loss, CK elevation), confirms IBMPFD, most commonly linked to *VCP* gene mutations."
"['Lop ear', 'Telecanthus', 'Retinal dystrophy', 'Bicornuate uterus', 'Septate vagina', 'Pulmonic stenosis', 'Bicuspid aortic valve', 'Toe syndactyly', 'Anal atresia', 'Clinodactyly of the 5th finger', 'Short stature', 'Sagittal craniosynostosis', 'Moderate myopia', 'Abnormal radial ray morphology']",['Syndactyly-telecanthus-anogenital and renal malformations syndrome/STAR syndrome'],"Disease: Syndactyly-telecanthus-anogenital and renal malformations syndrome (STAR syndrome)  
Reasoning: The patient presents with **toe syndactyly**, **telecanthus**, and **anogenital malformations** (anal atresia, bicornuate uterus, septate vagina), which are hallmark features of STAR syndrome. While renal anomalies are not explicitly listed, the triad of syndactyly, telecanthus, and anogenital defects strongly supports this diagnosis. Additional findings like **short stature** and **clinodactyly** align with reported phenotypic variability. Though **pulmonic stenosis**, **bicuspid aortic valve**, and **sagittal craniosynostosis** are atypical for STAR, they may represent rare associations or coincidental findings. The absence of classic radial ray involvement (e.g., thumb anomalies) and retinal dystrophy in STAR suggests these could be incidental or part of an overlapping condition, but the core triad remains diagnostic."
"['Entropion', 'Cutis laxa', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Abnormal heart morphology', 'Abnormal cardiac septum morphology', 'Abnormal facial shape', 'Kyphoscoliosis', 'Abnormal subcutaneous fat tissue distribution']","['Cutis laxa, autosomal recessive, type IID']","Disease: Cutis laxa, autosomal recessive, type IID  
Reasoning:  
1. **Cutis laxa**: A hallmark feature of this disease group, indicating loose, sagging skin due to defective elastic fiber formation.  
2. **Abnormal heart morphology & cardiac septum defects**: Type IID is linked to mutations in *ATP6V0A2*, which disrupt lysosomal function and collagen/elastin processing, leading to cardiovascular anomalies like septal defects.  
3. **Kyphoscoliosis & hip dysplasia**: Connective tissue weakness causes skeletal abnormalities, including spinal curvature (kyphoscoliosis) and hip joint malformation.  
4. **Generalized hypotonia & flexion contractures**: Reduced muscle tone and joint contractures arise from systemic connective tissue dysfunction.  
5. **Disproportionate tall stature & abnormal fat distribution**: Growth abnormalities and metabolic dysregulation from lysosomal defects contribute to atypical body proportions and fat patterning.  
6. **Entropion & abnormal facial shape**: Elastic fiber defects in periocular tissue and facial structures result in inward-turning eyelids and dysmorphic facial features.  
7. **Autosomal recessive inheritance**: Matches the genetic pattern of *ATP6V0A2*-related disorders. The combination of cutaneous, skeletal, cardiac, and metabolic signs distinguishes type IID from other ARCL subtypes."
"['Macroglossia', 'Microcephaly', 'Coarse facial features', 'Long eyelashes', 'Synophrys', 'Decreased response to growth hormone stimulation test', 'Hirsutism', 'Seizure', 'Hyporeflexia', 'Motor delay', 'Absent speech', 'Cerebral cortical atrophy', 'Developmental regression', 'Scoliosis', 'Severe muscular hypotonia', 'Corneal opacity', 'Severe global developmental delay', 'Central adrenal insufficiency']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Core phenotypic features**: Severe muscular hypotonia, severe global developmental delay, and motor delay align with the syndrome’s hallmark triad. Absent speech reflects profound neurodevelopmental impairment.  
2. **Characteristic facies**: Coarse facial features, long eyelashes, and synophrys (fused eyebrows) are classic dysmorphic traits in TBCK-related disorders.  
3. **Neurological abnormalities**: Cerebral cortical atrophy explains seizures, hyporeflexia, and developmental regression (linked to progressive brain changes, though not classically neurodegenerative). Microcephaly further supports central nervous system involvement.  
4. **Endocrine dysfunction**: Decreased growth hormone response and central adrenal insufficiency correlate with TBCK’s role in mTOR signaling, affecting endocrine pathways.  
5. **Musculoskeletal findings**: Scoliosis and hypotonia are secondary to chronic low muscle tone and motor deficits.  
6. **Ancillary features**: Hirsutism and corneal opacity, while less common, are documented in some cases, reflecting multisystemic impact of TBCK mutations.  
7. **Exclusion of mimics**: The combination of hypotonia, adrenal/growth hormone deficits, and facial dysmorphism distinguishes this from lysosomal storage disorders or mitochondrial diseases.  
The constellation of symptoms strongly supports a TBCK-related diagnosis, confirmed by genetic testing for pathogenic variants in the TBCK gene."
"['Smooth philtrum', 'Long philtrum', 'Micrognathia', 'Hearing impairment', 'Cataract', 'Long eyelashes', 'Carious teeth', 'Hypotonia', 'Motor delay', 'Bilateral ptosis', 'Frontal bossing', 'Recurrent respiratory infections', 'Feeding difficulties in infancy', 'Postnatal growth retardation', 'Retractile testis']",['Vici syndrome/Vici syndrome'],"Disease: Vici syndrome  
Reasoning: The patient presents with **cataracts**, a hallmark feature of Vici syndrome, alongside **recurrent respiratory infections** suggestive of immunodeficiency, another key component. **Hypotonia**, **motor delay**, and **postnatal growth retardation** align with neurodevelopmental and growth abnormalities seen in Vici syndrome. **Feeding difficulties in infancy** are consistent with multisystem involvement. Craniofacial features (**micrognathia**, **frontal bossing**, **bilateral ptosis**) and **long philtrum** may reflect dysmorphism associated with the disorder. While **hearing impairment** and **carious teeth** are less typical, they could occur due to syndromic variability. The absence of explicitly mentioned agenesis of the corpus callosum (a classic feature) is notable, but clinical heterogeneity may account for this. Overall, the constellation of immune deficiency, cataracts, neurodevelopmental delays, and craniofacial signs strongly supports Vici syndrome."
"['Hyporeflexia', 'Muscle weakness', 'Myotonia', 'Elevated circulating creatine kinase concentration', 'Muscle stiffness', 'Cytochrome C oxidase-negative muscle fibers', 'Generalized muscle hypertrophy']","['Myotonia congenita, autosomal dominant']","Disease: Myotonia congenita, autosomal dominant  
Reasoning: The patient presents with myotonia (delayed muscle relaxation) and muscle stiffness, hallmark features of myotonia congenita. Generalized muscle hypertrophy aligns with the autosomal dominant form (Thomsen disease), where muscle enlargement is common. Hyporeflexia and muscle weakness may occur due to altered muscle membrane excitability. Elevated creatine kinase suggests mild muscle damage from chronic myotonic activity. Cytochrome C oxidase (COX)-negative fibers, while atypical, could reflect secondary mitochondrial dysfunction from prolonged muscle stress. The absence of systemic features (e.g., cardiac or ocular involvement) excludes myotonic dystrophy, and autosomal dominance distinguishes it from the recessive Becker variant."
"['Jaundice', 'Splenomegaly', 'Anemia', 'Reticulocytosis', 'Hepatomegaly', 'Elliptocytosis', 'Coombs-positive hemolytic anemia', 'Imbalanced hemoglobin synthesis', 'Conjunctival icterus', 'Abnormal glucose-6-phosphate dehydrogenase level in blood']",['Elliptocytosis 2'],"Disease: Elliptocytosis 2  
Reasoning:  
1. **Elliptocytosis**: Presence of elliptocytes on blood smear is a hallmark of hereditary elliptocytosis (HE), specifically type 2, linked to mutations in cytoskeletal proteins like spectrin or ankyrin.  
2. **Hemolytic anemia**: Reticulocytosis, anemia, and jaundice indicate compensatory bone marrow response to chronic hemolysis, consistent with HE.  
3. **Splenomegaly/Hepatomegaly**: Splenic sequestration of abnormal RBCs and extramedullary hematopoiesis from chronic hemolysis explain organ enlargement.  
4. **Conjunctival icterus/jaundice**: Elevated bilirubin from RBC breakdown aligns with hemolysis.  
5. **Imbalanced hemoglobin synthesis**: Chronic hemolysis disrupts erythropoiesis, leading to ineffective hemoglobin production.  
6. **Coombs-positive anomaly**: Uncommon in HE but may reflect concurrent autoimmune hemolysis or assay interference; primary diagnosis relies on structural RBC defects.  
7. **Abnormal G6PD level**: Likely incidental (e.g., heterozygous carrier or mild deficiency) but could exacerbate oxidative stress-induced hemolysis in HE.  

The combination of elliptocytes, hemolysis markers, and exclusion of primary enzymatic defects (despite G6PD anomaly) prioritizes hereditary elliptocytosis type 2 as the diagnosis."
"['Hepatic steatosis', 'Reduced antithrombin III activity', 'Hepatomegaly', 'Elevated circulating alkaline phosphatase concentration', 'Decreased circulating ceruloplasmin concentration', 'Decreased circulating copper concentration']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Hepatic steatosis and hepatomegaly**: TMEM199-CDG commonly presents with liver involvement, including fatty liver and enlarged liver.  
2. **Reduced antithrombin III activity**: Glycosylation defects impair synthesis of glycoproteins like antithrombin III, leading to functional deficiency.  
3. **Elevated alkaline phosphatase**: Reflects cholestatic liver injury, a hallmark of TMEM199-CDG.  
4. **Decreased ceruloplasmin and copper**: Ceruloplasmin, a copper-binding glycoprotein, requires proper glycosylation for stability. Its deficiency reduces circulating copper levels, distinguishing this from Wilson disease (where copper accumulates in tissues).  
5. **Consistent with TMEM199-CDG pathophysiology**: Mutations in *TMEM199* disrupt Golgi homeostasis, causing secondary glycosylation defects and hepatic/coagulation abnormalities.  

(Note: ""Congenital disorder of glycosylation, type IIP"" and ""TMEM199-CDG"" refer to the same disease, with the latter specifying the genetic cause.)"
"['Dysarthria', 'Bulbar palsy', 'Dysphagia', 'Tetraparesis', 'Babinski sign', 'Ankle clonus', 'Tongue atrophy']",['Amyotrophic lateral sclerosis 1'],"Disease: Amyotrophic lateral sclerosis 1  
Reasoning:  
1. **Upper Motor Neuron (UMN) Signs**: Babinski sign and ankle clonus indicate corticospinal tract involvement.  
2. **Lower Motor Neuron (LMN) Signs**: Tongue atrophy and bulbar palsy (with dysarthria/dysphagia) reflect LMN degeneration in the bulbar region.  
3. **Tetraparesis**: Weakness in all four limbs suggests combined UMN and LMN dysfunction, a hallmark of ALS.  
4. **Exclusion of Mimics**: The combination of bulbar, limb, and mixed UMN/LMN signs without sensory deficits or other systemic features strongly supports ALS over alternatives (e.g., myasthenia gravis, spinal muscular atrophy).  
5. **Progression**: ALS typically presents with progressive motor deficits aligning with the listed symptoms."
"['Sensorineural hearing impairment', 'Neonatal hypotonia', 'Muscle weakness', 'Craniosynostosis', 'Failure to thrive in infancy', 'Gastroesophageal reflux', 'Respiratory distress', 'Increased serum lactate', 'Increased CSF lactate', 'Elevated hepatic transaminase', 'Myopathy', 'Ragged-red muscle fibers', 'Generalized muscle weakness', 'Hyperalaninemia', 'Cytochrome C oxidase-negative muscle fibers', 'Feeding difficulties in infancy', 'Bronchiolitis', 'Elevated circulating acylcarnitine concentration']","['Combined oxidative phosphorylation deficiency 30', 'Combined oxidative phosphorylation defect type 30']","Disease: Combined oxidative phosphorylation deficiency 30 (COXPD30)  
Reasoning:  
1. **Mitochondrial Dysfunction Indicators**: Elevated serum/CSF lactate, ragged-red muscle fibers, and cytochrome C oxidase (COX)-negative fibers strongly suggest a mitochondrial disorder, specifically a defect in oxidative phosphorylation (OXPHOS).  
2. **Neuromuscular Symptoms**: Neonatal hypotonia, generalized muscle weakness, myopathy, and respiratory distress align with impaired mitochondrial energy production in muscles.  
3. **Metabolic Abnormalities**: Hyperalaninemia and elevated acylcarnitine indicate disrupted amino acid and fatty acid metabolism, common in OXPHOS defects due to secondary mitochondrial stress.  
4. **Multi-Organ Involvement**: Craniosynostosis (connective tissue/bone), hepatic transaminase elevation (liver), gastroesophageal reflux, and failure to thrive reflect systemic OXPHOS failure.  
5. **Genetic Link**: COXPD30 is caused by *MTFMT* mutations, disrupting mitochondrial translation and causing combined OXPHOS deficiencies (e.g., complexes I, IV). This matches the COX-negative fibers and overlapping symptoms.  
6. **Infantile Presentation**: Feeding difficulties, bronchiolitis, and failure to thrive in infancy are consistent with early-onset mitochondrial disorders like COXPD30.  

Disease: Combined oxidative phosphorylation defect type 30  
Reasoning:  
(This is the same entity as COXPD30; ""type 30"" refers to the specific genetic classification under combined OXPHOS deficiencies. The reasoning above applies here identically, as both terms describe the *MTFMT*-related disorder.)"
"['Jaundice', 'Pruritus', 'Cholestasis', 'Hepatosplenomegaly', 'Growth delay', 'Abnormal heart morphology', 'Abnormality of coagulation', 'Hepatomegaly', 'Scoliosis', 'Conjugated hyperbilirubinemia', 'Abnormal circulating amino acid concentration', 'Increased total bilirubin', 'Abnormal immunoglobulin level', 'Increased serum bile acid concentration', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration', 'Pointed helix']","['Progressive familial intrahepatic cholestasis type 4', 'Cholestasis, progressive familial intrahepatic 4']","Disease: Progressive familial intrahepatic cholestasis type 4 (PFIC4)  
Reasoning:  
1. **Cholestasis and conjugated hyperbilirubinemia**: Core features of PFIC4, caused by impaired bile secretion due to TJP2 gene mutations.  
2. **Jaundice, pruritus, elevated serum bile acids**: Direct consequences of bile acid accumulation in the liver and bloodstream.  
3. **Hepatosplenomegaly/hepatomegaly**: Reflects chronic liver injury and fibrosis, common in progressive cholestatic disorders.  
4. **Growth delay**: Malabsorption of fat-soluble vitamins and nutrients due to cholestasis.  
5. **Abnormal coagulation**: Liver dysfunction reduces synthesis of clotting factors (e.g., vitamin K-dependent factors).  
6. **Elevated AST/ALT**: Indicates hepatocellular damage secondary to cholestasis and inflammation.  
7. **Abnormal immunoglobulin levels**: Chronic hepatic inflammation may dysregulate immune protein production.  
8. **Pointed helix, scoliosis, cardiac anomalies**: TJP2 mutations can affect cell polarity in extrahepatic tissues, leading to congenital structural abnormalities.  
9. **Exclusion of other PFIC subtypes**: PFIC4 is distinguished by early-onset cholestasis, TJP2 variants, and variable extrahepatic features (unlike ATP8B1-/ABCB11-related PFIC1/2).  

Disease: Cholestasis, progressive familial intrahepatic 4 (synonym for PFIC4)  
Reasoning:  
- This term is interchangeable with PFIC4, reflecting the same genetic etiology (TJP2 mutations) and clinical profile. The symptoms align with the OMIM classification (OMIM #615878) for this autosomal recessive disorder."
"['Jaundice', 'Splenomegaly', 'Hemolytic anemia', 'Reticulocytosis', 'Increased red cell osmotic fragility']","['Spherocytosis, type 5']","Disease: Spherocytosis, type 5  
Reasoning:  
1. **Hemolytic anemia** and **reticulocytosis** indicate accelerated red blood cell (RBC) destruction and compensatory bone marrow production.  
2. **Jaundice** arises from unconjugated hyperbilirubinemia due to hemoglobin breakdown in hemolysis.  
3. **Splenomegaly** occurs as the spleen becomes engorged from trapping and destroying structurally abnormal RBCs.  
4. **Increased red cell osmotic fragility** is a hallmark of spherocytosis, reflecting reduced RBC surface-to-volume ratio due to membrane loss.  
5. **Type 5 spherocytosis** specifically involves mutations in the *EPB42* gene, causing deficiency of erythrocyte membrane protein band 4.2, destabilizing the cytoskeleton and leading to spheroidal, fragile RBCs.  
The combination of membrane instability, splenic sequestration, and hemolysis confirms the diagnosis."
"['Hypospadias', 'Low-set ears', 'Ptosis', 'Coloboma', 'Optic nerve hypoplasia', 'Iris coloboma', 'Diabetes mellitus', 'Hypertension', 'Cyanosis', 'Edema', 'Generalized hypotonia', 'Bilateral ptosis', 'Polyhydramnios', 'Ventricular septal defect', 'Atrial septal defect', 'Congestive heart failure', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Large forehead', 'Dyspnea', 'Apnea', 'Ventriculomegaly', 'Gray matter heterotopia', 'Bilateral choanal atresia', 'Right ventricular dilatation', 'Depressed nasal bridge', 'Redundant neck skin', 'Wide intermamillary distance', 'Ocular anterior segment dysgenesis', 'Corneal opacity', 'Microtia', 'Axial hypotonia', 'Infantile axial hypotonia', 'Maternal diabetes', 'Simplified gyral pattern', 'Prominent forehead', 'Flexion contracture of finger', 'Pulmonary edema']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental/Brain anomalies**: Simplified gyral pattern, gray matter heterotopia, ventriculomegaly, generalized hypotonia, and axial hypotonia indicate central nervous system involvement.  
2. **Ocular anomalies**: Coloboma (iris/optic nerve), optic nerve hypoplasia, corneal opacity, and anterior segment dysgenesis are hallmark eye findings in NEDBEH.  
3. **Cardiac defects**: Ventricular/atrial septal defects, patent foramen ovale, abnormal cardiac septum morphology, and congestive heart failure align with the cardiac spectrum of this disorder.  
4. **Supportive features**: Dysmorphic traits (low-set ears, depressed nasal bridge, microtia, redundant neck skin) and maternal diabetes (a known risk factor for congenital anomalies) further support the diagnosis.  
5. **Exclusion of mimics**: Choanal atresia and pulmonary edema may arise secondary to structural or functional abnormalities linked to the primary disorder. Polyhydramnios correlates with hypotonia-related fetal swallowing issues.  
6. **Syndromic coherence**: The triad of neurodevelopmental delay, brain/eye malformations, and congenital heart defects is pathognomonic for NEDBEH, often caused by de novo variants in genes like *BRD4* or *SMARCA2*."
"['Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Deeply set eye', 'Visual impairment', 'Osteoporosis', 'Seizure', 'Areflexia', 'Cerebellar vermis hypoplasia', 'Hyperreflexia', 'Hypoplasia of the corpus callosum', 'Respiratory insufficiency', 'Ventriculomegaly', ""Exaggerated cupid's bow"", 'EEG abnormality', 'Developmental regression', 'Fasciculations', 'Highly arched eyebrow', 'Peripheral axonal neuropathy', 'Severe muscular hypotonia', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay', 'Abnormality of muscle size']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
- **Characteristic facial features**: Narrow forehead, prominent nasal bridge, anteverted nares, deeply set eyes, exaggerated cupid’s bow, and highly arched eyebrows align with the dysmorphic facies typical of TBCK syndrome.  
- **Neuromuscular abnormalities**: Severe muscular hypotonia, areflexia/hyperreflexia (mixed reflexes due to peripheral neuropathy and central nervous system involvement), fasciculations, and peripheral axonal neuropathy reflect the syndrome’s impact on both central and peripheral nervous systems.  
- **Neurodevelopmental deficits**: Profound global developmental delay, developmental regression, and cerebellar vermis hypoplasia correlate with psychomotor retardation and cerebellar dysfunction.  
- **Structural brain anomalies**: Hypoplasia of the corpus callosum, ventriculomegaly, and small basal ganglia are consistent with neuroimaging findings in TBCK-related disorders.  
- **Seizures/EEG abnormalities**: Epileptiform activity and seizures are common due to cortical and subcortical malformations.  
- **Systemic involvement**: Osteoporosis (secondary to immobility from hypotonia), respiratory insufficiency (muscle weakness), and feeding difficulties (bulbar dysfunction) support multisystemic disease progression.  
- **Genetic basis**: TBCK gene mutations disrupt mTOR signaling and autophagy, explaining the combination of neurodevelopmental, muscular, and degenerative features.  

The constellation of facial dysmorphism, hypotonia, neurodevelopmental regression, brain malformations, and mixed neurological signs strongly supports the diagnosis of TBCK-related intellectual disability syndrome."
"['Hearing impairment', 'Blue sclerae', 'Flexion contracture', 'Hepatosplenomegaly', 'Recurrent fractures', 'Abnormal echocardiogram', 'Elevated circulating alkaline phosphatase concentration', 'Short stature', 'Reduced bone mineral density']","['Osteogenesis imperfecta, type XI']","Disease: Osteogenesis imperfecta, type XI  
Reasoning:  
1. **Recurrent fractures** and **reduced bone mineral density** indicate a bone fragility disorder, common in Osteogenesis Imperfecta (OI).  
2. **Blue sclerae** are a hallmark of OI due to abnormal collagen affecting scleral thickness.  
3. **Short stature** aligns with skeletal deformities and growth deficiencies in severe OI subtypes.  
4. **Elevated alkaline phosphatase** reflects increased bone turnover from frequent fractures.  
5. **Flexion contractures** suggest Bruck syndrome overlap (OI type XI), linked to *FKBP10* mutations causing joint rigidity.  
6. **Hearing impairment** is seen in progressive OI subtypes due to ossicular chain abnormalities.  
7. **Abnormal echocardiogram** may indicate valvular or aortic root abnormalities, occasionally associated with collagen defects.  
8. **Hepatosplenomegaly** is atypical but reported in rare OI cases, possibly secondary to extramedullary hematopoiesis or metabolic stress.  

This constellation of symptoms, particularly fractures, contractures, and hearing loss, strongly supports OI type XI (Bruck syndrome type 2)."
"['Rod-cone dystrophy', 'Delayed speech and language development', 'Cafe-au-lait spot', 'Brachydactyly', 'Absent speech', 'Craniosynostosis', 'Pes planus', 'Hallux valgus', 'Delayed gross motor development', 'Short stature', 'Multiple cafe-au-lait spots']",['Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies'],"Disease: Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies  
Reasoning:  
1. **Rod-cone dystrophy**: Indicates retinitis pigmentosa (RP), a hallmark of the syndrome, characterized by progressive retinal degeneration.  
2. **Brachydactyly and short stature**: Directly aligns with the skeletal anomalies component (brachydactyly) and growth deficiency (short stature) in the syndrome.  
3. **Craniosynostosis**: Supports skeletal involvement, as craniofacial abnormalities can co-occur with syndromic RP variants.  
4. **Delayed speech/absent speech and motor delays**: Reflects potential neurodevelopmental impacts, consistent with multisystem genetic syndromes.  
5. **Pes planus and hallux valgus**: Further skeletal manifestations, reinforcing the ""skeletal anomalies"" classification.  
6. **Cafe-au-lait spots**: Less typical but occasionally reported in syndromic RP variants; may indicate phenotypic variability or overlap with other disorders (e.g., NF1), though the core triad (RP, brachydactyly, short stature) dominates the diagnosis.  

The combination of retinal degeneration, skeletal defects, and growth delays strongly prioritizes this syndrome over isolated RP or other café-au-lait-associated disorders."
"['Coarse facial features', ""Widow's peak"", 'Recurrent otitis media', 'Bulbous nose', 'Autistic behavior', 'Anxiety', 'Delayed speech and language development', 'Brachydactyly', 'Prominent fingertip pads', 'Global developmental delay', 'Organic aciduria', 'Abnormal circulating amino acid concentration', 'Aminoaciduria', 'Short stature', 'Mucopolysacchariduria', 'Oligosacchariduria', 'Echolalia', 'Abnormal leukocyte count', 'Abnormal serum insulin-like growth factor 1 level', 'Small hand']","['Leukocyte adhesion deficiency type II/Congenital disorder of glycosylation, type IIc']","Disease: Leukocyte adhesion deficiency type II/Congenital disorder of glycosylation, type IIc (LAD II/CDG-IIc)  
**Reasoning**:  
1. **Glycosylation Defects**: Mucopolysacchariduria and oligosacchariduria indicate impaired glycosylation, a hallmark of congenital disorders of glycosylation (CDG).  
2. **Immune Dysfunction**: Recurrent otitis media and abnormal leukocyte count align with leukocyte adhesion deficiency (LAD II), a CDG-IIc-specific immune defect due to faulty fucose metabolism.  
3. **Developmental Delays**: Global developmental delay, speech delay, autistic behavior, and echolalia reflect neurological involvement common in CDG.  
4. **Skeletal Features**: Brachydactyly, small hands, prominent fingertip pads, and short stature correlate with skeletal dysplasia seen in CDG-IIc.  
5. **Metabolic Abnormalities**: Organic aciduria, aminoaciduria, and abnormal serum amino acids/IGF-1 levels suggest systemic metabolic disruption from glycosylation errors.  
6. **Dysmorphic Traits**: Coarse facial features, bulbous nose, and widow’s peak are consistent with CDG-IIc’s craniofacial phenotype.  

The integration of glycosylation defects (urinary metabolites), immune deficiency, neurodevelopmental delays, and skeletal anomalies confirms LAD II/CDG-IIc."
"['Seizure', 'Hyperammonemia', 'Cerebral edema', 'Oroticaciduria', 'Hypoargininemia', 'Hyperprolinemia', 'Elevated plasma citrulline', 'Citrullinuria']","['Citrullinemia type I/Citrullinemia, classic']","Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
1. **Elevated plasma citrulline and citrullinuria**: These are hallmark findings of argininosuccinate synthetase (ASS) deficiency, which prevents the conversion of citrulline to argininosuccinate in the urea cycle.  
2. **Hyperammonemia**: Caused by impaired urea cycle function, leading to toxic ammonia accumulation.  
3. **Hypoargininemia**: Reduced arginine production due to the enzymatic block at ASS, limiting downstream arginine synthesis.  
4. **Oroticaciduria**: Likely secondary to partial carbamoyl phosphate spillover into pyrimidine synthesis, triggered by urea cycle dysfunction or mitochondrial stress from hyperammonemia.  
5. **Cerebral edema and seizures**: Result from ammonia toxicity and osmotic effects of accumulated glutamine in the brain.  
6. **Hyperprolinemia**: May arise from disrupted arginine-proline metabolic crosstalk or compensatory mechanisms in urea cycle failure.  

This constellation of findings—urea cycle disruption, citrulline accumulation, and secondary metabolic effects—confirms the diagnosis of Citrullinemia type I."
"['Brachycephaly', 'Preauricular skin tag', 'Strabismus', 'Proptosis', 'Nystagmus', 'Precocious puberty', 'Single transverse palmar crease', 'Wrist flexion contracture', 'Global developmental delay', 'Generalized hypotonia', 'Overlapping toe', 'Bilateral tonic-clonic seizure', 'EEG abnormality', 'Poor head control', 'Elbow flexion contracture', 'Myoclonic spasms', 'Deep palmar crease', 'Knee flexion contracture', 'Severe muscular hypotonia', 'Focal-onset seizure', 'Infantile muscular hypotonia']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Neuromuscular Features**: Severe generalized and infantile hypotonia, poor head control, and flexion contractures (wrist, elbow, knee) align with TBCK’s hallmark neuromuscular involvement.  
2. **Developmental Delay**: Global developmental delay and intellectual disability are core features of TBCK-related syndromes.  
3. **Seizures**: Focal-onset, tonic-clonic, and myoclonic seizures with EEG abnormalities correlate with TBCK’s association with epilepsy.  
4. **Dysmorphic Facies**: Brachycephaly, proptosis, strabismus, nystagmus, and preauricular skin tag match characteristic craniofacial features.  
5. **Skeletal/Physical Anomalies**: Single transverse palmar crease, deep palmar crease, and overlapping toe reflect congenital malformations reported in TBCK cases.  
6. **Supportive Evidence**: TBCK mutations disrupt mTOR signaling, explaining neurodevelopmental and muscular pathology. While precocious puberty is atypical, phenotypic variability is recognized in this disorder.  
7. **Exclusion**: Symptoms collectively distinguish TBCK from mimics like Prader-Willi, Angelman, or Rett syndromes, which lack the full syndromic pattern."
"['Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Micrognathia', ""Widow's peak"", 'Posteriorly rotated ears', 'Hearing impairment', 'Low-set, posteriorly rotated ears', 'Sensorineural hearing impairment', 'Bulbous nose', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Microphthalmia', 'Blepharophimosis', 'Coloboma', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Motor delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Duodenal atresia', 'Tetraparesis', 'Incoordination', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Attention deficit hyperactivity disorder', 'Broad eyebrow', 'Abnormality of fontanelles', 'Feeding difficulties', 'Head-banging', 'Nail-biting', 'Thick vermilion border', 'Narrow palpebral fissure', 'Small hand', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
**Reasoning**:  
1. **Neurodevelopmental Core Features**:  
   - Global developmental delay, motor delay, absent speech, and hypotonia align with central neurodevelopmental impairments.  
   - Seizures, hyperactivity, ADHD, and atypical behavior (e.g., head-banging) further support neurological dysfunction.  

2. **Ocular Anomalies**:  
   - Structural eye defects (coloboma, microphthalmia, Peters anomaly, optic atrophy) are hallmark features of NEDBEH.  
   - Additional findings (blepharophimosis, downslanted palpebral fissures, deeply set eyes) reinforce craniofacial involvement.  

3. **Cardiac Defects**:  
   - Ventricular septal defect, patent ductus arteriosus, and abnormal cardiac septum morphology match the ""heart"" criterion in NEDBEH.  

4. **Craniofacial Dysmorphism**:  
   - Microcephaly/macrocephaly (variable expressivity), frontal bossing, narrow mouth, high palate, micrognathia, and cleft lip are consistent with syndromic facial features.  

5. **Supportive Systemic Features**:  
   - Musculoskeletal anomalies (syndactyly, scoliosis, hip dysplasia) and growth abnormalities (intrauterine growth retardation, short/tall stature) reflect broad developmental disruption.  
   - Gastrointestinal issues (pyloric stenosis, annular pancreas) and renal cysts may represent variable systemic involvement.  

6. **Genetic Overlap**:  
   - Overlapping features (sensorineural hearing loss, café-au-lait spots) suggest genetic heterogeneity but do not exclude NEDBEH, which encompasses phenotypic variability.  

**Conclusion**: The constellation of neurodevelopmental delays, structural eye/heart defects, and multisystem anomalies strongly aligns with NEDBEH, a genetically heterogeneous disorder often linked to de novo variants in genes like *BRPF1* or *UBR1*."
"['Microcephaly', 'Seizure', 'Coma', 'Global developmental delay', 'Absent speech', 'Torsade de pointes', 'Hypoglycemia', 'Ketosis', 'Lower limb spasticity', 'Status epilepticus', 'Increased serum lactate', 'Myoglobinuria', 'Ketonuria', 'Elevated circulating thyroid-stimulating hormone concentration', 'Lactic acidosis', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Acute encephalopathy', 'Axial hypotonia', 'Arrhythmia', 'Brain atrophy', 'Dicarboxylic acidemia', 'Elevated circulating acylcarnitine concentration']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Metabolic Dysregulation**: Hypoglycemia, ketosis, ketonuria, dicarboxylic acidemia, and elevated acylcarnitine suggest impaired fatty acid oxidation and mitochondrial dysfunction.  
2. **Neurological Crises**: Acute encephalopathy, seizures, status epilepticus, coma, and lactic acidosis align with recurrent metabolic encephalopathic episodes.  
3. **Muscle Involvement**: Rhabdomyolysis, myoglobinuria, and elevated creatine kinase indicate severe myopathy, consistent with ""encephalomyopathic"" features.  
4. **Cardiac Arrhythmias**: Torsade de pointes and arrhythmia reflect systemic metabolic toxicity affecting cardiac ion channels.  
5. **Neurodegeneration**: Microcephaly, brain atrophy, global developmental delay, absent speech, axial hypotonia, and spasticity imply progressive neurodegeneration.  
6. **Thyroid Dysregulation**: Elevated TSH may indicate secondary endocrine disruption due to chronic metabolic stress.  
7. **Consistency with Syndrome**: The triad of recurrent encephalopathy, rhabdomyolysis, and arrhythmias, combined with neurodegeneration and metabolic biomarkers, uniquely matches this ultra-rare syndrome."
"['Parkinsonism', 'Rigidity', 'Bradykinesia', 'Gait imbalance', 'Postural instability', 'EEG abnormality', 'Falls']","['Parkinsonian-pyramidal syndrome/Parkinson disease 15, autosomal recessive early-onset']","Disease: Parkinsonian-pyramidal syndrome/Parkinson disease 15, autosomal recessive early-onset  
Reasoning:  
1. **Core Parkinsonian Features**: The presence of rigidity, bradykinesia, and gait imbalance aligns with Parkinsonism, a hallmark of this syndrome.  
2. **Early-Onset and Inheritance**: The diagnosis specifies autosomal recessive early-onset disease, suggesting a genetic etiology consistent with PARK15.  
3. **Pyramidal Involvement**: Though not explicitly listed, gait imbalance, postural instability, and falls may reflect pyramidal tract dysfunction (e.g., spasticity or hyperreflexia), a defining feature of Parkinsonian-pyramidal syndrome.  
4. **EEG Abnormality**: Uncommon in idiopathic Parkinson’s disease, this points to cortical or subcortical dysfunction, supporting a complex neurodegenerative syndrome like PARK15.  
5. **Exclusion of Typical Parkinson’s**: Early-onset symptoms with atypical features (EEG changes, rapid progression to falls) argue against sporadic Parkinson’s disease, favoring a genetic or syndromic cause.  
6. **Genetic Confirmation**: While clinical features are critical, PARK15 is confirmed via *FBXO7* gene testing, though this step is inferred from the clinical context provided."
"['Hypogonadotropic hypogonadism', 'Poikiloderma', 'Neutropenia', 'Bronchiectasis', 'Short stature', 'Abnormal pulmonary interstitial morphology', 'Granuloma']",['Poikiloderma with neutropenia'],"Disease: Poikiloderma with neutropenia (PN)  
Reasoning:  
1. **Poikiloderma**: A hallmark feature of PN, characterized by skin changes (reticular pigmentation, telangiectasia, atrophy).  
2. **Neutropenia**: Directly named in the diagnosis, often chronic and linked to recurrent infections.  
3. **Bronchiectasis/Abnormal pulmonary interstitial morphology**: PN is associated with progressive pulmonary fibrosis and bronchiectasis due to recurrent infections or intrinsic lung tissue abnormalities.  
4. **Short stature**: Common in PN due to growth hormone insensitivity or systemic chronic inflammation.  
5. **Granuloma**: May arise from chronic inflammation or recurrent infections secondary to neutropenia.  
6. **Hypogonadotropic hypogonadism**: Rarely reported in PN, potentially linked to hypothalamic-pituitary axis dysfunction or systemic disease burden.  

Excluded alternatives (e.g., Rothmund-Thomson syndrome, dyskeratosis congenita) due to absence of key features (e.g., skeletal defects, nail dystrophy) and stronger alignment with PN’s core triad (poikiloderma, neutropenia, pulmonary complications)."
"['Renal cyst', 'Macrocephaly', 'Narrow chest', 'Specific learning disability', 'Ventriculomegaly', 'Hematochezia', 'Short distal phalanx of finger', 'Prominent forehead', 'Large intestinal polyposis']",['Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome/Smith-Kingsmore syndrome'],"Disease: Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome/Smith-Kingsmore syndrome  
Reasoning:  
1. **Macrocephaly**: A hallmark feature of Smith-Kingsmore syndrome, caused by MTOR gene mutations affecting cerebral growth.  
2. **Specific learning disability/neurodevelopmental disorder**: Aligns with intellectual disability and neurodevelopmental delays characteristic of the syndrome.  
3. **Narrow chest**: Matches the ""small thorax"" phenotype due to skeletal dysplasia.  
4. **Ventriculomegaly**: Reflects brain abnormalities linked to MTOR dysregulation, commonly seen in this disorder.  
5. **Prominent forehead**: Part of the distinct craniofacial features (macrocephaly with frontal bossing).  
6. **Short distal phalanx of finger**: Consistent with skeletal anomalies reported in MTOR-related syndromes.  
7. **Renal cyst**: Rarely reported but plausible, as MTOR pathway disruptions can affect renal development.  
8. **Large intestinal polyposis/Hematochezia**: Atypical but may represent gastrointestinal manifestations of MTOR hyperactivity, though further evaluation is needed to exclude concurrent conditions (e.g., PTEN-related syndromes).  

The diagnosis prioritizes core features (macrocephaly, neurodevelopmental deficits, small thorax, ventriculomegaly) while acknowledging atypical symptoms as potential phenotypic expansions or comorbidities. Genetic testing for MTOR variants is critical for confirmation."
"['Abnormal heart morphology', 'Macrocytic anemia', 'Morphological central nervous system abnormality', 'Abnormal platelet count', 'Abnormal leukocyte count']",['先天性纯红细胞再生障碍性贫血/Blackfan-Diamond anemia; DBA/Blackfan-Diamond anemia/Diamond-Blackfan anemia 1'],"Disease: 先天性纯红细胞再生障碍性贫血/Blackfan-Diamond anemia (DBA)  
Reasoning:  
1. **Macrocytic anemia**: DBA is characterized by macrocytic anemia due to defective erythroid progenitor maturation in the bone marrow, typically presenting in infancy.  
2. **Abnormal heart morphology**: Approximately 30-50% of DBA patients have congenital anomalies, including cardiac defects (e.g., atrial/ventricular septal defects), aligning with ""abnormal heart morphology.""  
3. **Morphological CNS abnormality**: While less common, rare DBA cases may involve craniofacial or CNS structural anomalies linked to ribosomal gene mutations (e.g., RPS19 variants).  
4. **Abnormal platelet/leukocyte counts**: DBA primarily affects erythropoiesis, but mild thrombocytopenia or leukopenia can occur in ~20% of patients, reflecting subtle bone marrow dysregulation.  
5. **Exclusion of alternatives**: Fanconi anemia (pancytopenia + chromosomal breaks) and transient myeloproliferative disorders were considered but deemed less likely given the prominence of macrocytic anemia and congenital features.  

This constellation of symptoms strongly supports DBA, a ribosomopathy caused by mutations in genes encoding ribosomal proteins."
"['Cataract', 'Hematuria', 'Hypoparathyroidism', 'Tetany', 'Malabsorption', 'Vertigo', 'Chronic mucocutaneous candidiasis', 'Hypocalcemia', 'Enamel hypoplasia', 'Primary adrenal insufficiency']","['Autoimmune polyendocrinopathy type 1/Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia']","Disease: Autoimmune polyendocrinopathy type 1 (APS-1/APECED)  
Reasoning:  
1. **Chronic mucocutaneous candidiasis**: A hallmark of APS-1, often presenting early in childhood.  
2. **Hypoparathyroidism and hypocalcemia**: Key features of APS-1, causing **tetany** (muscle spasms due to low calcium) and **enamel hypoplasia** (defective tooth enamel from calcium dysregulation).  
3. **Primary adrenal insufficiency (Addison’s disease)**: Completes the diagnostic triad of APS-1.  
4. **Cataracts**: Linked to chronic hypocalcemia from hypoparathyroidism.  
5. **Malabsorption**: May reflect autoimmune enteropathy, a recognized APS-1 manifestation.  
6. **Hematuria**: Could indicate autoimmune nephritis or nephrocalcinosis secondary to chronic hypocalcemia.  
7. **Vertigo**: Possibly related to electrolyte imbalances (e.g., hypocalcemia, adrenal crisis).  

The combination of mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency is pathognomonic for APS-1. Additional features align with multi-organ autoimmune involvement, confirming the diagnosis."
"['Cryptorchidism', 'High palate', 'Large fontanelles', 'Brachycephaly', 'Low-set, posteriorly rotated ears', 'Downslanted palpebral fissures', 'Proptosis', 'Polyhydramnios', 'Atrial septal defect', 'Wide intermamillary distance', '2-4 finger syndactyly', '1-5 toe syndactyly', 'Prominent forehead', 'Midface retrusion']",['Apert syndrome/Apert syndrome'],"Disease: Apert syndrome  
Reasoning: The patient exhibits craniofacial features (brachycephaly, prominent forehead, midface retrusion, proptosis, downslanted palpebral fissures, low-set ears) consistent with craniosynostosis syndromes. The bilateral 2-4 finger syndactyly and 1-5 toe syndactyly are pathognomonic for Apert syndrome. Additional supportive findings include high palate, atrial septal defect, and polyhydramnios (linked to fetal swallowing difficulties from craniofacial anomalies). Midface hypoplasia explains proptosis and midface retrusion, while wide fontanelles may reflect abnormal calvarial suture dynamics. These collective features strongly align with Apert syndrome, a FGFR2-related disorder."
"['Hyperglycemia', 'Maturity-onset diabetes of the young', 'Multiple renal cysts', 'Abnormal pancreas morphology', 'Anti-glutamic acid decarboxylase antibody positivity', 'Elevated hemoglobin A1c']",['HNF1B-related autosomal dominant tubulointerstitial kidney disease/Renal cysts and diabetes syndrome'],"Disease: HNF1B-related autosomal dominant tubulointerstitial kidney disease/Renal cysts and diabetes syndrome  
Reasoning:  
1. **Hyperglycemia & Elevated HbA1c**: Indicates diabetes, consistent with the ""diabetes"" component of Renal Cysts and Diabetes Syndrome (RCAD).  
2. **Maturity-Onset Diabetes of the Young (MODY)**: HNF1B mutations cause MODY type 5, characterized by early-onset, autosomal dominant inheritance, and atypical features like renal/pancreatic involvement.  
3. **Multiple Renal Cysts**: A hallmark of HNF1B-related disease, distinguishing it from other MODY subtypes (e.g., HNF1A/HNF4A) and aligning with RCAD.  
4. **Abnormal Pancreas Morphology**: HNF1B is critical for pancreatic development; structural anomalies (e.g., atrophy, cysts) are common in this syndrome.  
5. **Anti-GAD Antibody Positivity**: Though atypical for MODY, rare cases of HNF1B-MODY report autoimmune markers, possibly due to overlapping autoimmune mechanisms or incidental findings.  
6. **Exclusion of Alternatives**: The combination of diabetes, renal cysts, and pancreatic defects rules out other MODY subtypes (e.g., GCK, HNF1A) and isolated autoimmune diabetes (e.g., type 1).  
Conclusion: The constellation of symptoms strongly supports HNF1B-related disease, fulfilling both renal and pancreatic/diabetic criteria for RCAD."
"['High palate', 'Neck muscle weakness', 'Intellectual disability', 'Muscle weakness', 'Breech presentation', 'Respiratory insufficiency due to muscle weakness', 'Kyphoscoliosis', 'Gowers sign', 'Knee flexion contracture', 'Muscle fibrillation', 'Delayed ability to walk', 'Abnormal nerve conduction velocity']",['Nemaline myopathy 7'],"Disease: Nemaline myopathy 7  
Reasoning:  
1. **Muscle Weakness**: Central feature of nemaline myopathy (NM), evident in neck muscles, respiratory insufficiency, and delayed walking.  
2. **Respiratory Insufficiency**: Common in severe NM subtypes like NEM7 due to diaphragmatic and intercostal muscle involvement.  
3. **Kyphoscoliosis**: Results from chronic axial muscle weakness, a hallmark of congenital myopathies.  
4. **Gowers Sign**: Indicates proximal muscle weakness, typical in NM.  
5. **Breech Presentation/Knee Flexion Contracture**: Suggests reduced fetal movement (arthrogryposis spectrum), consistent with severe congenital NM7 (KLHL40 mutations).  
6. **Delayed Walking**: Reflects early-onset muscle hypotonia.  
7. **High Palate**: Linked to orofacial muscle weakness/hypotonia in congenital myopathies.  
8. **Abnormal Nerve Conduction Velocity**: Uncommon in NM but may occur secondary to severe muscle pathology or testing artifact.  
9. **Muscle Fibrillation**: Rarely reported in NM; could indicate overlap with neurogenic processes or misinterpretation of myopathic features.  
10. **Intellectual Disability**: Atypical for NM7 but possible in severe cases with prolonged hypoxia or comorbidities.  

While intellectual disability and nerve conduction abnormalities are less typical, the constellation of severe congenital muscle weakness, contractures, respiratory failure, and structural anomalies strongly aligns with NEM7. Genetic testing for KLHL40 mutations would confirm the diagnosis."
"['Hyporeflexia', 'Hyporeflexia', 'Polyneuropathy', 'Decreased number of peripheral myelinated nerve fibers', 'Basal lamina onion bulb formation', 'Recurrent bacterial skin infections', 'Pain insensitivity', 'Peripheral demyelination', 'Abnormal autonomic nervous system physiology', 'Abnormal systemic blood pressure', 'Abnormal heart rate variability', 'Digital ulcer', 'Abnormal sensory nerve conduction velocity']","['Neuropathy, hereditary sensory and autonomic, type II']","Disease: Neuropathy, hereditary sensory and autonomic, type II (HSAN II)  
Reasoning:  
1. **Hyporeflexia**: Consistent with peripheral nerve dysfunction, as damaged sensory/motor fibers impair reflex arcs.  
2. **Polyneuropathy & Peripheral demyelination**: Indicates widespread peripheral nerve damage, aligning with HSAN II’s axonal and demyelinating features.  
3. **Decreased myelinated nerve fibers**: HSAN II is characterized by early loss of myelinated fibers, particularly in sensory nerves.  
4. **Basal lamina onion bulb formation**: Suggests repeated demyelination/remyelination cycles, seen in hereditary neuropathies like HSAN II.  
5. **Recurrent bacterial skin infections & Digital ulcers**: Result from pain insensitivity (due to sensory nerve loss), leading to unnoticed injuries and poor wound healing.  
6. **Abnormal autonomic physiology (blood pressure, heart rate variability)**: Autonomic involvement is a hallmark of HSAN disorders, reflecting sympathetic/parasympathetic dysfunction.  
7. **Abnormal sensory nerve conduction velocity**: Demyelination and axonal loss directly slow sensory signal transmission.  
8. **Pain insensitivity**: Distinctive in HSAN II due to severe sensory neuron degeneration.  
HSAN II integrates sensory, autonomic, and motor deficits (e.g., hyporeflexia) with pathological features (onion bulbs, demyelination), excluding other neuropathies (e.g., CMT lacks autonomic symptoms)."
"['Neutrophilia', 'Delayed umbilical cord separation', 'Neonatal omphalitis', 'Skin ulcer']","['Leukocyte adhesion deficiency type I', 'Leukocyte adhesion deficiency, type I']","Disease: Leukocyte adhesion deficiency type I  
Reasoning:  
1. **Neutrophilia**: Elevated neutrophil count occurs due to impaired adhesion and migration of neutrophils to tissues, causing their accumulation in the bloodstream.  
2. **Delayed umbilical cord separation**: Normally, neutrophils mediate inflammation for cord detachment. In LAD-I, defective neutrophil function delays this process beyond 3 weeks.  
3. **Neonatal omphalitis**: Recurrent bacterial/fungal infections (e.g., umbilical stump infection) arise from neutrophils' inability to extravasate and combat pathogens.  
4. **Skin ulcers**: Impaired wound healing and chronic tissue necrosis result from deficient neutrophil recruitment to sites of injury or infection.  
**Genetic basis**: Autosomal recessive mutation in _ITGB2_ (CD18 subunit), critical for integrin-mediated leukocyte adhesion. Confirmatory testing includes flow cytometry for CD18/CD11b expression."
"['Abnormality of male external genitalia', 'Hearing impairment', 'Atypical behavior', 'Autistic behavior', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Motor delay', 'Absent speech', 'Abnormality of the cardiovascular system', 'Feeding difficulties', 'Heart murmur']",['Stankiewicz-Isidor syndrome'],"Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Abnormality of male external genitalia**: A hallmark feature of Stankiewicz-Isidor syndrome, often due to urogenital anomalies like hypospadias or cryptorchidism.  
2. **Hearing impairment**: Reported in some cases, though less common, possibly linked to neurodevelopmental deficits.  
3. **Neurodevelopmental delays (absent speech, motor delay, intellectual disability)**: Core features of the syndrome, driven by pathogenic *PACS1* gene variants affecting neuronal development.  
4. **Seizures**: Observed in affected individuals, consistent with neurological involvement.  
5. **Autistic behavior/atypical behavior**: Aligns with the syndrome’s behavioral phenotype, including social communication challenges.  
6. **Cardiovascular abnormalities/heart murmur**: Congenital heart defects (e.g., septal defects) are recurrent findings.  
7. **Feeding difficulties**: Common in infancy due to hypotonia or oromotor dysfunction.  
The combination of genitourinary, cardiac, and severe neurodevelopmental symptoms strongly supports Stankiewicz-Isidor syndrome, with *PACS1* testing recommended for confirmation."
"['High palate', 'Long philtrum', 'Low-set ears', 'Congenital hypothyroidism', 'Hirsutism', 'Death in infancy', 'Polyhydramnios', 'Dysphagia', 'Poor suck', 'Limb hypertonia', 'Central apnea', 'Short nose', 'Bilateral single transverse palmar creases', 'Bilateral microphthalmos', 'Feeding difficulties in infancy', 'Axial hypotonia', 'Intracranial cystic lesion', 'Feeding difficulties', 'Fetal distress', 'Abnormality of fundus pigmentation', 'Abnormality of movement', 'Postaxial polydactyly']","['PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies']","Disease: PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies  
Reasoning:  
1. **Neurodevelopmental and Brain Anomalies**: Symptoms like *intracranial cystic lesions* and *central apnea* indicate structural brain abnormalities and brainstem dysfunction, aligning with the disease’s hallmark brain anomalies.  
2. **Axial Hypotonia and Limb Hypertonia**: The combination of *axial hypotonia* (trunk weakness) and *limb hypertonia* reflects progressive spasticity, a core feature of PLAA-associated disorder.  
3. **Feeding and Swallowing Issues**: *Dysphagia*, *poor suck*, and *feeding difficulties in infancy* correlate with neurological impairment and are consistent with early-onset neurodevelopmental deficits.  
4. **Congenital Dysmorphisms**: Features like *high palate*, *long philtrum*, *bilateral microphthalmos*, and *postaxial polydactyly* suggest multisystem involvement, often seen in genetic neurodevelopmental syndromes.  
5. **Perinatal Complications**: *Polyhydramnios* (due to impaired fetal swallowing) and *fetal distress* are linked to in utero neurological dysfunction, supporting a congenital etiology.  
6. **Severe Prognosis**: *Death in infancy* and *central apnea* underscore the disorder’s severity, typical of PLAA mutations causing progressive neurological decline.  
7. **Overlap with Known Features**: While *congenital hypothyroidism* and *hirsutism* are less typical, they may represent phenotypic variability or secondary endocrine dysregulation in severe multisystem disorders. Genetic testing for PLAA mutations would confirm the diagnosis."
"['Hematuria', 'Hip dysplasia', 'Anemia', 'Metabolic acidosis', 'Leukocytosis', 'Hyperoxaluria', 'Calcium oxalate nephrolithiasis', 'Elevated circulating C-reactive protein concentration', 'Abnormality of urine calcium concentration', 'Pyuria', 'Abnormal circulating creatinine concentration']","['Primary hyperoxaluria type 2/Hyperoxaluria, primary, type II']","Disease: Primary hyperoxaluria type 2/Hyperoxaluria, primary, type II  
**Reasoning**:  
1. **Hyperoxaluria and Calcium oxalate nephrolithiasis**: The patient’s hyperoxaluria and calcium oxalate kidney stones are hallmark features of primary hyperoxaluria (PH), a rare disorder of glyoxylate metabolism. PH type 2 specifically results from a deficiency in glyoxylate reductase/hydroxypyruvate reductase (GRHPR), leading to excessive oxalate production.  
2. **Metabolic acidosis**: Impaired renal function due to nephrolithiasis and tubular damage reduces the kidneys’ ability to excrete acid, contributing to acidosis.  
3. **Hematuria and Pyuria**: These are secondary to urinary tract irritation and inflammation caused by oxalate crystals and stones.  
4. **Elevated creatinine**: Indicates reduced glomerular filtration rate (GFR) from chronic kidney damage due to recurrent nephrolithiasis and oxalate nephropathy.  
5. **Anemia**: Likely anemia of chronic disease secondary to renal failure.  
6. **Leukocytosis and elevated CRP**: Suggest systemic inflammation, possibly from recurrent urinary tract infections or stone-related tissue injury.  
7. **Abnormal urine calcium**: While PH primarily involves oxalate, calcium oxalate stone formation may indirectly affect calcium handling.  
8. **Hip dysplasia**: Unrelated to PH2 but could be a coincidental finding or misattributed to skeletal manifestations of systemic oxalosis in advanced disease (though skeletal involvement is more typical in PH1).  

The constellation of hyperoxaluria, nephrolithiasis, and metabolic derangements aligns with PH2, necessitating genetic testing for *GRHPR* mutations to confirm."
"['Abnormality of the kidney', 'Hearing impairment', 'Choanal atresia', 'Abnormality of the eye', 'Delayed speech and language development', 'Precocious puberty', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Absent speech', 'Abnormal heart morphology', 'Scoliosis', 'Cerebellar dysplasia', 'Intellectual disability, severe', 'Feeding difficulties', 'Frequent temper tantrums']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Core neurodevelopmental features**: Severe intellectual disability, global developmental delay, absent speech, and delayed speech align with the hallmark neurodevelopmental deficits of NEDBEH.  
2. **Hypotonia**: Generalized hypotonia is a common finding in NEDBEH, often linked to HECW2 gene variants.  
3. **Brain anomalies**: Cerebellar dysplasia directly corresponds to structural brain abnormalities associated with the disorder.  
4. **Eye and heart involvement**: Abnormality of the eye and abnormal heart morphology match the ""anomalies of the brain, eye, or heart"" specified in NEDBEH.  
5. **Atypical features**: Choanal atresia and hearing impairment are not classic features but may reflect phenotypic variability. Precocious puberty could arise from hypothalamic dysfunction secondary to brain malformations.  
6. **Supportive findings**: Feeding difficulties, scoliosis, and temper tantrums are consistent with severe developmental delay and hypotonia.  
7. **Exclusion of mimics**: While CHARGE syndrome could explain choanal atresia and heart defects, the absence of coloboma, cranial nerve anomalies, and the presence of severe intellectual disability favor NEDBEH.  

The diagnosis integrates characteristic features (neurodevelopmental delay, brain/eye/heart anomalies) and accommodates less common manifestations (choanal atresia, hearing loss) within the disorder’s phenotypic spectrum."
"['Hypotonia', 'Generalized hypotonia', 'Joint hypermobility', 'Patellar aplasia', 'Nail dystrophy', ""Lester's sign""]",['Nail-patella syndrome/Nail-Patella syndrome'],"Disease: Nail-Patella syndrome  
Reasoning:  
1. **Patellar aplasia** (absence of the kneecap) is a cardinal feature of Nail-Patella syndrome, directly linked to its name.  
2. **Nail dystrophy** (abnormal nail growth, often hypoplastic/ridged nails, especially on thumbs) is a hallmark symptom.  
3. **Lester's sign** (cloverleaf-shaped pigmentation of the iris) is pathognomonic for this syndrome.  
4. **Joint hypermobility** aligns with connective tissue abnormalities caused by LMX1B gene mutations in Nail-Patella syndrome.  
5. **Hypotonia** (generalized low muscle tone) may occur due to musculoskeletal involvement, though it is less specific.  
6. The combination of skeletal (patellar/hip anomalies), ectodermal (nail), and ocular (Lester's sign) findings is diagnostic for Nail-Patella syndrome, ruling out other connective tissue disorders (e.g., Ehlers-Danlos syndrome lacks the nail/patellar specificity)."
"['Furrowed tongue', 'Hypohidrosis', 'Cutis laxa', 'Paresthesia', 'EMG: decremental response of compound muscle action potential to repetitive nerve stimulation', 'Facial-lingual fasciculations']","['AGel amyloidosis/Amyloidosis, Finnish type']","Disease: AGel amyloidosis/Amyloidosis, Finnish type  
Reasoning:  
1. **Facial-lingual fasciculations** and **EMG decremental response**: Suggest neuromuscular junction dysfunction, often seen in amyloid neuropathy due to amyloid deposits disrupting nerve or muscle function.  
2. **Cutis laxa** and **hypohidrosis**: Indicate systemic connective tissue and autonomic nervous system involvement, consistent with AGel amyloidosis, which disrupts extracellular matrix proteins and autonomic fibers.  
3. **Furrowed tongue**: A pathognomonic feature of AGel amyloidosis caused by amyloid infiltration in the tongue.  
4. **Paresthesia**: Reflects peripheral neuropathy, a hallmark of systemic amyloidosis due to nerve compression/damage from amyloid deposits.  
5. **Finnish type specificity**: AGel amyloidosis is linked to a gelsolin gene mutation prevalent in Finland, presenting with this triad: cranial neuropathy, cutis laxa, and corneal lattice dystrophy (latter not listed but inferred in systemic context)."
"['Long philtrum', 'Macrotia', 'Bulbous nose', 'Tachycardia', 'Bilateral tonic-clonic seizure', 'Apnea', 'Abnormal cortical gyration', 'Recurrent infections', 'Breathing dysregulation', 'Respiratory acidosis', 'Diffuse white matter abnormalities', 'EEG with frontal sharp waves', 'Low APGAR score', 'Postaxial polydactyly']","['PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies']","Disease: PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies  
Reasoning:  
1. **Neurodevelopmental and Brain Anomalies**: Symptoms like abnormal cortical gyration, diffuse white matter abnormalities, and EEG with frontal sharp waves align with structural and functional brain abnormalities characteristic of PLAA-NDD.  
2. **Seizures and Autonomic Dysregulation**: Bilateral tonic-clonic seizures, apnea, breathing dysregulation, and respiratory acidosis suggest central nervous system involvement, particularly brainstem dysfunction, which is consistent with this disorder.  
3. **Craniofacial Features**: Long philtrum, macrotia, and bulbous nose match reported dysmorphic traits in PLAA-NDD.  
4. **Postaxial Polydactyly**: While uncommon, polydactyly has been observed in some cases, possibly linked to broader developmental disruptions.  
5. **Early Neonatal Compromise**: Low APGAR score reflects perinatal distress, often seen in congenital neurodevelopmental disorders.  
6. **Recurrent Infections**: May result from respiratory compromise (e.g., aspiration due to dysphagia or breathing irregularities) rather than primary immunodeficiency.  
7. **Progressive Microcephaly**: Though not explicitly listed, abnormal cortical gyration and white matter changes imply evolving brain pathology, fitting the ""progressive"" nature of the disorder.  

The constellation of neurological, dysmorphic, and systemic features strongly supports PLAA-NDD, driven by PLAA gene mutations impacting neurodevelopment and autonomic regulation."
"['Strabismus', 'Rod-cone dystrophy', 'Macular degeneration', 'Global developmental delay', 'Specific learning disability', 'Obesity', 'Attenuation of retinal blood vessels']",['Bardet-Biedl syndrome 1'],"Disease: Bardet-Biedl syndrome 1  
Reasoning:  
1. **Rod-cone dystrophy and macular degeneration**: Hallmark features of Bardet-Biedl syndrome (BBS), causing progressive vision loss.  
2. **Strabismus and attenuated retinal blood vessels**: Secondary to retinal degeneration, common in BBS.  
3. **Obesity**: A primary diagnostic criterion, typically developing in early childhood.  
4. **Global developmental delay and specific learning disability**: Neurocognitive impairments are frequent in BBS due to ciliopathy affecting neuronal development.  
5. **Syndromic consistency**: The combination of retinal dystrophy, obesity, developmental delay, and ocular abnormalities aligns with BBS1, a subtype linked to pathogenic variants in the *BBS1* gene.  
6. **Exclusion of mimics**: Differentiated from similar disorders (e.g., Alström syndrome) by the absence of sensorineural hearing loss and presence of polydactyly (if noted, though not listed here)."
"['Tall stature', 'Myopia', 'Pectus excavatum', 'Thin skin', 'Arachnodactyly', 'Mitral regurgitation', 'Aortic root aneurysm', 'Scoliosis', 'Kyphoscoliosis', 'Decreased body weight', 'Lens luxation']","['Marfan syndrome', 'Marfan syndrome type 1']","Disease: Marfan syndrome  
Reasoning: The patient exhibits cardinal features of Marfan syndrome, including skeletal manifestations (tall stature, pectus excavatum, arachnodactyly, scoliosis/kyphoscoliosis), ocular involvement (myopia, lens luxation), cardiovascular complications (mitral regurgitation, aortic root aneurysm), and connective tissue abnormalities (thin skin, decreased body weight). Lens luxation and aortic root aneurysm are major diagnostic criteria, while the other findings fulfill systemic involvement.  

Disease: Marfan syndrome type 1  
Reasoning: Marfan syndrome type 1 refers specifically to cases caused by pathogenic variants in the *FBN1* gene, which encodes fibrillin-1. The clinical presentation aligns with *FBN1*-related Marfan syndrome, as lens luxation and aortic root aneurysm are hallmark features of this subtype. Genetic testing for *FBN1* mutations would confirm the molecular basis of the diagnosis."
"['Thin vermilion border', 'Wide anterior fontanel', 'Hypertelorism', 'Micrognathia', 'Low-set ears', 'Anteverted nares', 'Short neck', 'Thickened nuchal skin fold', 'Upslanted palpebral fissure', 'Wrist flexion contracture', 'Agenesis of corpus callosum', 'Dandy-Walker malformation', 'Intrauterine growth retardation', 'Abnormal heart morphology', 'Metabolic acidosis', 'Deep philtrum', 'Ventriculomegaly', 'Agenesis of cerebellar vermis', 'Short nose', 'Depressed nasal bridge', 'Distal arthrogryposis', 'Knee flexion contracture', 'Ankle flexion contracture', 'Increased nuchal translucency', 'Abnormal renal morphology', 'Camptodactyly', 'Sepsis']","['COG8-CDG/Congenital disorder of glycosylation, type IIh']","Disease: COG8-CDG/Congenital disorder of glycosylation, type IIh  
Reasoning:  
1. **Neurological & Structural Brain Abnormalities**: Agenesis of corpus callosum, Dandy-Walker malformation, ventriculomegaly, and agenesis of cerebellar vermis are hallmark features of CDG-II subtypes, reflecting impaired glycosylation critical for brain development.  
2. **Dysmorphic Features**: Hypertelorism, micrognathia, low-set ears, anteverted nares, short nose, depressed nasal bridge, deep philtrum, and upslanted palpebral fissures align with facial dysmorphisms seen in COG8-CDG.  
3. **Skeletal/Joint Abnormalities**: Wrist, knee, and ankle flexion contractures, camptodactyly, and distal arthrogryposis suggest glycosylation defects impacting connective tissue and neuromuscular function, common in COG8-CDG.  
4. **Prenatal/Systemic Involvement**: Intrauterine growth retardation, increased nuchal translucency, and thickened nuchal skin fold indicate early developmental disruption, typical of severe CDG forms.  
5. **Metabolic & Organ Dysfunction**: Metabolic acidosis (linked to glycosylation-dependent mitochondrial function), abnormal heart and renal morphology, and sepsis (immune dysfunction due to glycosylation defects in immunoglobulins) further support COG8-CDG.  
6. **Consistency with Type II CDG**: COG8-CDG (Type IIh) disrupts Golgi trafficking via COG complex defects, leading to multi-systemic anomalies as listed, distinguishing it from other CDG subtypes."
"['Strabismus', 'Myopia', 'Upslanted palpebral fissure', 'Synophrys', 'Anxiety', 'Delayed speech and language development', 'Brachydactyly', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Failure to thrive', 'Pes planus', 'Truncal obesity', 'Gastroesophageal reflux', 'Asthma', 'Spontaneous pneumothorax', 'Generalized non-motor (absence) seizure', 'Sleep disturbance', 'Downturned corners of mouth', 'Clinodactyly of the 5th finger', 'Short middle phalanx of the 5th finger', 'Short stature', 'Mild global developmental delay', 'Head-banging', 'Self-injurious behavior']",['Smith-Magenis syndrome/Smith-Magenis syndrome'],"Disease: Smith-Magenis syndrome  
Reasoning:  
1. **Facial features**: Upslanted palpebral fissures, synophrys (conjoined eyebrows), and downturned corners of the mouth align with the characteristic craniofacial dysmorphisms of SMS.  
2. **Developmental delays**: Intellectual disability, delayed speech, and mild global developmental delay are hallmark neurocognitive features of SMS.  
3. **Behavioral phenotype**: Self-injurious behavior (e.g., head-banging), anxiety, and sleep disturbances (e.g., inverted melatonin rhythm) are pathognomonic for SMS.  
4. **Skeletal anomalies**: Brachydactyly, clinodactyly of the 5th finger, and short middle phalanx of the 5th finger are common in SMS.  
5. **Growth/medical issues**: Hypotonia, failure to thrive in infancy, truncal obesity, and pes planus fit the SMS growth trajectory.  
6. **Neurological features**: Seizures (including absence seizures) and sleep disruption are frequently reported in SMS.  
7. **Supportive features**: Gastroesophageal reflux and asthma are common comorbidities, while spontaneous pneumothorax is a rare but documented association.  

The combination of distinct facial, behavioral, developmental, and skeletal features strongly supports SMS, typically caused by a *RAI1* gene mutation or 17p11.2 deletion."
"['Gingival bleeding', 'Epistaxis', 'Petechiae', 'Thrombocytopenia', 'Impaired ADP-induced platelet aggregation', 'Impaired epinephrine-induced platelet aggregation', 'Impaired arachidonic acid-induced platelet aggregation', 'Impaired ristocetin-induced platelet aggregation', 'Increased mean platelet volume', 'Decreased circulating ferritin concentration']",['Bernard-Soulier syndrome/Bernard-Soulier syndrome'],"Disease: Bernard-Soulier syndrome  
Reasoning:  
1. **Thrombocytopenia with increased mean platelet volume (MPV):** Indicates abnormally large platelets (macrothrombocytopenia), a hallmark of Bernard-Soulier syndrome (BSS) due to defective platelet formation.  
2. **Impaired ristocetin-induced platelet aggregation:** Directly points to a defect in the GPIb-IX-V complex, which is essential for von Willebrand factor (vWF)-mediated platelet adhesion. This is pathognomonic for BSS.  
3. **Normal agonists (ADP, epinephrine, arachidonic acid) showing impaired aggregation:** While these agonists typically test platelet activation pathways (e.g., GPIIb/IIIa in aggregation), technical limitations (e.g., low platelet count, large platelet size) or secondary platelet dysfunction may artifactually reduce responses.  
4. **Bleeding symptoms (gingival bleeding, epistaxis, petechiae):** Consistent with platelet dysfunction and thrombocytopenia.  
5. **Decreased ferritin:** Likely reflects chronic iron loss from recurrent bleeding, a common complication in BSS.  
6. **Exclusion of other disorders:** Glanzmann thrombasthenia (normal platelet count/size, isolated GPIIb/IIIa defect) and immune thrombocytopenia (normal platelet size/function) are ruled out by the clinical and laboratory profile."
"['Generalized hypotonia', 'Hepatosplenomegaly', 'Death in infancy', 'Thrombocytopenia', 'Decreased beta-glucocerebrosidase level', 'Decreased body weight', 'Congenital nonbullous ichthyosiform erythroderma']","['Fetal Gaucher disease/Gaucher disease, perinatal lethal']","Disease: Fetal Gaucher disease/Gaucher disease, perinatal lethal  
Reasoning:  
1. **Decreased beta-glucocerebrosidase level**: Directly confirms enzyme deficiency, the hallmark of Gaucher disease.  
2. **Hepatosplenomegaly**: Caused by glucocerebroside accumulation in liver/spleen macrophages (Gaucher cells).  
3. **Thrombocytopenia**: Results from bone marrow infiltration by Gaucher cells, impairing platelet production.  
4. **Congenital nonbullous ichthyosiform erythroderma**: Seen in severe perinatal forms due to skin barrier defects and lipid metabolism disruption.  
5. **Generalized hypotonia**: Reflects neurologic involvement typical of acute neuronopathic (Type 2) or perinatal lethal subtypes.  
6. **Decreased body weight & Death in infancy**: Consistent with rapid progression of the perinatal lethal variant, often fatal prenatally or within days post-birth.  
7. Exclusion of other lysosomal disorders (e.g., Niemann-Pick) by clinical and enzymatic findings solidifies the diagnosis."
"['Cryptorchidism', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Broad alveolar ridges', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Strabismus', 'Deeply set eye', 'Downslanted palpebral fissures', 'Visual impairment', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Hypotonia', 'Global developmental delay', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar vermis hypoplasia', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Macrodontia', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Abnormal facial shape', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Ventriculomegaly', 'Delayed gross motor development', 'Duodenal atresia', 'Tetraparesis', 'Focal impaired awareness seizure', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Incisor macrodontia', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Squared superior portion of helix', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Cerebral visual impairment', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental core features**: The patient exhibits *global developmental delay*, *absent speech*, *delayed speech/language development*, *hyperactivity*, and *ADHD*, aligning with the neurodevelopmental axis of NEDBEH.  
2. **Brain anomalies**: *Abnormal corpus callosum morphology*, *cerebellar vermis hypoplasia*, *CNS/cerebral hypomyelination*, and *abnormal pons/hippocampus morphology* are hallmark brain structural defects in NEDBEH.  
3. **Ocular involvement**: *Coloboma*, *microphthalmia*, *strabismus*, *visual impairment*, *optic atrophy*, and *Peters anomaly* match the ""eye anomalies"" spectrum of the disorder.  
4. **Cardiac defects**: *Ventricular septal defect*, *patent ductus arteriosus*, and *abnormal cardiac septum morphology* fulfill the ""heart anomalies"" criterion.  
5. **Craniofacial/somatic features**: *Microcephaly/macrocephaly*, *triangular face*, *micrognathia*, *cleft lip*, *hypertelorism*, and *epicanthus* are consistent with facial dysmorphisms seen in NEDBEH. Additional features like *syndactyly*, *sacral hypertrichosis*, and *growth delay* support syndromic overlap.  
6. **Systemic/gastrointestinal anomalies**: *Annular pancreas*, *duodenal/pyloric stenosis*, and *hip dysplasia* correlate with reported gastrointestinal/musculoskeletal involvement in NEDBEH.  
7. **Genetic plausibility**: While not specified here, NEDBEH is often linked to *de novo SMARCC2* variants, which disrupt chromatin remodeling—a process critical for neurodevelopment and organogenesis, explaining the multi-system phenotype.  

The convergence of neurodevelopmental delay, brain malformations, ocular/cardiac defects, and variable dysmorphic/systemic features strongly supports this diagnosis over isolated syndromes (e.g., CHARGE, Noonan) due to the absence of pathognomonic features (e.g., choanal atresia in CHARGE is nonspecific here) and the broad phenotypic spectrum of NEDBEH."
"['Delayed speech and language development', 'Asthma', 'Delayed skeletal maturation', 'Short stature', 'Sleep apnea', 'Delayed fine motor development']","['Microcephaly 3, primary, autosomal recessive']","Disease: Microcephaly 3, primary, autosomal recessive  
Reasoning:  
1. **Core Diagnostic Features**: The diagnosis hinges on the presence of **primary microcephaly** (reduced head circumference at birth), which is a hallmark of MCPH3, though not explicitly listed in the provided symptoms. This omission suggests either an incomplete symptom list or an assumption of microcephaly as part of the clinical context.  
2. **Developmental Delays**: The patient exhibits **delayed speech, language, and fine motor development**, consistent with neurodevelopmental impairments caused by defective cerebral cortical growth in MCPH3.  
3. **Growth Abnormalities**: **Short stature** and **delayed skeletal maturation** may reflect secondary growth disturbances, though these are not classic features of MCPH3. They could arise from systemic genetic effects or nutritional/endocrine factors compounded by the underlying condition.  
4. **Ancillary Symptoms**: **Asthma** and **sleep apnea** are likely unrelated to MCPH3. However, sleep apnea could indirectly stem from craniofacial anomalies (e.g., midface hypoplasia) occasionally associated with severe microcephaly.  
5. **Genetic Basis**: Autosomal recessive mutations in *CDK5RAP2* disrupt neuronal proliferation, aligning with global developmental delays but not directly explaining non-neurological symptoms.  
**Conclusion**: The diagnosis prioritizes neurodevelopmental and structural brain anomalies (microcephaly), while other symptoms are either coincidental or secondary to the broader phenotypic spectrum."
"['Optic disc pallor', 'Seizure', 'Hypertonia', 'Generalized hypotonia', 'Myoclonus', 'Organic aciduria', 'Respiratory insufficiency', 'Increased serum lactate', 'EEG abnormality', 'Poor head control', 'Progressive muscle weakness', 'Hyperactive deep tendon reflexes', 'Frontotemporal cerebral atrophy', 'CNS demyelination', 'Nasogastric tube feeding in infancy', 'Hypoplastic hippocampus', 'Vegetative state', 'Enlarged sylvian cistern']",['Developmental and epileptic encephalopathy 28'],"Disease: Developmental and epileptic encephalopathy 28 (DEE28)  
Reasoning:  
1. **Seizures & EEG abnormalities**: Core features of epileptic encephalopathy, consistent with DEE28's presentation of early-onset refractory seizures. Myoclonus further supports a seizure spectrum disorder.  
2. **Neuromotor symptoms**: Hypertonia, hyperactive reflexes, and progressive muscle weakness suggest upper motor neuron degeneration. Generalized hypotonia and poor head control reflect severe developmental delay, typical of infantile-onset DEEs.  
3. **Neuroimaging findings**: Frontotemporal cerebral atrophy, CNS demyelination, hypoplastic hippocampus, and enlarged sylvian cistern align with progressive neurodegeneration and structural brain abnormalities seen in WDR45-related disorders (e.g., BPAN, a subtype of NBIA).  
4. **Developmental regression**: Nasogastric tube feeding in infancy and progression to a vegetative state indicate profound neurological deterioration, characteristic of DEE28's neurodegenerative course.  
5. **Metabolic disturbances**: Organic aciduria and elevated serum lactate may arise from mitochondrial dysfunction secondary to impaired autophagy (WDR45 mutation) or metabolic stress from recurrent seizures.  
6. **Respiratory insufficiency**: Likely due to combined effects of CNS dysfunction and progressive muscle weakness.  
7. **Consistency with WDR45 pathology**: While iron accumulation (a hallmark of NBIA) is not explicitly listed, the constellation of seizures, hypotonia-to-hypertonia progression, and cerebral atrophy strongly aligns with DEE28/BPAN phenotypes linked to WDR45 mutations."
"['Thin vermilion border', 'Triangular face', 'Low-set ears', 'Narrow nose', 'Blue sclerae', 'Thin skin', 'Cutis laxa', 'Atrophic scars', 'Global developmental delay', 'Joint hypermobility', 'Hip dysplasia', 'Pes planus', 'Delayed gross motor development', 'Excessive wrinkled skin', 'Adipose tissue loss', 'Dermal translucency']","['Autosomal recessive cutis laxa type 2B', 'Cutis laxa, autosomal recessive, type IIB']","Disease: Autosomal recessive cutis laxa type 2B  
Reasoning: The patient presents with cardinal features of cutis laxa, thin/translucent skin, joint hypermobility, and atrophic scars, consistent with connective tissue fragility. Facial dysmorphism (triangular face, narrow nose, low-set ears) and systemic involvement (hip dysplasia, pes planus) align with ARCL2B. Global developmental delay and motor delays suggest multisystemic disease. Adipose loss, excessive wrinkling, and progeroid-like features (thin skin, blue sclerae) reflect mitochondrial dysfunction linked to PYCR1 mutations, a hallmark of ARCL2B.  

Disease: Cutis laxa, autosomal recessive, type IIB  
Reasoning: This is synonymous with ARCL2B. The terminology ""type IIB"" uses Roman numerals but refers to the same PYCR1-associated disorder. Symptoms like triangular facies, cutis laxa, and developmental delay match the phenotypic spectrum. Hip dysplasia and dermal translucency further confirm the diagnosis, as these are recurrent findings in genetic cutis laxa syndromes with progeroid overlap."
"['Thin vermilion border', 'Abnormality of skull size', 'Long philtrum', 'Brachydactyly', 'Global developmental delay', 'Limited elbow extension', 'Bilateral ptosis', 'Polyhydramnios', 'Recurrent respiratory infections', 'Delayed skeletal maturation', 'Hypoplasia of the ulna', 'Limited knee extension', 'Short femur', 'Short stature', 'Short phalanx of finger', 'Short metacarpal']",['Geleophysic dysplasia 1'],"Disease: Geleophysic Dysplasia 1  
Reasoning:  
1. **Facial Features**: Thin vermilion border and long philtrum align with the characteristic ""happy-looking"" facies seen in geleophysic dysplasia.  
2. **Skeletal Abnormalities**: Brachydactyly, short metacarpals, short phalanx of finger, hypoplasia of the ulna, short femur, and delayed skeletal maturation are hallmark skeletal features of this disorder.  
3. **Growth Issues**: Short stature and prenatal polyhydramnios (often due to reduced fetal swallowing) are consistent with growth restriction patterns in geleophysic dysplasia.  
4. **Joint Limitations**: Limited elbow/knee extension and recurrent respiratory infections suggest connective tissue/joint contractures and potential tracheobronchial stenosis, common in this condition.  
5. **Developmental Delay**: Global developmental delay, though nonspecific, is reported in some cases, particularly due to systemic complications.  
6. **Ptosis**: Bilateral ptosis reflects craniofacial connective tissue involvement, a subtle but supportive feature.  
7. **Exclusion of Mimics**: Symptoms differentiate from similar disorders (e.g., acromicric dysplasia lacks recurrent infections; Myhre syndrome has distinct facial/skeletal features).  
Key genetic confirmation would involve *FBN1* or *ADAMTSL2* mutations, but clinical findings strongly prioritize geleophysic dysplasia 1."
"['Urinary incontinence', 'Spastic paraplegia', 'Dysarthria', 'Brisk reflexes', 'Spastic gait', 'Difficulty walking', 'Babinski sign', 'Pes valgus']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Core HSP Features**: Spastic paraplegia, spastic gait, difficulty walking, brisk reflexes, and Babinski sign are hallmark signs of hereditary spastic paraplegia (HSP), indicating upper motor neuron dysfunction.  
2. **Urinary Incontinence**: Common in HSP due to spinal cord involvement disrupting bladder control.  
3. **Dysarthria**: Suggests possible bulbar or cerebellar involvement, observed in some HSP subtypes, including SPG76.  
4. **Pes Valgus**: May arise from altered muscle tone or peripheral neuropathy, occasionally linked to HSP.  
5. **Autosomal Recessive Inheritance**: Matches SPG76’s genetic pattern (CAPN1 mutations), distinguishing it from dominant or X-linked HSP subtypes.  
6. **Exclusion of Mimics**: Symptoms align with SPG76’s progressive phenotype, ruling out acquired causes (e.g., spinal cord compression) and other HSP subtypes with overlapping features (e.g., SPG11/SPG15, which often include cognitive decline or thin corpus callosum)."
"['Nephrocalcinosis', 'Cutis laxa', 'Abnormal heart morphology', 'Abnormal facial shape']","['Cutis laxa, autosomal recessive, type IIC']","Disease: Cutis laxa, autosomal recessive, type IIC (ARCL2C)  
Reasoning:  
1. **Cutis laxa**: A primary feature of ARCL2C, caused by mutations in the PYCR1 gene, which disrupts mitochondrial function and collagen/proline metabolism, leading to loose, inelastic skin.  
2. **Nephrocalcinosis**: Linked to metabolic dysfunction in ARCL2C, where impaired mitochondrial energy production may cause renal tubular acidosis or calcium deposition in the kidneys.  
3. **Abnormal heart morphology**: PYCR1 mutations are associated with cardiac anomalies such as pulmonary artery stenosis or septal defects, contributing to structural heart abnormalities.  
4. **Abnormal facial shape**: ARCL2C presents with distinct facial dysmorphism (triangular face, prominent eyes, large fontanelles, and a prematurely aged appearance), aligning with the patient’s symptoms.  
5. **Consistency with ARCL2C**: The combination of connective tissue, renal, cardiac, and craniofacial anomalies strongly supports this diagnosis, as other cutis laxa subtypes (e.g., ARCL2A/B) typically involve different organ systems or lack nephrocalcinosis."
"['High palate', 'Thin upper lip vermilion', 'Small anterior fontanelle', 'Hypertelorism', 'Macrotia', 'Anteverted nares', 'Ptosis', 'Death in infancy', 'Frontal bossing', 'Depressed nasal bridge', 'Short hallux', '1-5 finger syndactyly', '1-5 toe syndactyly', 'Bicoronal synostosis', 'Metopic synostosis', 'Midface retrusion']",['Apert syndrome/Apert syndrome'],"Disease: Apert syndrome  
Reasoning:  
1. **Craniosynostosis**: Bicoronal and metopic synostosis are hallmarks of Apert syndrome, causing frontal bossing and midface retrusion.  
2. **Midface Hypoplasia**: Depressed nasal bridge, hypertelorism, and anteverted nares align with characteristic midface underdevelopment.  
3. **Syndactyly**: 1-5 finger/toe syndactyly (""mitten hands/socks"") is pathognomonic for Apert syndrome.  
4. **Craniofacial Features**: High palate, thin upper lip vermilion, and ptosis are consistent with FGFR2 mutation-related dysmorphology.  
5. **Severe Prognosis**: Death in infancy may occur due to airway complications or severe cranial constraints.  
6. **Exclusion of Alternatives**: Features like macrotia and short hallux further support Apert over similar syndromes (e.g., Crouzon/Pfeiffer)."
"['Renal insufficiency', 'Horseshoe kidney', 'Platyspondyly', 'Brachydactyly', 'Hepatic cysts', 'Abnormal facial shape', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Skeletal dysplasia', 'Tachypnea', 'Multiple renal cysts', 'Limb undergrowth', 'Abnormal T cell count', 'Preterm intraventricular hemorrhage']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: Platyspondyly, brachydactyly, skeletal dysplasia, and limb undergrowth align with ISDNA’s hallmark skeletal defects caused by *EXOC6B* mutations.  
2. **Renal and Hepatic Involvement**: Horseshoe kidney, multiple renal cysts, renal insufficiency, and hepatic cysts reflect multisystemic ciliopathy-like features seen in ISDNA.  
3. **Neurodevelopmental Defects**: Hypoplasia of the corpus callosum, ventriculomegaly, and preterm intraventricular hemorrhage indicate severe neurodevelopmental abnormalities consistent with ISDNA.  
4. **Immune Dysregulation**: Abnormal T cell count points to the immunologic component unique to ISDNA.  
5. **Additional Features**: Tachypnea (respiratory compromise) and abnormal facial shape further support the diagnosis, as these are commonly reported in ISDNA.  
6. **Exclusion of Alternatives**: The combination of skeletal, renal, neurodevelopmental, and immune abnormalities distinguishes ISDNA from isolated ciliopathies or skeletal dysplasias."
"['Hydrocephalus', 'Macrocephaly', 'Hypertelorism', 'Low-set ears', 'Short neck', 'Strabismus', 'Ptosis', 'Pectus excavatum', 'Seizure', 'Cubitus valgus', 'Short stature', 'Relative macrocephaly', 'Sparse hair', 'Mild global developmental delay']",['Noonan syndrome 3'],"Disease: Noonan syndrome 3  
Reasoning:  
1. **Facial Features**: Hypertelorism, ptosis, low-set ears, and strabismus align with classic Noonan syndrome dysmorphology.  
2. **Skeletal Anomalies**: Pectus excavatum and cubitus valgus are common skeletal findings in Noonan syndrome.  
3. **Growth Issues**: Short stature and relative macrocephaly (head size disproportionate to body growth) are hallmark features.  
4. **Developmental Delay**: Mild global developmental delay is consistent with the syndrome’s neurocognitive profile.  
5. **Neurological Involvement**: Seizures and hydrocephalus suggest KRAS-related Noonan syndrome 3, which is associated with more severe neurological manifestations.  
6. **Cutaneous Features**: Sparse hair is occasionally reported in Noonan syndrome variants.  
7. **Exclusion of Alternatives**: Symptoms overlap with other RASopathies (e.g., Costello syndrome), but the combination of hydrocephalus, seizures, and KRAS-specific features (Noonan 3) solidifies the diagnosis."
"['Inguinal hernia', 'Cryptorchidism', 'Tall stature', 'Abnormality of the genitourinary system', 'Entropion', 'Cutis laxa', 'Seizure', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Death in infancy', 'Abnormal heart morphology', 'Congestive heart failure', 'Abnormal cardiac septum morphology', 'Abnormal facial shape', 'Kyphoscoliosis', 'Aortic aneurysm', 'Abnormal subcutaneous fat tissue distribution']","['Cutis laxa, autosomal recessive, type IID']","Disease: Cutis laxa, autosomal recessive, type IID  
Reasoning:  
1. **Cutis laxa** is a hallmark feature, involving loose, sagging skin, directly aligning with the diagnosis.  
2. **Abnormal cardiac septum morphology**, **aortic aneurysm**, and **congestive heart failure** indicate severe cardiovascular involvement, characteristic of type IID due to connective tissue defects.  
3. **Hip dysplasia**, **kyphoscoliosis**, and **flexion contractures** reflect skeletal abnormalities linked to systemic connective tissue dysfunction.  
4. **Abnormality of the genitourinary system** (e.g., cryptorchidism, inguinal hernia) and **abnormal facial shape** (entropion) are common in autosomal recessive cutis laxa subtypes.  
5. **Generalized hypotonia** and **seizures** suggest potential neurological compromise, reported in severe cases of type IID.  
6. **Disproportionate tall stature** and **abnormal subcutaneous fat distribution** further support a systemic connective tissue disorder.  
7. **Death in infancy** correlates with the severe prognosis of this subtype, driven by cardiovascular complications.  
The combination of cutaneous, cardiovascular, skeletal, and genitourinary anomalies with autosomal recessive inheritance confirms the diagnosis."
"['Abnormality of the kidney', 'Hypertelorism', 'Abnormal location of ears', 'Hearing impairment', 'Small earlobe', 'Prominent antihelix', 'Progressive sensorineural hearing impairment', 'Wide nasal bridge', 'Choanal atresia', 'Chorioretinal coloboma', 'Coloboma', 'Iris coloboma', 'Atypical behavior', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Absent speech', 'Flexion contracture', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Tachycardia', 'Respiratory distress', 'Difficulty walking', 'Developmental regression', 'Scoliosis', 'Thoracolumbar scoliosis', 'Difficulty standing', 'Short stature', 'Type I truncus arteriosus', 'Bilateral choanal atresia', 'Supraventricular tachycardia', 'Abnormal bone ossification', 'Flat face', 'Anisometropia']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental Features**: Intellectual disability, global developmental delay, absent speech, seizures, hypotonia, developmental regression, and atypical behavior align with the core neurodevelopmental phenotype of NEDBEH.  
2. **Ocular Anomalies**: Chorioretinal coloboma, iris coloboma, and anisometropia indicate structural eye defects, a hallmark of NEDBEH.  
3. **Cardiac Defects**: Type I truncus arteriosus and supraventricular tachycardia correlate with the ""heart anomalies"" component of the disorder.  
4. **Craniofacial Dysmorphism**: Hypertelorism, wide nasal bridge, flat face, abnormal ear location, small earlobes, and prominent antihelix match the facial gestalt seen in NEDBEH.  
5. **Systemic Involvement**: Bilateral choanal atresia, respiratory distress, growth delay, skeletal anomalies (abnormal bone ossification, hip dysplasia, scoliosis), and renal abnormalities support multi-organ involvement typical of NEDBEH.  
6. **Progressive Features**: Sensorineural hearing impairment and developmental regression suggest a degenerative trajectory, consistent with reported BRD4-related NEDBEH cases.  
7. **Exclusion of Overlap Syndromes**: While CHARGE syndrome (coloboma, choanal atresia) was considered, the presence of truncus arteriosus, hypotonia, and regression favors NEDBEH, which encompasses broader neurodevelopmental and systemic anomalies.  

This constellation of symptoms, particularly the triad of neurodevelopmental regression, structural eye/heart defects, and multi-system involvement, strongly supports a diagnosis of NEDBEH, likely linked to BRD4 mutations."
"['Hamartomatous polyposis', 'Oral melanotic macule', 'Labial melanotic macule']",['Peutz-Jeghers syndrome; PJS/Peutz-Jeghers syndrome/Peutz-Jeghers syndrome'],"Disease: Peutz-Jeghers syndrome (PJS)  
Reasoning:  
1. **Hamartomatous polyposis** is a hallmark of PJS, characterized by non-cancerous hamartomatous polyps in the gastrointestinal tract.  
2. **Oral and labial melanotic macules** (dark pigmented spots on the lips and oral mucosa) are pathognomonic mucocutaneous features of PJS.  
3. The triad of gastrointestinal polyposis, mucocutaneous pigmentation, and familial inheritance aligns definitively with PJS diagnosis.  
4. Other differentials (e.g., Cronkhite-Canada syndrome) lack the distinct melanotic macules or hamartomatous polyp subtype."
"['Plantar hyperkeratosis', 'Localized epidermolytic hyperkeratosis', 'Palmar hyperkeratosis']","['Epidermolytic palmoplantar keratoderma/Palmoplantar keratoderma, epidermolytic']","Disease: Epidermolytic palmoplantar keratoderma/Palmoplantar keratoderma, epidermolytic  
Reasoning:  
1. **Plantar and palmar hyperkeratosis** indicates involvement of both soles and palms, characteristic of palmoplantar keratoderma (PPK).  
2. **Localized epidermolytic hyperkeratosis** suggests histopathological findings of epidermolysis (blistering) in the granular layer, a hallmark of epidermolytic PPK.  
3. The combination of palmoplantar hyperkeratosis with epidermolytic features aligns specifically with mutations in keratin genes (e.g., *KRT1* or *KRT9*), which disrupt epidermal integrity.  
4. Diffuse or focal PPK subtypes without epidermolysis (e.g., non-epidermolytic PPK) are excluded due to the presence of epidermolytic changes.  
5. Clinical and histopathological coherence confirms the diagnosis of epidermolytic PPK."
"['Delayed speech and language development', 'Global developmental delay', 'Hypertonia', 'Delayed CNS myelination', 'EEG with burst suppression', 'Focal tonic seizure']","['Epileptic encephalopathy, early infantile, 4']","Disease: Epileptic encephalopathy, early infantile, 4  
Reasoning:  
1. **EEG with burst suppression** is a hallmark of early infantile epileptic encephalopathies (EIEE), specifically associated with EIEE4 (STXBP1-related encephalopathy).  
2. **Focal tonic seizures** align with seizure types observed in EIEE4, typically presenting in the first months of life.  
3. **Global developmental delay** and **delayed speech/language development** reflect the neurodevelopmental impairment caused by persistent epileptiform activity disrupting brain maturation.  
4. **Hypertonia** is a common neurological feature in STXBP1 mutations due to disrupted synaptic vesicle release and neuronal communication.  
5. **Delayed CNS myelination** on imaging supports a genetic/metabolic etiology affecting white matter development, consistent with EIEE4.  
6. The combination of seizure phenotype, developmental regression, and EEG findings strongly prioritizes EIEE4 over other encephalopathies."
"['Atrioventricular block', 'Sinus bradycardia', 'Prolonged QTc interval', 'Left ventricular noncompaction']",['Long QT syndrome 15'],"Disease: Long QT syndrome 15  
Reasoning:  
1. **Prolonged QTc interval** is a cardinal feature of Long QT syndrome (LQTS), specifically implicating a calmodulinopathy (e.g., CALM1/2/3 mutations) in LQTS15.  
2. **Sinus bradycardia** and **atrioventricular block** are characteristic of calmodulin-related LQTS subtypes due to disrupted calcium signaling in cardiac pacemaker and conduction systems.  
3. **Left ventricular noncompaction (LVNC)** is less directly linked but reported in some CALM2-associated cases, suggesting a potential overlap between electrical and structural cardiomyopathies in this genetic disorder.  
4. The combination of electrical abnormalities (prolonged QTc, bradycardia, AV block) with structural LVNC aligns with the pleiotropic effects of CALM2 mutations, distinguishing LQTS15 from other LQTS subtypes."
"['High palate', 'Mixed hearing impairment', 'Microcornea', 'Chorioretinal coloboma', 'Microphthalmia', 'Iris coloboma', 'Oligodontia', 'Delayed speech and language development', 'Abnormality of the nail', 'Aplasia cutis congenita over parietal area', 'Lacrimal duct stenosis', 'Inferior lens subluxation', 'Abnormal renal morphology']",['Branchio-oculo-facial syndrome/Branchiooculofacial syndrome'],"Disease: Branchio-oculo-facial syndrome (BOFS)  
Reasoning:  
1. **Ocular Features**: Microcornea, chorioretinal coloboma, microphthalmia, iris coloboma, and inferior lens subluxation align with BOFS’s hallmark ocular abnormalities, including colobomas and structural eye defects.  
2. **Branchial/Craniofacial Signs**: Aplasia cutis congenita (parietal scalp defect), high palate, oligodontia, and lacrimal duct stenosis correlate with BOFS’s craniofacial and ectodermal manifestations.  
3. **Hearing and Speech**: Mixed hearing impairment explains delayed speech development, consistent with BOFS-associated auditory defects.  
4. **Ancillary Features**: Nail abnormalities and renal morphology anomalies, while less specific, are occasionally reported in BOFS.  
5. **Syndrome Triad**: The combination of branchial (skin), ocular, and facial defects strongly supports BOFS diagnosis, excluding other coloboma-related syndromes (e.g., CHARGE) due to the presence of aplasia cutis and dental anomalies."
"['Microcephaly', 'Global developmental delay', 'Motor delay', 'Absent speech', 'EEG abnormality', 'Intellectual disability, severe', 'Abnormality of brain morphology']","['Microcephaly, primary autosomal recessive, 6']","Disease: Microcephaly, primary autosomal recessive, 6 (MCPH6)  
Reasoning:  
1. **Microcephaly**: A hallmark of MCPH syndromes, reflecting reduced brain size due to impaired neurogenesis.  
2. **Global developmental delay/Motor delay/Absent speech/Severe intellectual disability**: Consistent with severe cortical malformations and neuronal dysfunction in MCPH6, caused by mutations in *CENPJ*, critical for centrosome and microtubule organization.  
3. **EEG abnormality**: Suggests cortical hyperexcitability or dysrhythmia, common in neurodevelopmental disorders with disrupted neuronal migration or connectivity.  
4. **Abnormality of brain morphology**: Likely simplified gyral patterns or cortical thinning, as seen in MCPH6 due to defective progenitor cell proliferation.  
5. **Autosomal recessive inheritance**: Matches the genetic etiology of MCPH6, requiring biallelic pathogenic variants in *CENPJ*.  
The constellation of severe neurological deficits, structural brain anomalies, and microcephaly prioritizes MCPH6 over other syndromic microcephalies."
"['Narrow mouth', 'High palate', 'Prominent supraorbital ridges', 'Sensorineural hearing impairment', 'Protruding ear', 'Delayed eruption of teeth', 'Dentinogenesis imperfecta', 'Scoliosis', 'Recurrent fractures', 'Short stature', 'Reduced bone mineral density', 'Thoracic platyspondyly', 'Depressed nasal bridge', 'Prominent forehead', 'Midface retrusion', 'Knee joint hypermobility']","['Osteogenesis imperfecta, type XII']","Disease: Osteogenesis imperfecta, type XII  
Reasoning:  
1. **Recurrent fractures** and **reduced bone mineral density** indicate a skeletal fragility disorder, central to osteogenesis imperfecta (OI).  
2. **Dentinogenesis imperfecta** is a hallmark of OI, affecting tooth structure.  
3. **Short stature**, **scoliosis**, and **thoracic platyspondyly** align with skeletal dysplasias seen in OI.  
4. **Midface retrusion**, **depressed nasal bridge**, **narrow mouth**, **high palate**, **prominent supraorbital ridges**, and **prominent forehead** suggest craniofacial abnormalities typical of OI subtypes.  
5. **Sensorineural hearing impairment** is a known feature in some OI types, including type XII.  
6. **Knee joint hypermobility** reflects connective tissue involvement, consistent with collagen defects (OI type XII is linked to SP7 mutations, critical for bone formation).  
7. **Delayed eruption of teeth** and **protruding ear** further support a syndromic diagnosis involving developmental anomalies.  
8. Type XII is distinguished by autosomal recessive inheritance and specific SP7-related pathology, matching the symptom constellation."
"['Areflexia', 'Pes cavus', 'Decreased motor nerve conduction velocity', 'Decreased sensory nerve conduction velocity', 'Impaired distal tactile sensation', 'Distal upper limb muscle weakness', 'Anti-ganglioside antibody positivity']","['Hereditary neuropathy with liability to pressure palsies/Neuropathy, hereditary, with liability to pressure palsies']","Disease: Hereditary neuropathy with liability to pressure palsies (HNPP)  
Reasoning:  
1. **Areflexia**: Indicates peripheral neuropathy, consistent with HNPP, which disrupts nerve function.  
2. **Pes cavus**: Though more common in Charcot-Marie-Tooth disease (CMT), it can occur in HNPP due to chronic nerve damage and muscle imbalance.  
3. **Decreased motor/sensory nerve conduction velocity**: Demyelination (a hallmark of HNPP) slows conduction. HNPP often shows diffuse slowing with focal delays at compression sites.  
4. **Impaired distal tactile sensation and distal muscle weakness**: Distal nerve involvement aligns with HNPP’s predisposition to affect vulnerable nerve segments.  
5. **Anti-ganglioside antibody positivity**: Uncommon in HNPP but may represent a concurrent autoimmune process or incidental finding. HNPP is primarily genetic (PMP22 deletion), so clinical and electrophysiological features take precedence.  
6. Exclusion of mimics: Guillain-Barré syndrome (acute onset) and CMT (progressive course) are less likely. Recurrent pressure palsies and family history (implied by hereditary nature) further support HNPP.  

Final diagnosis hinges on hereditary pattern, electrophysiological findings, and structural nerve susceptibility, despite atypical anti-ganglioside antibodies."
"['Blue irides', 'Heterochromia iridis', 'White eyebrow', 'White eyelashes', 'Hypopigmentation of the fundus', 'Congenital sensorineural hearing impairment']",['Tietz syndrome/Tietz albinism-deafness syndrome'],"Disease: Tietz syndrome/Tietz albinism-deafness syndrome  
Reasoning:  
1. **Hypopigmentation features**: Blue irides, white eyebrows, white eyelashes, and hypopigmentation of the fundus align with Tietz syndrome, which causes generalized pigment deficiency affecting skin, hair, and eyes.  
2. **Congenital sensorineural hearing impairment**: A hallmark of Tietz syndrome, present from birth due to cochlear dysfunction.  
3. **Heterochromia iridis**: While less commonly reported, it may reflect variable melanin distribution in the irises, consistent with pigmentary abnormalities in Tietz syndrome.  
4. **Exclusion of differentials**: Waardenburg syndrome often includes dystopia canthorum or white forelock (distinct from white eyebrows/lashes), while oculocutaneous albinism lacks congenital deafness.  
5. **Genetic correlation**: Tietz syndrome is linked to mutations in *MITF*, critical for melanocyte and cochlear development, explaining both hypopigmentation and hearing loss."
"['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Autism', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Dysphagia', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Duodenal atresia', 'Tetraparesis', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Delayed myelination', 'Thick vermilion border', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental features**: Intellectual disability, autism, delayed speech/absent speech, hyperactivity, seizures, and hypotonia align with the core neurodevelopmental phenotype of NEDBEH.  
2. **Brain anomalies**: Abnormal corpus callosum morphology, CNS/cerebral hypomyelination, and delayed myelination reflect the ""brain anomalies"" component, characteristic of SMARCC1-related NEDBEH.  
3. **Eye anomalies**: Coloboma, microphthalmia, Peters anomaly, optic atrophy, and blepharophimosis are hallmark ocular findings in NEDBEH, particularly Peters anomaly (a corneal defect linked to SMARCC1 mutations).  
4. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return satisfy the ""heart anomalies"" criterion.  
5. **Craniofacial/dysmorphic features**: Microcephaly/macrocephaly (variable expressivity), triangular face, micrognathia, high palate, and narrow mouth are consistent with reported facial gestalt.  
6. **Supportive systemic features**: Gastrointestinal anomalies (annular pancreas, duodenal atresia) and genitourinary defects (hypospadias, cryptorchidism) overlap with SMARCC1-related multisystem involvement.  
7. **Exclusion of mimics**: While symptoms like café-au-lait spots or syndactyly might suggest other syndromes (e.g., RASopathies), the triad of neurodevelopmental delay + brain/eye/heart anomalies prioritizes NEDBEH.  

Key confirmatory clues include Peters anomaly, hypomyelination, and congenital heart defects, which collectively distinguish NEDBEH from phenocopies like CHARGE syndrome or chromosomal disorders."
"['Renal cyst', 'Hydronephrosis', 'Wide mouth', 'Microcephaly', 'Short chin', 'Macrotia', 'Bulbous nose', 'Strabismus', 'Upslanted palpebral fissure', 'Jaundice', 'Hypotonia', 'Global developmental delay', 'Decreased fetal movement', 'Bell-shaped thorax', 'Small nail', 'Talipes', 'Short columella', 'Respiratory distress', 'Frontal upsweep of hair', 'Thoracolumbar scoliosis', 'Chiari type I malformation', 'Bilateral cryptorchidism', 'High anterior hairline', 'Submucous cleft soft palate', 'Camptodactyly', 'Chronic constipation', 'Oral aversion', 'Bronchogenic cyst', 'Recurrent ear infections']",['Pierpont syndrome/Pierpont syndrome'],"Disease: Pierpont syndrome  
Reasoning:  
1. **Craniofacial Features**: The patient exhibits hallmark facial characteristics of Pierpont syndrome, including a wide mouth, microcephaly, short chin, macrotia, bulbous nose, upslanted palpebral fissures, short columella, and frontal hairline anomalies (high anterior hairline, frontal upsweep). These align with the distinct facial gestalt described in Pierpont syndrome.  
2. **Neurological & Developmental Signs**: Hypotonia, global developmental delay, and decreased fetal movement reflect the syndrome’s neurological involvement. Chiari type I malformation, though less common, has been reported in some cases.  
3. **Musculoskeletal Anomalies**: Bell-shaped thorax, talipes, thoracolumbar scoliosis, camptodactyly, and small nails correlate with skeletal abnormalities typical of the syndrome.  
4. **Urogenital & Renal Involvement**: Renal cysts, hydronephrosis, and bilateral cryptorchidism are consistent with genitourinary anomalies observed in Pierpont syndrome.  
5. **Respiratory & Gastrointestinal Issues**: Respiratory distress (potentially linked to bronchogenic cyst) and chronic constipation align with neuromuscular dysfunction secondary to hypotonia.  
6. **Associated Features**: Submucous cleft soft palate and recurrent ear infections may stem from craniofacial structural defects, while oral aversion is often seen in developmental disorders.  

The combination of these features, particularly the unique facial dysmorphology with multisystem involvement, strongly supports Pierpont syndrome as the diagnosis."
"['Gingival fibromatosis', 'Hypomelanotic macule', 'Dental enamel pits', 'Rhabdomyoma']",['Tuberous sclerosis-2'],"Disease: Tuberous sclerosis-2  
Reasoning:  
1. **Hypomelanotic macule**: A major diagnostic criterion for tuberous sclerosis complex (TSC), commonly appearing as ash-leaf spots.  
2. **Rhabdomyoma**: A cardiac manifestation strongly associated with TSC, particularly in infancy, and classified as a major diagnostic criterion.  
3. **Dental enamel pits**: A minor diagnostic criterion for TSC, reflecting ectodermal involvement.  
4. **Gingival fibromatosis**: Rarely reported in TSC but consistent with connective tissue hyperplasia, which may occur due to TSC2 gene mutations affecting mTOR pathway regulation.  
5. **Genetic correlation**: TSC2 mutations (compared to TSC1) are linked to more severe phenotypes, encompassing multi-organ manifestations like those listed.  
6. **Diagnostic confirmation**: Presence of ≥2 major criteria (hypomelanotic macule, rhabdomyoma) + 1 minor criterion (enamel pits) fulfills clinical diagnostic criteria for TSC."
"['Large fontanelles', 'Parietal bossing', 'Hypertelorism', 'Delayed eruption of primary teeth', 'Narrow chest', 'Short clavicles', 'Frontal bossing', 'Wormian bones', 'Scoliosis', 'Hypoplastic iliac wing', 'Short stature', 'Abnormal facility in opposing the shoulders', 'Depressed nasal bridge', 'Enamel hypoplasia', 'Delayed pubic bone ossification', 'Broad femoral head', 'Metopic depression', 'Midface retrusion', 'Short femoral neck']",['Cleidocranial dysplasia/Cleidocranial dysplasia'],"Disease: Cleidocranial dysplasia  
Reasoning:  
1. **Cranial/Facial Features**:  
   - **Large fontanelles**, **frontal/parietal bossing**, **metopic depression**, and **midface retrusion** indicate defective membranous bone ossification, a hallmark of CCD due to *RUNX2* gene mutations.  
   - **Hypertelorism** and **depressed nasal bridge** align with midface hypoplasia characteristic of CCD.  
   - **Wormian bones** (extra sutural bones) further support calvarial dysplasia.  

2. **Dental Abnormalities**:  
   - **Delayed eruption of primary teeth** and **enamel hypoplasia** result from impaired osteoblast differentiation and abnormal dental follicle development.  

3. **Clavicular/Skeletal Defects**:  
   - **Short clavicles** (or aplasia) explain **abnormal facility in opposing the shoulders** and **narrow chest**.  
   - **Hypoplastic iliac wings**, **delayed pubic bone ossification**, **broad femoral head**, and **short femoral neck** reflect pelvic and long bone dysplasia.  

4. **Growth and Axial Skeleton**:  
   - **Short stature** and **scoliosis** stem from generalized skeletal involvement.  

5. **Exclusion of Alternatives**:  
   - Overlap with hypophosphatasia or osteogenesis imperfecta is excluded by the absence of biochemical abnormalities (e.g., low alkaline phosphatase) or fragility fractures.  

This constellation of craniofacial, dental, clavicular, and pelvic abnormalities is pathognomonic for cleidocranial dysplasia."
"['Visual impairment', 'Photophobia', 'Nyctalopia', 'Visual field defect']",['Cone rod dystrophy/Cone-Rod dystrophy 2'],"Disease: Cone rod dystrophy/Cone-Rod dystrophy 2  
Reasoning:  
1. **Photophobia** and **visual impairment** suggest primary cone dysfunction, as cones mediate photopic (daylight) vision.  
2. **Nyctalopia** (night blindness) indicates subsequent rod involvement, as rods are responsible for scotopic (low-light) vision.  
3. **Visual field defects** (e.g., peripheral loss) align with progressive degeneration of both photoreceptor types, leading to concentric field narrowing or central scotomas.  
4. Cone-rod dystrophy classically presents with early cone system decline (photophobia, color/acuity loss) followed by rod degeneration (nyctalopia), distinguishing it from rod-cone dystrophies like retinitis pigmentosa.  
5. Genetic subtypes (e.g., *CRD2* linked to *ABCAA4* mutations) correlate with phenotypic variability but share this symptom triad."
"['Hearing impairment', 'Neonatal hypotonia', 'Decreased liver function', 'Failure to thrive in infancy', 'Left ventricular hypertrophy', 'Acidosis', 'Poor suck', 'Respiratory distress', 'Polymicrogyria', 'Increased serum lactate', 'Increased CSF lactate', 'Elevated hepatic transaminase', 'Lactic acidosis', 'Feeding difficulties in infancy', 'Nasogastric tube feeding']","['Combined oxidative phosphorylation deficiency 30', 'Combined oxidative phosphorylation defect type 30']","Disease: Combined oxidative phosphorylation deficiency 30 (COXPD30)  
Reasoning:  
1. **Lactic acidosis** (elevated serum and CSF lactate) indicates impaired mitochondrial energy metabolism, a hallmark of oxidative phosphorylation defects.  
2. **Neurological involvement**: Polymicrogyria (abnormal brain development), neonatal hypotonia, and hearing impairment align with mitochondrial encephalopathies caused by defective mitochondrial translation (e.g., MTFMT gene mutations in COXPD30).  
3. **Multi-organ dysfunction**:  
   - **Hepatic**: Elevated transaminases and decreased liver function suggest mitochondrial hepatopathy.  
   - **Cardiac**: Left ventricular hypertrophy reflects energy-deficient cardiac tissue stress.  
   - **Failure to thrive** and feeding difficulties (poor suck, nasogastric dependence) stem from systemic metabolic insufficiency.  
4. **Respiratory distress** may arise from combined metabolic acidosis and neuromuscular weakness.  
5. **MTFMT mutations** disrupt mitochondrial protein synthesis, causing combined respiratory chain deficiencies, consistent with the patient’s multi-systemic presentation.  

Disease: Combined oxidative phosphorylation defect type 30  
Reasoning:  
- This is a synonym for COXPD30, reaffirmed by the same genetic basis (MTFMT) and phenotypic overlap:  
  - **Biochemical markers**: Persistent lactic acidosis and elevated hepatic transaminases.  
  - **Clinical triad**: Encephalopathy (polymicrogyria, hypotonia), cardiomyopathy, and hepatopathy.  
  - **Infantile onset**: Symptoms like respiratory distress, feeding difficulties, and failure to thrive manifest early, typical of severe mitochondrial disorders.  
- The dual elevation of lactate in serum and CSF excludes isolated organ defects, supporting a systemic oxidative phosphorylation defect."
"['Seizure', 'Global developmental delay', 'Generalized hypotonia', 'Absent speech', 'Interictal epileptiform activity']",['Developmental and epileptic encephalopathy 14'],"Disease: Developmental and epileptic encephalopathy 14  
Reasoning:  
1. **Seizures**: A core feature of developmental and epileptic encephalopathies (DEEs), including DEE14, which is linked to *KCNT1* gene mutations.  
2. **Global developmental delay**: Consistent with DEEs, where seizure activity and neurodevelopmental disruption impair milestones.  
3. **Generalized hypotonia**: Observed in DEE14 due to neuronal hyperexcitability and cortical dysfunction.  
4. **Absent speech**: Reflects severe neurodevelopmental impairment, common in DEE subtypes.  
5. **Interictal epileptiform activity**: Supports epileptic encephalopathy diagnosis, as abnormal electrical activity persists between seizures, exacerbating developmental delays.  
6. **Exclusion of mimics**: Symptoms align with DEE14 rather than other DEE subtypes (e.g., *SCN1A*-related Dravet syndrome lacks prominent interictal discharges early on). Genetic testing for *KCNT1* variants would confirm."
"['Ventricular fibrillation', 'Sinus bradycardia', 'Left ventricular noncompaction']",['Sick sinus syndrome 2'],"Disease: Sick sinus syndrome 2  
Reasoning:  
1. **Sinus bradycardia** is a hallmark of sick sinus syndrome (SSS), reflecting dysfunction of the sinoatrial node. SSS type 2 specifically involves intermittent sinoatrial block or sinus arrest, consistent with this symptom.  
2. **Ventricular fibrillation** may arise secondary to severe bradycardia in SSS2, as prolonged pauses or arrhythmias can trigger compensatory ventricular instability, especially in the presence of structural abnormalities.  
3. **Left ventricular noncompaction (LVNC)** is not directly linked to SSS2 but may coexist as a congenital structural anomaly. LVNC increases susceptibility to ventricular arrhythmias like fibrillation, compounding the arrhythmic risk from SSS2.  
4. Genetic overlap (e.g., ion channel or structural gene mutations) could explain concurrent SSS2 and LVNC, though SSS2 is primarily attributed to *HCN4* mutations affecting pacemaker function.  

Final diagnosis prioritizes SSS2 due to the pathognomonic sinus bradycardia, while LVNC and ventricular fibrillation are contextualized as contributing/comorbid factors."
"['Eczema', 'Hypopigmentation of the skin', 'Global developmental delay', 'Joint swelling', 'Hepatosplenomegaly', 'Abnormal bleeding', 'Fever', 'Vomiting', 'Diarrhea', 'Pneumonia', 'Increased circulating IgE level', 'Poor appetite', 'Sparse hair', 'Cough']",['Chédiak-Higashi syndrome/Chediak-Higashi syndrome'],"Disease: Chédiak-Higashi syndrome  
Reasoning:  
1. **Hypopigmentation of the skin and sparse hair**: Aligns with partial oculocutaneous albinism, a hallmark of CHS due to abnormal melanosome trafficking.  
2. **Recurrent infections (pneumonia, fever) and increased IgE**: Reflects immune dysfunction from defective neutrophil chemotaxis and lysosomal granule defects, leading to impaired bacterial killing and immune dysregulation.  
3. **Hepatosplenomegaly and abnormal bleeding**: Suggests the accelerated phase of CHS, characterized by hemophagocytic lymphohistiocytosis (HLH), causing organ infiltration, cytopenias, and coagulopathy.  
4. **Global developmental delay**: Correlates with neurological involvement, including cerebellar atrophy and peripheral neuropathy, common in CHS.  
5. **Gastrointestinal symptoms (vomiting, diarrhea, poor appetite)**: May stem from systemic inflammation during the accelerated phase or recurrent infections.  
6. **Eczema and joint swelling**: Linked to immune dysregulation and chronic inflammation.  
7. **Cough**: Likely secondary to recurrent respiratory infections (e.g., pneumonia).  
The constellation of pigmentary abnormalities, immune deficiency, neurologic deficits, and HLH features strongly supports CHS."
"['Keratoconus', 'Dysarthria', 'Dysmetria', 'Lower limb spasticity', 'Gait ataxia', 'Limb ataxia', 'Upper limb spasticity']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Lower and upper limb spasticity**: Core features of hereditary spastic paraplegias (HSPs), including SPG76, caused by *CAPN1* mutations. Spasticity reflects corticospinal tract dysfunction.  
2. **Gait ataxia, limb ataxia, dysmetria**: Indicate cerebellar involvement, consistent with SPG76’s reported association with cerebellar degeneration.  
3. **Dysarthria**: Aligns with cerebellar or bulbar dysfunction, seen in complex HSP subtypes like SPG76.  
4. **Keratoconus**: Less typical but plausible in SPG76, as calpain dysfunction (from *CAPN1* mutations) may disrupt corneal structural integrity. Calpains regulate cytoskeletal proteins critical in corneal homeostasis.  
5. **Exclusion of mimics**: Other HSPs (e.g., SPG7) or ataxia syndromes lack this specific combination of spasticity, ataxia, and keratoconus. Genetic testing for *CAPN1* variants would confirm SPG76."
"['Talipes equinovarus', 'Short humerus', 'Multiple prenatal fractures', 'Short lower limbs', 'Bowing of the long bones']","['Osteogenesis imperfecta, type IX']","Disease: Osteogenesis imperfecta, type IX  
Reasoning:  
1. **Multiple prenatal fractures** are a hallmark of severe Osteogenesis Imperfecta (OI), particularly types with early-onset skeletal fragility.  
2. **Short humerus** and **short lower limbs** indicate impaired bone growth and remodeling, consistent with OI-related collagen defects.  
3. **Bowing of the long bones** suggests repeated fractures and abnormal bone formation during development, a feature seen in severe OI subtypes.  
4. **Talipes equinovarus** (clubfoot) is associated with connective tissue abnormalities and intrauterine limb positioning due to bone fragility.  
5. OI type IX is caused by biallelic *PPIB* mutations, leading to defective collagen post-translational modification. This subtype aligns with severe prenatal presentation, fractures, and disproportionate limb shortening.  
6. Exclusion of other OI types (e.g., type II is typically lethal neonatally; type III has progressive deforming features but distinct genetic causes)."
"['Microcephaly', 'Hearing impairment', 'Optic atrophy', 'Delayed speech and language development', 'Global developmental delay', 'Dystonia', 'Failure to thrive', 'Hypoglycemia', 'Cerebral cortical atrophy', 'Drooling', 'Lactic acidosis', 'Ragged-red muscle fibers', '3-Methylglutaconic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Excessive salivation', 'Axial hypotonia', 'Infantile muscular hypotonia', 'Feeding difficulties', 'Subcortical cerebral atrophy', 'Elevated brain lactate level by MRS', 'Reduced brain N-acetyl aspartate level by MRS', 'Abnormal basal ganglia MRI signal intensity', 'Epileptic encephalopathy']","['MEGDEL syndrome', '3-Methylglutaconic aciduria with deafness, encephalopathy, and leigh-like syndrome']","Disease: MEGDEL syndrome  
Reasoning: The patient exhibits 3-methylglutaconic aciduria, a hallmark of MEGDEL syndrome. Key neurological features include sensorineural hearing impairment, dystonia (linked to basal ganglia abnormalities on MRI), and epileptic encephalopathy. Mitochondrial dysfunction is evidenced by lactic acidosis, ragged-red/COX-negative muscle fibers, and elevated brain lactate on MRS. Leigh-like syndrome correlates with subcortical cerebral atrophy and abnormal basal ganglia signal. Systemic manifestations (failure to thrive, hypoglycemia, feeding difficulties) and developmental delays (speech, global) align with multisystemic mitochondrial disorder. Excessive salivation, axial hypotonia, and optic atrophy further support this diagnosis.  

Disease: 3-Methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome  
Reasoning: This is a descriptive name for MEGDEL syndrome. The triad of 3-methylglutaconic aciduria, deafness, and Leigh-like MRI findings (basal ganglia lesions, cerebral atrophy) is pathognomonic. Encephalopathy manifests as developmental delay, dystonia, and epileptic seizures. Mitochondrial markers (ragged-red fibers, COX deficiency, lactic acidosis) confirm the underlying energy metabolism defect. Elevated brain lactate and reduced N-acetyl aspartate on MRS reflect neuronal injury and impaired mitochondrial function, consistent with this entity."
"['High palate', 'Thick eyebrow', 'Dental malocclusion', 'Postaxial hand polydactyly', 'Prominent fingertip pads', 'Seizure', 'Global developmental delay', 'Intrauterine growth retardation', 'Clinodactyly of the 5th finger', 'Recurrent subcortical infarcts', 'Cutaneous finger syndactyly']",['Orofaciodigital syndrome type 5/Orofaciodigital syndrome V'],"Disease: Orofaciodigital syndrome type 5/Orofaciodigital syndrome V  
Reasoning:  
1. **Oral features**: High palate and dental malocclusion align with characteristic oral abnormalities in OFD syndromes.  
2. **Facial features**: Thick eyebrows are consistent with facial dysmorphisms seen in OFD5.  
3. **Digital anomalies**: Postaxial hand polydactyly, clinodactyly of the 5th finger, cutaneous syndactyly, and prominent fingertip pads reflect the hallmark digital manifestations of OFD5.  
4. **Neurological involvement**: Seizures and global developmental delay suggest central nervous system involvement, which is reported in OFD5.  
5. **Prenatal and vascular findings**: Intrauterine growth retardation may correlate with systemic developmental disruptions, while recurrent subcortical infarcts could indicate rare vascular anomalies associated with the syndrome.  
6. **Syndrome differentiation**: The combination of postaxial polydactyly, oral/digital features, and neurological deficits distinguishes OFD5 from other OFD subtypes (e.g., OFD1 lacks polydactyly and has X-linked inheritance)."
"['Hepatic steatosis', 'Periportal fibrosis', 'Hypercholesterolemia', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating creatine kinase concentration', 'Decreased circulating ceruloplasmin concentration', 'Decreased circulating copper concentration']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Hepatic steatosis & periportal fibrosis**: TMEM199-CDG is characterized by chronic liver disease, including steatosis and fibrosis, due to impaired glycosylation affecting hepatic function.  
2. **Hypercholesterolemia**: Glycosylation defects disrupt lipid metabolism pathways, leading to elevated cholesterol.  
3. **Elevated alkaline phosphatase**: Reflects cholestatic liver injury, common in TMEM199-CDG.  
4. **Elevated creatine kinase**: Suggests mild myopathy, occasionally observed in this disorder.  
5. **Low ceruloplasmin & copper**: TMEM199-CDG causes hypocupremia and hypoceruloplasminemia secondary to disrupted copper transport (likely via defective glycosylation of COMMD1, a copper metabolism regulator).  
6. **Exclusion of Wilson disease**: While low ceruloplasmin/copper mimic Wilson disease, the absence of neuropsychiatric symptoms and presence of hypercholesterolemia/liver fibrosis favor TMEM199-CDG. Genetic testing for TMEM199 variants confirms the diagnosis."
"['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Narrow mouth', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Astigmatism', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Microdontia', 'Atypical behavior', 'Autistic behavior', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Poor suck', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Abnormal cerebellar vermis morphology', 'Sleep disturbance', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Delayed fine motor development', 'Laterally extended eyebrow', 'Abnormality of fontanelles', 'Abdominal colic', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  

**Reasoning:**  
1. **Neurodevelopmental Core Features:**  
   - *Autistic behavior, delayed speech, hyperactivity, ADHD, absent speech, delayed fine motor development* align with the ""neurodevelopmental disorder"" component.  
   - *Abnormal corpus callosum, cerebellar/pons/hippocampus anomalies, CNS hypomyelination* indicate structural brain abnormalities.  

2. **Ocular Involvement:**  
   - *Coloboma, microphthalmia, Peters anomaly, optic atrophy, astigmatism, deeply set eyes* reflect the ""eye anomalies"" criterion.  

3. **Cardiac Defects:**  
   - *Ventricular septal defect, patent ductus arteriosus, anomalous pulmonary return* satisfy the ""heart anomalies"" spectrum.  

4. **Craniofacial & Systemic Features:**  
   - *Microcephaly/macrocephaly, triangular face, micrognathia, high palate, bulbous nose* are common in genetic neurodevelopmental syndromes.  
   - *Growth delay, hypotonia, seizures, GI anomalies (pyloric stenosis, duodenal atresia)* support multisystem involvement.  

5. **Exclusion of Overlap Syndromes:**  
   - While features like *café-au-lait spots* or *syndactyly* may suggest RASopathies or chromosomal disorders, the triad of neurodevelopmental delay + brain/eye/heart anomalies is pathognomonic for NEDBEH (OMIM 618733).  

6. **Genetic Consistency:**  
   - NEDBEH is linked to *CABP4* or *UBR3* mutations, which disrupt neurodevelopment and organogenesis, explaining the observed phenotypic variability.  

**Conclusion:** The convergence of neurodevelopmental delays, structural brain/eye/heart defects, and variable dysmorphism strongly supports NEDBEH. Genetic testing for causative variants is recommended for confirmation."
"['Rod-cone dystrophy', 'Pigmentary retinopathy', 'Nyctalopia', 'Visual field defect', 'Reduced visual acuity', 'Attenuation of retinal blood vessels', 'Diffuse optic disc pallor', 'Hypoautofluorescent retinal lesion']",['Retinitis pigmentosa 78'],"Disease: Retinitis pigmentosa 78  
Reasoning:  
1. **Rod-cone dystrophy**: A hallmark of retinitis pigmentosa (RP), involving progressive degeneration of rod photoreceptors (causing nyctalopia) followed by cone loss (reducing visual acuity).  
2. **Pigmentary retinopathy**: Characteristic bone-spicule pigmentation due to retinal pigment epithelium migration, common in RP.  
3. **Nyctalopia**: Early symptom from rod dysfunction, aligning with RP progression.  
4. **Visual field defect**: Typically starts as peripheral vision loss (tunnel vision), progressing centrally as RP advances.  
5. **Attenuation of retinal blood vessels & diffuse optic disc pallor**: Reflects chronic retinal degeneration and optic nerve atrophy in late-stage RP.  
6. **Hypoautofluorescent retinal lesions**: Indicates areas of photoreceptor/RPE atrophy, consistent with advanced RP.  
7. **Genetic association**: RP78 is linked to biallelic variants in the *HK1* gene, which disrupts retinal metabolism, explaining the phenotype.  
All findings collectively match the clinical and molecular profile of retinitis pigmentosa 78."
"['Macrocephaly', 'Strabismus', 'Nystagmus', 'Intellectual disability', 'Seizure', 'Absent speech', 'Hypoplasia of the corpus callosum', 'Developmental regression', 'Areflexia of lower limbs', 'Severe muscular hypotonia', 'Periventricular leukomalacia', 'Severe global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Severe muscular hypotonia and areflexia**: Core features of TBCK syndrome, reflecting neuromuscular involvement due to TBCK gene mutations affecting mTOR signaling.  
2. **Intellectual disability, absent speech, and severe global developmental delay**: Consistent with neurodevelopmental deficits characteristic of TBCK syndrome.  
3. **Hypoplasia of the corpus callosum**: A hallmark neuroimaging finding in TBCK-related disorders, linked to disrupted neuronal connectivity.  
4. **Seizures and developmental regression**: Observed in severe TBCK cases, possibly due to progressive neuronal dysfunction or epileptic encephalopathy.  
5. **Macrocephaly**: Reported in some patients, though nonspecific, it aligns with brain structural anomalies.  
6. **Ocular abnormalities (strabismus, nystagmus)**: Common in neurogenetic syndromes, supporting central nervous system involvement.  
7. **Periventricular leukomalacia**: May overlap with white matter abnormalities seen in TBCK, though typically associated with preterm injury; here, it likely reflects dysmyelination from the genetic defect.  
8. **Exclusion of mimics**: Features distinguish it from similar disorders (e.g., Prader-Willi, Rett syndrome) by the absence of dysmorphism, metabolic markers, or specific regression patterns. Genetic testing for TBCK mutations would confirm the diagnosis."
"['Epicanthus', 'Triangular face', 'Short chin', 'Long philtrum', 'Posteriorly rotated ears', 'Low-set ears', 'Broad nasal tip', 'Torticollis', 'Downslanted palpebral fissures', 'Telecanthus', 'Osteoporosis', 'Flexion contracture', 'Macrodontia', 'Language impairment', 'Kyphosis', 'Depressed nasal bridge', 'Deep palmar crease', 'Severe global developmental delay', 'Cognitive impairment', 'Small hand']",['Al Kaissi syndrome'],"Disease: Al Kaissi syndrome  
**Step 1: Craniofacial Dysmorphism**  
- **Epicanthus**, **telecanthus**, and **downslanted palpebral fissures** indicate characteristic ocular abnormalities.  
- **Triangular face**, **short chin**, **long philtrum**, **broad nasal tip**, and **depressed nasal bridge** align with the facial gestalt of Al Kaissi syndrome.  
- **Posteriorly rotated ears** and **low-set ears** further support craniofacial dysmorphism.  

**Step 2: Skeletal and Musculoskeletal Abnormalities**  
- **Osteoporosis**, **kyphosis**, and **flexion contractures** reflect skeletal dysplasia, a hallmark of the syndrome.  
- **Torticollis** (neck muscle contracture) and **small hands** with **deep palmar creases** suggest connective tissue and skeletal involvement.  

**Step 3: Dental and Developmental Features**  
- **Macrodontia** (abnormally large teeth) is a rare but reported feature.  
- **Severe global developmental delay**, **cognitive impairment**, and **language impairment** indicate neurodevelopmental deficits consistent with the syndrome’s profile.  

**Step 4: Exclusion of Overlapping Syndromes**  
- Differentiated from Down, Williams, or Noonan syndromes by the unique combination of **macrodontia**, **flexion contractures**, and **skeletal dysplasia** without cardiac or metabolic hallmarks of other disorders.  

**Conclusion**: The constellation of craniofacial, skeletal, dental, and neurodevelopmental abnormalities strongly aligns with Al Kaissi syndrome, a rare genetic disorder linked to dysregulated skeletal development and connective tissue defects."
"['Microcephaly', 'Delayed speech and language development', 'Intellectual disability', 'Hypotonia', 'Spasticity', 'Global developmental delay', 'Difficulty walking']","['Mental retardation, autosomal recessive 18']","Disease: Mental retardation, autosomal recessive 18  
Reasoning:  
1. **Microcephaly**: A hallmark of RAB3GAP1-related disorders, including MRT18, due to impaired neuronal growth and synaptic function.  
2. **Global developmental delay + intellectual disability**: Core features of MRT18, linked to RAB3GAP1 mutations disrupting vesicular trafficking critical for brain development.  
3. **Hypotonia progressing to spasticity**: Early hypotonia (infancy) often transitions to spasticity (later childhood) in RAB3GAP1 disorders, reflecting evolving corticospinal tract dysfunction.  
4. **Delayed speech/language and motor deficits**: Reflects widespread cortical and cerebellar involvement, consistent with RAB3GAP1’s role in neurosecretory pathways.  
5. **Difficulty walking**: Secondary to spasticity, pyramidal tract damage, and motor coordination deficits.  
6. **Autosomal recessive inheritance**: Matches MRT18’s inheritance pattern; family history (if available) may reveal consanguinity or asymptomatic carriers.  
**Confirmatory testing**: Genetic sequencing of RAB3GAP1 to identify biallelic pathogenic variants."
"['Flexion contracture', 'Apnea', 'Inability to walk', 'Reduced vital capacity', 'Abnormal pattern of respiration', 'Respiratory failure', 'Skeletal muscle atrophy', 'Easy fatigability', 'Scapular winging', 'Distal upper limb muscle weakness', 'Foot dorsiflexor weakness', 'Distal lower limb muscle weakness', 'Stridor', 'Sleep apnea', 'Anti-muscle-specific tyrosine kinase antibody']","['Myasthenic syndrome, congenital, 8']","Disease: Myasthenic syndrome, congenital, 8 (CMS8)  
Reasoning:  
1. **Key Neuromuscular Symptoms**: The patient exhibits distal and proximal muscle weakness (scapular winging, distal upper/lower limb weakness, foot dorsiflexor weakness), skeletal muscle atrophy, and easy fatigability, all hallmarks of neuromuscular junction disorders like CMS.  
2. **Respiratory Involvement**: Respiratory failure, apnea, sleep apnea, stridor, and reduced vital capacity indicate severe respiratory muscle weakness, a critical feature of CMS8 due to DOK7 mutations impairing neuromuscular transmission.  
3. **Genetic Basis**: CMS8 is linked to autosomal recessive DOK7 mutations, causing postsynaptic neuromuscular junction dysfunction. While anti-MuSK antibodies are typically associated with autoimmune myasthenia gravis, CMS8 is genetic and antibody-negative. The listed antibody may be incidental or a reporting error, as CMS8 is diagnosed via genetic testing, not serology.  
4. **Clinical Overlap**: Symptoms align with CMS8’s typical presentation (proximal > distal weakness, respiratory crises, fatigability), though distal involvement can occur. Flexion contractures and inability to walk reflect chronic muscle atrophy and compensatory posturing.  
5. **Exclusion of Alternatives**: Autoimmune myasthenia gravis (MuSK-positive) would typically improve with immunotherapies, whereas CMS8 requires acetylcholinesterase inhibitors or β-adrenergic agonists. The congenital nature (implied by diagnosis) supports CMS8 over acquired conditions.  

Conclusion: Despite the atypical presence of anti-MuSK antibody, the constellation of progressive muscle weakness, respiratory failure, and structural features (e.g., scapular winging) strongly suggests CMS8, necessitating genetic confirmation of DOK7 mutations."
"['Hydrocephalus', 'Intellectual disability', 'Poor coordination', 'Eye of the tiger anomaly of globus pallidus', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating creatine kinase concentration', 'Abnormality of the pituitary gland']",['Pantothenate kinase-associated neurodegeneration/Neurodegeneration with brain iron accumulation 1'],"Disease: Pantothenate kinase-associated neurodegeneration/Neurodegeneration with brain iron accumulation 1 (PKAN/NBIA1)  
Reasoning:  
1. **""Eye of the tiger"" anomaly in the globus pallidus**: This MRI finding is pathognomonic for PKAN, caused by iron deposition and necrosis in the basal ganglia.  
2. **Neurological symptoms (intellectual disability, poor coordination)**: Consistent with progressive neurodegeneration in PKAN, affecting motor and cognitive functions.  
3. **Elevated creatine kinase (CK)**: Reflects muscle injury secondary to dystonia or rigidity, common in PKAN.  
4. **Elevated alkaline phosphatase (ALP)**: May indicate hepatic or bony involvement, though atypical; could suggest a metabolic compensatory mechanism or comorbidity.  
5. **Hydrocephalus and pituitary gland abnormality**: Less specific but may arise from structural brain changes or indirect effects of neurodegeneration.  
6. **Genetic basis**: PKAN is linked to mutations in *PANK2*, disrupting coenzyme A metabolism and leading to iron accumulation.  
The combination of pathognomonic imaging, neurodegeneration, and biochemical markers strongly supports PKAN/NBIA1."
"['Abnormality of the kidney', 'Wide mouth', 'Hypertelorism', 'Choanal atresia', 'Anteverted nares', 'Synophrys', 'Atypical behavior', 'Compulsive behaviors', 'Autistic behavior', 'Abnormal repetitive mannerisms', 'Anxiety', 'Delayed speech and language development', 'Global developmental delay', 'Abnormal heart morphology', 'Sleep disturbance', 'Expressive language delay', 'Scoliosis', 'Poor gross motor coordination', 'Localized hirsutism', 'Abnormal eye morphology', 'Separation insecurity']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental Core Features**: The patient exhibits global developmental delay, expressive language delay, delayed speech, autistic behavior, compulsive behaviors, abnormal repetitive mannerisms, and anxiety—all hallmark neurodevelopmental symptoms of NEDBEH.  
2. **Structural Anomalies**:  
   - **Heart**: Abnormal heart morphology aligns with the ""cardiac anomalies"" spectrum of NEDBEH.  
   - **Eye**: Hypertelorism, abnormal eye morphology, and synophrys (unibrow) suggest ocular involvement.  
   - **Other Craniofacial Features**: Wide mouth, anteverted nares, and choanal atresia are consistent with dysmorphic traits seen in NEDBEH.  
3. **Systemic Abnormalities**: Abnormality of the kidney and scoliosis fit the variable systemic anomalies associated with this disorder.  
4. **Behavioral/Motor Symptoms**: Poor gross motor coordination, sleep disturbances, and separation insecurity further support a complex neurodevelopmental etiology.  
5. **Exclusion of Overlap Syndromes**: While choanal atresia and heart defects may suggest CHARGE syndrome, the absence of coloboma, ear anomalies, and the prominence of autistic/compulsive behaviors favor NEDBEH. Similarly, synophrys and hirsutism could evoke Cornelia de Lange syndrome, but the lack of limb anomalies or growth restriction makes NEDBEH more likely.  
6. **Genetic Basis**: NEDBEH is often linked to de novo variants in genes like *BRD4* or *HNRNPU*, which disrupt neurodevelopment and organogenesis—consistent with the multisystemic presentation here.  

This diagnosis integrates the patient’s neurodevelopmental, craniofacial, cardiac, and renal findings into a single genetic framework, typical of NEDBEH."
"['Hyperactivity', 'Intellectual disability', 'Delayed skeletal maturation', 'Sparse lateral eyebrow']","['Trichorhinophalangeal syndrome, type I']","Disease: Trichorhinophalangeal syndrome, type I  
Reasoning:  
1. **Sparse lateral eyebrows**: A hallmark feature of TRPS type I, linked to characteristic facial dysmorphism (e.g., thin scalp hair, bulbous nose).  
2. **Delayed skeletal maturation**: Consistent with skeletal abnormalities in TRPS type I, such as cone-shaped epiphyses in the phalanges and short stature.  
3. **Intellectual disability**: Though typically mild or absent in TRPS type I, variable expressivity may explain its presence here.  
4. **Hyperactivity**: Not a classic feature but may overlap with behavioral phenotypes in rare cases or reflect comorbid ADHD-like traits.  
5. **Exclusion of TRPS type II**: Absence of exostoses or severe intellectual disability supports type I over type II (Langer-Giedion syndrome). Genetic testing for *TRPS1* mutations would confirm the diagnosis."
"['Abnormality of male external genitalia', 'Hypospadias', 'Abnormality of the kidney', 'Horseshoe kidney', 'Ectopic kidney', 'Abnormal mandible morphology', 'Microretrognathia', 'Abnormality of the outer ear', 'Posteriorly rotated ears', 'Hearing impairment', 'Low-set ears', 'Abnormality of the eye', 'Strabismus', 'Nystagmus', 'Horizontal nystagmus', 'Atypical behavior', 'Delayed speech and language development', 'Intellectual disability', 'Hypotonia', 'Motor delay', 'Generalized hypotonia', 'Absent speech', 'Abnormality of the cardiovascular system', 'Ventricular septal defect', 'Atrial septal defect', 'Patent ductus arteriosus', 'Truncus arteriosus', 'Pneumonia', 'Abnormality of the upper limb', 'Crossed fused renal ectopia', 'Recurrent pneumonia', 'Aplasia/Hypoplasia of the thumb', 'Feeding difficulties', 'Hypoplastic aortic arch']",['Stankiewicz-Isidor syndrome'],"Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Urogenital and Renal Abnormalities**: Hypospadias, horseshoe kidney, ectopic kidney, and crossed fused renal ectopia align with the renal and genital anomalies commonly seen in Stankiewicz-Isidor syndrome (STISS), caused by mutations in *PSMD12*.  
2. **Craniofacial Features**: Microretrognathia, posteriorly rotated ears, low-set ears, and strabismus/nystagmus match the craniofacial dysmorphism and ocular abnormalities reported in STISS.  
3. **Developmental and Neurological Issues**: Intellectual disability, absent speech, motor delay, and generalized hypotonia are hallmark features of STISS, reflecting its neurodevelopmental impact.  
4. **Cardiovascular Defects**: Ventricular/atrial septal defects, patent ductus arteriosus, truncus arteriosus, and hypoplastic aortic arch are consistent with congenital heart defects observed in STISS.  
5. **Limb Anomalies**: Thumb hypoplasia/aplasia correlates with the upper limb malformations associated with STISS.  
6. **Systemic Complications**: Recurrent pneumonia and feeding difficulties likely stem from hypotonia, dysphagia, and aspiration risks, further supporting the diagnosis.  
7. **Exclusion of Overlapping Syndromes**: The constellation of symptoms (renal, cardiac, craniofacial, limb) differentiates STISS from similar syndromes (e.g., CHARGE, 22q11 deletion), which lack this specific combination.  

The diagnosis is strongly supported by the convergence of neurodevelopmental, cardiovascular, renal, craniofacial, and limb anomalies, characteristic of *PSMD12*-related Stankiewicz-Isidor syndrome."
"['Optic disc pallor', 'Abnormality of visual evoked potentials', 'Horizontal nystagmus', 'Spasticity', 'Dystonia', 'Rotary nystagmus', 'Mutism', 'Poor head control', 'Abnormal auditory evoked potentials', 'Poor gross motor coordination', 'Infantile muscular hypotonia', 'Gastrostomy tube feeding in infancy', 'Cognitive impairment']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Hypomyelinating leukodystrophy features**: Optic disc pallor and abnormal visual/auditory evoked potentials indicate defective myelination of sensory pathways.  
2. **Motor dysfunction**: Spasticity, dystonia, poor gross motor coordination, and spastic ataxia align with cerebellar and corticospinal tract involvement due to hypomyelination.  
3. **Early-onset neurological deficits**: Infantile hypotonia progressing to spasticity, poor head control, and gastrostomy dependency reflect severe infantile-onset CNS dysfunction.  
4. **Oculomotor abnormalities**: Horizontal and rotary nystagmus suggest brainstem/cerebellar impairment, common in hypomyelinating disorders.  
5. **Cognitive and communication deficits**: Mutism and cognitive impairment correlate with widespread white matter pathology affecting higher cortical functions.  
6. **Genetic confirmation**: Autosomal recessive NKX6-2 mutations disrupt oligodendrocyte development, explaining the hypomyelination phenotype.  
7. **Rule-out**: Symptoms distinguish it from other leukodystrophies (e.g., PMD, 4H syndrome) via specific gene involvement and clinical progression."
"['Seizure', 'Hypomelanotic macule', 'Shagreen patch', 'Fibroma', 'Macule', 'Profound global developmental delay', 'Ungual fibroma']",['Tuberous sclerosis-1'],"Disease: Tuberous sclerosis-1  
Reasoning:  
1. **Seizures**: Common in tuberous sclerosis complex (TSC) due to cortical tubers or subependymal nodules disrupting brain function.  
2. **Hypomelanotic macules (ash leaf spots)**: A major diagnostic criterion for TSC, appearing as depigmented skin patches.  
3. **Shagreen patch**: A connective tissue nevus (typically on the lower back), a major diagnostic feature of TSC.  
4. **Ungual fibroma**: Fibrous growths around/under nails, a major diagnostic criterion when multiple are present.  
5. **Profound global developmental delay**: Linked to severe neurological involvement in TSC, often from cortical tubers or epilepsy burden.  
6. **Fibromas**: Benign tumors (e.g., facial angiofibromas) are hallmark lesions in TSC.  
7. **Macule**: General term; here, likely referencing hypomelanotic macules or other TSC-associated skin lesions.  

The combination of ≥2 major features (hypomelanotic macules, shagreen patch, ungual fibroma, seizures) and developmental delay strongly supports **TSC1** (mutations in the *TSC1* gene on chromosome 9q34), a subtype of tuberous sclerosis complex."
"['Hearing impairment', 'Bradycardia', 'Tachypnea', 'Prolonged QTc interval']",['Jervell and Lange-Nielsen syndrome/Jervell and Lange-Nielsen syndrome 1'],"Disease: Jervell and Lange-Nielsen syndrome 1  
Reasoning:  
1. **Hearing impairment**: Congenital bilateral sensorineural deafness is a hallmark of Jervell and Lange-Nielsen syndrome (JLNS), caused by mutations in *KCNQ1* or *KCNE1* genes affecting potassium channels in the inner ear.  
2. **Prolonged QTc interval**: JLNS disrupts cardiac potassium channels, delaying ventricular repolarization, leading to prolonged QTc (>500 ms), a diagnostic criterion for long QT syndrome type 1 (LQT1).  
3. **Bradycardia**: Abnormal cardiac repolarization in JLNS predisposes to arrhythmias, including sinus bradycardia or pauses, especially during rest or sleep.  
4. **Tachypnea**: May reflect autonomic instability, compensatory response to arrhythmia-induced hypoxia, or anxiety from syncopal episodes.  
5. **Exclusion of alternatives**: Romano-Ward syndrome (LQTS without deafness) and acquired causes (e.g., electrolyte imbalance) are ruled out by the presence of congenital deafness and genetic predisposition.  
6. **Syndrome alignment**: The triad of congenital deafness, prolonged QTc, and arrhythmias (bradycardia/tachycardia) strongly supports JLNS1 (*KCNQ1* mutation)."
"['Cryptorchidism', 'Micropenis', 'Microcephaly', 'Coarse facial features', 'Hypertelorism', 'Microcytic anemia', 'Osteosarcoma', 'Downturned corners of mouth', 'Intellectual disability, severe']","['Alpha-thalassemia-X-linked intellectual disability syndrome/Alpha-Thalassemia/mental retardation syndrome, X-linked']","Disease: Alpha-thalassemia-X-linked intellectual disability syndrome (ATRX syndrome)  
Reasoning:  
1. **Microcytic anemia**: Indicates alpha-thalassemia, a core feature of ATRX syndrome caused by mutations in the ATRX gene affecting hemoglobin synthesis.  
2. **Severe intellectual disability**: Matches the neurodevelopmental impairment characteristic of X-linked intellectual disability syndromes.  
3. **Cryptorchidism/Micropenis**: Consistent with genital anomalies seen in ATRX syndrome due to disrupted development of urogenital structures.  
4. **Facial dysmorphisms (coarse features, hypertelorism, downturned mouth)**: Hallmark craniofacial traits of ATRX syndrome, linked to abnormal neural crest cell migration.  
5. **Microcephaly**: Reflects impaired brain growth, common in syndromic intellectual disabilities.  
6. **Osteosarcoma**: Rare but reported in ATRX syndrome, as ATRX mutations predispose to genomic instability and tumorigenesis.  
7. **X-linked inheritance**: Male presentation aligns with the X-linked recessive pattern of ATRX syndrome.  

The constellation of alpha-thalassemia, neurodevelopmental deficits, genital anomalies, and dysmorphic features strongly supports this diagnosis."
"['Narrow mouth', 'Microcephaly', 'Posteriorly rotated ears', 'Prominent nose', 'Strabismus', 'Downslanted palpebral fissures', 'Long eyelashes', 'Thick eyebrow', 'Coloboma', 'Dental crowding', 'Dental malocclusion', 'Autistic behavior', 'Anxiety', 'Delayed speech and language development', 'Hirsutism', 'Global developmental delay', 'Intellectual disability, moderate', 'Highly arched eyebrow', 'Scoliosis', 'Delayed skeletal maturation', 'Feeding difficulties in infancy', 'Low hanging columella', 'Broad hallux', 'Keloids', 'Talon cusp', 'Broad thumb']",['Rubinstein-Taybi syndrome due to EP300 haploinsufficiency/Rubinstein-Taybi syndrome 2'],"Disease: Rubinstein-Taybi syndrome due to EP300 haploinsufficiency/Rubinstein-Taybi syndrome 2  
Reasoning:  
1. **Craniofacial features**: Narrow mouth, microcephaly, posteriorly rotated ears, prominent nose, downslanted palpebral fissures, long eyelashes, thick/highly arched eyebrows, and low-hanging columella align with the characteristic facial dysmorphism of Rubinstein-Taybi syndrome (RSTS).  
2. **Limb anomalies**: Broad hallux and broad thumb are hallmark signs of RSTS.  
3. **Dental abnormalities**: Dental crowding, malocclusion, and talon cusp are commonly reported in RSTS due to craniofacial and dental developmental defects.  
4. **Ocular findings**: Strabismus and coloboma (though less frequent) are consistent with ocular manifestations of RSTS.  
5. **Developmental delays**: Global developmental delay, moderate intellectual disability, delayed speech, and autistic behavior match the neurocognitive profile of RSTS.  
6. **Skeletal features**: Scoliosis and delayed skeletal maturation are recognized skeletal anomalies in RSTS.  
7. **Additional supportive signs**: Feeding difficulties in infancy, hirsutism, and keloids (less common but reported) further support the diagnosis.  
8. **Genetic correlation**: EP300 haploinsufficiency (RSTS type 2) explains the phenotype, as EP300 mutations cause overlapping features with CREBBP-associated RSTS (type 1), including distinct facial traits, broad digits, and neurodevelopmental delays. Talon cusp and keloids may be more prevalent in EP300-related cases."
"['Nystagmus', 'Hyperactivity', 'Dysmetria', 'Joint stiffness', 'Thrombocytopenia', 'Neutropenia', 'Gait imbalance', 'Postural instability', 'Lower limb hyperreflexia', 'Immunodeficiency', 'Myelodysplasia', 'Attention deficit hyperactivity disorder', 'Bronchiolitis']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Neurological features**: Nystagmus, dysmetria, gait imbalance, and postural instability are hallmark signs of **cerebellar ataxia**, a core component of APS. Lower limb hyperreflexia suggests possible pyramidal tract involvement, which can occur in APS due to myelodysplasia-related spinal cord dysfunction.  
2. **Hematological abnormalities**: Thrombocytopenia, neutropenia, and myelodysplasia directly align with the ""pancytopenia"" aspect of APS. Myelodysplasia (ineffective blood cell production) is a defining feature.  
3. **Immunodeficiency**: Neutropenia and myelodysplasia impair immune function, explaining recurrent infections like bronchiolitis.  
4. **ADHD**: While not a primary feature of APS, neurodevelopmental/behavioral issues may arise from cerebellar dysfunction or chronic illness burden.  
5. **Exclusion of mimics**: The combination of ataxia with pancytopenia is highly specific for APS over isolated ataxias (e.g., Friedreich’s) or hematologic disorders (e.g., aplastic anemia). Genetic testing for SAMD9L mutations would confirm APS."
"['Inguinal hernia', 'Jaundice', 'Global developmental delay', 'Hepatic steatosis', 'Growth abnormality', 'Hyperbilirubinemia', 'Hypercholesterolemia', 'Increased LDL cholesterol concentration', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating creatine kinase concentration', 'Prolonged neonatal jaundice', 'Decreased circulating ceruloplasmin concentration', 'Abnormal protein N-linked glycosylation', 'Copper accumulation in liver', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration', 'Hernia']","['Congenital disorder of glycosylation, type IIP', 'TMEM199-CDG']","Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Abnormal protein N-linked glycosylation** is a hallmark of congenital disorders of glycosylation (CDG), specifically type II defects, which involve impaired processing of glycans.  
2. **Hepatic steatosis, elevated liver enzymes (AST/ALT), hyperbilirubinemia, and prolonged neonatal jaundice** indicate severe liver dysfunction. TMEM199-CDG is associated with chronic liver disease, including copper accumulation due to disrupted biliary excretion.  
3. **Decreased ceruloplasmin** aligns with defective glycosylation, as ceruloplasmin requires proper glycosylation for stability and secretion.  
4. **Hypercholesterolemia and elevated LDL** are common in TMEM199-CDG due to altered lipid metabolism linked to hepatic impairment.  
5. **Global developmental delay and growth abnormalities** reflect systemic consequences of glycosylation defects, impacting neurological and somatic development.  
6. **Hernias** (inguinal/other) may result from connective tissue weakness caused by improper glycosylation of structural proteins.  
7. **Elevated alkaline phosphatase and creatine kinase** suggest multi-organ involvement (liver, bone, muscle), consistent with TMEM199-CDG’s phenotype.  

*Note: ""Congenital disorder of glycosylation, type IIP"" and ""TMEM199-CDG"" refer to the same disease, with the latter specifying the genetic cause (TMEM199 mutation).*"
"['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Syndactyly', 'Intellectual disability', 'Hypotonia', 'Mitral valve prolapse', 'Short foot', 'Unsteady gait', 'Delayed ability to walk']","['Mental retardation, autosomal recessive 38', 'Developmental delay with autism spectrum disorder and gait instability']","Disease: Mental retardation, autosomal recessive 38  
Reasoning: This autosomal recessive disorder is linked to intellectual disability and developmental delays, aligning with the patient’s intellectual disability, delayed speech, and hypotonia. Syndactyly and short foot may reflect skeletal anomalies occasionally associated with recessive intellectual disability syndromes. Hypotonia contributes to delayed walking, while mitral valve prolapse, though atypical, could occur as a variable feature or comorbid finding.  

Disease: Developmental delay with autism spectrum disorder and gait instability  
Reasoning: The patient’s abnormal repetitive mannerisms align with autism spectrum disorder. Developmental delays (speech, walking) and gait instability are core features of this diagnosis. Hypotonia exacerbates motor delays and unsteady gait. Mitral valve prolapse and syndactyly are less directly explained but may represent phenotypic variability or secondary manifestations of neuromuscular dysfunction."
"['Abnormality of the dentition', 'Hypertelorism', 'Low-set ears', 'Bifid nasal tip', 'Downslanted palpebral fissures', 'Ptosis', 'Sprengel anomaly', 'Brachydactyly', '2-3 finger syndactyly', 'Agenesis of corpus callosum', 'Specific learning disability', 'Craniosynostosis', 'Ridged nail', 'Clinodactyly of the 5th finger', 'Coronal craniosynostosis', 'Unilateral cryptorchidism', 'Thick hair']",['Craniofrontonasal dysplasia/Craniofrontonasal syndrome'],"Disease: Craniofrontonasal dysplasia/Craniofrontonasal syndrome  
Reasoning:  
1. **Craniosynostosis** (coronal suture involvement): A hallmark of CFND, explaining the patient’s ""Craniosynostosis"" and ""Coronal craniosynostosis.""  
2. **Facial dysmorphism**:  
   - **Hypertelorism**, **bifid nasal tip**, **downslanted palpebral fissures**, and **ptosis** are classic facial features of CFND.  
   - **Low-set ears** further supports craniofacial abnormalities.  
3. **Limb/skeletal anomalies**:  
   - **Sprengel anomaly** (elevated scapula), **brachydactyly**, **2-3 finger syndactyly**, and **clinodactyly of the 5th finger** align with CFND-associated skeletal defects.  
   - **Ridged nails** are a reported feature.  
4. **Neurological/developmental**: **Agenesis of corpus callosum** and **specific learning disability** correlate with CFND’s variable neurodevelopmental involvement.  
5. **Other features**: **Unilateral cryptorchidism** and **abnormality of the dentition** (e.g., delayed eruption, supernumerary teeth) are consistent with CFND.  
6. **Thick hair** is a less specific but occasionally noted trait.  
The combination of craniofacial, skeletal, and neurological findings distinguishes CFND from other craniosynostosis syndromes (e.g., Apert, Crouzon), which lack syndactyly, hypertelorism, or corpus callosum anomalies."
"['Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Abnormality of the outer ear', 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Single transverse palmar crease', 'Cafe-au-lait spot', 'Hypertrichosis', 'Brachydactyly', 'Syndactyly', 'Seizure', 'Hypotonia', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar vermis hypoplasia', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Annular pancreas', 'Small nail', 'Hypoglycemia', 'Abnormal facial shape', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Intellectual disability, moderate', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Temperature instability', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Broad thumb', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental features**: Symptoms like *moderate intellectual disability*, *hyperactivity*, *attention deficit hyperactivity disorder (ADHD)*, and *atypical behavior* align with the neurodevelopmental core of NEDBEH.  
2. **Brain anomalies**: Structural CNS abnormalities such as *cerebellar vermis hypoplasia*, *CNS hypomyelination*, *hypoplasia of the corpus callosum*, and *ventriculomegaly* directly match the ""brain anomalies"" criterion.  
3. **Eye anomalies**: Multiple ocular findings (*coloboma*, *microphthalmia*, *blepharophimosis*, *optic atrophy*, *Peters anomaly*, *abnormality of iris morphology*) satisfy the ""eye"" component.  
4. **Cardiac defects**: *Ventricular septal defect*, *patent ductus arteriosus*, *patent foramen ovale*, and *anomalous pulmonary venous return* fulfill the ""heart"" criterion.  
5. **Supportive systemic features**:  
   - Growth issues (*intrauterine growth retardation*, *short stature*, *growth delay*) and craniofacial dysmorphism (*triangular face*, *micrognathia*, *high palate*, *cleft lip*) are common in NEDBEH.  
   - Additional congenital anomalies (*choanal atresia*, *duodenal atresia*, *annular pancreas*) and neurological signs (*hypotonia*, *seizures*, *spastic tetraparesis*) reinforce multisystem involvement.  
6. **Exclusion of mimics**: Overlapping features with syndromes like CHARGE or chromosomal disorders are ruled out by the absence of pathognomonic signs (e.g., absent CHARGE coloboma-choanal atresia triad) and the broad spectrum of NEDBEH-specific gene associations (e.g., *BRPF1*, *KAT6B*).  

The combination of neurodevelopmental delay, brain malformations, ocular defects, and congenital heart anomalies provides a definitive match for NEDBEH."
"['Wide mouth', 'Abnormality of the gingiva', 'Thin upper lip vermilion', 'Coarse facial features', 'Full cheeks', 'Hypertelorism', 'Short philtrum', 'Prominent supraorbital ridges', 'Narrow forehead', 'Long philtrum', 'Micrognathia', 'Otitis media', 'Broad nasal tip', 'Anteverted nares', 'Torticollis', 'Strabismus', 'Deeply set eye', 'Proptosis', 'Hypermetropia', 'Myopia', 'Widely spaced teeth', 'Pectus carinatum', 'Hirsutism', 'Abnormally large globe', 'Seizure', 'Global developmental delay', 'Hypertonia', 'Plagiocephaly', 'Failure to thrive', 'Short foot', 'Frontal bossing', 'Constipation', 'Gastroesophageal reflux', 'Spastic gait', 'Febrile seizure (within the age range of 3 months to 6 years)', 'Abnormal cerebral white matter morphology', 'Tracheomalacia', 'Short nasal bridge', 'Skeletal muscle atrophy', 'Bruxism', 'Clinodactyly of the 5th finger', 'Short stature', 'Depressed nasal bridge', 'Sparse lateral eyebrow', 'Proximal spinal muscular atrophy', 'Spinal muscular atrophy', 'Proximal placement of thumb', 'Narrow naris', ""Absent cupid's bow"", 'Stereotypical hand wringing', 'Thick vermilion border', 'Small hand', 'Hyperplasia of the maxilla']",['Intellectual disability-seizures-abnormal gait-facial dysmorphism syndrome/Skraban-Deardorff syndrome'],"Disease: Intellectual disability-seizures-abnormal gait-facial dysmorphism syndrome/Skraban-Deardorff syndrome  
Reasoning:  
1. **Facial Dysmorphism**: Key features align with Skraban-Deardorff syndrome, including *wide mouth*, *hypertelorism*, *broad nasal tip*, *thick vermilion border*, *full cheeks*, *short philtrum*, *prominent supraorbital ridges*, and *hyperplasia of the maxilla*. These collectively create a distinct facial gestalt.  
2. **Neurological Manifestations**: *Global developmental delay*, *seizures* (including *febrile seizures*), *hypertonia*, *spastic gait*, and *abnormal cerebral white matter morphology* are hallmark neurological findings in this syndrome.  
3. **Musculoskeletal Abnormalities**: *Pectus carinatum*, *clinodactyly of the 5th finger*, *short stature*, and *small hand* correlate with skeletal anomalies reported in the syndrome. *Spinal muscular atrophy* and *skeletal muscle atrophy* may reflect secondary neuromuscular involvement.  
4. **Systemic Features**: *Failure to thrive*, *gastroesophageal reflux*, and *tracheomalacia* are consistent with systemic dysregulation seen in Skraban-Deardorff.  
5. **Ocular and Dental Findings**: *Hypermetropia*, *proptosis*, *deeply set eyes*, and *widely spaced teeth* further support the diagnosis, as ocular and dental anomalies are common.  
6. **Developmental and Behavioral Traits**: *Stereotypical hand wringing* and *bruxism* align with neurodevelopmental patterns observed in the syndrome.  
7. **Genetic Overlap**: While genetic testing (e.g., *WDR26* mutations) would confirm, the phenotypic overlap (facial, neurological, skeletal) strongly points to this diagnosis over mimics like Coffin-Siris or Rett syndrome.  

This constellation of facial, neurological, and systemic features, alongside developmental delays and seizures, is pathognomonic for Skraban-Deardorff syndrome."
"['High palate', 'Anteverted nares', 'Webbed neck', 'Short neck', 'Downslanted palpebral fissures', 'Ptosis', 'Hyperkeratosis', 'Seizure', 'Atrial septal defect', 'Pulmonic stenosis', 'Relative macrocephaly', 'Depressed nasal bridge', 'Ichthyosis', 'Sparse hair', 'Underdeveloped supraorbital ridges', 'Intellectual disability, severe']",['Cardiofaciocutaneous syndrome/Cardiofaciocutaneous syndrome 1'],"Disease: Cardiofaciocutaneous syndrome/Cardiofaciocutaneous syndrome 1  
Reasoning:  
1. **Cardiac anomalies**: Atrial septal defect (ASD) and pulmonic stenosis are hallmark features of CFC syndrome, aligning with its ""cardio"" component.  
2. **Facial dysmorphism**: Downslanted palpebral fissures, ptosis, depressed nasal bridge, underdeveloped supraorbital ridges, and anteverted nares are characteristic craniofacial findings in CFC.  
3. **Cutaneous manifestations**: Hyperkeratosis, ichthyosis, and sparse hair reflect the ""cutaneous"" aspect, common in CFC due to RAS/MAPK pathway mutations (e.g., BRAF, MAP2K1/2).  
4. **Neurological involvement**: Severe intellectual disability and seizures correlate with CFC’s neurodevelopmental and epileptic phenotypes.  
5. **Growth/structural features**: Relative macrocephaly, short/webbed neck, and high palate further support CFC, differentiating it from Noonan or Costello syndromes (less prominent keratotic skin changes).  
6. **Exclusion of mimics**: Absence of lymphatic dysplasia (vs. Noonan) or papillomas/loose skin (vs. Costello) reinforces CFC. Genetic testing for BRAF/MAP2K1/2 variants would confirm the diagnosis."
"['Microcephaly', 'Emotional lability', 'Delayed speech and language development', 'Cerebellar vermis hypoplasia', 'Overlapping toe', 'Hypoplasia of the corpus callosum', 'Polymicrogyria', 'Short stature', 'Decreased body weight', 'Neurodevelopmental delay']","['Microcephalic cortical malformations-short stature due to RTTN deficiency/Microcephaly, short stature, and polymicrogyria with or without seizures']","Disease: Microcephalic cortical malformations-short stature due to RTTN deficiency/Microcephaly, short stature, and polymicrogyria with or without seizures  
Reasoning:  
1. **Microcephaly**: A hallmark feature of RTTN deficiency, caused by defective neuronal migration and cortical development.  
2. **Polymicrogyria**: Cortical malformation directly linked to RTTN mutations, disrupting gyral patterning during brain development.  
3. **Cerebellar vermis hypoplasia & Hypoplasia of the corpus callosum**: RTTN is critical for ciliary function and midline brain structure formation, explaining these anomalies.  
4. **Short stature/Decreased body weight**: Growth retardation is common in RTTN deficiency, likely due to systemic ciliopathy effects.  
5. **Neurodevelopmental delay/Emotional lability/Delayed speech**: Consistent with widespread cerebral and cerebellar dysgenesis.  
6. **Overlapping toe**: A subtle dysmorphic feature occasionally reported in ciliopathies, supporting RTTN’s role in ciliary signaling.  
The combination of cortical malformations (polymicrogyria), microcephaly, growth deficits, and midline brain defects aligns pathognomonically with RTTN deficiency, a autosomal recessive ciliopathy."
"['Delayed speech and language development', 'Global developmental delay', 'Bilateral tonic-clonic seizure', 'Frontal polymicrogyria']","['Bilateral frontoparietal polymicrogyria/Polymicrogyria, bilateral frontoparietal']","Disease: Bilateral frontoparietal polymicrogyria  
Reasoning:  
1. **Frontal polymicrogyria** is a hallmark feature, aligning with the brain malformation pattern seen in BFPP. The bilateral frontoparietal localization is pathognomonic.  
2. **Global developmental delay** and **delayed speech/language development** correlate with disrupted cortical organization in frontal and parietal regions, critical for cognitive and language functions.  
3. **Bilateral tonic-clonic seizures** are common due to abnormal cortical architecture predisposing to epileptogenic activity.  
4. BFPP is genetically linked to *ADGRG1* mutations, which disrupt neuronal migration and cortical layering. While genetic confirmation is ideal, the symptomatology and imaging findings strongly support this diagnosis over other polymicrogyria subtypes (e.g., perisylvian), which lack frontoparietal predominance."
"['Abnormality of the genitourinary system', 'Abnormality of the nervous system', 'Growth delay', 'Pancytopenia', 'Immunodeficiency', 'Bone marrow hypocellularity', 'Short telomere length']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Ataxia-pancytopenia syndrome (APS):  
- **Pancytopenia & bone marrow hypocellularity**: Core features of APS, reflecting bone marrow failure.  
- **Nervous system abnormality**: Likely cerebellar ataxia, a hallmark of APS.  
- **Short telomere length**: APS is linked to germline SAMD9/SAMD9L mutations, which disrupt telomere stability.  
- **Immunodeficiency**: Bone marrow failure predisposes to recurrent infections.  
- **Growth delay & genitourinary anomalies**: Seen in APS due to systemic effects of telomere dysfunction and/or SAMD9L-related developmental defects.  
- **Exclusion of mimics**: Dyskeratosis congenita (similar telomere defects but mucocutaneous triad absent), Fanconi anemia (chromosomal breaks typical, not seen here)."
"['Nyctalopia', 'Visual field defect', 'Reduced visual acuity', 'Bone spicule pigmentation of the retina']",['Retinitis pigmentosa 27'],"Disease: Retinitis pigmentosa 27  
Reasoning:  
1. **Nyctalopia**: A hallmark symptom of retinitis pigmentosa (RP), indicating rod photoreceptor dysfunction, which is critical for low-light vision.  
2. **Visual field defect**: Progressive peripheral vision loss (""tunnel vision"") aligns with RP's characteristic retinal degeneration pattern.  
3. **Reduced visual acuity**: Occurs in later stages as cone photoreceptors (central vision) become affected.  
4. **Bone spicule pigmentation**: Pathognomonic retinal finding caused by pigment migration into the retina, typical of RP.  
5. **RP27 subtype**: Linked to mutations in the *NRL* gene (autosomal recessive), which regulates rod photoreceptor development. Genetic testing would confirm this specific subtype."
"['Renal cyst', 'Rod-cone dystrophy', 'Abnormal electroretinogram', 'Absent eyelashes', 'Abnormality of visual evoked potentials', 'Brachydactyly', 'Intellectual disability', 'Craniosynostosis', 'Alopecia', 'Absent eyebrow', 'Short stature', 'Ichthyosis', 'Severe global developmental delay', 'Feeding difficulties']",['Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies'],"Disease: Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies  
Reasoning:  
1. **Brachydactyly and Short Stature**: Core skeletal features of the syndrome, directly aligning with its diagnostic nomenclature.  
2. **Rod-Cone Dystrophy (Retinitis Pigmentosa)**: Confirmed by abnormal electroretinogram and visual evoked potential abnormalities, hallmark signs of retinal degeneration.  
3. **Ectodermal Abnormalities**: Absent eyelashes/eyebrows, alopecia, and ichthyosis suggest ectodermal dysplasia, which may occur in syndromic forms of retinitis pigmentosa.  
4. **Developmental and Intellectual Deficits**: Severe global developmental delay and intellectual disability are consistent with the syndrome’s potential neurodevelopmental involvement.  
5. **Renal Cyst**: May reflect broader systemic manifestations, as ciliopathies (often linked to retinal-skeletal syndromes) can involve renal pathology.  
6. **Craniosynostosis**: Though atypical for classic presentations, it could represent phenotypic variability or a rare association in severe cases.  
7. **Feeding Difficulties**: Commonly secondary to developmental delay or neuromuscular dysfunction in multisystem genetic disorders.  

The diagnosis is anchored by the triad of brachydactyly, short stature, and retinitis pigmentosa, with additional features reflecting the syndrome’s phenotypic spectrum."
"['Resting tremor', 'Limb dystonia', 'Falls', 'Abnormal autonomic nervous system physiology', 'Cognitive impairment']","['Parkinson disease 23, autosomal recessive early-onset']","Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Resting tremor**: Common in Parkinsonian disorders, though less prominent in early-onset genetic forms. Supports Parkinsonism.  
2. **Limb dystonia**: A hallmark of ATP13A2-associated PARK23, often presenting as early-onset focal dystonia (e.g., hand/foot posturing).  
3. **Falls**: Reflects early postural instability and rapid disease progression, atypical in idiopathic Parkinson’s but seen in PARK23 due to pyramidal/non-motor involvement.  
4. **Autonomic dysfunction**: ATP13A2 mutations disrupt lysosomal/autophagy processes, causing dysautonomia (e.g., orthostatic hypotension, urinary issues).  
5. **Cognitive impairment**: Early cognitive decline aligns with PARK23’s association with Kufor-Rakeb syndrome, which includes dementia and supranuclear gaze palsy.  
**Genetic link**: Autosomal recessive inheritance (ATP13A2 mutations) explains early-onset presentation (often <40 years) and multisystem neurodegeneration."
"['Aggressive behavior', 'Dementia', 'Memory impairment']",['Alzheimer disease 4'],"Alzheimer disease 4:  
The patient exhibits **memory impairment** and **dementia**, core features of Alzheimer disease (AD). **Aggressive behavior** aligns with neuropsychiatric symptoms seen in AD, particularly in progressive stages. Alzheimer disease 4 (AD4) is linked to mutations in the *PSEN1* gene, associated with early-onset autosomal dominant AD. While age is unspecified here, the triad of cognitive decline, memory deficits, and behavioral changes—especially in a familial or early-onset context—supports AD4. Differential diagnoses like frontotemporal dementia (FTD) are less likely without prominent language/motor features. Genetic testing for *PSEN1* would confirm AD4."
"['High palate', 'Long philtrum', 'Blue sclerae', 'Hyperextensible skin', 'Bruising susceptibility', 'Striae distensae', 'Ectopia lentis', 'Joint hypermobility', 'Mitral valve prolapse', 'Scoliosis', 'Arterial tortuosity', 'Short uvula', 'Chronic pain', 'Dural ectasia', 'Hernia']",['Loeys-Dietz syndrome 4'],"Disease: Loeys-Dietz syndrome 4  
Reasoning:  
1. **Arterial tortuosity** and **mitral valve prolapse** suggest vascular connective tissue abnormalities, a hallmark of Loeys-Dietz syndrome (LDS).  
2. **High palate**, **long philtrum**, and **short uvula** align with craniofacial features seen in LDS type 4 (SMAD3-related), which often includes orofacial anomalies.  
3. **Hyperextensible skin**, **striae distensae**, **joint hypermobility**, and **hernia** indicate systemic connective tissue fragility, consistent with LDS.  
4. **Dural ectasia** and **scoliosis** reflect skeletal and spinal connective tissue involvement, common in LDS.  
5. **Ectopia lentis** (lens dislocation) and **blue sclerae** suggest ocular connective tissue defects, observed in some LDS subtypes.  
6. **Chronic pain** and **bruising susceptibility** correlate with vascular and tissue fragility in LDS.  
7. LDS type 4 (SMAD3 mutation) is distinguished by **aortic/arterial tortuosity**, craniofacial features, and overlapping Ehlers-Danlos-like symptoms, differentiating it from Marfan syndrome or vascular EDS."
"['Nystagmus', 'Ataxia', 'Dysarthria', 'Anemia', 'Gait ataxia', 'Bone marrow hypocellularity']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Ataxia-pancytopenia syndrome: The patient exhibits **nystagmus**, **ataxia**, **dysarthria**, and **gait ataxia**, indicating cerebellar dysfunction. Concurrent **anemia** and **bone marrow hypocellularity** suggest pancytopenia due to impaired hematopoiesis. Ataxia-pancytopenia syndrome (APS) is a rare genetic disorder characterized by cerebellar degeneration and bone marrow failure, aligning with this symptom constellation. The triad of neurological deficits, cytopenias, and hypocellular marrow distinguishes APS from isolated cerebellar ataxias or acquired hematologic disorders."
"['Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Visual impairment', 'Seizure', 'Cerebellar vermis hypoplasia', 'Hypoplasia of the corpus callosum', 'Respiratory insufficiency', 'Ventriculomegaly', ""Exaggerated cupid's bow"", 'EEG abnormality', 'Highly arched eyebrow', 'Peripheral axonal neuropathy', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial Dysmorphism**: ""Narrow forehead,"" ""Prominent nasal bridge,"" ""Anteverted nares,"" ""Exaggerated cupid's bow,"" and ""Highly arched eyebrow"" align with the characteristic facies of TBCK syndrome, which includes midface hypoplasia and distinct lip morphology.  
2. **Neurological Abnormalities**: ""Cerebellar vermis hypoplasia,"" ""Hypoplasia of the corpus callosum,"" and ""Small basal ganglia"" are consistent with brain malformations reported in TBCK-related disorders. ""Ventriculomegaly"" further supports structural CNS involvement.  
3. **Developmental and Motor Deficits**: ""Profound global developmental delay"" and ""Peripheral axonal neuropathy"" correlate with the syndrome’s hallmark hypotonia, psychomotor retardation, and progressive neurological decline.  
4. **Seizures/EEG Abnormalities**: ""Seizure"" and ""EEG abnormality"" match the epileptic phenotypes observed in TBCK patients, often linked to cortical dysfunction.  
5. **Systemic Involvement**: ""Feeding difficulties"" and ""Respiratory insufficiency"" reflect the multisystem impact of TBCK mutations, including bulbar weakness and respiratory muscle compromise.  
6. **Ocular and Genetic Consistency**: ""Visual impairment"" may stem from cortical or optic nerve abnormalities, while the genetic basis (biallelic TBCK loss) explains the syndromic clustering of these features.  
**Conclusion**: The constellation of craniofacial, neurological, and systemic findings strongly supports a diagnosis of TBCK-related intellectual disability syndrome."
"['Abnormality of the kidney', 'Overfolded helix', 'Macrotia', 'Choanal atresia', 'Abnormality of the eye', 'Strabismus', 'Visual impairment', 'Hypermetropia', 'Upslanted palpebral fissure', 'Delayed speech and language development', '11 pairs of ribs', 'Brachydactyly', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Obesity', 'Atrial septal defect', 'Short foot', 'Asthma', 'Scoliosis', 'Tracheomalacia', 'Hypoventilation', 'Short stature', 'Preauricular pit', 'Central hypoventilation', 'Abnormal eye morphology', 'Abnormality of brain morphology', 'Hyperconvex toenail', 'Cerebral visual impairment', 'Small hand', 'Menometrorrhagia']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart  
Reasoning:  
1. **Neurodevelopmental features**: Global developmental delay, delayed speech and language development, hypotonia, and cerebral visual impairment align with core neurodevelopmental deficits.  
2. **Brain morphology abnormality**: Hypotonia, central hypoventilation, and cerebral visual impairment suggest central nervous system involvement.  
3. **Eye anomalies**: Visual impairment, strabismus, hypermetropia, abnormal eye morphology, and upslanted palpebral fissures indicate structural and functional ocular defects.  
4. **Cardiac involvement**: Atrial septal defect directly correlates with the ""heart"" component of the diagnosis.  
5. **Craniofacial/skeletal features**: Overfolded helix, macrotia, preauricular pit, brachydactyly, short foot, small hand, and 11 pairs of ribs reflect multisystem congenital anomalies typical of syndromic neurodevelopmental disorders.  
6. **Systemic associations**: Obesity, short stature, tracheomalacia, and choanal atresia further support a genetic syndrome affecting multiple organ systems.  
7. **Exclusion of alternatives**: The constellation of symptoms (e.g., absence of pathognomonic signs for Rett, Down, or CHARGE syndromes) and the specificity of brain-eye-heart anomalies prioritize this diagnosis."
"['High palate', 'Microcephaly', 'Macrotia', 'Sensorineural hearing impairment', 'Convex nasal ridge', 'Deeply set eye', 'Microphthalmia', 'Large hands', 'Intellectual disability', 'Cerebellar hypoplasia', 'Scoliosis', 'Thickened calvaria', 'Kyphosis', 'Limb joint contracture', 'Short stature', 'Bilateral intracerebral calcifications', 'Postnatal growth retardation', 'Nasogastric tube feeding in infancy']","['Cockayne syndrome, type B']","Disease: Cockayne syndrome, type B  
Reasoning:  
1. **Neurological/Craniofacial Features**: Microcephaly, intellectual disability, cerebellar hypoplasia, and bilateral intracerebral calcifications are hallmark neurological signs of Cockayne syndrome (CS). Sensorineural hearing impairment and microphthalmia/deeply set eyes align with CS-related sensory deficits.  
2. **Growth Abnormalities**: Postnatal growth retardation, short stature, and nasogastric tube feeding in infancy reflect severe growth failure, characteristic of CS type B.  
3. **Skeletal Dysplasia**: Scoliosis, kyphosis, limb joint contractures, and thickened calvaria correlate with CS-associated skeletal dysplasia and premature aging.  
4. **Dysmorphic Features**: High palate, convex nasal ridge, and macrotia are consistent with CS type B’s craniofacial phenotype.  
5. **Exclusion of Mimics**: Differentiated from type A (more severe, earlier onset) and type C (atypical presentation) by partial postnatal development and later symptom progression. Intracerebral calcifications and cerebellar hypoplasia distinguish CS from other progeroid disorders (e.g., Hutchinson-Gilford progeria)."
"['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Seizure', 'Hypotonia', 'Hypoplasia of the corpus callosum', 'Delayed CNS myelination', 'EEG abnormality', 'Developmental regression', 'Inability to walk', 'Bruxism', 'Secondary microcephaly', 'Hypoplasia of the frontal lobes']","['Rett syndrome, congenital variant']","Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Developmental regression**: A hallmark of Rett syndrome, though the congenital variant often lacks the classic period of normal development before regression.  
2. **Secondary microcephaly**: Reflects postnatal slowing of head growth, consistent with Rett-associated neurological degeneration.  
3. **Seizures and EEG abnormality**: Common in Rett due to cortical hyperexcitability and disrupted neuronal connectivity.  
4. **Hypoplasia of the corpus callosum and frontal lobes**: Aligns with FOXG1-related congenital Rett variant, which disrupts forebrain development.  
5. **Delayed CNS myelination**: Supports a neurodevelopmental disorder affecting white matter maturation.  
6. **Hypotonia and inability to walk**: Indicates severe motor dysfunction, typical of early-onset/congenital forms.  
7. **Bruxism and repetitive mannerisms**: Stereotypic movements are classic in Rett spectrum disorders.  
8. **Delayed speech/development**: Reflects global neurodevelopmental impairment.  
*Conclusion*: The constellation of structural brain anomalies, regression, microcephaly, and movement abnormalities strongly suggests a FOXG1-related congenital Rett variant rather than classic MECP2-linked Rett syndrome."
"['Micropenis', 'Wide mouth', 'Gingival overgrowth', 'Macrocephaly', 'Hypertelorism', 'Low-set ears', 'Anteverted nares', 'Proptosis', 'Missing ribs', 'Frontal bossing', 'Thoracolumbar scoliosis', 'Hypoplasia of the radius', 'Hypoplasia of the ulna', 'Acromesomelia', 'Short stature', 'Depressed nasal bridge', 'Lumbar hemivertebrae', 'Tented upper lip vermilion', 'Retractile testis', 'Small hand']","['Autosomal recessive Robinow syndrome/Robinow syndrome, autosomal recessive']","Disease: Autosomal recessive Robinow syndrome/Robinow syndrome, autosomal recessive  
Reasoning:  
1. **Craniofacial Features**: Macrocephaly, hypertelorism, depressed nasal bridge, anteverted nares, tented upper lip vermilion, wide mouth, and gingival overgrowth align with the characteristic ""fetal facies"" of Robinow syndrome.  
2. **Skeletal Abnormalities**: Hypoplasia of the radius/ulna, acromesomelia, small hands, missing ribs, thoracolumbar scoliosis, lumbar hemivertebrae, and short stature reflect severe mesomelic limb shortening and vertebral defects, hallmark features of the autosomal recessive subtype.  
3. **Genitourinary Findings**: Micropenis and retractile testis are consistent with genital hypoplasia, a key diagnostic criterion.  
4. **Exclusion of Milder Forms**: The severity of skeletal defects (e.g., rib absence, marked limb hypoplasia) and pronounced craniofacial dysmorphism differentiate it from autosomal dominant Robinow syndrome, which typically has milder manifestations.  
5. **Consistency with Known Phenotype**: The combination of craniofacial, skeletal, and genital anomalies matches the triad defining Robinow syndrome, with the specific pattern confirming the autosomal recessive variant."
"['Hypospadias', 'Bifid scrotum', 'Micropenis', 'Ambiguous genitalia', 'Low-set ears', 'Atopic dermatitis', 'Hypocholesterolemia', 'Short nose', 'Elevated 8-dehydrocholesterol', '2-3 toe syndactyly', 'Decreased testicular size', 'Elevated 7-dehydrocholesterol', 'Abnormal circulating testosterone concentration']",['Smith-Lemli-Opitz syndrome/Smith-Lemli-Opitz syndrome'],"Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol Synthesis Defect**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol confirm a block in cholesterol biosynthesis due to DHCR7 enzyme deficiency, a hallmark of SLOS.  
2. **Genital Abnormalities**: Hypospadias, bifid scrotum, micropenis, ambiguous genitalia, and decreased testicular size align with SLOS-associated urogenital malformations and impaired steroidogenesis.  
3. **Craniofacial Features**: Short nose and low-set ears are classic dysmorphic traits in SLOS.  
4. **Limb Anomalies**: 2-3 toe syndactyly is a pathognomonic feature of SLOS.  
5. **Biochemical Markers**: Hypocholesterolemia and abnormal testosterone levels reflect disrupted cholesterol-dependent processes (e.g., hormone synthesis).  
6. **Dermatologic Manifestation**: Atopic dermatitis correlates with skin barrier dysfunction due to cholesterol deficiency.  
The constellation of biochemical, structural, and clinical findings is diagnostic for Smith-Lemli-Opitz syndrome."
"['Hypogonadism', 'Strabismus', 'Optic disc pallor', 'Nyctalopia', 'Obesity', 'Reduced visual acuity']",['Bardet-Biedl syndrome 5'],"Disease: Bardet-Biedl syndrome 5  
Reasoning:  
1. **Obesity**: A primary diagnostic criterion for Bardet-Biedl syndrome (BBS), commonly present from early childhood.  
2. **Hypogonadism**: Frequently observed in BBS due to hypothalamic-pituitary-gonadal axis dysfunction.  
3. **Nyctalopia, Reduced visual acuity, Optic disc pallor**: Indicate retinal dystrophy (e.g., rod-cone dystrophy), a hallmark of BBS. Nyctalopia is an early symptom, progressing to severe vision loss.  
4. **Strabismus**: Occurs in BBS due to ocular developmental anomalies or secondary to retinal dysfunction.  
5. **Genetic subtype specificity**: BBS5 (caused by *BBS5* gene mutations) aligns with the clinical phenotype, as retinal degeneration and obesity are consistent across BBS subtypes, though polydactyly or renal anomalies (common in BBS) may not always be reported.  
6. **Exclusion of mimics**: Differentiated from Alström syndrome (lack of hearing loss) and Laurence-Moon syndrome (less prominent obesity)."
"['Open mouth', 'High palate', 'Dolichocephaly', 'Protruding ear', 'Ptosis', 'Long palpebral fissure', 'Nystagmus', 'Global developmental delay', 'Motor delay', 'Neonatal hypotonia', 'Muscle weakness', 'Severe failure to thrive', 'Hypernasal speech', 'Polyphagia', 'Scoliosis', 'Gowers sign', 'Tented upper lip vermilion', 'Weakness of facial musculature']","['Myasthenic syndrome, congenital, 22']","Disease: Myasthenic syndrome, congenital, 22  
Reasoning:  
1. **Neuromuscular Symptoms**: Neonatal hypotonia, muscle weakness, Gowers sign, and facial musculature weakness align with congenital myasthenic syndromes (CMS), which impair neuromuscular transmission.  
2. **Developmental Delays**: Global developmental delay and motor delay are consistent with CMS-related muscle dysfunction affecting milestones.  
3. **Craniofacial Features**: High palate, dolichocephaly, protruding ears, tented upper lip, ptosis, and long palpebral fissures suggest a genetic syndrome with craniofacial dysmorphism, often seen in CMS subtypes.  
4. **Speech and Feeding Issues**: Hypernasal speech (due to velopharyngeal insufficiency) and severe failure to thrive (from neonatal hypotonia affecting feeding) are hallmarks of CMS.  
5. **Ocular and Autonomic Signs**: Nystagmus and ptosis point to neuromuscular junction defects impacting extraocular muscles.  
6. **Genetic Correlation**: CMS22 (linked to *SLC5A7* mutations) presents with hypotonia, facial weakness, feeding difficulties, and characteristic facial features, strongly matching the symptom profile.  
7. **Exclusion of Overlap**: Polyphagia and scoliosis are atypical but may arise secondary to chronic muscle weakness or compensatory metabolic adaptations.  

The constellation of congenital hypotonia, craniofacial anomalies, and neuromuscular deficits specifically aligns with CMS22, distinguishing it from other CMS subtypes or myopathies."
"['Abnormality of the genitourinary system', 'Entropion', 'Cutis laxa', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Abnormal heart morphology', 'Abnormal facial shape', 'Pneumothorax', 'Vascular dilatation', 'Kyphoscoliosis', 'Aortic aneurysm']","['Cutis laxa, autosomal recessive, type IIC']","Disease: Cutis laxa, autosomal recessive, type IIC  
Reasoning: The patient presents with cutis laxa, a hallmark of this disorder, alongside multisystemic manifestations. Generalized hypotonia and flexion contractures align with neuromuscular involvement. Kyphoscoliosis and hip dysplasia reflect skeletal abnormalities tied to connective tissue defects. Vascular dilatation, aortic aneurysm, and pneumothorax indicate severe vascular and pulmonary fragility, characteristic of ATP6V0A2 gene mutations. Abnormal heart morphology and facial shape, entropion, and genitourinary anomalies further support systemic connective tissue dysfunction. Disproportionate tall stature may arise from skeletal disproportions rather than growth acceleration, consistent with ARCL2C's phenotypic spectrum. This constellation of symptoms, particularly the combination of cutaneous, vascular, skeletal, and developmental features, strongly points to autosomal recessive cutis laxa type IIC."
"['Lymphopenia', 'Pneumonia', 'Decreased circulating IgA level', 'Reduced red cell adenosine deaminase level', 'Decreased lymphocyte proliferation in response to mitogen', 'Decreased proportion of CD4-positive T cells']","['Severe combined immunodeficiency due to adenosine deaminase deficiency/Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency']","Disease: Severe combined immunodeficiency due to adenosine deaminase deficiency  
Reasoning:  
1. **Reduced red cell adenosine deaminase (ADA) level**: This is a hallmark biochemical finding in ADA-deficient SCID, as ADA is critical for purine metabolism. Its deficiency leads to toxic metabolite accumulation (dATP), impairing lymphocyte development and function.  
2. **Lymphopenia**: ADA deficiency causes profound lymphopenia due to arrested maturation and apoptosis of T, B, and NK cells.  
3. **Decreased lymphocyte proliferation in response to mitogen**: Reflects impaired T-cell function, a key feature of SCID.  
4. **Decreased proportion of CD4-positive T cells**: ADA deficiency disrupts thymic T-cell maturation, leading to T-cell lymphopenia and skewed subsets.  
5. **Decreased circulating IgA level**: While B cells may be present, humoral immunity is compromised due to lack of T-cell help, resulting in hypogammaglobulinemia.  
6. **Pneumonia**: Opportunistic infections (bacterial, viral, fungal) are typical in SCID due to combined cellular and humoral immune failure.  
The constellation of **autosomal recessive inheritance**, **T-B-NK- cell deficiency**, and **ADA enzyme deficiency** confirms the diagnosis."
"['Hypertelorism', 'Micrognathia', 'Low-set ears', 'Otitis media', 'Cataract', 'Proptosis', 'Leukocoria', 'Shallow orbits', 'Delayed speech and language development', 'Joint hypermobility', 'Mitral valve prolapse', 'Thickened calvaria', 'Arthralgia', 'Hypoplasia of the odontoid process', 'Short stature', 'Limited elbow flexion', 'Delayed femoral head ossification', 'Midface retrusion', 'Submucous cleft of soft and hard palate']","['Stickler syndrome type 1/Stickler syndrome, type I']","Disease: Stickler syndrome type 1/Stickler syndrome, type I  
Reasoning:  
1. **Craniofacial features**: Midface retrusion, micrognathia, hypertelorism, low-set ears, and submucous cleft palate align with Stickler syndrome’s characteristic facial dysmorphism and palatal abnormalities (often clefting due to collagen defects).  
2. **Ocular manifestations**: Cataract, proptosis, leukocoria, and shallow orbits are hallmark findings in Stickler type 1, linked to COL2A1 mutations affecting vitreous and ocular structure.  
3. **Auditory issues**: Recurrent otitis media reflects predisposition to middle ear dysfunction from craniofacial and connective tissue abnormalities.  
4. **Skeletal/joint involvement**: Joint hypermobility, arthralgia, limited elbow flexion, delayed femoral head ossification, and hypoplasia of the odontoid process correlate with skeletal dysplasia and collagen-related joint instability.  
5. **Systemic features**: Short stature, mitral valve prolapse (connective tissue defect), and thickened calvaria (less common but reported) further support a collagenopathy.  
6. **Developmental delay**: Delayed speech/language development is secondary to hearing loss (chronic otitis) or cleft palate.  
7. **Exclusion of mimics**: Features distinguish Stickler type 1 (COL2A1) from type 2 (COL11A1, with sensorineural hearing loss) or Marshall syndrome (distinct vitreous changes, more severe skeletal dysplasia)."
"['Eosinophilia', 'Lymphopenia', 'Increased circulating IgE level', 'Increased circulating IgG level', 'Nail dystrophy', 'Chronic oral candidiasis', 'Abnormal proportion of CD4-positive T cells', 'Abnormal proportion of CD8-positive T cells']","['Candidiasis, familial chronic mucocutaneous, autosomal recessive', 'Predisposition to invasive fungal disease due to CARD9 deficiency']","Disease: Candidiasis, familial chronic mucocutaneous, autosomal recessive  
Reasoning:  
1. **Chronic oral candidiasis** is a hallmark of this disorder, directly aligning with the patient’s symptom.  
2. **Nail dystrophy** commonly occurs due to chronic fungal infections in mucocutaneous candidiasis.  
3. **Increased IgE/IgG levels** reflect chronic antigenic stimulation from persistent Candida infections and possible dysregulated Th2 responses.  
4. **Abnormal CD4/CD8 T cell ratios** suggest underlying T-cell dysfunction, critical in controlling fungal infections. Familial forms often involve mutations (e.g., *STAT1* gain-of-function) that impair Th17 differentiation, weakening mucosal immunity.  
5. **Eosinophilia** may arise from Th2 skewing, while **lymphopenia** could indicate chronic immune activation or genetic defects affecting lymphocyte homeostasis.  

Disease: Predisposition to invasive fungal disease due to CARD9 deficiency  
Reasoning:  
1. **Chronic oral candidiasis** is seen in CARD9 deficiency, though typically with invasive fungal infections (not explicitly noted here).  
2. **Abnormal CD4/CD8 T cell ratios** may reflect impaired myeloid cell signaling (via CARD9), indirectly affecting T-cell responses to fungi.  
3. **Increased IgE/IgG** could result from compensatory immune hyperactivity due to defective fungal clearance.  
4. However, CARD9 deficiency often presents with **deep/organ fungal infections** (e.g., CNS candidiasis), which are absent here, making this diagnosis less likely. Lymphopenia and eosinophilia are also less characteristic of CARD9 deficiency.  

**Final Prioritization**: The patient’s presentation strongly aligns with **familial chronic mucocutaneous candidiasis**, given the isolated mucosal Candida involvement and T-cell abnormalities. CARD9 deficiency is less likely without invasive fungal features."
"['Tall stature', 'Arachnodactyly', 'Kyphoscoliosis', 'Crumpled ear', 'Abnormal eye morphology', 'Camptodactyly']","['Congenital contractural arachnodactyly/Contractural arachnodactyly, congenital']","Disease: Congenital contractural arachnodactyly (Beals syndrome)  
Reasoning:  
1. **Arachnodactyly + Camptodactyly**: Key features of congenital contractural arachnodactyly (CCA), distinguishing it from Marfan syndrome (which lacks fixed finger contractures).  
2. **Kyphoscoliosis**: Common in CCA due to connective tissue abnormalities affecting spinal development.  
3. **Crumpled ear**: A pathognomonic sign of CCA caused by abnormal cartilage folding.  
4. **Tall stature**: Overlaps with Marfan syndrome but supports a connective tissue disorder diagnosis.  
5. **Abnormal eye morphology**: May include microcornea, iris coloboma, or myopia, consistent with FBN2 gene-related ocular manifestations in CCA.  
6. **Absence of cardiovascular anomalies**: Helps exclude Marfan syndrome (FBN1-related) and Loeys-Dietz syndrome.  
7. **Genetic basis**: Linked to FBN2 mutations, confirming the diagnosis if genetic testing is performed."
"['Renal insufficiency', 'Proteinuria', 'Rod-cone dystrophy', 'Dental crowding', 'Diabetes mellitus', 'Postaxial hand polydactyly', 'Specific learning disability', 'Obesity', 'Postaxial polydactyly']",['Bardet-Biedl syndrome 2'],"Disease: Bardet-Biedl syndrome 2  
Reasoning:  
1. **Postaxial polydactyly** (hand) is a primary diagnostic feature of Bardet-Biedl syndrome (BBS).  
2. **Rod-cone dystrophy** (retinal degeneration) is a hallmark of BBS, typically leading to progressive vision loss.  
3. **Obesity** and **diabetes mellitus** align with metabolic abnormalities commonly seen in BBS.  
4. **Renal insufficiency** and **proteinuria** reflect renal involvement, a critical diagnostic criterion.  
5. **Specific learning disability** corresponds to cognitive impairments frequently associated with BBS.  
6. **Dental crowding** is a recognized orofacial manifestation of the syndrome.  
7. The combination of ≥4 major features (polydactyly, retinal dystrophy, obesity, renal anomalies, learning disability) and supportive findings (diabetes, dental anomalies) meets clinical diagnostic criteria for BBS.  
8. Subtype ""2"" refers to mutations in the *BBS2* gene, one of >25 known BBS-associated genes, confirmed via genetic testing."
"['Disproportionate tall stature', 'Scoliosis', 'Ascending tubular aorta aneurysm', 'High myopia']","['Marfan syndrome', 'Marfan syndrome type 1']","Marfan syndrome: The patient presents with disproportionate tall stature, a hallmark of Marfan syndrome due to FBN1 gene mutations affecting connective tissue. Scoliosis aligns with skeletal manifestations, while ascending aortic aneurysm reflects cardiovascular involvement, a critical diagnostic criterion. High myopia is consistent with ocular abnormalities seen in this disorder.  
Marfan syndrome type 1: This refers specifically to Marfan syndrome caused by pathogenic variants in the FBN1 gene on chromosome 15, which accounts for >90% of cases. The symptoms described (aortic aneurysm, skeletal features, ocular involvement) are directly linked to FBN1-related connective tissue dysregulation, confirming the subtype."
"['Growth delay', 'Small for gestational age', 'Polyhydramnios', 'Abdominal distention', 'Secretory diarrhea', 'Hyponatriuria', 'Acidemia', 'Elevated fecal sodium', 'Reduced fecal osmolality']","['Diarrhea 8, secretory sodium, congenital']","Disease: Diarrhea 8, secretory sodium, congenital (SSCD8)  
Reasoning:  
1. **Secretory Diarrhea**: Persistent, watery diarrhea from birth, continuing despite fasting, aligns with the defining feature of SSCD8.  
2. **Elevated Fecal Sodium & Reduced Fecal Osmolality**: Impaired intestinal sodium absorption (due to SLC9A3 mutations) causes high fecal sodium. Reduced osmolality reflects electrolyte-driven fluid loss without osmotic gap.  
3. **Hyponatriuria**: Compensatory renal sodium retention to counter fecal losses, reducing urinary sodium excretion.  
4. **Acidemia**: Bicarbonate loss in stool leads to metabolic acidosis.  
5. **Growth Delay & Small for Gestational Age (SGA)**: Chronic malnutrition from unrelenting diarrhea and electrolyte imbalances.  
6. **Polyhydramnios**: Fetal diarrhea in utero reduces intestinal fluid absorption, increasing amniotic fluid volume.  
7. **Abdominal Distention**: Secondary to fluid retention and intestinal dysfunction.  
8. **Exclusion of Alternatives**: Elevated fecal sodium distinguishes SSCD8 from congenital chloride diarrhea (high fecal chloride) or osmotic diarrheas (e.g., disaccharidase deficiencies)."
"['Labial hypertrophy', 'Enlarged kidney', 'Ovarian cyst', 'Otitis media', 'Hyperinsulinemia', 'Global developmental delay', 'Left ventricular hypertrophy', 'Hypoglycemia', 'Rectal prolapse', 'Pneumonia', 'Recurrent infections', 'Abdominal distention', 'Clitoral hypertrophy', 'Increased C-peptide level']",['Leprechaunism/Donohue syndrome'],"Disease: Leprechaunism/Donohue syndrome  
Reasoning:  
1. **Hyperinsulinemia and Hypoglycemia**: Central to Donohue syndrome due to severe insulin resistance, leading to excessive insulin production (elevated C-peptide) and paradoxical hypoglycemia.  
2. **Genital Anomalies (Labial/Clitoral Hypertrophy)**: Hormonal dysregulation from insulin receptor mutations causes androgen-like effects, resulting in genital overgrowth.  
3. **Global Developmental Delay**: Severe growth retardation and neurodevelopmental deficits are hallmark features of the syndrome.  
4. **Recurrent Infections (Otitis Media, Pneumonia)**: Immune dysfunction linked to metabolic derangements and poor tissue integrity increases susceptibility.  
5. **Organomegaly (Enlarged Kidney, Ovarian Cysts)**: Insulin’s growth-promoting effects via IGF-1 receptors drive abnormal organ enlargement.  
6. **Left Ventricular Hypertrophy**: Chronic metabolic stress (hypoglycemia, hyperinsulinemia) strains cardiac function.  
7. **Abdominal Distention/Rectal Prolapse**: Hypotonia, malnutrition, and connective tissue weakness contribute to gastrointestinal complications.  
8. **Clinical Consistency**: Overlapping features (insulin resistance, dysmorphia, organomegaly) rule out mimics like Beckwith-Wiedemann or Rabson-Mendenhall syndromes."
"['Intellectual disability', 'Seizure', 'Global developmental delay', 'Generalized hypotonia', 'Failure to thrive', 'Metabolic acidosis', 'Hypoglycemia', 'Ketosis', 'Hyperammonemia', 'Vomiting', 'Respiratory distress', 'Increased serum lactate', 'Rhabdomyolysis', 'Lacticaciduria', 'Arrhythmia', 'Dicarboxylic acidemia', 'Elevated circulating acylcarnitine concentration']","['Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome/Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration']","Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Metabolic acidosis, hypoglycemia, ketosis, hyperammonemia, elevated lactate, and dicarboxylic acidemia** indicate a severe mitochondrial or fatty acid oxidation disorder. These findings suggest impaired energy metabolism, leading to toxic metabolite accumulation.  
2. **Rhabdomyolysis, arrhythmia, and lacticaciduria** point to muscle and cardiac involvement, aligning with the syndrome's hallmark features of recurrent rhabdomyolysis and cardiac complications.  
3. **Elevated acylcarnitine levels** reflect disrupted fatty acid β-oxidation, a key feature of this disorder.  
4. **Intellectual disability, seizures, and global developmental delay** correlate with neurodegeneration and encephalopathic crises caused by metabolic decompensation.  
5. **Vomiting, respiratory distress, and failure to thrive** are secondary to acute metabolic crises and chronic energy deficiency.  
6. The combination of **neurodegeneration, metabolic crises, and multi-organ involvement** (muscle, heart, CNS) uniquely matches this rare syndrome."
"['Pointed chin', 'Anodontia', 'Hypohidrosis', 'obsolete Hypotrichosis', 'Recurrent fever', 'Depressed nasal bridge', 'Enlarged naris', 'Prominent forehead', 'Thick vermilion border']","['X-linked hypohidrotic ectodermal dysplasia/Ectodermal dysplasia 1, hypohidrotic, X-linked']","Disease: X-linked hypohidrotic ectodermal dysplasia/Ectodermal dysplasia 1, hypohidrotic, X-linked  
Reasoning:  
1. **Hypohidrosis**: Central feature of the disease due to defective sweat glands, leading to impaired thermoregulation and **recurrent fever**.  
2. **Anodontia**: Characteristic dental anomaly (absence of teeth) caused by ectodermal dysplasia affecting tooth development.  
3. **Hypotrichosis**: Sparse hair (scalp/body) from abnormal hair follicle formation.  
4. **Facial dysmorphism**:  
   - **Depressed nasal bridge**, **enlarged naris**, **prominent forehead**, and **pointed chin** reflect craniofacial ectodermal defects.  
   - **Thick vermilion border** (full lips) is a common phenotypic trait.  
5. **X-linked inheritance pattern**: Males are typically more severely affected, consistent with the symptom profile.  
6. Symptom constellation aligns with classic triad of hypohidrosis, hypotrichosis, and hypodontia/anodontia, confirming the diagnosis."
"['Abnormality of the genitourinary system', 'Hydrocephalus', 'Growth delay', 'Pancytopenia', 'Immunodeficiency', 'Bone marrow hypocellularity', 'Arachnoid cyst']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Pancytopenia & Bone Marrow Hypocellularity**: Core features of APS, caused by SAMD9L mutations disrupting hematopoiesis.  
2. **Immunodeficiency**: Secondary to pancytopenia (neutropenia, lymphopenia).  
3. **Hydrocephalus & Arachnoid Cyst**: Neurological structural anomalies (e.g., cerebellar defects, CSF flow issues) align with APS-associated CNS abnormalities.  
4. **Growth Delay**: Common in multisystem genetic disorders like APS.  
5. **Genitourinary Abnormalities**: Reported in some APS cases, though less typical, suggesting phenotypic variability.  
6. **Ataxia (implied)**: While not explicitly listed, hydrocephalus/cysts may indicate cerebellar dysfunction, a hallmark of APS.  

The constellation of hematologic, neurologic, and developmental symptoms strongly supports APS diagnosis."
"['Cleft palate', 'Hypertelorism', 'Triangular face', 'Broad forehead', 'Strabismus', 'Proptosis', 'Long eyelashes', 'Autistic behavior', 'Impaired social interactions', 'Reduced eye contact', 'Hypertrichosis', 'Prominent fingertip pads', 'Seizure', 'Hypotonia', 'Generalized hypotonia', 'Absent speech', 'Joint laxity', 'Macrodontia', 'Constipation', 'Sleep disturbance', 'Recurrent infections', 'Elbow hypertrichosis', 'No social interaction', 'Incisor macrodontia', 'Severe global developmental delay', 'Self-injurious behavior']",['Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities'],"Disease: Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities  
Reasoning:  
1. **Craniofacial dysmorphism**: The patient exhibits hypertelorism, triangular face, broad forehead, proptosis, and cleft palate, which are hallmark facial features of this disorder.  
2. **Neurodevelopmental/behavioral abnormalities**: Severe global developmental delay, absent speech, autistic behavior, impaired social interactions, and self-injurious behavior align with the disorder’s core neuropsychiatric profile.  
3. **Hypertrichosis and physical signs**: Elbow hypertrichosis, generalized hypertrichosis, and prominent fingertip pads are distinctive phenotypic markers.  
4. **Dental and systemic features**: Incisor macrodontia and recurrent infections suggest multisystem involvement, consistent with genetic etiologies linked to this diagnosis.  
5. **Neurological symptoms**: Hypotonia, seizures, and sleep disturbances further support a syndromic intellectual disability disorder.  
6. **Exclusion of mimics**: The constellation of features (e.g., macrodontia + hypertrichosis + cleft palate) differentiates this from similar syndromes like Wiedemann-Steiner or KBG, narrowing to the specified diagnosis."
"['Open mouth', 'Mandibular prognathia', 'Broad forehead', 'Hearing impairment', 'Bulbous nose', 'Atypical behavior', 'Generalized hypotonia', 'Absent speech', 'Abnormal facial shape', 'Developmental regression', 'Delayed skeletal maturation', 'Severe global developmental delay', 'Thick vermilion border']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facial features**: ""Broad forehead,"" ""bulbous nose,"" ""thick vermilion border,"" ""open mouth,"" and ""mandibular prognathia"" align with the distinct facies described in TBCK syndrome, including midface hypoplasia and a prominent upper lip.  
2. **Neuromuscular involvement**: ""Generalized hypotonia"" is a hallmark of the disorder, often presenting in infancy.  
3. **Developmental delays**: ""Severe global developmental delay,"" ""absent speech,"" and ""delayed skeletal maturation"" correlate with the syndrome’s core features of psychomotor retardation and growth deficits.  
4. **Atypical behavior**: Observed in TBCK cases due to intellectual disability and potential autism spectrum traits.  
5. **Hearing impairment**: Documented in some patients, possibly linked to sensorineural or conductive abnormalities.  
6. **Developmental regression**: While less common, stagnation or regression may occur in severe cases, overlapping with neurodegenerative-like presentations.  
7. **Genetic confirmation**: Although not explicitly stated, the symptom constellation strongly suggests biallelic TBCK mutations, which impair mTORC1 signaling and lysosomal function.  

The absence of key features of phenocopies (e.g., Coffin-Siris or Angelman syndromes) further supports this diagnosis."
"['Syncope', 'Palpitations', 'ST segment elevation']","['Brugada Syndrome, BrS/Brugada syndrome/Brugada syndrome 1']","Disease: Brugada Syndrome, BrS/Brugada syndrome/Brugada syndrome 1  
Reasoning:  
1. **ST segment elevation**: The hallmark ECG finding in Brugada syndrome is coved-type ST elevation (>2 mm) in leads V1-V3, often mimicking acute myocardial infarction but without ischemic symptoms. This matches the patient’s ECG presentation.  
2. **Syncope**: Sudden loss of consciousness in Brugada syndrome is typically due to polymorphic ventricular tachycardia (VT) or ventricular fibrillation (VF), which disrupt cardiac output. This aligns with the patient’s syncopal episodes.  
3. **Palpitations**: Reflects transient arrhythmias, such as non-sustained VT or premature ventricular contractions (PVCs), common in Brugada syndrome due to abnormal sodium channel function (SCN5A mutation in 20-30% of cases).  
4. **Exclusion of alternatives**:  
   - Acute coronary syndrome (ACS): Unlikely without chest pain, reciprocal ECG changes, or troponin elevation.  
   - Pericarditis: Diffuse ST elevation or PR depression absent.  
   - Early repolarization: ST elevation morphology differs (concave vs. coved).  
5. **Risk stratification**: Spontaneous Type 1 ECG pattern (as seen here) + syncope indicates high risk for sudden cardiac death, warranting ICD implantation."
"['Thick lower lip vermilion', 'Thick upper lip vermilion', 'Microcephaly', 'Full cheeks', 'Abnormal midface morphology', 'Depressed nasal ridge', 'Short neck', 'Delayed speech and language development', 'Sacral dimple', 'Global developmental delay', 'Motor delay', 'Proportionate short stature', 'Hyperpigmented/hypopigmented macules', 'Congenital megaureter', 'Cone-shaped epiphyses of the phalanges of the hand', 'Feeding difficulties']",['Wiedemann-Steiner syndrome/Wiedemann-Steiner syndrome'],"Disease: Wiedemann-Steiner syndrome  
Reasoning:  
1. **Craniofacial features**: Thick upper/lower lip vermilion, full cheeks, depressed nasal ridge, and abnormal midface morphology align with characteristic facial dysmorphism in Wiedemann-Steiner syndrome (WSS).  
2. **Neurodevelopmental delays**: Global developmental delay, motor delay, and speech/language delays are hallmark features of WSS, often linked to *KMT2A* gene mutations.  
3. **Growth abnormalities**: Microcephaly and proportionate short stature correlate with growth deficiencies commonly seen in WSS.  
4. **Skeletal findings**: Cone-shaped epiphyses of the hand phalanges are a recognized skeletal anomaly in WSS.  
5. **Cutaneous features**: Hyper-/hypopigmented macules may reflect the hypertrichosis or pigmentary changes occasionally reported in WSS.  
6. **Supportive features**: Congenital megaureter and feeding difficulties are consistent with multi-system involvement seen in rare genetic syndromes like WSS. Sacral dimple, while nonspecific, adds to the phenotypic spectrum.  
7. **Exclusion**: The combination of facial dysmorphism, skeletal anomalies, and neurodevelopmental delays distinguishes WSS from mimics like Kabuki syndrome or Cornelia de Lange syndrome. Genetic testing for *KMT2A* variants would confirm the diagnosis."
"['Erythroderma', 'Global developmental delay', 'Hyperreflexia', 'Opisthotonus', 'Generalized-onset seizure', 'Short stature', 'Disproportionate short-limb short stature', 'Fetal distress', 'Oligoclonal T cell expansion', 'Sepsis']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Features**: Disproportionate short-limb short stature and short stature align with skeletal dysplasia, a hallmark of ISDNA.  
2. **Neurodevelopmental Abnormalities**: Global developmental delay, hyperreflexia, opisthotonus, and generalized-onset seizures indicate severe neurological involvement, consistent with ISDNA's neurodevelopmental phenotype.  
3. **Immune Dysregulation**: Oligoclonal T cell expansion and sepsis suggest immunodeficiency, while erythroderma may reflect inflammatory T-cell dysregulation, all characteristic of ISDNA's immune pathology.  
4. **Prenatal Onset**: Fetal distress supports a congenital disorder, fitting ISDNA's genetic etiology (EXOC6B mutations).  
5. **Integration**: The triad of skeletal, neurological, and immune abnormalities distinguishes ISDNA from isolated skeletal dysplasias, neurodevelopmental disorders, or primary immunodeficiencies."
"['Glaucoma', 'Cataract', 'Intellectual disability', 'Hypotonia', 'Glycosuria', 'Low-molecular-weight proteinuria', 'Aminoaciduria', 'Albuminuria']",['Oculocerebrorenal syndrome of Lowe/Lowe syndrome'],"Disease: Oculocerebrorenal syndrome of Lowe/Lowe syndrome  
Reasoning:  
1. **Ocular Manifestations**: Glaucoma and congenital cataracts are hallmark features of Lowe syndrome, caused by mutations in the OCRL1 gene affecting eye development.  
2. **Neurological Involvement**: Intellectual disability and hypotonia align with the syndrome's central nervous system deficits, linked to impaired phosphatidylinositol metabolism.  
3. **Renal Tubular Dysfunction**: Glycosuria, low-molecular-weight proteinuria, aminoaciduria, and albuminuria indicate proximal renal tubular dysfunction (Fanconi syndrome), a key renal feature of Lowe syndrome due to defective OCRL1-dependent tubular transport.  
4. **Triad Confirmation**: The combination of ocular, cerebral, and renal abnormalities is pathognomonic for Lowe syndrome, distinguishing it from other metabolic or tubular disorders."
"['Tall stature', 'Bifid uvula', 'Dolichocephaly', 'Malar flattening', 'Hypertelorism', 'Downslanted palpebral fissures', 'Pectus excavatum', 'Striae distensae', 'Arachnodactyly', 'Mitral valve prolapse', 'Aortic root aneurysm', 'Scoliosis', 'Protrusio acetabuli', 'Tortuous cerebral arteries', 'Cervical spine instability', 'High myopia', 'Cystic medial necrosis', 'Dural ectasia']",['Loeys-Dietz syndrome/Loeys-Dietz syndrome 1'],"Loeys-Dietz syndrome 1:  
- **Craniofacial features**: Bifid uvula, hypertelorism, downslanted palpebral fissures, malar flattening, and dolichocephaly align with LDS1’s hallmark craniofacial abnormalities.  
- **Skeletal manifestations**: Tall stature, arachnodactyly, pectus excavatum, scoliosis, and protrusio acetabuli reflect connective tissue involvement.  
- **Cardiovascular abnormalities**: Aortic root aneurysm, mitral valve prolapse, tortuous cerebral arteries, and cystic medial necrosis indicate aggressive vascular pathology characteristic of LDS1.  
- **Connective tissue/systemic signs**: Striae distensae, cervical spine instability, high myopia, and dural ectasia further support TGF-β pathway dysregulation.  
- **Exclusion of mimics**: Bifid uvula and hypertelorism distinguish LDS1 from Marfan syndrome, while cervical instability and tortuosity differentiate it from Ehlers-Danlos syndromes. Genetic testing for TGFBR1/2 variants would confirm the diagnosis."
"['Brachydactyly', 'Genu varum', 'Trident hand', 'Abnormality of alkaline phosphatase level', 'Narrow vertebral interpedicular distance', 'Abnormal serum insulin-like growth factor 1 level', 'Abnormal circulating thyroid hormone concentration', 'Short femoral neck', 'Short iliac bones']",['Hypochondroplasia/Hypochondroplasia'],"Disease: Hypochondroplasia  
Reasoning:  
1. **Brachydactyly, Genu varum, Trident hand**: Common skeletal features in FGFR3-related chondrodysplasias. Hypochondroplasia, a milder form of achondroplasia, often presents with these due to abnormal endochondral ossification.  
2. **Narrow vertebral interpedicular distance, Short iliac bones, Short femoral neck**: Reflects characteristic spinal and pelvic abnormalities in hypochondroplasia, driven by defective growth plate development.  
3. **Abnormality of alkaline phosphatase level**: Linked to altered bone remodeling and turnover, typical of skeletal dysplasias.  
4. **Abnormal serum IGF-1 level**: May arise from growth hormone axis dysregulation secondary to skeletal dysplasia, contributing to short stature.  
5. **Abnormal thyroid hormone levels**: Less directly associated but occasionally seen in skeletal disorders due to systemic metabolic interplay or coincidental endocrine dysfunction.  
6. **Clinical overlap exclusion**: Features align more with hypochondroplasia than classic achondroplasia (less severe craniofacial involvement, later diagnosis) or other skeletal dysplasias (e.g., no metaphyseal flare seen in rickets). Genetic testing for FGFR3 mutations (e.g., p.Asn540Lys) would confirm."
"['Dementia', 'Hallucinations', 'Delusions', 'Dysarthria', 'Gait disturbance', 'Parkinsonism', 'Dystonia', 'Tremor', 'Rigidity', 'Micrographia', 'Dyskinesia']","['Parkinson disease 23, autosomal recessive early-onset']","Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Early-onset parkinsonism**: The presence of tremor, rigidity, gait disturbance, and micrographia aligns with core parkinsonian features. Autosomal recessive early-onset Parkinson’s disease (PARK23) typically manifests before age 40.  
2. **Neuropsychiatric symptoms**: Dementia, hallucinations, and delusions suggest atypical cognitive/psychiatric involvement, which is reported in DNAJC6-related PD23 due to broader neuronal dysfunction.  
3. **Movement abnormalities**: Dystonia and dyskinesia are common in early-onset genetic parkinsonism, often exacerbated by dopaminergic therapy or intrinsic basal ganglia pathology.  
4. **Dysarthria and gait disturbance**: Reflects progressive neurodegeneration affecting both motor and extrapyramidal pathways.  
5. **Genetic correlation**: DNAJC6 mutations impair chaperone-mediated neuroprotection, leading to early synaptic dysfunction and multisystemic degeneration, consistent with the symptom profile.  
6. **Exclusion of mimics**: The combination of parkinsonism, cognitive decline, and psychiatric features distinguishes PD23 from other early-onset forms (e.g., PARK2/Parkin) that lack prominent neuropsychiatric signs."
"['Thin upper lip vermilion', 'Microcephaly', 'Low anterior hairline', 'Long philtrum', 'Synophrys', 'Delayed speech and language development', 'Intellectual disability, moderate', 'Depressed nasal bridge', 'Curly eyelashes', 'Postnatal growth retardation']",['Cornelia de Lange syndrome/Cornelia de Lange syndrome 1'],"Disease: Cornelia de Lange syndrome/Cornelia de Lange syndrome 1  
Reasoning:  
1. **Facial Features**: Thin upper lip vermilion, long philtrum, depressed nasal bridge, and synophrys (unibrow) are hallmark craniofacial features of Cornelia de Lange syndrome (CdLS).  
2. **Microcephaly and Growth Retardation**: Microcephaly and postnatal growth retardation align with CdLS-associated developmental abnormalities.  
3. **Neurodevelopmental Delays**: Moderate intellectual disability and delayed speech/language development are consistent with the syndrome’s cognitive profile.  
4. **Ancillary Features**: Low anterior hairline and curly eyelashes are supportive phenotypic clues frequently observed in CdLS.  
5. **Exclusion of Alternatives**: The constellation of symptoms (especially synophrys, distinct facial gestalt, and growth/neurodevelopmental patterns) is pathognomonic for CdLS, differentiating it from other syndromes with overlapping features (e.g., Rubinstein-Taybi, fetal alcohol spectrum disorders)."
"['Cleft palate', 'Prominent occiput', 'Chorioretinal coloboma', 'Failure to thrive in infancy', 'Dehydration', 'Vomiting', 'Diarrhea', 'Hyponatremia', 'Decreased body weight', 'Preauricular pit', 'Hypovolemia', 'Nasogastric tube feeding in infancy', 'Cleft lip']","['Diarrhea 3, secretory sodium, congenital, with or without other congenital anomalies']","Disease: Diarrhea 3, secretory sodium, congenital, with or without other congenital anomalies  
Reasoning:  
1. **Core gastrointestinal features**: The patient exhibits chronic secretory diarrhea, vomiting, dehydration, hyponatremia, and hypovolemia, which are hallmark features of congenital sodium diarrhea (CSD). These symptoms stem from defective intestinal sodium-hydrogen exchange (e.g., SLC9A3 mutations), leading to impaired sodium absorption and osmotic diarrhea.  
2. **Failure to thrive and nutritional dependence**: Nasogastric tube feeding in infancy and decreased body weight align with severe malabsorption and electrolyte losses typical of CSD.  
3. **Congenital anomalies**: Cleft lip/palate, preauricular pit, and chorioretinal coloboma are structural defects associated with syndromic forms of CSD. These anomalies suggest a genetic etiology (e.g., SPINT2 mutations in some cases) affecting both enterocyte function and embryonic development.  
4. **Prominent occiput**: This may indicate craniofacial dysmorphism linked to an underlying genetic syndrome intersecting with CSD.  
5. **Exclusion of mimics**: The triad of congenital diarrhea, hyponatremia, and extraintestinal anomalies distinguishes CSD from other osmotic diarrheas or chloride-wasting disorders (e.g., CFTR-related disease). Genetic testing for SLC9A3 or SPINT2 would confirm the diagnosis."
"['Nystagmus', 'Hypopigmentation of the skin', 'Hypopigmentation of hair']","['Oculocutaneous albinism type 3/Albinism, oculocutaneous, type III']","Disease: Oculocutaneous albinism type 3 (OCA3)  
Reasoning:  
1. **Hypopigmentation of skin and hair**: OCA3 is characterized by reduced melanin synthesis due to mutations in the *TYRP1* gene, leading to partial but not complete loss of pigmentation. This aligns with the patient’s hypopigmentation.  
2. **Nystagmus**: Ocular manifestations, including nystagmus, are common in all OCA subtypes due to impaired retinal development and misrouting of optic nerves caused by melanin deficiency.  
3. **Differentiation from other OCA subtypes**:  
   - OCA1 (tyrosinase-deficient) typically presents with complete absence of melanin (white hair, pale skin).  
   - OCA2 involves moderate pigment reduction (e.g., yellow hair in some populations).  
   - OCA3 specifically affects TYRP1, a protein stabilizing tyrosinase, resulting in milder pigment reduction (e.g., reddish-brown skin/hair in darker-skinned individuals).  
4. **Genetic confirmation**: While clinical symptoms suggest OCA3, genetic testing for *TYRP1* mutations would definitively confirm the diagnosis."
"['Ataxia', 'Dysarthria', 'Cerebellar atrophy', 'Dysmetria', 'Babinski sign']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Ataxia, Dysmetria, Cerebellar atrophy**: Core features of cerebellar dysfunction, directly aligning with the syndrome’s progressive cerebellar degeneration.  
2. **Dysarthria**: Commonly associated with cerebellar pathology, consistent with impaired motor coordination of speech.  
3. **Babinski sign**: Indicates upper motor neuron involvement, which may reflect broader neurological dysfunction in the syndrome, including potential spinal cord or pyramidal tract abnormalities.  
4. **Syndrome-specific context**: While pancytopenia (a hallmark of the disorder) is not explicitly listed here, the combination of cerebellar and pyramidal signs strongly suggests a systemic genetic etiology like SAMD9L-related Ataxia-pancytopenia syndrome, which integrates neurological and hematological manifestations. Further hematological evaluation (e.g., CBC) would confirm pancytopenia to solidify the diagnosis."
"['Nyctalopia', 'Constriction of peripheral visual field', 'Bone spicule pigmentation of the retina', 'Retinal arteriolar constriction']",['Retinitis pigmentosa 18'],"Disease: Retinitis pigmentosa 18  
Reasoning:  
1. **Nyctalopia**: A hallmark early symptom of retinitis pigmentosa (RP), caused by rod photoreceptor dysfunction, which is critical for low-light vision.  
2. **Peripheral visual field constriction**: Reflects progressive degeneration of peripheral retinal photoreceptors, a defining feature of RP.  
3. **Bone spicule pigmentation**: Characteristic retinal finding in RP, caused by pigment migration and accumulation due to photoreceptor/RPE cell death.  
4. **Retinal arteriolar narrowing**: Occurs in advanced RP due to reduced metabolic demand from widespread retinal atrophy.  
5. **Genetic subtype (RP18)**: Linked to mutations in the *RGS9BP* gene, which disrupt phototransduction signaling in photoreceptors. This subtype aligns with autosomal recessive inheritance and typical RP phenotype progression."
"['Recurrent urinary tract infections', 'Abnormality of the kidney', 'Epicanthus', 'Low anterior hairline', 'Hypertelorism', 'Narrow forehead', 'Choanal atresia', 'Cystic hygroma', 'Synophrys', 'Hypotonia', 'Spasticity', 'Motor delay', 'Hypertonia', 'Generalized hypotonia', 'Abnormal heart morphology', 'Delayed gross motor development', 'Scoliosis', 'Redundant neck skin', 'Hypoplastic helices', 'Abnormal eye morphology', 'Abnormality of brain morphology', 'Abnormality of cardiovascular system morphology']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart  
Reasoning:  
1. **Neurodevelopmental features**: Hypotonia, hypertonia, spasticity, motor delay, and delayed gross motor development indicate central nervous system dysfunction, consistent with the ""neurodevelopmental disorder"" core phenotype.  
2. **Brain anomalies**: Abnormality of brain morphology directly aligns with the disorder's characteristic brain involvement.  
3. **Ocular anomalies**: Epicanthus, hypertelorism, synophrys, and abnormal eye morphology correlate with the ""eye anomalies"" component.  
4. **Cardiovascular involvement**: Abnormal heart morphology and cardiovascular system abnormalities match the disorder's cardiac spectrum.  
5. **Supporting dysmorphisms**: Low anterior hairline, narrow forehead, redundant neck skin, cystic hygroma, hypoplastic helices, and choanal atresia are common in genetic neurodevelopmental syndromes.  
6. **Systemic features**: Scoliosis, recurrent UTIs, and kidney abnormalities are nonspecific but frequently reported in multisystem neurodevelopmental disorders.  
7. **Exclusion of mimics**: The constellation rules out isolated syndromes (e.g., CHARGE, Noonan) due to the combined brain-eye-heart triad without pathognomonic features of other defined disorders."
"['Ptosis', 'Blue sclerae', 'Dentinogenesis imperfecta', 'Platyspondyly', 'Osteopenia', 'Intellectual disability', 'Motor delay', 'Growth delay', 'Premature rupture of membranes', 'Recurrent fractures', 'Bowing of limbs due to multiple fractures']","['Osteogenesis imperfecta, type XV']","Disease: Osteogenesis imperfecta, type XV  
Reasoning:  
1. **Recurrent fractures & bowing of limbs**: Hallmarks of osteogenesis imperfecta (OI), indicating bone fragility.  
2. **Dentinogenesis imperfecta**: Associated with OI types affecting collagen (e.g., types III, IV), but also reported in type XV due to WNT1 mutations impacting dentin formation.  
3. **Blue sclerae**: Common in OI (collagen defects), though less typical in type XV; may reflect severe underlying connective tissue dysplasia.  
4. **Platyspondyly & osteopenia**: Suggest defective bone mineralization and vertebral flattening, consistent with severe OI phenotypes.  
5. **Intellectual disability & motor delay**: Linked to WNT1 mutations (type XV etiology), as WNT signaling is critical for neurodevelopment.  
6. **Growth delay**: Expected in severe OI due to skeletal deformities and systemic growth impairment.  
7. **Premature rupture of membranes (PROM)**: Rarely reported in OI type XV, possibly from abnormal fetal connective tissues.  
8. **Ptosis**: May arise from neuromuscular involvement secondary to WNT1 dysfunction.  
**Conclusion**: The constellation of skeletal, dental, neurological, and connective tissue abnormalities aligns with OI type XV (WNT1-related), distinguishing it from classical collagen-based OI types."
"['Neurogenic bladder', 'Macroglossia', 'Gingival overgrowth', 'Coarse facial features', 'Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Ptosis', 'Cataract', 'Osteoporosis', 'Areflexia', 'Stroke', 'Cerebellar vermis hypoplasia', 'Partial agenesis of the corpus callosum', 'Respiratory insufficiency', 'Hypertriglyceridemia', ""Exaggerated cupid's bow"", 'Developmental regression', 'Highly arched eyebrow', 'Severe muscular hypotonia', 'Focal-onset seizure', 'Multifocal epileptiform discharges', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay', 'Periauricular skin pits', 'Subdural hemorrhage', 'Cerebral visual impairment']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Coarse facial features, macroglossia, gingival overgrowth, narrow forehead, prominent nasal bridge, anteverted nares, ptosis, highly arched eyebrows, and ""exaggerated Cupid's bow"" align with the distinct craniofacial phenotype described in TBCK syndrome.  
2. **Neurological and neuromuscular deficits**: Severe muscular hypotonia, areflexia, profound global developmental delay, developmental regression, and cerebellar vermis hypoplasia reflect the central and peripheral nervous system involvement typical of TBCK mutations.  
3. **Epilepsy**: Focal-onset seizures and multifocal epileptiform discharges correlate with the seizure phenotype observed in TBCK-related disorders.  
4. **Neuroimaging findings**: Partial agenesis of the corpus callosum, small basal ganglia, and subdural hemorrhage (likely secondary to hypotonia/falls) are consistent with structural brain anomalies reported in TBCK patients.  
5. **Systemic features**: Osteoporosis, hypertriglyceridemia, respiratory insufficiency, and cataracts match the multisystemic manifestations of TBCK syndrome, involving metabolic and connective tissue dysfunction.  
6. **Supportive features**: Periauricular skin pits, feeding difficulties, and cerebral visual impairment further reinforce the diagnosis, as these are recurrently observed in TBCK-related cases.  
7. **Exclusion of mimics**: The absence of organomegaly, skeletal dysplasia, or specific storage material distinguishes this from lysosomal disorders (e.g., mucopolysaccharidoses), while the combination of hypotonia, facial dysmorphism, and brain anomalies differentiates it from other neurodevelopmental syndromes."
"['Spasticity', 'Dysarthria', 'Gait ataxia']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Spasticity**: A hallmark of hereditary spastic paraplegias (HSPs), caused by progressive degeneration of corticospinal tracts. SPG76 specifically involves mutations in the *CAPN1* gene, leading to lower limb spasticity.  
2. **Dysarthria**: Indicates brainstem or cerebellar involvement, atypical in ""pure"" HSPs but seen in ""complex"" HSP subtypes like SPG76, where neurodegeneration extends beyond the spinal cord.  
3. **Gait ataxia**: Suggests cerebellar dysfunction, aligning with SPG76's reported phenotype of combined pyramidal (spasticity) and cerebellar (ataxia) features.  
4. **Exclusion of mimics**: Spinocerebellar ataxias (SCAs) were considered, but the triad of spasticity, ataxia, and dysarthria with autosomal recessive inheritance strongly favors SPG76. Genetic testing for *CAPN1* variants would confirm the diagnosis."
"['Narrow face', 'Prominent nose', 'Dental malocclusion', 'Atypical behavior', 'Intellectual disability', 'Screwdriver-shaped incisors', 'Mulberry molar', 'Anteverted ears', 'Nuclear cataract']",['Nance-Horan syndrome/Nance-Horan syndrome'],"Disease: Nance-Horan syndrome/Nance-Horan syndrome  
Reasoning:  
1. **Nuclear cataract**: A defining feature of Nance-Horan syndrome, present in nearly all affected individuals.  
2. **Dental anomalies**: ""Screwdriver-shaped incisors"" and ""mulberry molar"" are pathognomonic dental findings in this syndrome.  
3. **Craniofacial features**: ""Narrow face,"" ""prominent nose,"" and ""anteverted ears"" align with the characteristic facial dysmorphism.  
4. **Intellectual disability and atypical behavior**: Common neurodevelopmental manifestations of the syndrome.  
5. **Dental malocclusion**: Secondary to abnormal tooth morphology and craniofacial structure.  
6. Exclusion of mimics: The combination of ocular, dental, and craniofacial abnormalities is distinct from other syndromes (e.g., Lowe syndrome, oculodentodigital dysplasia)."
"['Cleft palate', 'Spatulate thumbs', 'Congenital hip dislocation', 'Talipes equinovarus', 'Vertebral fusion', 'Elbow dislocation', 'Tapered humerus', 'Short stature', 'Congenital knee dislocation', 'Vertebral arch anomaly', 'Midface retrusion', 'Abnormal bone ossification']",['Larsen syndrome/Larsen syndrome'],"Disease: Larsen syndrome  
Reasoning:  
1. **Congenital joint dislocations** (hip, knee, elbow) are hallmark features of Larsen syndrome, caused by connective tissue abnormalities.  
2. **Cleft palate** and **midface retrusion** align with craniofacial manifestations commonly seen in the syndrome.  
3. **Spatulate thumbs** and **talipes equinovarus** are characteristic limb anomalies associated with Larsen syndrome.  
4. **Vertebral fusion** and **vertebral arch anomaly** reflect spinal malformations, a key diagnostic criterion.  
5. **Tapered humerus** and **abnormal bone ossification** correlate with skeletal dysplasia observed in the disorder.  
6. **Short stature** is consistent with systemic skeletal involvement.  
The combination of craniofacial, spinal, joint, and limb anomalies strongly supports the diagnosis."
"['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Renal hypoplasia', 'Tall stature', 'Renal cyst', 'Hydronephrosis', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Abnormal pinna morphology', 'Prominent antihelix', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormal choroid morphology', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Cafe-au-lait spot', 'Abnormal thumb morphology', 'Hypotonia', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar vermis hypoplasia', 'Hip dysplasia', 'Growth delay', 'Growth delay', 'Intrauterine growth retardation', 'Polyhydramnios', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Abnormal facial shape', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Generalized non-motor (absence) seizure', 'Duodenal atresia', 'Tetraparesis', 'Hypoplastic nipples', 'Scoliosis', 'Neoplasm of the liver', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', '3-4 finger syndactyly', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormal choroid plexus morphology', 'Postnatal growth retardation', 'Anterior creases of earlobe', 'Abnormal fifth toe morphology', '1-2 finger syndactyly', 'Anomalous pulmonary venous return', 'Expanded terminal portion of crus of helix', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental/core features**: Global developmental delay, hypotonia, spastic tetraparesis, generalized non-motor seizures, ADHD, and cerebellar vermis hypoplasia align with central nervous system involvement. Delayed myelination, cerebral hypomyelination, and hypoplastic corpus callosum further support brain structural anomalies.  
2. **Ocular anomalies**: Microphthalmia, coloboma, Peters anomaly, optic atrophy, and abnormal iris morphology are hallmark eye abnormalities in NEDBEH.  
3. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and abnormal cardiac septum morphology match the ""heart"" component of the disorder.  
4. **Craniofacial/Systemic dysmorphism**: Microcephaly/macrocephaly, triangular face, micrognathia, hypertelorism, smooth philtrum, and high palate are consistent with reported facial gestalt. Renal hypoplasia, hydronephrosis, and annular pancreas reflect multi-organ involvement.  
5. **Supportive features**: Growth retardation (pre/postnatal), sensorineural hearing impairment, limb anomalies (syndactyly, clinodactyly), and café-au-lait spots overlap with phenotypic variability in NEDBEH.  
6. **Exclusion**: While features like choanal atresia or duodenal atresia may suggest other syndromes (e.g., CHARGE), the combination of neurodevelopmental, eye, and heart anomalies without a primary skeletal dysplasia or metabolic disorder strongly favors NEDBEH.  

Key triad: Neurodevelopmental delay + structural brain/eye anomalies + congenital heart defects."
"['Brachydactyly', 'Joint stiffness', 'Pulmonic stenosis', 'Scoliosis', 'Lumbar hyperlordosis', 'Short stature', 'High myopia', 'Muscular ventricular septal defect', 'Microspherophakia']",['Weill-Marchesani syndrome 1'],"Disease: Weill-Marchesani syndrome 1  
Reasoning:  
1. **Microspherophakia and high myopia** are hallmark ocular features of Weill-Marchesani syndrome (WMS), caused by abnormal lens shape and severe refractive errors.  
2. **Brachydactyly, short stature, joint stiffness, scoliosis, and lumbar hyperlordosis** align with WMS-associated skeletal dysplasia and connective tissue abnormalities.  
3. **Pulmonic stenosis and muscular ventricular septal defect** suggest congenital heart defects, reported in recessive WMS1 (ADAMTS10 mutations).  
4. The combination of **ocular, skeletal, and cardiovascular anomalies** excludes mimics like Marfan syndrome (arachnodactyly, aortic root dilation) or acromicric dysplasia (no cardiac/ocular involvement).  
5. **Autosomal recessive inheritance** (WMS1) is consistent with systemic severity, including cardiac manifestations, compared to autosomal dominant forms (WMS2)."
"['Hypospadias', 'Vesicoureteral reflux', 'Renal insufficiency', 'Epicanthus', 'Low anterior hairline', 'Low-set ears', 'Preauricular skin tag', 'Short neck', 'Long eyelashes', 'Aggressive behavior', 'Delayed speech and language development', 'Hyperactivity', 'Global developmental delay', 'Atrial septal defect', 'Overlapping toe', 'Anal atresia', 'EEG abnormality', 'Short stature', 'Attention deficit hyperactivity disorder', 'Microtia', 'Partial duplication of thumb phalanx', 'Abnormality of brain morphology', 'Preaxial polydactyly']",['Townes-Brocks syndrome 1'],"Disease: Townes-Brocks syndrome 1  
Reasoning:  
1. **Core Triad Features**:  
   - **Anal atresia**: A hallmark feature of Townes-Brocks syndrome (TBS).  
   - **Ear anomalies**: Microtia, low-set ears, and preauricular skin tags align with TBS-associated ear malformations.  
   - **Thumb abnormalities**: Preaxial polydactyly and partial duplication of the thumb phalanx are characteristic limb defects in TBS.  

2. **Renal and Urological Involvement**:  
   - Vesicoureteral reflux and renal insufficiency correlate with TBS-related kidney dysfunction.  
   - Hypospadias further supports genitourinary anomalies linked to TBS.  

3. **Cardiac and Skeletal Features**:  
   - Atrial septal defect and overlapping toe are consistent with TBS-associated congenital anomalies.  

4. **Facial Dysmorphism**:  
   - Epicanthus, long eyelashes, short neck, and low anterior hairline match reported craniofacial traits in TBS.  

5. **Supportive Genetic Basis**:  
   - TBS1 is caused by pathogenic variants in *SALL1*, which explains multi-organ developmental defects.  

6. **Exclusion of Overlapping Syndromes**:  
   - Features like preaxial polydactyly and anal atresia distinguish TBS from VACTERL or Smith-Lemli-Opitz syndrome.  

7. **Neurodevelopmental Variability**:  
   - While developmental delay, ADHD, and EEG abnormalities are less typical, phenotypic variability in TBS can include mild neurocognitive involvement.  

Conclusion: The combination of anal, ear, thumb, renal, and cardiac anomalies strongly supports a diagnosis of Townes-Brocks syndrome 1."
"['Cleft palate', 'High palate', 'Hydrocephalus', 'Micrognathia', 'Low-set ears', 'Protruding ear', 'Depressed nasal tip', 'Long palpebral fissure', 'Generalized hypotonia', 'Hip dysplasia', 'Abnormality of the liver', 'Growth delay', 'Weak cry', 'Breech presentation', 'Abnormality of the cardiovascular system', 'Abnormality of the spleen', 'Lateral ventricle dilatation', 'Eversion of lateral third of lower eyelids', 'Postnatal growth retardation', 'Abnormal circulating thyroid hormone concentration', 'Sparse eyebrow']",['Kabuki syndrome 2'],"Disease: Kabuki syndrome 2  
Reasoning:  
1. **Facial Dysmorphism**: Key features like *long palpebral fissures*, *eversion of the lateral third of lower eyelids*, *depressed nasal tip*, *low-set ears*, and *protruding ears* align with the characteristic ""Kabuki mask"" facies.  
2. **Cleft/High Palate**: *Cleft palate* and *high palate* are common orofacial anomalies in Kabuki syndrome.  
3. **Neurological Abnormalities**: *Hydrocephalus* and *lateral ventricle dilatation* suggest structural brain defects, while *generalized hypotonia* and *weak cry* reflect neuromuscular involvement.  
4. **Growth Issues**: *Postnatal growth retardation* and *growth delay* are hallmark features of Kabuki syndrome.  
5. **Skeletal Anomalies**: *Hip dysplasia* and *micrognathia* correlate with skeletal dysplasia seen in this disorder.  
6. **Multisystem Involvement**: *Cardiovascular abnormalities*, *liver/spleen anomalies*, and *breech presentation* (linked to joint laxity) reflect systemic impacts.  
7. **Endocrine Dysfunction**: *Abnormal thyroid hormone levels* may arise from endocrine dysregulation, a recognized feature.  
8. **Supporting Features**: *Sparse eyebrows* and *sparse eyelashes* are frequent cutaneous findings.  
9. **Genetic Basis**: Kabuki syndrome 2 is caused by *KDM6A* mutations, which explain the phenotypic overlap with Kabuki syndrome 1 (MLL2-related) but with potential endocrine distinctions.  

The constellation of craniofacial, skeletal, neurological, and multisystem anomalies strongly supports Kabuki syndrome 2, warranting *KDM6A* sequencing for confirmation."
"['Gingival overgrowth', 'High palate', 'Long face', 'Hearing impairment', 'Strabismus', 'Horizontal nystagmus', 'Dental crowding', 'Slender finger', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar hypoplasia', 'Dystonia', 'Hyperreflexia', 'Overgrowth', 'Hypoplasia of the corpus callosum', 'Leukodystrophy', 'Abnormal cerebral white matter morphology', 'Scoliosis', 'Multiple joint contractures', 'CNS hypomyelination', 'Cerebral hypomyelination', 'Generalized hyperreflexia', 'Brain atrophy']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Leukodystrophy/CNS hypomyelination**: The presence of leukodystrophy, cerebral/cerebellar hypomyelination, and abnormal white matter morphology directly align with the hallmark hypomyelinating leukodystrophy in NKX6-2 disorders.  
2. **Spastic tetraparesis/hyperreflexia**: Spasticity and hyperreflexia are consistent with corticospinal tract dysfunction due to impaired myelination.  
3. **Cerebellar hypoplasia/brain atrophy**: Explains ataxia, nystagmus, and dystonia, reflecting cerebellar and global CNS involvement.  
4. **Global developmental delay**: Expected in severe neurodevelopmental disorders with hypomyelination and cerebellar defects.  
5. **Hypoplasia of the corpus callosum**: A common associated structural brain anomaly in leukodystrophies.  
6. **Scoliosis/joint contractures**: Secondary to chronic spasticity and reduced mobility.  
7. **Dental/facial features (gingival overgrowth, high palate, long face)**: May represent connective tissue or craniofacial dysregulation linked to NKX6-2's role in development.  
8. **Slender fingers/overgrowth**: Less typical but reported in some genetic leukodystrophies with multisystemic effects.  
9. **Generalized hypotonia**: Early presentation, evolving into spasticity as myelination deficits progress.  

The combination of hypomyelination, spasticity, cerebellar anomalies, and developmental delay strongly supports NKX6-2-related disease, with minor features (e.g., dental crowding) reflecting broader developmental impacts of NKX6-2 mutations."
"['Renal dysplasia', 'Microcephaly', 'Hypothyroidism', 'Cyanosis', 'Eczematoid dermatitis', 'Myoclonus', 'Abnormal facial shape', 'Apnea', 'Immunodeficiency', 'Respiratory failure', 'Elevated circulating thyroid-stimulating hormone concentration', 'Limb joint contracture', 'Severe T-cell immunodeficiency', 'Secondary microcephaly', 'Respiratory arrest', 'Axial hypotonia', 'Abnormality of the umbilical cord', 'Inflammatory abnormality of the skin', 'Abnormal renal physiology', 'Oligoclonal T cell expansion']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Immunodeficiency**: Severe T-cell immunodeficiency and oligoclonal T cell expansion indicate a profound defect in T-cell development, a hallmark of ISDNA caused by *EXTL3* mutations.  
2. **Skeletal/Renal Involvement**: Limb joint contractures and renal dysplasia align with the ""immunoskeletal"" aspect of ISDNA, which disrupts glycosaminoglycan synthesis critical for skeletal and renal development.  
3. **Neurodevelopmental Abnormalities**: Microcephaly (primary and secondary), axial hypotonia, and myoclonus reflect neurodevelopmental deficits due to impaired EXTL3-dependent neural and cerebellar development.  
4. **Cutaneous and Endocrine Features**: Inflammatory skin abnormalities (eczematoid dermatitis) and hypothyroidism (elevated TSH) may stem from dysregulated immune responses and multisystemic dysfunction.  
5. **Respiratory Complications**: Apnea and respiratory failure/arrest likely result from hypotonia, immunodeficiency-related infections, or central nervous system dysregulation.  
6. **Congenital Anomalies**: Abnormal facial shape and umbilical cord abnormalities further support a syndromic congenital disorder like ISDNA.  

The convergence of severe T-cell defects, skeletal/renal malformations, neurodevelopmental delays, and multisystem involvement strongly points to ISDNA as the unifying diagnosis."
"['Hemolytic anemia', 'Spherocytosis', 'Increased red cell osmotic fragility']","['Spherocytosis, type 4']","Disease: Spherocytosis, type 4 (Hereditary Spherocytosis type 4)  
Reasoning:  
1. **Hemolytic anemia**: Caused by premature destruction of spherical red blood cells (spherocytes) in the spleen due to membrane instability.  
2. **Spherocytosis**: Results from mutations in the *SPTB* gene, leading to beta-spectrin deficiency. This disrupts the erythrocyte cytoskeleton, reducing membrane stability and causing loss of surface area, forming spherocytes.  
3. **Increased red cell osmotic fragility**: Spherocytes have decreased surface-to-volume ratio, making them prone to lysis in hypotonic solutions. This confirms the membrane defect.  
4. **Type 4 specificity**: Beta-spectrin deficiency (type 4) is distinguished from other hereditary spherocytosis subtypes (e.g., ankyrin or band 3 mutations) by its genetic etiology and biochemical profile, though clinical overlap exists."
"['Hyperkeratosis', 'Hypopigmentation of the skin', 'Growth delay', 'Restrictive ventilatory defect', 'Bronchiectasis', 'Neoplasm', 'Immunodeficiency', 'Oral leukoplakia', 'Exudative retinopathy', 'Nail dystrophy', 'Subpleural honeycombing', 'Acantholysis']","['Dyskeratosis congenita, autosomal dominant 3']","Dyskeratosis congenita, autosomal dominant 3:  
The patient exhibits the classic triad of dyskeratosis congenita (DC): **oral leukoplakia**, **nail dystrophy**, and **skin abnormalities** (here, hypopigmentation and hyperkeratosis). Additional systemic features align with DC complications: **immunodeficiency** and **neoplasm** risk (due to telomere biology defects), **growth delay** (from bone marrow failure/metabolic stress), **restrictive ventilatory defect**, **bronchiectasis**, and **subpleural honeycombing** (reflecting progressive pulmonary fibrosis, a hallmark of DC). **Exudative retinopathy** and **acantholysis** are rare but reported in DC variants. The autosomal dominant subtype 3 (TINF2 mutation) often presents with severe phenotypes, including early-onset bone marrow failure and multisystem involvement, consistent with this patient’s presentation."
"['Autistic behavior', 'Delayed speech and language development', 'Seizure', 'Global developmental delay', 'Nausea', 'Constipation', 'Reduced brain creatine level by MRS']",['X-linked creatine transporter deficiency/Cerebral creatine deficiency syndrome 1'],"Disease: X-linked creatine transporter deficiency/Cerebral creatine deficiency syndrome 1  
Reasoning:  
1. **Reduced brain creatine level by MRS** is a hallmark of cerebral creatine deficiency syndromes (CCDS), narrowing the diagnosis to AGAT, GAMT, or SLC6A8 (creatine transporter) deficiencies.  
2. **Neurological symptoms** (autistic behavior, delayed speech, seizures, global developmental delay) align with CCDS.  
3. **Gastrointestinal symptoms** (nausea, constipation) are more characteristic of SLC6A8 deficiency than AGAT/GAMT defects.  
4. **X-linked inheritance** (implied by the diagnosis) supports SLC6A8 deficiency, as AGAT/GAMT deficiencies are autosomal recessive.  
5. **Normal/high plasma creatine with low brain creatine** (not explicitly stated but inferred from MRS) suggests a transporter defect rather than a synthesis defect (AGAT/GAMT), where plasma creatine would be low.  
6. Confirmation would require genetic testing for *SLC6A8* mutations or elevated urinary creatine/creatinine ratio, consistent with transporter dysfunction."
"['Narrow face', 'Micrognathia', 'Ptosis', 'Diplopia', 'Dysarthria', 'Hyporeflexia', 'Impaired vibratory sensation', 'Waddling gait', 'Falls', 'Scoliosis', 'High, narrow palate', 'Myoglobinuria', 'Skeletal muscle atrophy', 'Myalgia', 'Gowers sign', 'Scapular winging', 'Proximal muscle weakness', 'Difficulty running', 'Impaired tactile sensation', 'Abnormal nerve conduction velocity']",['Nemaline myopathy 1'],"Disease: Nemaline myopathy 1  
Reasoning:  
1. **Proximal muscle weakness**, **scapular winging**, and **Gowers sign** indicate a primary myopathy affecting proximal muscles, consistent with congenital muscle disorders like nemaline myopathy.  
2. **Skeletal muscle atrophy**, **waddling gait**, **difficulty running**, and **falls** reflect progressive muscle degeneration and functional impairment, hallmark features of nemaline myopathy.  
3. **High, narrow palate** and **scoliosis** suggest congenital musculoskeletal involvement, often seen in nemaline myopathy due to chronic muscle weakness and developmental adaptations.  
4. **Ptosis** and **dysarthria** point to facial and bulbar muscle weakness, aligning with nemaline myopathy’s systemic muscle involvement.  
5. **Myoglobinuria** and **myalgia** may indicate episodic rhabdomyolysis, a rare but documented feature in some nemaline myopathy cases, particularly during metabolic stress.  
6. **Hyporeflexia** and **abnormal nerve conduction velocity** are atypical but could stem from secondary neuropathy or overlap with neuromuscular junction dysfunction in advanced disease.  
7. **Impaired vibratory/tactile sensation** is less common but may arise from prolonged immobilization or comorbid neuropathic changes in chronic myopathy.  

The constellation of congenital craniofacial features (narrow face, micrognathia), skeletal abnormalities, and progressive myopathic symptoms strongly supports **nemaline myopathy type 1** (NEM1), linked to mutations in *TPM3* affecting tropomyosin function in muscle fibers."
"['Spastic paraplegia', 'Dysarthria', 'Gait ataxia', 'Limb ataxia']","['Autosomal recessive spastic paraplegia type 76/Spastic paraplegia 76, autosomal recessive']","Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Spastic paraplegia** indicates upper motor neuron dysfunction, a hallmark of hereditary spastic paraplegias (HSPs).  
2. **Gait and limb ataxia** suggest cerebellar involvement, distinguishing SPG76 from ""pure"" HSP subtypes.  
3. **Dysarthria** further supports cerebellar or bulbar pathology, aligning with SPG76’s association with combined pyramidal and cerebellar features.  
4. SPG76, caused by biallelic *CAPN1* mutations, is characterized by progressive spasticity, ataxia, and dysarthria, consistent with the symptom profile.  
5. Exclusion of mimics (e.g., SPG7, SPG11) relies on genetic testing, but the clinical triad strongly supports SPG76."
"['Multicystic kidney dysplasia', 'Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Abnormal pinna morphology', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Hypotelorism', 'Iris coloboma', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Hip dysplasia', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Abnormal cerebellar vermis morphology', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'Clinodactyly of the 5th finger', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Postnatal growth retardation', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental and CNS anomalies**: Global developmental delay, hypotonia, seizures, spastic tetraparesis, ADHD, and cerebral hypomyelination/delayed myelination align with core neurodevelopmental deficits. Structural brain abnormalities (hypoplastic corpus callosum, ventriculomegaly, cerebellar/pons malformations) further support this.  
2. **Ocular anomalies**: Microphthalmia, iris coloboma, Peters anomaly, optic atrophy, and blepharophimosis are hallmark features of NEDBEH-associated eye involvement.  
3. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return match the cardiac spectrum of the disorder.  
4. **Dysmorphic features**: Triangular face, micrognathia, high palate, hypertelorism, and epicanthus are consistent with reported craniofacial patterns. Conflicting micro/macrocephaly may reflect variable expressivity.  
5. **Multisystem involvement**: Urogenital (cryptorchidism, hypospadias, renal dysplasia), gastrointestinal (pyloric stenosis, annular pancreas), and skeletal (syndactyly, scoliosis) anomalies align with NEDBEH’s systemic nature.  
6. **Growth abnormalities**: Intrauterine and postnatal growth retardation, alongside tall stature (paradoxical but possible in genetic mosaicism or metabolic dysregulation).  
7. **Overlap with RAC1-related phenotype**: NEDBEH is linked to RAC1 mutations, which can manifest with brain-eye-heart anomalies, hypotonia, and variable dysmorphism, as seen here.  
8. **Exclusion of mimics**: While café-au-lait spots or hypertrichosis might suggest RASopathies, the triad of neurodevelopmental delay, structural brain/eye/heart defects, and absence of pathognomonic features of other syndromes (e.g., NF1, Noonan) favors NEDBEH.  

Key confirmatory features include the combination of neurodevelopmental delay, cerebellar/pontine malformations, Peters anomaly, and congenital heart defects, which collectively prioritize NEDBEH over isolated organ-system diagnoses."
"['Thrombocytopenia', 'Abnormal bleeding', 'Increased megakaryocyte count', 'Myelofibrosis', 'Abnormal number of alpha granules']","['Bleeding disorder, platelet-type, 17']","Disease: Bleeding disorder, platelet-type, 17  
Reasoning:  
1. **Thrombocytopenia**: Low platelet count aligns with platelet production or maturation defects, consistent with GFI1B mutation impairing megakaryocyte differentiation.  
2. **Abnormal bleeding**: Caused by dysfunctional platelets due to alpha granule abnormalities, a hallmark of GFI1B-related disorders.  
3. **Increased megakaryocyte count**: GFI1B mutations disrupt megakaryocyte maturation, leading to compensatory hyperplasia despite ineffective platelet production.  
4. **Myelofibrosis**: Reactive fibrosis secondary to cytokine release from abnormal megakaryocytes, a reported feature in GFI1B-associated myelodysplasia.  
5. **Abnormal alpha granules**: GFI1B regulates megakaryocyte development; mutations cause alpha granule deficiency (gray platelet syndrome-like phenotype), confirming platelet-type bleeding disorder 17."
"['Intellectual disability, mild', 'Rectal prolapse', 'Wide pubic symphysis', 'Irregular iliac crest', 'Rhizomelia', 'Short metacarpal', 'Short metatarsal']",['Dyggve-Melchior-Clausen disease/Dyggve-Melchior-Clausen disease'],"Disease: Dyggve-Melchior-Clausen disease  
Reasoning:  
1. **Skeletal Dysplasia Indicators**: Rhizomelia (proximal limb shortening), short metacarpals/metatarsals, and pelvic abnormalities (wide pubic symphysis, irregular/lacy iliac crest) align with DMC’s hallmark skeletal features.  
2. **Intellectual Disability**: Mild cognitive impairment supports DMC, distinguishing it from Smith-McCort dysplasia (a phenocopy without intellectual disability).  
3. **Rectal Prolapse**: Likely secondary to pelvic connective tissue weakness or structural pelvic anomalies, a rare but plausible complication in DMC due to altered musculoskeletal integrity.  
4. **Exclusion of Alternatives**: Mucopolysaccharidoses or spondyloepiphyseal dysplasias lack the specific iliac crest irregularity and intellectual disability pattern seen here.  
5. **Genetic Confirmation**: Autosomal recessive *DYM* mutations confirm DMC, though clinical features alone strongly suggest the diagnosis."
"['Cleft palate', 'Hypertelorism', 'Breech presentation', 'Scoliosis', 'Hip dislocation', 'Cervical kyphosis', 'Elbow flexion contracture', 'Knee dislocation', 'Depressed nasal bridge', 'Short metacarpal', 'Spinal dysraphism', 'High maternal circulating alpha-fetoprotein concentration']",['Larsen syndrome/Larsen syndrome'],"Disease: Larsen syndrome  
Reasoning:  
1. **Multiple congenital joint dislocations** (hip, knee, elbow) are hallmark features of Larsen syndrome, caused by FLNB gene mutations affecting skeletal development.  
2. **Craniofacial anomalies** (hypertelorism, depressed nasal bridge, cleft palate) align with characteristic facial features of the syndrome.  
3. **Spinal abnormalities** (scoliosis, cervical kyphosis, spinal dysraphism) reflect vertebral malformations and neural tube defects associated with Larsen syndrome.  
4. **Short metacarpals** and **elbow/knee contractures** suggest skeletal dysplasia, consistent with the disorder’s connective tissue involvement.  
5. **High maternal alpha-fetoprotein (AFP)** correlates with spinal dysraphism, a neural tube defect often seen prenatally in Larsen syndrome.  
6. **Breech presentation** is common due to restricted fetal movement from joint dislocations.  

The constellation of orthopedic, spinal, and craniofacial findings, alongside elevated AFP, strongly supports Larsen syndrome over other skeletal dysplasias (e.g., Ehlers-Danlos, Stickler syndrome). Genetic testing for FLNB variants would confirm the diagnosis."
"['Progressive microcephaly', 'Short philtrum', 'Strabismus', 'Thick eyebrow', 'Pigmentary retinopathy', 'Tapered finger', 'Global developmental delay', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Joint hypermobility', 'Growth delay', 'Truncal obesity', 'Poor suck', 'Abnormal brainstem morphology', 'Short stature', 'Thick corpus callosum', 'Thick vermilion border', 'Thick hair']",['Cohen syndrome/Cohen syndrome'],"Disease: Cohen syndrome/Cohen syndrome  
Reasoning: The patient presents with key features of Cohen syndrome, including progressive microcephaly, pigmentary retinopathy (a hallmark finding), global developmental delay, generalized hypotonia, and truncal obesity. Characteristic facial features such as short philtrum, thick eyebrows, and thick vermilion border align with the syndrome's phenotype. Additional supportive signs include tapered fingers, joint hypermobility, growth delay/short stature, thick hair, and thick corpus callosum. Poor suck in infancy correlates with hypotonia, while abnormal cerebellum/brainstem morphology may reflect broader neurodevelopmental anomalies. The combination of retinal dystrophy, developmental delay, distinct craniofacial traits, and obesity strongly confirms the diagnosis."
"['Cataract', 'Global developmental delay', 'Choreoathetosis', 'Motor delay', 'Generalized hypotonia', 'Anal atresia', 'Cerebral atrophy', 'Lower limb spasticity', 'Abnormal circulating amino acid concentration', 'Increased serum pyruvate', 'Short stature', 'Generalized tonic seizure', 'Abnormal circulating creatine kinase concentration']",['CODAS syndrome/CODAS syndrome'],"Disease: CODAS syndrome  
Reasoning: The patient presents with cataracts (ocular anomaly), global developmental delay, motor delay, cerebral atrophy (cerebral anomalies), and short stature (skeletal anomaly), aligning with core features of CODAS syndrome. Generalized hypotonia and lower limb spasticity suggest neuromuscular involvement, while abnormal circulating amino acids and increased serum pyruvate indicate mitochondrial dysfunction, consistent with LONP1 gene mutations affecting mitochondrial protein homeostasis. Choreoathetosis and seizures may arise from cerebral atrophy or metabolic disturbances. Although anal atresia is atypical for CODAS, the constellation of cerebral, ocular, metabolic, and skeletal findings strongly supports this diagnosis over other mitochondrial or peroxisomal disorders."
"['Autistic behavior', 'Intellectual disability', 'Seizure', 'Specific learning disability', 'Cortical tubers', 'Hypomelanotic macule', 'Angiofibromas']",['Tuberous sclerosis-1'],"Disease: Tuberous sclerosis-1  
Reasoning:  
1. **Cortical tubers** and **seizures** are hallmark neurological features of tuberous sclerosis complex (TSC), caused by abnormal brain development.  
2. **Hypomelanotic macules** (ash-leaf spots) and **angiofibromas** are classic dermatological signs of TSC.  
3. **Intellectual disability**, **autistic behavior**, and **specific learning disability** align with TSC-associated neurodevelopmental disorders.  
4. The combination of neurological, cutaneous, and neuropsychiatric symptoms strongly supports a TSC diagnosis.  
5. The specified subtype ""Tuberous sclerosis-1"" corresponds to mutations in the *TSC1* gene (9q34), one of two genetic causes of TSC."
"['High palate', 'Thin upper lip vermilion', 'Long face', 'Smooth philtrum', 'Broad forehead', 'Macrotia', 'Deeply set eye', 'Ptosis', 'Hypotelorism', 'Intrauterine growth retardation', 'Tetralogy of Fallot', 'Gastroesophageal reflux', 'Feeding difficulties', 'Neurodevelopmental delay']","['Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome/Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies']","Disease: Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome/Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies  
Reasoning:  
1. **Facial dysmorphism**: The patient exhibits multiple facial features characteristic of the syndrome, including a *high palate*, *thin upper lip vermilion*, *long face*, *smooth philtrum*, *broad forehead*, *macrotia* (large ears), *deeply set eyes*, *ptosis* (droopy eyelids), and *hypotelorism* (reduced interpupillary distance). These align with the ""dysmorphic facies"" hallmark of the disorder.  
2. **Neurodevelopmental delay**: *Intrauterine growth retardation* and *neurodevelopmental delay* correlate with the syndrome’s ""global developmental delay"" component, reflecting prenatal and postnatal growth/developmental impairments.  
3. **Seizures**: While not explicitly listed, the diagnosis name includes seizures as a key feature. This suggests either an oversight in symptom reporting or variability in presentation (e.g., seizures may develop later or were not yet documented).  
4. **Distal limb anomalies**: Though not mentioned in the patient’s symptoms, the syndrome’s name highlights distal limb abnormalities (e.g., brachydactyly, camptodactyly). Their absence here may reflect phenotypic variability or incomplete clinical documentation.  
5. **Associated anomalies**: *Tetralogy of Fallot* (congenital heart defect) and *gastroesophageal reflux/feeding difficulties* are consistent with multisystem involvement seen in neurodevelopmental-genetic syndromes.  

**Conclusion**: The patient’s facial dysmorphism, neurodevelopmental delays, and systemic anomalies strongly align with the syndrome’s core features. Absence of explicitly reported seizures or limb anomalies may reflect diagnostic variability or incomplete phenotyping, but the overall pattern justifies the diagnosis. Genetic testing (e.g., WES) is recommended to confirm."
"['Abnormality of the kidney', 'High palate', 'Hearing impairment', 'Sensorineural hearing impairment', 'Choanal atresia', 'Abnormality of the eye', 'Deeply set eye', 'Ptosis', 'Esotropia', 'Compulsive behaviors', 'Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Cyanosis', 'Spatulate thumbs', 'Intellectual disability', 'Ataxia', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Bilateral ptosis', 'Atrial septal defect', 'Abnormal cardiac septum morphology', 'Hyperconvex nail', 'Myopathic facies', 'Hypoplasia of the corpus callosum', 'Apnea', 'Abnormal brainstem morphology', 'Language impairment', 'Expressive language delay', 'Aortic root aneurysm', 'Scoliosis', 'Myopathy', 'Sleep apnea', 'Abnormal eye morphology', 'Choking episodes']","['Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart']","Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
**Reasoning**:  
1. **Neurodevelopmental Core Features**: Intellectual disability, global developmental delay, delayed speech/language development, expressive language delay, and compulsive behaviors with abnormal repetitive mannerisms align with the neurodevelopmental axis of NEDBEH.  
2. **Brain Anomalies**: Hypoplasia of the corpus callosum and abnormal brainstem morphology directly correspond to structural brain abnormalities in NEDBEH.  
3. **Ocular Involvement**: Abnormality of the eye, deeply set eyes, bilateral ptosis, esotropia, and abnormal eye morphology satisfy the ""eye anomalies"" criterion.  
4. **Cardiac Defects**: Atrial septal defect, abnormal cardiac septum morphology, and aortic root aneurysm reflect cardiac anomalies associated with NEDBEH.  
5. **Systemic Features**: Hypotonia, ataxia, myopathy, scoliosis, hyperconvex nails, spatulate thumbs, and myopathic facies suggest multisystem involvement, common in genetic neurodevelopmental disorders.  
6. **Auxiliary Symptoms**: Cyanosis, apnea, choking episodes, and sensorineural hearing impairment are secondary to neuromuscular, cardiac, or brainstem dysfunction.  
7. **Exclusion of Overlap**: The constellation of symptoms (brain-eye-heart triad) is distinct from isolated syndromes (e.g., CHARGE, Cornelia de Lange), favoring NEDBEH’s broader diagnostic scope.  

This synthesis of neurodevelopmental delays, structural brain/eye/cardiac defects, and supportive systemic features confirms NEDBEH as the unifying diagnosis."
"['Brachycephaly', 'Hearing impairment', 'Recurrent otitis media', 'Strabismus', 'Delayed speech and language development', 'Intellectual disability', 'Global developmental delay', 'Motor delay', 'Generalized hypotonia', 'Truncal obesity', 'Sleep disturbance', 'Scoliosis', 'Short stature', 'Midface retrusion', 'Self-injurious behavior']",['Smith-Magenis syndrome/Smith-Magenis syndrome'],"Disease: Smith-Magenis syndrome  
**Reasoning**:  
1. **Craniofacial features**: Brachycephaly (short skull) and midface retrusion align with the characteristic facial dysmorphism in Smith-Magenis syndrome (SMS).  
2. **Neurodevelopmental delays**: Global developmental delay, intellectual disability, motor delay, and speech/language delays are hallmark features of SMS, often linked to *RAI1* gene haploinsufficiency.  
3. **Behavioral phenotype**: Self-injurious behavior (e.g., head-banging, nail-pulling) is pathognomonic for SMS, alongside sleep disturbances (inverted melatonin rhythm causing fragmented sleep).  
4. **Musculoskeletal findings**: Hypotonia in infancy, scoliosis, and short stature are common due to connective tissue and skeletal involvement.  
5. **Otolaryngologic issues**: Recurrent otitis media and hearing impairment stem from craniofacial abnormalities (e.g., Eustachian tube dysfunction).  
6. **Metabolic features**: Truncal obesity emerges in late childhood/adolescence, likely due to hormonal dysregulation and behavioral factors.  
7. **Ocular involvement**: Strabismus is frequently observed in SMS due to craniofacial and neuromuscular factors.  

This constellation of symptoms, particularly the triad of developmental delay, self-injury, and circadian rhythm-driven sleep disturbances, strongly supports SMS, typically caused by a 17p11.2 deletion or *RAI1* mutation."
"['Torticollis', 'Motor delay', 'Pachygyria', 'Myoclonus', 'Lissencephaly', 'Hyperreflexia', 'Hip dysplasia', 'Bilateral tonic-clonic seizure', 'Postural tremor', 'Genu valgum', 'Hyperlordosis', 'Babinski sign', 'Abnormal muscle tone', 'Lateral ventricle dilatation', 'Attention deficit hyperactivity disorder', 'Cerebellar dysplasia', 'Cerebral palsy', 'Cognitive impairment']","['Cortical dysplasia, complex, with other brain malformations 7']","Disease: Cortical dysplasia, complex, with other brain malformations 7  
Reasoning:  
1. **Brain Malformations**: The presence of *lissencephaly* (smooth brain surface) and *pachygyria* (broad, simplified gyri) directly aligns with cortical dysplasia. *Cerebellar dysplasia* and *lateral ventricle dilatation* further support complex brain malformations.  
2. **Neurological Symptoms**: *Bilateral tonic-clonic seizures*, *myoclonus*, and *hyperreflexia* are consistent with cortical hyperexcitability and abnormal neuronal migration, hallmarks of cortical dysplasia.  
3. **Developmental Delays**: *Motor delay*, *cognitive impairment*, and *cerebral palsy* correlate with disrupted cortical organization and cerebellar dysfunction.  
4. **Motor and Musculoskeletal Features**: *Abnormal muscle tone*, *hyperlordosis*, *hip dysplasia*, and *genu valgum* arise from aberrant motor control and secondary musculoskeletal adaptations.  
5. **ADHD and Tremors**: *Attention deficit hyperactivity disorder* and *postural tremor* may reflect disrupted cortico-striatal or cerebellar circuits due to malformations.  
6. **Babinski Sign**: This upper motor neuron sign reinforces central nervous system involvement.  
The combination of cortical dysgenesis (lissencephaly/pachygyria), cerebellar dysplasia, seizures, and developmental deficits strongly matches the genetic and phenotypic profile of *Cortical dysplasia, complex, with other brain malformations 7* (OMIM #618737), often linked to mutations in *CNTNAP2* or related pathways."
"['Brachydactyly', 'Delayed ossification of carpal bones', 'Abnormal facial shape', 'Waddling gait', 'Flared femoral metaphysis', 'Genu varum', 'Metaphyseal irregularity', 'Short long bone', 'Hypoplasia of the capital femoral epiphysis', 'Flat acetabular roof', 'Short stature', 'Beaking of vertebral bodies', 'Mucopolysacchariduria', 'Irregular acetabular roof', 'Disproportionate short-limb short stature', 'Irregular epiphyses', 'Lower limb pain']",['Pseudoachondroplasia/Pseudoachondroplasia'],"Disease: Pseudoachondroplasia  
**Reasoning**:  
1. **Disproportionate short-limb short stature** and **short long bones** are hallmark features of pseudoachondroplasia, a skeletal dysplasia caused by *COMP* gene mutations.  
2. **Metaphyseal irregularity**, **flared femoral metaphysis**, and **hypoplasia of the capital femoral epiphysis** align with characteristic metaphyseal/epiphyseal dysplasia seen radiographically.  
3. **Genu varum** and **waddling gait** result from abnormal lower limb alignment and hip dysplasia, exacerbated by **flat/irregular acetabular roof**.  
4. **Beaking of vertebral bodies** reflects vertebral anomalies common in pseudoachondroplasia, though less severe than in mucopolysaccharidoses (MPS).  
5. **Delayed ossification of carpal bones** and **brachydactyly** correlate with delayed skeletal maturation and shortened bones.  
6. **Mucopolysacchariduria** is atypical but may represent a coincidental finding or lab overlap; dominant skeletal features outweigh this.  
7. **Lower limb pain** stems from early-onset joint degeneration, a known complication.  
8. **Abnormal facial shape** is mild/nonspecific in pseudoachondroplasia, contrasting with coarse facies in MPS, reinforcing the diagnosis."
"['Nystagmus', 'Pancytopenia', 'Bone marrow hypocellularity']",['Ataxia-pancytopenia syndrome/Ataxia-Pancytopenia syndrome'],"Disease: Ataxia-Pancytopenia Syndrome  
Reasoning: The triad of nystagmus (indicative of cerebellar dysfunction/ataxia), pancytopenia, and bone marrow hypocellularity aligns with Ataxia-Pancytopenia Syndrome (APS). APS is a rare genetic disorder characterized by bone marrow failure (hypocellularity and pancytopenia) and neurological manifestations like ataxia, often accompanied by nystagmus. The absence of typical features of other marrow failure syndromes (e.g., physical anomalies in Fanconi anemia or hypercellular marrow in myelodysplastic syndromes) further supports this diagnosis."
"['Syncope', 'Cardiomyopathy', 'Ventricular fibrillation', 'Cardiac arrest', 'Right bundle branch block', 'Myocarditis']","['Cateeholaminergic polymorphic ventricular tachycardia, CPVT/Catecholaminergic polymorphic ventricular tachycardia/Ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy']","Disease: CPVT/Catecholaminergic polymorphic ventricular tachycardia  
Reasoning:  
1. **Syncope and Cardiac Arrest**: CPVT is characterized by adrenergically mediated ventricular arrhythmias, typically triggered by physical/emotional stress. These episodes manifest as syncope or sudden cardiac arrest, aligning with the patient’s symptoms.  
2. **Ventricular Fibrillation**: A hallmark of CPVT is bidirectional/polymorphic ventricular tachycardia (VT) progressing to ventricular fibrillation (VF), especially under catecholamine surge.  
3. **Cardiomyopathy**: While CPVT is primarily an electrical disorder, advanced cases may develop atrial dysfunction or dilated cardiomyopathy due to chronic arrhythmia burden or genetic overlap (e.g., RYR2 mutations).  
4. **Right Bundle Branch Block (RBBB)**: Not a classic CPVT feature but may arise secondary to structural remodeling from cardiomyopathy or myocardial inflammation.  
5. **Myocarditis**: Could be coincidental or misdiagnosed; CPVT-associated arrhythmias may mimic myocarditis symptoms (e.g., palpitations, syncope). Further evaluation (e.g., cardiac MRI, biopsy) would exclude primary inflammation.  
6. **Diagnostic Confirmation**: Genetic testing for RYR2 or CASQ2 mutations and exercise stress testing (provoking VT/VF) are critical to confirm CPVT, especially in the presence of adrenergically driven arrhythmias.  

**Exclusion**: Structural causes (e.g., ischemic cardiomyopathy) and acquired myocarditis should be ruled out via imaging and lab studies (e.g., troponin, viral PCR)."
"['Irritability', 'Hypertonia', 'Generalized hypotonia', 'Hyperreflexia', 'Fever', 'Recurrent pneumonia']",['Krabbe disease'],"Disease: Krabbe disease  
Reasoning:  
1. **Neurological symptoms** (hypertonia, hyperreflexia, irritability) suggest demyelination, a hallmark of Krabbe disease caused by galactocerebrosidase deficiency.  
2. **Generalized hypotonia** may reflect peripheral neuropathy due to psychosine toxicity, a feature seen in early-infantile Krabbe disease.  
3. **Recurrent pneumonia** aligns with bulbar dysfunction or aspiration risk from impaired swallowing/airway control.  
4. **Fever** is atypical in Krabbe but could stem from secondary infections (e.g., pneumonia) or autonomic dysregulation.  
5. Symptom progression (irritability → spasticity → hypotonia) matches the classic trajectory of infantile-onset Krabbe.  
6. **Combined UMN/LMN signs** (hyperreflexia + hypotonia) point to a neurodegenerative disorder affecting both central and peripheral nervous systems."
"['Supranuclear gaze palsy', 'Dysarthria', 'Hyporeflexia', 'Athetosis']","['Ataxia-oculomotor apraxia type 1/Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia']","Disease: Ataxia-oculomotor apraxia type 1 (AOA1)  
Reasoning:  
1. **Supranuclear gaze palsy**: Likely reflects oculomotor apraxia, a hallmark of AOA1, where patients struggle to initiate voluntary horizontal eye movements despite intact cranial nerves.  
2. **Dysarthria**: Common in cerebellar ataxia, a core feature of AOA1 due to progressive cerebellar degeneration.  
3. **Hyporeflexia**: Indicates peripheral neuropathy, which occurs in AOA1 as a result of axonal sensorimotor neuropathy.  
4. **Athetosis**: Less typical but may arise from basal ganglia dysfunction or overlap with other movement disorders (e.g., dystonia/myoclonus) seen in neurodegenerative ataxias.  
5. **Early-onset**: AOA1 typically manifests in childhood, aligning with the disease’s classification as an early-onset ataxia.  
6. **Hypoalbuminemia**: A key biochemical marker of AOA1, caused by impaired hepatic albumin synthesis.  
The combination of cerebellar ataxia, oculomotor apraxia, neuropathy, and systemic features (hypoalbuminemia) strongly supports AOA1, despite atypical athetosis, which may reflect phenotypic variability."
"['Sensorineural hearing impairment', 'Increased circulating renin level', 'Hypotonia', 'Polyhydramnios', 'Hyperuricemia', 'Hypercalciuria', 'Hyponatremia', 'Hypochloremia', 'Metabolic alkalosis']","['Bartter syndrome, type 4A, neonatal, with sensorineural deafness']","Disease: Bartter syndrome, type 4A, neonatal, with sensorineural deafness  
Reasoning:  
1. **Metabolic alkalosis, hypochloremia, and hyponatremia** indicate renal salt-wasting, a hallmark of Bartter syndrome.  
2. **Hypercalciuria** and **hyperuricemia** align with defective electrolyte reabsorption in the thick ascending limb of Henle (TAL), consistent with Bartter syndrome.  
3. **Increased circulating renin** reflects secondary hyperreninemia due to chronic volume depletion from renal salt loss.  
4. **Polyhydramnios** is a prenatal feature of neonatal Bartter syndromes, caused by fetal polyuria.  
5. **Sensorineural hearing impairment** specifically points to type 4A (BSND gene mutation), which disrupts chloride transport in both the kidney and inner ear.  
6. **Hypotonia** in neonates is linked to electrolyte imbalances (e.g., hypokalemia, though not explicitly listed) and chronic volume depletion.  
7. Type 4A is distinguished from other Bartter subtypes (types 1-3) by the presence of deafness and mutations affecting the barttin protein, critical for renal and cochlear function."
"['Macroglossia', 'Bifid uvula', 'Craniosynostosis', 'Patent foramen ovale', 'Lymphopenia', 'Hypoglycemia', 'Abnormal facial shape', 'Recurrent respiratory infections', 'Skeletal dysplasia', 'Hyperbilirubinemia', 'Lumbar kyphosis', 'Cleft anterior mitral valve leaflet']",['Immunoskeletal dysplasia with neurodevelopmental abnormalities'],"Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal dysplasia** and **lumbar kyphosis**: Core features of ISDNA, linked to EXTL3 gene mutations affecting glycosaminoglycan synthesis and skeletal development.  
2. **Lymphopenia** and **recurrent respiratory infections**: Reflect immunodeficiency, a hallmark of ISDNA due to abnormal lymphopoiesis and T-cell dysfunction.  
3. **Craniosynostosis** and **abnormal facial shape**: Align with craniofacial anomalies reported in ISDNA, though less common than other skeletal findings.  
4. **Patent foramen ovale** and **cleft anterior mitral valve leaflet**: Suggest connective tissue/cardiac involvement, potentially secondary to dysregulated extracellular matrix remodeling.  
5. **Hypoglycemia** and **hyperbilirubinemia**: May indicate metabolic dysregulation, occasionally observed in ISDNA due to systemic glycosylation defects.  
6. **Macroglossia** and **bifid uvula**: Less typical but possible in syndromic craniofacial dysmorphism.  
7. **Neurodevelopmental abnormalities** (implied in diagnosis name): Consistent with ISDNA’s phenotype, though not explicitly listed in symptoms.  

The combination of skeletal, immune, and subtle craniofacial/cardiac anomalies strongly supports ISDNA, despite atypical symptoms like macroglossia. Genetic testing for EXTL3 variants is critical for confirmation."
"['Petechiae', 'Thrombocytopenia', 'Decreased mean platelet volume', 'Megakaryocytopenia']",['Thrombocytopenia 3'],"Thrombocytopenia 3: The patient presents with thrombocytopenia, megakaryocytopenia (reduced bone marrow megakaryocytes), and decreased mean platelet volume (MPV), all indicative of impaired platelet production. Thrombocytopenia 3 (THC3), a rare autosomal recessive disorder caused by mutations in the *MPL* gene, disrupts thrombopoietin receptor signaling, leading to defective megakaryocyte maturation and platelet synthesis. Petechiae arise from severe thrombocytopenia. Unlike immune-mediated thrombocytopenia (e.g., ITP), THC3 features hypocellular megakaryocytes and low MPV due to reduced platelet turnover, aligning with the observed profile. Genetic testing for *MPL* variants would confirm the diagnosis."
"['Gingival overgrowth', 'Nystagmus', 'Dystonia', 'Respiratory failure', 'Cerebellar vermis atrophy', 'Poor gross motor coordination', 'Reduced visual acuity', 'Infantile muscular hypotonia', 'Cognitive impairment']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Neurological and Motor Symptoms**: The patient exhibits **cerebellar vermis atrophy**, **poor gross motor coordination**, **nystagmus**, and **dystonia**, consistent with cerebellar dysfunction and spastic ataxia, hallmark features of NKX6-2-related disorders.  
2. **Hypomyelination Evidence**: **Cognitive impairment**, **reduced visual acuity** (optic nerve hypomyelination), and **respiratory failure** (brainstem involvement) align with progressive hypomyelinating leukodystrophy.  
3. **Developmental History**: **Infantile muscular hypotonia** often precedes spasticity in early disease stages.  
4. **Uncommon Features**: **Gingival overgrowth** is atypical but may represent a phenotypic variant or secondary effect of chronic neurological dysfunction.  
5. **Genetic Correlation**: NKX6-2 mutations disrupt oligodendrocyte function, causing hypomyelination, cerebellar atrophy, and motor deficits, strongly matching the symptom profile."
"['Hepatosplenomegaly', 'Neurodegeneration', 'Memory impairment', 'Psychomotor deterioration', 'Progressive encephalopathy', 'Falls', 'Neuronal loss in central nervous system', 'Central nervous system degeneration', 'Progressive forgetfulness', 'Progressive language deterioration', 'Social and occupational deterioration', 'Slowed slurred speech', 'Progressive psychomotor deterioration', 'Atrophy/Degeneration affecting the cerebrum']","['Niemann-Pick disease type C; NPD-C/Niemann-Pick disease type C/Niemann-pick disease, type C1']","Disease: Niemann-Pick disease type C (NPC1)  
Reasoning:  
1. **Hepatosplenomegaly**: A hallmark of NPC1 due to lysosomal accumulation of sphingolipids and cholesterol in visceral organs.  
2. **Neurodegenerative symptoms**: Progressive encephalopathy, memory impairment, psychomotor deterioration, and neuronal loss align with NPC1’s characteristic central nervous system (CNS) involvement, driven by lipid trafficking defects.  
3. **Speech and language decline**: Slurred speech and progressive language deterioration reflect cerebellar and cortical atrophy, common in NPC1.  
4. **CNS degeneration patterns**: Atrophy in the cerebrum and neuronal loss correlate with NPC1’s neuropathology, particularly in the thalamus, cerebellum, and cortex.  
5. **Progressive course**: Symptoms like occupational/social decline and worsening forgetfulness mirror NPC1’s insidious progression, often beginning with visceral symptoms before neurological decline.  
6. **Exclusion of mimics**: Symptoms overlap with other lysosomal disorders (e.g., Gaucher disease), but the combination of visceral and CNS features strongly supports NPC1."
"['Microcephaly', 'Sensorineural hearing impairment', 'Deeply set eye', 'Carious teeth', 'Cutaneous photosensitivity', 'Generalized hypotonia', 'Short stature']",['Cockayne syndrome A'],"Disease: Cockayne syndrome A  
Reasoning:  
1. **Cutaneous photosensitivity** - A hallmark feature of Cockayne syndrome, linked to DNA repair defects.  
2. **Microcephaly** and **short stature** - Reflect progressive growth failure and neurodegeneration characteristic of the syndrome.  
3. **Sensorineural hearing impairment** - Caused by neurodegeneration and cochlear dysfunction.  
4. **Deeply set eyes** - Common facial dysmorphism due to facial adipose tissue loss.  
5. **Carious teeth** - Results from enamel hypoplasia and reduced salivary flow.  
6. **Generalized hypotonia** - Indicates central/peripheral nervous system involvement.  
7. **Exclusion of mimics** - Differentiated from xeroderma pigmentosum (no skin cancer predisposition) and trichothiodystrophy (no brittle hair/ichthyosis).  
8. **Consistency with Type A (Classic form)** - Matches early childhood onset and typical multisystem progression."
"['Sloping forehead', 'Bulbous nose', 'Intellectual disability', 'Seizure', 'Global brain atrophy', 'Severe muscular hypotonia', 'Tented upper lip vermilion', 'Severe global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial Dysmorphisms**: Sloping forehead, bulbous nose, and tented upper lip vermilion align with characteristic facies described in TBCK syndrome.  
2. **Neurological Features**: Severe global developmental delay, intellectual disability, and seizures correlate with TBCK-associated central nervous system involvement.  
3. **Hypotonia**: Severe muscular hypotonia is a hallmark of the disorder, reflecting neuromuscular dysfunction.  
4. **Neuroimaging Findings**: Global brain atrophy supports a progressive neurodegenerative process linked to TBCK mutations.  
5. **Genetic Consistency**: The constellation of symptoms matches the phenotype of TBCK-related syndromes, caused by biallelic loss-of-function variants in the *TBCK* gene, which disrupts mTOR signaling and lysosomal function.  
6. **Exclusion of Mimics**: Features distinguish it from other hypotonia-associated disorders (e.g., Prader-Willi, Rett syndrome) by the unique facial gestalt and absence of metabolic/storage disease markers."
"['Neurogenic bladder', 'Macroglossia', 'Macrocephaly', 'Coarse facial features', 'Thick eyebrow', 'Hyperthyroidism', 'Intellectual disability', 'Seizure', 'Reduced tendon reflexes', 'Absent speech', 'Developmental regression', 'Scoliosis', 'Severe muscular hypotonia', 'Severe global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Severe muscular hypotonia and reduced tendon reflexes**: Core features of TBCK syndrome, reflecting neuromuscular dysfunction.  
2. **Severe global developmental delay and intellectual disability**: Consistent with the syndrome’s hallmark neurocognitive impairments.  
3. **Coarse facial features, macrocephaly, thick eyebrows, and macroglossia**: Align with characteristic dysmorphic findings in TBCK-related disorders.  
4. **Seizures and developmental regression**: Reported in severe cases, possibly linked to progressive neurological involvement.  
5. **Neurogenic bladder and scoliosis**: Suggestive of autonomic and skeletal muscle involvement, common in neuromuscular genetic disorders.  
6. **Absent speech**: Expected in severe developmental delay associated with TBCK mutations.  
7. **Hyperthyroidism**: Atypical but may represent a comorbid condition or phenotypic expansion; primary diagnosis remains anchored to neuromuscular and dysmorphic features.  
8. **Exclusion of mimics**: Differentiated from lysosomal storage disorders (no organomegaly/ocular findings) and Rett syndrome (no regression pattern or typical hand stereotypies). Genetic testing for TBCK mutations would confirm."
"['Abnormality of facial musculature', 'Bulbar palsy', 'Flexion contracture', 'Joint laxity', 'Loss of ambulation', 'Elevated circulating creatine kinase concentration', 'Scapular winging', 'Generalized muscle hypertrophy', 'Pelvic girdle muscle weakness', 'Progressive pulmonary function impairment', 'Proximal muscle weakness in lower limbs', 'Flaky paint dermatosis', 'Abnormal emotion/affect behavior']","['Muscular dystrophy, limb-girdle, type 2Z', 'POGLUT1-related limb-girdle muscular dystrophy R21']","Disease: Muscular dystrophy, limb-girdle, type 2Z (POGLUT1-related limb-girdle muscular dystrophy R21)  
Reasoning:  
1. **Pelvic girdle weakness** and **proximal lower limb weakness** align with the limb-girdle muscular dystrophy (LGMD) phenotype.  
2. **Elevated creatine kinase** indicates muscle breakdown, consistent with muscular dystrophy.  
3. **Scapular winging** and **loss of ambulation** reflect progressive shoulder and pelvic muscle degeneration.  
4. **Generalized muscle hypertrophy** (e.g., pseudoathletic appearance) is reported in POGLUT1-related LGMD due to fibrofatty muscle replacement.  
5. **Facial musculature abnormality** and **bulbar palsy** suggest cranial nerve involvement, a recognized feature of POGLUT1 mutations affecting Notch signaling.  
6. **Flaky paint dermatosis** (scaly/dry skin) may link to Notch pathway disruption, which impacts epidermal integrity.  
7. **Joint laxity** with **flexion contractures** mirrors the mixed connective tissue phenotype seen in collagen/Notch-related disorders.  
8. **Progressive pulmonary impairment** results from respiratory muscle weakness in advanced disease.  
9. **Abnormal emotion/affect behavior** could stem from chronic disability or rare CNS involvement via Notch signaling.  
10. Genetic confirmation of **POGLUT1 mutations** (causing LGMD2Z/R21) explains the multisystemic features, unifying muscular, dermatologic, and bulbar symptoms.  

*Note: Both listed diagnoses refer to the same condition (LGMD2Z is the historical name; R21 denotes the OMIM classification).*"
"['Cleft palate', 'Hydrocephalus', 'Microcephaly', 'Narrow forehead', 'Micrognathia', 'Posteriorly rotated ears', 'Low-set ears', 'Recurrent otitis media', 'Prominent nasal bridge', 'Short neck', 'Broad neck', 'Downslanted palpebral fissures', 'Long eyelashes', 'Exotropia', 'Delayed speech and language development', 'Pectus excavatum', 'Shield chest', 'Adducted thumb', 'Global developmental delay', 'Growth delay', 'Decreased fetal movement', 'Talipes equinovarus', 'Overlapping toe', 'Frontal bossing', 'Constipation', 'Asthma', 'Coarse hair', 'Drooling', 'Babinski sign', 'Prominent metopic ridge', 'Wide intermamillary distance', 'Curly eyelashes', 'Abnormal cranial nerve physiology', 'Long fingers']",['Desmosterolosis/DESMOSTEROLOSIS'],"Disease: Desmosterolosis  
Reasoning:  
1. **Craniofacial Dysmorphism**: Narrow forehead, micrognathia, posteriorly rotated ears, low-set ears, prominent nasal bridge, downslanted palpebral fissures, and frontal bossing align with craniofacial features of desmosterolosis, a disorder of cholesterol biosynthesis.  
2. **Neurological Abnormalities**: Hydrocephalus, microcephaly, Babinski sign, and abnormal cranial nerve physiology reflect impaired brain development and myelination due to defective cholesterol metabolism.  
3. **Skeletal Malformations**: Adducted thumb, talipes equinovarus, pectus excavatum, and overlapping toe are consistent with skeletal defects seen in cholesterol biosynthesis disorders.  
4. **Developmental Delays**: Global developmental delay, delayed speech, and growth delay correlate with systemic impacts of desmosterol accumulation on cellular function and neurodevelopment.  
5. **Ectodermal Features**: Coarse hair, long/curly eyelashes, and recurrent otitis media (secondary to cleft palate) suggest ectodermal and structural anomalies linked to cholesterol pathway disruption.  
6. **Prenatal/Neonatal Signs**: Decreased fetal movement and congenital anomalies (e.g., cleft palate) are reported in desmosterolosis, stemming from in utero cholesterol deficiency.  
7. **Exclusion of Similar Disorders**: Overlap with Smith-Lemli-Opitz syndrome (SLOS) is ruled out by the absence of classic SLOS features (e.g., syndactyly, genital anomalies) and presence of hydrocephalus, which is more specific to desmosterolosis.  

Biochemical confirmation (elevated desmosterol) would solidify the diagnosis, but phenotypic alignment strongly supports DESMOSTEROLOSIS."
"['Triangular face', 'Cafe-au-lait spot', 'Flexion contracture', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Short stature', 'Bone marrow hypocellularity']","['Fanconi anemia, complementation group C']","Disease: Fanconi anemia, complementation group C  
Reasoning:  
1. **Bone marrow hypocellularity**: A hallmark of Fanconi anemia (FA), reflecting progressive bone marrow failure and predisposition to aplastic anemia.  
2. **Cafe-au-lait spots**: Common in FA due to genetic instability and pigmentation abnormalities.  
3. **Intrauterine growth retardation (IUGR) & Short stature**: Growth defects align with FA’s systemic developmental impacts.  
4. **Ventricular septal defect (VSD)**: Congenital heart anomalies are frequently associated with FA.  
5. **Flexion contracture**: Skeletal abnormalities, including joint contractures, are typical in FA due to radial ray defects or connective tissue involvement.  
6. **Triangular face**: Facial dysmorphism (e.g., triangular facial shape, micrognathia) is consistent with FA’s phenotypic spectrum.  
7. **Genetic subtype (complementation group C)**: Confirmed via genetic testing (FANCC gene mutations) and chromosomal breakage assays (e.g., diepoxybutane sensitivity).  
This constellation of congenital, hematologic, and developmental features strongly supports FA complementation group C."
"['Macrocephaly', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Reduced tendon reflexes', 'Abnormal facial shape', 'Ventriculomegaly', 'Developmental regression', 'Severe global developmental delay']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Hypotonia and reduced tendon reflexes** are hallmark features of TBCK syndrome, reflecting neuromuscular involvement.  
2. **Severe global developmental delay** and **intellectual disability** align with the syndrome’s core neurocognitive phenotype.  
3. **Macrocephaly** and **ventriculomegaly** correlate with reported structural brain anomalies, including cortical atrophy or white matter changes.  
4. **Seizures** are commonly observed due to underlying neuronal dysfunction.  
5. **Abnormal facial shape** (e.g., coarse facies, hypertelorism, broad nasal tip) matches the characteristic dysmorphology.  
6. **Delayed speech/language development** and **developmental regression** (in some cases) reflect progressive neurological deterioration or static encephalopathy.  
7. Genetic confirmation would identify biallelic *TBCK* mutations, but clinical consistency suffices for preliminary diagnosis."
"['Open mouth', 'Brachycephaly', 'Sloping forehead', 'Long philtrum', 'Deeply set eye', 'Shallow orbits', 'Reduced eye contact', 'Motor delay', 'Cerebellar atrophy', 'Areflexia', 'Absent septum pellucidum', 'Absent speech', 'Hyperreflexia', 'Microcytic anemia', 'Bilateral tonic-clonic seizure', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Status epilepticus', 'Enlarged cisterna magna', 'Global brain atrophy', 'Hypokinesia', 'Respiratory failure', 'Os odontoideum', 'Severe muscular hypotonia', 'CNS demyelination', 'Tented upper lip vermilion', 'Severe global developmental delay', 'Lipoma', 'Brain atrophy', 'EMG: myokymic discharges']","['TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3']","Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Features like *brachycephaly*, *sloping forehead*, *long philtrum*, *tented upper lip vermilion*, and *deeply set eyes* align with the facial dysmorphisms described in TBCK syndrome.  
2. **Neurological and developmental deficits**: *Severe muscular hypotonia*, *motor delay*, *absent speech*, *severe global developmental delay*, and *hypokinesia* correlate with the syndrome’s hallmark hypotonia and psychomotor retardation.  
3. **Brain abnormalities**: *Cerebellar atrophy*, *global brain atrophy*, *hypoplasia of the corpus callosum*, *ventriculomegaly*, and *enlarged cisterna magna* reflect widespread CNS involvement, consistent with TBCK’s neurodegenerative features.  
4. **Seizure phenotype**: *Bilateral tonic-clonic seizures* and *status epilepticus* are reported in severe TBCK cases due to cortical and cerebellar dysfunction.  
5. **EMG findings**: *Myokymic discharges* suggest peripheral nerve hyperexcitability, observed in some TBCK patients with neuromuscular involvement.  
6. **Absent septum pellucidum** and **CNS demyelination**: These rare structural anomalies further support a complex neurodevelopmental disorder like TBCK.  
7. **Respiratory failure**: Likely secondary to severe hypotonia and brainstem dysfunction, a known complication in advanced stages.  
8. **Mixed reflex abnormalities**: *Areflexia* (from hypotonia) and *hyperreflexia* (from upper motor neuron involvement) highlight the multisystem neurological impact.  
9. **Lipoma** and **os odontoideum**: While less specific, they may represent connective tissue dysregulation linked to TBCK’s genetic pathway (mTORC1 dysregulation).  

The combination of facial dysmorphism, neurodevelopmental regression, CNS structural defects, and electrophysiological findings strongly points to TBCK-related syndrome. Genetic testing for *TBCK* mutations would confirm the diagnosis."
"['Torticollis', 'Vertical supranuclear gaze palsy', 'Hypometric saccades', 'Supranuclear gaze palsy', 'Nystagmus', 'Ataxia', 'Dysarthria', 'Motor delay', 'Cerebellar atrophy', 'Dystonia', 'Morphological abnormality of the pyramidal tract', 'Spastic ataxia', 'Inability to walk', 'CNS hypomyelination', 'Somatic sensory dysfunction', 'Demyelinating peripheral neuropathy', 'Peripheral neuropathy', 'Abnormal involuntary eye movements', 'Titubation']","['NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy']","Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8  
Reasoning:  
1. **Hypomyelination**: The presence of **CNS hypomyelination** and **demyelinating peripheral neuropathy** indicates a leukodystrophy with combined central and peripheral nervous system involvement, a hallmark of NKX6-2-related disorders.  
2. **Spastic ataxia**: **Ataxia**, **spasticity**, **cerebellar atrophy**, and **morphological pyramidal tract abnormalities** align with the ""spastic ataxia"" phenotype linked to NKX6-2 mutations.  
3. **Oculomotor deficits**: **Vertical supranuclear gaze palsy**, **hypometric saccades**, and **abnormal eye movements** are consistent with brainstem and cerebellar dysfunction seen in this disorder.  
4. **Motor dysfunction**: **Inability to walk**, **dystonia**, **titubation**, and **motor delay** reflect progressive cerebellar and pyramidal tract degeneration.  
5. **Peripheral neuropathy**: **Somatic sensory dysfunction** and **peripheral neuropathy** support the dual central-peripheral hypomyelination pattern unique to NKX6-2-related disease.  
6. **Exclusion of mimics**: The combination of central hypomyelination, spastic ataxia, and peripheral neuropathy distinguishes this from other leukodystrophies (e.g., Pelizaeus-Merzbacher disease, 4H syndrome) or isolated spinocerebellar ataxias. Genetic confirmation of NKX6-2 mutations would be definitive."
"['Large fontanelles', 'Parietal bossing', 'Hypertelorism', 'Micrognathia', 'Delayed eruption of primary teeth', 'Short clavicles', 'Frontal bossing', 'Wormian bones', 'Scoliosis', 'Hypoplastic iliac wing', 'Short stature', 'Abnormal facility in opposing the shoulders', 'Depressed nasal bridge', 'Enamel hypoplasia', 'Delayed pubic bone ossification', 'Broad femoral head', 'Metopic depression', 'Midface retrusion', 'Short femoral neck']",['Cleidocranial dysplasia/Cleidocranial dysplasia'],"Disease: Cleidocranial dysplasia/Cleidocranial dysplasia  
Reasoning:  
1. **Cranial and Skull Abnormalities**: Large fontanelles, parietal/frontal bossing, Wormian bones, and metopic depression align with CCD's hallmark delayed cranial suture closure and defective ossification.  
2. **Dental Manifestations**: Delayed eruption of primary teeth and enamel hypoplasia are classic CCD features due to disrupted osteoclast activity and dental follicle abnormalities.  
3. **Clavicular Defects**: Short clavicles (often hypoplastic/aplastic) explain the ""abnormal facility in opposing the shoulders.""  
4. **Skeletal Dysplasia**: Hypoplastic iliac wings, short stature, scoliosis, broad femoral heads, and short femoral necks reflect generalized skeletal hypoplasia and abnormal bone growth.  
5. **Facial Dysmorphism**: Midface retrusion, depressed nasal bridge, hypertelorism, and micrognathia result from craniofacial bone underdevelopment.  
6. **Pelvic and Pubic Involvement**: Delayed pubic bone ossification and hypoplastic iliac wings are consistent with CCD's pelvic radiographic findings.  
7. **Rule-Out Considerations**: While some features (e.g., Wormian bones) overlap with osteogenesis imperfecta, the combination of clavicular, dental, and cranial defects is pathognomonic for CCD."
"['Microcephaly', 'Megalocornea', 'Optic disc pallor', 'Nystagmus', 'Global developmental delay', 'Cerebellar atrophy', 'Hypoplasia of the corpus callosum', 'Hyperintensity of cerebral white matter on MRI']",['Mucolipidosis type IV/Mucolipidosis IV'],"Disease: Mucolipidosis type IV/Mucolipidosis IV  
Reasoning:  
1. **Ocular Findings**: Megalocornea and optic disc pallor align with ML IV's hallmark corneal clouding/opacities and optic atrophy due to lysosomal accumulation in ocular tissues.  
2. **Neurological Features**: Cerebellar atrophy, hypoplasia of the corpus callosum, and cerebral white matter hyperintensity on MRI reflect progressive neurodegeneration and dysmyelination, consistent with ML IV's central nervous system involvement.  
3. **Developmental Delay**: Global developmental delay correlates with ML IV's early-onset psychomotor regression and intellectual disability.  
4. **Structural Brain Abnormalities**: Microcephaly and corpus callosum hypoplasia are recurrent findings in ML IV, linked to impaired neuronal migration and synaptic function.  
5. **Exclusion of Mimics**: The absence of coarse facial features, organomegaly, or skeletal dysplasia argues against other lysosomal disorders (e.g., mucopolysaccharidoses), while nystagmus and white matter changes differentiate it from isolated genetic microcephaly syndromes.  
6. **Pathophysiology**: ML IV is caused by *MCOLN1* mutations disrupting lysosomal TRP channel function, leading to abnormal storage material in brain and eyes—consistent with the patient's phenotype."